<SEC-DOCUMENT>0001558370-25-007269.txt : 20250512
<SEC-HEADER>0001558370-25-007269.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512090036
ACCESSION NUMBER:		0001558370-25-007269
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioXcel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001720893
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				821386754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38410
		FILM NUMBER:		25932837

	BUSINESS ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-643-8060

	MAIL ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>btai-20250331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/12/2025 12:17:14 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 26194253-f544-460d-b97b-cfaf67470e32 -->
<html xmlns:btai="http://www.bioxceltherapeutics.com/20250331" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>BioXcel Therapeutics, Inc._March 31, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" xs:nil="true" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_YLTqldmlUUS3H6k8IvPT2A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" xs:nil="true" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_RFjC0V2uSE6algVQh2dd3Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" xs:nil="true" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" name="us-gaap:PreferredStockValue" id="Hidden_b5JoQh6N7E6brugxzrI3EQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" xs:nil="true" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" name="us-gaap:PreferredStockValue" id="Hidden_mcJCqgCzOEyIE8YyyX6Ltw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityCentralIndexKey" id="Tc_K88lX1VtPkCOy5lnJyRi1A_2_1">0001720893</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:CurrentFiscalYearEndDate" id="Tc_JI-v0c6v4kCvhPCE4AMFxQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:DocumentFiscalYearFocus" id="Tc_qlDoZb0Cu0qgSie7sM3ryQ_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:DocumentFiscalPeriodFocus" id="Tc_HfkoLrwnbE6q_5EdtgzXlg_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:AmendmentFlag" id="Tc_YhLsiArug0SzwB_47HFSvg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_9ME-9m_E10Sp7UrzgYpmtg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_iisnM82KOEe0mVroHBrApg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" name="us-gaap:CommonStockSharesIssued" id="Hidden_Z4ZTLN7dfECi7gUXpMYpWQ">3102000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_IVJ2GMA4IEyILNkhoDpVvA">5468000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_-dJ9RC_4H0GYGleZlqoJAg">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_PWqzCLVmi0aOXGZBWK1euA">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_J06tcXhzNUq7mLhmMVU1aQ">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_pBakmeRXJUyagPAg9k_X7w">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_buvaqAws5kSR-ouHGNXICQ">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Hidden_OkIKnOdDH0OalG3pChCxZg">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="btai-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_vRuLpGrNJEaqdiLygHHIHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_NP8nyepU-UeJtuBMku2PLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QmfvUlDnnkmlBuPCyWobCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2025_To_3_3_2025_Oqo3T2TPe0OI8F2BWWq60A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-03</xbrli:startDate><xbrli:endDate>2025-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_IqGrgtq8dk2Nmswn-jlaBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_1rBX_Jky_0K75YP6H-89Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JAHXTaO7WkO65OTNPeHiow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_FqusdZHmpEqdtLr0_l7HNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v4f9SlUsOUa4HdcmJWR1dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ev2K8DxaV0a9uKxJ00_XoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_10N7rnTIFU-ky4gxaDiVmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHjW0xYSkU2ePhegrPo-8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kELM8qU0EkWCrI-UkaL8Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JZy4BCURekiYxiqHcge_Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_x1Uqp2p3T0mT8txSjrqjPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zYjQFfZEOk2XX8euLUmtMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_QwlhBl02BUqKZ_B8CPqQ3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EqWnEmSp7UWllrfrANJBsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Pg-jCHaINE-WLGJKl1HB8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_6FxRGu28wE6I304fkcl32w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_afsb0jOiYk26yty0TiCjbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_jAh-mRl7UkGV1NOK3PBR4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:StockPlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ntB7xLQOW0eFtXjIxuvYzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_RtIxFX89CUiClmbyPTCq5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_2u5ZZheCfUSWL-ojEEShPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_9F-wNPBED0-yN2cUEWfCsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_lfzf6M4c4ESx9byf41wzhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_4V56383kUUSE1c7Tg5oaUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FrgKxTMEe0mg8BmgwnLOgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_QM1oFtti-EyHphWNZ9znYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3GMwf3ANwkuAIoCkKRuAEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_yCdJXfvBaESj-7sAWiLUgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uo-sJMUAtUm-XDTcsRgyog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_8_2025_To_4_8_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_P9AZ6PXW1kOHAK6MhEcNgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-08</xbrli:startDate><xbrli:endDate>2025-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_G-3oLaoblUKb9ZcelJ9fng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">btai:RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">btai:RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_17_2024_To_9_17_2024_c8nGfcMfH0inkxdc7P07ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-17</xbrli:startDate><xbrli:endDate>2024-09-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2024_To_5_8_2024_FZp7GPdyrUG_vHhSf2SCHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-08</xbrli:startDate><xbrli:endDate>2024-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_kf6oTMRck0makoAqk28SXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ExIBEjJWbUexxXRMxChHSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_YzddE2_98UmIfS9DblB46w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_P-yi1ob4hUyuvFlo5q8PKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2PQahnIyZk-fOICX6AbWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_i3zFP68HVkiSR0fcAIqY9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lMS_6iH8DUiU4QxSYfIVZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2024_To_3_27_2024_jrj6VftXi0yzxC3W-d_BuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-03</xbrli:startDate><xbrli:endDate>2025-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iLcqzUZ0Ck-Z78lS626m2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_yGKiJmxfzE6HxLbjuYjZzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_mIIdBbQCCEaqnQyKXoN7yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_phf-6MSC-kS6bA7Oa1W-TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0oceliyn7UahFDyUqrBf7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pvRGjtD70kW6s3ZG9tjiZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BWpsZSV2f0yNufbJUffcOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_McmLj4N3TUGjlqTWqM7wYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_4mTezm6jGU2Tt0387MyZ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_11_2024_To_7_11_2024_v4ITxGp84kCgCzwKJY2GDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-11</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_Vj8qPsXKFkSdJSawI_izbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kHi1rm9DF0qHlbl4VlnXNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cVbjkTPdU0mE_eF3eSJOLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__iSlOGcFMUmoZ6cGWFMGPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2025_To_3_18_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_zFe6GfQFg0-WdZKVa-mIuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-18</xbrli:startDate><xbrli:endDate>2025-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_9wVA-iTdq0y5EEN-cGB0Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2025AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_RvkyKbPjBEK4lRpESDkZxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_Cn5-JcfDR0qcNSKrdqLIBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_nOFA42sxOU-Rl_psGJmlJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_10sTlzzOBUiJqkaSyPhFIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_XbHYq2dE_UGUYLas9E-Hnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_dtp7DCTeaEab_MgJIlQTmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t0gcHwftwUuD02CHseIM2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_nF7LfoZnP0eXge2zjCLJew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_FbkYU21lwUS7EtQCr_4AQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_SVurPgE3cUqj3MtsSbmcYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_PLtorYr2Ck-Sp5y9dKuZjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_rp6M6rMw0kqyDbuEBr22PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eQXdiGPGikaZ3eg2SLqU6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wMIMNY2AHE6iuFOidhFOtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__892NuyTDUO55WW4yX_gTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_dmsZTMfbJUO8_pb6kAYEhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_QjBKLYfu3UOftjkz3HF_ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZQ9kR5BADEqDL0CF2MD1zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_DFyNXKIPgEKmArMsW0gQGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xATPzL0AD0u1BGyIwTMdLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_ZVXHoCZAKU-UscfH64BvJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfJEoyAEkke0QHoyrB3b0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_TcgKfaj7gUmuOyYcYRMQNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_BggKgNfY0USZzws7g5S5Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_vZatyzeFWUKoVmXlyUbWJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pLWARFxxtEigtbUjIwm1fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_3xEadpqpTkSF6M_S7kMmYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_y8iIi7tP7ku5odeEUQmnRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wV5E2FZOwUyvzrEwdAj5sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_6Gs70ljVX0-T7tm9G61m5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_q2bl4kv7E02ZqMbp6lNHdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_c8VoZNoCiEe75FKiODf1LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CWILIty2pkCdQ4BijefAOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eZWNvJQCgEqQKzXrXgAoJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_gukmUIFIc0iqBD5w9_5uHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_mzVT50GU30m-ov3gJU8nPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ub31Uz9ocEKq02canhoV-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__xc5-0WLKUuKskXTA4r91g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2M20XZ8qKEKKmuDwGSOUAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_5SJ7xQVeDkK5uvXlaHFGNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_jchly8ehyE2tL32MrOzqYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_zeDW5gQHa0eSgEOzkDCljA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_9KILTf0tCkqIWN0JAKeHVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jJnh5eroP0GCxqLxuMWfvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_um20DfDizEmScCi5XDUA2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5nb_8Nk5UEyJL1GzeHRhRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_raXKhs6OsEWwo5Ew1U2bVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Otlhw_JHk0O7aWKiFegSPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MucGrtBbn0W75wiVlwPE0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_uNtDcCko1UyxQn5jeaw1_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EPMTFamnQUKwjPkhv202_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rqZf9XPGIECruOB5VZyF7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bQalOe5mP0y-IbH-aKaF9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Gzu0uopwJUi4ddhDOAgn4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P_Qm7GZ7c02Je803Yy_hCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RUa6fxCGUUmCyEdDsmfEsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2zTp8JJdwEuWNCrhPNXy7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_prSUZ2Vk1keXeIwPcPdHBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NU_bnWHgP0u3mu2YN8K9VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SMshi1uQUeFzJdBkvobzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qG6PA1YTT0mFdtjqdPZt5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_PbHyP1wRzkWN4ZQmOt6QaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2025AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_QLIVwjVCD0quI55_NwdJQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_k-Kye-ecsEGNgr32jEq1GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_dwaRvaALY0OiHiyuF7H6Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2025AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__NmDuNpoV06Ia2-1ixub5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tlr0bx5Lk0umFnmNNGd4sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vgkPllpRpE6UxSwit2t12w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_a7UuWWdWIEerkqNo73GtgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wRxXXGVLeEmgQL5oobXHSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AYpdz6Od1kSaVgoALMsuJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_c2LU5Sjq3USpPWVHuKrnqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RSoI2qJZEEOhEloDLwu0WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_znla2RdJtUGZPRsAxS6c6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VPNR0fGdgUKLLXoJnK_u5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_G6llnlti5k20g5RAYF9w8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_I6j_31dAZkOaSKH03J-dWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7HNwLTU3EyiG-P0bxBDiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zFMC5T7CfU-D5CYy3DpF5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qVwLBWQhP0C7ghgBC6SW2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zeDII7Hjq0G2YU6LERXHGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_S352yBVXFEqz_Y-5P-1a6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_yclrnHVBYEmASqLsg1GLwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_fdyMamGLJEanvbZYQzjwvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7jkhG9xOeECCQCuuL2gEdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nwCEzZi7MUOLNYUtq0AhqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fGM3WlQIOkCMWEoncwc2Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mWRWF3v2JEGzrKxCrcvnRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_hFX2ulHzj0Wonqj3FtS7mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_9zAfUgBtvEi6ov_a7qysFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_eSxn4MEvbkq34vrvkL54Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-0WZ3XTjU0qB5FR91C9j6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wQc4SgRdUEicS5pdoMt99A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_YlCT5Ht1C0ySlRxPWi7pMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:PrefundedWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_H1m79MxGEESZ-YgtaaXWXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_sOc9QAFpIkiocfp6gFyENg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_g5MICnEV20aws4tbDts1AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_ZjpISjnlM0KcHdFRUWnJgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_wQUERamXr06SR40KJckzOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:IntraCoastalCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_PVo46D0n4k6-QNq-niA4gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HudsonBayCapitalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_m8B2gPtU0ESdDuqJrEcuow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HeightsCapitalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_piXKgE8oLECIyWjuYpp4BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:ArmisticeCapitalMasterFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_3dKYWVuao0m_9mO0sa3-sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_MIO3Q71fCk-LePjJ87vN6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_UjYm4-P8Z0eyskPAdnjmLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_4DLfIusP5UOtgAlpPFhBiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_zb2gHq4d8UOFHYORuG5uDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_QFx83QhiX0OZiI-xchFZ7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_W4qAVPHELES2fLUz4KcqKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_Wz5TY_agyEaaN18D5dyCEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OriginalWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2024PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2024AccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JbvOkxvjdkmJ6LmN2Rd0Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_mCSz1-9t-k2mWS0W2FTi7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_PJWCjTtyrkmhOnNFeBDLAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_J7mlkOfyo0Wnq0ZjtLDsPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_85gLhLsX40qMOQrtKaj64g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_tqFj1TLzLE-k4JolNuUzZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wE7ROgr2I0i_O7Oti3HboA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_ZTqvtqbD3U6ROpLx6ZSAKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cwe90g33bUq1Ikc8GOiESA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_uh20TIQks06ogYnvmFGT-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbpFUXyy0EK9y5v8zoZeAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_pfEI4UeUmEGDh7VF6gPIkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hYwcEJOWJEqWIWLY9H5bPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q7_XqlxfsUekbErhlfT5sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_aQAnItAirkePUH0weLiB8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e7w7dYu6okaQM-X3HL0_TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_9_2025_u6AbsaWNyUmdMz8bODSDew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jEJ-6V5VnEiejCS4zWZhwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_gxIXr8TElEqM_4GFJfzkTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_jTTHkTj0IUGtiV9lleK50A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Wdm82uT0iEGxg_xqO2sS2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Q7rgAxV2QUiFwGQkmwTNSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2024PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4ANH0Ryp-E-Q8Hcq8ycu6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2025_To_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_B7tCQZI3s0-d2yjT-Ceoug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-03</xbrli:startDate><xbrli:endDate>2025-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_sIswvAbnK0SSZ3U84h3-cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_4HyrlxwEJEq43QPtl9kACg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_8_2025_To_4_8_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKVZkA0td0assUa8qAOlvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-08</xbrli:startDate><xbrli:endDate>2025-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_PoDngmaLSkWSK6VPUhLyWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_5K0sWmEJwUa7Vv6SUtp_GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_52So6KoOMEungxS0l0MsEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_bbbkIzsXpkmOj02U5piNIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_SSD-lVaNm0i_gSF3npZAOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_5oKzEf9LG0ObCnvYEfaywQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_CsZ-KkxpOUakCJAE_KixSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterFundingOfTrancheBLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T63fAxu4W0KEPABUzNyrnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3m8_BPw0G0OPp__QShJQ-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hgzEHqmylEubMQ6IsaLqbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_TgEuBFjXIkKWUIDM6bWI0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eKfoQwlPkUyNgcgidh5-dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kzDv9FgG30O_Q6Inae8txA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fJEBahyH2E68UBP6QHFHZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7PXdMmavEKzCaO6o0HcTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qwP76czkUUiKqJXva8OQCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3EM8qIytm0Ke9WUqaxD5ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tKgYE7x10U2ucISeOhEC6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jAx_EojGEketsDRJCeRRzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_gtTfRBkLIUCQ1ZyESr-Bhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eeKV4-Us0k-PErQbocl43A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_j4lmqYFO50Sd2zbIjyRJlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_OFejCh9UM0ObmQn7f9J2Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_J81r1ZkU4U-0Pa_Y2zZH7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_VHV8Q0yfikOv6dYy4wL6Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_hZBCN15vmkq8K-1LPWLUKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_Fkdg6L1osUqn8ergQvAGeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TM9ElQRCBUSIjpJ3xXkJVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg"><xbrli:measure>btai:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g"><xbrli:measure>btai:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_548bad61_64a4_4bf7_801d_8d4f3038a704"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 1pt 0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:DocumentType" id="Narr_uqronKZxlE6CTNeKnI00aQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_8a148e01_495a_488d_866b_6be6c4ba7e14"></a><a id="Tc_lHzgTXbAWUaFX__QgnUY0Q_1_0"></a><a id="Tc_vHsQJStm00SJ2_eCQiLE-g_3_1"></a><a id="Tc_IHWZ3cC-WU6dkkz_yhLJrg_5_0"></a><a id="Tc_9kNfKFZZmEexHl7YDmczzw_7_0"></a><a id="Tc_-5mQE6qKeka-l4ikM2yj7A_9_1"></a><a id="Tc_KDYOUxF2hk-v4lNuJ-eh9w_10_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.15%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:92.84%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:DocumentQuarterlyReport" id="Tc_OQ_1pw4nsUmLpKo7YX3G5A_3_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:92.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:DocumentPeriodEndDate" id="Narr_QW3FQQb4-UyN5e2UnatbXw"><b style="font-weight:bold;">March 31, 2025</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:DocumentTransitionReport" id="Tc_mJ4AYh3lUkW0vEKxt01n0g_9_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:92.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from                                    to</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityFileNumber" id="Narr_UJbkk3dTfkyHgXKYYxCsgA"><b style="font-size:8pt;font-weight:bold;">001-38410</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityRegistrantName" id="Narr_3Toet0QqHEKSs2X7gO_OGw"><b style="font-weight:bold;">BioXcel Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_2a788f4d_2bf8_41d4_a2de_63cd207d5bd6"></a><a id="Tc_Ls38Dl6dTkyR72NKfzZ22w_3_0"></a><a id="Tc_Ea-1UnDhe0KQxbQBcuxEFw_3_1"></a><a id="Tc_-V9DC8Hsv0GGjAeEfgqTkw_6_0"></a><a id="Tc_yhVYxnKBXkCt8ZD7uzWeMw_7_0"></a><a id="Tc_rRqzxrXXiUqWKcrVhkXIPA_7_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityIncorporationStateCountryCode" id="Tc_m3DyQSbeoUydtOnKW85r-Q_2_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityTaxIdentificationNumber" id="Tc__S31qwkfK0iVhCFzXwwGWQ_2_1"><b style="font-size:8pt;font-weight:bold;">82-1386754</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">(State or other jurisdiction of<br/>incorporation or organization)</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer<br/>Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityAddressAddressLine1" id="Tc_Gtv4HyyH6UKaaKKDgj_G2g_5_0"><b style="font-size:8pt;font-weight:bold;">555 Long Wharf Drive</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityAddressCityOrTown" id="Narr_HpabPqN1aUOJdsgmc-KHrg"><b style="font-size:8pt;font-weight:bold;">New Haven</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityAddressStateOrProvince" id="Narr_h_448Cu7wkyqFK6zE6s--Q"><b style="font-size:8pt;font-weight:bold;">CT</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityAddressPostalZipCode" id="Tc_bozhomSi_USQQEMlY0p1vQ_6_1"><b style="font-size:8pt;font-weight:bold;">06511</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:CityAreaCode" id="Narr_tAJyAMaMkE6edIvG6nP0Ag"><b style="font-size:8pt;font-weight:bold;">475</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:LocalPhoneNumber" id="Narr_-kzWJPc_FkirW1Av73Ybgw"><b style="font-size:8pt;font-weight:bold;">238-6837</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Former name, former address and former fiscal&#160;year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_b8579348_8ad9_4f20_8f21_12e843bbbb48"></a><a id="Tc_cUb4JK4HFUaYC2e-G2CQsQ_2_0"></a><a id="Tc_VSbA6tEREUK6UdoCRXlUcQ_4_0"></a><a id="Tc_5nYl--JDeUSkTF41Z_vXfw_4_2"></a><a id="Tc_fNDMOG7B0EuUfd3jGOvwpg_4_4"></a><a id="Tc__sXykZm5_0C4zmwaz7wM9A_5_0"></a><a id="Tc_No2hrbG_TkC1N1b6Yw9D3Q_5_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"/><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.9%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"/><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.03%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"/></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"/><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.9%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"/><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.03%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"/></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p></td></tr><tr style="height:1pt;"><td colspan="5" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.9%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.03%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:Security12bTitle" id="Narr_0H7R66owuUWzLGWqUz2Ghw"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric><span style="font-size:8pt;">,</span><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">$0.001 par value per share</span></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.9%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:TradingSymbol" id="Tc_KTA_1gPbJEi8VnMac-larg_5_2"><span style="font-size:8pt;">BTAI</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:39.03%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:SecurityExchangeName" id="Narr_oit348FIzE2XW1Y_TulnJA"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityCurrentReportingStatus" id="Narr_CtbZI3DsDEutbeWLCAJ8rQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityInteractiveDataCurrent" id="Narr_7chLKACUXk-nDLBOMsaB6w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityFilerCategory" id="Narr_UOrFs0JcWEeXJnXxAsJPFQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntitySmallBusiness" id="Narr_b6R5GcfDJ0OUvKcocnvPNA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityEmergingGrowthCompany" id="Narr_T3bhdZJjU0WYenyR2R75Pg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="dei:EntityShellCompany" id="Narr_S6HrDQZYEEaytcIU592gdw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">The number of shares of the registrant&#8217;s common stock, $0.001 par value per share, outstanding at May 9, 2025 was <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_5_9_2025_u6AbsaWNyUmdMz8bODSDew" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_oFfN2MDzNEKWCJvzAviJeQ">6,056,046</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt 0pt 8pt 5.65pt;"><span style="font-size:0pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9363916f_1275_4179_8b3f_709df4665dcb"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">PART&#160;I&#160;- FINANCIAL INFORMATION</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#FORWARDLOOKINGSTATEMENTS_531719"><span style="font-style:normal;font-weight:normal;">Forward Looking Statements</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Summary_Risk_Factors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1FinancialStatements_877614"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1FinancialStatements_877614"><span style="font-style:normal;font-weight:normal;">Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#BALANCESHEETS_142330"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_842353"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in Stockholders&#8217; (Deficit) Equity for the three months ended March 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_929012"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#NOTESTOFINANCIALSTATEMENTS_349172"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item2MANAGEMENTSDISCUSSIONANDANALYSIS_22"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2MANAGEMENTSDISCUSSIONANDANALYSIS_22"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item4ControlsandProcedures_79336"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4ControlsandProcedures_79336"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">PART&#160;II&#160;OTHER INFORMATION</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1LegalProceedings_771938"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1LegalProceedings_771938"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1ARiskFactors_143189"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a><span style="white-space:pre-wrap;">  </span></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_143189"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_782584"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_782584"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_613042"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_613042"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item5OtherInformation_348642"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5OtherInformation_348642"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:bottom;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item6Exhibits_836986"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:82.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6Exhibits_836986"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">132</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:90.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SIGNATURES_228043"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">135</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_aa8e3da7_6d76_445b_9d21_b57ef651df3f"></a><a id="FORWARDLOOKINGSTATEMENTS_531719"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements contained in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sales strategy for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategy relating to, anticipated benefits from, and cost savings from our Reprioritization (as defined herein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital and continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our TRANQUILITY program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of our total addressable markets and related underlying estimates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans relating to clinical trials and marketing applications for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to research, develop and commercialize our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to seek to enter into collaborations for the development and commercialization of certain product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of any future collaboration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and results of discussions we have with regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance, clinical utility, number of prescribers and formulary wins of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and manufacturing capabilities and strategy, including the potential benefits from any advertising campaigns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our participation in, and any potential benefits from, events, conferences, presentations and conventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and need for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential investments in, or other strategic options for, our subsidiary, OnkosXcel Therapeutics, LLC (&#8220;OnkosXcel&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with covenants under our financing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments related to legal proceedings and investigations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our relationship with BioXcel LLC.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those listed under &#8220;Summary Risk Factors,&#8221; Part&#160;II, Item&#160;1A. &#8220;Risk Factors,&#8221; and Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Quarterly Report on Form 10-Q. These and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) could cause actual results to differ materially from those indicated by the forward-looking statements made in this filing. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. While we may elect to update forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">As used in this Quarterly Report on Form 10-Q, unless otherwise specified or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;BTI&#8221; refer to BioXcel Therapeutics, Inc. and &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent company and significant stockholder, BioXcel LLC and its predecessor, BioXcel Corporation.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt;">We may use our website as a distribution channel for material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors &amp; Media section of its website at <i style="font-style:italic;">www.bioxceltherapeutics.com</i>. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the &#8220;Email Alerts&#8221; option under the News / Events menu of the Investors &amp; Media section of our website at <i style="font-style:italic;">www.bioxceltherapeutics.com</i>. The information contained in, or accessible through, our website does not constitute part quarterly of this report and the inclusion of our website address in this quarterly report is an inactive textual reference only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a5daecbd_6ecd_4b61_b1a4_5c5ca459e253"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><a id="Summary_Risk_Factors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We could be delisted from The Nasdaq Capital Market, which could seriously harm the liquidity of our stock and our ability to raise capital or complete a strategic transaction.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement (as defined herein) would trigger an event of default thereunder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our strategic reprioritization and other workforce reductions in force may not achieve our intended outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience in drug discovery and drug development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting in the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the near term, we are dependent on the success of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and four of our product candidates, BXCL501, BXCL502, BXCL701 and BXCL702. If we are unable to complete the clinical development of or obtain marketing approval for our product candidates or successfully commercialize </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or our other product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the Food and Drug Administration (&#8220;FDA&#8221;), and comparable foreign authorities are lengthy, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, time-consuming, difficult to design, difficult to conduct and involve an uncertain outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on enrollment and evaluation of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The discovery and development of product candidates based on EvolverAI, BioXcel LLC&#8217;s proprietary pharmaceutical discovery and development engine, and our AI platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Although the FDA has approved IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and for any product candidates for which we obtain approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are found in violation of federal, state or foreign health care &#8220;fraud and abuse&#8221; laws, we may be required to pay significant fines and penalties, including, without limitation, debarment, suspension or exclusion from participation in federal, state or similar health care programs, which may adversely affect our business, financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We continue to depend on BioXcel LLC to provide us with certain services for our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on third parties for the manufacture of our clinical supplies of our product candidates and our commercial supplies of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and we intend to rely on third parties to produce commercial supplies of any other approved product candidate. Therefore, our development of our products could be stopped or delayed, and our commercialization of any future product could be stopped, delayed or made less profitable if third-party manufacturers fail to obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug product in sufficient quantities or at acceptable prices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data breaches or cyber-attacks could disrupt our business operations and information technology systems or those of third parties on which we rely, adversely impact our financial results, or result in the loss or exposure of confidential or sensitive product candidate, clinical trial, employee, or Company information.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Increased scrutiny of and evolving expectations for environmental, social and governance (&#8220;ESG&#8221;) initiatives may impose additional costs or otherwise adversely impact our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business. Such proceedings, claims and investigations could be costly and time-consuming to defend and could result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">TRADEMARKS, TRADE NAMES AND SERVICE MARKS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This Quarterly Report includes our trademarks, trade names and service marks, including, without limitation, &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221;  and our logo, which are our property and are protected under applicable intellectual property laws. Solely for convenience, trademarks, trade names and service marks may appear in this Quarterly Report without the <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> symbols, but such references are not intended to indicate, in any way, that we or the applicable owner forgo or will not assert, to the fullest extent permitted under applicable law, our rights or the rights of any applicable licensors to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">INDUSTRY AND OTHER DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless otherwise indicated, information contained in this Quarterly Report concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. While we believe the information from these third-party publications, research, surveys and studies included in this Quarterly Report is reliable, we do not guarantee the accuracy or completeness of such information, and we have not independently verified this information. Management&#8217;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in this Quarterly Report under &#8220;Forward-Looking Statements&#8221; and Part II, Item 1A &#8220;Risk Factors.&#8221; These and other factors could cause our future performance and market expectations to differ materially from our assumptions and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_09071bfe_6b1d_4099_9a6a_6bc885a0ee21"></a><a id="PART1FINANCIALINFORMATION_422919"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART I. FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_877614"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item 1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">BIOXCEL THERAPEUTICS,&#160;INC.</p><a id="BALANCESHEETS_142330"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts)</b></p><a id="_6d6a86f9_eb22_49fa_8096_7b0529b174c7"></a><a id="Tc_uI_AJofKgk-fGSpc85CzMQ_3_2"></a><a id="Tc_ZVadXi789Ea-4Fp7g-xW8A_4_2"></a><a id="Tc_ssGgxNqyBkGJTJEMCZq_Ew_4_5"></a><a id="Tc_dKXOMUOfkUW5C_ZP_wxb2g_5_2"></a><a id="Tc_s3VUA1-KqkOGitqAlmwlgQ_5_5"></a><a id="Tc_nm-xjKttmUmaYv7I-WTSxw_6_0"></a><a id="Tc_jiHu0ilo7kGGt81lK7pyRA_7_0"></a><a id="Tc_mkYn7tp51EGJxO3N1rCokg_8_0"></a><a id="Tc_fP14unlpfUijHRSrYbLNpA_8_2"></a><a id="Tc_g1HcuJlkvUq7jO5iaNQ4iw_8_5"></a><a id="Tc_SUN-Z_isG0S55OUMDJPqvg_9_0"></a><a id="Tc_q1ruilKHmEKpktT544ZwSA_9_3"></a><a id="Tc_rkn5hYBkN0WxWuaOnxi8FQ_10_0"></a><a id="Tc_bcWWSgvudku-v5tcwFoQlg_11_0"></a><a id="Tc_d31TUWaETUmFqpKlyIY2aQ_12_0"></a><a id="Tc_LLqm4DwQWES3FIxwv3oycA_13_0"></a><a id="Tc_5HWohxOe3ky3shv48M23GA_14_0"></a><a id="Tc_du40xkR-W0GM5WPAv_rmgg_15_0"></a><a id="Tc_AxqY7uVy30m-nvSlx1AeRg_16_0"></a><a id="Tc_Q8zcArTPpUGvN6dUivw73w_17_0"></a><a id="Tc_wBZe9e_yGkmtP70U4_TrZg_17_2"></a><a id="Tc_McD0YHWuzUyJaRdRrv67Nw_17_5"></a><a id="Tc_f1BbRuWteke76Z3fCSUj6A_19_0"></a><a id="Tc_27jO9FtNx0eVxFz1-oAvaQ_20_0"></a><a id="Tc_uizuFKWgAkSqzEPf41a4eA_21_0"></a><a id="Tc_PlFnbsxEHkaSmgDU5iJyMQ_21_2"></a><a id="Tc_guA_LNjpWk-iiymTdFcp1Q_21_5"></a><a id="Tc_XPihQ_b-S02B0EGn9G6CBQ_22_0"></a><a id="Tc_2TCeT9Mg7ESzguotPlbsCw_23_0"></a><a id="Tc_UWiKLJm81EqG0YkxX3xwUA_23_6"></a><a id="Tc_u7RUHYcJ2ku13U9YpiuCHg_24_0"></a><a id="Tc_XKwuAkHF3kCLc9h9RS7ihw_25_0"></a><a id="Tc_BO1vsV00EkGHR3jsoHWM_g_26_0"></a><a id="Tc_RolfsQJrqEm5ISwBrz-jTA_27_0"></a><a id="Tc_dBxGKJTXeEGeXLNg30CaDQ_27_3"></a><a id="Tc_n5OgUlXs7kOFAdVvOeJtQQ_28_0"></a><a id="Tc_pTGLk-YO_UGlT0aJSqbweQ_29_0"></a><a id="Tc_Vf4xFAYA306GLJIW4LQOnQ_30_0"></a><a id="Tc_g58v4xicLk-_WNMW1_Ciqw_32_0"></a><a id="Tc_BRVH3USv_U2DZpYNQOL-sA_33_0"></a><a id="Tc_bFnpnt6gaUOshxbTS_uj6A_34_0"></a><a id="_abab3656_a825_4328_94cd_3e2375d8789e"></a><a id="_abab3656_a825_4328_94cd_3e2375d8789e_2"></a><a id="_abab3656_a825_4328_94cd_3e2375d8789e_3"></a><a id="Tc_UquzwRFT20OxNt0A0YpjpA_35_0"></a><a id="Tc_6nipUATccEql4xxAI2vPLA_36_0"></a><a id="Tc_kIKRRSVyVUyC4S8JDnju-g_37_0"></a><a id="Tc_NFjwWOKCS0yErTFcJ0Q_CA_38_0"></a><a id="Tc_Oqhdxq9NwkSFQq_yzSV9jw_39_0"></a><a id="Tc_pH8qO5vGvE2NnVWo9ZgdSw_39_2"></a><a id="Tc_LYxt88Ynm0SHx73RUxFYlw_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.89888763%;padding-left:0pt;padding-right:0pt;width:101.79%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_BGYhB6mlpkOKaN_Ka6p8tg_8_3">31,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_2bFgcVrY-kmKrzoV_7s_mw_8_6">29,854</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_tsURDEG6G0CfedYN7SZmIA_9_6">131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_5x7HHi2eG02KO7EPQWD5_A_10_3">642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_SDiYJ0n9p0Oad_4uRRSPJA_10_6">679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_bTIXueNq_UK2IHnnQ0HF-w_11_3">4,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_6h1PfaHjGEiufke9EM_7Ow_11_6">5,290</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_H4a1dbF29UCswaBzgnC5IA_12_3">1,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_ND2rJV_Pw0GlVVF_DZiw-Q_12_6">1,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_wy3Ks9IwQ0aRJ9sq3Vzxxg_13_3">37,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_y1E_T5bgg0efLv9ckXdIWQ_13_6">37,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_lcTPOg9yo0GUudXGCrSJUg_14_3">399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_bNnrhzB73k-bUQ5x-nrpAQ_14_6">475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_ZL0TQKWZ6U2Kj1-2XzS-nA_15_3">303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc__5uSUnOORUuTcz7Qjk8McQ_15_6">382</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_69aeuP56zk674ylP_VcrZQ_16_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_j-_u60Qhg0-_KsrfjPJVnw_16_6">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_C7qBDBvLSUOFnPGtTSjOYw_17_3">38,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_ONfqky5f0ECjcdtz-N2tuw_17_6">38,338</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_rwQZ5-cwTEir8Zkr4BypUQ_21_3">15,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_nLQw5JnTXUaLLXDhCfiFYg_21_6">15,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_oYs5GWsHhkiNCa48A8BGmA_22_3">3,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Nk1Zwm_rCUOlAXI6O0vsiQ_22_6">5,762</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_Qv2WzGe0DEShHQDgejes_w_23_3">5,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_yGKiJmxfzE6HxLbjuYjZzA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_8FUXtphr3Eaj_XOb0Ea-QQ_24_3">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_phf-6MSC-kS6bA7Oa1W-TA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_tIY3EB0TUESz6zsGNxibQA_24_6">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_mIIdBbQCCEaqnQyKXoN7yw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_yPBCnxFMPk-f0DBxMhS7VQ_25_3">383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0oceliyn7UahFDyUqrBf7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_zbQgbTp4-E-dJY7V4ZZCPA_25_6">374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_j0MjXSH6bUe5UnDvqsiK_Q_26_3">25,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_2jKqUAqLLEeMx1VkQMaKgA_26_6">22,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_luMPkZzH_E-HxQ5F2QZ81Q_27_6">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_LDr-CJDzv0S1LM7monZ3FA_28_3">3,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_CLTy-sXx00SBkPfbb-HueQ_28_6">6,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc__8YOi5PczU-nF7AdiM_bmw_29_3">99,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_ZxIdnx8CbEe4qN_yHLVHXQ_29_6">102,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">     Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_6tSBCZEEoU6P0KKgSZftwg_30_3">128,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_I43Uqg6FPkiiLFGERsgEQQ_30_6">131,439</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_n8lO1HXP-0e2Cl6b2VB9Gg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_KMHGFR7X1Uua9x0suJasIQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_mP9JZRkO_UGZ_aecHojIoA"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_ScfVgRbxe0O9nyhnA2zlSQ">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_-esvLFtPjUqMJzAyEeb31Q"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_WppOmELbFEOGX9S2xaQNog">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31,&#160;2025 and December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b5JoQh6N7E6brugxzrI3EQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_mcJCqgCzOEyIE8YyyX6Ltw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_TwpDJNT5MEmZCUVUUMdJcg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_bb60RFBYykOAZRgCmzdmYA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_O5tGoNMebk-sIH1PW3ZJuQ"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_vyAD-cHgdU2yicBxgVyzzg">200,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31,&#160;2025 and December&#160;31,&#160;2024; <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Narr_uPbFPdeXeEqxsCJv3OWqXg">5,468</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Narr_gRrVLbUr0U6pFP6OYsdicg">3,102</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_Z4ZTLN7dfECi7gUXpMYpWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_IVJ2GMA4IEyILNkhoDpVvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of March&#160;31,&#160;2025 and December&#160;31,&#160;2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_G1K64MlSl0CHtsPXL-2oXw_35_3">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_q-2GQt4TmEqkSSrueBKyDw_35_6">49</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Additional paid-in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_qcegY7ZGx0aYxt33eF2IYA_36_3">567,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_QsvA3EsGhEyYxFe0C9azvQ_36_6">557,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_TnrqGR8mP0aXP9dFF77pVg_37_3">657,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_V4aTZ23GREa8-nUAJAvf2A_37_6">650,197</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cP-sSgxtqEaFScwD0t_3Rw_38_3">90,172</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i493rVQhoECoM7XZuKu7Qw_38_6">93,101</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Total liabilities and stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_3fSH791VHUuzjt-Dkwl47Q_39_3">38,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_a8RIE9E5CkuM_yIMsKCScA_39_6">38,338</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="_11c2f13f_f440_4c98_a4f6_e83de856a7ff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS,&#160;INC.</p><a id="STATEMENTSOFOPERATIONS_842353"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_22d046b9_a0ab_4da7_a73a_abc482023c0a"></a><a id="_075bd9ed_50a5_4472_bcc4_fcab4a3012c4"></a><a id="Tc_a38kApATn0WYBjhaQvwzWg_1_2"></a><a id="Tc_dQct5U2isEeMfFW5SUY9gA_2_2"></a><a id="Tc_hjFsXQcj9keoe0umvDtoRw_2_5"></a><a id="Tc_uCL3pZ2uNEKzEuzc5EhsYQ_4_0"></a><a id="Tc_BYP_sOkTDEiGb9GzGEPAAg_5_0"></a><a id="Tc_I53yNSAw9EGkhOvMfg_Sug_5_2"></a><a id="Tc_3M49Crv3z02iRqt29J1QZQ_5_5"></a><a id="Tc_csXQFObCXkC62Ep3kJ8CVg_7_0"></a><a id="Tc_EI1sCAcdLEqUt4VgHFYRTQ_8_0"></a><a id="Tc_dJcB2Xomu0WIU9uoSeabmg_9_0"></a><a id="Tc_hr_twKm1lkaCwRv0HnXxXg_10_0"></a><a id="Tc_3ovssotkPk6_RNCp-qNMHQ_11_0"></a><a id="Tc_D8skYN1HcUuwSIC-5-m94A_12_0"></a><a id="Tc_r3ubDlrxSkyJS97Vz8qYSQ_13_0"></a><a id="Tc_sOBR2xWti0edJfYnRr-Isw_14_0"></a><a id="Tc_ssUDVlH37EG3s-SF1f2SxA_15_0"></a><a id="Tc_FLxVdL2vyEivmrAOsJGrzQ_16_0"></a><a id="Tc_BDgmQvt5JESCqtGOKoyfWg_17_0"></a><a id="Tc_yYODOiMpUk6e7-HGLi0o0g_17_2"></a><a id="Tc_hYuGyJeCtk-sqROOwTrFGg_17_5"></a><a id="Tc_hwhzcmYMPESOqLswxFtUnA_18_0"></a><a id="Tc_yDQJC4TAhEKhsk3J0dHDdA_18_2"></a><a id="Tc_9fAt7ZYD4EioWEhg1IUGFQ_18_5"></a><a id="Tc_iNCpbGstAkSwVormzwLjjw_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07793808%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_20FgNCTGDEqOvbq5YnLvXQ_5_3">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_NcSVyU0_EkavnkzwsIRYOA_5_6">582</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_Fu6OLYc2G0WE2UdsjYFdLw_8_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_FKg-57WjykGKUksGQKO6Qg_8_6">80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_NHBu7OCZB02a5bGvXTIDUA_9_3">4,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_xOdN4DI2hEqGCQWTWLakTQ_9_6">11,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_Ur41bK3Qx0OzQgsuMLnAyw_10_3">5,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_qgToWbWB6kWwVWPwXtloAg_10_6">13,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_ja7yb9mb-0env_3baEk6gQ_11_3">10,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_e3BPtX1pgEi2S-tVedcvFA_11_6">24,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_9o3q5H7X0E-63S4Z-TV8ig_12_3">10,099</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_IUW7U6QHqkuL5u4MELpGbQ_12_6">24,163</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_3wGexc4p1U-QrVmjEsSvsg_14_3">3,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_-JvVuM2zmEuLnpONyOSBPg_14_6">3,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_KSqPBe-tY02XPSmmkhkADw_15_3">279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_eQBG_Kai70ODDPlQbu2VVw_15_6">947</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_8HNPbgLYW0u9JDABI8ZsLQ_16_3">6,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_a9PHp0HVoU-uQjGBU0amcQ_16_6">32</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6EtiTmfH-E6wd__XmOAyEA_17_3">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zaC6UztEYU-waPxXa8OLqw_17_6">26,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_4cDgM4P3tkazxtBTiea7VQ_18_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_4cDgM4P3tkazxtBTiea7VQ_18_3_2">1.50</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_-yhV02bAw02P5w40SvQVKg_18_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_-yhV02bAw02P5w40SvQVKg_18_6_2">13.89</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_ukyjyq9cZ0KQdSatgsuSTg_19_3"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_ukyjyq9cZ0KQdSatgsuSTg_19_3_2">4,834</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_aSOir70HNUitltrSq1esVA_19_6"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_aSOir70HNUitltrSq1esVA_19_6_2">1,929</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6099386e_b6cf_434e_a618_12a883a550a3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><a id="STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_a03717f8_08f6_4876_baa9_dd271f2b2e08"></a><a id="Tc_hY5eHtzVJEyx_NdnTP4MMg_1_7"></a><a id="Tc_AENIpvTMXE6P7voKuGWbjg_2_2"></a><a id="Tc_4xpoNzsPgESQH3ilr_v67A_2_7"></a><a id="Tc_adJMewKay0udrCrPoQqDcQ_2_10"></a><a id="Tc_reN_p_pwLUSx7S-I-G-RZA_3_2"></a><a id="Tc_XpFRzio8U0Wp9glvNZgARQ_3_4"></a><a id="Tc_1IiMCFOkckO0GrC3eDJnNA_3_7"></a><a id="Tc_T5clJ03Ct0i53rvHFS1PfQ_3_10"></a><a id="Tc_txgT_Y1LbkiaVXTFN7SFsA_3_13"></a><a id="Tc_mE9QL7GCo0m4fDLErFWs2g_4_0"></a><a id="Tc_Ey2Pkd_rkUe4rmJV6zpGLg_4_4"></a><a id="Tc_hQqfFOrhLE6JZgkXt84Q-w_4_7"></a><a id="Tc_PcmTJ-qgkkevfUswuYN-dA_4_10"></a><a id="Tc_T_TbEhVT-UqeC5cvga_2Dw_4_13"></a><a id="Tc_t0I-l79NW0GQg3R3aBPKtA_5_0"></a><a id="Tc_EWbRcmZifECjV_xzac3Ntg_5_11"></a><a id="Tc_U6bKYbH2Tk-nzeEkXyU7Gw_6_0"></a><a id="Tc___p_aoJ6CkynsdSas1ujtg_6_2"></a><a id="Tc_oVhrxNZW-EyPlptrzTL2Cg_6_5"></a><a id="Tc_LAbiBHkDS0GXWmtifQUNKw_6_11"></a><a id="Tc_0NQJcKANNkuFu1PAI5gPbw_7_0"></a><a id="Tc_WkzpInjuU0-ZxL_APZEk9A_7_2"></a><a id="Tc_9aAjTYUoaUOGGK_L8ajfrg_7_5"></a><a id="Tc_B-86Zg1XWUCPo3FSlUAGtA_7_11"></a><a id="Tc_mn39HOHBGkm2cJjaONSmlw_8_0"></a><a id="Tc_e-tBU_wHUUGpYIl_kZ96Lw_8_2"></a><a id="Tc_k2k6fl3eEEeeIHMOgSimHg_8_5"></a><a id="Tc_jqIkIVRcf0quqcMEZIL_Cg_8_11"></a><a id="Tc_MyVpkZEKPEOGsvk_9TUuNg_9_0"></a><a id="Tc_Ai7A14eDLE2Qkhy1K4-bKA_9_2"></a><a id="Tc_lW9V5ZZoLUityqhzbYIYmw_9_5"></a><a id="Tc_-_xRaYQ2nkOoGnnZkuZhzA_9_8"></a><a id="Tc_LCXFup5XVkim4fK9bPjShA_10_0"></a><a id="Tc_i3MVKLb6jk62L4bg2NvTbA_10_4"></a><a id="Tc_4Yh-D_YQ7EW4RnaF7Cqnxg_10_7"></a><a id="Tc_AyCL1YFY8EOgk0JzQ3JBqg_10_10"></a><a id="Tc_wSNXIcbHJEemJCTqjsZErw_10_13"></a><a id="Tc_JNwIpNLhRUaDblHsO4GN5w_12_7"></a><a id="Tc_8a6k_Tvh9Umn-1F3gtXqWA_13_2"></a><a id="Tc_lwfB8CG3MEOnZF9RGP3ViQ_13_7"></a><a id="Tc_usur7cgmhkC1TOhKBzEVXA_13_10"></a><a id="Tc_fTs5smHrm0OBD6g6AU9Z1w_14_2"></a><a id="Tc_oQO6w6r8-06ETHbWpyrdIw_14_4"></a><a id="Tc_dPiX7pSUhUe30dJFNbe-UA_14_7"></a><a id="Tc_SXqawqKWrEKouyTo_ruUqg_14_10"></a><a id="Tc_WU16Qhs9A0m35YMVbF-U-A_14_13"></a><a id="Tc_7y-hywG1H0iNkWiHmzDVIQ_15_0"></a><a id="Tc_zfH8Og2bMkyXJj1C8E3WpQ_15_4"></a><a id="Tc_WUdYk_CUkUCfkswxN_RkBg_15_7"></a><a id="Tc_12Ytw49WjUC0RbfQhwfobA_15_10"></a><a id="Tc_MSiB1QxZgUCe9998758AzQ_15_13"></a><a id="Tc_1u559GWdZkiupHPu5EBqbw_16_0"></a><a id="Tc_Iadl3JtWekCETsAYy8HnGQ_16_11"></a><a id="Tc_DKLnr6FN4U2N7E7-09DBTQ_17_0"></a><a id="Tc_an9xyOv9XUKFuY_ezfckHA_17_2"></a><a id="Tc_XUh0axxy8UmUYlGevz2mkw_17_5"></a><a id="Tc_dpC8cty7AUujkeZr82nwhg_17_11"></a><a id="Tc_SZ9KRsACNkiu8Q0oNcipUw_18_0"></a><a id="Tc_wzIWm4gt-UakVzrhsF9J4A_18_2"></a><a id="Tc_RSD2_6B6LUmXeGrAV0tSfw_18_5"></a><a id="Tc_2oMvV5wgt0CNKeqT6a1CqA_18_11"></a><a id="Tc_MEWYEQmZF0iScja7BmZeYQ_19_0"></a><a id="Tc_iwSNp07-60awUKEx_ggOhw_19_5"></a><a id="Tc_U5undcf6TkaRqg8IiF4LFg_19_11"></a><a id="Tc_ACJXWBeqQEmbonQAW6IMQw_20_0"></a><a id="Tc_nYyxrUEHMEWNjkLA66J5sA_20_2"></a><a id="Tc_fxt6q0tCGkidX-YiBXK2HQ_20_5"></a><a id="Tc_G2DT0jd-IE-ZGKV9fYzFGA_20_8"></a><a id="Tc_ehIM6Du-TkSpdnkz15F1TQ_21_0"></a><a id="Tc_z5xqoL-5HEOAu712AkGayg_21_4"></a><a id="Tc_wMzQHh7xaU2yrtpvf2-KMQ_21_7"></a><a id="Tc_tW_hpT0w8kGD2GGgyu7wrw_21_10"></a><a id="Tc_Ep6pQpJFaEiozgYvl_2fQQ_21_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_TVku3ywrDUqG03p9usSRkw_4_2">1,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HaTAU02hM0O6ZWsOSf5CnA_4_5">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zYjQFfZEOk2XX8euLUmtMw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_s6jjjVsxvk64Whx48MCIbg_4_8">534,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_x1Uqp2p3T0mT8txSjrqjPg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4e3Xb6ufCkOhbytn0ZOjhQ_4_11">590,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rssXW_pXPEKUfxPONp-OxA_4_14">56,508</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of common shares, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JAHXTaO7WkO65OTNPeHiow" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_Q0skpKvPkU2uKA0DIouRvw_5_2">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JAHXTaO7WkO65OTNPeHiow" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_XY3eT6xxbEC8_jiQjz_YeA_5_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_gYKSOkCk606zg8uNrZnSdg_5_8">3,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_6F1loFMOYEGUa7_CZh5XCQ_5_14">3,709</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_dwqspjrGYka-gGbaEmykEw_6_8">3,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_1c0NOqO4FEyEIAL_xJotEw_6_14">3,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_p4-EVVrinEO7OGZwEA1dYw_7_8">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_O5wp-YkNpkqT-IGQ7yOPeA_7_14">224</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of pre-funded stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" scale="3" id="Tc_rubojnGGi0mB7QUgXRAEIQ_8_8">3,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" scale="3" id="Tc_v-U7yb_p80amio2xP9snVw_8_14">3,570</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BWpsZSV2f0yNufbJUffcOw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_htRKlPn9OUO2pkhd6bGYZQ_9_11">26,791</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_hp2qvvFVh0q8z2A-QOoKKw_9_14">26,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fGM3WlQIOkCMWEoncwc2Vw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_d9_tKbdD9kSXhLE_CsdCUQ_10_2">2,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fGM3WlQIOkCMWEoncwc2Vw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EpMvTVG6kkKpGO57H7Qj0g_10_5">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JZy4BCURekiYxiqHcge_Zw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2iSD650MUU-isRXi7tYuYQ_10_8">544,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kELM8qU0EkWCrI-UkaL8Ng" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7rkL1AJs1kOZt06uCNOmqA_10_11">617,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_imMOsm49pk25SJuovjqVOw_10_14">72,363</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid-in-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nwCEzZi7MUOLNYUtq0AhqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_5kqnn53Pb0qK-Q587rn1GA_15_2">3,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nwCEzZi7MUOLNYUtq0AhqQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__3-PPNOaeE6LXvIV80S_gg_15_5">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHjW0xYSkU2ePhegrPo-8A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YA0tEoWVtEiqmbAljxFfDw_15_8">557,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_10N7rnTIFU-ky4gxaDiVmg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_esPPD851_EaJnN9zbrbaRA_15_11">650,197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HHnb6Y4S10GnuAq_EmcELg_15_14">93,101</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of common shares, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_k-xb6n3GlEuzEYkvZF4K9A_16_2">2,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_cUZGFe7aRE6V8X6KrgGh5Q_16_5">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Qr8xZhy8D0y5HEMU7sH-hA_16_8">471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_o068Q1lUzkqrcC13yEIP3w_16_14">481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_FStI0W4O7EKWJpFSUiqJqg_17_8">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_d4slw6FoJUiXdAF-g7xRgw_17_14">180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of pre-funded stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" scale="3" id="Tc_2x30uDGRzEqeJPZKnr3Tlg_18_8">9,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" scale="3" id="Tc_jQZm5f_nm0e6I0pkyZKfnQ_18_14">9,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vesting of restricted stock units, net of employee tax obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="3" id="Tc_ZXfhlb9XnkSllCRoMzkTMg_19_2">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_HDQYc2VU90GEjKOxFbAAuQ_19_8">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_3pv0qyYnXEGinIxrVhNXjA_19_14">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pvRGjtD70kW6s3ZG9tjiZQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8-434SxgzkekhlgMoASdCw_20_11">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bHZSbHjFwESV0tG2U_4n-g_20_14">7,254</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of March 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7jkhG9xOeECCQCuuL2gEdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_qpaNYeAee0CyOEluIbyC7w_21_2">5,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7jkhG9xOeECCQCuuL2gEdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yTaFV6-ueESed8fQtx0Z8Q_21_5">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ev2K8DxaV0a9uKxJ00_XoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6KmkgtYbsEmodcgEZ97Ljw_21_8">567,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v4f9SlUsOUa4HdcmJWR1dQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xjMldEq5tEKw_UDctJgQEw_21_11">657,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Q-Q1P2l6Pk-fCd9TaG7oLg_21_14">90,172</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9587c877_48ba_4708_97c6_a9c46037edab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">BIOXCEL THERAPEUTICS,&#160;INC.</p><a id="STATEMENTSOFCASHFLOWS_929012"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_c42f751b_e921_4abf_948e_33e23a0a9bd2"></a><a id="Tc__uX1jwEm7UKrhhZe3l47mw_1_2"></a><a id="Tc_PXbfjjYMNUSWPsK0TJ6SKQ_2_2"></a><a id="Tc_rwt_Y8l4tUG-KjD4oV7gkA_2_5"></a><a id="Tc_7LyJ4MNAAUu749ybbSAWNA_3_0"></a><a id="Tc__nX9rSMO1kmHP0qzccIc4A_4_0"></a><a id="Tc_hzKGPYi6CEavJHyIdo6ItQ_4_2"></a><a id="Tc_3a2sdMf8w0W6QZvP3JO81Q_4_5"></a><a id="Tc_sfV8OP4BHEm72badkLUfcg_5_0"></a><a id="Tc_1MqgJUOETEO15HVjRzOu9w_6_0"></a><a id="Tc_s8Wf6cVvhUG1H3qtK0iysQ_7_0"></a><a id="Tc_yh3uYsjtyEO5lhNG6R0aXg_8_0"></a><a id="Tc_dpDmdQqfe0KxDmOrw56rNg_9_0"></a><a id="Tc_wGRQhm-IIE2jt8_mg3HVTA_10_0"></a><a id="Tc_R8NS-QJBmkWfx1meoJV1kA_11_0"></a><a id="Tc_k9z9Ja-jrEG-3Vpt_w5Urg_12_0"></a><a id="Tc_J98M5GSzRESv3qufhUxB0Q_13_0"></a><a id="Tc_Qoj2CqXSikmKjfxKiteEJQ_14_0"></a><a id="Tc_yF3Tu5uUv0KkTkn1KamIaQ_15_0"></a><a id="Tc_1DLL1HCl70-E5kyUgeXXKA_16_0"></a><a id="Tc_X2B8nQ-zR0SPZTSvib6R0w_17_0"></a><a id="Tc_CdgexwItWE-ttFGO8LEwtw_17_3"></a><a id="Tc_Pmd4OJbeNUCMQfTLxJ1r_A_18_0"></a><a id="Tc_9vMN0dUvn02Alq-rk956Ng_19_0"></a><a id="Tc_sCrespKblUqArwuipSaMbA_21_0"></a><a id="Tc_Mi1BTMGwskiT-KumJTouMQ_22_0"></a><a id="Tc_GN0YEztC3Eyq3rDAFZ9v-w_22_3"></a><a id="Tc_NAPhrVdHf0Cq4-pq8JbHDg_22_6"></a><a id="Tc_2cK1_phTakuJw-iYRR3sqw_23_0"></a><a id="Tc_LxzKxtvVVkCmqf1uTis0SQ_23_3"></a><a id="Tc_NI3ROK1MyEaMARbL34lKuQ_23_6"></a><a id="Tc_YmFFUQ--jEah1lhMsgoc-Q_25_0"></a><a id="Tc_ipaGj6QMAU2HDaN74fTQAA_26_0"></a><a id="Tc_7n5Dih8PnU2ODG2efw4xGg_27_0"></a><a id="Tc_fvuw2n5VrE6QyOTL94H5Eg_28_0"></a><a id="Tc_LIn48mTq2ES7ctBNSZdwKw_28_6"></a><a id="Tc_HPyNu8rktkCtFLbXR8QlPQ_29_0"></a><a id="Tc_dN2DBqY_z0Kkz8TJM6lwtw_31_0"></a><a id="Tc_kCXM2so4_kquzZIAeK3kkw_31_2"></a><a id="Tc_5h6HtG1FckWuMZkdfQL3ig_31_5"></a><a id="Tc_4pqgNa9RtE-__jP7wSEftg_32_0"></a><a id="Tc_huP9ehO5TUWZWhV6zKZtCw_33_0"></a><a id="Tc_OLFUFchxgUaQnKKFxo67-Q_33_2"></a><a id="Tc_0boI6kslEUK8zv3c_A7yyA_33_5"></a><a id="Tc_qFJU_MhWGEyrsSmlDvuR4Q_35_0"></a><a id="Tc_Z019oD7fxEC4fr3P9vqX6w_36_0"></a><a id="Tc_qcsCqASRz0SVOUrv0eUfog_36_2"></a><a id="Tc_COtO5v_F6Eq9fPXLnew6iQ_36_3"></a><a id="Tc_VkiNZbiwO0uzDqnwrdp7iQ_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc__hsh5T_8MEuEAC7jd5rfcw_4_3">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_28zsInTZbUm56TedMJk4ag_4_6">26,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reconciliation of net loss to net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_9PxNyn2bu0aLHMRTR_LkzQ_6_3">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_GqerzlI8G0aCFFH0t5gLcw_6_6">78</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_Pn_24HVvgkO5cMLUuoT-Eg_7_3">350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_Eq3tVeOuC0ap40Szj-QjWw_7_6">43</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in fair value of derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_z5uVzBvPy0WekLhsNlYkKA_8_3">6,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_TR67a-ZU3kikNR-ppjsnWQ_8_6">30</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gqvkWElcKk6iYPPDdIk94A_9_3">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Hazdtor4ZkWJ54peQZSQbw_9_6">3,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Payable-in-kind interest on Credit Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_wChajgkgK06l4ZycssWV8A_10_3">2,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_9_FYEB55HEOcGddgMSkW9w_10_6">1,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_0ofR3vVHdU-OwJjl7VsVZw_11_3">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_m5NYo-ly3kSvCYIuAF0vOQ_11_6">75</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">   Accounts receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_RJD9o-BIyUmLZrIBsr6vuA_13_3">131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_ARj6vv2CnUusdYsUqAKpJg_13_6">307</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_gpkcJsQXdUqLWfytQtBjGg_14_3">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_65Sy3DBmu0KUzxYMHfMnJw_14_6">448</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses, other current assets and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_OXt_CFlMEE2VLgzxNvWSZw_15_3">608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_N06ZirE7tUWLNa7bK9OPHQ_15_6">901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accounts payable, accrued expenses, due to related parties, and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_m_WxvdYfIEidXKnA2CTYRA_16_3">2,269</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_MYLHrlH87EioC5qkbvVGCQ_16_6">4,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInterestPayableNet" sign="-" scale="3" id="Tc_e9RWj5SQGU-M-IlqvgbMMA_17_6">619</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_QZ3i24hHxU-SX6yK7MVBjA_18_3">90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_uX_eco8BcEmwJ1mwgJhSQQ_18_6">83</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_87gn77u-sUWoT9YHPRgtJQ_19_3">12,043</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_VIKbdc6RUkeOWNpupiBmSA_19_6">17,706</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INVESTING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of equipment and leasehold improvements </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Tc_UlCYuE0jnEeorzpK1dTccw_26_3">14,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Tc_ob87L1D97kq5XErwuR61ig_26_6">26,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Offering costs for common stock and warrants issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_jSlyNVEyckiOoKugRsBNbg_27_3">803</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_NKqqnxg8xEyWX1zQvNMl5A_27_6">117</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payment of employee tax obligations related to vesting restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_VLdiwQx7GkCHJfqaF5OCGQ_28_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_TdwsSd3qu0atgjgo52Izfg_29_3">13,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_UBnYETnO4k6V8KTHUilaBQ_29_6">26,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_zoEdxoPaNkWfQTNj80J1KQ_31_3">1,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_ryFTv1NTu0azNgTzGkFWXw_31_6">8,920</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of the&#160;period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_UNt8P3memkS5tjWGx0Rnxw_32_3">29,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Np3MJU2XOUyeyAyB75Ii6w_32_6">65,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, end of the&#160;period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_tsQaEGSb6E2o-lucvY179w_33_3">31,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_2cRrhxBqdkS33_IVLSKu-w_33_6">74,141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_FQOmFq6-kk6afqUPSHMVOA_36_6">224</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4fa05723_49f5_4948_9f87_591908b9e1bd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS,&#160;INC.</p><a id="NOTESTOFINANCIALSTATEMENTS_349172"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts and where otherwise noted)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:NatureOfOperations" id="Tb_QKpiBihNwUWEomU_cTelLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#8217;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has proven its potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these condensed consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#8220;OnkosXcel&#8221; refers to BTI&#8217;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#160;(dexmedetomidine or &#8220;Dex&#8221;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#160;is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s most advanced neuroscience clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#239;ve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#8217;s principal office is in New Haven, Connecticut. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_XvkIWEFRIECovXReHQztDg" continuedAt="Tb_XvkIWEFRIECovXReHQztDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2. Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim condensed consolidated financial statements do not include all the information and notes required by Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) in the U.S. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2025, the results of its operations for the three ended March 31, 2025 and 2024 and its cash flows for the three months ended March 31, 2025 and 2024. The results for the three months ended March 31, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025, any other interim periods or any future year or period. The accompanying unaudited interim condensed consolidated financial statements of the Company should be read in </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_XvkIWEFRIECovXReHQztDg_cont1" continuedAt="Tb_XvkIWEFRIECovXReHQztDg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March&#160;28, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying condensed consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_k2sFvzopJ0StYyicaMInsw">31,013</ix:nonFraction> and an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_fpZrSxJqPE6itvqjTw5T5A">657,451</ix:nonFraction>. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_IR4YQXSQoUSiJjuX2uxF6w">7,254</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_j7HweqjjmEy-1PK4rCu_cA">26,791</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively, and had net cash used in operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_SZ4pSdvk10OOVBxrnApwBw">12,043</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_CxJMzn0QQk6wHnrkbn9ACQ">17,706</ix:nonFraction> for the three months ended March, 2025 and 2024, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement (as defined in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>), its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report on Form 10-Q. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">This going concern evaluation takes into consideration the potential mitigating effect of management&#8217;s Reprioritization (as defined in Note 4, <i style="font-style:italic;">Restructuring</i>). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#8217;s Board of Directors.&#160; The Company&#8217;s Reprioritization was approved by the&#160;Board of Directors on August 8, 2023; however, such plans, including the additional restructuring actions taken in the second and third quarters of 2024, will not mitigate the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>) or other potential sources of debt or equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other actions, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise funding through the sale of the Company&#8217;s equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise funding through third-party investments in or other strategic options for OnkosXcel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise funding through debt financing and/or restructuring of its existing Credit Agreement; </span></td></tr></table></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_XvkIWEFRIECovXReHQztDg_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish collaborations with potential marketing partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce overhead and headcount to focus on core priorities; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any combination of the foregoing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt;">If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_V88yNeFo3UKe0zTDkjYXww" continuedAt="Tb_V88yNeFo3UKe0zTDkjYXww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3. Summary of Significant Accounting Policies </p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:UseOfEstimates" id="Tb_EbWPiUw9i0yR8pZMzlMHUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been no material changes to the significant accounting policies previously disclosed in Note&#160;3 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2024.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_qc7rmp_GAUuykOWzcItPKw" continuedAt="Tb_qc7rmp_GAUuykOWzcItPKw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures beginning in the first quarter of fiscal year 2025. For additional information, see Note 17,&#160;<i style="font-style:italic;">Segment Information</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2024, the FASB issued ASU 2024-01, Compensation &#8211; Stock Compensation (Topic 718) &#8211; Scope application of profit interest and similar awards, which clarifies how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or if it is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. The adoption of this guidance did not have a significant impact on our financial statements, and the Company does not expect this guidance to have a material impact prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_V88yNeFo3UKe0zTDkjYXww_cont1"><ix:continuation id="Tb_qc7rmp_GAUuykOWzcItPKw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, Income statement-reporting comprehensive income-expense disaggregation disclosures, which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the effect of adopting this guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_fIyalb_42ky0c2Fl5nDYQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 4. Restructuring </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On May 8, 2024, the Company took actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. The Company reduced its workforce by approximately </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_5_8_2024_To_5_8_2024_FZp7GPdyrUG_vHhSf2SCHQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_xCA0EtwwhUWFXk6Ug091ZQ">15</ix:nonFraction>%</span><span style="background:#ffffff;"> and notified impacted employees on May 8, 2024. All related restructuring costs were paid in the second quarter of 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On September 17, 2024, the Company reduced its workforce by an additional </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_9_17_2024_To_9_17_2024_c8nGfcMfH0inkxdc7P07ZA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_G0ygoEtRS0SlG-DvPXAoIA">28</ix:nonFraction>%</span><span style="background:#ffffff;"> to extend its cash runway and prioritize clinical development of BXCL501. </span>The Company completed the Clinical Prioritization in October 2024, paid $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="3" id="Narr_zxSHi03phUyvr5v2MlI9cg">475</ix:nonFraction> of the related costs during the first quarter of 2025, and expects to pay approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="3" id="Narr_OpupRuwi7EKxoz5TEKruSA">128</ix:nonFraction>, the remaining costs, in the second quarter of 2025, which are included in Accrued Expenses on the Condensed Consolidated Balance at March 31, 2025.</p></ix:nonNumeric><a id="Tc_TvMtfIrD_UKBVzewQv-0IQ_1_2"></a><a id="Tc_awo0W-SdNE-_Xkm4mwsSqw_1_5"></a><a id="Tc_U_xLnWQDJ0aFG0-okyTQOQ_2_2"></a><a id="Tc_0H-j9khG3U-01XFr83zX3A_2_5"></a><a id="Tc_uGF1T26Jrku1FFV1XOroIA_4_0"></a><a id="Tc_cEa9HW4Gp02O3P2G1r3d7A_4_2"></a><a id="Tc_93SPHX-fPU6yRi8POzQ7Yw_4_5"></a><a id="Tc_IaRYUpwXqEiC65_rg7qcGg_5_0"></a><a id="Tc_NTZevW_XQUqhHPE-oi0cqw_5_3"></a><a id="Tc_uiNjw0vt-UuVhoMO12gbkg_5_6"></a><a id="Tc_yR08umsyNkaJs_h9mt0XLA_6_0"></a><a id="Tc_wVl8qVQvIE-dZcCO5BLTRw_7_0"></a><a id="Tc_Xdy-X7gXcEaYBHov-njGnw_7_2"></a><a id="Tc_rV5-q6v_dUy-gMNckXjDlw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_1VNM2pQxQ0-vpqRGB8ylGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Inventory consists of the following:</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_fNrUpF509EmLhtlgDFcfQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_Jax1uo4Ja0i-KA5eD9eaCA_4_3">464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_TVE56Lnb806QK9SBfsbsXA_4_6">506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_reVjJ22oAUu2GfHn07XaNg_6_3">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_0ORLjJA100uUVCSSgwMmBg_6_6">173</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_nA-YEIIbr0OqnaGJoZUuCg_7_3">642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Ec7WggKvVEm1XshUQh5i5g_7_6">679</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">The Company recorded inventory write-downs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_x_X-fbJCq02apQz6JEugHw">0</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> and </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" id="Narr_s9A_0jYASkWsyva0Qd5VKg">45</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> for the three months ended March 31, 2025 and 2024, respectively. </span></p></ix:nonNumeric><a id="Tc_lRP07UkgsESl5-NImvStiQ_1_2"></a><a id="Tc_zvRNn3DrKUyWBa03tI7rUg_1_5"></a><a id="Tc_NjM2XDNN1kaFZZ0eYge6PQ_2_2"></a><a id="Tc_AS1PbTFNf06G9-VCIQg_vw_2_5"></a><a id="Tc_RfsVhA0Su0qJiG75S-740g_4_0"></a><a id="Tc_IZ_P7QgXQEu-UXrmok40nw_4_2"></a><a id="Tc_N3lQ4laYo0Ov6qOeh1mKRw_4_5"></a><a id="Tc_lX_ZHxoPEkeGpVdiUamCow_5_0"></a><a id="Tc_6MsgXDdm6Ey6XZcsNzREiw_6_0"></a><a id="Tc_2Ur5AYaN4k-21-Kw9BNqaA_7_0"></a><a id="Tc_vNPThvvNkE2n0gs5vqjH-w_7_2"></a><a id="Tc_cYUsKGt38kmfFtqJvg-iEQ_7_5"></a><a id="Tc_V9wJC9TZ6UuvJQmVbxg2Uw_8_0"></a><a id="Tc_-bODLYiS_0msd0Oghjmv8Q_9_0"></a><a id="Tc_1AeFM5n-P0eB5viFJaaOfw_9_2"></a><a id="Tc_-b95_J5anUGIIXLwaO0jVA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_fHSWQ9KOsEuBixUxoSENRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment, net consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_G3Jon0HWSEiRwxHnxstD8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_P-yi1ob4hUyuvFlo5q8PKA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Vl0sNv-nZEyv-E1abjO6gA_4_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lMS_6iH8DUiU4QxSYfIVZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_V67unltS7EeTJ4ROhAogBw_4_6">202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_YzddE2_98UmIfS9DblB46w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Dtqaytnjhku4khxFDdcIJA_5_3">575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_i3zFP68HVkiSR0fcAIqY9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zgSPRF-F0EK6ELXIwmxvwQ_5_6">575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ExIBEjJWbUexxXRMxChHSQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_06JQ8hAsX0eSghWdqFA_Ng_6_3">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2PQahnIyZk-fOICX6AbWrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6mbVL-l6UUWFIS4JpZJVEw_6_6">1,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_m1j2m1BFtky3EWz5VfXFYA_7_3">1,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_1HpcbyJ-yE2QmmigIZl5eg_7_6">1,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_59A1ZxHpfEuscbe77tUsJA_8_3">1,578</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_U_Xdq9p2dEW9bV_x8DCGQg_8_6">1,502</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_10lvV1EszkWDRNXYjFkT7Q_9_3">399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_EDbD5zEsa0qsdtI8vw2sWA_9_6">475</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Narr_YE9vVST5z06q0AZadlJL2A">76</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Narr_JJ18TKyzAUGFqEgGUaWLdg">78</ix:nonFraction><span style="white-space:pre-wrap;"> for the three months ended March 31, 2025 and 2024, respectively.  </span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_qDwY1NSGwkWEFcnAZR58LA_1_2"></a><a id="Tc_HsDYw0sACkCnhkZ7YGjTzg_1_5"></a><a id="Tc_Bb-E2ndCv0O_Kjjo-dEWlw_3_0"></a><a id="Tc_pjhd_qkgV0SkFnkb3478mw_3_2"></a><a id="Tc_4D7MVGzoN0KFv4cv_eNQKQ_3_5"></a><a id="Tc_fHpGWd85FkiT_4z4AySVHQ_4_0"></a><a id="Tc_-DtH0PhPt0-QPiEIEWxoGg_5_0"></a><a id="Tc_NjQwjNxz1kikhGt8omULmw_6_0"></a><a id="Tc_j0Eyhq6N3Eml_VJhU9_sRQ_7_0"></a><a id="Tc_1H-0oEF1wUym3Vg4qVHjFg_8_0"></a><a id="Tc_QjlQ5_Vnu0OxDTggt11R_A_9_0"></a><a id="Tc_b4WUHwQZQUK38Ztle8HVRQ_9_2"></a><a id="Tc_yIEmLXkOH0WscBk0MxK6DQ_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_m5yR8PzQ9k6e4j9RPxF5Sw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_gctuQFYE80G-sbMARVNKmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="btai:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_Z5ESN5GuJEycXAN6noBRRQ_3_3">2,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="btai:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_lk3_VuR-1Uu-v1QcMZsdzw_3_6">3,107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_m5M_sFXLh0KifYMCUGcQgQ_4_3">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_gMPJeEI_H0aaLT2FM7C1CQ_4_6">35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_Rfcnz5MiRECwLXdU-wuQRw_5_3">1,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_M6mh63iSvUerFETtAbilCA_5_6">1,604</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_LLvKu83rdEu8VWdYlkZYgQ_6_3">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_S9VfD9-H60SAw4Kak49QBw_6_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc__J7IAcaogUCVgzWft3InKQ_7_3">423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_6Ftd1Z78zUGQQdI-xERHDw_7_6">322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="3" id="Tc_oGxJfPhMxkqh2XdZGKoYow_8_3">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveCurrent" scale="3" id="Tc_FEhyLbHm8EWZFdf76-9q0Q_8_6">603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_bQOjifLnEU2DIhHk-4h-Sg_9_3">3,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_dKjnAwleYkuMwCNedF8LCg_9_6">5,762</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_UWqmYafECUS4mFtZTVqAng_1_2"></a><a id="Tc_QrINpONQoEmIPHm-xH8i6Q_2_2"></a><a id="Tc_uJiFnzWszUqNkcd2CTSRhw_2_5"></a><a id="Tc_1VeZIsFq_kW_cnD9d8qM0w_4_0"></a><a id="Tc_O5vn4cmkJESjbsB5AdmWnA_4_2"></a><a id="Tc_ZxjL7pNEsU6w4AzBlaZr-A_4_5"></a><a id="Tc_3RedOlxUt0-R1OXMn6UD_w_5_0"></a><a id="Tc_BNbUHwzV-k-vPO2Hlyxh6A_6_0"></a><a id="Tc_dGNh9470A0aqXXi6F-YocQ_6_2"></a><a id="Tc_WUTqUyk1ukGkym_o5lJeYw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_2Z25b_qQsEGkR9cB5av9Hw" continuedAt="Tb_2Z25b_qQsEGkR9cB5av9Hw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8. Transactions with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which BioXcel LLC has agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Services Agreement, the Company had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. The Company agreed to pay BioXcel LLC $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TM9ElQRCBUSIjpJ3xXkJVA" decimals="-3" format="ixt:num-dot-decimal" name="btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" scale="3" id="Narr_b8PaEwpQZkezcHfO80YscA">18</ix:nonFraction> per month from March 13, 2023 to December 31, 2024 in exchange for this option. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the original contract. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_Fkdg6L1osUqn8ergQvAGeA" decimals="-3" format="ixt:num-dot-decimal" name="btai:CollaborativeArrangementMilestonePaymentsPotential" scale="3" id="Narr_kLmhGMbgtUyd0_8e6pBwxQ">10,000</ix:nonFraction> in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_hZBCN15vmkq8K-1LPWLUKg" decimals="2" format="ixt:num-dot-decimal" name="btai:CollaborativeArrangementMilestonePotentialPercent" scale="-2" id="Narr_w3uXHUhZaEqA-pYX9paT3A">3</ix:nonFraction>% of the applicable net sales level, and not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_hZBCN15vmkq8K-1LPWLUKg" decimals="-3" format="ixt:num-dot-decimal" name="btai:CollaborativeArrangementMilestonePaymentsPotential" scale="3" id="Narr_-BqdsHKOakmkBw4M4ESfNA">30,000</ix:nonFraction> in the aggregate. The Company did not exercise its option to renew the agreement for product identification and related services utilizing BioXcel LLC&#8217;s EvolverAI. Subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement for the three months ended March 31, 2025 and 2024, respectively were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_cAIYV4gsg0q9TD5XNV16Fg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Xf7eyBrRI0uZq9Wjw7M0IA_4_3">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_v4artByUh0eHg3w2HNCZMg_4_6">186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_aZm7WAyr4EGT2PVUe0gaPg_5_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_nG6Y-Qdya0OGeVCUjHtRUw_5_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_WXbfoIsVqUqq_RCRt6eg-Q_6_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_yIoL3gyKbE-xipN1ifobdg_6_6">234</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, there were <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iLcqzUZ0Ck-Z78lS626m2g" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Narr_PVbJO_fkVku13w4GvjM9Ng">no</ix:nonFraction> outstanding service charges related to the Services Agreement included in Due to related parties in the Company&#8217;s Condensed Consolidated Balance Sheets.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2Z25b_qQsEGkR9cB5av9Hw_cont1"></ix:continuation><a id="Tc_0kQ0GCiSBUWS_2cQD0PD8w_1_2"></a><a id="Tc_IKL36tjVMEufYmVAuGNQ0A_1_5"></a><a id="Tc_FBlJc-n-CUKyq_IOZS8bXA_3_0"></a><a id="Tc_WYtX-GVZn06_rnPf5KrD3w_3_2"></a><a id="Tc_TLmHKdkJcUyX2LRv9oYNIA_3_5"></a><a id="Tc_Aa7kM_moMEqMFBfJQX1-dQ_4_0"></a><a id="Tc_ubeSDcGaF0CBG-popbjsOg_5_0"></a><a id="Tc_eKP2eXG_B0y5e0VItCjxwg_5_2"></a><a id="Tc_qp76OTktFkGQPt0s8OhcYA_5_5"></a><a id="Tc_nFqYRlZ_k0q4_nbHHlgxtQ_6_0"></a><a id="Tc_1b7F-fdwCEOGuzVgvOiupg_7_0"></a><a id="Tc_KAKlmCY4VkChOwQqg1IYaw_7_2"></a><a id="Tc_TPhyCW0nHkm8NnRR4Q1LHg_7_5"></a><a id="Tc_mdl_DLc-mUSIibFrZwa4wQ_8_0"></a><a id="Tc_fRlkrrvfz02XVwwbTVsAZA_8_6"></a><a id="Tc_I2MrPiC6LUGSKFGKgymiJw_9_0"></a><a id="Tc_DqdQ3gKuQU6SbuImSnddBA_9_2"></a><a id="Tc_htKevvq82Ea6O8ItMEexeg_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_JYnfHra8vkyWm71oFneiAg" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 9. Debt and Credit Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Debt, net of unamortized discounts and financing costs, consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_ERBliN8vpk-f27_dI9q1yQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_AZvD0YliGUCIn_fhYNTOyg_3_3">102,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zFMC5T7CfU-D5CYy3DpF5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_xP94nh4mc0Su6G4P7eHoBw_3_6">102,319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" id="Tc_OrJaxA6Fk0ivHxEVgAcPaA_4_3">7,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_I6j_31dAZkOaSKH03J-dWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" id="Tc_2EjHfkzMSUuIrhRdq1-4pw_4_6">4,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_ro16ndM-eECS_bxPC-YRbw_5_3">109,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_vZcflGXuw0mykEzUPesHeQ_5_6">106,722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_WEMePayZsU6dStd8zwwIOA_6_3">3,865</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_zOgunhuDcUSye26AgSHIQg_6_6">4,214</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_YSVE0wq3JEaHMhsQyjoNjg_7_3">105,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_xkhhu5xsBkOXa4066pOsVQ_7_6">102,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_nEgu4BEdK0mxBtUVL4pi_w_8_3">5,608</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_SO7nwWwPd0qIvfZZYb-pyw_9_3">99,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_dr1AKYxN1UGpZsmfu1c9Jw_9_6">102,508</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#8220;RIFA&#8221;; and together with the Credit Agreement, the &#8220;OFA Facilities&#8221;) by and among the Company, the purchasers party thereto (the &#8220;Purchasers&#8221;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_V2aVxdPV1EugrUHgH1ieUQ">260,000</ix:nonFraction> in gross funding to support the Company&#8217;s commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#8217;s disease, and for general corporate purposes. The Lenders and Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and First Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_ET_JSuZ2nUizs3bQGwP0Mw">30,000</ix:nonFraction> at any time outstanding in OnkosXcel, increased from $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3EM8qIytm0Ke9WUqaxD5ng" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_bDp4fo_XlEientrmNrO6eA">25,000</ix:nonFraction> at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#8217;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="Narr_m4X6QITRAE6X8iC3QSqpfQ">180</ix:nonFraction> (representing <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jAx_EojGEketsDRJCeRRzw" decimals="4" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityAmendmentFeePercentage" scale="-2" id="Narr_CIufEuGEtkKJWKLXvT6BFA">0.25</ix:nonFraction>% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jAx_EojGEketsDRJCeRRzw" decimals="4" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityExitFeePercentage" scale="-2" id="Narr_p2OsbnxaXk292yJAtIxLkQ">0.25</ix:nonFraction>% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.26;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On December 5, 2023, (the &#8220;Second Amendment Effective Date&#8221;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qwP76czkUUiKqJXva8OQCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_jW01q8c3hEyis4xvIJxB_A">202,319</ix:nonFraction> in senior secured term loans, including the initial Tranche A of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7HNwLTU3EyiG-P0bxBDiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_73XUK6M3hkmVy6tNk7SgGw">70,000</ix:nonFraction>, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zeDII7Hjq0G2YU6LERXHGQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Narr_hQByeHFNcUW7_p8qTUxo7Q">72,319</ix:nonFraction>. In addition, the $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qVwLBWQhP0C7ghgBC6SW2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Narr_IyWbm0-zGESKBrI2vSo1uA">30,000</ix:nonFraction> in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qwP76czkUUiKqJXva8OQCg" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_hX6qKVqeK0e-AY3wjBFVrg">30,865</ix:nonFraction> at any time outstanding in OnkosXcel, increased from $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA" decimals="-3" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_TbIbM7g0PEKbSe3Hy-Qirw">30,000</ix:nonFraction>. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tKgYE7x10U2ucISeOhEC6w" decimals="4" format="ixt:num-dot-decimal" name="btai:LineOfCreditFacilityExitFeePercentage" scale="-2" id="Narr_wPjvOYiLeEyBbYZZagRUFw">0.25</ix:nonFraction>% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont1" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First Amendment). As of March 31, 2025, $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="3" id="Narr_-IXiJ2AID0a5M81rdGMG8w">80,000</ix:nonFraction> in commitments under the Credit Agreement remains unfunded. The blended effective interest rate on the Tranches A-1 and A-2 as of March 31, 2025 was approximately <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_bBxEvuxxsEWgFITA28122A">15.3</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The remaining tranches may be borrowed at the Company&#8217;s option subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__iSlOGcFMUmoZ6cGWFMGPA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_y8HwnHvl80GxoDP0pP_V4Q">20,000</ix:nonFraction> and is available upon satisfaction of certain conditions and financial milestones. Tranche B expired on December 31, 2024. Tranche C of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cVbjkTPdU0mE_eF3eSJOLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_gb1QCMBKYkOq8WWX3IHdpg">30,000</ix:nonFraction> and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kHi1rm9DF0qHlbl4VlnXNQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_4BaRUrMM1EWxezUYTuWq1Q">50,000</ix:nonFraction> and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025. As of March 31, 2025, Tranches C and D, totaling $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="3" id="Narr_4LC0LAVYF0-O3ckB-KrX4Q">80,000</ix:nonFraction>, remain available for borrowing if the milestones above are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw" decimals="4" format="ixt:num-dot-decimal" name="btai:DebtInstrumentInterestRateDiscountRatePercentage" scale="-4" id="Narr_qmhxTzqyIEOGkbCT21lweA">200</ix:nonFraction></span><span style="font-size:10pt;">-basis point original issue discount and bear interest at a variable annual rate of TERM </span><span style="-sec-ix-hidden:Hidden_buvaqAws5kSR-ouHGNXICQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> (but not less than </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_S352yBVXFEqz_Y-5P-1a6A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_6F9KP-sYZUqTYrUXhnK2zg">2.5</ix:nonFraction>%</span><span style="font-size:10pt;"> or more than </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_yclrnHVBYEmASqLsg1GLwQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_wifQrJ1x50yiFWhy9O3Mqg">5.5</ix:nonFraction>%</span><span style="font-size:10pt;">) plus </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw" decimals="3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentIncrementalOnVariableRatePercent" scale="-2" id="Narr_w1CE-yFx6UqRFtZ7tqiLVA">7.5</ix:nonFraction>%</span><span style="font-size:10pt;">, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_SSD-lVaNm0i_gSF3npZAOQ" decimals="2" format="ixt:num-dot-decimal" name="btai:PaidInKindInterestPercentage" scale="-2" id="Narr_pnSgZqb4WEu8OUdPcPvX2w">8</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum is, at the Company&#8217;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through</span> <span style="font-size:10pt;">March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw" decimals="4" format="ixt:num-dot-decimal" name="btai:TickingFeesPercentage" scale="-2" id="Narr_kMFRxwfmqUeHlvAvvstGVQ">0.75</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s obligations under the Credit Agreement are guaranteed by BTI&#8217;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#8217;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) a pledge of all of the equity interests of all of the Company&#8217;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#8217; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_SF0bSfVFl0CNeni6znFtWA">15,000</ix:nonFraction>, (b) from and after the funding of the Tranche B loans, $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_CsZ-KkxpOUakCJAE_KixSw" decimals="-3" format="ixt:num-dot-decimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_DAVXDX_iKkyEkhspJkDgrA">20,000</ix:nonFraction>, and (c) from and after the Company&#8217;s satisfaction of the funding conditions for the Tranche C loans, $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_5oKzEf9LG0ObCnvYEfaywQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_bpyB-7FBKkeKRTaXfuRrvA">15,000</ix:nonFraction>, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_jPbckXWC80KwAJknjNhaoA">37,500</ix:nonFraction>), provided that the minimum liquidity amount will in no event exceed <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_52So6KoOMEungxS0l0MsEA" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfOutstandingLoan" scale="-2" id="Narr_J4YK9eBxBUWSRKOOFHq8pg">50</ix:nonFraction>% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#8217;s fiscal quarter ending on December 31, 2024 (such six-month period the &#8220;Revenue Covenant Measurement Period&#8221;), that requires it and its subsidiaries&#8217; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#8220;Revenue Covenant Measurement Testing Date&#8221; and the covenant described in this clause (ii) the &#8220;Revenue Covenant&#8221;). The Company&#8217;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#8217;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont2" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">minimum required revenue amount and the Company&#8217;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#8220;Employee Holdings&#8221;), a subsidiary of BTI, and their respective subsidiaries, the &#8220;BXCL701 Subsidiaries&#8221;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#8217;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#8217;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events, including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ" decimals="2" format="ixt:num-dot-decimal" name="btai:SubsidiaryOwnershipPercentage" scale="-2" id="Narr_SSyREBTQF0m1Zj1Z2EZ6gw">20</ix:nonFraction>% of the equity interests in the BXCL701 Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#8217;s secured creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and Third and Fourth Amendments to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#8217;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7PXdMmavEKzCaO6o0HcTg" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_o65q4EVkHUWEMoiTSnFWag">40,000</ix:nonFraction></span><span style="background:#ffffff;"> in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants</span> on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 20, 2024 (the &#8220;Effective Date&#8221;), the Company entered into the Fourth Amendment to the Credit Agreement and Guaranty (the &#8220;Fourth Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Fourth Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to the Company&#8217;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#8217;s independent registered public accounting firm&#8217;s report contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fJEBahyH2E68UBP6QHFHZA" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_xQq-4k3TQUGHQPYO0un8dg">25,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_z_B4NyRt4UaSWstx_7Z1Cw">50,000</ix:nonFraction> (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont3" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kzDv9FgG30O_Q6Inae8txA" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="0" id="Narr_B-jLIeVb-Ei4utDPb3Mttw">40,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_J81r1ZkU4U-0Pa_Y2zZH7g" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="0" id="Narr_FSCwh_6mukWRp_mmDiEVSg">25,000</ix:nonFraction> from $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_OFejCh9UM0ObmQn7f9J2Fw" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="0" id="Narr_MC0dnrCUSUqMAkCpfsUXuQ">15,000</ix:nonFraction>, unless and until the Company has received, after the Effective Date and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_9Ej2eOK9TESD_olNitC7Ug">50,000</ix:nonFraction><span style="white-space:pre-wrap;"> in gross proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.  On March 27, 2024, the Company received </span>$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_27_2024_To_3_27_2024_jrj6VftXi0yzxC3W-d_BuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_2QBSF2C8O0SB704xhD0YnA">25,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants, and pre-funded warrants discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, satisfying the April 15, 2024 covenant requirement of the Fourth Amendment. During the third quarter of 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr_v_YbOHNsdUCs5oWI64z4MQ">467</ix:nonFraction><span style="white-space:pre-wrap;"> of gross proceeds from the issuance of the Company&#8217;s common stock.  As of September 30, 2024, the Company had satisfied </span>$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_n63wG0rDMESvLjt0bxfqkg">30,943</ix:nonFraction> of the $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T63fAxu4W0KEPABUzNyrnA" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_5v5IVqqinEuzPg7cp02K4A">40,000</ix:nonFraction> required to maintain the Minimum Liquidity Amount and the $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3m8_BPw0G0OPp__QShJQ-g" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_WTg5Pj--cEOOBS30qKr5ZQ">50,000</ix:nonFraction><span style="white-space:pre-wrap;"> gross proceeds requirement.  As a result, at September 30, 2024, the Minimum Liquidity Amount increased to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_JLDCcgEkekCF-MtISKefUg">25,000</ix:nonFraction>. As of March 31, 2025, we were in compliance with all restrictive and financial covenants under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Waiver and Fifth Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#8220;Fifth Amendment&#8221;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2024, and the Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024 (the &#8220;Fourth Amendment&#8221;), the &#8220;Existing Credit Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_E6Gd8VExjUqWXAtvs3bd6g">50,000</ix:nonFraction> in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fifth Amendment includes a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eKfoQwlPkUyNgcgidh5-dA" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_-1ZZiGFMbkaRH9F35F1X5Q">7,000</ix:nonFraction> in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hgzEHqmylEubMQ6IsaLqbg" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_kXhnf__9UkO5n3cAaidwpQ">18,000</ix:nonFraction> in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont4" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_TgEuBFjXIkKWUIDM6bWI0w" decimals="-3" format="ixt:num-dot-decimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_TDjncDpiwkmKbN-mD0tTgw">29,000</ix:nonFraction> in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_j4lmqYFO50Sd2zbIjyRJlg" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_eBFj_rBtX0OWD-TXiZ3r_Q">7,500</ix:nonFraction> (instead of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_VHV8Q0yfikOv6dYy4wL6Cg" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_sxd7HZpfzUCcG9kZ4KrJug">25,000</ix:nonFraction>) from and after the closing of Raise 1until March 30, 2025. On March 31, 2025, the minimum liquidity amount increased to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_gtTfRBkLIUCQ1ZyESr-Bhw" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_Nolqq53EaEe8E09GSis57w">10,000</ix:nonFraction> and on September 30, 2025, the minimum liquidity amount will further increase to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eeKV4-Us0k-PErQbocl43A" decimals="-3" format="ixt:num-dot-decimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_-htMwCZ7q0WC_ASww4BObg">15,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Narr_gQJcacuNkEmJOiNwGJKsmQ">2,500</ix:nonFraction> principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The Fifth Amendment also modifies the interest rate of the loans provided under the Credit Agreement from a floating rate of Term </span><span style="-sec-ix-hidden:Hidden_OkIKnOdDH0OalG3pChCxZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> plus </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_c6HixluuLkGvNf2UfVTc_Q">7.50</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum, to a fixed rate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_bbbkIzsXpkmOj02U5piNIA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Lh_AyaxMiEeBrKxQffT1eg">13</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates ending December 31, 2024, March 31, 2025, and June 30, 2025, the Company will have the ability to make interest payments of up to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_bbbkIzsXpkmOj02U5piNIA" decimals="INF" format="ixt:num-dot-decimal" name="btai:PaidInKindInterestPercentage" scale="-2" id="Narr_vSyh34LLbEWYfui8aS-8Ng">10</ix:nonFraction>%</span><span style="font-size:10pt;"> per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement. In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw" decimals="INF" format="ixt:num-dot-decimal" name="btai:DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" scale="-2" id="Narr_koO1iwrsLEOuwkC_29BAhw">5.0</ix:nonFraction>%</span><span style="font-size:10pt;"> of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fifth Amendment amends the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company (including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw" decimals="INF" format="ixt:num-dot-decimal" name="btai:MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" scale="-2" id="Narr_EnJWHrZps0Sk--_NRmLoyg">115</ix:nonFraction>% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses for its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024. </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont5" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Sixth Amendment to Credit Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March 4, 2025, the Company entered into the Sixth Amendment to our Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which the Lenders agreed to, among other things, delay the date on which the Company is required to engage an investment banker (which date has been subsequently extended to July 31, 2025).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants and Equity Investment Right</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_Nusdrt7Ky0-Jp1IGc0j19w">17</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_AOKQtlv1Xk-o_rO30uAP-A">320.64</ix:nonFraction> per share (the &#8220;Closing Date Warrants&#8221;). Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Closing Date Warrants&#8221;), the exercise price of the Closing Date Warrants has been reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Akd-DquezkiuvIusVVXpnQ">58.3232</ix:nonFraction> per share. In addition, the Company granted new warrants to the Lenders to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_QquPmgzRZ0WYBnul_osNTA">4</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_oJYH5zuHH0-3Pa_HIIGXtg">58.3232</ix:nonFraction> per share (the &#8220;2023 Warrants&#8221;<span style="font-size:12pt;"> </span>and together with the Amended and Restated Closing Date Warrants, the &#8220;Warrants&#8221;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holders election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#8217;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:RightToPurchaseStockLenders" scale="3" id="Narr_OprJj3f0sUCdvt5hHOfKdQ">5,000</ix:nonFraction> at a price per share equal to a <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_5K0sWmEJwUa7Vv6SUtp_GQ" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_2_MAwfm9JUq2H7s3kaURGg">10</ix:nonFraction>% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). BTI entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of the Company&#8217;s common stock issuable under the Warrants (including the Closing Date Warrants and the 2023 Warrants) and Lenders&#8217; Equity Investment Right was <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_g5MICnEV20aws4tbDts1AA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="3" id="Narr_JZ9Q_7Ro8EyUGthnFBllrQ">366</ix:nonFraction> as of March 31, 2024.<span style="font-size:12pt;"> </span>On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_-MNoZx_CEkKH3_W0xnLgvA">175</ix:nonFraction> individual limited liability company units (which number of units is not in thousands; referred to herein as the &#8220;OnkosXcel Warrants&#8221;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_dKzcGfRdiUy_hEPb2RjynQ">20,000</ix:nonFraction>. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_3sv8vxzenUW6PdJZUvcUlA">20,000</ix:nonFraction> to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_Avv9JhWcE0GV7KpzysOfNg">10</ix:nonFraction>% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfFairValueConsiderationToBePaid" scale="-2" id="Narr_CvoxaBiyVEqXIbeW6BnQHA">75</ix:nonFraction>% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfValuationApplicableToInitialProfits" scale="-2" id="Narr_gnlivZrOeEeKhf6qXZEHFQ">150</ix:nonFraction>% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the closing of the Fourth Amendment discussed below, the Company granted new warrants to the Lenders to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_Ugub2pdp5Ee8MPrlzMC2lA">6</ix:nonFraction> shares of its common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_hD1vILFM802rzqkBjHPU9g">49.1568</ix:nonFraction> per share (the &#8220;2024 Warrants&#8221;), which represents a <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_PoDngmaLSkWSK6VPUhLyWQ" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_KxRdtqfqmke7jupw6zAbAA">10</ix:nonFraction>% premium over the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont6" continuedAt="Tb_JYnfHra8vkyWm71oFneiAg_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Fifth Amendment Warrants, Registration Rights Agreement and Equity Investment Right Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:RightToPurchaseStockLenders" scale="3" id="Narr_sCLIQ9CdckCNwS0KkeZwcQ">5,000</ix:nonFraction> at a price per share equal to a <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_5K0sWmEJwUa7Vv6SUtp_GQ" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_eE_PrTU1eUS5efOi6QktMg">10</ix:nonFraction>% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). The Equity investment Right was terminated as part of the Fifth Amendment. We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#8220;Amended and Restated Registration Rights Agreement&#8221;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Closing Date Warrants, 2023 Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Closing Date Warrants, the 2023 Warrants and the Lenders&#8217; Equity Investment Right was <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="3" id="Narr_CpRuAXCYekKVbzwA6x8LAA">366</ix:nonFraction>. On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_Yf24vsh8ZkS80_4LySKjIg">313</ix:nonFraction> shares of common stock on the closing date of the Fifth Amendment, at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_yKrzdEKZgUatg-09xo3Z3g">0.16</ix:nonFraction> per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_Wz5TY_agyEaaN18D5dyCEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_ZO0kQzz9ok6uuapq4qeHcw">28</ix:nonFraction> shares of common stock of the Company, and the exercise prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_PQoFYQ0to0Scq1RsRvTCaA">58.3232</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_rB45BgqP4kWt0-Sf4Gcb4g">49.1568</ix:nonFraction> per share were reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_Wz5TY_agyEaaN18D5dyCEg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_oyAeXy_HekuIpN92EgRlWw">7.68</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the date of issuance of the New Warrants, the Company agreed to amend and restate its Second Amended and Restated Registration Rights Agreement with the Lenders, dated March 20, 2024. Pursuant to such amendment and restatement (the &#8220;Third Amended and Restated Registration Rights Agreement&#8221;), the Company will agree to register the shares of common stock issuable under the New Warrants, in addition to all Original Warrants, for resale. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_1-OnY9QwIU-2I3qgq5l0Bw">175</ix:nonFraction> individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_k_fjrhKA1UaomHWjHiHy1w">20,000</ix:nonFraction>. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_j553MuLZOUmRRl-dZTxihA">20,000</ix:nonFraction> to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg" decimals="2" format="ixt:num-dot-decimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_ETLqvgzK3Umj_LTiOJ2Etg">10</ix:nonFraction>% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfFairValueConsiderationToBePaid" scale="-2" id="Narr_FdieiwjGxU-uKrt2x7GSfA">75</ix:nonFraction>% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg" decimals="2" format="ixt:num-dot-decimal" name="btai:PercentageOfValuationApplicableToInitialProfits" scale="-2" id="Narr_bDadVCSPA0aM3mKgCk1Tgw">150</ix:nonFraction>% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_BBVoJfS5NkacjgXWtNn5Bg_1_2"></a><a id="Tc_kyLgS-Q_SkKZqctA23k_zQ_3_0"></a><a id="Tc_jCAImYoO0U231LlImPkYxg_3_2"></a><a id="Tc_wwsxqzR180a6NOChgnQJ_g_3_3"></a><a id="Tc_3uPyMIfuC0O2_6NUu0KkKQ_4_0"></a><a id="Tc_XRQ8jt_kIk23_27EBDoZ4A_4_2"></a><a id="Tc_9VCLAvPo2ECx-1jNr6MVKA_5_0"></a><a id="Tc_ClVxyXkbfkSk_ayFZ12lWg_5_2"></a><a id="Tc_b9Lmj_3Pz0On2vq7bCkE6w_6_0"></a><a id="Tc_80uIIRcbTUO-Tf15doJxnQ_6_2"></a><a id="Tc__UIiGnje6kKZ9epwTJr8XA_6_3"></a><a id="Tc_Ml-7Kvdy80yadBCxuFAYpg_1_2"></a><a id="Tc_1PejD_edmk6xPC1lY8wRig_2_2"></a><a id="Tc_h4-8nboEp02JUky0btWdyg_3_2"></a><a id="Tc_IbI_VO0E-U2asI866swm6g_3_5"></a><a id="Tc_HLfKYQjqUk-iKmofgvbV9w_5_0"></a><a id="Tc_p8GNIUQJekms5hmphN1DQQ_5_2"></a><a id="Tc_Kk5qeIZ5EECZ-08aptQOeA_5_5"></a><a id="Tc_P1w2RIsU2Emizini4k-T9w_6_0"></a><a id="Tc__SGXVCgaY0W4mb_j3-NaZw_7_0"></a><a id="Tc_i71Gg8N3pk-nxQNd2oLCiA_7_2"></a><a id="Tc_SxDJCvJeU0-tQufAdRb_oQ_7_5"></a><ix:continuation id="Tb_JYnfHra8vkyWm71oFneiAg_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Maturities of debt are expected to be as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_VYXA8rwQ-USsiGrhCGQlsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_p4FaSRK9e0Wt7iI3diAyUQ_4_3">22,431</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_92GG_V2XEE2SkCplrImyww_5_3">86,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" id="Tb_h3S_A-f9c0SdGHhFphqidA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_k39CFQXGu06A3g6A-Zi7qQ_5_3">3,643</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_ERNFZlsspk2FJlmcZxp_2Q_5_6">3,564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_-UqVi4ZVdEK114UbWmabkA_6_3">350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_7iWeBUQ4ekyIJpdwiU5yHQ_6_6">43</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_3SbvQfPwokafItwjzQFKWg_7_3">3,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_SuYnewcyBUOGdYIfCcLgsg_7_6">3,607</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Tb_0xsm2UKLIkmdDealGReivQ" continuedAt="Tb_0xsm2UKLIkmdDealGReivQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 10. Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options. The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#8217;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheets. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement, and the Company recorded a termination gain, reducing the carrying value of the Equity Investment Right to $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_G6llnlti5k20g5RAYF9w8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_7oR53ca7d0SBfcMF6jJ9fA">0</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">With respect to the Purchase Agreement discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, BTI determined that the Accompanying Warrants fail the equity classification criteria and are therefore classified as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. We value the Accompanying Warrants using the Black-Scholes option pricing model as discussed in Note 14, <i style="font-style:italic;">Fair value measurements</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 21, 2024, the exercise price of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_eSxn4MEvbkq34vrvkL54Cw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_7wRr52jYpkuQs2or4qT5aA">534</ix:nonFraction>&#160;of the Accompanying Warrants was reduced from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JbvOkxvjdkmJ6LmN2Rd0Jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0OHkElaKcUermWCCfB8xbA">51.20</ix:nonFraction>&#160;to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_W4qAVPHELES2fLUz4KcqKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_jZ1UbKdZJEml7DLgaSdrHw">9.136</ix:nonFraction>&#160;per share. For the three months ended March 31, 2025, the Company recorded total net gains of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_RvkyKbPjBEK4lRpESDkZxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_AFBIEoo0SkCe4YGqvraByA">1,679</ix:nonFraction> in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the Accompanying Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_QLIVwjVCD0quI55_NwdJQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_2GaAJ78U002gCMntORvf9g">641</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 25, 2024, with respect to the Underwriter Agreement discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, the Company issued additional warrants (the &#8220;November 2024 Accompanying Warrants&#8221;). The November 2024 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_0xsm2UKLIkmdDealGReivQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. For the three months ended March 31, 2025, the Company recorded total net gains of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_Cn5-JcfDR0qcNSKrdqLIBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_tfPdn6qzLE6BJNNpZtYCNQ">3,080</ix:nonFraction>&#160;in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the November 2024 Accompanying Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_k-Kye-ecsEGNgr32jEq1GA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_aTPZrSF9vUmwJtX-vVhQog">1,193</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On March 3, 2025, with respect to the March 2025 Offering discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, the Company issued additional warrants (the &#8220;March 2025 Accompanying Warrants&#8221;). The March 2025 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_dwaRvaALY0OiHiyuF7H6Aw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_oXx_FqVL_0WbvQSri4KITA">2,831</ix:nonFraction>&#160;and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. For the three months ended March 31, 2025, the Company recorded total net gains of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_9wVA-iTdq0y5EEN-cGB0Ng" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_XuOa1xMYLEi25DzL0OIdgg">1,429</ix:nonFraction>&#160;in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the March 2025 Accompanying Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_PbHyP1wRzkWN4ZQmOt6QaA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_kLHN-vq0t0-Ut38jiQ9S0g">1,402</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">In connection with the March 2025 Offering discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, the Company also issued option warrants (the &#8220;Option Warrants&#8221;). The Option Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are initially recorded as Derivative liabilities. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_H1m79MxGEESZ-YgtaaXWXQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Narr_U05FxyORNECXPzDCuaW4ig">369</ix:nonFraction>. The Option Warrants expired on March 18, 2025 without being exercised, and the Company recorded a termination gain of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="Narr_dt7xq0HK9EGets_uJI0vEg">369</ix:nonFraction> in Other (income) expense, net, in the Company&#8217;s Condensed Consolidated Statements of Operations. As of March 31, 2025, the fair value of the Option Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_vRuLpGrNJEaqdiLygHHIHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Narr_5aY7tjK8kU2PUavzGgCH_A">0</ix:nonFraction>.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="btai:FinancingActivitiesDisclosureTextBlock" id="Tb_OUpZAMjxNEqewdQQXOsf5A" continuedAt="Tb_OUpZAMjxNEqewdQQXOsf5A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;11. Common Stock Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;">Jeffries At-the-Market Program </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">In May 2021, the Company entered into</span><span style="font-weight:normal;"> an </span><span style="font-weight:normal;">Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_4HyrlxwEJEq43QPtl9kACg" decimals="-3" format="ixt:num-dot-decimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_54oatrIlnEC8PFoKJwaC3w">100,000</ix:nonFraction></span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#8220;at the market offering" program to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_sIswvAbnK0SSZ3U84h3-cQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_9RD4ePdPEUWUS-5iQWm9XQ">150,000</ix:nonFraction></span><span style="font-weight:normal;">. On March 26, 2025, the Company and Jefferies terminated that certain Open Market Sales Agreement. There have been </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_IqGrgtq8dk2Nmswn-jlaBg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_ePsiydr92kuHApMDXv3CAg">no</ix:nonFraction></span><span style="font-weight:normal;"> sales of the Company&#8217;s common stock under the Sale Agreement for the three months ended March 31, 2025. </span><span style="font-weight:normal;">For the three months ended March 31, 2024, the Company sold </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_-ZabsaVCkkKinWn-C7EWeA">40</ix:nonFraction></span><span style="font-weight:normal;"> shares under the Sale Agreement for gross proceeds of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_8PSFjxMgpEmO4oI7HA--cA">1,743</ix:nonFraction></span><span style="font-weight:normal;"> and received proceeds of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_keY8EBe2j0qEYy7z0wjx-Q">1,691</ix:nonFraction></span><span style="font-weight:normal;">, net of issuance costs of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr__hD-luAkSUOeKWLN09u_UQ">52</ix:nonFraction></span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">March 2024 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers in a registered direct offering (the &#8220;Offering&#8221;) under an effective shelf registration statement on Form S-3 (File No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission on March 25, 2024 (the &#8220;Prospectus Supplement&#8221;) an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_1rBX_Jky_0K75YP6H-89Qg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_cfpljdxjU0SxjOhOTV9RAA">191</ix:nonFraction> shares (the &#8220;Shares&#8221;) of Common Stock, and accompanying warrants (the &#8220;Accompanying Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_m7xbJumbEUWcpgV0WvmWLA">191</ix:nonFraction> shares of common stock at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Pg-jCHaINE-WLGJKl1HB8Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_OaA8bHo9W0WGiS_yf0_Vaw">46.416</ix:nonFraction> per Share and Accompanying Warrant and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_E2N9f66_n0Womqu3AFWETw">348</ix:nonFraction> shares of common stock and Accompanying Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_ZK4WSaPeCEKtX4Hua4x6vg">348</ix:nonFraction> shares of common stock, at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_8LFsZpvbW0GGl6QO_xIKVg">46.40</ix:nonFraction> per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_OUpZAMjxNEqewdQQXOsf5A_cont1" continuedAt="Tb_OUpZAMjxNEqewdQQXOsf5A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_88sfhZ6fsU2kp3yWy33fjg">0.016</ix:nonFraction> exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants and Accompanying Warrants are not listed on the Nasdaq Capital Market or any other securities exchange or trading system and the Company does not intend to list them. On March 27, 2024, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Narr__vAMzMOz0UGZkCfKIunpEw">25,000</ix:nonFraction> of gross proceeds from the Offering, incurred costs of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_mEeo4iaQ3k2OWEA383PYJg">248</ix:nonFraction>, and received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_2w5pJ1RYiU-vjDQe_843ig">24,752</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_OqDOhESpX0KG-H3-WzA96g">0.016</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. For the year ended December 31, 2024, all <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Q7rgAxV2QUiFwGQkmwTNSA" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_GOpUKy28rkCmht_P9yinhw">348</ix:nonFraction> Pre-Funded Warrants were exercised and the same number of shares of common stock were issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Accompanying Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_FEF5uC8sO0avIWV7EbOZ8w">51.20</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">November 2024 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On November 22, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Canaccord Genuity LLC, as underwriter (the &#8220;Underwriter&#8221;), in connection with the issuance and sale by the Company in a public offering of (i)&#160;</span><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_kaFbGhRea0uEzHbo0OEBTg">350</ix:nonFraction><span style="background:#ffffff;">&#160;shares of the Company&#8217;s common stock, and accompanying warrants (the &#8220;November 2024 Accompanying Warrants&#8221;) to purchase&#160;</span><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_sOc9QAFpIkiocfp6gFyENg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_NTZxVpUI-0a5xKFdwdXpzg">350</ix:nonFraction><span style="background:#ffffff;">&#160;shares of Common Stock, at a combined public offering price of </span><span style="background:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EqWnEmSp7UWllrfrANJBsA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Ejc77HM2X0e9RXZT7PZ_jA">7.68</ix:nonFraction><span style="background:#ffffff;">&#160;per share, and, in lieu thereof to certain investors, (ii) Pre-Funded Warrants to purchase&#160;</span><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_IO25txozL0WZYXIKN936sQ">563</ix:nonFraction><span style="background:#ffffff;">&#160;shares of Common Stock, and accompanying warrants to purchase&#160;</span><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_ag7KHAJoqEqCXY70D5FRRg">563</ix:nonFraction><span style="background:#ffffff;">&#160;shares of Common Stock, at a combined public offering price of </span><span style="background:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_sOc9QAFpIkiocfp6gFyENg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_gaTbbJitKkO4JdfRmpk3Sw">7.664</ix:nonFraction><span style="background:#ffffff;">&#160;per pre-funded warrant, which equals the public offering price per share of Common Stock and accompanying warrant less the </span><span style="background:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_MEpEniBljUSe9bgq1NJy9g">0.016</ix:nonFraction><span style="background:#ffffff;">&#160;exercise price per share of the pre-funded warrants, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission. </span>The Company received net proceeds from the offering of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_iTc_x8NGYEi-r2L5hH1PIg">6,128</ix:nonFraction>, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_PUYFwUaDUEa9dxGKRGYxmA">871</ix:nonFraction>. The Company intends to use the net proceeds of the offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Q25F8g0LPEStGgwJpWlBuw">0.016</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. <span style="background:#ffffff;">For the year ended December 31, 2024,&#160;</span><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Wdm82uT0iEGxg_xqO2sS2Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_LoOmVuOAnEiPmOVDqkP9EA">80</ix:nonFraction><span style="background:#ffffff;">&#160;Pre-Funded Warrants were exercised and the same number of shares of common stock were issued. For the three months ended March 31, 2025, the remaining </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_gxIXr8TElEqM_4GFJfzkTg" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr__179mpJ7rEaxVQoRCOLNBw">483</ix:nonFraction></span><span style="background:#ffffff;"> Pre-Funded Warrants were exercised and the same number of common stock were issued in exchange for </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_gxIXr8TElEqM_4GFJfzkTg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Narr_hN1y9MZFvk2k1ngpOPaPnw">8</ix:nonFraction></span><span style="background:#ffffff;"> of proceeds received. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The November 2024 Accompanying Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EqWnEmSp7UWllrfrANJBsA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_-lCIQhZ2602e25x6Mg-VQg">7.68</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the November 2024 Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The November 2024 </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_OUpZAMjxNEqewdQQXOsf5A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accompanying Warrants are exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The November 2024 Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">March 2025 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 3, 2025, the Company entered into a purchase agreement (the &#8220;March 2025 Offering&#8221;) with a purchaser. Pursuant to the March 2025 Offering, the Company agreed to issue and sell to the purchaser and the purchaser agreed to buy in a registered direct offering (i) an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_LLXyYLIB5kSdZw0B9rsgZQ">188</ix:nonFraction> shares (the &#8220;Shares&#8221;) of Common Stock at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_QwlhBl02BUqKZ_B8CPqQ3A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_LI1GXYykG06y1O-2TWhp_g">3.50</ix:nonFraction> per Share, (ii) Pre-Funded Warrants to purchase up<span style="font-size:11pt;"> </span>to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_sx_AlcnVcEyoZ34-lalxJA">3,812</ix:nonFraction> shares of Common Stock, at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ" decimals="3" format="ixt:num-dot-decimal" name="btai:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" scale="0" id="Narr_ts4SPO3LFUGLwnp7VOm7Og">3.499</ix:nonFraction> per share underlying the Pre-Funded Warrants, which equals the offering price per share less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_4DLfIusP5UOtgAlpPFhBiQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_nRmIYxdyKE6TvGG9_jNgRw">0.001</ix:nonFraction> exercise price per share of the Pre-Funded Warrants, and (iii) an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_GsNMnu4G7UuiwrbhiKaaNA">4,000</ix:nonFraction> accompanying warrants (the &#8220;March 2025 Accompanying Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_6UK25BcJhk2b_lbE62uNCA">4,000</ix:nonFraction> shares of Common Stock at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_7AC2eHPXG0SikqDDFHFtdA">4.20</ix:nonFraction> per accompanying warrant, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the SEC on March 4, 2025. The Company received net proceeds from the offering of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_mMnnTd72s062joMimhI9FQ">12,957</ix:nonFraction>, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_3DgU88YnhEukmK-HiIQZ0Q">1,039</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8P00Y3XytkKSAVqF_W21OA">0.001</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. For the three months ended March 31, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_jTTHkTj0IUGtiV9lleK50A" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr_rbIqauXYXUiUseoEGdCu3w">1,688</ix:nonFraction> Pre-Funded Warrants were exercised and the same number of common stock were issued in exchange for $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_jTTHkTj0IUGtiV9lleK50A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="Narr_sLmyBU5kiE-QZViCx_nSqA">2</ix:nonFraction> of proceeds received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The March 2025 Accompanying Warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ExCiqPmE3EGzvzjVQ1bGGw">4.20</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the March 2025 Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The March 2025 Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The March 2025 Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the March 2025 Offering, the Company also issued to the purchaser option warrants, to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_zb2gHq4d8UOFHYORuG5uDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_JcCAtgSlPkCyPvqGAkniQQ">4,000</ix:nonFraction> shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_I9Pq4eoG40-r-VhvIEUPng">4,000</ix:nonFraction> shares of Common Stock. The exercise price of the Option Warrant is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_zb2gHq4d8UOFHYORuG5uDg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0_YEhVNg20O4Wbd2Tu0D5w">3.50</ix:nonFraction> per underlying share of Common Stock or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ" decimals="3" format="ixt:num-dot-decimal" name="btai:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" scale="0" id="Narr_mcVwIDg2zUanqNMzOZjlIg">3.499</ix:nonFraction> per underlying pre-funded warrant to purchase one share of Common Stock and accompanying warrant. The option accompanying warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_MWFeU0KZJUiRpjs9dWRtVQ">4.20</ix:nonFraction> per share. The Option Warrants expired on March 18, 2025 without being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_JdYEe5xmXEue-I1n6bu2vQ" continuedAt="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;12. Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">2017 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_ZhgoQq3u7UCekSd4t5ntJQ_2_2"></a><a id="Tc_PGxu8msmV0iEQ1JTju39og_3_2"></a><a id="Tc_C0-1G73Cw0W6grYgJatI0Q_5_0"></a><a id="Tc_7kreLnAkZk-HHqtxqsBkXQ_6_0"></a><a id="Tc_VHiJOSZM3kiw02oqVPwzPQ_7_0"></a><a id="Tc__EOPFs4RwkO6qhkQCZZyoA_8_0"></a><a id="Tc_swSf_jWrhkyZMkowPHROuA_9_0"></a><a id="_2ee90c07_8eaa_49df_865a_82f75ff73027"></a><a id="Tc_jbehDlmUHUyE0X90h2FXww_1_2"></a><a id="Tc_mie0yE5DpUym-OAdnMBgrQ_2_2"></a><a id="Tc_aVa4PTBejUqthScCYa16-A_4_0"></a><a id="Tc_Ps2Kbee1fUWh5y_fJ1ft_g_5_0"></a><a id="Tc_6Kh8wpuVhU2sK6ABKfBanw_5_2"></a><a id="Tc_MBth9Y-IsEakJz6gWIMLLg_6_0"></a><a id="Tc_mLYxwDAdckSkL0b10-WPwQ_7_0"></a><a id="Tc_VnTstN9H60euTt3wEg66zw_7_2"></a><a id="Tc_qiOMX8bV5ECFMVh0yXUmAQ_8_0"></a><ix:continuation id="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont1" continuedAt="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">2020 Incentive Award Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2020 Plan was approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ntB7xLQOW0eFtXjIxuvYzw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="Narr_bLQrPhiNkkCLKyxrLDlUbQ">57</ix:nonFraction> shares of the Company&#8217;s common stock and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_jAh-mRl7UkGV1NOK3PBR4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_qBdTNn-6RUac-m8dmptzIw">15</ix:nonFraction> shares of the Company&#8217;s common stock, which represents the number of shares that remained available for issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww" decimals="2" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" scale="-2" id="Narr_VK-K27yRM0mcXLiD3-JCVQ">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_2u5ZZheCfUSWL-ojEEShPw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_IZW9rxmpQ0W6W7egWYhGgQ">124</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_lfzf6M4c4ESx9byf41wzhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_uetiJ6kZIUyAuyDImacvkg">75</ix:nonFraction> shares on January 1, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock options granted under the 2020 Plan have a term of <ix:nonNumeric contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_R1oZqgIGCECd97TQFKiFaA">ten years</ix:nonNumeric>. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally <ix:nonNumeric contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_i_aiaRbPyE6dGun0ljsY7g">four years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, there were <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_6FxRGu28wE6I304fkcl32w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_FENCp3v3W0ORa1iStMLqbQ">118</ix:nonFraction> shares available to be granted under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BTI Restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to BTI RSUs.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_-b2e5On20kGBBeTSxjkxtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FrgKxTMEe0mg8BmgwnLOgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_MZVb6IZP5UOBLYfJx5VLjw_5_2">27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Tc_SkU2K72AE0qwRvLnQR7IMg_6_2">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="3" id="Tc_NRVtg8GGnUmoaufc0WGfWQ_7_2">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Tc_wiOpRE-IWEG7dcjcFFhdww_8_2">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_10sTlzzOBUiJqkaSyPhFIw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_Vi2Vuuvtd06dHZxqytSRXw_9_2">20</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the three months ended March 31, 2025, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_RIGV_r2Ol0GbCafGGHSK7Q">3</ix:nonFraction> time-based BTI RSUs which fully vest on the <span style="-sec-ix-hidden:Hidden_pBakmeRXJUyagPAg9k_X7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-year anniversary of the grant date. The weighted average grant date fair value per share for the BTI RSUs for the three months ended March 31, 2025 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_PQRM_jweckGOGrTdl7pmPA">6.14</ix:nonFraction>. The remaining outstanding RSUs generally vest over <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_G-3oLaoblUKb9ZcelJ9fng" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_8Rz0mBl3pkCTCRAkXRq5Hg">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_G-3oLaoblUKb9ZcelJ9fng" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_k0F9zJJKPk2dmmL1MfJNEA">25</ix:nonFraction>% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. Unrecognized stock-based compensation expense related to the BTI RSUs was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_10sTlzzOBUiJqkaSyPhFIw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_dSUwBsdN80223TW-meIaxw">537</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t0gcHwftwUuD02CHseIM2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_n5GH0O2ISUesAM5aT_9Cvw">1,308</ix:nonFraction> as of March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Performance stock units </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes activity relating to Performance Units related to BTI common stock.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="Tb_6_pWbf-aC06Ul0ox8AK4Gw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_QM1oFtti-EyHphWNZ9znYg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_0bDf6E3JVESf4kSz7_5pfA_4_2">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="3" id="Tc_oSiQIfkCi06lBKiRLdKTaQ_6_2">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_XbHYq2dE_UGUYLas9E-Hnw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_Ov6U_-E5tEirgdaFkO4KDg_8_2">60</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_h1d3r5syQ0O7Q7xcuFGwUA_2_4"></a><a id="Tc_zVseTt_HWkmZLBbvfs_3pw_3_2"></a><a id="Tc_-zBwPPFg_kC8iU7xGDX2oQ_3_4"></a><a id="Tc_bvgDBk03CUKmA9c7YuCKKA_4_2"></a><a id="Tc_Z6EIa9XRx0C0W-_jyQPaEQ_4_4"></a><a id="Tc_A05X1bg1skimINNb0N4ROw_6_0"></a><a id="Tc_oLwo4_8nUUqgwgg9s9K3xQ_6_4"></a><a id="Tc_z1zdSwABSkyb42Y3yPkF2w_7_0"></a><a id="Tc_eDFNC-tj50KAHTukku-2rw_7_2"></a><a id="Tc_JCI27v4Q2EaB3-ZvQQJL-A_7_4"></a><a id="Tc_V6IfQoM4UE64FSogf8eVEA_7_5"></a><a id="Tc_lpeOdRR6aESPNcIvDg-DwA_8_0"></a><a id="Tc_zJ5S6iLsiUCjLv1frq90mw_8_4"></a><a id="Tc_34eezn54nU6mC1LZreODUQ_9_0"></a><a id="Tc_dTf6iA17LEOU_Ia3vDizAw_9_2"></a><a id="Tc_iRLgwjBf_UOuLN4Y5T1KFQ_9_4"></a><a id="Tc_LRPlZEYbIEqP8W6d5RPcHg_9_5"></a><a id="Tc_qYUXl2OtKkKQvSjKOUdpgQ_10_0"></a><a id="Tc_LDrJadA6y0u22Wr-iDLq4w_12_0"></a><a id="Tc_wH4IrSkQ8kCt4bNxBxjmEw_12_4"></a><a id="Tc_fFZ5HLD8PEeJIJrw2gMP2g_2_2"></a><a id="Tc_rGadszCLa0GEkOOxvKU34w_4_0"></a><a id="Tc_96YLOwV2iUumh8iN1aYbUg_4_3"></a><a id="Tc_w_685kd10UeSmCA91NtpoA_5_0"></a><a id="Tc_kUz3-28hoU-u9tgiKM7tdg_5_3"></a><a id="Tc_OPSUba8w3UWS7nV76hfjbw_6_0"></a><a id="Tc_ie9hWTus1UC_pggfbdtvTg_6_3"></a><a id="Tc_5Xry2-7iz0WaKl6l5FMXYw_7_0"></a><a id="Tc_NCfuRCJx_0ac8BNtVo7pTA_7_3"></a><ix:continuation id="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont2" continuedAt="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In July 2024, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_Hn9F2YpkGU-6gXC3Hhefjg">87</ix:nonFraction> Performance Units to employees. The Performance Units vest on the <ix:nonNumeric contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_b0ywWvG7y0G_sEEJofVPfw">one-year</ix:nonNumeric> anniversary of the grant date, provided certain performance criteria are met. The weighted average value per share of Performance Units granted in 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_na_rGJBuqUOgKoBEMMh3yw">19.20</ix:nonFraction>. <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Narr_eyYsffCdr0-6eMZ6evCSFA">None</ix:nonFraction> of the Performance Units had vested as of March 31, 2025. Unrecognized stock-based compensation expense related to these Performance Units expected to vest was <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_XbHYq2dE_UGUYLas9E-Hnw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_1KdjL1VOzkec-O-7AMn7dA">zero</ix:nonFraction> as of March 31, 2025 since it is uncertain whether any performance criteria will be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel profit sharing units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="Tb_TZArxxr86E-fSVYrSuiMkA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3GMwf3ANwkuAIoCkKRuAEw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_5VIfvFZx3kGpjXeMYqHiIA_6_2">1,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3GMwf3ANwkuAIoCkKRuAEw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_NiF8oCHDaUu9jPnP0sd1ZA_6_5">5,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA" decimals="INF" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_CRL6MAApKU2v1_yBAq7_KQ_8_2">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA" decimals="0" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" scale="0" id="Tc_LR8F4eeQfEOjV0zhl8c9hQ_8_5">6,006</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_sBmJPtJ-r0GwH6pLSU3G7Q_10_2">1,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_LFFUqSbfNE6RK5eL9sOQEQ_12_2">976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_kY_75ONLwky0Diu0rkMwvw_12_5">5,533</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, OnkosXcel Employee Holdings, LLC, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_Ana_llmjoEiXWcVwXB2AgA">15</ix:nonFraction> individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. These PSUs vest ratably over <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_7CLt5g94oku1djAE4ienIg">48 months</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair values of PSUs granted in 2024 were estimated at the date of grant using a Black-Scholes option pricing model and assumptions below. </p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_1TfuDOCf0E2KBNR6UV8cAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_q0ShDa4EKE2u3tTIYLRziQ_4_2">97.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_kr457Yl_20CwxYnUr9SDYA_5_2">3.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_bRZvcIQHJk250ch5w5EUDg_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_dzmnuoTN406jLXZ5vOwQ-w_7_2"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized stock-based compensation expense related to these awards was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_jQCemkubOE-vMHy1NvxRZg">319</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_nF7LfoZnP0eXge2zjCLJew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_zIjv4YIg7EynG7NSvxCAIQ">782</ix:nonFraction> as of March 31, 2025 and 2024, respectively.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc__8EcA6XKKESBceVz7kLniQ_2_2"></a><a id="Tc_dfhImxCZdEyPsv2wtI3XjQ_3_2"></a><a id="Tc__-I2ttxYukyeZ-9LZKlLXg_5_0"></a><a id="Tc_HqfeMMEYRUG8lHqwyu9lqg_6_0"></a><a id="Tc_7rLFdmqeNk2xNGNOefmEyw_6_2"></a><a id="Tc_Ax6pFBm8ikSNXUkrLYtAaA_7_0"></a><a id="Tc_oxgwaqFvPkWsrdJRIdBK1w_8_0"></a><a id="Tc_SqkLhkzvX0uv2ynaQwyzPA_9_0"></a><a id="Tc_HyMkEwdxzEaO6x0hSFCcAw_2_2"></a><a id="Tc_tCrjpZCTwUWOv67AylN4KQ_2_4"></a><a id="Tc_XharnmE7B0SqQ7J95HoHtg_3_2"></a><a id="Tc_ZSJ0xXutNk69Kbo2lt-5Qw_3_4"></a><a id="Tc_iHPy29J9s02zcyg0vNmz4w_5_0"></a><a id="Tc_1leb4Wf-TEeWxgtwGpGdsQ_5_4"></a><a id="Tc_7aBYZ21cg023FPhzGwji5g_6_0"></a><a id="Tc_utxknVmhmEW9I-BYSdHlkg_6_4"></a><a id="Tc_OA8gJqPmXEqCYWLX5aLr6Q_7_0"></a><a id="Tc_0VD1F-pTnkexLkuMW_tgHA_7_4"></a><a id="Tc_adK3NGlPrk-vPbOOiDrQsw_8_0"></a><a id="Tc_yHn85pJ1p0C-_sY0qXiEiA_8_4"></a><a id="Tc_C5u3J4rVqkmZ9_OXAM2AGQ_9_0"></a><a id="Tc_RFWyUsSsGkKoThdCiUiE2Q_9_2"></a><a id="Tc_qeARkbmuf0C0nnWQrTPKtQ_9_4"></a><a id="Tc_Dyfeopzew0GF11t8xoM5bQ_9_5"></a><a id="Tc_daQrJ74_4USrBDSWUz5INA_10_0"></a><a id="Tc_xPBWY79YGEOBHJLvQiJO-A_10_4"></a><a id="Tc_typtFyM9VUSes2b4fXlHYQ_12_0"></a><a id="Tc_gSmq6hyY3EGPJPpvBOn0Fw_12_4"></a><ix:continuation id="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont3" continuedAt="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the OnkosXcel RSUs.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_KGts1f1ozUuUsBEChXG6SA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_yCdJXfvBaESj-7sAWiLUgQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_KFXJ_dmJ2EKv7v4x1qlDDA_5_2">176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_2tqukdpf_UWjao8bm0qizQ_7_2">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Cancelled</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ" decimals="INF" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_cKXoPy_SHkGOpV7if_au_g_8_2">34</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_dtp7DCTeaEab_MgJIlQTmw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_aJrTY-g910WcJCSX1UZcfA_9_2">140</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uo-sJMUAtUm-XDTcsRgyog" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_y1w7oZKahECYN_WFzKigLg">140</ix:nonFraction> OnkosXcel Restricted Stock Units outstanding. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_dtp7DCTeaEab_MgJIlQTmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_6Wj_5orCXk6WmJK1K5MVhw">50</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_FbkYU21lwUS7EtQCr_4AQg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_MEVrPw0k3EyVysPxgEQSSw">420</ix:nonFraction> as of March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BTI Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A summary of the Company&#8217;s stock option activity for the three months ended March 31, 2025 is presented below.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_fZsOou0CJ0WZAa1Qy0CPfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="Tc_enCxRKCVTUKi895gV0thuw_5_2">311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_sh9BC7B15EOLfzg8zipmbw_5_5">265.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="Tc_jSHaO8d9oUu8fIoeu3jkhg_6_2">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vVKeh-CcmUC0IV9IwH4M8w_6_5">7.54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="Tc_DmIczcCQx0i3DOv9FJs0AA_7_2">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_J_3wbxww2UuyrVCQO7NHxQ_7_5">124.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" scale="3" id="Tc_CZhnImx9Bk-qboGBcsVC2Q_8_2">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="2" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ZZ26w920CUikloPG7yHS1A_8_5">384.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="Tc_DWry8VSt60eZxa5c2bAo7w_10_2">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_pHgsCnmRAUmLNxU16ChbtQ_10_5">210.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="Tc_fdqtQl_nQE-fgbkx3Xmm5A_12_2">259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_6eJEg11F60KjPcBmisiJ_w_12_5">268.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, the intrinsic value of options outstanding was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Narr_KeOl431OL0yVCcacpA5FFQ">0</ix:nonFraction>. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#8217;s common stock as of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Narr_Ix-xLFLTkUOMWsmT7mg7zg">No</ix:nonFraction> stock options were exercised for the three months ended March 31, 2025. As of March 31, 2025, the total intrinsic value of stock options exercisable was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_bCGA5qog-EKNOUxlXfuO1w">0</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value per share of options granted as of March 31, 2025 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_lNApnHZju0a9gU-O79HPbA">6.21</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value per share of options vested as of March 31, 2025 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_Ly6qcJNU_UOi7GoC2EivZg">196.53</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average remaining contractual life is <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_TZkyHfMXQUywyaosm9yywg">5.0</ix:nonNumeric> years for options exercisable as of March 31, 2025. The weighted average remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_IUQnTKSacUGh5jKHNejRKQ">6.2</ix:nonNumeric> years for options outstanding as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized compensation expense related to unvested stock option awards as of March 31, 2025 was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_R5_EeX_OgkqoHbsA5KrHJQ">1,675</ix:nonFraction> and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Se9Cjw5ua0aEkNJQXnJsFQ">1.1</ix:nonNumeric> years.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_EuptcOr8U0qoSZOFLi9o0A_2_2"></a><a id="Tc_CzBytNzggUCl3B2X14rmCw_2_9"></a><a id="Tc_Ep8ypnA4i0ahV5YpKP-wfA_3_3"></a><a id="Tc_437wg46Vq0qknx28keIimg_3_9"></a><a id="Tc_FDXef_8B8U6FSLVNGFoyEQ_5_0"></a><a id="Tc_BeEQ-L5SyUSmcZRI7n6tQg_5_6"></a><a id="Tc_gp-H53ZWbE2JqxZUwVMUag_5_12"></a><a id="Tc_RQEnMPC5gUGdrix3fmQvFQ_6_0"></a><a id="Tc_dptb2NruZ0CLlWnAXakNHQ_6_6"></a><a id="Tc_bzkpQvb9r0u16MMcjUVFIg_6_12"></a><a id="Tc_G6aOHbAF8U-g4FnMjQidmg_7_0"></a><a id="Tc_p3bgDtuKV0Gcq20MwhmP_Q_7_6"></a><a id="Tc_qUM8JrUcT0CnRZLVIYDtEA_7_12"></a><a id="Tc_6zymnIEsNEC_HemZF63qsw_8_0"></a><a id="Tc_e8ZfeAJE70aeB2mGRZ4Z5Q_8_6"></a><a id="Tc_6JpJpAbGOkqH3LFWJOETIg_8_12"></a><a id="Tc_TlVxIUcATkqhBnmS-uU7RA_1_2"></a><a id="Tc_qfFBxX22EkWfehxBV1Cm1A_2_2"></a><a id="Tc_98rV8hOWLUm3nEAT9wOQZw_2_5"></a><a id="Tc_1iVMyfg3wEW7ZYVd0MSkNg_4_0"></a><a id="Tc__5UQ-6QkKUGEZeZXPwAsgg_4_2"></a><a id="Tc_QkU-zpinkkuSuSMOnZkGlg_4_5"></a><a id="Tc_3YqWJw4F7kGlGmx-xbpO5A_5_0"></a><a id="Tc_ut-YoWAsqU29f5_axjzfRg_6_0"></a><a id="Tc_oobeXy5HfEC-jFq1YZt20A_6_2"></a><a id="Tc_ZslEkeHhcka0sZ4lzP7SAw_6_5"></a><ix:continuation id="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont4" continuedAt="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of stock options granted during the three months ended March 31, 2025 and 2024 was estimated using the Black-Scholes pricing model with the following assumptions: </p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_owKX_IoMs02TK9ezNrmcZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_l9Fqr0MrUkqqugZrUPz9Ww_5_5">5.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_YctY4vxVNkuG2TosURY9-Q_5_11">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_qgKoGgrw_kORsWCsrus0_Q_6_5">112.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_D-1iGgZVk0uzKL22hEcMxA_6_11">108.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_8RDw5YPXRUOcqsyYTc-Txg_7_5">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_flx-3v-xKUaww0y6U84sjQ_7_11">4.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_lc0TQD92TUC47K0BhX7jLg_8_5">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_dnRauHOQ_kSHyoa3Q6WkXA_8_11">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2025, the Company continued using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#8217;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the life of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_SNLZwJWouESQqKnAUUkyIA">zero</ix:nonFraction> percent as the Company has no history of paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel RSUs and PSUs, of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_mq7vwLe9A0e05YPDu8xOtA">180</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_4Iv-qd4p6kKuO6wsg3ZJlQ">3,433</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively, which were comprised as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_JchkmFacGE2sNtjNAQVZNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q7_XqlxfsUekbErhlfT5sw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_XrKpXd1e1EqU84hqAQHQ9g_4_3">514</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e7w7dYu6okaQM-X3HL0_TA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NrQHtNUxp0u5BsXWgpgVKw_4_6">1,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hYwcEJOWJEqWIWLY9H5bPw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uCMiw7n20UmcWW1AQrjREw_5_3">694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_aQAnItAirkePUH0weLiB8Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_MOO68BZrdU2YF9HdyxC9Qw_5_6">2,152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_AaT3OhHaDkiJSJZsVcG5RA_6_3">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_7X9Muc6nH0GQxFjb0d0NSA_6_6">3,433</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">2020 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was also approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#8217;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that were initially available to be issued pursuant to rights granted under the ESPP was <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_RtIxFX89CUiClmbyPTCq5Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="Narr_sR0nbRZJrkGonjF_mmOkHQ">6</ix:nonFraction> shares of common stock. In addition, the number of shares available for issuance under the ESPP increases on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg" decimals="2" format="ixt:num-dot-decimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" scale="-2" id="Narr_p2orEVKFwkm3MVMwOR4pDQ">1</ix:nonFraction>% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#8220;Section 423 Component&#8221;) shall not exceed <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg" decimals="-3" format="ixt:num-dot-decimal" name="btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" scale="3" id="Narr_QyRrZdaMnU6tlXt261lBhQ">31</ix:nonFraction> shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_-XukXa541EKRC3qXkU48GQ">85</ix:nonFraction>% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_9F-wNPBED0-yN2cUEWfCsw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_JlOX2JfrL0i05drD9ZVrwA">31</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_4V56383kUUSE1c7Tg5oaUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_pViPKXoEAEKaeg72QmYoWw">19</ix:nonFraction> </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JdYEe5xmXEue-I1n6bu2vQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">shares on January 1, 2025 and 2024, respectively. To date, <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_FqusdZHmpEqdtLr0_l7HNA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Narr_a8VqmBenYEKU1qOdhR-f2w">no</ix:nonFraction> shares have been sold under the ESPP. There were <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_afsb0jOiYk26yty0TiCjbw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_Ioc7yfAbik-K4offgEuqQg">106</ix:nonFraction> shares available for issuance as of March 31, 2025.</p></ix:continuation><a id="Tc_1PIfzEsmEE-7jtljwt6Ebw_1_0"></a><a id="Tc_5ri7AcCfq0eHLm0jUoBImw_1_2"></a><a id="Tc_I6tD42h5LkSYy2GUTBdKGg_3_0"></a><a id="Tc_ZeHxpD6C6EWsX7hzFEowyw_3_2"></a><a id="Tc_QFh1CNAmcki9YBDNgNtBvw_4_0"></a><a id="Tc_A08me0JoBUG40JkU91iWMw_5_0"></a><a id="Tc_1odfDw8CE0WxEhr44xlEtQ_5_3"></a><a id="Tc_adfkWzpfY0KOQNfp5FoJPg_6_0"></a><a id="Tc_MYBJq4kfHEKUtBKY2SDUNA_6_2"></a><a id="Tc_1QCDCPg_zkCG5bpCks6s-A_7_0"></a><a id="Tc_m1novmneEE2MXp0zKdcCkw_8_0"></a><a id="Tc_f6oG8Hc2UEujUOweniP4NQ_8_2"></a><a id="Tc_E_KQQUhg9Ui_3nnYAYK2fA_9_0"></a><a id="Tc_RYyubPPSjEiAED5hlqFdKQ_10_0"></a><a id="Tc_UdhomfGHHEOdd4LdL4Euhw_10_2"></a><a id="Tc_WK6fcO4K-Eq-D0CxXD7ofQ_10_3"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_eOWqTSOA8EGYBD6Jg_4viQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 13. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;) under an operating lease that expires in February 2026. The Company has an <ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" format="ixt:fixed-true" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_l7YhQdIfgEml264lHDZz9g">option to renew</ix:nonNumeric> the HQ Lease for one additional <ix:nonNumeric contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_PRWk0Efxz0qahPUH1dPy2Q">five-year</ix:nonNumeric> term. Payments under the HQ Lease are fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also leases equipment such as copiers and information technology equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The future minimum annual lease payments under operating leases, as of March 31, 2025, are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_D7XCjqsSykW5_rDW7i-r6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_HdRzB3PwO0mT_YPHOzpMiw_3_3">294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_F2nDra7u0E6dEvTegBJjWQ_4_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_McfNTSSfqkOjzIpWAFyRJQ_6_3">359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_UcXQQprsB0SLGwlpar3mrw_7_3">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_nYTByHvq40WPxAWYRTsDXA_8_3">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ov4EZzcjN0WN1htT51kzHw_9_3">350</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current portion of the Company&#8217;s operating lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Narr_Azu-f5WkNkiKLPs8xArLdg">350</ix:nonFraction> as of March 31, 2025, is included in <span style="-sec-ix-hidden:Hidden_-dJ9RC_4H0GYGleZlqoJAg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span> on the Condensed Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lease expense was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_Yda7ShRuRE2bzKnCcd6j6w">101</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_0pDs88YjVEeozj0IOslTjA">99</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lease renewal options are not included in the ROU asset or lease liability.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_84b72567_fbbd_4dbd_88bd_5f5e55403672"></a><a id="Tc_4vr_7wf7rkyfB2MyG0YtuQ_1_2"></a><a id="Tc_Y6Tv213dsUuFmZMtAM34WA_2_2"></a><a id="Tc_2c8jojrJLU6YB7rfaonyIg_3_2"></a><a id="Tc_A1Faho7SNk-mYVKBx3RXMA_3_5"></a><a id="Tc_sGP-9Glrpku9j7p9Teh4Qg_3_8"></a><a id="Tc_Yt6O9loADkOqooenUkm8Gw_3_11"></a><a id="Tc_OVaTiPnXxUySfbZpzD5MnQ_3_14"></a><a id="Tc_uQ9pFGCZ40OQ-SHzD_a3CA_5_0"></a><a id="Tc_QUcych9aXkmoFGglrbWXbg_5_2"></a><a id="Tc_XEAmQ9f0C0udi1TKjzdzGA_5_5"></a><a id="Tc_JhU9J3YQ7E-8PcGIDmYLCA_5_6"></a><a id="Tc_FCYTGcbS8kWJYO9VwxFkSQ_5_8"></a><a id="Tc_hGQuidpXs0i8g6WH57WX-g_5_11"></a><a id="Tc_C5zYBHKf6UuQCUlxmhiLhQ_5_14"></a><a id="Tc_67aghmdaK0-GfjJsxvJNgQ_6_0"></a><a id="Tc_gW_r1Vynk0SbGfFytXxpww_6_6"></a><a id="Tc_57OimVP6U06_su_SmjcJvw_6_9"></a><a id="Tc_KTzljqLiQUu6Dl3ekG6v1A_7_0"></a><a id="Tc_ptXOkAwJ8k6WzaHESRG57w_7_2"></a><a id="Tc_byaLB1GE1Eyoi-G-g9lsYQ_7_5"></a><a id="Tc_T-YrUONWfUqyqamCT5idrA_7_6"></a><a id="Tc_aZ1ADeDa6ESvG2NQ9SKdfg_7_8"></a><a id="Tc_upqtcnd27kqns6cxXI_e4A_7_11"></a><a id="Tc_a-iiQt5j5E2F0IPJIvcS1w_7_14"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_r6op1MIJ50mLD4eIhWZg2g" continuedAt="Tb_r6op1MIJ50mLD4eIhWZg2g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 14. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, <i style="font-style:italic;">Summary of Significant Accounting Policies</i>, for additional information on the accounting policies related to fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts of cash and cash equivalents, accounts receivable, net, and accounts payable approximate fair value due to the short-term nature of these instruments. As of March 31, 2025 and December 31, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_PJWCjTtyrkmhOnNFeBDLAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Narr_-6KQ23sSxUebZ3b14SMcSw">30,310</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_J7mlkOfyo0Wnq0ZjtLDsPg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Narr_iQpPW8CqxkGs5qk4RRdyug">29,036</ix:nonFraction>, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the three months ended March 31, 2025 and the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities measured at fair value on a recurring basis are summarized below.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_TZRlUyFAD0WIrNA_uTfAww" continuedAt="Tb_TZRlUyFAD0WIrNA_uTfAww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P_Qm7GZ7c02Je803Yy_hCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_nzFhLIRBl0uNxnwyzJ9nfw_5_3">3,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Gzu0uopwJUi4ddhDOAgn4g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_4q71JeqZokqvEet2zjei2Q_5_9">1,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bQalOe5mP0y-IbH-aKaF9w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_XXV8E5OLPkeIwgBaYiH4Vw_5_12">1,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SMshi1uQUeFzJdBkvobzA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_HXrRCSNoSEKlQZpJLGenWA_5_15">3,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rqZf9XPGIECruOB5VZyF7w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_NHOpQk75hk6aRi2ADS9J_g_6_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EPMTFamnQUKwjPkhv202_A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_0QaXw5isnEy8pCmviWmQNA_6_12">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NU_bnWHgP0u3mu2YN8K9VA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_697O9lZCw0i9ULiBz2z7sQ_6_15">38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_prSUZ2Vk1keXeIwPcPdHBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_sd_hXqdUHkCIiIg5ahn3ng_7_3">3,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2zTp8JJdwEuWNCrhPNXy7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_ofcc6-X17UGTYuY-mRgsFw_7_9">1,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RUa6fxCGUUmCyEdDsmfEsQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_3RYkRmq6S0ObCDbgwJ0K0Q_7_12">1,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qG6PA1YTT0mFdtjqdPZt5A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_1cXBNe_fDU-85cBmYOaSjQ_7_15">3,274</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dac1b6b1_54b7_497c_8cbd_ff29fec29f19"></a><a id="Tc_Iq8Cafvwx0-KI3ih53GW2A_1_2"></a><a id="Tc_lgB_IVAH9UadMXd4fxpoAQ_2_2"></a><a id="Tc_Li5uRt1ZXk2Q_y0YlWlg6w_4_2"></a><a id="Tc_S-I4xU4tSUGd3Sl6X8FMiw_4_5"></a><a id="Tc_qljpsN-jXEeZZpGTnqomlw_4_8"></a><a id="Tc_63F96cN5WkCj2KjrAEO2pg_4_11"></a><a id="Tc_ANZ6t_KIYESCqIpEo6MC8A_4_14"></a><a id="Tc_ktPUqpsepEmZuS3WOm_0AQ_6_0"></a><a id="Tc_NadMCKepVkGRLSZvAKH4Dg_6_2"></a><a id="Tc_kpnS5Sb3tUe4j8j5K091_w_6_5"></a><a id="Tc_bR54wk-aPEahaeuIIVKNRg_6_6"></a><a id="Tc_2Qwg5pZ1LUynXBe8TvVHmQ_6_8"></a><a id="Tc_kgMDI0b6rUOCxXWCANgmNw_6_11"></a><a id="Tc_wELItCIX5Ee4W1GZezNkmw_6_12"></a><a id="Tc_XASUx3bM_0OrgSQ-5kZrKg_6_14"></a><a id="Tc_gBD2sONHLk-6pZExNk6AsQ_7_0"></a><a id="Tc_kMoe980bmU-n4_AUjhIq_Q_7_6"></a><a id="Tc_AKZ7HuVd-0m7_8aaENneXA_7_9"></a><a id="Tc_SppgaqfnTUKqHaTS1w6YrA_8_0"></a><a id="Tc_71HDwfVa-EqilHFsOuIjpA_8_2"></a><a id="Tc_K45CjuAItEOMeN4cO1TJ2A_8_5"></a><a id="Tc_K2tGVOzOiky84W9W9RZzBA_8_6"></a><a id="Tc_ByZcqGyqmkyRpKO0B41mfQ_8_8"></a><a id="Tc_zixbf0oI-ECmIxqsDhXfcA_8_11"></a><a id="Tc_hlT8OPgujE2sfvBDfGznqg_8_14"></a><a id="Tc_fb147MNlxkmyiwHQzfNt-w_1_2"></a><a id="Tc_5IYRB0YoukyejNe0AIMCbw_2_2"></a><a id="Tc_MLfl1LRDyEmQ_8HDKvPQZw_3_2"></a><a id="Tc_tHsz90tQ_0Skr14sI8PNAA_3_5"></a><a id="Tc_vMaZNkZFYUiNI2noqJQVCg_5_0"></a><a id="Tc_fCHHZLtiNEqvoEOmFKCrcA_5_2"></a><a id="Tc_zl0FlpDRtUSUUZ1r1AhAvw_5_5"></a><a id="Tc_Kn2B9bDmpUaUcmaIYpDxOw_6_0"></a><a id="Tc_PzRQmHx-tkGi2aXvKQAVhg_6_6"></a><a id="Tc_9X7StNwxXk-BuDm5uJa2yA_7_0"></a><a id="Tc_qNVU5-a3zkyP-B8GlNRSFw_7_6"></a><a id="Tc_Bt-u3QhdhEGSLLoTCPlUVA_8_0"></a><a id="Tc_Sp4dQzIYgUy0okESG_zgXg_8_6"></a><a id="Tc_ZRjjF9EUgEStFKm_uOJyjg_10_0"></a><a id="Tc_76aeXxRKcEqa9tv-Cfa3bw_10_2"></a><a id="Tc_YT9mE5x_QE2WSkbGhD0yFg_10_5"></a><ix:continuation id="Tb_r6op1MIJ50mLD4eIhWZg2g_cont1" continuedAt="Tb_r6op1MIJ50mLD4eIhWZg2g_cont2"><ix:continuation id="Tb_TZRlUyFAD0WIrNA_uTfAww_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_a7UuWWdWIEerkqNo73GtgQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_18ONUEB-oEucVXYESCuvcg_6_3">6,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vgkPllpRpE6UxSwit2t12w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_myMCkizllk6ta0D6B7vlcQ_6_9">6,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_znla2RdJtUGZPRsAxS6c6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_HzyRDfzDpEGuWLK482Bpgw_6_15">6,593</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tlr0bx5Lk0umFnmNNGd4sg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_-aJcR4X7Dki3FH_T64OB0g_7_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__NmDuNpoV06Ia2-1ixub5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_G-vGIW8DnECaSs-a0oYAyw_7_12">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RSoI2qJZEEOhEloDLwu0WA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_T-BdzNrlyEaNWknHVg2W-A_7_15">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_c2LU5Sjq3USpPWVHuKrnqg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_H_jbH-jrb0-knveAwRKtNw_8_3">6,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AYpdz6Od1kSaVgoALMsuJg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_80jVbNGCokOxfs7oYLsLfw_8_9">6,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wRxXXGVLeEmgQL5oobXHSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_cp0wPDv-C06fROiz4613BQ_8_12">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VPNR0fGdgUKLLXoJnK_u5A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_w3WkcpSgjk6BH8hs_3Cqdw_8_15">6,633</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities are comprised of the OnkosXcel Warrants, BTI Warrants, and Option Warrants. The fair value of the derivative liabilities was determined using Binomial Option Pricing and Distribution models for the OnkosXcel Warrants and Option Warrants, and using a Black Scholes model for the BTI Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2025. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="Tb_R_GKmYTK0Uy5k8jGsygpPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_G6wdALPfqU6cdIrkeCl3rQ_5_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_C8HeOD2U4k63vC3r60EDOg_5_6">1,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Addition of derivative liabilities - BTI Warrant (March 2025 Accompanying Warrants)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_nOFA42sxOU-Rl_psGJmlJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="Tc_03He1_RdUE2r_Icr2xDJ7Q_6_3">2,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Addition of derivative liabilities - Option Warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="Tc_AScHMFUMvUiHr1GsHtS5eg_7_3">369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Termination of derivative liabilities - Option Warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" sign="-" scale="3" id="Tc_-95-E9yHiUy_qvNGaFv2bA_8_3">369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_PWqzCLVmi0aOXGZBWK1euA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_6AOaBjx_mkGOdca86o8trQ_9_3">1,431</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_NBQnhjJQkE6mhPBUBFmCng_9_6">88</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - March 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_KL1teDjPkUWDTqQUqMwHcA_10_3">1,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_xNuwPeYHIkGt3IMlkCACng_10_6">1,817</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The change in fair value of the derivative liabilities was reported in the Condensed Consolidated Statements of Operations as Other (income) expense, net, for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xATPzL0AD0u1BGyIwTMdLg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_1uStjDcJ-E2HLwHBv3fBQg">115</ix:nonFraction>% based on the historical volatility of the Company&#8217;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the Option Warrants, the valuation inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_DFyNXKIPgEKmArMsW0gQGQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_9YTu3GHVok6IWBb3eDqFzQ">3.50</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__892NuyTDUO55WW4yX_gTw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_9I90XMlJeUyF2LmUrW35Ig">2.70</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_QjBKLYfu3UOftjkz3HF_ZA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_uf3gflt7ME-_Tud6pIhKLg">39.2</ix:nonFraction>% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), a term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZQ9kR5BADEqDL0CF2MD1zg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_HQfTkgX8A0OIT-5YrX6DHw">0.04</ix:nonFraction> years and a risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_dmsZTMfbJUO8_pb6kAYEhQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_Zer7Lmtbd0WdOTU90B7J8w">4.39</ix:nonFraction>%. The Option Warrants expired on March 18, 2025 without being exercised, and the Company recorded a termination gain of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_3_18_2025_To_3_18_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_zFe6GfQFg0-WdZKVa-mIuA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="Narr_SUsfNz1VPkmGuocPwlGIEg">369</ix:nonFraction> in Other (income) expense, net, in the Company&#8217;s Condensed Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In estimating the fair value of the derivative liability related to the BTI Warrants &#8211; March 2025 Accompanying Warrants, the valuation inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_gukmUIFIc0iqBD5w9_5uHA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_qmv1yfXj1kKMvMMmfzZ2Dw">4.20</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_q2bl4kv7E02ZqMbp6lNHdw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_1hIPYihz4k24JyuviHcGtA">2.70</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CWILIty2pkCdQ4BijefAOA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_pF_XU4rNs0S_qskCCilz2Q">39.2</ix:nonFraction>% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), a term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eZWNvJQCgEqQKzXrXgAoJw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_7HlbxU7UgkaflM1_xn0w3w">5</ix:nonFraction> years and a risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_c8VoZNoCiEe75FKiODf1LA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_aBj_WvwHl0Od-KuIjk0oNw">4.01</ix:nonFraction>%. The Company remeasured the fair value at March 31, 2025 of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_BUMU9WOhW0-krXWounRc7A">1,402</ix:nonFraction> and recorded an unrealized gain of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_nOFA42sxOU-Rl_psGJmlJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_Y7tEzu--jUyr0VLeW-RKzw">1,429</ix:nonFraction> for the three months ended March 31, 2025 within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wV5E2FZOwUyvzrEwdAj5sA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_g_9P8m7CO0eOzudw9mvlyw">4.20</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_vZatyzeFWUKoVmXlyUbWJA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr__PGS33kbVEmmCGinE2hv5g">2.03</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_3xEadpqpTkSF6M_S7kMmYA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_j9rYBQbR6kKosNPIxPWAmA">38.5</ix:nonFraction>% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_y8iIi7tP7ku5odeEUQmnRg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_W6nZLQvIvEurD0LE77B7yQ">4.9</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pLWARFxxtEigtbUjIwm1fA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr__QUMsqXf8kmqQl4o1rFP8Q">3.96</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated fair value of the Credit Agreement as of March 31, 2025 and December 31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Narr_T2kyI0onDEuqXeHA1r6z3A">96,403</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zFMC5T7CfU-D5CYy3DpF5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Narr_azl2hFTncEia9FxL0ipt2A">94,204</ix:nonFraction>, respectively. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_N6FxoWT73EW3ye3uNo0lEg_1_0"></a><a id="Tc_8Vxff8j820mYA5v8zV2p2A_1_2"></a><a id="Tc_lbwZ0SAzPUeDeXAyb64ZHQ_1_4"></a><a id="Tc_dTFmBTKN0UqcdvYxqp_odQ_1_6"></a><a id="Tc_EU8wbok7xk-gSVwwn-D9jA_1_9"></a><a id="Tc_99aBgGQxu0-KaKD-rGSZTw_1_11"></a><a id="Tc_j2KgbiheT0GNxwkngo2Q5A_3_0"></a><a id="Tc_1W3j63LQpkqm89eex0maZg_3_2"></a><a id="Tc_sY57DGRkA0-2-AaPXDhBlg_3_4"></a><a id="Tc_WPxIGYKOw0C9bHgDamLh-A_3_6"></a><a id="Tc_p5EOyEyVjUG2HAB-tCKKSQ_3_11"></a><a id="Tc_V35SGAeYyUmvIv1WtrfNxQ_4_0"></a><a id="Tc_lZ2JVpn4Pk-tr3jveA4h-w_4_2"></a><a id="Tc_PsCdbEXb8EqbjGMlZp6zhw_4_4"></a><a id="Tc_k6R_H2VgU0mZ-JvjZqm--A_4_6"></a><a id="Tc_Yf8cX1En90KfGuCayP68uw_4_11"></a><a id="Tc_6t7qHwAy3kiV9q4e5ok6TA_5_0"></a><a id="Tc_JWSwkktYb0KlarwSd0f-bA_5_2"></a><a id="Tc_zSXl3sHOMkCl8YbFmZC7IQ_5_4"></a><a id="Tc_cLA8CkwwLEe9axiHJIZfFA_5_6"></a><a id="Tc_ncQ832OP-Eu8oVUjGmVOMQ_5_11"></a><a id="Tc_cy0YbGvRFEO07fjpfVgpGQ_6_0"></a><a id="Tc_t8I_xFk0uk6fZVZrPiyrtA_6_2"></a><a id="Tc_VPuxpoBlHkm0rMFvdGUrLA_6_4"></a><a id="Tc_yScws76bqEaThWoEda1drg_6_6"></a><a id="Tc__Nxm8AOA1Uud416IASGV7A_6_11"></a><a id="Tc_B9z40ey8ekKU0rYa34p88g_7_0"></a><a id="Tc_NXgkS6-c9EqhLBcFPwO1Ww_7_2"></a><a id="Tc_IXTmJfLGXUKgq8rO329iqw_7_4"></a><a id="Tc_Q9iX5XNErEKahz3Bh05ITg_7_6"></a><a id="Tc_11J0EAYY50mmcYivifc_0w_7_11"></a><a id="Tc_xUIj9WqMW0WRB-H47zrxyQ_8_0"></a><a id="Tc_rpBGh1scL0K9Vmr5h4FS4A_8_2"></a><a id="Tc_OI3whHrtREGD05uBkgILcg_8_4"></a><a id="Tc_ibwZPfr-40WUUaXeyF0Urg_8_6"></a><a id="Tc_PXAd3YdbVEOBN4NIDLfGKQ_8_11"></a><a id="Tc_4jXGyeqe4EizEnjlJ6fL7Q_9_0"></a><a id="Tc_sRpvMFju8k-ylXybhultIQ_9_2"></a><a id="Tc_nTBU0g9BSk6RlRGTGDgYeA_9_4"></a><a id="Tc_57XzydQKFEy6Tio6mMiVJA_9_6"></a><a id="Tc_srSAme3fHUSz0ru5QkdNQQ_9_11"></a><a id="Tc_4qXyuQPdakqtGgHELaGPPg_10_0"></a><a id="Tc_9Qt7HY7OWE62GifWE2bI7A_10_2"></a><a id="Tc_L2HsSeadn0aLlWXD-4V3Pg_10_4"></a><a id="Tc_hHViK1X0EEOhjdLScltsEg_10_6"></a><a id="Tc_awweEszxbki1nYJXGSaOVA_10_11"></a><a id="Tc_Pmr8Xz1xvkaCTMcvOjj0wA_11_0"></a><a id="Tc_E0lUZkKw0Eyl9RMHnVn3Ng_11_2"></a><a id="Tc_K9CIhoygTEe6xbqtucDRsA_11_4"></a><a id="Tc_3PP8B9dJi02HD8ghyHUFyA_11_6"></a><a id="Tc_5YK_7uvaJkSZEzYwG4uHsA_11_11"></a><a id="Tc_eFnKsTDqHU6c7RLqWbs_1w_12_0"></a><a id="Tc_pFcb6dg0PkCHiQD-VdCa-Q_12_2"></a><a id="Tc_bn_lbnDUV02o5wzUOnuTwg_12_4"></a><a id="Tc_YisLNFmJKUq320-ProX4Xg_12_6"></a><a id="Tc_o0NFtJfqFE6vA7tPnLAntA_12_11"></a><a id="Tc_vdPEYNOpOkSul-hIKDsQ_w_13_0"></a><a id="Tc_ODZ_bMiiAU-czdR12AEh-g_13_2"></a><a id="Tc_Ktxhfh_d-kup0f-eggcSaA_13_4"></a><a id="Tc_1cnSRWIWhkKedL63gC00Og_13_6"></a><a id="Tc_Hev2fqd2Rkidw9yo3Ktyow_13_11"></a><a id="Tc_ExG36kAgX0-IYaHRKbHbsA_14_0"></a><ix:continuation id="Tb_r6op1MIJ50mLD4eIhWZg2g_cont2" continuedAt="Tb_r6op1MIJ50mLD4eIhWZg2g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table presents the BTI warrants issued by the Company and the corresponding balance sheet classification:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_20_ToI0qv0KIJDft6Wst1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Warrant Recipient</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Closing Date Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">4/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_MIO3Q71fCk-LePjJ87vN6w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_B-bxM99r_0KHQ1nYI6yjVw_3_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_MIO3Q71fCk-LePjJ87vN6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_ZxKkTeHciUK7gEkSEbGz0g_3_9">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2023 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">12/5/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_3dKYWVuao0m_9mO0sa3-sA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_G1j-iMxW40mhNOh-uf8a0Q_4_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_3dKYWVuao0m_9mO0sa3-sA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_A5uuKo5ilEmduTXH9KzkOA_4_9">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2024 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/20/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_-EDvG0oEXEaZXId6fmwjgA_5_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_5qGKxLKUy0K5lbwEeSk8EQ_5_9">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">New Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_UjYm4-P8Z0eyskPAdnjmLA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_yLCYrB2mFkKN_kPQjxm6dg_6_7">0.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_UjYm4-P8Z0eyskPAdnjmLA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_34TN8-Y9t0yFQL45t95crQ_6_9">313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_VVfoAVPWgUGHEB-JtN1T5g_7_7">9.136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_B2CiWezAak6UxoACc7AUiw_7_9">534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_uYAJHmVOoUmoITxX2Gk2sw_8_7">51.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_wPKJvTHPaEWLruwVNHReAQ_8_9">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_piXKgE8oLECIyWjuYpp4BA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_xAwJ5qO5f0mjy8RIPRtTbw_9_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_piXKgE8oLECIyWjuYpp4BA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_WPNlWom2NEehMHwYMmuN6g_9_9">846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heights Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_m8B2gPtU0ESdDuqJrEcuow" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_xR7E47HMQEG0A_FYsKS5Rw_10_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_m8B2gPtU0ESdDuqJrEcuow" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_dFmgsjQ21kihkxoGAGrEKw_10_9">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hudson Bay Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_PVo46D0n4k6-QNq-niA4gg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_SUr2arkIYEOuV_M9TPHfOA_11_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_PVo46D0n4k6-QNq-niA4gg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_pUUiBvKhhUa9xuXvzeObJg_11_9">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IntraCoastal Capital, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_wQUERamXr06SR40KJckzOg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ehaOxtVJzE-AKjGKAWE2ug_12_7">7.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_wQUERamXr06SR40KJckzOg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_sXAHSGybI0S5hnMoed8Inw_12_9">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Murchison Capital Partners, LP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">March 2025 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/4/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_5ILpzN_OikWPmR6b4RncOg_13_7">4.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_Dg3-tOaDLkOMpeRY4TjnzA_13_9">4,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total warrants issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Tc_f33ZDocrJk-G42npgqxwwA_14_9">5,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of the Closing Date Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="Narr_xQTnNgpLS0CtX1UcE0J4CA">3,245</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_uNtDcCko1UyxQn5jeaw1_w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_ckQpEzL55UuJNnLjmShrWQ">320.64</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5nb_8Nk5UEyJL1GzeHRhRQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_F3a8JROprUiKP8yXg6ppZQ">238.88</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Otlhw_JHk0O7aWKiFegSPw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_wCQsOH1h90u6_Mq2N-Rn3w">95</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MucGrtBbn0W75wiVlwPE0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_6xmb4aUPJEancNtYlTn4WA">7</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_raXKhs6OsEWwo5Ew1U2bVw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_BNdSk4Yxy0uQgHO2iLHxnw">2.95</ix:nonFraction>%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment<span style="font-size:12pt;"> </span>of the<span style="font-size:12pt;"> </span>Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Closing Date Warrants granted to the Lenders to have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_kCH7Ze6dpUK7GYvGld_V4w">58.3232</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants&#8217; fair values at the original strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ySdHL0JHf0uEgrJO8fShSA">320.64</ix:nonFraction> and the amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_N2uQ46AbXE2hhzrNSfxOrg">58.3232</ix:nonFraction> were $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_4hdDEC87hkOpWib0KYhRwA">548</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_2a_-xDmW6EuSDJd_PB1Dig">802</ix:nonFraction>, respectively, as of the Second Amendment Effective Date. The Closing Date Warrants&#8217; incremental increase in fair value for the repricing of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QmfvUlDnnkmlBuPCyWobCw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Narr_mxpnOWuAr0egIK3BinUZTg">254</ix:nonFraction>, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Second Amendment, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_A_Kkk_C2rkyP3uwv9LaXDw">4</ix:nonFraction> &#8220;2023 Warrants&#8221; at a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_u2_oFZt5hESDCqGkOYwntw">58.3232</ix:nonFraction> per share. The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_6kf3kz3250CWfrEdfA78IA">200</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_um20DfDizEmScCi5XDUA2w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_2QCxRZKzsES6OENhJzwQyA">58.3232</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_jchly8ehyE2tL32MrOzqYQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_xSZ2G26huUCEyhK9auGQzg">59.36</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_9KILTf0tCkqIWN0JAKeHVQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_i7vStfEzP0WYLBVOKRrePg">99</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jJnh5eroP0GCxqLxuMWfvg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_x-Pjin08HkebLG4_z2zJ-w">5.4</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_zeDW5gQHa0eSgEOzkDCljA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_TxilxCZRgUe60gTXK_ygmA">4.14</ix:nonFraction>%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_waD4qw5SUkmzjQM-jP6eNQ">6</ix:nonFraction> &#8220;2024 Warrants&#8221; at a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_szGMNt2Rq0SPfNEjO4hHDQ">49.1568</ix:nonFraction><span style="white-space:pre-wrap;"> per share.  The fair value of the &#8220;2024 Warrants&#8221;, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_IkqBDGPfPkGClU5owR7Z6g">224</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_5SJ7xQVeDkK5uvXlaHFGNA" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_XBxG-O2TZEquVKEHSJFP7A">49.1568</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_mzVT50GU30m-ov3gJU8nPQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_NWdlJG9ce0e8RmK2G6oU3g">44.48</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__xc5-0WLKUuKskXTA4r91g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_MZy35e3jaU-0gm42lOvWwQ">112.2</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2M20XZ8qKEKKmuDwGSOUAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_jRf4R_44RUaZIPNyPubjdw">5</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ub31Uz9ocEKq02canhoV-Q" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_UDA4UXCDf0apd21YOyRmXw">4.25</ix:nonFraction>%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in connection with the Fifth Amendment of the Credit Agreement, on the Fifth Amendment Effective Date of November 25, 2024, the Company amended and restated the Closing Date Warrants, 2023 Warrants, and 2024 Warrants granted to the Lenders to have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_xZAXdb7OMUWxeAPVmb9bHw">7.68</ix:nonFraction> per share.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_r6op1MIJ50mLD4eIhWZg2g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; fair values at the previously amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_G0mw6mA3wkKxqBm9LkdKyA">58.3232</ix:nonFraction> and original strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_mCSz1-9t-k2mWS0W2FTi7A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_RyqT0n-DnkWT-T54VfQrrg">49.1568</ix:nonFraction> the amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ZFkch1B6zkyhuaQoLQJ-CQ">7.68</ix:nonFraction> were $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_mCSz1-9t-k2mWS0W2FTi7A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_W6GZ5F4Ar02XyWA5_AwfJA">105</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_dSfacofYr06y6vhi0CgARg">164</ix:nonFraction>, respectively, as of the Fifth Amendment Effective Date. The Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; incremental increase in fair value for the repricing of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_NP8nyepU-UeJtuBMku2PLg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Narr_0LGpv3GP_kSL-lP3J-foHA">59</ix:nonFraction>, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The fair value of the Accompanying Warrants at issuance on March 25, 2024 was determined using a Black-Scholes pricing model and was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2.  On November 25, 2024, </span><ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_hFX2ulHzj0Wonqj3FtS7mw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_CwvEY4Ao6kq7T0Nq6nnfIw">534</ix:nonFraction> of the <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_9zAfUgBtvEi6ov_a7qysFg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_sAOyH0tkHEihacvOmLUfQg">539</ix:nonFraction> Accompanying Warrants&#8217; strike price were amended to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_QFx83QhiX0OZiI-xchFZ7A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6T0NZfjJlkCza5sXk2Ot_w">9.136</ix:nonFraction>. The Company remeasured the Accompanying Warrants&#8217; fair value at March 31, 2025 of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_QLIVwjVCD0quI55_NwdJQw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_Kzd1hu85aU-JJFLvo3U7OA">641</ix:nonFraction> and recorded a net gain of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_RvkyKbPjBEK4lRpESDkZxg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr__QBzybRFOUGspZegqGLajQ">1,679</ix:nonFraction>, within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were strike prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_SVurPgE3cUqj3MtsSbmcYA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_z7EkTrFGUEe7bcLXFr5waA">9.136</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_6Gs70ljVX0-T7tm9G61m5w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_JGQKa89WKE6m01qRpMGYFw">51.20</ix:nonFraction> for <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_KKrD_1ZJ30udHN2ZjhelHQ">534</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="Narr_3m4EuMqgaESIxCixSugt9A">5</ix:nonFraction> Accompanying Warrants, respectively, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wMIMNY2AHE6iuFOidhFOtA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_Mw5WLZaS_UGiSalh70AyTA">2.03</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_rp6M6rMw0kqyDbuEBr22PQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_HJ_TGVDPrkeaG7r0NCg_Ng">120.2</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eQXdiGPGikaZ3eg2SLqU6Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_fkizeltnmka1DHCcrwn8fw">4.0</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_PLtorYr2Ck-Sp5y9dKuZjQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_uoq95ZPUWkKKdf9yqQYiCg">3.93</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the November 2024 Accompanying Warrants at issuance on November 25, 2024 was determined using a Black-Scholes pricing model and was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The Company remeasured the November 2024 Accompanying Warrants&#8217; fair value at March 31, 2025 of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_k-Kye-ecsEGNgr32jEq1GA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_Ro3XXqYyD0ySDo3zqzysSA">1,193</ix:nonFraction> and recorded a net gain of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_Cn5-JcfDR0qcNSKrdqLIBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="Narr_a4YkXqxyT0agdQNjYEDL1w">3,080</ix:nonFraction>, within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_ZjpISjnlM0KcHdFRUWnJgw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_tXwGBmqhOEO2LC2YtzSWgA">7.68</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_ZVXHoCZAKU-UscfH64BvJg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_XyXZfJt59k6dn3QazJWGvQ">2.03</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_TcgKfaj7gUmuOyYcYRMQNA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_ji5eZTJJJES3dUrLbQ4ckA">115.3</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_BggKgNfY0USZzws7g5S5Wg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_ovz-1cv7lkaoU7KFYskIRA">4.7</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg" contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfJEoyAEkke0QHoyrB3b0w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_1ivq3zuLlUO5JAWKGVg2yw">3.94</ix:nonFraction>%. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_Qs7_RGJRAkGD0VITCSveDA_1_2"></a><a id="Tc_pC6UygKzEU6qmSE2TR0ghg_2_2"></a><a id="Tc_80yC7XHOF0mRDVDzqHUsbQ_3_2"></a><a id="Tc_7PcUY0Q_nUqb4Aawh7FD0g_3_5"></a><a id="Tc_h-tHilY9NU2Y1LAnNVZqJQ_5_0"></a><a id="Tc_FG6y8uR_30-XsTTq5K2IjQ_5_2"></a><a id="Tc_i8vDl0ExMkyYLiokEJDmrw_5_5"></a><a id="Tc_mUxnK8899Eyme33ErCvcxg_6_0"></a><a id="Tc_gCCeY0F0dUyR4xOu-h6gbA_7_0"></a><a id="Tc_Rdj0_DLTR0ezercFckStsA_7_2"></a><a id="Tc_kS3c2n6zv0CS0Tmgqt0Dbg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_koLoXDJoTki476zjcnmQ1A" continuedAt="Tb_koLoXDJoTki476zjcnmQ1A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 15. Net Loss Per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Basic and diluted net loss per share are as follows</span>:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_830fA63lNkaCaGqI6EFK3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-JoEmTXnikeeSDfYZ5iYTg_5_3">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_piwMUdXWdU6YpxyMNu5z4g_5_6">26,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_hQvPYHezlkKpEd4dBB7Qbg_6_3">4,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_53EvMiFp8USu0xrZ53gOYw_6_6">1,929</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc__v1Pk3ulKEeVWS3W54SIiA_7_3">1.50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Zco8Yq3mUEa__-v1SufJ5A_7_6">13.89</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding are as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_6IOUpy2-L0uuJk7s3-cXYg" continuedAt="Tb_6IOUpy2-L0uuJk7s3-cXYg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_fFMiHPHZFkSSH5GYAmLaPw_1_2"></a><a id="Tc_7SFHH9j_mUKjBThR1jjnkg_2_2"></a><a id="Tc_YdrJ_pkzeUq4yi6p_NLSUA_3_2"></a><a id="Tc_P1Q1HLc4FkGE4jkuLPgfBg_3_5"></a><a id="Tc_sFkLYdFx2EudZ06a-Pax9g_5_0"></a><a id="Tc_73MK108CH0WqL_1MFTg0Pg_6_0"></a><a id="Tc_NA--d_fujkaX5X8yviG8hw_7_0"></a><a id="Tc_R4UkyeZjZ0yFldUSFpozCw_8_0"></a><a id="Tc_CihXbUbeyk63Qhn6YASb0A_9_0"></a><ix:continuation id="Tb_koLoXDJoTki476zjcnmQ1A_cont1"><ix:continuation id="Tb_6IOUpy2-L0uuJk7s3-cXYg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wE7ROgr2I0i_O7Oti3HboA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_ucRR1NbCPkWXwZi1BOCyBg_5_3">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbpFUXyy0EK9y5v8zoZeAQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_poefJqW46ESTBFuHj4XdOw_5_6">303</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_85gLhLsX40qMOQrtKaj64g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_IO6KsfT9H0yKmxBWcaEEYA_6_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cwe90g33bUq1Ikc8GOiESA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_umzcc8--WUKQruflBsyecQ_6_6">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_tqFj1TLzLE-k4JolNuUzZg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_1qnWIIt6ykiTAi0YWc-2Ew_7_3">60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_uh20TIQks06ogYnvmFGT-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_8eSZwdDFSE2z9oUtdP6YQA_7_6">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_ZTqvtqbD3U6ROpLx6ZSAKw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_M1sToJxRCUabo4zzqLU63A_8_3">5,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_pfEI4UeUmEGDh7VF6gPIkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_ZKCeramuwU-LIFDOrA2mNA_8_6">567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total common stock equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_iuDRoE0g-k2g4twL5sYMZQ_9_3">6,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_p8AzEcrxvU6m6LBtJ2DWDg_9_6">914</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_ae42lUotqEqDwqNqJi8I0w" continuedAt="Tb_ae42lUotqEqDwqNqJi8I0w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Note&#160;16. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the items below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned </span><i style="font-style:italic;background:#ffffff;">Martin v. BioXcel Therapeutics, et al.</i><span style="white-space:pre-wrap;background:#ffffff;">, 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. On February 24, 2025, while the Company&#8217;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint. The Company filed an opposition to the motion on March 17, 2025 and Plaintiffs filed a reply in support of the motion on April 7, 2025. On April 9, 2025, the parties filed a joint motion requesting that the Court stay the action pending the outcome of a private mediation session scheduled for May 12, 2025. The Court granted the motion, staying the action until May 23, 2025, by which date the parties are required to file either a motion to continue the stay or a motion to lift the stay.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Panancherry et al v. Mehta et al</i><span style="background:#ffffff;">, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation</i><span style="background:#ffffff;">, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Smith v. Mehta et al,</i><span style="background:#ffffff;"> 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i><span style="background:#ffffff;">, 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ae42lUotqEqDwqNqJi8I0w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On May 7, 2025, Plaintiff Yaakov Portnoy filed a stockholder derivative complaint in the Court of Chancery of the State of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep &#8220;Steve&#8221; Laumas, Michael P. Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Yaakov Portnoy, derivatively on behalf of BioXcel Therapeutics, Inc. v. Vimal Mehta, et al</i>, 2025-0508-BWD (Del. Ch.).&#160; The complaint alleges similar claims to those raised in <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i>, 1:24-cv-00041 (D. Del.), including business torts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_4_1_2022_To_4_30_2022_Vj8qPsXKFkSdJSawI_izbQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_GM8hVkWv_EuteYKeeewxxw">10,000</ix:nonFraction></span><span style="background:#ffffff;"> for the </span><ix:nonNumeric contextRef="Duration_4_1_2022_To_4_30_2022_Vj8qPsXKFkSdJSawI_izbQ" format="ixt-sec:durwordsen" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="Narr_GgSP9-qvN0GWyQduR6c8ZQ"><span style="background:#ffffff;">three-year</span></ix:nonNumeric><span style="background:#ffffff;"> period, of which </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_4_30_2022_kf6oTMRck0makoAqk28SXg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationDueInSecondYear" scale="3" id="Narr_dTz_l-PpN0yXMz23JP3HHA">5,000</ix:nonFraction></span><span style="background:#ffffff;"> was originally due in year ended 2024. On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the &#8220;Product Supply Agreement Amendment&#8221;) that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications. The Company&#8217;s renegotiated agreement reduced the minimum commitment for 2024 to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_7_11_2024_To_7_11_2024_v4ITxGp84kCgCzwKJY2GDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_5DjV9ezR20GesLVl9MvVGg">1,000</ix:nonFraction></span><span style="background:#ffffff;"> and thereafter for the term of the agreement in annual amounts ranging from </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_McmLj4N3TUGjlqTWqM7wYA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_cSNuTobhsEGDcJS49s9KDQ">2,000</ix:nonFraction></span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_4mTezm6jGU2Tt0387MyZ0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="3" id="Narr_gn8HTo7aSUqAg3uZAxA0Ww">5,000</ix:nonFraction></span><span style="background:#ffffff;"> subject, in certain instances, to the extent that the Company receives approval of an sNDA or NDA from the FDA for enumerated indications. In accordance with the Product Supply Agreement Amendment, the minimum commitments were reduced to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg" decimals="-3" format="ixt:num-dot-decimal" name="btai:PurchaseObligationPriorYear" scale="3" id="Narr_N3so0tjay0uf6xrYin4c8Q">1,000</ix:nonFraction></span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="Narr_dvtXq46p0Ei4neWoxfuWbQ">2,000</ix:nonFraction></span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="3" id="Narr_sgb5G-_WH0-yuPtywv3aUg">2,000</ix:nonFraction></span><span style="background:#ffffff;"> in the years 2024, 2025, and 2026.</span> <span style="background:#ffffff;">In addition, the Company agreed to make a reconciliation payment of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_7_1_2024_To_9_30_2024_fdyMamGLJEanvbZYQzjwvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="3" id="Narr_9laxNxOGVESrjfpBCVownQ">1,200</ix:nonFraction></span><span style="background:#ffffff;"> in the third quarter of 2024 for full settlement for amounts due prior to the July 11, 2024 amendment.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_5uaMargNHkmzTrKxMYny4w" continuedAt="Tb_5uaMargNHkmzTrKxMYny4w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Note&#160;17. Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company views its operations and manages its business as&#160;<ix:nonFraction unitRef="Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_ybBwAyVnqkOdYsTgTyOOwA"><ix:nonFraction unitRef="Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_NadIC7yMrkevWuYltwHkFw">one</ix:nonFraction></ix:nonFraction>&#160;operating and reportable segment, utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. The Company employs various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (&#8220;CODM&#8221;), reviews weekly cash usage and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company&#8217;s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_QLd-LiIq1E-NwwX0U41dVw" continuedAt="Tb_QLd-LiIq1E-NwwX0U41dVw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_UubW3uNgXEaimyAVslEJxQ_1_3"></a><a id="Tc_47rK7Hko6U-S7suYEOIOUw_2_3"></a><a id="Tc_AY3raLv-uEecMgKdyEGD7g_2_6"></a><a id="Tc_L83K15M6u0G5QLbZaviXjA_4_0"></a><a id="Tc_SM4FvAIlRky9701nN9NwZA_4_3"></a><a id="Tc_5f1m6Z23yEeIJ-UAuXG-nQ_4_6"></a><a id="Tc_PLD81COoBEKg8r_FpzWJCg_5_0"></a><a id="Tc_-bq9vDzRC0C2KKuQRoozOg_6_0"></a><a id="Tc_-i8hLNGEMEmyMTXZRbmukQ_6_3"></a><a id="Tc_BgwToT83DESmlbjhMLecvA_6_6"></a><a id="Tc_UX7jKaQyTEmqaZP9OzTypQ_7_0"></a><a id="Tc_FIUk63N3j0m549nA-q-Igg_8_0"></a><a id="Tc_U0ACfCimB0GY_Ag-_l9f_A_8_3"></a><a id="Tc_KBMLoaupX0-uy08N903heA_8_6"></a><a id="Tc_N_Xu3FPmbUmmBHggHsE_JA_9_0"></a><a id="Tc_5NUl82Q92U2yuE8moh72CA_10_0"></a><a id="Tc_EXt-TCD9ZkOjj5TkF24eZQ_11_0"></a><a id="Tc_6p452IgG1Ea-ZRDOtiB6Qg_12_0"></a><a id="Tc_9LMIwx9NBUufpTgaCMIA2Q_13_0"></a><a id="Tc_hvFBl0osqUqdE6NAWj9EAw_14_0"></a><a id="Tc_AykvskJTEk6htH_wKu7b5w_14_3"></a><a id="Tc_QFo7YudrcEmbAhSRQHYIpQ_14_6"></a><a id="Tc_Zy80WiPr8kO2_O9COn0s3A_15_0"></a><a id="Tc_deUVn70bykOSVN1VndL2Cw_16_0"></a><a id="Tc_Xr1_Bdg9qUOLDbjNdyCfDw_17_0"></a><a id="Tc_-lkFM2eZW0yWnN5_mptO5Q_17_4"></a><a id="Tc_YnzGx3ZM0kCRtTZYd2xqeA_18_0"></a><a id="Tc_4ZeX6DP77kO0HRFdCiPW4g_19_0"></a><a id="Tc_vIMj0EzP1UmYpFWY96D2Pw_20_0"></a><a id="Tc_FjaqATXR3UqtVSknQ9Zxlw_21_0"></a><a id="Tc_zbFlHRMPZU6lHmijuUa-hA_22_0"></a><a id="Tc_dDDtT9r3Gk6uwKynSVPaIQ_22_3"></a><a id="Tc_5gmSwn5hTEG3CN38OPgBvQ_22_6"></a><a id="Tc_xPbAKSgWVkqVZelXGUU9kQ_23_0"></a><a id="Tc_whLZ6Hic-kqH7QnYVQl80A_24_0"></a><a id="Tc_u2VsXr5Nx0GAQOoVt3YUgw_24_3"></a><a id="Tc_Tci6hpdDM0O8kmK_99Kpjg_24_6"></a><a id="Tc_YpHQpgP8aEueUwCJ4oWQ_w_25_0"></a><a id="Tc_vVag25aU-UCjXf2klVrBQg_26_0"></a><a id="Tc_qsUoN58vY0WhJRqxftEyAw_27_0"></a><a id="Tc_LocvF5djmkWj3rQ_TWVh4w_28_0"></a><a id="Tc_7o6TkW6JH0iBJbN3ahlIig_29_0"></a><a id="Tc_1IJqu69pYkWkHOiN7hhBmA_29_3"></a><a id="Tc_ee0HvDT-Gka_S3JCxV7uTQ_29_6"></a><a id="Tc_OI4hj47_4UOHU1EAzQW93Q_30_0"></a><a id="Tc_q8Ha_CL1LkqqvQeZ1CTk7g_30_3"></a><a id="Tc_nlkW5cjvDEaUYtztBkNb1g_30_6"></a><a id="Tc_DyyIwwsS4UGZimB2urxIzw_31_0"></a><a id="Tc_lEiaNbWRG0KZPiXBrZmCAA_32_0"></a><a id="Tc_Ky-ag5FlO0ytIk1ZT4VleA_33_0"></a><a id="Tc_pKaAfoxtWkCiVVPs0pVevA_34_0"></a><a id="Tc_2Px_RsflqkCG45wqecq5qQ_35_0"></a><a id="Tc_HkNMak4N_E-wExS2QY5KCg_35_3"></a><a id="Tc_xr3aixXeFU-RYfmKlqsb8A_35_6"></a><a id="Tc_6C2CkcTlGEqubb36_bpzvw_36_0"></a><a id="Tc_Cge9d5cdL0O9atoGLQRYSA_36_4"></a><a id="Tc__ErQc_X8ZUadK1vQO7-lIA_36_7"></a><a id="Tc_IVJpvjSCz0KUP-2yNt6a5w_37_0"></a><a id="Tc_ZBBHEWtg5kOYAteiuX5Uzw_37_3"></a><a id="Tc_kF-S0zNLgE6Renv5QwkWjg_37_6"></a><ix:continuation id="Tb_5uaMargNHkmzTrKxMYny4w_cont1"><ix:continuation id="Tb_QLd-LiIq1E-NwwX0U41dVw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Zthmw9t2JUOgpKJmVXGL8A_4_4">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_VQhEfyEx4kudg_wlWWPRmA_4_7">582</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_Q3J9VgcxrEKbcT4AgxLkuA_6_4">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_-ZyObqJBSkuadU8yC9tpyQ_6_7">80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense" scale="3" id="Tc_fpo_9hAE40ei4B0BDxdCsA_8_4">1,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense" scale="3" id="Tc_BwOh3NVu9U2PEQGF-T8KXA_8_7">3,630</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" sign="-" scale="3" id="Tc_4tm8FqlUSESOo8QzZBJifA_9_4">514</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_1wOhsm9KX0yBoItdB43s9g_9_7">1,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseProfessionalFees" scale="3" id="Tc_Rja9dFAP2EO2EDj6SYq2KA_10_4">779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseProfessionalFees" scale="3" id="Tc_7GF_NRNWFE6pVTAFaZJJNQ_10_7">1,307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense" scale="3" id="Tc_kgnGdjwBvEmGoB8wBkNTYQ_11_4">2,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense" scale="3" id="Tc_eKpPVg7zt0W7wThZs6SI_Q_11_7">4,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" scale="3" id="Tc_-5AfrujwaEeGxM3_ObpFrQ_12_4">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" scale="3" id="Tc_8EK4migwwkyL_U4xXLd8Pw_12_7">549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentCostsOtherExpenses" scale="3" id="Tc_29J3gtP0JUueQ7iZq_ZRTw_13_4">414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:ResearchAndDevelopmentCostsOtherExpenses" scale="3" id="Tc_5rrklZzqT0G8bKAHqxr0Bw_13_7">566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">     Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Zhlta-pMNECoWEIhOdsLhA_14_4">4,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_8CXvyO4L9kGaNhYqujEaXA_14_7">11,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsLaborAndRelatedExpense" scale="3" id="Tc_dhN3AlarK0i0x_QbMSRIKg_16_4">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsLaborAndRelatedExpense" scale="3" id="Tc_qc65ZCpKUUuzrdrL0AjFoQ_16_7">1,149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsShareBasedPaymentArrangementExpense" scale="3" id="Tc_Rc6q3FQQsUit5KDEiVdIFw_17_7">268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsProfessionalFees" scale="3" id="Tc_wyGfDXflakeKl2eyupw6fQ_18_4">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsProfessionalFees" scale="3" id="Tc_NKaeDa0XkkypzPl6vNkigw_18_7">71</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsCommercialAndMarketing" scale="3" id="Tc_fRyuWmSUCU6UQuooIq0BMw_19_4">169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsCommercialAndMarketing" scale="3" id="Tc_ddMsFUq9YkmXWZa0VJz1PA_19_7">1,347</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsTravelAndOtherExpenses" scale="3" id="Tc_kU_933TM10SFwPv9beXXaQ_20_4">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsTravelAndOtherExpenses" scale="3" id="Tc_xjJmW9H4dUGgy_UUpE4gxA_20_7">117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsOtherExpenses" sign="-" scale="3" id="Tc_r_vQogRMVECRiCCBplXQBg_21_4">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:CommercialCostsOtherExpenses" scale="3" id="Tc_swEbzDSgmUuhOMUFeQoMNQ_21_7">196</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">    Total commercial costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="Tc_0ppNlpysL0i6PnN-BVU3iw_22_4">207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostAndExpenseOperating" scale="3" id="Tc_vwsOYmgprEmSVH_gbAID0Q_22_7">3,148</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" scale="3" id="Tc_bR0j4b-g6EyhR-65Uul0Kw_24_4">993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" scale="3" id="Tc_Tc5gj7PP7UiNEHEp-grE1g_24_7">2,037</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_CSydnsbdnEKpuvn3SsMdXg_25_4">694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" scale="3" id="Tc_x0zq-z5i3EOjbrK8Vr7oJg_25_7">1,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseProfessionalFees" scale="3" id="Tc_6VDe9VTZJ0S1qDvoZKVl-A_26_4">2,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseProfessionalFees" scale="3" id="Tc_3mcmi9fEc0mwM7JUBzsizw_26_7">5,240</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" scale="3" id="Tc__1HqQdz_NkWBEvOBMtGHvQ_27_4">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" scale="3" id="Tc_C6PYnaECn0andZO_I8uBuA_27_7">247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeCostsOtherExpenses" scale="3" id="Tc_JoCE72KXmk6lOu7bPEU14A_28_4">855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:SellingGeneralAndAdministrativeCostsOtherExpenses" scale="3" id="Tc_iYzs1xSqbEWxmS8nujV7WQ_28_7">708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">    Total selling, general and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_0s_4yvFqbUWZaIDlYafyCw_29_4">5,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_lEywarm5yEe0so3GXsoMhQ_29_7">10,116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"> Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_5YGrcb8ajkeIa9X8Fw52QQ_30_4">10,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_5vVxYpsFv0u8ILluCRDE9g_30_7">24,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_yGVM21rziU-DnkN-OyM68w_32_4">3,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_0mkrLZLCwka1w0facmsQxw_32_7">3,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_WOIAlmXbN0KhobS_4ICQxA_33_4">279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_PCt-WH_eFUykHBfhD5juPQ_33_7">947</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_aLZA2sapQE2FF6QmGQgHGA_34_4">6,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_wETPHZu7IkGt9Vp5MKZNTw_34_7">32</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s7Lrsuy08UWY7JnhTk_izw_35_4">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NuwZiny8S0CdMdtBcTvKOg_35_7">26,791</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consolidated Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GtLnZobOKUSTOwsdf89xFQ_37_4">7,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZwfEWnZtRUGgTKag7g9Oiw_37_7">26,791</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_221b396b_4750_40ae_8196_6b23c23d5080"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_a2mkkn4MzkaH8vARVUpfTw" continuedAt="Tb_a2mkkn4MzkaH8vARVUpfTw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 18. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, in connection with the March 2025 issuance and sale in a public offering of (i) <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_3_3_2025_To_3_3_2025_Oqo3T2TPe0OI8F2BWWq60A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_tIapP-u_AU2CnFgpzmpXlQ">188</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_YlCT5Ht1C0ySlRxPWi7pMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_93dA_zupYUC7LV9mES8a4A">3,812</ix:nonFraction> shares of Common Stock, and (iii) accompanying warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_H1m79MxGEESZ-YgtaaXWXQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_lO1DQAq6ck-zn7N2gm8VsQ">4,000</ix:nonFraction> shares of Common Stock, after March 31, 2025 but before financial statement issuance, certain investors exercised <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wQc4SgRdUEicS5pdoMt99A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_n01gDUnMSkCJnkIBAyB50Q">300</ix:nonFraction> pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jEJ-6V5VnEiejCS4zWZhwQ" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Narr__Fn1tZUcd0CBaAgNr2WNyw">300</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>,<span style="font-size:12pt;"> </span>in connection with the Fifth Amendment of the Credit Agreement and issuance of new warrants to the Lenders to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_IXMUpkWok0ukKHQSRU950Q">313</ix:nonFraction> shares of common stock, after March 31, 2025 but before financial statement issuance, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4ANH0Ryp-E-Q8Hcq8ycu6g" decimals="-3" format="ixt:num-dot-decimal" name="btai:StockIssuedDuringPeriodSharesWarrantsExercise" scale="3" id="Narr_FHol3e52eEybHKKaG8P7jQ">284</ix:nonFraction> shares of Common Stock in connection with the cashless exercises of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="As_Of_5_13_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-0WZ3XTjU0qB5FR91C9j6g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_92uED-qTUEWGFqgT9tW2nQ">313</ix:nonFraction> warrants. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_a2mkkn4MzkaH8vARVUpfTw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">On April 3, 2025, the Company entered into</span><span style="font-weight:normal;"> an Equity Distribution Agreement (the &#8220;Equity Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) to sell shares of the Company&#8217;s common stock, par value </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA" contextRef="As_Of_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mWRWF3v2JEGzrKxCrcvnRQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_DiT9sXRJFEuASzRYg3Ecrg">0.001</ix:nonFraction></span><span style="font-weight:normal;"> per share, with aggregate gross sales proceeds of up to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_4_3_2025_To_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_B7tCQZI3s0-d2yjT-Ceoug" decimals="-3" format="ixt:num-dot-decimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_AZbSsxZNaEq7YAaspmRxKQ">8,135</ix:nonFraction></span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market&#8221; equity offering program under which Canaccord will act as sales agent. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On April 8, 2025, the Board unanimously approved (i) the payment of a retention bonus to all non-executive employees in the total aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A" contextRef="Duration_4_8_2025_To_4_8_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKVZkA0td0assUa8qAOlvw" decimals="-3" format="ixt:num-dot-decimal" name="btai:RetentionBonusExpense" scale="3" id="Narr_SGgEdTMQq06BuPXz0h5-eA">1,545</ix:nonFraction>, to be paid in two equal installments and (ii) the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA" contextRef="Duration_4_8_2025_To_4_8_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_P9AZ6PXW1kOHAK6MhEcNgw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_TpVRgk4EVUSn24XK84a52g">66</ix:nonFraction> RSUs which fully vest on the <ix:nonNumeric contextRef="Duration_4_8_2025_To_4_8_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_P9AZ6PXW1kOHAK6MhEcNgw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_1L9wtKzKmk2cktSQ77vrXQ">one-year</ix:nonNumeric> anniversary of the grant date. The first installment of the retention bonus was paid on April 30, 2025 and the second installment shall be paid upon successful completion of the Serenity Trial data readout and securing additional financing. Each such installment payment is subject to the applicable employee&#8217;s continued employment through December 31, 2025. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_52f91534_e197_498b_bd99_30ab9dacf56b"></a><a id="Item2MANAGEMENTSDISCUSSIONANDANALYSIS_22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this report and the audited financial statements and related notes contained in our Annual Report on Form 10-K for the year ended December 31, 2024. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below and in the forward-looking statements. Factors that could cause or contribute to these differences include, without limitation, those discussed in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, those listed under &#8220;Summary Risk Factors,&#8221; and those discussed in the section titled &#8220;Risk Factors&#8221; included in Part II, Item 1A. of this report. All dollar amounts in the below Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations are presented in U.S. dollars, and all dollar and share amounts are presented in thousands, unless otherwise noted or the context otherwise provides.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">BioXcel Therapeutics, Inc. (Nasdaq: BTAI,  &#8220;the Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. We utilize cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ our proprietary AI platform to reduce therapeutic development costs and potentially accelerate development timelines. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe this differentiated approach has proven its potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Nasdaq Notice</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On September 20, 2024, we received a letter from Nasdaq Staff notifying us that for the 30 consecutive business days prior to the date of the letter, the Company&#8217;s market value of listed securities (&#8220;MVLS&#8221;) closed below the minimum $35 million requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a period of 180 calendar days, or until March 19, 2025, to regain compliance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As anticipated, on March 20, 2025, we received another letter from the Staff stating that, as a result of the Company&#8217;s continued non-compliance with the MVLS requirement, its securities would be delisted from Nasdaq unless the Company appealed the Staff&#8217;s delisting determination by requesting a hearing before the Nasdaq Panel. The Company made a timely request for a hearing before the Panel to appeal the Staff&#8217;s determination. The hearing was held on May 1, 2025. At the hearing, we presented our plan for regaining compliance with the MVLS requirement and requested a further extension so that we may complete the execution of our plan. No assurance can be provided that Nasdaq will ultimately accept our plan or that we will ultimately regain compliance with the MVLS requirement. As of the date of this report, we have not received a determination from the hearings panel. Our common stock will remain listed and eligible for trading on Nasdaq pending the ultimate conclusion of the hearing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our most advanced neuroscience candidate is BXCL501. In indications other than those approved by the U.S. Food and Drug Administration (FDA) as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. Our most advanced immuno-oncology asset, BXCL701, is an investigational oral innate immune activator from OnkosXcel Therapeutics as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On April 6, 2022, we announced that the FDA approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is approved to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> was commercially available in doses of 120 and 180 micrograms (&#8220;mcg&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are currently conducting our SERENITY At-Home pivotal Phase 3 safety trial intended to support a supplemental new drug application (&#8220;sNDA&#8221;) submission to potentially expand the label of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>into the at-home setting. On September 5, 2024, we announced the initiation of the trial, a double-blind, placebo-controlled study to evaluate the safety of a 120 mcg dose of BXCL501 in 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. On November 12, 2024, we announced that the first patient had been randomized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On May 12, 2025, we announced the trial was fully enrolled, and that more than 165 patients had been dosed. Topline data results from the trial are expected in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our TRANQUILITY program is designed to evaluate BXCL501 for the potential acute treatment of agitation with Alzheimer&#8217;s dementia in the at-home setting and in-care facilities. We have had several FDA meetings to discuss the development program, and the FDA has commented on the proposed protocol for our TRANQUILITY In-Care Phase 3 trial, which is designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer&#8217;s dementia. The Company is advancing plans for initiation of the trial upon funding. See further discussion in <i style="font-style:italic;">&#8220;Our Neuroscience Clinical Programs&#8221;</i> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As described further below, we have<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>deprioritized the development of BXCL501 for certain other proposed indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator from OnkosXcel Therapeutics as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. As described further below, we have<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>deprioritized the development of our BXCL701 programs, except as noted under &#8220;Immuno-Oncology&#8221; below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">2024 Clinical Prioritization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On May 8, 2024 the Company took actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. The Company reduced its workforce by approximately 15% and notified impacted employees on May 8, 2024. All related restructuring costs were paid in the second quarter of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 17, 2024, the Company reduced its workforce by an additional 28% to extend its cash runway and prioritize clinical development of BXCL501. The Company completed the Clinical Prioritization in October 2024, paid $475 of the related costs during the first quarter of 2025, and expects to pay approximately $128, the remaining costs, in the second quarter of 2025, which are included in Accrued Expenses on the Condensed Consolidated Balance at March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IGALMI</b><sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> Commercialization Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;">We are continuing to supply IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> through existing distribution channels. At the same time, while seeking potential commercial partners, we are maintaining IGALMI&#8217;s market presence with minimal commercial resources following our Clinical Prioritization in 2024. Our commercialization efforts are designed to build the foundation to launch additional potential follow-on indications. If IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> would be approved outside the U.S., we would consider launching the product through collaborations with third parties.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:248pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Our Neuroscience Clinical Programs and Investigator-Sponsored Trials</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the status of our major neuroscience clinical development programs and investigator-sponsored trials as of the date of this Quarterly Report on Form 10-Q. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><img src="btai-20250331x10q006.jpg" alt="Graphic" style="display:inline-block;height:248pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:481.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">About BXCL501</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">BXCL501 is our most advanced neuroscience clinical candidate. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine, a selective alpha-2 receptor agonist, targeting symptoms from stress-related behaviors such as agitation. BXCL501 is currently being evaluated for the acute treatment of agitation related to bipolar disorders or schizophrenia in the at-home setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">As a selective adrenergic agent with a sublingual or buccal route of administration, BXCL501 is designed to be easily administered and has shown a relatively rapid onset of action in multiple clinical trials, including those studying patients with bipolar disorders, schizophrenia, and Alzheimer&#8217;s disease. We believe results from these studies suggest that BXCL501 has the potential to reduce agitation without producing excessive sedation. We also believe BXCL501 is highly differentiated from antipsychotics, which are currently used as first-line standard-of-care treatment for agitation despite often producing unwanted side effects such as excessive sedation or extra pyramidal motor effects. Managing patient agitation in neuropsychiatric and neurodegenerative disorders represents a significant challenge for physicians and caregivers. We believe BXCL501 has the potential to address these challenges and, if approved for the respective indications, has the potential to become the standard of care for the acute treatment of agitation associated with these disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, based on its potential mechanism of action, we believe BXCL501 has the potential to address some symptoms of several additional diseases or conditions, including opioid use disorder (&#8220;OUD&#8221;), acute stress disorder (&#8220;ASD&#8221;) and post-traumatic stress disorder (&#8220;PTSD&#8221;). BXCL501 is currently being evaluated for treatment of patients with those conditions in clinical trials sponsored by leading academic research institutions. See Government-Supported Investigator-Sponsored Trials (&#8220;ISTs&#8221;) below.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">BXCL501 Late-Stage Clinical Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SERENITY Program: Acute Treatment of Agitation Associated with Bipolar I or II Disorder or Schizophrenia</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Under our SERENITY program, we are focused on the continued development of BXCL501 (currently marketed and commercialized as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>as a potential treatment option for agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The Company is currently advancing its SERENITY At-Home pivotal Phase 3 trial, which is designed as a double-blind, placebo-controlled study to evaluate the safety of a 120 mcg dose of BXCL501 in 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. We also plan to initiate a clinical study designed to enroll approximately 30 patient-informant dyads to evaluate the correlation between patient-and informant-reported efficacy measurement and the Positive and Negative Syndrome Scale-Excitatory Component (&#8220;PEC&#8221;) scale, conducted by trained raters as recommended by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Following engagement with and feedback from FDA, on September 5, 2024, we announced the initiation of the SERENITY At-Home trial, followed by our announcement on November 12, 2024 that the first patient had been randomized. On May 12, 2025, we announced the trial was fully enrolled, and that more than 165 patients had been dosed. Topline data results, which are expected in the second half of 2025, are intended to support a supplemental new drug application (&#8220;sNDA&#8221;) submission to potentially expand the label of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>into the at-home setting, beyond its current indication for use under healthcare provider supervision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">TRANQUILITY Program: Acute Treatment of Agitation Associated with Dementia due to Probable Alzheimer&#8217;s Disease (&#8220;AAD&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">Under our TRANQUILITY program, we are evaluating BXCL501 as a potential treatment option for the acute treatment of agitation associated with Alzheimer&#8217;s dementia (&#8220;AAD&#8221;). On June 29, 2023, we announced positive topline results from our TRANQUILITY II Phase 3 trial.  The randomized, double-blind, placebo-controlled, parallel group trial evaluated the safety and efficacy of BXCL501 for the acute treatment of AAD in adults 65 years and older with mild to moderate dementia in assisted living facilities and residential care settings who required minimal assistance with activities of daily living.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On June 29, 2023, we also announced that we had learned that an investigator in the TRANQUILITY II study engaged in misconduct. Since that time, we have taken steps to further investigate and evaluate the conduct of the trial at the investigator&#8217;s clinical site. On October 25, 2023, we announced that an independent third-party audit of data integrity at the trial site did not identify any findings that they believed impacted the data reliability or integrity, nor did they find any evidence of additional misconduct or fraud.&#160;On March 3, 2025, we announced that the FDA concluded that the inspection of the single site in the trial was closed under&#160;21 C.F.R.20.64(d)(3)&#160;and released the Establishment Inspection Report, designating &#8220;Voluntary Action Indicated&#8221; for the site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Based on subsequent meetings with and feedback from the FDA, we plan to generate additional Phase 3 efficacy and safety data, in relevant care-facility settings and across severity of dementia, in our TRANQUILITY In-Care trial.&#160; On September 5, 2024, we submitted to the FDA the proposed protocol for the trial, a double-blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for acute treatment of AAD in the care setting. On November 12, 2024, we announced that we had received FDA feedback on the proposed protocol.&#160;The Company is advancing plans for initiation of the trial upon funding. At a future meeting with the FDA, we plan to further discuss our trial design and the details of the requirement for long-term safety data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Pediatric Study</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In June 2021, we initiated a clinical trial designed to evaluate the safety and efficacy of BXCL501 in the acute treatment of agitation associated with schizophrenia or bipolar disorders to fulfill pediatric study requirements agreed to with the FDA in connection with the approval of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. The trial protocol has been reviewed and agreed to by the FDA, to fulfill the commitment to study BXCL501 in pediatric patients ages 13 to 17 with schizophrenia and ages 10 to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">17 with bipolar disorders. Enrollment of patients with schizophrenia, schizoaffective disorder, bipolar I, and bipolar II disorder is ongoing in this multi-site, double-blind, placebo-controlled parallel group trial. Approximately 63% of the 150 total subjects have been enrolled in the U.S. and 95 of such subjects have completed the clinical trial. Similar to our registration trials in schizophrenia and bipolar disorder (SERENITY I and II), the primary endpoint is the change from baseline PEC total score at two hours. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In October 2024, we submitted a request to the FDA for a deferral extension to complete enrollment requirements for pediatric patients with schizophrenia or schizoaffective disorder. The FDA granted a 3-year extension to complete the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IGALMI</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> Post-Marketing Requirement Study </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On June 25, 2024, we announced topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. During the single-arm, open-label study, 28 inpatient adults with frequent episodes of agitation associated with bipolar disorders or schizophrenia self-administered 180 mcg dose of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as needed over seven days. A total of 83 episodes were treated. There was no evidence of tachyphylaxis, tolerance, or withdrawal, and IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> was generally well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Neuroscience Opportunities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">BXCL501 Pipeline Opportunities for Franchise Expansion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Based on its potential mechanism of action, we believe BXCL501 has the potential for broad applicability across several indications where agitation is a symptom of a condition or underlying disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Government-Supported Investigator-Sponsored Trials (&#8220;ISTs&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our research partners have been awarded grants for the development of BXCL501 in alcohol use disorder (&#8220;AUD&#8221;) with comorbid post-traumatic stress disorder (&#8220;PTSD&#8221;), opioid use disorder (&#8220;OUD&#8221;), and acute stress disorder (&#8220;ASD&#8221;). The Company is providing regulatory and operational support and supplying investigational product for these development opportunities, which are being funded through Cooperative Agreements with the U.S. Department of Defense Congressionally Directed Medical Research Program and National Institute on Drug Abuse (&#8220;NIDA&#8221;). Clinical and regulatory responsibilities are led by clinical researchers and regulatory staff at the Veterans Affairs Connecticut Healthcare System, Yale University Medical School, RTI International, Columbia University New York State Psychiatric Institute, and University of North Carolina at Chapel Hill<span style="white-space:pre-wrap;">.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><b style="font-weight:bold;background:#ffffff;">Opioid Use Disorder (&#8220;OUD&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"><span style="background:#ffffff;">As the Company previously announced, NIDA awarded a grant to Columbia University to fund clinical testing of BXCL501 as a potential treatment for opioid withdrawal symptoms in patients diagnosed with OUD. The original 160-patient, three-site, four-arm</span><span style="background:#ffffff;">&#160;</span><span style="color:#212121;">study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 mcg and 240 mcg BID), lofexidine (as a positive control), and placebo. The study&#8217;s goal is to evaluate the safety and efficacy of BXCL501 relative to lofexidine and placebo in subjects with OUD.</span><span style="color:#212121;">&#160; A </span><span style="color:#212121;">majority of OUD patients participating in the study are anticipated to be exposed to</span><span style="background:#ffffff;"> fentanyl adulterated or associated with xylazine</span><span style="color:#212121;">. To date, a</span><span style="background:#ffffff;">ll three initial sites have recruited, enrolled, and dosed patients diagnosed with OUD who are physically dependent on opioids, including prescription opioids. The Company is supplying BXCL501 for the study, which is sponsored by Columbia University</span><span style="color:#212121;">. We expect that the results from current study will be used to select a recommended dose of BXCL501 to compare to placebo in a later outpatient Phase 3 study sponsored by </span><span style="background:#ffffff;">NIDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;background:#ffffff;">Alcohol Use Disorder (&#8220;AUD&#8221;) with Comorbid Post-traumatic Stress Disorder (&#8220;PTSD&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2020, the Veterans Affairs Connecticut Healthcare System and Yale University Medical School were awarded a grant by the U.S. Department of Defense&#8217;s Congressionally Directed Medical Research Program with the overall objective to evaluate BXCL501 in patients who suffer from AUD with comorbid PTSD. The Company provided BXCL501 for the inpatient Alcohol Interaction Study, which has been completed. We understand Yale is currently </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">seeking approval from its Institutional Review Board (&#8220;IRB&#8221;) and allowance from the FDA to proceed with a trial evaluating the effects of up to 80 mcg BID of BXCL501 per day for 28 days on alcohol consumption, PTSD symptoms, cognitive function, memory, sleep, and mood in patients diagnosed with mild, moderate, or severe AUD and who meet Criterion A for comorbid PTSD. The outpatient study has received funding approval from the Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (funded through a Cooperative Agreement between the U.S. Department of Defense Congressionally Directed Medical Research Program and RTI International). Patient screening and enrollment is expected to begin in 2025.  We believe study results may be used to inform a Phase 3 study intended to commence with support by the alliance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Acute Stress Disorder (&#8220;ASD&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On October 15, 2024, we announced a U.S. Department of Defense grant to the University of North Carolina at Chapel Hill (&#8220;UNC&#8221;) to fund a study of BXCL501 for treating ASD. The award provides $2,800 to the UNC Institute for Trauma Recovery from September 15, 2024 through September 14, 2026 to evaluate the potential efficacy of BXCL501 to reduce ASD symptom severity and/or posttraumatic neuropsychiatric symptoms. The double-blind, placebo-controlled trial is expected to enroll 100 patients experiencing ASD resulting from motor vehicle collisions in 2025, with BXCL501 supplied by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BXCL502</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We identified a second neuropsychiatric drug candidate, BXCL502 &#8722; Latrepirdine (Dimebon) &#8722; through our AI-based platform. We had planned to evaluate BXCL502 initially as a monotherapy and possibly in combination with BXCL501 for the chronic treatment of agitation in patients with dementia and acute stress disorder. The active pharmaceutical ingredient (&#8220;API&#8221;) underlying BXCL502 affects serotonergic signaling in the brain. Our preclinical data suggests BXCL502 has the potential to treat stress-related neuropsychiatric symptoms in dementia and other stress-related disorders. In previously published third-party clinical trial data, daily administration of the API of BXCL502 demonstrated improvement in behaviors using a well-established, clinically validated symptom scale. Formulation and further clinical development planning for BXCL502 was paused as part of the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Additional Product Candidates Identified Leveraging our AI Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Our AI platform is comprised of a series of customized and specific AI applications aimed at identifying, predicting efficacy and testing of late-stage assets with known mechanisms of action and associated pharmacology and safety data. We target neuropsychiatric and neurological rare disorders, where the compounds are either disease-modifying or symptom-mitigating. Compounds are tested in relevant models of disease and rank-ordered based on the potential to enter the clinic and ease of development. Disease areas of interest are stress-related such as agitation, or neuropsychiatric symptoms associated with dementia and responsible for increased levels of healthcare burden.  For example, our pipeline concepts BXCL503 and BXCL504 putatively have the potential to address apathy and aggression in dementia, respectively. Further development of these concepts is currently paused.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our policy is to protect and enhance the proprietary technologies, inventions, and improvements that are commercially important to our business by filing patent applications in the U.S. and other jurisdictions related to our proprietary technology, inventions, improvements, and product candidates. We also rely on trademarks, trade secrets, and know-how relating to our proprietary technologies and product candidates, continuing innovation, and in-licensing technology and products. This reliance is expected to develop, maintain, and strengthen our proprietary position for novel therapeutics and novel formulations of existing therapeutics across multiple therapeutic areas. We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when available.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have multiple patent families filed to protect our neuroscience program, including BXCL501.&#160;As of May 1, 2025, our neuroscience patent portfolio included five Patent Cooperation Treaty (&#8220;PCT&#8221;) applications not yet in national phase, 14 U.S. utility applications, 16 issued U.S. utility patents, 62 pending non-U.S. utility applications, 26 allowed or granted non-U.S. patents (including four in Japan), one pending U.S. design patent application, and two registered design patents in Japan. Thirteen U.S. utility patents, directed to our proprietary sublingual film formulation </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of dexmedetomidine and methods of treating agitation, are listed in the<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span>FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the &#8220;Orange Book&#8221;) for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>with expiration dates between 2037 and 2043. In the formulation family, we have granted or allowed patents in China, Europe, Eurasia, Japan, Mexico, and the U.S., and pending applications in the U.S., China, and other major markets. We expect that patents issued in this family will expire no earlier than 2039. We have also filed applications in additional patent families that are relevant to BXCL501. We have one granted European patent and applications pending in the U.S. and Japan directed to methods of treating insomnia using sublingual dexmedetomidine. We expect that patents issued from these applications will expire no earlier than 2035. We also have granted patents and pending applications filed in major markets, including the U.S., Europe, Japan, and China, directed to methods of treating agitation. We expect that patents issued from these applications will expire between 2039 and 2043. We also have four PCT applications directed to treating mania, depression, stress, and agitation. If patents are issued from those cases, we expect them to expire in 2043 or 2044.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. Depending upon the timing, duration, and specifics of FDA approval of our product candidates, a U.S. patent that we own or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (a.k.a., the &#8220;Hatch-Waxman Act&#8221;). The act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the drug approval regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of a new drug application (&#8220;NDA&#8221;), plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the application for extension must be made prior to patent expiration. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of a patent can also be extended by PTA established in 35 U.S.C. 154(b). The intention of the PTA is to accommodate for delays caused by the USPTO during the prosecution of a U.S. utility or plant patent application. Under PTA, the USPTO delay is divided into three types: type A (delays after 14 months from the filing date of the application until the USPTO issues a first Office Action and delays after four months from the filing of certain actions by the applicant until the USPTO responds to such actions); type B (delays after three years from the earliest effective filing date until a patent is granted); and type C (delays due to interferences, secrecy orders, and successful appeals). The total amount of PTA is calculated by adding the types A, B, and C delays, and then subtracting any delay that is overlapped among three types or that is attributable to the applicant.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of a patent can also be shortened by a terminal disclaimer. A terminal disclaimer is a statement filed by a patent owner in which the owner disclaims or dedicates to the public the terminal part of the term of a patent. Often, the terminal disclaimer is filed in cases where at least one claim of a pending application would have been obvious in light of at least one claim in an earlier-filed patent, (or non-statutory obviousness-type double patenting rejection).&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The patent positions of companies such as ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of method of use patents or reformulation patents has emerged in the U.S. patent laws and their interpretation outside of the U.S. are also uncertain. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our technology or product candidates and enforce the patent rights that we license and also could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company owned intellectual property, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">methods of use, or the manufacture of those products. In addition, if a pending patent application is granted, it is possible that only a subset of the claims that are currently contained in the pending patent application will be issued. Further, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and the issued patents that we in-license and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies outside the scope of the rights granted under any issued patents that we own or exclusively in license. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. For additional information regarding intellectual property regulations and risks, see below under &#8220;Immuno-Oncology Intellectual Property&#8221; and Part II, Item 1A, &#8220;Risk Factors - Risks Related to Our Intellectual Property&#8221; elsewhere in this Quarterly Report on Form 10-Q.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Immuno-Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, we announced the formation of a wholly owned subsidiary, OnkosXcel Therapeutics (&#8220;OnkosXcel&#8221;) to develop potentially transformative medicines in oncology. OnkosXcel uses proprietary AI capabilities to drive the capital-efficient development of innovative anti-cancer therapeutics. The Company is continuing to evaluate strategic options for OnkosXcel and further work on the immuno-oncology programs described below has been paused, except as noted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our approach to drug discovery leverages the application and methodology of our proprietary AI-based research and development platform, utilized in the successful development of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> with the aim of efficiently identifying and developing immuno-oncology product candidates. We believe that BXCL701 reflects the potential of this discovery approach in immuno-oncology. BXCL701 is an investigational, oral innate immune activator which demonstrated a 25% composite response rate in a Phase 2a clinical trial to treat patients with small cell neuroendocrine carcinoma (&#8220;SCNC&#8221;) phenotype metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;). On February 12, 2024, the Company announced that the FDA designated as a Fast Track development program the investigation of BXCL701 in combination with a checkpoint inhibitor for the treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability. We have finalized a potential registrational trial design in mCRPC patients with SCNC phenotype. However due to our Clinical Prioritization, further planning on the trial has been paused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">mCRPC is often characterized as a &#8220;cold&#8221; tumor, which is a tumor with an immunosuppressive tumor microenvironment (&#8220;TME&#8221;) and poor immune cell infiltration. Currently approved checkpoint inhibitors (&#8220;CPIs&#8221;) that target programmed cell death 1 (&#8220;PD-1&#8221;) or cytotoxic T-lymphocyte-associated protein 4 (&#8220;CTLA-4") have failed to demonstrate meaningful single-agent activity against such difficult-to-treat tumor types, including mCRPC. BXCL701 is designed to promote an immune-induced inflammatory response in the TME primarily via inhibition of dipeptidyl peptidases (&#8220;DPP&#8221;) 8 and 9, which we believe can provide enhanced CPI therapeutic utility. We believe BXCL701 can potentially provide significant benefits for the approximately 20% of the estimated 299,010 men diagnosed with prostate cancer in the U.S. in 2024 and who we are expected to progress to the more aggressive mCRPC form of the disease, including approximately 20%, or 11,960, of those patients expected to develop the SCNC phenotype, for which there are currently limited treatment options. Immune checkpoints represent a myriad of inhibitory pathways that act to regulate the duration and intensity of an antigen-induced immune response and factor prominently in mediating immune tolerance. They function as critical gatekeepers that prevent the indiscriminate attack of normal host cells by components of the immune system. Certain cancers co-opt these pathways and overexpress immune checkpoint molecules to camouflage themselves to avoid detection and destruction. CPIs, designed to harness the intrinsic power resident in the immune system, work by disabling the suppressive function of immune checkpoints, allowing the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">immune system to bypass such cancers&#8217; shield of immune tolerance. CPIs are expected to generate sales of more than $50 billion worldwide by 2025, up from sales of approximately $29 billion in 2020. While CPIs have proven to be a significant advancement in cancer therapy, those currently approved by the FDA do not produce meaningful results in a majority of patients, as the clinical benefit is generally viewed to be limited to between 13% and 30% of cancer patients, and the duration of response is relatively short.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the limited efficacy of approved CPIs results primarily from their intervention at later stages of the immune response. As a result, other targets and pathways can be exploited by the tumor to create a TME that can evade the enhanced immunological response enabled by approved CPIs. While numerous agents designed to target the earlier stages of an immune response are in development for use in combination with CPIs, their activity is restricted to a single component of the immune response. In contrast, we have developed BXCL701 to simultaneously address multiple components of the immune response, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cancer antigen presentation by dendritic cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of dendritic cell trafficking to tumor draining lymph nodes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priming and activation of T cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: acceleration of tumor-induced priming of T cells and the formation of potent cytotoxic T lymphocytes (&#8220;CTLs&#8221;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Infiltration of immune cells into the tumor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of release of chemokines that attract effector T cells but block regulatory T cells and also induce NK cell and neutrophil migration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Killing of tumor cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: induction of formation of CTLs and NK cells expressing tumor-killing perforins and granzymes, as well as the formation of memory T cells that can selectively kill returning tumor cells.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accordingly, we believe BXCL701 may have utility in stimulating increased activation, proliferation, and infiltration of tumor cells by immune effector cells, enabling its potential application in combination with currently approved CPIs, across a range of solid tumors and hematological malignancies, to potentially:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Convert immunological cold tumors into ones sensitive to CPIs;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Enhance hot tumors&#8217; response rate and depth of response to CPIs; and</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Restore CPI sensitivity to tumors that were previously responsive.</i></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Central to our drug discovery initiatives are proprietary, AI-driven platform technologies we employ to identify novel therapeutic uses for approved therapeutics and candidates in clinical evaluation. The first and most advanced of our AI-driven discovery programs is our innate immune modulation program, which supported the pursuit of BXCL701 as a development candidate. We believe the application of this program provides us actionable insights into the inflammasome, a component of the innate immune system responsible for activation of the inflammatory response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Immuno-Oncology Programs and Investigator-Sponsored Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Below is a summary of the status of our immuno-oncology clinical development programs as of the date of this Quarterly Report on Form 10-Q. We believe our product candidates, if successfully developed and approved, have the potential to become compelling treatment options for their respective indications. However, further work on our immuno-oncology programs has been paused, other than as noted below.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:234pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><img src="btai-20250331x10q007.jpg" alt="Graphic" style="display:inline-block;height:233.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:481.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Leveraging the insights enabled by the application and methodology of our proprietary AI-based platform which was used to identify novel therapeutic uses for our approved therapeutics and product candidates in clinical evaluation, and our industry expertise, we are pursuing two proprietary discovery programs to advance our goal of developing anti-cancer therapeutics. The first program, which encompasses BXCL701 across a range of indications, is based on the application of innate immune modulation technology. This program has been constructed to embrace key distinguishing characteristics of the innate immune system and we believe it is supported by our development efforts. This approach has driven the development of BXCL701, as a potential treatment for mCRPC with either SCNC or adenocarcinoma phenotype. Fundamental to the innate immune modulation program is BXCL701&#8217;s potential to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Convert cold tumors into ones sensitive to CPIs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enhance hot tumors&#8217; response rate and depth of response to CPIs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restore CPI sensitivity to tumors which had previously been responsive.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for mCRPC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe BXCL701 may have utility in stimulating increased activation, proliferation, and infiltration of tumor cells by immune effector cells, enabling its potential use in combination with currently approved CPIs to treat cold tumors, such as mCRPC. We elected to pursue mCRPC as an indication for BXCL701 due to its enrichment for DPP mutations, which are especially prevalent in tumors with SCNC phenotype.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We received initial comments from the FDA on our proposed clinical development plan and received positive feedback regarding dose-optimization around the recommended Phase 2 dose (&#8220;RP2D&#8221;) for use in future studies. However, the start of any such additional trial is paused following the Company&#8217;s Reprioritization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Phase 2a portion of the trial was segregated into two 28-patient trial cohorts, one cohort consisting of mCRPC patients with SCNC phenotype and a second cohort consisting of mCRPC patients with adenocarcinoma phenotype. Initially, we focused on mCRPC with SCNC phenotype as the primary patient population for BXCL701, since DPP9 is amplified in approximately 17% of treatment-emergent mCRPC with SCNC phenotype, compared to 5% or less in the broader prostate cancer population. However, we also observed responses in mCRPC patients with adenocarcinoma phenotype who were microsatellite stable in the Phase 1b portion of the trial. On this basis, we widened our Phase 2a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">trial to include relapsed mCRPC patients with either SCNC or adenocarcinoma phenotype. Both cohorts employed a Simon two-stage trial design of 15 trial participants followed by 13 additional patients. The primary endpoint of the Phase 2a portion of this trial was a composite response rate, determined as either a RECIST 1.1 response (defined as a reduction in RECIST score of 30% or more), and/or a reduction in prostate specific antigen (&#8220;PSA&#8221;) level of 50% or more, and/or a conversion in circulating tumor cells (&#8220;CTCs&#8221;) from 5 or more CTCs/7.5 milliliter (&#8220;ml&#8221;) to less than 5 CTCs/7.5 ml. Secondary endpoints included duration of response, progression-free survival, overall survival, changes in circulating cytokines, and certain disease-specific biomarkers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the results observed in the Phase 2a trial of BXCL701 administered in combination with pembrolizumab support further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were particularly encouraged by the results observed in the cohort consisting of mCRPC patients with SCNC phenotype. Updated Phase 2a results for the SCNC cohort were presented at the 30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Prostate Cancer Foundation Scientific Retreat (PCF 2023). BXCL701 in combination with pembrolizumab demonstrated a 25% (seven out of 28 evaluable patients) composite response rate in mCRPC patients with SCNC phenotype, for whom there is no standard of care. As of a data cutoff of September 6, 2023, five of these responders were RECIST 1.1 responders (four confirmed responses and one unconfirmed response) with decreases in tumor size ranging from -45% to -67% and a median duration of response of 7.6 months. Overall survival (OS) results from the Phase 2a portion of the trial in SCNC patients. BXCL701 in combination with pembrolizumab demonstrated a compelling median OS and 12-month survival rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">The most frequently observed TEAEs (&#8805;15% of patients) that appear to be related to talabostat included Fatigue, Hypotension, Dizziness, Nausea, and Pruritus. The events have generally been manageable and reversible. When combined with the immune checkpoint inhibitor pembrolizumab, the most frequently reported talabostat-related TEAEs (&#8805;15% of patients) have been Fatigue, Hypotension, Pruritus, Dizziness, Nausea and Diarrhoea. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Phase 2a trial has also been completed for the adenocarcinoma cohort. The CRR was 18.2% (n = 6). In 29 patients with disease evaluable for response, the confirmed ORR per RECIST 1.1 per investigator assessment was 13.8% (n = 4). Decreases in tumor size ranged from -67% to -90%. Two patients had an unconfirmed RECIST 1.1 response, 5 patients had a PSA<sub style="font-size:7.5pt;vertical-align:sub;">50</sub> response, and 2 patients had a CTC response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The median OS of evaluable patients was 12.1 months (95% CI 5.5 &#8211; 16.4) and the 12-month survival rate was 53.4%. Median rPFS was 1.9 months and the 6-month rPFS rate was 16.8%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:12pt;"> </span>The most frequently observed TEAEs &gt;15% of patients that appear to be related to talabostat included Fatigue, Nausea, Hypotension, Platelet count decreased, Vomiting, Dizziness, White blood cell count decreased and decreased appetite. The events have generally been manageable and reversible. When combined with the immune checkpoint inhibitor pembrolizumab, the most frequently reported talabostat-related AEs have been Fatigue, Nausea, Vomiting, Hypotension, Platelet count decreased, Pruritus, Dizziness, White blood cell count decreased, Diarrhoea and Decreased appetite.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for Small Cell Lung Cancer (&#8220;SCLC&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">We are encouraged by the therapeutic potential of BXCL701 for SCLC given the activity it has demonstrated in the  SCNC clinical trial. We have prepared a robust synopsis for a Phase 1b/2 trial design to be a dose-escalation safety lead-in to establish a RP2D in combination with atezolizumab, a CPI approved for SCLC. However, the start of any such trial has been paused. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for Other Cancers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to its potential use in combination with CPIs to treat mCRPC, an immunologically cold tumor, we are developing BXCL701 as a therapeutic for pancreatic cancer, and other solid tumors with greater, or &#8220;non-cold,&#8221; immunological activity that are nonetheless regarded as difficult-to-treat, and hematological malignancies. We believe the synergistic potential of BXCL701 and CPIs, when administered in combination, could increase cancer cell susceptibility to an enhanced immune response, potentially increasing the clinical benefit of CPIs, whose single-agent </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">efficacy in treating these tumor types is generally viewed to be limited to between 13% and 30% of cancer patients and the duration of response to treatment is often short. As such, we envision the potential therapeutic benefit of BXCL701 increasing the sensitivity of cold tumors to CPI therapy, enabling the potential treatment of a range of cancers including pancreatic cancer, breast cancer, colorectal cancer, and ovarian cancer, as well as enhancing the depth of response to CPIs in other cancers. Based on the preclinical observation that BXCL701 showed direct cytotoxic activity against certain leukemic cells, an investigator sponsored trial is being pursued at the Dana Farber Cancer Institute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pancreatic Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimated that in 2024, approximately 66,000 cases of pancreatic cancer were expected to be diagnosed in the U.S. We are supporting a Phase 2 investigator-sponsored trial (&#8220;IST&#8221;) sponsored by Georgetown Lombardi Comprehensive Cancer Center (&#8220;Georgetown Lombardi&#8221;), designed to evaluate the use of BXCL701 along with pembrolizumab to treat pancreatic cancer. Few therapeutic options are available for patients with this disease, which has a five-year survival rate of less than 10%, among the lowest of all cancers. Pancreatic cancer has among the highest levels of overexpression and amplification of DPPs. Preclinical models demonstrated synergy between DPP inhibition with BXCL701 and anti-PD-1 antibody in the pancreatic cancer tumor microenvironment. Based on these preclinical observations, Georgetown Lombardi has initiated a Phase 2 IST to assess the safety of BXCL701 when administered in combination with pembrolizumab (safety lead-in), as well as to estimate the 18-week progression-free survival rate (primary objective of the efficacy phase) in previously treated metastatic pancreatic ductal adenocarcinoma. This trial started in the third quarter of 2023. On February 6, 2024, we announced the completion of patient enrollment in the safety lead-in portion of the trial. As part of the trial&#8217;s safety lead-in, the first six patients have been enrolled and will be observed for a six-week safety window period. The trial is then expected to enroll approximately 39 patients in its efficacy phase in a Simon 2-stage single-arm, open-label design (19 patients in stage 1 and 20 patients in stage 2). Patients will be monitored radiographically and by tumor markers for response assessment. Tumor biopsies and blood samples will also be collected over the course of treatment to better understand the potential mechanism of action for the combination. The human proof of concept portion of the trial started in the first half of 2024. On April 24, 2024, we announced that an abstract entitled &#8220;Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings,&#8221; was selected for presentation at the poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Investigators reported that, as of the applicable cutoff date, one patient was progression-free at 18 weeks, three patients showed substantial reductions in serum CA19-9, a tumor marker that may correlate with increased T-cell infiltration, and one patient showed a best response of partial responses, out of six patients that had been treated with the combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Relapsed or Refractory AML</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimated that in 2024, approximately 21,000 new cases of AML were expected to be diagnosed in the U.S. We are supporting a Phase 1b IST sponsored by the Dana-Farber Cancer Institute (&#8220;Dana-Farber&#8221;) designed to evaluate the use of BXCL701, along with the current standard of care to treat relapsed or refractory AML. We believe that pyroptosis triggered by BXCL701 may provide potent single agent cytotoxicity directed towards AML. We also believe that DPP9 copy number may provide an actionable biomarker, as high copy number has been observed to correlate with BXCL701 toxicity in human AML cell lines. DPP8/9 inhibition has been shown to be cytotoxic to THP-1 cells, monocytic cancer cells cultured from a patient with AML, but not other cell lines, suggesting a specific vulnerability of AML to these inhibitors which we believe can be exploited for therapeutic benefit. Based on these preclinical observations, Dana-Farber has initiated a Phase 1b trial to assess the safety of BXCL701 and to determine the maximum tolerated dose or the RP2D of BXCL701 as a single agent in AML. This trial started in the first quarter of 2023. Subject to successful completion of this Phase 1b trial, we anticipate that Dana-Farber will conduct further studies to determine BXCL701's objective response rate in AML in combination with the standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Potential Anti-cancer Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe BXCL701 may have potential application in breast cancer, as its use in combination with monoclonal antibody therapy generated encouraging in vivo data in a preclinical disease model where enhanced antibody-dependent cellular cytotoxicity was observed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA has granted BXCL701 orphan drug designation for the treatment of AML, stage IIb to IV melanoma, pancreatic cancer, and soft tissue sarcoma. As we consider BXCL701&#8217;s mechanistic potential to be combined with other CPIs for additional indications that represent unmet medical needs we may be able to apply for additional orphan drug designations for BXCL701 plus CPI combinations. However, all BXCL701 ongoing development activity has been paused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Biomarker Development Initiatives Intended to Complement BXCL701 Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We also engaged in the identification and development of predictive biomarkers that we believe could be used in conjunction with BXCL701 to predict the likelihood of patient response to therapy across the range of targeted indications. Based on preliminary data from AML patients, we believe DPP9 copy number could correlate to BXCL701 response rate, with a greater likelihood of BXCL701 cytotoxicity in patients with increased DPP9 copy number. We presented data from the Phase 2a trial in SCNC patients at the Society for Immunotherapy of Cancer&#8217;s 38<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Meeting (SITC 2023). The data indicated DPP9 overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Intellectual property is of vital importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, enforcing, and defending patent and other intellectual property rights, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity, and patent term extensions where available.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of May 1, 2025, we have multiple patent families filed to protect our immuno-oncology program, including our core patent family directed to methods of using BXCL701 with immune checkpoint inhibitors, which is granted in the U.S., Japan, Australia, Canada, Russia, China, India, Taiwan, South Africa, Mexico, New Zealand, Europe, and United Arab Emirates.&#160; Additional applications in this family are pending in major markets. Patents issued from this family are expected to expire no earlier than 2036. We have an additional patent issued in the U.S. directed to a method of selecting patients based on a biomarker and methods of treating certain cancers, with an expected expiration date no earlier than 2039.&#160;A corresponding European Patent case directed to selecting patients is issued and is expected to expire no earlier than 2038.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additional applications are directed to administering BXCL701 in combination with various other molecules, biomarkers, and dosing regimens. We also have three PCT applications directed to novel formulations of BXCL701, various dosing regimens, methods of use, combination therapies, and to methods of treating small cell lung cancer. We expect that any patents issuing from the PCT and provisional applications will expire no earlier than 2043 to 2044.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We expect to file additional patent applications in support of current and new immuno-oncology clinical candidates as well as new platform and core technologies. For additional information regarding intellectual property regulations and risks, see above under &#8220;Neuroscience Intellectual Property&#8221; and Part II, Item 1A, &#8220;Risk Factors - Risks Related to Our Intellectual Property&#8221; elsewhere in this Quarterly Report on Form 10-Q.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Product Revenue, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Revenue relates to sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and reflect limited market access since commercial launch in July 2022. The revenues are net of rebates, chargebacks, discounts, and other adjustments. During the fourth quarter of 2022, we began contracting directly with intermediaries such as GPOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Operating Costs and Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;"><span style="font-weight:bold;">Cost of Goods Sold</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold primarily relates to the costs of producing, packaging, and delivering our product to customers, as well as costs related to excess or obsolete inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;"><span style="font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our research and development expenses reflect costs associated with the identification of our preclinical and clinical product candidates. Expenditures primarily consist of salary, benefits and non-cash stock-based compensation for our research and development personnel, costs incurred under agreements with contract research organizations and sites that conduct our non-clinical studies and clinical trials, costs of outside consultants engaged in research and development activities, travel expenses, the cost of acquiring, developing and manufacturing preclinical and clinical trial materials and lab supplies, and depreciation and other expenses. Payments to BioXcel LLC are also included in research and development expenses. Costs associated with third parties that provide non-clinical services such as toxicology, pharmacology, research and discovery, biomarker studies and similar services are included in the professional fees category of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expense research and development costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our research and development costs by program for the three months ended March 31, 2025 and 2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">BXCL501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,918</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,709</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">BXCL701</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (48)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 995</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other research and development programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 118</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 183</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total direct external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,988</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,887</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,168</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,911</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sub-total direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,156</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,798</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indirect costs and overhead</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 398</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 603</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total research and development expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,401</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;"><span style="font-weight:bold;">Selling, General and Administrative</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Selling, general and administrative expenses primarily consist of salaries, benefits and non-cash stock-based compensation for our sales, executive and administrative personnel. Selling, general and administrative expenses also </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">include legal expenses to pursue patent protection of our intellectual property and other corporate matters, professional fees for audit and tax services and insurance charges. We may also incur increased costs to comply with corporate governance, internal controls, investor relations and disclosures and similar requirements applicable to public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a result of our restructuring activities completed during 2024, we expect that our selling, general and administrative expenses will decline due to IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8217;s restructured commercialization plan and reduced personnel costs. However, we may also experience increased selling, general and administrative expenses due to higher fees for outside consultants, attorneys, and accountants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Restructuring Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2023 Strategic Reprioritization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On August 8, 2023, our Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). We took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend our cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of this strategy, the Company&#8217;s Board of Directors approved a reduction of approximately 60% of the Company&#8217;s workforce. The Company notified impacted employees on August 14, 2023. <span style="background:#ffffff;">The Reprioritization was substantially complete as of December 31, 2023, and the remaining restructuring costs were paid during the first quarter of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">2024 Clinical Prioritization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;background:#ffffff;">On May 8, 2024 the Company took actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. The Company reduced its workforce by approximately 15% and notified impacted employees on May 8, 2024. All related restructuring costs were paid in the second quarter of 2024.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On September 17, 2024, the Company reduced its workforce by an additional 28% to extend its cash runway and prioritize clinical development of BXCL501. </span>The Company completed the Clinical Prioritization in October 2024, and paid $475 of the related costs during the first quarter of 2025, and expects to pay the remaining $128 in the second quarter of 2025, which is included in Accrued Expenses on the Condensed Consolidated Balance at March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Management believes that, after giving effect to the</span> <span style="background:#ffffff;">Reprioritization and additional restructuring activities completed, the Company&#8217;s cash and cash equivalents of $31,013 as of March 31, 2025 will allow the Company to fund its operations and meet its liquidity requirements into the third quarter of 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense (Income)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other (income) expense primarily consists of interest costs associated with the Credit Agreement the Company entered into in April 2022, changes in fair value of derivative financial instruments, and interest income earned on cash and cash equivalents that were comprised primarily of money market funds. Interest expense may increase in the future if we meet required milestones, and we are able to draw down additional funds under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A description of recently issued accounting pronouncements is set forth in Note&#160;3 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form&#160;10-Q.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Comparison of the Three Months Ended March 31, 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Product Revenue, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Commercial sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> launched in July 2022. As part of the Company&#8217;s Reprioritization, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> commercial team shifted focus to a hospital/contracting strategy with a CAD team. The goal of the realigned CAD team is to work with large IDNs and drive sales utilizing a top-down approach, allowing the Company to continue to make inroads into the institutional market in a more cost-efficient manner. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> product revenue, net was $168 and $582 in the three months ended March 31, 2025 and 2024, respectively. The decrease in sales was primarily due to a reduction in bulk sales to existing customers coupled with a reduction in commercial activities due to the Clinical Prioritization in May 2024 and September 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;"><span style="font-weight:bold;">Cost of Goods Sold</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Cost of goods sold for the three months ended March 31, 2025 and 2024, were $14 and $80, respectively. Cost of goods sold is related to the costs to produce, package and deliver IGALMI</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;"> to customers, as well as costs related to excess or obsolete inventory.  We entered into a commercial supply agreement with ARx, LLC (&#8220;ARx&#8221;) pursuant to which ARx has agreed to exclusively manufacture and supply us with all of our worldwide demand of film formulation of Dex to be used for the commercial supply of IGALMI</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:normal;font-weight:normal;"> and for ongoing clinical trials of our product candidate BXCL501, subject to certain alternative supply provisions. The decrease in Cost of goods sold for the three months ended March 31, 2025 is primarily the result of a $45 decrease in inventory write-downs, compared to the prior year. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses for the three months ended March 31, 2025 and 2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,682</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,948)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (54)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (514)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,281</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,795)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (140)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,307</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (528)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,068</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,050)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (50)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 549</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (374)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (152)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (27)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,401</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,847)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (60)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The overall decrease of $6,847 for the three months ended March 31, 2025 relative to the same period in 2024 was primarily attributable to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased clinical trials expense as a result of reduced costs associated with the wind down of TRANQUILITY II and III study of BXCL501 for the potential treatment of agitation in patients with Alzheimer&#8217;s disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased professional fees due to lower pharmacology costs, research and discovery costs, toxicology, and consulting costs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased personnel and related costs as a result of our Clinical Prioritization in May 2024 and September 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased non-cash stock compensation costs as a result of lower headcount coupled with reversals in accelerated stock compensation expense for employees terminated in the first quarter of 2025.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased chemistry, manufacturing and controls (&#8220;CMC&#8221;) costs related to decreased clinical trial activities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8217;s approval by the FDA, we capitalize costs related to commercial production of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as inventory and expense those CMC costs related to clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Selling, General and Administrative Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses for the three months ended March 31, 2025 and 2024 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,072</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,186</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,114)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (66)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,152</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,458)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,872</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,311</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,439)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 169</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,347</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,178)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (87)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 383</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 396</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 509</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 872</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (363)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,699</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,264</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,565)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (57)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The overall decrease of $7,565 for the three months ended March 31, 2025, relative to the same period in 2024 was primarily attributable to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased personnel and related costs as a result of the Clinical Prioritization in May 2024 and September 2024. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased professional fees, primarily related to lower legal costs in 2025 compared to 2024 and reductions in consulting and recruiting for the three months ended March 31, 2025. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased commercial and marketing expense.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased non-cash stock based compensation costs as a result of lower headcount.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased other expenses, primarily travel expenses, as a result of lower headcount.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Other Expense (Income)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense increased to $3,993 for the three months ended March 31, 2025 from $3,607 in the same period in 2024 primarily due to higher debt balances and interest rates under the Credit Agreement. The expense was partially offset by lower interest income earned on lower levels of cash and cash equivalents that were held primarily in short-term money market funds. Interest income decreased to $279 for the three months ended March 31, 2025 compared to $947 for three months ended March 31, 2024, due to lower average cash balances during the year. Other (income) expense, net is primarily associated with changes in fair value of derivative financial instruments for the period, which relate to instruments associated with the Credit Agreement and the Company&#8217;s registered direct equity offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Inflation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented. For a discussion of inflationary risks to our future revenues under the Inflation Reduction Act, see &#8220;<i style="font-style:italic;">Health care reform measures could hinder or prevent </i></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">our product candidates&#8217; commercial success.</i><span style="white-space:pre-wrap;">&#8221;  in Part II, Item 1A, &#8220;Risk Factors&#8221; elsewhere in this Quarterly Report on Form 10-Q.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reverse&#160;Stock&#160;Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 10, 2025, the Company effected a 1-for-16&#160;reverse&#160;stock&#160;split&#160;of its issued and outstanding common stock (the &#8220;Reverse Stock Split&#8221;). As a result of the&#160;Reverse&#160;Stock&#160;Split, each 16 shares of common stock issued and outstanding immediately prior to February 10, 2025&#160;were automatically converted into 1 share of common stock. The&#160;Reverse&#160;Stock&#160;Split&#160;did not change the par value of the common stock or the authorized number of shares of common stock. All outstanding convertible notes, stock options and RSUs entitling their holders to purchase or obtain or convert into shares of our common stock were adjusted, as required by the terms of these securities. All applicable common share and per share amounts have been retrospectively restated to show the effect of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, we had cash and cash equivalents of $31,013, working capital of $12,231 and stockholders&#8217; deficit of $90,172. Net cash used in operating activities was $12,043 and $17,706 for the three months ended March 31, 2025 and 2024, respectively. We incurred losses of approximately $7,254 and $26,791 for the three months ended March 31, 2025 and 2024, respectively. We will need to generate significant product revenues to achieve profitability. Our history of significant losses, negative cash flows from operations, potential near-term increased covenant-driven amortization payments or full repayment obligations under our Credit Agreement, the regulatory event of default triggers under the Credit Agreement, other funding requirement covenants under the Credit Agreement, limited liquidity resources currently on hand, and dependence on our ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through debt financing and/or restructuring of its existing Credit Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>reduce overhead and headcount to focus on core priorities, and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To date, we have continued research and development activities while managing our cash position. However, we require additional funding to continue as a going concern. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly when there is market uncertainty or an economic downturn or if other events make investment in our securities less appealing. If we are unable to secure adequate additional funding as and when needed on acceptable or commercially reasonable terms, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates. In addition, there are various macro-economic trends affecting the financing markets whose impact on our liquidity and future funding requirements are uncertain as of the filing date of this Quarterly Report on Form 10-Q. We will need substantial additional funding, and if we are unable to raise capital when needed, we could be compelled to pursue alternative options, including, without limitation, implementing further workforce reductions, reducing or ceasing product development programs and advancement of our clinical trials and product candidates, selling our assets or seeking other strategic alternatives. See &#8220;Risks Related to Financial Position and Need for Additional Capital &#8212; <i style="font-style:italic;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or </i></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">commercialization efforts or otherwise seek strategic alternatives.</i>&#8221; in Part II. Item 1A., &#8220;Risk Factors&#8221; elsewhere in this Quarterly Report on Form 10-Q. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have primarily focused our efforts on raising capital and building the products in our pipeline, and, although we generate revenue from sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, we do not expect to generate positive cash flows from operations in the near term. Since our inception, our operations have been financed primarily from proceeds from the sale of equity securities, including our initial public offering, private placements of our common stock, registered offerings of our common stock, an Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), and borrowings under our Credit Agreement (as described below). We have not yet established an ongoing source of revenue sufficient to cover our operating costs and will need to do so in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, we entered into two financing agreements: the Credit Agreement and the RIFA. Pursuant to the Credit Agreement, the Lenders originally agreed to provide up to $135,000 in senior secured term loans to us. On April 28, 2022, we borrowed the first $70,000 tranche of loans under the Credit Agreement. Pursuant to the RIFA, the Purchasers agreed to provide us with up to $120,000 in financing for our near-term commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, development and commercialization of BXCL501 and other general corporate purposes. On July 8, 2022, we drew down the first tranche of $30,000 under the RIFA. In connection with the Credit Agreement, we granted to the Lenders (i) warrants to purchase up to 17 shares of our common stock (the &#8220;Closing Date Warrants&#8221;), (ii) rights to purchase up to $5,000 of our common stock and (iii) warrants to purchase up to 175 individual ownership units (i.e., not in thousands) in OnkosXcel (the &#8220;OnkosXcel Warrants&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 13, 2023, we, the Lenders and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for, among other things, a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel, pursuant to which we were permitted to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from the $25,000 at any time outstanding. The First Amendment waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of our obligation to notify OFA of such default, including our investment in an amount in excess of what was previously permitted under the OnkosXcel investment covenant. In connection with the First Amendment, we paid to the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, we entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;) with the Lenders and OFA, as administrative agent. The Second Amendment terminated the RIFA and converted the financing previously provided to us thereunder to term loans under the Credit Agreement. In addition, the Second Amendment replaced the Credit Agreement&#8217;s existing &#8220;Tranche B&#8221; and &#8220;Tranche C&#8221; term loan opportunities with three new tranches aggregating up to $100,000 in potential funding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $20,000 &#8220;Tranche B&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2024: (i) us raising an aggregate of at least $40,000 after the date of the First Amendment from (a) equity proceeds or (b) a bona fide contract with a governmental authority to use BXCL501 for opioid withdrawal, (ii) initiation of a new clinical trial in the TRANQUILITY program based on our meeting with the FDA held on October 11, 2023, and (iii) the total pro forma indebtedness outstanding under the Credit Agreement as a percentage of our trailing 30-day market capitalization being less than 30%;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $30,000 &#8220;Tranche C&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2025: (i) either (a) receipt of approval from the FDA of an sNDA in respect of the use of </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BXCL501 for the acute treatment of agitation associated with dementia or (b) the receipt of approval from the FDA of an sNDA in respect of the use of BXCL501 for (x) the acute treatment of agitation associated with schizophrenia in adults and (y) the acute treatment of agitation associated with bipolar I or II disorder in adults, in each case, in the community/at home setting without the requirement for administration under the supervision of a healthcare provider, and (ii) the total pro forma indebtedness outstanding under the Credit Agreement as a percentage of our trailing 30-day market capitalization being less than 30%; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $50,000 &#8220;Tranche D&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2025: (i) the conditions precedent to the borrowing of Tranche C (as described in the preceding bullet point) have been satisfied, and (ii) our total net revenue attributable to sales of BXCL501 (for the avoidance of doubt, including any revenues attributable to use of BXCL501 for opioid withdrawal) for the trailing twelve consecutive month period exceeding a specified amount.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, $80,000 remains available for borrowing if the milestones above are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Second Amendment also modified the interest rate of the loans provided under the Credit Agreement to be a floating rate per annum equal to the secured overnight financing rate (&#8220;SOFR&#8221;) (subject to a SOFR floor of 2.5% and a cap of 5.5%) plus 7.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following the Second Amendment, we were required to comply with certain covenants under the Credit Agreement, including a financial covenant that requires we maintain a minimum cash liquidity amount of $15,000 (or higher upon certain events) and a modified minimum revenue requirement measured on a quarterly basis based on the revenue attributable to BXCL501 for the six consecutive month period ending on the last day of the relevant quarter (the &#8220;Revenue Covenant&#8221;), subject to cure payments of not less than $1,000 if we failed to meet the minimum revenue requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, we amended and restated the Closing Date Warrants granted to the Lenders on April 19, 2022 to purchase up to 17 shares of the Company&#8217;s common stock at an exercise price of $320.64 per share. Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Closing Date Warrants&#8221;), the exercise price of the Closing Date Warrants was reduced to $58.3232 per share, which represented the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Second Amendment Effective Date. In addition, the Company granted new warrants to the Lenders to purchase up to 4 shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $58.3232 per share (the &#8220;2023 Warrants&#8221;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On February 12, 2024 (the &#8220;Third Amendment Effective Date&#8221;), we entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), pursuant to which the Lenders agreed to waive the covenant that we shall not receive a report and opinion from our independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to our financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, we shall have received at least $40,000 in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants on or before February 20, 2024. We did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March 20, 2024, we entered into the Fourth Amendment to the Credit Agreement (&#8220;the Fourth Amendment&#8221;), pursuant to which the Lenders waived the Credit Agreement&#8217;s covenant that the report and opinion the Company received from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2023 not contain a &#8220;going concern&#8221; or similar qualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment included covenants that we receive, (i) after the effective date of the Fourth Amendment and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the effective date of the Fourth Amendment (so long as such partnering transactions would not require us or any of our subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), and (ii) after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the effective date of the Fourth Amendment. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, in the case of clause (i) of the preceding sentence, until May 15, 2024 (for the avoidance of doubt, failure to perform clause (ii) would constitute an immediate event of default under the Credit Agreement without any cure or grace period). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Fourth Amendment provided that if we had not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the effective date of the Fourth Amendment, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that we are required to maintain at all times will increase to $25,000 from $15,000, unless and until we had received, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the effective date of the Fourth Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fourth Amendment, on the effective date of the Fourth Amendment, we granted new warrants to the Lenders to purchase up to 6 shares of our common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $49.1568 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of our common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#8220;Fifth Amendment&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Fifth Amendment included a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27,2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1 until March 30, 2025. On March 31, 2025, the minimum liquidity amount increased to $10,000 and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the Fifth Amendment, the Company made the required one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable by December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Fifth Amendment also modified the interest rate of the loans provided under the Credit Agreement from a floating rate of Term SOFR plus 7.50% per annum, to a fixed rate of 13% per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates <span style="color:#202020;">ending December 31, 2024, March 31, 2025, and June 30, 2025, t</span>he Company will have the ability to make interest payments of up to 10% per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement<span style="color:#202020;">. </span>In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to 5.0% of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;">The Fifth Amendment amended the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company (including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On March 4, 2025, the Company entered into the Sixth Amendment to our Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which the Lenders agreed to, among other things, delay the date on which we are required to engage an investment banker (which date has been subsequently extended to July 31, 2025).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;">As of March 31, 2025, we had aggregate principal indebtedness of $109,391 outstanding under the Credit Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><b style="color:#202020;font-weight:bold;">Company Warrants and Registration Rights Agreement </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). The Equity Investment Right was terminated as part of the Fifth Amendment. Also, in connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of 313 shares of common stock, at an exercise price of $0.16 per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We entered into a registration rights agreement with the Lenders in connection with the original closing of the Credit Agreement, which has been amended and restated since in connection with each issuance of additional warrants to the Lenders, including most recently, in connection with the Fifth Amendment (as so amended and restated the &#8220;Amended and Restated Registration Rights Agreement&#8221;). Pursuant to the Amended and Restated Registration Rights Agreement, we have filed registration statements on Form S-3 to register the shares issuable upon exercise of the Original Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Original Warrants and the New Warrants is 366.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#202020;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">See Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> included elsewhere in this Quarterly Report on Form 10-Q for additional information relating to the Credit Agreement and RIFA, including applicable interest rates, payment obligations and certain restrictive and financial covenants thereunder. As of March 31, 2025, we were in compliance with all restrictive and financial covenants under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In May 2021, we entered into the Sale Agreement with Jefferies pursuant to which we could offer and sell shares of our common stock, having an aggregate offering price of up to $100,000, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. On November 1, 2023, we entered into an amendment to the Sale Agreement with Jefferies to increase the size of the &#8220;at the market offering&#8221; program; pursuant to the Sale Agreement, as amended, we can offer and sell shares of our common stock having an aggregate offering price of up to $150,000 (excluding any shares of common stock already sold in the &#8220;at the market offering&#8221; program prior to the date of the amendment), from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">sale agent. We terminated the Sales Agreement with Jefferies on March 26, 2025. There were no sales of the Company&#8217;s common stock under the Sale Agreement for the three months ended March 31, 2025. For the three months ended March 31, 2024, we sold 40 shares under the Sale Agreement for gross proceeds of $1,743 and received proceeds of $1,691, net of issuance costs of $52. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Cash Flows</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,043)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,706)</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,202</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,626</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities for the three months ended March 31, 2025 was $12,043 and was primarily attributable to our net loss of $7,254, a $6,559 increase in the change in the fair value of our derivative liability, a $2,269 decrease in accounts payable, accrued expenses, due to related parties, and other current liabilities, offset by $2,668 in payable in kind interest on our credit agreement, a $608 decrease in prepaid expenses, and $180 in non-cash stock-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operating activities for the three months ended March 31, 2024 was $17,706 and was primarily attributable to our net loss of $26,791, a $448 increase in Inventory, a $307 increase in Accounts receivable and a $619 reduction in Accrued interest, in part offset by $3,433 of non-cash stock-based compensation, a $4,826 increase in accounts payable, accrued expenses due to related parties, and other current liabilities, and a $901 decrease in prepaid expenses, other current assets and other assets. The decrease in cash used in operating activities compared to the prior year reflects our actions taken under the Reprioritization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in investing activities for the three months ended March 31, 2025 and 2024 was $0 and $0, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the three months ended March 31, 2025, was $13,202 and was primarily attributable to net proceeds of $12,957 received from the March 2025 registered direct offering. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Net cash provided by financing activities for the three months ended March 31, 2024, was $26,626 and was attributable to $25,000 proceeds received from the sale of common stock and warrants under the March 2024 registered </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">direct offering and the net proceeds received from the sale of common stock under the Sale Agreement with Jefferies of $1,691.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Operating Capital and Capital Expenditure Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We expect to continue to incur significant and increasing operating losses at least for the next several years as we commercialize IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-weight:normal;"> and as we expand our clinical trials of and seek marketing approval focused on BXCL501 while pursuing development of additional product candidates for BXCL502, BXCL701 and BXCL702. We expect to continue to incur net losses in the near term. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our planned clinical trials and our expenditures on other research and development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. We anticipate that our expenses will increase substantially as we:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and continue our clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct additional research and development with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify, acquire, license, develop and commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate acquired technologies into a comprehensive regulatory and product development strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire scientific, clinical, quality control and administrative personnel and utilize professional services, including consultants, lawyers, and accountants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development and commercial efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fully develop a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any product candidates for which we may obtain regulatory approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to operate as a public company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We believe that our existing cash and cash equivalents as of March 31, 2025 will not be sufficient to enable us to fund operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, including funding our ongoing research and development and commercialization efforts. In particular, we believe that our cash and cash equivalents of $31,013 as of March 31, 2025 will allow us to fund our operations and meet our liquidity requirements into the third quarter of 2025, assuming we are able to comply with the covenants under our Credit Agreement. We expect that we will need to obtain substantial additional funding to fund our ongoing operations. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted, and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, which could adversely impact our ability to conduct our business. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves. To date, we have continued research and development activities while managing our cash position. However, we can provide no assurance that will be successful in obtaining additional necessary resources and, if we are unable to fund our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">operations, including our clinical trials, we may need to focus on advancing fewer of our product candidates or otherwise consider strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Contractual Obligations and Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In July 2024, the Company signed an amendment to its commercial supply agreement that requires minimum annual payments for the first five years of the agreement ending in 2026 that in aggregate total $10,000.  The Company has met the minimum requirements for the first 3 years ending in 2024. The remaining minimum commitments for years 4 and 5 (2025 and 2026) is $2,000 each year. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February 2022, we signed a distribution agreement with a third-party to distribute product related to BXCL501 in the U.S. The distributor will be paid defined fees for its services under the agreement, which can be terminated by either party for cause. The distribution agreement can also be terminated by us without cause, subject to payment of agreed upon termination fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;). The HQ Lease expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed. The Company has approximately $359 of payments remaining under the HQ Lease. For additional details, see Note 13, <i style="font-style:italic;">Leases</i> in the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information relating to the Company&#8217;s leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we are obligated to make quarterly interest payments under our Credit Agreement. For additional details, see Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> in the Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information relating to the Company&#8217;s debt payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our critical accounting policies and estimates are described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and Estimates&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. We have reviewed and determined that those critical accounting policies and estimates remain our critical accounting policies and estimates as of and for the three months ended March 31, 2025. No material changes were made to our existing critical accounting policies and estimates during the period presented. Refer to Note 3, <i style="font-style:italic;">Summary of Significant Accounting Policies</i> in the Notes to Condensed Consolidated Financial Statements elsewhere in this Form 10-Q.</p><a id="_d7acb44e_887c_4afe_be08_58e373bcacad"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 9pt 0pt;">Not applicable.</p><a id="_48441732_de06_4f48_bde4_1cf8e69b1ed2"></a><a id="Item4ControlsandProcedures_79336"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;4. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation of our disclosure controls and procedures as of March 31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_856d6cb2_16b8_49b7_a1a8_e4755c7204f0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART II. OTHER INFORMATION</b></p><a id="Item1LegalProceedings_771938"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1. </b></span><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may be subject to litigation and claims arising in the ordinary course of business, which could have a material adverse effect on our business, operating results, cash flows or financial condition. Please refer to Note 16, <i style="font-style:italic;">Commitments and Contingencies</i> of our unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for information regarding material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, in February 2024, we became aware that the SEC had initiated a formal investigation involving the Company and certain of its directors and officers. This formal investigation relates to the Company&#8217;s public disclosures, including about product sales and the receipt of a Form 483 by an investigator at one of the Company&#8217;s clinical trial sites in the TRANQUILITY II study, and trading in the securities of the Company. We are cooperating fully with the investigation including producing documents, and current and former officers and employees of the Company have testified before the SEC. We cannot predict or determine whether any proceeding may be instituted by the SEC in connection with its investigation or the outcome of any proceeding that may be instituted, or the effects any such proceeding could have on the Company&#8217;s business or financing efforts.</p><a id="Item1ARiskFactors_143189"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">You should carefully consider the risks described below, as well as general economic and business risks and the other information in this Quarterly Report on Form&#160;10-Q and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We were incorporated in March 2017 and our operations to date have been largely focused on staffing our Company, raising capital, advancing the development of our product candidates, including conducting clinical and preclinical studies and establishing our commercial organization. We have only one product approved for commercial sale, and have limited experience in obtaining marketing approvals, manufacturing products on a commercial scale, and conducting sales and marketing activities necessary for successful commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We are focused primarily on research and development while continuing to support IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Since our inception, we have incurred significant operating losses. Our net loss was $7.3 million and $26.8 million for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had a stockholders&#8217; deficit of approximately $90.2 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We have only one product candidate approved for marketing in the U.S., none in any other jurisdiction, and may never receive approval beyond the one product approved to date. It could be several years, if ever, before we have a commercialized product that generates significant revenues through sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or our product candidates, if approved. As a result, we are uncertain when or if we will achieve profitability and, if so, whether </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">we will be able to sustain it. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses may increase in the long term as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluate the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct preclinical studies and clinical trials for our current product candidates and any future product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop an appropriate sales, marketing, and distribution infrastructure to commercialize IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any other product candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potentially hire additional clinical, commercial, regulatory, scientific and finance personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting and other expenses in operating as a public company.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To become and remain profitable, we must develop and commercialize more products or product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing, and selling IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any current and future product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient revenue to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we have obtained U.S. FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will obtain marketing approval to commercialize any additional product candidates. If we are required by the FDA, or other regulatory authorities such as the European Medicines Agency (&#8220;EMA&#8221;) to perform studies and trials in addition to those currently expected, or if there are any delays in the development, or in the completion of any planned or future preclinical studies or clinical trials of our current or future product candidates, our expenses could increase and profitability could be further delayed. For example, developments with respect to our TRANQUILITY program evaluating BXCL501 in patients with dementia due to probable Alzheimer&#8217;s disease may increase the likelihood that we experience such costs or delays, as discussed in the risk factor below entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our failure to become and remain profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our Company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We could be delisted from The Nasdaq Capital Market, which could seriously harm the liquidity of our stock and our ability to raise capital or complete a strategic transaction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As previously reported, on September 20, 2024, we received a letter from Nasdaq Staff notifying us that for the 30 consecutive business days prior to the date of the letter, the Company&#8217;s market value of listed securities closed below the minimum $35 million requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was granted a period of 180 calendar days, or until March 19, 2025, to regain compliance. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As anticipated, on March 20, 2025, the Company received another letter from the Staff stating that, as a result of the Company&#8217;s continued non-compliance with the MVLS Requirement, its securities would be delisted from Nasdaq unless the Company appeals the Staff&#8217;s delisting determination by requesting a hearing before the Nasdaq Panel. The Company made timely request for a hearing before the Panel to appeal the Staff&#8217;s determination. The Company had a hearing with the Nasdaq Hearing Panel on May 1, 2025. At the hearing, we presented our plan for regaining compliance with the MVLS Requirement and requested a further extension so that we may complete the execution of our plan. Although we believe our plan will be sufficient to enable us to regain compliance, no assurance can be provided that Nasdaq will ultimately accept our plan or that we will ultimately regain compliance with the MVLS Requirement. As of the date hereof, we have not received a determination from the hearings panel. Our common stock will remain listed and eligible for trading on Nasdaq pending the ultimate conclusion of the hearing process; however, there can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If our common stock is delisted by Nasdaq, the price of our common stock may decline and our common stock may be eligible to be quoted on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, which would negatively affect the liquidity of our common stock and an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. Any such delisting action may materially adversely affect our ability to raise capital or pursue strategic transactions on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, if our common stock is delisted from the Nasdaq Capital Market and the trading price remains below $5.00 per share, trading in our common stock might also become subject to the requirements of certain rules&#160;promulgated under the Exchange Act, which require additional disclosure by broker-dealers in connection with any trade involving a stock defined as a &#8220;penny stock&#8221; (generally, any equity security not listed on a national securities exchange that has a market price of less than $5.00 per share, subject to certain exceptions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We continue to actively monitor our performance with respect to the listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules. There can be no assurance that we will be able to maintain compliance or, if we fall out of compliance, regain compliance with any deficiency, or if we implement an option that regains our compliance, maintain compliance thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives. In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement (as defined herein) would trigger an event of default thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We will require additional future funding to support current and anticipated future expenses. We currently anticipate continuing to develop and conduct clinical trials with respect to our current and any future product candidates; seek to identify and develop additional product candidates; acquire or in-license other product candidates or technologies; seek regulatory approvals for our product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to support the commercialization of products for which we may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; hire and retain limited additional personnel, such as clinical, quality control and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support our product development and help us comply with our obligations as a public company; and add equipment and physical infrastructure to support our research and development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have been and may continue to be required to expend significant funds to continue to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the U.S. and advance the development of BXCL501, BXCL701, BXCL502 and our other product candidates. In addition, while we may seek one or more collaborators for future development of our current product candidates or any future product candidates that we may develop for one or more indications, we may not be able to enter into a collaboration for any of our product candidates for such indications on suitable terms, on a timely basis or at all. In any event, our existing cash will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of our product candidates or our other preclinical programs. Accordingly, we will be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We may also seek third-party investments in or other strategic options for our subsidiary, OnkosXcel. Further financing may not be available to us on acceptable terms, or at all. In addition, we are reliant on the financial institutions with which we hold our cash and cash equivalents. If such institutions were to close, we may not be able to recover all of our cash or cash equivalents held at such institutions. Moreover, market volatility, credit crises, adverse macroeconomic conditions, such as high interest or inflation rates, or other factors, as well as Company-specific factors such as the progress of our development pipeline, adverse clinical events or results, regulatory investigations, or ongoing or potential legal proceedings, could also adversely impact our ability to access capital as and when needed. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Management believes that the Company&#8217;s cash and cash equivalents of $31.0 million as of March 31, 2025 will allow the Company to fund its operations and meet its liquidity requirements into the third quarter of 2025. However, there can be no assurance that we will be able to extend our cash runway by meeting the conditions for additional funding under the terms of our Credit Agreement (defined above) or otherwise. In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement would trigger an event of default thereunder. The Fifth Amendment to our Credit Agreement included a new capital raising covenant requiring, among other things, that the Company receive on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, an aggregate of at least $29.0 million in net cash proceeds (&#8220;Raise 3&#8221;) (including net proceeds raised in the interim).  The Company has raised net proceeds of $19.1 million to date under these capital raising requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7.5 million (instead of $25.0 million) from and after the closing of Raise 1 until March 30, 2025. On March 31, 2025, the minimum liquidity increased to $10.0 million, and on September 30, 2025, the minimum liquidity amount will further increase to $15.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, our estimate as to how long we expect our existing cash to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, timing, costs, and results of clinical trials of our product candidates, including any delays that have occurred or may occur due to the recent developments with the TRANQUILITY program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and for any of our product candidates that receive marketing approval, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue received from commercial sales of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory policies or laws that may affect our operations;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in physician acceptance or medical society recommendations that may affect commercial efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of acquiring potential new product candidates or technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our operations continue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of legal proceedings and investigations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any adverse market conditions or other macroeconomic factors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As we continue our research and development activities, we will require additional resources to continue as a going concern. We can provide no assurance that we will successfully obtain additional resources to improve our financial condition. If we are unable to obtain necessary additional capital, we could be compelled to pursue alternative options, including, without limitation, implementing further workforce reductions, reducing or ceasing product development programs and advancement of our clinical trials and product candidates, selling our assets or seeking other strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2025, we had aggregate principal indebtedness of $109.4 million outstanding under our Credit Agreement and Guaranty (as amended, the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restrictive covenants in the Credit Agreement place limits on our ability to conduct our business. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. In addition, certain events, including receipt of a warning letter from the FDA, may constitute an event of default. We must also comply with certain covenants under the Credit Agreement, including a financial covenant that requires we maintain certain minimum cash liquidity amounts. In addition, certain events, including certain regulatory events and any &#8220;going concern&#8221; or similar qualification in a report of the Company&#8217;s independent registered public accountants relating to the Company&#8217;s annual financial statements (except for the years ended December 31, 2024 and 2023, respectively), constitute an event of default under the Credit Agreement. The Credit Agreement also includes other covenants relating to certain change of control events can also trigger an event of default under the Credit Agreement, including control by any entity or group of entities, other than BioXcel LLC and its affiliates, that acquires 35% or more of our voting capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to make scheduled payments or payments to maintain compliance with covenants or to restructure or refinance these and other outstanding debt obligations depends on our financial and operating performance, including growth in revenue from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and BXCL501, which will be affected by prevailing economic, industry and competitive conditions and by financial, business and other factors beyond our control. A failure to pay our debt, fixed costs and other obligations or a breach of our contractual obligations or other event of default could result in a variety of adverse consequences, including the acceleration of our obligations or the exercise of remedies by our creditors and lessors. In such a situation, it is unlikely that we would be able to cure our breach, fulfill our obligations, make required payments or otherwise cover our fixed costs, which would have a material adverse effect on our business, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, historically we have relied on debt and equity financings as our primary sources of liquidity. If our future cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay expenditures, sell assets, seek additional capital or seek to restructure or refinance our indebtedness. Any </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">refinancing or restructuring of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants. These alternative measures may not be successful and may not permit us to meet our scheduled or any accelerated debt service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and might be required to sell material assets or pursue other strategic alternatives to attempt to meet our debt service obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">As of March 31, 2025, we had $31.0 million in cash and cash equivalents. Based on our existing cash, cash equivalents and lack of current availability under our funding facilities, we do not believe we have sufficient cash on hand to support current operations and service our debt obligations for at least one year from the date of issuance of the audited consolidated financial statements appearing in this Quarterly Report on Form 10-Q. This condition raises substantial doubt about our ability to continue as a going concern for at least one year from the date that our financial statements for the quarter ended March 31, 2025 are issued. In order to mitigate liquidity issues, we have undertaken the Reprioritization and other restructuring actions, and may, among other things, seek to raise capital through the issuance of common stock, or by restructuring, refinancing, and/or amending the terms of the Credit Agreement (including with respect to regulatory related events of default that do not contain a cure period) or pursue other strategic alternatives.  However, such transactions may not be successful and we may not be able to raise additional equity and/or financing necessary to meet our obligations. Moreover, our Credit Agreement contains covenants that we may be unable to comply with and which could result in the acceleration of our debt service obligations, further reducing our capital resources and ability to fund our operations. As such, there can be no assurance that we will be able to continue as a going concern and we may be forced to delay, reduce or discontinue our product development programs or commercialization efforts in order to preserve cash. For additional cost-saving and other strategic initiatives we may be compelled to pursue, see the risk factor entitled, </span><i style="font-style:italic;">&#8220;We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our strategic reprioritization and other workforce reductions may not achieve our intended outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2023, we announced a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;) and have taken further restructuring actions since then. As part of these efforts, we have taken actions to reduce certain operational and workforce expenses that are no longer deemed core to our ongoing operations in order to extend our cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions include a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization on at-home treatment setting opportunities for BXCL501. As part of this strategy, we reduced our workforce in 2023 by approximately 60%.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In May and September 2024, we initiated further workforce reductions, and we may undertake further similar cost-saving initiatives, which may include additional restructuring or workforce reductions. These types of cost-reduction activities can be complex and result in unintended consequences and costs, including decreased employee morale, loss of institutional knowledge and expertise and adversely impact our business. We completed these additional restructuring actions to further reduce the workforce by 50%, ending the year ended December 31, 2024 with 37 full-time employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The reduction in force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction in force. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. The workforce reduction could also harm our reputation, making our ability to recruit skilled personnel </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">difficult.  If we are unable to realize the anticipated benefits from the reduction in force, or if we experience significant adverse consequences from the reduction in force, our business, financial condition, and results of operations may be materially adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In addition, we may not realize the benefits of or there may be unanticipated costs associated with our Reprioritization. As a result of the Reprioritization, including our strategic refocus, we may not generate material revenues from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the near term because our commercial force will be significantly reduced. If we are unable to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in a different setting or unable to develop, receive marketing approval for and successfully commercialize BXCL501, BXCL701 and any of our other product candidates on our own or with any future collaborator, or experience delays because of any of these factors or otherwise, our business could be materially and substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In addition, because we have limited financial and managerial resources, under our Reprioritization, we intend to focus on specific product candidates, indications and development programs. We may also conduct several clinical trials for our product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. As a result, we may forgo or delay pursuit of opportunities with other product candidates or other indications that could have had greater commercial potential or likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. If we are not successful in increasing our efficiency as a result of this Reprioritization, our efforts to develop and commercialize our product candidates may be delayed or halted and our business could be materially adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Discovery and Development of Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in drug discovery and drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the acquisition of our product and product candidates, we were not involved in and had no control over their preclinical and clinical development. In addition, we are relying upon the parties we acquired our product candidates from to have conducted research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, accurately reported the results of all clinical trials conducted prior to our acquisition of the applicable product candidate, and correctly collected and interpreted the data from these studies and trials. To the extent any of these activities did not occur, our expected development time and costs could increase, which could adversely affect our prospects for marketing approval of, and receiving any future revenue from, these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Following our discovery of principal investigator misconduct at one of the clinical sites in our TRANQUILITY II Phase 3 clinical trial, we initiated an investigation into the issues associated with the trial.  This principal investigator had previously been subject to a December 2022 FDA inspection of her clinical site in connection with the TRANQUILITY II clinical trial.  At the conclusion of this inspection, the FDA issued an FDA Form-483 identifying three inspectional observations. These observations related to the principal investigator&#8217;s failure to adhere to the informed consent form approved by the Institutional Review Board for a limited number of subjects whose records the FDA reviewed, maintain adequate case histories for certain patients whose records the FDA reviewed, and adhere to the investigational plan in certain instances. For example, the FDA cited the principal investigator&#8217;s delay in informing the sponsor&#8217;s medical monitor or pharmacovigilance safety vendor of an SAE, for one of the subjects, which report was made to our vendor outside of the 24 hour time period prescribed by the clinical trial protocol. The principal investigator for this clinical site responded to the FDA observations within the time period requested. The FDA </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">concluded that the inspection of a single site in its TRANQUILITY II Phase 3 trial is closed under 21 C.F.R.20.64(d)(3) and released the Establishment Inspection Report. The FDA has designated &#8220;Voluntary Action Indicated&#8221; for the site.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In May 2023, it came to our attention that this same principal investigator in the TRANQUILITY II clinical trial may have fabricated email correspondence around the time of the FDA inspection, purporting to demonstrate that the investigator timely submitted to our pharmacovigilance safety vendor a report of an SAE from a different subject than the one cited in the FDA Form-483, and purporting to show that the vendor had confirmed receipt. Upon receipt of this information, we promptly initiated an investigation and received confirmation that the principal investigator fabricated the email correspondence related to the timing of the reporting of this SAE to our pharmacovigilance vendor to make it appear as though this SAE had been timely reported as required by the clinical trial protocol. This principal investigator has not participated in any other clinical trial sponsored or conducted by us. Both we and the principal investigator&#8217;s employer have reported this incident to the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The primary efficacy endpoint in TRANQUILITY II was the change in PEC score, which is a measurement of agitation severity captured by trained raters during an agitation episode.  While change in PEC score has been used to support the approval of IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;"> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, it has not been used as a primary endpoint to support the approval of a drug candidate for the treatment of agitation associated with Alzheimer&#8217;s Disease.  Prior to initiating our TRANQUILITY II trial, we believe we reached alignment with FDA regarding the use of PEC scores as a primary endpoint to assess individual agitation episodes in dementia patients.  In the normal course, we have been in communication with the FDA regarding the data and information needed to further support the consistency of the measurement of PEC ratings, and we believe that we have generated sufficient data to demonstrate such consistency.  Following submission of certain data on PEC score from a separate study of raters assessing video vignettes, the FDA expressed certain concerns with respect to the reliability of PEC scores in that study. The FDA has requested that we provide additional information to support the consistency of the measurement of PEC ratings to assess the treatment of agitation associated with Alzheimer&#8217;s Disease. While we believe that we have generated sufficient data to demonstrate such consistency, and we plan to submit these data and analyses to the FDA, if the FDA disagrees, it may require that we provide more information to demonstrate reliability in the measurement of PEC scores and/or may require that we generate additional data to support the reliability of PEC score measurements in our TRANQUILITY II trial. There can be no assurances that any information or data we provide to FDA will sufficiently demonstrate the consistency and reliability of the PEC-score data from our TRANQUILITY II trial, or that our PEC-score data will not represent a potential review issue in connection with any application we may submit to FDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In addition, we are continuing to seek feedback from the FDA with respect to our TRANQUILITY program. For example, on February 20, 2024, we held a Type B/Breakthrough Therapy designation meeting with the FDA. The original purpose of this meeting was to obtain feedback on the design of a proposed at-home study that did not include caregiver-collected efficacy endpoints, based on our belief that obtaining caregiver assessments of efficacy would be challenging. We believe there are no validated caregiver endpoints for assessing efficacy in Alzheimer&#8217;s disease patients in the at-home setting. As a result, we focused on requesting feedback from the FDA regarding our proposal for an at-home clinical study with safety as the primary objective, and to better understand what additional data would be required to submit an sNDA to support labeling for BXCL501 to include the acute treatment of agitation associated with dementia in probable Alzheimer&#8217;s disease or, in the alternative, in this population in the care setting only. In its preliminary responses, the FDA reiterated its prior comments that we generate additional efficacy data, including repeat-dose efficacy data, to support an sNDA submission, as the FDA indicated that our proposed efficacy database, which currently includes the 70 patients who have been treated with 60 mcg of BXCL501 in TRANQUILITY I and TRANQUILITY II, would not contain substantial evidence of effectiveness absent additional data.  The FDA advised that we generate the necessary efficacy data in care facilities prior to conducting any trials in the at-home setting. In addition, the FDA indicated the need to generate long-term safety data to support an sNDA submission, including from probable Alzheimer&#8217;s disease patients exposed to BXCL501, for up to one year. We have received the final meeting minutes from the FDA, which we believe are consistent with the FDA&#8217;s preliminary responses and the subsequent </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">meeting discussion. Based on the FDA&#8217;s feedback, we are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia, including through, among other things, conducting our planned TRANQULITY In-Care Phase 3 trial. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. Also, although we announced in November 2023 that we were planning to conduct a Phase 3 trial in the at-home setting, with safety as the primary objective (TRANQUILITY At Home), given the priority to expand the database to generate additional efficacy and safety data in care facilities, we are re-evaluating the timing for initiating TRANQUILITY At Home. Conducting any new clinical trial can take significant time, funding and resources, and there are no assurances we could raise sufficient capital or have the liquidity and resources to conduct further clinical trials in our TRANQUILITY program, including our planned TRANQUILITY In-Care Trial. Any new clinical trials conducted in our target patient populations may have different safety or efficacy results from the topline data the Company previously announced for the TRANQUILITY II clinical trial. Further, any government investigation, disqualification, or debarment of, or proceeding or action against the principal investigator, or any government investigation, proceeding or action against us, could further delay development and approval of BXCL501 for this indication, and otherwise have a material adverse effect on us, our financial condition (including triggering a potential event of default under our Credit Agreement), results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting in the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August 2023, we announced our intention to pursue the Reprioritization, including among other things, a shift in focus to primarily develop BXCL501 for use in expanded settings, including the at-home setting and care facilities, for the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease and the acute treatment of agitation in schizophrenia and bipolar patients in the at-home setting. Although we have conducted several clinical trials that evaluated BXCL501 in the institutional setting, and we are conducting the SERENITY At-Home Phase 3 trial evaluating the safety of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting, but we have not conducted a clinical trial evaluating the at-home use of BXCL501 in the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we will seek additional feedback from the FDA regarding the potential of its ongoing or completed clinical trials to support submission of one or more sNDAs and to support a label for use in the home, it is possible that the FDA may not consider our available data adequate to support such submissions. For example, on October 11, 2023, we received feedback from the FDA that TRANQUILITY I and TRANQUILITY II alone are not sufficient to support an sNDA submission for the use of BXCL501 to treat acute agitation (non-daily) in patients with dementia due to probable Alzheimer&#8217;s disease in either the at-home setting or care facilities, and the FDA indicated that we should, among other things, conduct a further clinical trial to evaluate safety and collect efficacy data of BXCL501 before we are able to submit an sNDA seeking approval of BXCL501 for use in such populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a description of recent developments relating to our TRANQUILITY program, please see the prior risk factor, &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</i>&#8221; We cannot provide assurance that we will be able to seek or obtain approval of BXCL501 for treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease in the at-home setting based on this updated development plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although we continue to seek feedback from the FDA with respect to our TRANQUILITY program, the FDA may not agree that any trial designs we propose are sufficient to establish both the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer&#8217;s disease in either a care setting or an at-home setting. For example, to assess safety, the FDA has indicated that we need to expose more patients to BXCL501 for a longer period of time and that an efficacy trial of a shorter duration, combined with the patients in its previous trials, would not support submissions of an sNDA. Further, to assess efficacy in the home setting, the FDA may determine that we cannot rely on our previous studies of BXCL501 for this proposed indication since those studies were conducted in assisted living facilities and they are not comparable to the at-home setting. The FDA may also require us to seek approval for BXCL501 for use in care facilities prior to seeking any approval for at-home use in the targeted AD patient population. In particular, we are planning to generate additional Phase 3 safety and efficacy data in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">a variety of relevant care-facility settings, but even if our planned clinical efforts are successful and even if we are able to obtain approval of BXCL501 for use in patients with dementia due to probable Alzheimer's disease, we cannot provide assurance that we will be able to seek or obtain approval of BXCL501 for the treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease in the at-home setting based on this data and we will be required to generate additional data to evaluate the at-home use of BXCL501 in our targeted Alzheimer's dementia population before we are able to seek approval for such at-home use in this population, if ever. In addition, the FDA may determine that we cannot rely on the data from our prior TRANQUILITY II Phase 3 trial to support an sNDA as a result of potential data integrity issues at the trial site, as the FDA may not agree with our belief that data reliability and integrity remain intact. See Part II, Item 1A, &#8220;Risk Factors&#8212;Risks Related to the Discovery and Development of Product Candidates&#8212;<i style="font-style:italic;">Developments relating to its TRANQUILITY II Phase 3 trial may impact the timing of its development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>&#8221; for additional information. If the FDA does not accept the data from our prior TRANQUILITY II Phase 3 trial, we could be required to conduct additional clinical trials beyond those we currently contemplate, which would increase our costs and delay potential submission of an sNDA for BXCL501 which in turn would adversely affect our financial position and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accordingly, if the FDA reaches these conclusions or otherwise finds that our proposed clinical studies would not adequately evaluate the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer&#8217;s disease in an at-home setting and/or care setting, we may need to evaluate more patients for a longer period of time to demonstrate the safety and efficacy of BXCL501.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">With respect to our SERENITY program, we also held a Type C Meeting with the FDA on March 6, 2024 to obtain further feedback on our proposed changes to the design of SERENITY III Part 2, including with respect to the trial endpoints, and to discuss the content and format of a potential sNDA submission to expand the label of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 micrograms to the acute treatment of agitation associated with schizophrenia and bipolar disorders in the outpatient setting. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is already approved at the 120 mcg dose based on efficacy data that we previously generated in treating a single episode of agitation. Consistent with the data generated to date, the label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> currently includes a limitation on use (&#8220;LOU&#8221;), noting the lack of efficacy or safety data beyond 24 hours following the first dose. During our March 6, 2024 Type C meeting with the FDA, we discussed, among other things, whether evaluating the at-home use of BXCL501 120 mcg, with safety as the primary objective and efficacy measures as exploratory endpoints, if successful, could support the submission of an sNDA seeking expansion of the current label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 mcg to allow at-home use and labeling without the current LOU. Based on current FDA feedback, we have amended the Part 2 of the SERENITY III protocol to evaluate the safety and efficacy of the 120 mg dose in the at-home setting, and now refer to this revised trial as the SERENITY At-Home trial. We believe that our ability to seek labeling without the current LOU will depend, in part, on the number of agitation episodes we observe during our planned study period. Even if our planned SERENITY At-home trial is successful in demonstrating safety in the at-home setting, and even if the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 120 mcg label is expanded to allow outpatient use, there is no guarantee that we will observe and/or treat a sufficient number of agitation episodes during the study period to support removal of the current LOU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any modifications to our proposed trial designs, whether by us or by the FDA would delay our initiation of such proposed trials, increase the costs of any trial that we do conduct and delay any potential submission of an sNDAs for BXCL501. Requirements to conduct additional clinical trials evaluating BXCL501 in support of our planned sNDAs seeking approvals for BXCL501 for our targeted patient populations in at-home settings would increase our costs, and in either case, such modifications or requirements could have a material adverse effect on our prospects and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">In the near term, we are dependent on the success of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and the development of four of our product candidates, BXCL501, BXCL502, BXCL701 and BXCL702. If we are unable to complete the clinical development of or obtain marketing approval for our product candidates or successfully commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our other product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We currently have only one product that has received regulatory approval and may never be able to develop additional marketable product candidates. We are continuing to invest a significant portion of our efforts and financial </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">resources in the commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and development of our four product candidates, BXCL501, BXCL502, BXCL701 and BXCL702, as well as other product candidates. In connection with the Reprioritization, we have significantly reduced the resources devoted to commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and it is possible that will have adverse consequences on the revenue that we are able to generate from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the near term. As part of the Company&#8217;s Reprioritization, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> commercial team shifted focus to a hospital/Integrated Delivery Network (&#8220;IDN&#8221;) contracting strategy with a Corporate Account Director (CAD) team. The goal of the realigned CAD team is to work with large IDNs and drive sales utilizing a top-down approach. Over time, the revised commercial effort is expected to allow the Company to continue to make inroads into the institutional market in a more cost-efficient manner. However, we have limited experience in drug development and commercialization, and our prospects are substantially dependent on our ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize product candidates in one or more additional disease indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The success of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="white-space:pre-wrap;">,  and of BXCL501, BXCL701, BXCL502 and our other product candidates will depend on several factors, including the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of an investigational new drug application (&#8220;IND&#8221;) by the FDA or acceptance of comparable applications by foreign regulatory authorities allowing us to conduct clinical trials of our product candidates in the U.S. or in foreign jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation, progress, timing, costs and results of clinical trials of our product candidates and potential product candidates, including any delays caused by the developments relating to the TRANQUILITY program, and any additional trials we may need to conduct prior to seeking approvals for BXCL501 in at-home and/or care facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of safety and efficacy of our product candidates to the satisfaction of the FDA, or any comparable foreign regulatory authority, and sufficient for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and performance of our current and future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature of any required post-marketing clinical trials or other commitments to applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of supply arrangements with third-party raw materials suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection of our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community and third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with other therapies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many of these factors are beyond our control, including the results of clinical trials, the time required for the FDA, or any comparable foreign regulatory authorities, to review any regulatory submissions we may make, potential threats </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or develop, receive marketing approval for and successfully commercialize BXCL501, BXCL701 and our other product candidates, on our own or with any future collaborator, or experience delays because of any of these factors or otherwise, our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials, that we announce or publish from time to time, may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions based on such preliminary data are subject to change, and have in the past changed, following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our Company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the biopharmaceutical industry to suffer significant setbacks in advanced clinical trials due to nonclinical findings made while clinical studies are underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Our future clinical trial results may not be successful, and notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. The historical failure rate for product candidates in our industry is high. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. We obtained regulatory approval for our first product candidate for the acute treatment of agitation associated with schizophrenia or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">bipolar I or II disorder, which is in the early stages of commercialization. It is possible that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our current product candidates, or any that may be developed in the future, could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA, or comparable foreign regulatory authorities, that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA, or comparable foreign regulatory authorities, for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree that our changes to branded reference drugs meet the criteria for the 505(b)(2) regulatory pathway or comparable foreign regulatory pathways;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, or comparable foreign regulatory authorities, may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have limited experience in completing clinical trials of product candidates. Consequently, we may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, even if we were to obtain approval, regulatory authorities may approve our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate or may restrict its distribution. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have only submitted one NDA to the FDA and have not submitted any similar marketing applications to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates currently in development, or any than may be developed in the future, will be successful in clinical trials or receive regulatory approval. Further, our product candidates currently in development, or any that may be developed in the future, may not receive regulatory approval even if we believe they are successful in clinical trials. If we do not receive regulatory approvals for additional product candidates, we may not be able to continue our operations. For any regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients that we are targeting for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or our other product candidates are not as significant as we estimate, we may not generate significant revenues from sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or such other product candidates, if approved.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to seek regulatory approval to commercialize our product candidates in the U.S., the European Union (&#8220;EU&#8221;) and in additional foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical trials are expensive, time-consuming, difficult to design, difficult to conduct, and involve an uncertain outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Before obtaining marketing approval from the FDA, or other comparable foreign regulatory authorities, for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates, in accordance with applicable law and regulations. Failure can occur at any time during the clinical trial process. Although we are planning for certain clinical trials relating to BXCL501, BXCL701, BXCL502 and our other product candidates, there can be no assurance that the FDA, or other comparable foreign regulatory authorities, will accept our proposed trial designs as sufficient to establish the safety and/or efficacy of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may experience delays in our clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory allowances or authorizations to commence a trial or consensus with regulatory authorities on trial designs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board approval at each site, or independent ethics committee approval at any sites outside the U.S.;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dependence on the needs and timing of third-party collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of SAEs in trials of the same class of agents conducted by other companies or institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to initiate or continue clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a facility manufacturing our product candidates or any of their components being ordered by the FDA, or comparable foreign regulatory authorities, to temporarily or permanently shut down due to violations of current good manufacturing practice (&#8220;cGMP&#8221;) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our manufacturing process that may be necessary or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCPs or other regulatory requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">third-party contractors not performing data collection or analysis in a timely or accurate manner;  third-party contractors not complying with training and trial protocol; or third-party contractors becoming debarred or suspended or otherwise penalized by the FDA, such as in the case of the recent events relating to the TRANQUILITY II clinical trial, or other government or regulatory authorities, for violations of regulatory requirements, in which case, we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, which increases the risk that such CROs or trial sites may fail to perform in accordance with regulatory requirements, clinical trial protocols or with the agreements governing their services to us. For example, investigator misconduct affecting our TRANQUILITY II trial, which evaluated BXCL501 in patients with probable Alzheimer&#8217;s disease, may have a material adverse impact on our development program for BXCL501 in these patients, as described more fully in the risk factor above entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, conducting clinical trials in foreign countries, as we may do for our current and future product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol due to differences in health care services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. For example, current geopolitical conflicts in Eastern Europe and the Middle East may adversely impact our ability to conduct trials in those regions and elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on enrollment and evaluation of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll and evaluate a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or evaluation in our clinical trials for a variety of reasons. Patient enrollment and evaluation is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the size of the patient population required for analysis of the trial&#8217;s primary endpoints, our ability to recruit clinical trial investigators with the appropriate competencies and experience, our ability to obtain and maintain patient consents, the risk that patients enrolled in clinical trials will drop out of the trials before evaluation or completion, the frequency of acute agitation symptoms in enrolled patients, the opportunity for evaluation of patients enrolled in our trials, and competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Many pharmaceutical companies are conducting clinical trials in patients with the disease indications that our product candidates are designed to target. As a result, we must compete with them for clinical sites, physicians and the limited number of patients who fulfill the stringent requirements for participation in clinical trials. Also, due to the confidential nature of clinical trials, we do not know how many of the eligible patients may be enrolled in competing studies and who are consequently not available to us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients. The delay or inability to meet planned patient enrollment may result in increased costs and delay or termination of our trials, which could have a harmful effect on our ability to develop products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the FDA or other comparable foreign authorities. The clinical evaluation of BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates in patients, in many cases, is ongoing and it is possible that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. For example, in our Phase 2 clinical trial of BXCL701 for the treatment of emergent neuroendocrine prostate cancer, one patient experienced acidosis with a fatal outcome. Although the clinical investigator could not determine that the fatality was related to treatment with BXCL701, it is possible that BXCL701 could be tied to unacceptable side effects in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we observe drug-related AEs or other unacceptable safety concerns in clinical trials, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA, or comparable foreign regulatory authorities, could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. For example, the FDA placed Point Therapeutics, Inc.&#8217;s IND for BXCL701 on clinical hold following an increase in observed mortality in patients receiving BXCL701 in a Phase 3 trial in patients with non-small cell lung cancer. Though we believe that this result was caused by, among other things, an imbalance in the disease severity of patients enrolled in the active arm of the clinical trial, there is no guarantee that excess mortality will not be observed in future clinical studies. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles observed in our clinical trials and upon commercialization of any of our product candidates that may receive regulatory approval. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, if we or others later identify undesirable side effects caused by IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any other product candidate that receives marketing approval, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such a product is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing or distribution of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or create a medication guide outlining the risks of such side effects for distribution to patients, or similar risk management measures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The discovery and development of product candidates based on EvolverAI, BioXcel LLC&#8217;s proprietary pharmaceutical discovery and development engine, and our AI platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are leveraging our own AI platform and BioXcel LLC&#8217;s EvolverAI, a proprietary pharmaceutical discovery and development engine, to create a pipeline of neuroscience and immuno-oncology product candidates for patients whose diseases have not been adequately addressed to date by other approaches and to design and conduct efficient clinical trials with a higher likelihood of success. While we believe that applying our AI platform and BioXcel LLC&#8217;s EvolverAI to create medicines for defined patient populations may potentially enable drug research and clinical development that is more efficient than conventional drug research and development, our approach is novel. Although we obtained FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, because our approach is novel, the cost and time needed to develop our product candidates is difficult to predict, and our efforts may not result in the discovery and development of commercially viable medicines. We may also be incorrect about the effects of our product and product candidates on the diseases of our defined patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore, our estimates of our defined patient populations available for study and treatment may be lower than expected, which could adversely affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully commercialize. Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore we may not be able to commercialize our approach as originally expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If we, our vendors, or our third-party partners experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our&#160;reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, our use of AI and machine learning may be subject to laws and evolving regulations regarding the use of AI or machine learning, controlling for data bias, and anti-discrimination, and we may not always be able to anticipate how to respond to these laws or regulations. Further, there is an increase in litigation in a number of jurisdictions, including the United States, relating to the use of AI, particularly generative AI. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may fail to help us discover and develop additional potential product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any drug discovery that we are conducting using the Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may not be successful in identifying compounds that have commercial value or therapeutic utility. The Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may initially show promise in identifying potential product candidates, yet fail to yield viable additional product candidates for clinical development or potential commercialization for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new product candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compounds found through the Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may not demonstrate efficacy, safety or tolerability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential product candidate may not be capable of being produced at an acceptable cost.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our future success depends on our ability to continue to develop and implement our proprietary AI algorithms and models, and to maintain the confidentiality of this technology. Changes to existing regulations, their interpretation or implementation, or new regulations could impede our use of this technology or require that we disclose our proprietary technology to our competitors, which could impair our competitive position and result in an adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We obtained Fast Track designation for certain of our product candidates, and we may seek Fast Track designation for other indications or for our other product candidates, but we might not receive such designations, and even if we do, such designations may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review if the relevant criteria are met. An NDA for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We obtained Fast Track designation for BXCL501 for the acute treatment of mild-to-moderate agitation associated with schizophrenia, bipolar disorder, and dementia, and we further obtained Fast Track designation for BXCL701, in combination with a checkpoint inhibitor, for the treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability, and we may seek additional Fast Track designation for BXCL501 or BXCL701 or for one or more of our other product candidates, but we might not receive such designations from the FDA. However, even if we receive Fast Track </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We obtained Breakthrough Therapy Designation for BXCL501 for the acute treatment of agitation associated with dementia, and we may seek additional Breakthrough Therapy designations for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as Breakthrough Therapies by the FDA also receive the benefits associated with Fast Track designation, including the potential for rolling review of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the period for FDA review or approval will not be shortened.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA does not conclude that our product candidates satisfy the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements for approval of any of our product candidates under Section 505(b)(2) are not as we expect, the approval pathway for our product candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We intend to seek FDA approval through the 505(b)(2) regulatory pathway for certain of our product candidates. The Hatch-Waxman Act added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;). Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant. If the FDA does not allow us to pursue the 505(b)(2) regulatory pathway for our product candidates as anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates would likely substantially increase. Moreover, the inability to pursue the 505(b)(2) regulatory pathway could result in new competitive products reaching the market faster than our product candidates, which could materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the 505(b)(2) regulatory pathway for a product candidate, we cannot assure you that we will receive the requisite or timely approvals for commercialization of such product candidate. In addition, we expect that our competitors will file citizens&#8217; petitions with the FDA in an attempt to persuade the FDA that our product candidates, or the clinical studies that support their approval, contain deficiencies. Such actions by our competitors could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are required by the FDA, or similar regulatory authorities, to obtain approval (or clearance, or certification) of a companion diagnostic device in connection with approval of one of our product candidates, and we do not obtain, or face delays in obtaining approval (or clearance, or certification) of a companion diagnostic device, we will not be able to commercialize the product candidate, and our ability to generate revenue will be materially impaired</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. For example, we may decide to collaborate with patient diagnostic companies during our clinical trial enrollment process for BXCL701 to help identify patients with tumor gene alterations that we believe may be most likely to respond to treatment with BXCL701. The process of obtaining or creating such diagnostic is time consuming and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable foreign regulatory authorities, and, to date, the FDA has generally required premarket approval of companion diagnostics for cancer therapies. Generally, when a companion diagnostic is essential to the safe and effective use of a therapeutic product, the FDA requires that the companion diagnostic be approved before or concurrent with approval of the therapeutic product and before a product can be commercialized. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect. In January 2024, the FDA announced that it intends to initiate the process to reclassify most in vitro diagnostic tests (&#8220;IVDs&#8221;) that are currently Class III into Class II, including companion diagnostic IVDs.  If such reclassification efforts occur, any companion diagnostics that are the subject of the down-classification may no longer require premarket approval, but rather may be marketed pursuant to the generally less burdensome 510(k) clearance process.  However, there is no assurance that any companion diagnostic required for our pharmaceutical development programs will benefit from the reclassification, or that the reclassification, even if it does occur, will result in a shorter timeline to development or marketing of the companion diagnostic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the FDA, or a comparable foreign regulatory authority, requires approval (or certification or clearance) of a companion diagnostic for any of our product candidates, whether before or after the product candidate obtains marketing approval, we and/or third-party collaborators may encounter difficulties in developing and obtaining approval (or clearance, or certification) for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval (or clearance, or certification) of a companion diagnostic could </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">delay or prevent approval or continued marketing of our related product candidates. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidates, if approved, on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Approval, clearance or certification of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU. On May 25, 2017, the new In Vitro Medical Devices Regulation No. 2017/746 (&#8220;IVDR&#8221;) entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member states laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. The IVDR became effective in May 2022. However, on October 14, 2021, the European Commission proposed a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. The European Parliament and Council adopted the proposed regulation on December 15, 2021. The IVDR has applied since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The regulation of companion diagnostics in the EU is subject to further requirements since the IVDR became applicable as it introduced a new classification system for companion diagnostics. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization (&#8220;MA&#8221;) application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These modifications may make it more difficult and costly for us to obtain regulatory clearances, approvals or certifications for our companion diagnostics or to manufacture, market or distribute our products after clearance, approval or certification is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Although the FDA has approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and for any product candidates for which we obtain approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any regulatory approvals that we may receive for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any of our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA-approved label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> includes certain warnings and precautions regarding hypotension, orthostatic hypotension, bradycardia, somnolence, and QT interval prolongation. The FDA may also require a REMS to approve a product candidate, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> are and will remain subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, and on-going compliance with cGMPs, and GCPs for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory authority discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, discovery of previously unknown AEs or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product manufacturing, distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, the policies of the FDA and other regulatory authorities may change, and additional government regulations may be enacted that could impose extensive and ongoing regulatory requirements and obligations on any product candidate for which we obtain marketing approval. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA and other regulatory authorities strictly regulate marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA or any other regulatory authority may grant is limited to those specific diseases and indications for which a product is deemed to be safe and effective. For example, the FDA-approved label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is currently limited to the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults to be self-administrated by patients under the supervision of a health care provider. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">While physicians in the U.S. may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote the products is narrowly limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. For example, other formulations of Dex, the active ingredient in IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, have been approved for uses beyond those authorized in IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> approved labeling, such as for use in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">sedation of surgical patients, and we are continuing to develop BXCL501 for potential use in patients with dementia, MDD, Alzheimer&#8217;s disease and other indications. We do not market or promote IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for these uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on off-label use. If we are found to have promoted our products for any off-label uses, the U.S. federal government (and other foreign governments) could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, or other regulatory authorities, could also require that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA and other government agencies caused by funding shortages or staffing reductions could prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result of some of these aforementioned issues. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April 2025, the Trump administration conducted unprecedented layoffs at several U.S. health agencies, including the FDA, the Department of Health and Human Services, the Centers for Disease Control and Prevention and the National Institutes of Health, which is expected to impact the FDA&#8217;s ability to review and approve new medicines and conduct necessary inspections. In addition, government funding of the FDA, SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To the extent the FDA&#8217;s normal operations are disrupted or delayed, for example due to travel restrictions, public health or geopolitical issues, staffing shortages, layoffs or lack of funding, the FDA may not be able to complete the necessary inspections or provide feedback in a timely manner during our clinical development or review period. If any such delays or disruptions were to occur, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may choose to conduct one or more of our clinical trials or a portion of our clinical trials for our product candidates outside the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the clinical trial was not otherwise subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study was conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an on-site inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and could result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to extensive regulations outside the U.S. and may not obtain marketing approvals for products in Europe and other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the U.S., should we or our collaborators pursue marketing approvals for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and for BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates internationally, we and our collaborators will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we, or our collaborators, obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect to pursue marketing approvals for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and may pursue marketing approvals for BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates in Europe and other jurisdictions outside the U.S. with collaborative partners. The time and process required to obtain regulatory approvals and reimbursement in Europe and other jurisdictions may be different from those in the U.S. Also, regulatory approval in one jurisdiction does not ensure approvals in any other jurisdiction; however, negative regulatory decisions in any jurisdiction may have a negative impact on the regulatory process in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following a national referendum and enactment of legislation by the government of the United Kingdom (&#8220;UK&#8221;), the UK formally withdrew from the EU on January 31, 2020 and ratified a trade and cooperation agreement governing its future relationship (commonly referred to as &#8220;Brexit&#8221;). The agreement, which was applied provisionally from January 1, 2021 and entered into force on May 1, 2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and requires complex additional bilateral negotiations between the UK and the EU as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since January 1, 2021, the UK operates under a distinct regulatory regime to the EU. EU pharmaceutical laws only apply in respect of the UK to Northern Ireland (as set out in the Protocol on Ireland/Northern Ireland). EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. While the UK has indicated a general intention that new laws regarding the development, manufacture and commercialization of medicinal products in the UK will align closely with EU law, there are limited detailed proposals for future regulation of medicinal products. The trade and cooperation agreement includes specific provisions concerning medicinal products, which include the mutual recognition of cGMP, inspections of manufacturing facilities for medicinal products and cGMP documents issued (such mutual recognition can be rejected by either party in certain circumstances) but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. For example, it is not clear to what extent the UK will adopt legislation aligned with, or similar to, the EU CTR which became applicable on January 31, 2022 and which significantly reforms the assessment and supervision processes for clinical trials throughout the EU. On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) launched an eight-week consultation on reframing the UK legislation for clinical trials which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The MHRA responded to the consultation on March 21, 2023 and confirmed that it would bring forward changes to the legislation. The final legal texts introduced by the UK Government will ultimately determine the extent to which the UK clinical trials framework aligns with or diverges from the EU CTR. A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Therefore, there remains political and economic uncertainty regarding to what extent the regulation of medicinal products will differ between the UK and the EU in the future. Any divergences will increase the cost and complexity of running our business, including with respect to the conduct of clinical trials. Brexit also materially impacted the regulatory regime with respect to the approval of our product candidates. Great Britain is no longer covered by the EU&#8217;s procedures for the grant of MAs (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). As of January 1, 2021, all existing centralized MAs were automatically converted into UK MAs effective in Great Britain and issued with a UK MA number on January 1, 2021 (unless MA holders opted out of this scheme). A separate MA is now required to market drugs in Great Britain. It is currently unclear whether the regulator in the UK, the MHRA, is sufficiently prepared to handle the increased volume of MA applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in Great Britain and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in Great Britain for our product candidates, which could significantly and materially harm our business. Any of these factors could have a significant adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are found in violation of federal, state or foreign health care &#8220;fraud and abuse&#8221; laws, we may be required to pay significant fines and penalties, including, without limitation, debarment, suspension or exclusion from participation in federal, state or similar health care programs, which may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the U.S., we are subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti- kickback laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect us, and our ability to successfully commercialize our products in the U.S. We may have to comply with similar laws and regulations outside the U.S. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false claims laws prohibit anyone from knowingly and willfully presenting or causing to be presented for payment to third-party payers, including government payers, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically unnecessary items or services. Cases have been brought under false claims laws alleging that off-label promotion of pharmaceutical products or the provision of kickbacks has resulted in the submission of false claims to governmental health care programs. In addition, the government may assert that a claim, including items or services resulting from a violation of the federal Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the false claims laws. Further, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) prohibits persons or entities from knowingly and willfully executing a scheme to defraud any health care benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows, or should know, it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician sunshine requirements under the Patient Protection and Affordable Care Act, (&#8220;ACA&#8221;), which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to health care providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures and pricing information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to health care providers.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state or foreign health care programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to market our products and adversely impact our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may be unable to maintain sufficient clinical trial liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our inability to retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability claims could prevent or inhibit our ability to conduct clinical trials for product candidates we develop. We may be unable to obtain appropriate levels of such insurance. Even if we do secure clinical trial liability insurance for our programs, we may not be able to achieve sufficient levels of such insurance. Any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that exceeds the limits of our insurance coverage. We have supplemented our clinical trial coverage with product liability coverage in connection with the commercial launch of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and expect that we would similarly supplement our coverage for any of our other product candidates that may receive regulatory approval, but we may be unable to obtain such increased coverage on acceptable terms or at all. If we are found liable in a clinical trial lawsuit or a product liability lawsuit in the future, we will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Commercialization of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If our products do not gain market acceptance or if we fail to accurately forecast demand or manage our inventories, our business will suffer because we might not be able to fund future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A number of factors may affect the market acceptance of our products or any other products or product candidates we develop or acquire, including, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of our products relative to other products for the same or similar treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception by patients, physicians and other members of the health care community of the effectiveness, utility and safety of our products for their indicated applications and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to fund our sales and marketing efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts, including our strategic refocus to hospital/IDNs as part of the Reprioritization.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products, which would cause our business to suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to continue to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, to be self-administered by patients under the supervision of a healthcare provider, which is our only approved product to date. However, in connection with the Reprioritization, we significantly reduced the resources devoted to commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and it is possible that will have adverse consequences on the revenue that we are able to generate from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. Revenues for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for the three months ended March 31, 2025 were $0.2 million. If our commercial products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for an sNDA for other BXCL501 indications, including in the at-home setting for the acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease, or for other product candidates that it may develop. Our results of operations could be materially harmed if we are unable to successfully commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for any currently or additionally approved indications or any future product candidates that we may have approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and manage our inventory. To ensure adequate inventory supply, we must forecast inventory needs and place orders with our suppliers based on our estimates of future demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. Our ability to accurately forecast demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or for products of our competitors, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters, and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, our third-party contract manufacturer may not be able to deliver products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers or our third-party manufacturers may not be able to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We seek to maintain sufficient levels of inventory to protect ourselves from supply interruptions. As a result, we are subject to the risk that a portion of our inventory will become obsolete or expire, which could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:14pt 0pt 10pt 0pt;">We have based our potential market opportunity on a number of internal and third-party estimates and resources, including, without limitation, management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties, which may be incorrect.&#160; Our estimated potential market opportunity is based on estimates of episodes of agitation across our indications, and these estimated episodes of agitation are also based on internal and third-party estimates and market resources using data self-reported by patients. The conditions supporting our assumptions or estimates and the market data supporting these assumptions and estimates may change at any time or otherwise be inaccurate, thereby reducing the predictive accuracy of these underlying factors.  Our total addressable market will ultimately depend upon, among other things, the number of actual treatable episodes, the diagnosis criteria included in the final label for each of our product candidates, if approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients and treatable episodes in the United States and other major markets and elsewhere may turn out to be materially lower than expected, the number of treatable episodes may be significantly fewer than total episodes experienced, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would harm our results of operations and our business. For example, our estimates of the monthly average episodes for patients diagnosed with bipolar disorder and patients diagnosed with schizophrenia and, therefore, our estimated total addressable market are based on third-party market surveys which differ from an observational study in the EU of inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar disorder conducted which found that only 40% of enrolled patients reported agitation episodes in the six-month study period. If third-party or internally generated data prove to be inaccurate or we make errors in our assumptions based on that data, our total addressable market may be meaningfully smaller than we have estimated, our future growth opportunities and sales growth may be impaired, any of which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We obtained Orphan Drug Designation for BXCL701 for the treatment of pancreatic cancer, melanoma, acute myeloid leukemia and soft tissue sarcoma and we may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities in some jurisdictions, including the U.S. and EU, may designate drugs intended for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, orphan drug designation is granted by the European Commission based on a scientific opinion of the EMA&#8217;s Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application for orphan designation must be submitted before the application for MA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the U.S. provides that the FDA may not </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">approve any other applications, including a full NDA, to market the same drug for the same disease or condition for seven years. In limited circumstances, the applicable exclusivity period is 10 years in the EU. The EU exclusivity period can be reduced to six years if, at the end of the fifth year, it is established that a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January 2021, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of soft tissue sarcoma. In September 2019, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of acute myeloid leukemia. Prior to 2019, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of pancreatic cancer and melanoma. We may seek Orphan Drug Designations for BXCL701 in other diseases or conditions or for other product candidates. There can be no assurances that we will be able to obtain such designations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan- designated indication due to the uncertainties associated with developing pharmaceutical products, and it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same disease or condition before we do. If that were to happen, our applications for that disease or condition may not be approved until the competing company&#8217;s period of exclusivity expires. In addition, exclusive marketing rights in the U.S. and abroad may be limited if we seek approval for an indication broader than the orphan-designated disease or condition or may be lost if the FDA or foreign regulatory authorities later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same disease or condition. Even after an orphan drug is approved, the FDA or foreign regulatory authorities can subsequently approve the same drug with the same active ingredient for the same condition if the FDA or foreign regulatory authorities conclude that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process and does not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any product candidate for which we may obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have limited experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501, BXCL502, BXCL701, BXCL702 or any other product candidate. Typically, pharmaceutical companies would employ groups of sales representatives and associated sales and marketing staff numbering in the hundreds to thousands of individuals to call on the large number of physicians and hospitals. Following our Reprioritization, we may need to rebuild a commercial sales and marketing team if we seek to modify our commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or initiate commercial sales for any product candidate in the future, which will likely require significant cost. We may seek to collaborate with a third-party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate with a third-party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us. We may also need to hire additional personnel skilled in marketing and sales for our direct marketing and selling efforts. We cannot be sure that we will be able to acquire, or establish third-party relationships to provide, any or all of these marketing and sales capabilities. The maintenance and expansion of our direct sales force or establishment of a contract sales force, or a combination thereof, as applicable, to market our products is expensive and time-consuming and could delay any product launch. In addition, reputational harm from the Reprioritization may adversely impact our efforts to hire personnel skilled in marketing and sales. Further, we can give no assurances that we will be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to grow our revenues or that our sales efforts will ever lead to profits. A direct sales force has in the past subjected and may in the future subject us to higher fixed costs than those of companies that market competing products through independent third parties, due to the costs that we bear associated with employee benefits, training, and managing sales personnel. As a result, we could be at a competitive disadvantage. Additionally, these </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">fixed costs may slow our ability to reduce costs if needed, which could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We operate in a highly competitive and rapidly changing industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biopharmaceutical product development is highly competitive and subject to rapid and significant technological advancements. Our success is highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated, well-established pharmaceutical companies who already possess a large share of the market, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in the U.S., the EU and other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industry could result in even more resources being concentrated among a small number of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Competition may further increase as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Established biopharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge for products and product candidates, if any, that we commercialize. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Although we obtained FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, our products and product candidates may not be accepted by physicians or the medical community in general, and there may be insufficient insurance coverage and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, or BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates or any other product candidate successfully developed by us, independently or with partners, if approved, will be accepted by physicians, hospitals and other health care facilities. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> competes, and BXCL501, BXCL502, BXCL701, BXCL702 and any future product candidates we develop will compete, with a number of products manufactured and marketed by major pharmaceutical and biotechnology companies. The degree of market acceptance of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any drugs we develop depends on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our demonstration of the clinical efficacy and safety of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market approval and commercial launch of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indication(s) for which our products and product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product label and package insert requirements;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advantages and disadvantages of our products and product candidates compared to existing therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued interest in and growth of the market for anti-cancer or anti-agitation drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strength of sales, marketing, and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product pricing in absolute terms and relative to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future changes in health care laws, regulations, and medical policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of coverage and reimbursement in select jurisdictions, and future changes to coverage and reimbursement policies of government and third-party payors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or any product candidate for which we obtain regulatory approval. In the U.S. and other countries, sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any other products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government health administrative authorities, such as Medicaid and Medicare, managed care providers, private health insurers and other organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Third-party payors are increasingly challenging the prices charged for medical products and services. It will be time consuming and expensive for us to go through the process of seeking coverage and reimbursement from Medicare and private payors. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any other products for which we receive regulatory approval may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our proposed products on a profitable basis. Further federal, state and foreign government proposals and health care reforms are likely which could limit the prices that can be charged for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>and the product candidates that we develop and may further limit our commercial opportunities. Our results of operations could be materially adversely affected by proposed health care reforms, by the Inflation Reduction Act and other drug pricing legislation in the U.S., by the possible effect of such current or future legislation on amounts that private insurers will pay and by other health care reforms that may be enacted or adopted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Health care reform measures could hinder or prevent our product candidates&#8217; commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The U.S. government and other governments have shown significant interest in pursuing health care reform. Any government-adopted reform measures could adversely impact the pricing of health care products and services in the U.S. or internationally and the amount of reimbursement available from governmental agencies or other third-party payors for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and the product candidates that we develop. The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability to set prices for our products, which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">New laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to health care availability, methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging due to several reasons, including policies advanced by the current executive administration in the U.S., new health care legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For example, in the U.S., the ACA, which was enacted in 2010, has substantially changed the way health care is financed by both government health plans and private insurers, and significantly impacts the pharmaceutical industry. For example, the ACA imposed a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to government programs. In addition, as part of the ACA&#8217;s provisions closing a funding gap that existed in the Medicare Part D prescription drug program, manufacturers are required to provide a discount on branded prescription drugs for drugs provided to certain beneficiaries who fall within the &#8220;donut hole.&#8221; Similarly, the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ACA increased the level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1% of the average manufacturer price and required collection of rebates for drugs paid by Medicaid managed care organizations. The ACA also included changes to the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) including expansion of the list of eligible covered entities that may purchase drugs under the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These changes include the Budget Control Act of 2011, which resulted in aggregate reductions of Medicare payments to providers, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional Congressional action is taken. Furthermore, the American Taxpayer Relief Act of 2012, further reduced Medicare payments to several types of providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, beginning January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The cost of prescription pharmaceuticals in the U.S. will likely continue to be the subject of considerable discussion. Members of Congress and the Biden Administration have indicated they will continue to pursue further legislative or administrative measures to control prescription drug costs. There have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Individual states in the U.S. continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">It is likely that federal and state legislatures within the U.S. and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect the demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and any other drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain adequate coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the U.S. and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. While the regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We participate in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;) and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. As a condition of having federal funds being made available for covered outpatient drugs under Medicaid and Medicare Part B, a manufacturer must enroll in the MDRP. Under this program, we must pay a rebate to state Medicaid programs for each unit of our covered outpatient drug dispensed to a Medicaid beneficiary and paid for by a state Medicaid program. Medicaid drug rebates are based on pricing data that we must report on a monthly and quarterly basis to CMS. For the MDRP, this data includes the average manufacturer price (&#8220;AMP&#8221;) for each drug and, in the case of an innovator product, like IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, the best price. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after the data originally was due. Further, under the IRA, AMP figures we report will also be used to calculate a rebate on Medicare Part D utilization, triggered by price increases that outpace inflation. If we fail to provide information timely or are found to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered outpatient drugs under Medicaid or, if applicable, Medicare Part B. Failure to make necessary disclosures and/or to identify overpayments additionally could result in allegations against us under the Federal False Claims Act and other laws and regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Federal law requires that a manufacturer that participates in the MDRP also participate in the 340B program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B, and we participate in the 340B program. The 340B program is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;) and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs used in an outpatient setting. These 340B program covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B program discounted pricing on drugs used in an inpatient setting.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, we also must participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we must report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Individual states continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time-consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we may be required to offer products under the 340B program. Civil monetary penalties can be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit required price data on a timely basis, or if we are found to have charged 340B program covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, pursuant to which we participate in the MDRP, no federal payments would be available under Medicaid or Medicare for our covered outpatient drugs. We cannot assure you that price data submissions we make will not be found to be incomplete or incorrect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Relationship with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">BioXcel LLC has significant influence over the direction of our business, and the concentrated ownership of our common stock will prevent you and other stockholders from influencing significant decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, BioXcel LLC owned approximately 8.8% of the economic interest and voting power of our outstanding common stock and BioXcel LLC is controlled by BioXcel Holdings, Inc. Our Chief Executive Officer and member of our board of directors, Vimal Mehta, Ph.D., is the Chief Executive Officer, President, Treasurer and Secretary and a member of the board of managers of BioXcel LLC and Chief Executive Officer, President, Treasurer and Secretary and the sole member of the board of directors of BioXcel Holdings, Inc. See &#8220;<i style="font-style:italic;">The management of and beneficial ownership in BioXcel LLC by our executive officers and our directors may create, or may create the appearance of, conflicts of interest.</i>&#8221; below. Even though BioXcel LLC controls less than a majority of the voting power of our outstanding common stock, it may influence the outcome of such corporate actions so long as it owns a significant portion of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Approval of commercial terms between us and BioXcel LLC does not preclude the possibility of stockholder litigation, including but not limited to derivative litigation nominally against BioXcel LLC and against its directors and officers and also against us and our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The commercial terms of the Separation and Shared Services Agreement (as amended and/or restated and in effect as of the date hereof, the &#8220;Services Agreement&#8221;), and the Amended and Restated Asset Contribution Agreement (as amended and/or restated and in effect as of the date hereof, the &#8220;Contribution Agreement&#8221;), that we entered into with BioXcel LLC have not been negotiated by persons consisting solely of disinterested directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No assurance can be given that any equity or debt holder of BioXcel LLC or the Company will not claim in a lawsuit that such terms in fact are not in the best interests of BioXcel LLC or the Company and its applicable equity holders, that the directors and officers of BioXcel LLC or the Company breached their fiduciary duties in connection with such agreements and that any disclosures by the Company to its stockholders regarding these agreements and the relationship between BioXcel LLC and us did not satisfy applicable requirements. In any such instance, we and our directors and officers may also be named as defendants and we would have to defend ourselves and our directors and officers. While we would seek indemnification from BioXcel LLC under the terms of these agreements against any damages or other costs, which could be substantial, no such indemnification has yet been agreed to or may be agreed to and be in effect. Further, any such litigation would be time-consuming and would divert focus and resources from the development of our product candidates and our business, including but not limited to possibly delaying our clinical trials due to our management having to spend time and attention on such litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We continue to depend on BioXcel LLC to provide us with certain services for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely, in part, on BioXcel LLC and access to its EvolverAI, to complement our in-house, uniquely integrated AI-to-drug-development capability. EvolverAI is a research and development engine created and owned by BioXcel LLC, to identify, research and develop potential product candidates in neuroscience and immuno-oncology. We negotiated the Services Agreement with BioXcel LLC pursuant to which BioXcel LLC agreed to perform certain intellectual property prosecution and management and research and development activities for us utilizing its EvolverAI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Under the Services Agreement, we had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI.  We agreed to pay BioXcel LLC $18,000 per month </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">from March 13, 2023, to December 31, 2024 in exchange for this option. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10 million in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate.  We did not exercise this option, which expired on December 31, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, at the time of our initial public offering (&#8220;IPO&#8221;), BioXcel LLC granted us (i) a first right to negotiate exclusive rights to any additional product candidates in the fields of neuroscience and immuno-oncology that BioXcel LLC may identify on its own and not in connection with BioXcel LLC&#8217;s provision of services to us under the Services Agreement and (ii) an exclusivity agreement in the neuroscience and immuno-oncology fields whereby BioXcel LLC agreed not develop drugs, or engage in preclinical discovery for the purpose of developing drugs, in the neuroscience and immuno-oncology fields for or on behalf of a third party, utilizing EvolverAI or otherwise. This first right to negotiate and exclusivity period expired on March 12, 2023, and there is no assurance that we will extend the terms of the agreement. We are continuing to assess our ongoing business needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On September 19, 2023, the Company, Krishnan Nandabalan, Ph.D., InveniAI LLC (&#8220;Inveni&#8221;) and Invea Therapeutics, Inc. (&#8220;Invea&#8221;) and the other parties thereto entered into a non-compete agreement pursuant to which Dr. Nandabalan, Inveni and Invea agreed not to compete with the Company and its controlled affiliates in the fields of neuroscience and immuno-oncology for a period of five years from September 19, 2023 and not to solicit employees of the Company or its controlled affiliates for a period of two years from September 19, 2023. Inveni and Invea are subsidiaries of BioXcel LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our rights under the Services Agreement were to become limited or if we are otherwise precluded from conducting research and development using EvolverAI, or if BioXcel LLC, Inveni or Invea do not fulfill their obligations under the agreements, such development could materially adversely affect our future operating results, financial condition, and prospects. Furthermore, certain individuals conducting services on our behalf are not our employees, and we cannot control whether they devote sufficient time, skill and resources to our ongoing development programs. We also cannot ensure that BioXcel LLC retains sufficient resources or personnel or otherwise to conduct its operations. BioXcel LLC may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting research and development activities, which could impede their ability to devote appropriate time to our research and development programs. BioXcel LLC is not currently restricted from using EvolverAI to perform drug discovery services for our direct competitors, and if we do not extend the exclusivity period in the neuroscience and immuno-oncology fields, this could harm our competitive position and adversely affect our future operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The management of and beneficial ownership in BioXcel LLC may create, or may create the appearance of, conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Chief Executive Officer and member of our board of directors, Vimal Mehta, Ph.D., is the Chief Executive Officer, President, Treasurer and Secretary and a member of the board of managers of BioXcel LLC and Chief Executive Officer, President, Treasurer and Secretary and the sole member of the board of directors of BioXcel Holdings, Inc. Additionally, as of March 31, 2025, Dr. Mehta, through his beneficial ownership of BioXcel LLC, beneficially owned approximately 8.8% of the Company. The management and ownership of BioXcel LLC by Dr. Mehta may create the appearance of conflicts of interest when Dr. Mehta is faced with decisions that could have different implications for BioXcel LLC than the decisions have for us, including decisions that relate to our Services Agreement and Contribution Agreement, as well as potential agreements relating to future product candidates and AI-related services or collaborations. Any perceived conflicts of interest resulting from investors questioning the independence of our management or the integrity of corporate governance procedures may materially affect our stock price and expose us to litigation risk.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any disputes that arise between us and BioXcel LLC with respect to our past and ongoing relationships could harm our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Disputes may arise between BioXcel LLC and us in a number of areas relating to our past and ongoing relationships, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with contractual provisions applicable to BioXcel LLC and us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labor, tax, employee benefit, indemnification and other matters arising from the separation of BTI from BioXcel LLC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution and supply obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee retention and recruiting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business combinations involving us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales or distributions by BioXcel LLC of all or any portion of its ownership interest in us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature, quality and pricing of services BioXcel LLC has agreed to provide us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business opportunities that may be attractive to both BioXcel LLC and us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into the Services Agreement with BioXcel LLC related to the separation of our business operations from those of BioXcel LLC that contains certain limitations on BioXcel LLC&#8217;s ability to control various aspects of our business and operations, notwithstanding BioXcel LLC&#8217;s substantial ownership position. This agreement may be amended upon agreement between us and BioXcel LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">BioXcel LLC may experience challenges with the acquisition, development, enhancement, or deployment of technology necessary for EvolverAI. We may face similar challenges with other AI platforms that we utilize, including our own in-house proprietary platform.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel LLC operates in businesses that require sophisticated computer systems and software for data collection, data processing, cloud-based platforms, analytics, statistical projections and forecasting, mobile computing, social media analytics and other applications and technologies. BioXcel LLC seeks to address its technology risks by increasing its reliance on the use of innovations by cross-industry technology leaders and adapt these for their pharmaceutical, biotechnology, biopharmaceutical, diagnostic, medical device and contract research and manufacturing clients. Some of the technologies supporting the industries they serve are changing rapidly and we must continue to adapt to these changes in a timely and effective manner at an acceptable cost. They also must continue to deliver data to their clients in forms that are easy to use while simultaneously providing clear answers to complex questions. We also utilize our own in-house AI platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There can be no guarantee that we or BioXcel LLC will be able to develop, acquire or integrate new technologies, that these new technologies will meet our and BioXcel LLC&#8217;s needs or achieve our expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors. Significant technological change could render BioXcel LLC&#8217;s EvolverAI or other AI platforms that we utilize obsolete. BioXcel LLC&#8217;s and our continued success will depend on the ability to adapt to changing technologies, manage and process ever-increasing amounts of data and information and improve the performance, features and reliability of these services in response to changing client and industry demands. If EvolverAI or other AI and machine learning models that we use are incorrectly designed, do not operate properly, the data we use to train them is incomplete, inadequate or biased in some way, or if we do not have sufficient rights to use the data on which our AI and machine learning models rely, the performance of our products, services and businesses, as well as our reputation, could suffer or we could incur liability through the violation of laws, third-party privacy rights or contracts to which we are a party. BioXcel LLC or we may experience difficulties that could delay or prevent the successful design, development, testing, and introduction of advanced versions of EvolverAI, limiting our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ability to identify new product candidates. New services, or enhancements to existing EvolverAI services, may not adequately meet our requirements. Any of these failures could have a material adverse effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are substantially dependent on third parties for the manufacture of our clinical supplies of our product candidates and our commercial supplies of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and we intend to rely on third parties to produce commercial supplies of any other approved product candidate. Therefore, our development of our products could be stopped or delayed, and our commercialization of any future product could be stopped, delayed or made less profitable if third-party manufacturers fail to obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug product in sufficient quantities or at acceptable prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into a commercial supply agreement with ARx, LLC (&#8220;ARx&#8221;) pursuant to which ARx has agreed to exclusively manufacture and supply us with all of our worldwide demand of film formulation of Dex to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and for ongoing clinical trials of our product candidate BXCL501, subject to certain alternative supply provisions. If ARx is unable or ceases to produce our supply of Dex in sufficient quantities as and when needed or if the ARx agreement becomes too costly, our business would be harmed because there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our ability to sell our products to customers could occur if we encounter delays or difficulties in securing Dex, or if the quantity or quality supplied does not meet our specifications, or if we cannot then obtain an acceptable substitute. If any of these events occur, our business and operating results could be harmed. Our specified minimum annual payment could adversely affect our cash flows in the future, such as in times when we have sufficient inventory and would otherwise be able to use our cash for other purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The manufacture of biotechnology and pharmaceutical products is complex and requires significant expertise, capital investment, process controls and know-how. Common difficulties in biotechnology and pharmaceutical manufacturing may include: sourcing and producing raw materials, transferring technology from chemistry and development activities to production activities, validating initial production designs, scaling manufacturing techniques, improving costs and yields, establishing and maintaining quality controls and stability requirements, eliminating contaminations and operator errors, and maintaining compliance with regulatory requirements. We do not currently have nor do we plan to acquire the infrastructure or capability internally to produce an adequate supply of compounds to meet future requirements for clinical trials and commercialization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing facilities are subject to inspection before the FDA or foreign regulatory authorities will issue an approval to market a new drug product, and ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., and any other manufacturers that we may use must adhere to the cGMP or similar foreign regulations prescribed by the FDA or foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As such, these third-party manufacturers will be required to comply with cGMPs, and other applicable laws and regulations. We have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities of these third parties for the manufacture of our other product candidates or any products that we may successfully develop, or if it withdraws any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture for us, we may need to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers for clinical or commercial supply on acceptable terms, or at all. Any of these factors would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We, ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., and/or our other third-party manufacturers may be adversely affected by developments outside of our control, and these developments may delay or prevent further manufacturing of our products. Adverse developments may include labor disputes, resource constraints, shipment delays, inventory shortages, lot failures, unexpected sources of contamination, lawsuits related to our manufacturing techniques, equipment used during manufacturing, or composition of matter, unstable political environments, acts of terrorism, war, natural disasters, and other natural and man-made disasters. If we, ARx, the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patheon pharma services division of Thermo Fisher Scientific Inc., or our other third-party manufacturers were to encounter any of the above difficulties, or otherwise fail to comply with contractual obligations, our ability to provide any product for clinical trial or commercial purposes would be jeopardized. This may increase the costs associated with completing our clinical trials and commercial production. Further, production disruptions may cause us to terminate ongoing clinical trials and/or commence new clinical trials at additional expense. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications or pass safety inspections. If production difficulties cannot be solved with acceptable costs, expenses, and timeframes, we may be forced to abandon our clinical development and commercialization plans, which could have a material adverse effect on our business, prospects, financial condition, and the value of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We, or third-party manufacturers on whom we rely, including ARx, may be unable to successfully scale-up manufacturing of our product and product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing any approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, we, or our manufacturers, including ARx, and the Patheon pharma services division of Thermo Fisher Scientific Inc., will need to manufacture them in large quantities. We, or our manufacturers, may be unable to successfully increase the manufacturing capacity for any of our approved products or product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any of our manufacturers, are unable to successfully scale up the manufacture of our approved products or product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our approved products, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our approved products or product candidates successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our failure to find third-party collaborators to assist or share in the costs of product development could materially harm our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our strategy for the development and commercialization of our proprietary products and product candidates may include the formation of collaborative arrangements with third parties. Collaborators have significant discretion in determining the efforts and resources they apply and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funding research, preclinical development, clinical trials and manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully commercializing IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or product candidates.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are not able to establish collaboration agreements, we may be required to undertake product development and commercialization at our own expense. Such an undertaking may limit the number of product candidates that we will be able to develop, significantly increase our capital requirements and place additional strain on our internal resources. Our failure to enter into collaborations could materially harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our product candidates. To the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization of product candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop or commercialize successfully any product candidate to which they have obtained rights from us could materially harm our business, financial condition and results of operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have relied upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCPs, which are regulations and guidelines enforced by the FDA, the competent authorities of the European Economic Area (&#8220;EEA&#8221;) countries and comparable foreign regulatory authorities for all of our products in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If regulatory authorities determine that we or any of our CROs failed to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP and similar foreign regulations. Any failure, whether by us or our CROs, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, if any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. For example, investigator misconduct during our TRANQUILITY II trial evaluating BXCL501 in patients with probable Alzheimer&#8217;s disease could require us to conduct additional clinical trials before we are able to seek or obtain approval for BXCL501 for use in this patient population, as described more fully in the risk factor above entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221; As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our GCP preclinical studies or our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions, including as a result of an economic downturn and geopolitical events, such as changes in U.S. federal policy that affect the geopolitical landscape. In addition, the global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. In addition, events such as pandemics, epidemics, or outbreaks of an infectious disease may materially and adversely impact our business if we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions. Furthermore, geopolitical conflicts and war, such as the current military conflict between Russia and Ukraine and the war between Israel and Hamas, and other conflicts in the Middle East, could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, trade policies and geopolitical disputes and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures affect regions where raw materials are sourced. For example, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from China, as well as other business restrictions. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact our operations and supply chain. As these tensions continue to rise, more targeted approaches on certain products, industries or companies could significantly impact our development and commercialization efforts. The U.S. government has recently imposed tariffs on certain foreign goods, and some foreign governments have threatened or instituted retaliatory tariffs on certain U.S. goods and have indicated a willingness to impose additional tariffs on U.S. products, which could increase the cost of goods needed to commercialize our products and continue development of our product candidates. Further, such actions by the U.S. could result in other retaliatory actions by those countries which could impact our ability to profitably commercialize our products in those jurisdictions. As a result, our business, operations, and financial condition could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A severe or prolonged economic downturn, or additional global financial or political crises, could result in a variety of risks to our business, including delayed clinical studies or preclinical studies, delayed approval of our product candidates, delayed ability to obtain patents and other intellectual property protection, weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. The extent of the impact of these conditions on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected timeframe, as well as that of third parties upon whom we rely, will depend on future developments which are uncertain and cannot be predicted. A weak or declining economy also could strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our future success may depend on our ability to attract and retain qualified personnel, including consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are dependent on the principal members of our management and scientific teams. Our success and the execution of our operating strategy, to the extent we continue operations, depend largely on the continued service of our employees. In addition to our employees, we have access to certain of BioXcel LLC&#8217;s employees and resources through the various agreements we have with BioXcel LLC. We have expanded our management team to include an operational ramp-up of additional technical staff required to achieve our business objectives. We will need to retain such </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">employees, and may need to continue to expand our managerial, commercial, operational, technical, and scientific, financial, and other resources to manage our operations and clinical trials, continue our research and development activities, and any approved product candidates. Our management and scientific personnel, systems and facilities currently in place may not be adequate to support our future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may utilize the services of third-party vendors to perform tasks including preclinical and clinical trial management, statistics and analysis, regulatory affairs, medical advisory, market research, formulation development, chemistry, manufacturing and control activities, other drug development functions, legal, auditing, financial advisory, and investor relations. Because we rely on numerous consultants to outsource many key functions of our business, we will need to be able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for our product candidate or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to recruit and retain qualified personnel, we may be unable to successfully implement the tasks necessary to further develop and commercialize our product candidate and, accordingly, may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our success depends largely upon the continued services of our key executive officers, including Vimal Mehta, our Chief Executive Officer, President and a member of our Board, as well as the other principal members of our management, scientific, clinical teams and commercial readiness teams. We do not maintain &#8220;key person&#8221; insurance for any of these executive officers or any of our other key employees. We also rely on our leadership team in the areas of research and development, marketing, services and selling, general and administrative functions. From time to time, there may be changes in our executive management and leadership teams resulting from the hiring or departure of executives or other key employees, which could disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To continue to execute our business strategy, we also must attract and retain highly skilled personnel. We might not be successful in maintaining our unique culture and continuing to attract and retain qualified personnel. We have, from time to time, had difficulty hiring and retaining highly skilled personnel with appropriate qualifications, including as a result of the Reprioritization and related consequences for our reputation. We may experience such difficulties in the future, and any further restructuring or related reduction in force could exacerbate such difficulties. The pool of qualified personnel with experience working within the biopharmaceutical and biotechnology market is limited overall. In addition, many of the companies with which we compete for experienced personnel have greater resources than we have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, prior workforce reductions and any future similar cost-saving initiatives may make it difficult for us to maintain valuable aspects of our culture, retain institutional knowledge and expertise, to prevent a negative effect on employee morale or attrition beyond our planned reduction in headcount, and to attract competent personnel who are willing to embrace our culture in the future. Our executive officers and other employees are at-will employees, which means they may terminate their employment relationship with us at any time, and their knowledge of our business and industry would be extremely difficult to replace. We may not be able to retain the services of any members of our senior management or other key employees. If we do not succeed in retaining and motivating existing employees or attracting well-qualified employees in the future, our business, financial condition and results of operations could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in making employment decisions, particularly in the biotechnology and high-technology industries, job candidates often consider the value of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the price of our stock might, therefore, adversely affect our ability to attract or retain highly skilled personnel. Furthermore, the requirement to expense the fair value of stock options and other equity </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">instruments might discourage us from granting the size or type of stock option or equity awards that job candidates require to join our Company. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may acquire other companies or technologies, which could divert our management&#8217;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may in the future seek to acquire or invest in businesses, applications and services or technologies that we believe could complement or expand our services, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we do not have any experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to integrate or benefit from acquired technologies or services in a profitable manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated costs or liabilities associated with the acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty integrating the accounting systems, operations and personnel of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty converting the customers of the acquired business onto our platform and contract terms, including disparities in the revenue, licensing, support or professional services model of the acquired company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s attention from other business concerns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse effects to our existing business relationships with business partners and customers as a result of the acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential loss of key employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of resources that are needed in other parts of our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of substantial portions of our available cash to consummate the acquisition.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial position may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with any regulations applicable to us, to provide accurate information to regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state health care fraud and abuse laws and regulations, or to report financial information or data accurately or disclose unauthorized </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes, floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical epidemics, and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss, negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man- made disasters. Several of our employees conduct business outside of our headquarters and leased or owned facilities. These locations may be subject to additional security and other risk factors due to the limited control of our employees. If such an event as described above were to occur in the future, it may cause interruptions in our operations, delay research and development programs, clinical trials, regulatory activities, manufacturing and quality assurance activities, sales and marketing activities, hiring, training of employees and persons within associated third parties, and other business activities. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Likewise, we will rely on third parties, including ARx, to manufacture IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and our product candidates and to conduct clinical trials, and similar events as those described in the prior paragraph relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidate could be delayed or altogether terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data breaches or cyber-attacks could disrupt our business operations and information technology systems or those of third parties on which we rely, adversely impact our financial results, or result in the loss or exposure of confidential or sensitive product candidate, clinical trial, employee, or Company information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including our mobile and web-based applications, our e-commerce platform and our enterprise software. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, clinical trial data, and personal information (collectively, &#8220;Confidential Information&#8221;) of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our information technology systems and those of third parties on which we rely have been and may in the future be attacked or breached by individuals or organizations intending to obtain our Confidential Information; harm or disrupt our business operations; or otherwise misappropriate information or Company funds. A security compromise of our information technology systems or business operations, or those of third parties on which we rely, could occur through a variety of methods such as from cyber-attacks and cyber-intrusions over the Internet, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, malware, computer viruses, email spoofing, attachments to e-mails, persons inside or outside our organization or persons with access to systems inside our organization. The risk of such intrusions, threats to data and information technology systems and breaches has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While we maintain some of our own critical information technology systems, we also depend on third parties to provide important information technology services relating to several key business functions. Our measures to prevent, detect and mitigate these threats, including password protection, firewalls, backup servers, threat monitoring and periodic penetration testing, may not be successful in preventing a data breach or limiting the effects of a breach. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the security measures employed by third-party service providers may prove to be ineffective at preventing breaches of their systems. Any attack that results in disruptions to our operations, or the unauthorized release or loss of Confidential Information, could have a material adverse effect on our business reputation, increase our costs and expose us to material legal claims and liability (such as class actions) and result in regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. If the unauthorized release or loss of Confidential Information were to occur, our operations and financial results and our share price could be adversely affected. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission, and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. If we are determined to act as a covered entity or business associate under HIPAA and be directly regulated under HIPAA, any person acting on our behalf may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;), requires covered businesses that process the personal information of California residents to, among other things: provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information, and enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. If we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In Europe, the General Data Protection Regulation (&#8220;GDPR&#8221;) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, since January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR (i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover). On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increased scrutiny of and evolving expectations for environmental, social and governance (&#8220;ESG&#8221;) initiatives may impose additional costs or otherwise adversely impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There has been an increased focus from investors, capital providers, shareholder advocacy groups, other market participants, customers, and other stakeholder groups regarding companies&#8217; ESG initiatives. While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) or commitments to improve the ESG profile of our Company and/or offerings, such initiatives or achievements of such commitments may be costly and may not have the desired effect. Additionally, some investors may use third-party or proprietary ESG ratings to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our ESG practices are inadequate. The criteria by which companies&#8217; ESG practices are assessed are evolving, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we elect not to or are unable to satisfy new criteria or do not meet the criteria, some investors may conclude that our policies with respect to ESG are inadequate and choose not to invest in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our ESG practices do not meet evolving investor or other stakeholder expectations and our standards, reputation, ability to attract or retain employees and desirability as an investment or business partner could be negatively impacted. Similarly, our failure or perceived failure to adequately pursue or fulfill any ESG goals and objectives or to satisfy various reporting standards, if any, could expose us to additional regulatory, social or other scrutiny, the imposition of unexpected costs, or damage to our reputation, which in turn could have a material adverse effect on our business and could cause the market value of our common stock to decline.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our failure to successfully acquire, develop and market additional product candidates or approved drug products could impair our ability to grow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of our growth strategy, we may evaluate, acquire, license, develop and/or market third-party products or product candidates and technologies. Our internal research capabilities are limited and we may be dependent upon pharmaceutical and biotechnology companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify, select and acquire promising pharmaceutical product candidates and products. The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, future acquisitions may entail numerous operational and financial risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of our business and diversion of our management&#8217;s and technical personnel&#8217;s time and attention to develop acquired products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition and integration costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key employees of any acquired businesses.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any products that we develop or approved products that we acquire will be manufactured profitably or achieve market acceptance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our net operating losses and tax credits to offset future taxable income and income tax liabilities may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At December 31, 2024 the Company had approximately $432.6 million of gross federal and $443.5 million of gross state net operating loss carry-forwards. Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) in 2017 amended the net operating losses carryforward rules. Net operating losses generated after December 31, 2017, may be carried forward indefinitely, subject to certain limitations on their use. Net operating losses generated prior to 2018 may be carried forward for twenty years. If not utilized, these net operating losses will expire by 2037. State net operating losses have varying carryforward and applicable expiration periods. $430.0 million of the federal net operating losses were incurred after December 31, 2017, and will be carried forward indefinitely; the balance of the federal net operating losses are subject to expiration no later than 2037. The utilization of such net operating loss carry-forwards and realization of tax benefits </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">in future years depends predominantly upon having taxable income. The Company has approximately $16.0 million of federal orphan drug credits and research and development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $1.5 million of state research and development credits which will begin to expire in 2040 if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, under sections 382 and 383 of the Code, our federal net operating losses and tax credit carryforwards, such as research/development credits and orphan drug credits, may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders (or groups of stockholders) in excess of 50% over a rolling three-year period. Similar state provisions may also exist. These ownership changes may limit the amount of the net operating losses and tax credit carryforwards that can be utilized annually to offset future taxable income and income tax, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain federal or state income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2024, there were no uncertain tax positions. The Company's U.S. federal and state net operating losses have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant tax year to audit by The U.S. Internal Revenue Service (&#8220;IRS&#8221;) and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the 12 months ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success will depend in part on obtaining, maintaining enforcing and defending our patents, trademarks, trade secrets and other intellectual property rights and proprietary technology for our current and future approved products and product candidates, the processes used to manufacture them and the methods for using them, as well as successfully defending these patents against third-party challenges. We are the owner of record of certain patents and patent applications pending in the U.S. and in certain foreign jurisdictions. Patents issued from non-provisional applications, which are typically filed from provisional patent applications or from PCT applications that enter the national phase. Neither provisional patent applications nor PCT applications issue directly as patents. We own PCT patent applications relating to our platform technologies covering methods of use and applications of the platform technologies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We cannot be certain that any future patents will issue with claims that cover our product candidates. Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents, trademarks, trade secrets and other intellectual property rights and proprietary technology that cover these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions that have been the subject of much litigation in recent years and for which important legal principles remain unresolved. Therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the U.S. or in foreign jurisdictions outside of the U.S. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict which of our patent applications will issue, the breadth of claims that may be enforced in the patents that may be issued from the applications we currently, or may in the future, own or license from third parties, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third-party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition, reexamination, review, reissue, post grant review or invalidity proceedings before U.S. or non-U.S. patent offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to independently develop, make and commercialize compounds that are similar to, or are alternatives or duplicates of any of our product candidates, but that are not covered by the claims of our patents or are not infringing, misappropriating, or otherwise violating our other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to make the inventions covered by our issued patents or pending patent applications that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pending patent applications or those that we may own in the future may not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of our issued patents or patent applications when issued may not cover our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents that we obtain may not provide us with any competitive advantages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop, manufacture and commercialize competitive products or product candidates for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to seek patent protection for some of our proprietary technology or product candidates to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any granted patents may be held invalid or unenforceable as a result of legal challenges by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. In addition, the USPTO and various foreign governmental patent agencies require compliance with various procedural, document submission, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be required to enter into intellectual property license agreements that are important to our business. These license agreements may impose various diligence, payment, and other obligations on us. For example, we may enter into exclusive license agreements with universities, research institutions, or peer industry third parties pursuant to which we may be required to use commercially reasonable efforts to engage in various development and commercialization activities with respect to licensed products and may need to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations under our agreements with any of these licensors, we may be subject to termination of the license agreement in whole or in part; increased financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop or commercialize products covered by the license agreement will be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, disputes may arise regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a third-party expresses interest in an area under a license that we are not pursuing, under the terms of certain of our license agreements, we may be required to sublicense rights in that area to a third-party, and that sublicense could harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We or our licensors may be subject to claims that third parties have an interest in our patents, trade secrets, or other intellectual property that we regard as our own or our licensor&#8217;s, based on claims that the relevant agreements with employees or consultants obligating them to assign their intellectual property rights to us or our licensor are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. We may also be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">others who are involved in developing our product candidates. Although it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets, or other intellectual property, and it may be necessary or we may desire to obtain a license to a third party&#8217;s intellectual property rights to settle any such claim; however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If we or our licensors fail in defending any such claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. A court could prohibit us from using technologies, features or other intellectual property rights that are essential to our products or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our products or product candidates could have a material adverse effect on our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our products or technologies. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our products or services, which could materially and adversely affect our business, financial condition and results of operations. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our product candidates have been or will be submitted to the FDA for approval under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not obtained a right of reference. The 505(b)(2) application would enable us to reference published literature and/or the FDA&#8217;s previous findings of safety and effectiveness for a branded reference drug with the same active ingredient. For NDAs submitted under Section 505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act, such NDAs may be required to include paragraph IV certifications, that certify that any patents listed in the FDA&#8217;s Orange Book, with respect to any product referenced in the 505(b)(2) application, are invalid, unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the Hatch-Waxman Act, the holder of patents that the 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the paragraph IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2) applicant within 45 days of the patent owner&#8217;s receipt of notice triggers a one-time, automatic, 30-month stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA, unless patent litigation is resolved in the favor of the paragraph IV certification filer, or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2) application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the branded reference drug product has expired. The FDA may also require us to perform one or more additional clinical studies or measurements to support the change from the branded reference drug, which could be time consuming and could substantially delay our achievement of regulatory approvals for such product candidates. The FDA may also reject our future 505(b)(2) submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which would require us to provide extensive data to establish </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">safety and effectiveness of the drug product for the proposed use and could cause delay and be considerably more expensive and time consuming. These factors, among others, may limit our ability to successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our intellectual property related to IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> BXCL501, BXCL502, BXCL701, BXCL702 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property rights, the commercial value of our products or product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. We regularly monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek enforce our rights against potential infringement, misappropriation or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we choose to commence a proceeding or litigation to prevent another party from infringing our patents, that party could counterclaim  that our patents are invalid or should not be enforced against them. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is a risk that the examiner or court will decide that our patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the related inventions. There is also the risk that, even if the validity of our patents is upheld, the examiner or court may construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that such other party&#8217;s activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court has recently modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge to any patents we obtain or license. Any proceedings or litigation to enforce our intellectual property rights or defend ourselves against claims of infringement of third-party intellectual property rights could be costly and divert the attention of managerial and scientific personnel, regardless of whether such litigation is ultimately resolved in our favor. We may not have sufficient resources to bring these actions to a successful conclusion. If a defendant were to prevail on its legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we could lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.  Moreover, if we are unable to </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">successfully defend against claims that we have infringed the intellectual property rights of others, we may be prevented from using certain intellectual property and may be liable for damages, which in turn could materially adversely affect our business, financial condition or results of operations. Even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings. Further, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, the monetary cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, and/or third party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success will depend in part on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products, or the manufacture or use of our product candidates. In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the United States or abroad. Such mechanisms include interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. If third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. The costs of these lawsuits could affect our results of operations and divert the attention of managerial and scientific personnel. Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that we are infringing the third-party&#8217;s patents and would order us to stop the activities covered by the patents. In that event, we may not have a viable way around the patent and may need to halt commercialization of the relevant product candidate. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&#8217;s patents. We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents or other intellectual property rights. In addition, we may be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">brought by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">some patent applications in the U.S. may be maintained in secrecy until the patents are issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications in the U.S. are typically not published until 18 months after the priority date; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publications in the scientific literature often lag behind actual discoveries.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed U.S. patent applications on inventions similar to ours that claim priority to any applications filed prior to the priority dates of our applications, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar inventions prior to our own inventions, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Finally, a Unitary Patent and Unified Patent Court (&#8220;UPC&#8221;) system was implemented in Europe on June 1, 2023. This new regime may present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our trademarks could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our products or technologies, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Further, there can be no assurance that competitors will not infringe on our trademarks or that we will have adequate resources to enforce our trademarks. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely on our trademarks, trade names and brand names, such as &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#8221; and our logo, to distinguish our company and our products from our competitors and the products of our competitors, and have registered or applied to register many of these trademarks in the United States and certain countries outside the United States, however, we have not yet registered all of our trademarks in all of our current and potential markets. There can be no assurance that our trademark applications will be approved for registration. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties may also oppose our trademark applications and may seek to cancel trademark registrations or otherwise challenge our use of the trademarks. Opposition or cancellation proceedings may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the United States, where trademark rights are acquired based on use and not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Our trademarks or trade names may be infringed, circumvented, declared generic or determined to be violating or infringing on other marks.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how and/or other proprietary information to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. In addition, despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property rights by employees, consultants and other third parties who have access to such intellectual property or other proprietary rights is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. There can be no assurances that such employees, consultants, advisors or third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant or other third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee, consultant or other third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products or services that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. While we use commonly accepted security measures, trade secret violations are often a matter of state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our intellectual property rights or confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Furthermore, any license agreements we enter into in the future may require us to notify, and in some cases license back to the licensor, certain additional proprietary information or intellectual property that we developed using the rights licensed to us under these agreements. Any such licenses back to the licensor could allow our licensors to use that proprietary information or intellectual property in a manner that could harm our business. In addition, others may </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">independently discover our trade secrets and proprietary information. For example, the FDA, as part of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Further, it is possible that others will independently develop the same or similar technology, products or services or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology or products similar to ours, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have misappropriated the intellectual property rights, including know-how or trade secrets of a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be subject to claims that our employees or consultants have wrongfully used for our benefit or disclosed to us confidential information of third parties. As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or engagement. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how, or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or our employees, consultants or independent contractors have, inadvertently or otherwise misappropriated the intellectual property, including know-how, trade secrets or other proprietary information of their former employers or clients. To the extent that our employees, consultants or contractors use intellectual property rights or proprietary information owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely impact our business. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our intellectual property may not be sufficient to protect our products from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be subject to competition despite the existence of intellectual property we license or own. We can give no assurances that our intellectual property claims will be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing competitive products. The existence of competitive products that avoid our intellectual property could materially adversely affect our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, limitations, or perceived limitations, in our intellectual property may limit the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable risk to commercialization of our products or future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our drug re-innovation approach involves the filing of patent applications covering new methods of use and/or new formulations of previously known, studied and/or marketed drugs. Although the protection afforded by our patent and patent applications may be significant with respect to BXCL501, BXCL502, BXCL701 and BXCL702, when looking at our patents&#8217; ability to block competition, the protection offered by our patents may be, to some extent, more limited than the protection provided by patents claiming the composition of matter of entirely new chemical structures previously unknown. If a competitor were able to successfully design around any method of use and formulation patents we may have in the future, our business and competitive advantage could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights that we either own </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">or license from BioXcel LLC. If we do not prevail in enforcing our intellectual property rights in this type of litigation, we may be subject to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">paying monetary damages related to the legal expenses of the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facing additional competition that may have a significant adverse effect on our product pricing, market share, business operations, financial condition, and the commercial viability of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restructuring our company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical trial, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A third-party may also challenge the validity, enforceability or scope of the intellectual property rights that we license or own; and the result of these challenges may narrow the scope or claims of or invalidate patents that are integral to our product candidates in the future. There can be no assurance that we will be able to successfully defend patents we own in an action against third parties due to the unpredictability of litigation and the high costs associated with intellectual property litigation, amongst other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Intellectual property rights and enforcement may be less extensive in jurisdictions outside of the U.S.; thus, we may not be able to protect our intellectual property and third parties may be able to market competitive products that may use some or all of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Changes to patent law, including the Leahy-Smith America Invents Act of 2011 and the Patent Reform Act of 2009 and other future article of legislation, may substantially change the regulations and procedures surrounding patent applications, issuance of patents, and prosecution of patents. We can give no assurances that patents we own or license and can be successfully defended or will protect us against future intellectual property challenges, particularly as they pertain to changes in patent law and future patent law interpretations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">In Europe, a new unitary patent system took effect on June 1, 2023, and may significantly impact European patents, including those granted before the introduction of the new system. Under the new system, Applicants can, upon grant of a patent, opt for that patent to become a Unitary Patent which will be subject to the jurisdiction of a new Unitary Patent Court (UPC).  Patents granted before the implementation of the new system can be opted out of UPC jurisdiction, remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be challenged in a single UPC-based revocation proceeding that, if successful, could invalidate the patent in all countries who are signatories to the UPC.&#160; Further, because the UPC is a new court system and there is little precedent for the court&#8217;s laws, there is increased uncertainty regarding the outcome of any patent litigation. We are unable to predict what impact the new patent regime may have on our ability to exclude competitors in the European market. In addition to changes in patent laws, geopolitical dynamics, including Russia&#8217;s incursion into Ukraine, and the imposition of tariffs and responses to tariffs, may impact our ability to obtain and enforce patents in particular jurisdictions.  If we are unable to obtain and enforce patents as needed in particular markets, our ability to exclude competitors in those markets may be reduced.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, enforcing and maintaining our intellectual property protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by the USPTO, courts and foreign government patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Owning our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The price of our common stock may fluctuate substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">You should consider an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a significant loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this "Risk Factors" section, are:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sale of our common stock by our stockholders, executives, and directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">volatility and limitations in trading volumes of our shares of common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">speculative trading in and short sales of our stock, as well as trading phenomena such as the &#8220;short squeeze&#8221; and &#8220;short and distort&#8221; schemes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical trials, and other business activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible delays in the expected recognition of revenue due to lengthy and sometimes unpredictable sales timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and success of introductions of new applications and services by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">network outages or security breaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract new customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customer renewal rates and the timing and terms of customer renewals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement, enrollment or results of our clinical trials for our product candidates or any future clinical trials we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays or adverse developments or perceived adverse developments with respect to the FDA&#8217;s review of our preclinical and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated safety concerns related to the use of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failures to meet external expectations or management guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements and events surrounding financing efforts, including debt and equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to enter into new markets or develop new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reputational issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from existing technologies and products or new technologies and products that may emerge;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general economic, political and market conditions in or any of the regions in which we conduct our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in industry conditions or perceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in valuations of similar companies or groups of companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analyst research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departures and additions of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which may be out of our control.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales and issuances of our common stock, including common stock that may be sold following exercise of outstanding warrants, would result in additional dilution of the percentage ownership of our stockholders and could adversely impact the share price of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect that significant additional capital will be needed in the future to continue our planned operations, including, without limitation, funding our trials and studies, marketing and commercializing our products and funding our operations. Accordingly, we have sold, and in the future may sell, common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. To the extent we raise additional capital by issuing additional shares of common stock or securities convertible or exchangeable for our common stock, our stockholders may experience substantial dilution, and new investors could gain rights superior to our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2024, we issued and sold in a registered direct offering 190,913 shares of our common stock, accompanying warrants to purchase up to 538,728 shares of our common stock and pre-funded warrants to purchase up to 347,814 shares of our common stock. In November 2024, we issued and sold in a registered direct offering 350,000 shares of our common stock, accompanying warrants to purchase up to 912,500 shares of our common stock and pre-funded warrants to purchase up to 562,500 shares of our common stock, (see Note 11, <i style="font-style:italic;">Common Stock Financing Activities </i>in this Annual Report on Form 10-K for additional information). In addition, we issued additional warrants to purchase up to 312,506 shares of common stock in connection with the Fifth Amendment of our Credit Agreement (see Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> in this Annual Report on Form 10-K for additional information). In March 2025, we issued and sold in a registered direct offering 188,383 shares of common stock, pre-funded warrants to purchase up to 3,811,617 shares of our common stock, accompanying warrants to purchase up to 4 million shares, and option warrants to purchase an additional 4 million shares of common stock (or pre-funded warrants in lieu thereof) and 4 million warrants. The option warrants expired on March 18, 2025 without being exercised. The number of shares of common stock underlying our outstanding warrants is significant in relation to our outstanding common stock (121% as of May 9, 2025), which could have a negative effect on the market price of our common stock and make it more difficult for us to raise funds through future equity offerings. In the event these warrants are exercised, our stockholders will experience additional dilution. To the extent outstanding stock options or warrants are exercised, there would be further dilution to our existing stockholders, which could impact the price of our common stock.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase, if any, of our share price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If we were deemed to be an investment company under the Investment Company Act of 1940, as amended (the &#8220;1940 Act&#8221;), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under Sections 3(a)(1)(A) and (C) of the 1940 Act, a company generally will be deemed to be an &#8220;investment company&#8221; for purposes of the 1940 Act if (1) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. We do not believe that we are an &#8220;investment company,&#8221; as such term is defined in the 1940 Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding Sections 3(a)(1)(A) and (C) of the 1940 Act, we are a research and development company and comply with the safe harbor requirements of Rule 3a-8 of the 1940 Act. We intend to conduct our operations so that we will not be deemed an investment company. However, if we were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on our capital structure and our ability to transact with affiliates, could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a &#8220;smaller reporting company&#8221; and are able to avail ourselves of reduced disclosure requirements applicable to smaller reporting companies, which could make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company, and we will remain a smaller reporting company until we determine that either (1) our annual revenues are at least $100 million and our voting and non-voting common stock held by non-affiliates is at least $250 million measured on the last business day of our most recent second fiscal quarter, or (2) our voting and non-voting common stock held by non-affiliates is at least $700 million measured on the last business day of our most recent second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. In addition, as a non-accelerated filer, we are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have elected to take advantage of certain of the reduced reporting obligations. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business. Such proceedings, claims and investigations could be costly and time-consuming to defend and could result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are, and may in the future become, subject to various legal proceedings, claims and investigations that arise in or outside the ordinary course of business. For example, on July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned <i style="font-style:italic;">Martin v. BioXcel Therapeutics, et al.</i>, 3:23-cv-00915 (D. Conn). The case has since been renamed to <i style="font-style:italic;">Hills et al v. BioXcel Therapeutics, Inc. et al</i>. On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. <span style="white-space:pre-wrap;background:#ffffff;">On February 24, 2025, while the Company&#8217;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint.  The Company filed an opposition to the motion on March 17, 2025 and Plaintiffs filed a reply in support of the motion on April 7, 2025. On April 9, 2025, the parties filed a joint motion requesting that the Court stay the action pending the outcome of a private mediation session scheduled for May 12, 2025. The Court granted the motion, staying the action until May 23, 2025, by which date the parties are required to file either a motion to continue the stay or a motion to lift the stay.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Panancherry et al v. Mehta et al</i>, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Exchange Act. The cases have been consolidated under the caption <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation</i>, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Smith v. Mehta et al</i>, 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Exchange Act. The cases have been consolidated under the caption <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Derivative Litigation,</i> 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On May 7, 2025, Plaintiff Yaakov Portnoy filed a stockholder derivative complaint in the Court of Chancery of the State of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep &#8220;Steve&#8221; Laumas, Michael P. Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Yaakov Portnoy, derivatively on behalf of BioXcel Therapeutics, Inc. v. Vimal Mehta, et al</i>, 2025-0508-BWD (Del. Ch.).&#160; The complaint alleges similar claims to those raised in <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i>, 1:24-cv-00041 (D. Del.), including business torts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company is also cooperating with a formal investigation of the Company and certain of its officers and directors by the SEC, relating to the Company&#8217;s public disclosures, including about product sales and the receipt of a Form 483 by an investigator at one of the Company&#8217;s clinical trial sites in the TRANQUILITY II study, and trading in the securities of the Company. The Company has produced documents, and current and former officers and employees of the Company have testified before the SEC. The above-captioned proceedings, as well as any investigation or proceeding that may be instituted by the SEC may result in substantial costs or liabilities, as well as a diversion of management&#8217;s attention and resources, which could harm our business, result in a decline in the market price of our common stock and impact our financing efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The potential costs and liabilities associated with legal proceedings, claims and investigations involving us or members of our leadership team is uncertain, and the results of such legal proceedings, claims and investigations cannot be predicted with certainty. Lawsuits and other administrative or legal proceedings that may arise can involve substantial costs, including the costs associated with investigation, litigation and possible settlement, judgment, penalty or fine. In addition, lawsuits and other legal proceedings may be time consuming to defend or prosecute and may require a commitment of management and personnel resources that will be diverted from our normal business operations. Also, our insurance coverage may be insufficient, our assets may be insufficient to cover any amounts that exceed our insurance coverage, and we may have to pay damage awards or otherwise may enter into settlement </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">arrangements in connection with such claims. Moreover, we may be unable to continue to maintain our existing insurance at a reasonable cost, if at all, or to secure additional coverage, which may result in costs associated with lawsuits and other legal proceedings being uninsured. Any such payments or settlement arrangements in current or future litigation could have a material adverse effect on our business, operating results or financial condition. Even if the plaintiffs&#8217; claims are not successful, current or future litigation could result in substantial costs and significantly and adversely impact our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock. In addition, such lawsuits may make it more difficult to finance our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biotechnology and pharmaceutical companies with publicly traded stock or who obtain funding through the stock market often experience significant stock price volatility, based on events beyond their control, including outcomes of clinical trials, actions of regulators and product approvals. Such further litigation, may result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business and result in a decline in the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our certificate of incorporation, our bylaws, and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 10 million shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. No preferred stock is currently outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Provisions of our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law also could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, the certificate of incorporation and bylaws and Delaware law, as applicable, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide the board of directors with the ability to alter the bylaws without stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">place limitations on the removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management is required to devote substantial time to compliance matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a publicly traded company we have incurred and will continue to incur significant legal, accounting and other expenses. The obligations of being a public company in the U.S. require significant expenditures and place significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing requirements of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming and costly, particularly as we are no longer an &#8220;emerging growth company.&#8221; In addition, we expect these and similar rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain such insurance. Our continued compliance with applicable requirements and to keep pace with new regulations requires management and other personnel to devote a substantial amount of their time, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock, the lack of research coverage may adversely affect the market price of our common stock. Furthermore, if one or more of the analysts who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, which has occurred in the past, our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline and may also impair our ability to expand our business with existing customers and attract new customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to comply with the rules&#160;under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting. If we fail to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. We have discovered material weaknesses in the past. If future material weaknesses or significant deficiencies are discovered or if we otherwise fail to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The tax regimes we are subject to or operate under, including income and non-income taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of existing laws and regulations, could materially adversely affect our business, financial condition, results of operations, and prospects. For example, the TCJA, the Coronavirus Aid, Relief and Economic Security Act, and the Inflation Reduction Act (the &#8220;IRA&#8221;) made many significant changes to the U.S. tax laws. Beginning in 2022, the TCJA requires taxpayers to capitalize and amortize certain research and development expenditures over five years if incurred in the U.S. and 15 years if incurred in foreign jurisdictions, rather than deducting them currently. Although there have been legislative proposals to repeal or defer the research and development expenditure capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. As another example, the IRA includes provisions that will impact the U.S. federal income taxation of certain corporations, including imposing a minimum tax on the book income of certain large corporations and a 1% excise tax on the value of certain corporate </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">stock repurchases by publicly traded companies that would be imposed on the company repurchasing such stock. Regulatory or accounting guidance with respect to existing or future tax laws could materially affect our tax obligations and effective tax rate. It is uncertain if, and to what extent, various states will conform to current federal law or any newly enacted federal tax legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Additional indirect taxes in various jurisdictions could materially adversely affect our business, financial condition, results of operations, and prospects. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently collect and remit applicable indirect taxes in jurisdictions where we, through our employees or economic activity, have a presence and where we have determined, based on applicable legal precedents, that our activities are taxable. We do not currently collect and remit indirect taxes, including state and local excise, utility user, and ad valorem taxes, fees, and surcharges in jurisdictions where we believe we do not have sufficient &#8220;nexus.&#8221; Tax authorities may challenge our position that we do not have sufficient nexus in a taxing jurisdiction or that our activities are not taxable in such jurisdiction and may decide to audit our business and operations with respect to indirect taxes, which could result in significant tax liabilities (including related penalties and interest) for us or our customers, which could materially adversely affect our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_65821fe6_fe8f_44f7_86d9_b2dec87441f7"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;2. </b><b style="font-weight:bold;">Unregistered Sales of Equity Securities, and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_fe13e38d_2e76_4ae2_be6a_98925524798f"></a><a id="Item3DefaultsUponSeniorSecurities_782584"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;3. Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_2cbf4b7f_2c4d_49e8_ab02_811a63a295ed"></a><a id="Item4MineSafetyDisclosures_613042"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;4. Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_29a9b4ad_3af2_4113_880f_b8fe41d58134"></a><a id="Item5OtherInformation_348642"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(a) None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">(b) None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">(c)</span> <span style="font-size:10pt;">During the three months ended March 31, 2025, none of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#8220;Rule </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_81HwXJ5FSUu8eIcgFf6ZHQ"><span style="font-size:10pt;">10</span></ix:nonNumeric><span style="font-size:10pt;">b</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_9YG4M5oLsUaRF4IvQUdGFg"><span style="font-size:10pt;">5</span></ix:nonNumeric><span style="font-size:10pt;">-1 trading arrangement&#8221; or &#8220;non-Rule </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_ZgILvsNOkUOL8JneR9YO3Q"><span style="font-size:10pt;">10</span></ix:nonNumeric><span style="font-size:10pt;">b</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_ymo9XH7pC0CaS3FiXM1nVA"><span style="font-size:10pt;">5</span></ix:nonNumeric><span style="font-size:10pt;">-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5221823f_959f_403a_a781_3322f6d9b8db"></a><a id="Item6Exhibits_836986"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;6. Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.18%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.32%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.23%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.09%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.16%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.66%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 5pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 5pt;"><b style="font-weight:bold;">File No.</b></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">&#160;3.1</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837021011074/btai-20210630xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Certificate of Incorporation, as amended.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">10-Q</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">3.1</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">8/10/2021</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">&#160;3.2</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924070503/tm249625d6_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of BioXcel Therapeutics, Inc., as amended, dated June 10, 2024.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">8-K</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">3.1</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">6/11/2024</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr style="height:20.8pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925009906/tm255604d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioXcel Therapeutics, Inc.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">8-K</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">2/6/2025</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr style="height:2.9pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr style="height:11.8pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">8-K</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.2</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">3/13/2018</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">4.1</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925002583/tm251419d2_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Fourth Amendment, Warrant</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">333-284224</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/10/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">4.2</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/tm258193d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Accompanying Warrant</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/4/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">4.3</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/tm258193d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/4/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">4.4</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/tm258193d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Option Warrant</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-38410</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/4/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">10.1</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Executive Employment Agreement dated January 7, 2025 by and between BioXcel Therapeutics, Inc. and Vimal Mehta.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/8/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:5.05pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">10.2</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Executive Employment Agreement dated January 7, 2025 by and between BioXcel Therapeutics, Inc. and Richard Steinhart.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/8/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:5.05pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">10.3</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Executive Employment Agreement dated January 7, 2025 by and between BioXcel Therapeutics, Inc. and Frank Yocca.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/8/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:5.05pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">10.4</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/tm258193d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement dated as of March 3, 2025, between BioXcel Therapeutics, Inc. and each purchaser identified therein.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/4/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:5.05pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:5.05pt;"><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">10.5</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231xex10d226.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sixth Amendment to Credit Agreement and Guaranty, dated March 4, 2025, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.6</p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/28/2025</p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">31.1</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20250331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">31.2</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20250331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">32.1</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20250331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">**</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">32.2</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20250331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">**</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">101.INS</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">101.SCH</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">101.CAL</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">101.DEF</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">101.LAB</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">101.PRE</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">104</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:2pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:2pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:2pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:2pt;">Furnished herewith.</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0f4dd88d_86cc_4cf3_8e7a_1c14fdf87a8c"></a><a id="SIGNATURES_228043"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">BioXcel Therapeutics,&#160;Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Dated: May 12, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Vimal Mehta</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Dated: May 12, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:11.03%;margin-top:30pt;page-break-after:avoid;width:78.62%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>btai-20250331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/12/2025 12:17:10 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Vimal Mehta, Ph.D., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BioXcel Therapeutics,&#160;Inc.</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Date: May 12, 2025</p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Vimal Mehta, Ph.D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>btai-20250331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/12/2025 12:17:10 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Richard Steinhart, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 of BioXcel Therapeutics,&#160;Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><font style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 0pt 54pt;"><font style="font-size:9pt;line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Date: May 12, 2025</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>btai-20250331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/12/2025 12:17:10 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In connection with the Quarterly Report on Form&#160;10-Q of BioXcel Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the quarterly period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or Section 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:2.7pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:2.7pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><font style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Date: May 12, 2025</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>btai-20250331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/12/2025 12:17:10 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;">In connection with the Quarterly Report on Form&#160;10-Q of BioXcel Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the quarterly period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or Section 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:2.7pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:2.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Date: May 12, 2025</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>btai-20250331x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20250331x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'P \,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*^7_VN
M?VNM7_9M\2:#IVG^'[+68=2M'N&>YG>-D97VX&T<C&*\#_X>G>)O^A%TG_P,
ME_PKVZ&38W$TU5I1O%^:..>+I4Y.,GJC]'**_./_ (>G>)O^A%TG_P #)?\
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M7WK_ #&\;16C?X'Z.45^<?\ P].\3?\ 0BZ3_P"!DO\ A1_P].\3?]"+I/\
MX&2_X57^K^8?R+[U_F+Z]0[_ ('Z.45^<?\ P].\3?\ 0BZ3_P"!DO\ A1_P
M].\3?]"+I/\ X&2_X4?ZOYA_(OO7^8?7J'?\#]'**_./_AZ=XF_Z$72?_ R7
M_"C_ (>G>)O^A%TG_P #)?\ "C_5_,/Y%]Z_S#Z]0[_@?HY17YQ_\/3O$W_0
MBZ3_ .!DO^%'_#T[Q-_T(ND_^!DO^%'^K^8?R+[U_F'UZAW_  /T<HK\X_\
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MI/\ X&2_X57^K^8?R+[U_F+Z]0[_ ('Z.45^<?\ P].\3?\ 0BZ3_P"!DO\
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M\/3O$W_0BZ3_ .!DO^%3'(<?.*DH*S\U_F-XVBG9O\#]'**_./\ X>G>)O\
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MFM'\:?$M](N/$&H:@NIQ^&K73+>X24I]I@ ^UG!X4ER26/WO4U)XK_:4\$>
M_&=[H%YXHUWQ'=-X@U:2XU:XLR)?#OFQ2P". %B9 C-U0J-JG !P*R_M#%J?
MLW1UM?KV].CT_!:E>PI6YN8^)-1^&_BW2+G4;>^\+ZU97&FPK<7T5QI\T;VL
M3<*\H*@HIR,%L U>L?@U\0-4EDBLO WB6[DC95=(-(N'*ED$B@@)P2C*P_V6
M!Z&OJ)_V@/AMJ.A7/@35?&FN:I8OX9;2I/&MYICR37$QNA. 82^_:H^4;F/3
MKW.CK'[6G@S3M1'_  COB/4[>V;Q=HU]+(EM+$TVG06EK#/O '.3$X*=_?BM
M'CL6](T=?1VZ>7773==2?8TMW/\ (^6/A]\#/&WQ,F/]BZ!>FQ7S0^ISV\B6
M<;1H79&FVE0V%P%)SD@5PCH8W93U4X-?=6C?M0?#IM3BU1_&>M:)!I\FN0CP
M_!I\C6VI+=32O#.[*0%(#KPRD\#[N#GX7G8//(PZ%B1^==V$KUZTY^UARI6M
MH^[ZO?IMW,:L(02Y7<CHHHKTC ] ^,'^O\'_ /8LZ?\ ^@&O/Z] ^,'^O\'_
M /8LZ?\ ^@&O/ZY\/_"B7/XF%%%%=!!W$/P6\8WWA_P]K&F:'=ZW;:Y;W%U;
M1:5!)<RI'#.8':1$4E!O& 3UR*JZ3\(_&FM>*)_#MOX6U@:Q:[3=VCV$PDLT
M8C$DR[<QI\P)9@!@YKW[X;?M%^&O!?P:T_1X]7N[#Q):>#]:TJ-[>&0-'>7%
MZ\T&UP./E8'<#P?>NXC_ &I? 6LW/ES>+=9\-7(CT2^N-<L;*26:_EM$*S6D
MF&5L-QASE3EL@]#X,\9C(.25*Z3=G9]]'YZ=CM5*DTO>_JQ\P>,/@'XR\&ZU
M#I$^E3ZCJ<U[-I\-OIEM/.9IH@I=8V$>V3AAPA)'<"L:S^$OCG4=2U+3K3P9
MXAN=0TW;]NM(=+G>6UR,CS4"93(Y&X#BOL#5_P!K#X=WWB%O)UK4;*&]N-=B
M_M:ULI/.TY;L6_DW"J<%C^Z8$*0P!K.\#?'GX8^&/%$6JW7Q-\9:IJ.GS6"R
MZCJ-G(\>J01)^\1(4=1'\V,--YC@ C+9S64<=C%3O*D[V[/>_DO^#UV&Z-+F
MTEI\CYPN/V<_'UCX4LO$=YH%Y:Z3>6%SJ4<[6TTF(85W,7V(WEY&2-^T8!)(
M'-<N/AMXN.GZ5?\ _"+:U]AU:58=/NO[.F\J\D.=J0MMQ(QP<!<G@U];ZU^T
MWX&U?P*\+^*]1^W0^'/$.BKI!L9C#<273/\ 99"Y.!A=J\KP&/3&*T+7]K'X
M?6FKSZ\_B37-2BUN?2Q_PBUW9,+;P^MNP:22-LE7^[A1&JGGG/4..-QJ3O1N
M[OH^_P#EK?;2V[!T:/21\E6GP7\;2^)-%T.\\-:GHM[K$IBLSJUG+:I(1]XA
MG495>K$9QWKO-7_8[\=:3IT\PO/#U]J$.F_VM_8MGJR2:B]J!DR);\.PQD\#
MG&!D\5ZMJW[3WA/6] UZZU'7=0U#7[/6=>O]"6XAE8>7<Q-#;IN(PBA9"=O&
M-@KE?C%^UI=7SZ1IO@B\M+?3#X<M-+OM0&EI'?A@N)XEN&7S A  X..3BJ6(
MQ]6<5&"CWNG;^K"Y*$4VW<\4;X+?$)+JRMF\">)EN+T,UK"='N \X4 L4&S+
M8!!.,XS5;2OA1XWUU[U--\':_J#65P]G=+::7/*8)U!+1/M4[7 !)4X(QTKZ
M>U3]IWPUXI\=^/;*;QGKGA[0]:TNQMM)\0V<$LKZ8\*1^=&D 965967YBA&3
M&I.>H]&@^-WA7Q#X#UKQ:?&&O>$="MO&FGVJ:O:VIEN=6,%@,^>B8*B81L3U
MP0N1U F>/Q=-+FI;VZ/K;RUW:MOIV8U0I2>DOR/@^R\ ^)]2T&]UNS\.:M=:
M+8DK=:C!8RO;VY&,B20+M4C(ZD=:=??#WQ3I>B6.LWGAK6+31[XJ+34)["5+
M>X+<KY<A7:^>V"<U]A6'[6?@*ZEA\1-KFN:$=,?6O^*+MK,M:ZO]KFFDB>20
M-L4@3+NW \J<''6+1OVI/ &F^'_!>H^(=<U#Q=KFDW=E,MC9Z9-8"V2/@B56
MN'@F,:XV%54ED!)R<BWCL6G_  'OY^?E;L[[:VW%[&E_.?)<_P *_&MKXC@\
M/S>#]>BUZXC,T.E/IDZW4B#.66(KN(X/(&.#5GQK\)O$'@#Q/I&@:S#%;ZGJ
M=K;7<,0<_*D_W ^0"K#N.U?7'BO]JOP/KWBF;3T\7366G7>BZA90>)])T.ZA
MN=-EN)[>4 B6ZD>48@(^4(%W#'!.WPW]HCXJ>'/'OQH\,:_HNJW>KZ7IVGZ=
M:SW][ T<\KPG]X[*>K'J<<9)Q6F'Q>*JS2G3Y59O9[]-_P MR9TJ<4VI7U.&
MUCX"?$'2=5UBR3PCK.III5S/:W-[IFGS7%L'A8K*1*J;2%(.3V[TWPA\#?&G
MC30-0UVQT2Z@T.SLIKXZG=PR16LR1??6.4KM=^#\H.>#Z5]66G[7O@[3_&?A
MZYM?$&HVVCQ^+]:U748XK>95EM+@2^064#Y^64[3G!Y[5E']H[X?W'@O4GB\
M5ZKITDW@^;PW#X.2PD-FD^YBMP) =GS# QLR,\MCBN?Z[CK).EKIK9]VMOE?
MMJ:>QHW^(^8=3^"_C2PU?6-/@\-ZOJ<FD(DE])9:9<LMLK+N!D#1JR#&3E@.
MA(XJMIWPD\;:M9:5>VOA'6Y=/U6>.VL;[^SY1;W,CMM14E*[6).1P>Q]*^P/
M&/[4?P]\9ZIJIL_'?B/P7%;ZS'JL=WHU@S2:M%]E6)H3G 1@RG!D5EY^Z>V$
MW[0?PW\.?"NYTWPYXO\ $4U_-!I,T.FZM#/(]M<6UY#--B;<5&Y8R%2-508X
M//%1QV,<8WHN[MT?7>^EO/\ !ZB=&E=^]I\CYS\7_ +QQX(N#:ZIH5\EZ=3_
M +)BMHK.=VGG,8=1$WE[)-P88"L6/7&,&L>/X2>.9=:N='3P9XA?5[6-99[!
M=*G,\*,<*SQ[-R@D@ D8-?8M[^U7\.K+5[UX_%FLZHFI^)K[4%OTL)(Y]*M[
MG3DMT>(2$@F%P< 8Z9"]CS.H_M/^%M!\%ZOH&D>+]9UO6K;PM+IEIXLN+:6W
MN;VYDN1*%Y9GC5%! 9FZL<4H8W&M).EJ[=&OTZ=M];[('1HZ^]^1\A:UH>I>
M&]4N--U?3[K2M1MVVS6=["T,T1P#AD8 @X(/([U1KU[]J;XC:)\5/BJ?$&A7
M,EW;2Z;9PS3RQ-&SS1Q!')##)Y'7O7D->Y0G*I2C.:LVM5V..:49-)W04445
ML2>C_&7_ (]_A_\ ]BK9_P#HR:O.*]'^,O\ Q[_#_P#[%6S_ /1DU><5SX?^
M$OG^9<_B"O3/AU\ M=^)/A>Z\0VNK^'M%TFWNUL6N->U1+)6F9=P12_!)&>,
MYX->9U[O\-OCY!\,_@-J6AZ<EA=>)KC7XKQ+;5-,2\A%N(64N/,4J&#;<=^M
M9XJ5:-->P7O715-0;]_8X?Q-\ _B%X5OM6@N_"&L3PZ7*T5U?6=C+/:H5 )/
MG*I7&&4YST8>M9%Q\*_&EGXBMO#\_A#7H->N4,L&ER:9.MU*@SEEB*[F'!Y
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M!E0+N0'(^\!UJZWP<\9!+-%\.:M)J-W>36,>EIIMR;HS1('==GE\D*<E02P
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MC#_T(&K_ /?"_P"-?KW11_K#B?Y(_C_F'L8>?]?(_(3_ (9)^,/_ $(&K_\
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MC#_T(&K_ /?"_P"-'_#)/QA_Z$#5_P#OA?\ &OU[HH_UAQ/\D?Q_S#V,//\
MKY'Y"?\ #)/QA_Z$#5_^^%_QH_X9)^,/_0@:O_WPO^-?KW11_K#B?Y(_C_F'
ML8>?]?(_(3_ADGXP_P#0@:O_ -\+_C1_PR7\8MN/^$!U?'7&Q?\ XJOU[HH_
MUAQ/\D?Q_P P]C#S_KY'Y"?\,D_&'_H0-7_[X7_&C_ADGXP_]"!J_P#WPO\
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M /?"_P"-'_#)/QA_Z$#5_P#OA?\ &OU[HH_UAQ/\D?Q_S#V,//\ KY'Y"?\
M#)/QA_Z$#5_^^%_QH_X9)^,/_0@:O_WPO^-?KW11_K#B?Y(_C_F'L8>?]?(_
M(3_ADGXP_P#0@:O_ -\+_C1_PR3\8?\ H0-7_P"^%_QK]>Z*/]8<3_)'\?\
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MA_Z$#5_^^%_QK]>Z*/\ 6'$_R1_'_,/8P\_Z^1^0G_#)/QA_Z$#5_P#OA?\
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MXO G_0)\1?\ @-!_\>H_LK'?\^F']OY7_P _XGT/17SQ_P -Q>!/^@3XB_\
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M_P!E8[_GTR?[?RO_ )_Q/H>BOGC_ (;B\"?] GQ%_P" T'_QZC_AN+P)_P!
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M_P"&XO G_0)\1?\ @-!_\>H_X;B\"?\ 0)\1?^ T'_QZC^RL=_SZ8?V_E?\
MS_B?0]%?/'_#<7@3_H$^(O\ P&@_^/4?\-Q>!/\ H$^(O_ :#_X]1_96._Y]
M,/[?RO\ Y_Q/HRY_X^)/K45?/<W[<O@.25F&D^(L$YYMH/\ X_3/^&XO G_0
M)\1?^ T'_P >I+*L=;^$RI9_E;;_ '\3Z'HKYX_X;B\"?] GQ%_X#0?_ !ZC
M_AN+P)_T"?$7_@-!_P#'J?\ 96._Y],G^W\K_P"?\3Z'HKYX_P"&XO G_0)\
M1?\ @-!_\>H_X;B\"?\ 0)\1?^ T'_QZC^RL=_SZ8?V_E?\ S_B?0]%?/'_#
M<7@3_H$^(O\ P&@_^/4?\-Q>!/\ H$^(O_ :#_X]1_96._Y],/[?RO\ Y_Q/
MH>BOGC_AN+P)_P! GQ%_X#0?_'J/^&XO G_0)\1?^ T'_P >H_LK'?\ /IA_
M;^5_\_XGT/17SQ_PW%X$_P"@3XB_\!H/_CU'_#<7@3_H$^(O_ :#_P"/4?V5
MCO\ GTP_M_*_^?\ $^B!U%/N/]>_UKYU'[<7@0'_ )!/B+_P&@_^/4Z7]N7P
M(\C,-)\18)SS;0?_ !ZE_96.O_"97]OY7;^/$^A**^>/^&XO G_0)\1?^ T'
M_P >H_X;B\"?] GQ%_X#0?\ QZG_ &5CO^?3)_M_*_\ G_$^AZ*^>/\ AN+P
M)_T"?$7_ (#0?_'J]F\"^/-'^(OA^'6-%N//M9.&1P!)&W]UQDX-<]?!8G#1
MYJL&D=F%S3!8V?L\/54GV1T-%%%<)Z@4444 %%%% !1110!T<7^J3Z"BB+_5
M)]!17EO<]];(S=8_UL?TKB/%?CFW\+ZYX:TEK=[F[URZD@CPX18HXXFEEE8G
MLJKT[D@5V^L?ZV/Z5YE\0? MUXD\7>#-9M CKI5Q=0W<3/L+6UQ;O$[*<'YE
M;8<=QFO5PRBTE/:S_)V_$\;$?Q'8Q+3]I;P==ZWJ5NMS,FD6.EQZF^JRV\R+
M('G:%4CC:,/)D@;60,&W +DUJZA\?_ >E6MA<7FN-;)?^<+=9+&Y#N\3!9(M
MGE[A*"P'E$!^?NUP$O[)YOM/FM+_ ,6&Y2+2+72-/*:<J?9TM[@SPM(/,/FG
M)PP^7<.FVKNL?LR2ZQINAVP\3QZ:^D7<VJP'3M*2&,W[NI29DWG<B(&4(26;
M>2SGBO5<,"VO??\ 2].YR7GV.GU/]H?X=Z-J][:7.K3KJ%K+-:2B+2+N0F2'
M!EC5EA(<H"&(4G"Y;H"1I6WQ4\!G7[31[?4[0WVHQ1/'Y5LYB<2J7B5Y0FQ6
M=065&8,1R <UR$W[-BW&NG5)/$+>8VHZMJ#(ME@$WUMY!7_6=$^]GOTXZU#X
M?_9=L= \3Z9JJZNES%!%8?:8I].1Y)9K2 0QO'(S$1 A4) 5FRORNN:EPP=M
M)N]OQ^X=Y=C2M_VD/!%_XBOM*5R=%L=*&IOJ<EM*L3?Z1Y CBC:,-)EL;60,
M&SA<U/-\;O Z^*O#NEV]K),^K_:W:\;3I(ELS;Y\T3AT#1L&^\'"[1\S8!&>
M2'[)*S02V]WXK>XMH=(BT?3D&G*IMXXKK[1$TA\P^:0?E;A=PZ;:UIOV9+6Z
M?2)9=6MXWMQJ4=[':Z:(8KB.\4*XC59-T;*J@!G:0GJVZM''!+:3Z]^VCV[B
M]\Z+_A>GPYATQ;UM1,,'G06B(^E7*2N;C/D[(C%O9).<.JE3ZU3D_:+^'\6C
MZMJ&F:@K26-D]XZW-A=6BO%&XC?#-!EMC':RJK,IR"!@UD_\,VSWUYHU_JOB
MG[9J.EW>DR0RPZ>(4:WL)"Z1%/,;YW+,6DSCGA .*H:Q^RC#J^A/II\3/$&T
M_4;#S/L0/_'U=?:"V/,_A^[COUXZ5*A@KZS?]?(+S['4Z]^T1X<TGQ/INA6H
MDU"ZN)Y;>XE6.5(;9D@,S#S#'MD(  (0DKN&1R ;.D?M#^"=2?1K>35O*OM3
MCM'C2.TN7A4W(S #,855=_.-^TG'0'BN;N?V:6E\017<?B8Q:9#?W.HQV)L
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M3TRZLKR2"*^L1?6HB)"H(#DRJ0< $#[PXS7T916;QGP\D;6_R:_4.7NSX?\
M#T'C>SU9+^UL]5TN_FTZVLVN;2P\IE1M:Q(  FT'RB2>.G/O7J/P7USQZ?B#
MI]MK=YK5YI<\NLP2C4(2$1(;A1;-G:,$KG!S\PKZ/HJZF.52+3@M04+=0HHH
MKRC0EN/^6?\ N"HJEN/^6?\ N"HJ4=BI;A1113)(KN?[+:S3;=WEHS[<XS@9
MKSWP7\>O"OBKPDNLW&HV^E2Q6<=Y>6DLC$VZNQ488JN\%@5!4<GCK7H5W!]J
MM)H0=ID1DSZ9&*\,U7]F6;4M)TFU_P"$@\F?3-&MM.AEBCDB)FANEN%DW)(K
MJI*[<*P89R&!K>FJ;5INPCTB\^+W@[3])MM2N->MXK.X:1(W(;=F/_697&Y=
MF1N)  R,XR*\U\<?&GP7;>,=2L]:\)6VK:QI;3Q:;>20).)1'8QWA_>%"80W
MF;1C=R,G -5O$'[,FL:SX>_LR#Q6]C%="^.H0QSWS1W,DZQJDKLUR9)601D;
M9'93N/R\"K6I?LV7UW=RW,6OVZ32^8K![1BH233(K%L8?KF+>/KCWKH@J$7?
MF[_\ -3I=#\8_##6]'L/$1MM$AN-+6 1DV2M/8R3C>B1?('^8LQ!0?-R?6KU
MOXF^&"7AAM_[#$^O/#--Y5FO^E.781&8A,;MX<+YG.0<<YK NO@)>)XGMO$-
MEK5NFHV4.F):QSVI>'?:QSQN7 8$AUG;&""I .35?Q1\#/$_C#Q+9ZIJ?B])
M889K&X^Q1)<1V\;P3-(VR%9A&=X*C=(K,"H(/:IM2;^)V_KR Z.\\<_"ZZOH
M_$%S-HUS?I,;.+47LA)/OBR[*C["Q"%"21PI7G%:&IGX=>"-/M]3N;/0M,M=
M5NXIHIXK.,?:[D9DB<;%R\F064\G/3FN"U#]FBXFT'PS;V^O%+_1I-34R*]S
M;1SPWDSRLI-O-')E24&-Y5L'(Y&-3XC>!M6LM)^%>E>&X5=]$UBW!F:!Y88(
MX[69-[C=N"9(&2V?F'.:+4VTHR8'2:K\0?ASK1B34M0TC4 U@]XOVJ(2JEHQ
M97=BRD*A,3*<XY3!YQ5_2O'G@R]N'^Q7]DMS?M,TJ^48Y)6AC4R>8"H.50J?
MFYV].!7GB_LT/+;ZZEQKP+ZMH@TUWCM\;)_MLUV90"Q^3=,%V>B]>:T-<^ U
M[XGT_4IK[6X;;7;[5H]2>ZL;<I'&@@^S20JI8MAX&D4DGJV>U+EH[<S#4=8>
M*?AQI=CXAM_[$\/6&C.\5M"EI;QO_::2VB77SPI'E1B0G:P;@;CC.*3PEXD^
M%_C#P]X6M[S1/#ME<ZE EY:Z.]I%,D#3@@8/EA5+[2 2%+8P,TM_\"[VW\;W
MOB?1=7M;6ZDN2\%M<VK/#'"UA#:,A"N#N_<*X88ZD$&N<T']E1]&U;2KB371
M?6L2Z:U[;NUU$DLEGC:Z1QSK&<[5_P!8K[2,CKBKO2:OS.X'I5EJ'P]U[1;S
M6((-'N=+TZ25IKQ[-?+C?9LD(8KR2HVDC.0,>U+X5\4?#^PT^+3= ?2M.LYS
M<,+"TMA;J3$JM-F(*,$*Z$Y'0BHM&^%QTOX0R^"IKBUO_,@N(6EN;;="_F2.
M_P T>[)'SXZ@\9!%<9_PH7Q)%)8WD7BR.6]M6O8XXK];B\BB@N8(XG5'EF:7
M(:,.-SD#<0 !6:5-W3D!TFA>(_A/::U9Z7HX\/6NHR/#)!%:6:1D.Z&2$@A
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MH_U@QW=?<'^J.5_RR^\^(?\ AASQQ_T&/#__ '_G_P#C-'_##GCC_H,>'_\
MO_/_ /&:^WJ*/]8,=W7W!_JCE?\ ++[SXA_X8<\<?]!CP_\ ]_Y__C-'_##G
MCC_H,>'_ /O_ #__ !FOMZBC_6#'=U]P?ZHY7_++[SXA_P"&'/''_08\/_\
M?^?_ .,T?\,.>./^@QX?_P"_\_\ \9K[>HH_U@QW=?<'^J.5_P LOO/B.3]A
MGQS&Y4ZQX?)'I//_ /&:;_PPYXX_Z#'A_P#[_P __P 9K[DNO^/AZAI+B#'-
M7NON&^$,K3:Y9?\ @1\0_P###GCC_H,>'_\ O_/_ /&:/^&'/''_ $&/#_\
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MU]P?ZHY7_++[SXA_X8<\<?\ 08\/_P#?^?\ ^,T?\,.>./\ H,>'_P#O_/\
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M/ML__/5_SIZB]AYEW%&*I?;9_P#GJ_YT?;9_^>K_ )T:A[#S+N*,52^VS_\
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M>C7XM;9I;GS0 K>64_>;,>F$^AKUZ[NX+"UFN;F:.WMH4:26:5@J(@&2S$\
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MZE_X"_\ (/;4_P"9?>>CT5YQ_P -$?#[_H8/_)*X_P#C='_#1'P^_P"A@_\
M)*X_^-T?4,7_ ,^I?^ O_(/;4_YE]YZ/4]__ ,?3_0?R%>8_\-$?#[_H8/\
MR2N/_C=37?[1GP\EN&9?$.5..?L5QZ?]<Z7U#%W_ (,O_ 7_ )![:E_,OO/0
M:*\X_P"&B/A]_P!#!_Y)7'_QNC_AHCX??]#!_P"25Q_\;I_4,7_SZE_X"_\
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MY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6/W/_,/J-/N_Z^1\5_\ #._Q!_Z%_P#\G;?_ ..4?\,[_$'_ *%__P G;?\
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M /R=M_\ XY7VI11_K'B_Y8_<_P#,7U&GW?\ 7R/BO_AG?X@_]"__ .3MO_\
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M5YV:4^GZ)_J/G6]CZBC^'_A>%)$C\-Z0B2[PZK81 /O&'S\O.X 9]>]1>)?
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M;OK%_P!<UJ"I5[%,F^QR>J?]]C_&C[')ZI_WV/\ &H:*>HM";[')ZI_WV/\
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MQR>J?]]C_&H:*-0T)OL<GJG_ 'V/\:/L<GJG_?8_QJ&BC4-";[')ZI_WV/\
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M#IW]BNO;JT^W39&3I3M\1Y*_Q*U2.[M';4V74KG5I+(Z ;="%A#LF5(7=O7
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M17PI_P +@\:_]#-J/_?XT?\ "X/&O_0S:C_W^-'^K=?^=?B'U^'9GW74]_\
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M)1=6]S/$]M&K!FA56,7+ ^8X8E1C!V-DCC/GGC3]HR+3?+N- L[G44CTNYU
MV[01@7)6UAN$ D,J[-J3*6&#G.!R!FZ3DTER71,DNYP?BSQ/XX\4>*/$NBA-
M3ATVZM]5L)+<2.V2EJ?*9(_LRK$CNIVGS79@QR >!-X)D\8W=EH]M#K?B"UT
M]-3TW3$18@H6T:P1IC\T>>),C<?NG(KNOAK\?KKQ#XGU/2->T6\LA)KG]F6%
MU''%Y$9^PP7(@E82EC)EY>54KC:,Y(SK?%KXNR^ _$FBV%I+9"%$_M#66NF
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MCNY7<8P5W2-C/!.<<CK['KGQ]\#ZW!XDT>]M+V_TJ&VOT>95C,5_]E0FZBA
MD$FY<.,NJ*Q1BC$#-5M!\0:?\'M#DOU\.ZE%9>(+Q)+#3VNDN-2E?R,N]Q<7
M%R5)VQC:#*2%"J!GY1JI\NO)9]";7ZG!Z'XM\5Q:[X-TG3Y-7ATB,Z=8W+3R
MOO:%[8>8ZPBVVA [ >:TVX,N-F.:Y_X6R^*/"G@_0+.!=2L+&.UTJTU>\6S_
M -)M(?.N1.$;9N.UA$O?:KDCUKZ>U[XA6>A>'](U/[!?WTNKR0PV.G01HES-
M)(I=4Q*R*A"AB=[*!M->6^#OVHK&7P[%<>(+*[-[]HO'N_LL4<:V%JE[)!&\
MRO*&)PG*QAV^5CMQ24Y2B^6';]0:2>K.6UKQ'\1I_"5[?PZEK<%UIWAN\O[,
M0VP!NYDOI$MC*NP[F>!8V*#!.XG KT7X_P#B?Q#I'AW14T&.]CO;XS!IK:9H
M4B80,RABL$S,Q;&U,*&(P77O-/\ M&:2-4GL;3PWXAU)TNKRSCEM8K;R[B6U
M)\\(7G7@*-P9L @X!+?+4^F_M&>%=7UC3[.T2^FM;PVT?]I;8E@BFGC$D4+
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MOC,_QE!P^KVYI_E_P?(]7!4IWY]E^9?HHHKX(]@**** "BBB@ HHHH GOO\
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M<B'45->_\?<O^\:06TF1PO\ WT/\:EO+=S=2D!?O?WA2ZCNK%6BI?LTGHO\
MWT/\:/LTGHO_ 'T/\:=Q77<BHJ7[-)Z+_P!]#_&C[-)Z+_WT/\:+A==R*BI?
MLTGHO_?0_P :/LTGHO\ WT/\:+A==R*BI?LTGHO_ 'T/\:/LTGHO_?0_QHN%
MUW(J*E^S2>B_]]#_ !H^S2>B_P#?0_QHN%UW(J*E^S2>B_\ ?0_QH^S2>B_]
M]#_&BX77<Z^W_P!1'_NC^5%$'^HC_P!T?RHKRWN=AR_C/_CYMO\ </\ .N=K
MHO&?_'S;?[A_G7.U]!AOX,3XW'?[Q/\ KH%%%%=1PA1110 4444 %%%% !11
M10 4444 6K_K;_\ 7%:JU:O^MO\ ]<5JK40^%&E3XF%%%%69A1110 4444 %
M%<IXF^(EMX>U<Z5;Z5JFO:FEK]NFM=*B1VA@RP#L7=!\Q5@J@EFVG .*U]#\
M4:5XDTNRU'3KZ*YL[Q!) _*EP?\ 9;!!X/! (P:?*TKCL:E%96A^)+?7+!;H
M0W&G[YI8%AOX_)E8HY0D*3R"5R#W!![U1?QW86^@:SJ]U!>65MI<EU'(EU#Y
M<DOD%MS1@GYE;:2I_B!%'*PL='1533=5M]4TVSO8F*PW<*SQB3 ;:RAAD?0U
M,EW!)($6:-G*[@H8$D>N/2D(EHID-Q%< F*5)0#@E&!P:YCQ%\2-+\.>(=(T
M62&\OK[4FVQK8Q"41@21QLTF#E5!E4DXX 8]J:3;L@M<ZJBHA=P,)")HR(^'
M(<?+]?2C[9!B,^?'B3[GSCYOIZT@):*PX?&>F3^)[O0EE)N[:RCOI),CRA&\
MCHHW9^]F-LCZ5H7NJ0V=J\PS<N$+I!!AI)?0(,C)/UQZD4[,"Y16-X,\2IXR
M\):/KL5N]I'J-K'=+!*06C#J&VDC@D9[5LTFK.S **** "BBB@ HHHH Y36_
MBUI%E?-9O;7IEM?W#E8TP64D''S]*H?\+AT;_GVO_P#OVG_Q=>:^+O\ D:-6
M_P"OJ3_T(UDU]O2RC"NG%M/5=S\OQ'$6/C6G%-:-K;L>P?\ "X=&_P"?:_\
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M/_BZ\?HH_L?"]G]X?ZQX_NON/8/^%PZ-_P ^U_\ ]^T_^+H_X7#HW_/M?_\
M?M/_ (NO'Z*/['PO9_>'^L>/[K[CV#_A<.C?\^U__P!^T_\ BZ/^%PZ-_P ^
MU_\ ]^T_^+KQ^BC^Q\+V?WA_K'C^Z^X]@_X7#HW_ #[7_P#W[3_XNC_A<.C?
M\^U__P!^T_\ BZ\?HH_L?"]G]X?ZQX_NON/9[WXT:)<W4DBVNH!6/&8TST_W
MZ@_X7#HW_/M?_P#?M/\ XNO'Z*2R;")62?WC?$N82;;:^X]@_P"%PZ-_S[7_
M /W[3_XNC_A<.C?\^U__ -^T_P#BZ\?HI_V/A>S^\7^L>/[K[CV#_A<.C?\
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MJWJG_(0G_P!ZH?Q+Y_H:+X'ZK]2I1115F84444 %%%% !1110 4444 %%%%
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MG_05N_\ OZ:/[&Q/_/W\9!_K)@O^@?\ ")[Q_P (_P"'O^A=T[_OR*/^$?\
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M:R:UO%W_ "-&K?\ 7U)_Z$:R:_4:'\*/HOR/PC%?QZGJ_P PHHHK<Y@HHHH
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MM_-+_P "7^9S_P!H</\ \D/_  !_Y'8_\*H\,?\ /&#_ +_S?XT?\*H\,?\
M/&#_ +_S?XUQW_"Z?^H-_P"37_V%'_"Z?^H-_P"37_V%'U3-OYI?^!+_ ##^
MT.'_ .2'_@#_ ,CL?^%4>&/^>,'_ '_F_P :/^%4>&/^>,'_ '_F_P :X[_A
M=/\ U!O_ ":_^PH_X73_ -0;_P FO_L*/JF;?S2_\"7^8?VAP_\ R0_\ ?\
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M'_CW^%'V./\ Y^X/_'O\*JT46?<.:/\ +^9:^QQ_\_<'_CW^%'V./_G[@_\
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M !_3_P"^:KK]X?6K&H_\?T_^^:A_$C1? _5?J5J***LS"BBB@ HHHH ****
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MO(D_YYO_ -\FCR)/^>;_ /?)KL?-?^^WYT>:_P#?;\Z/KS_E_$/[*7\_X?\
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MFSM(FEPR01NYB,3&63<-S*6.P(I!84OJ,[7NK_,?ME?8^P*C6YA>=X%E1ID
M9XPP+*#G!(Z@'!_*OF.;XH?$+[=9ZO=:M<::(+GPO;W7AY;& 0LU\(Q=J[-&
M905+MC#C:1SD<5H>-=?\1#]I.?0-'U9] M]2CTN">_LK"U>Y\LQW[L!)+$^>
M8UQN#!<G &3G/ZI+JUM?\O\ ,?M%V/I"HX;B*Y#&&5)0C%&*,#A@<$''<'M7
MAI^(WB-O@+X9UR[UE]-NKJ_CM-5\0""$-9VXN'C>Y*,AB!PJY)3:NXG&!7BW
MASXH>*_#-M?6^E^)([/3IM3UB_L]5ND@A76[@WQPI5H'+Y0JWE6X1V\W*G
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ML**** /#OCQXCU;2/%UE#8ZI>V4)L(W,=O</&I;?(,X!'/ _*O./^$W\1?\
M0?U3_P #)/\ XJNW_:(_Y'2Q_P"P='_Z,DKRV@#;_P"$W\1?]!_5/_ R3_XJ
MC_A-_$7_ $']4_\  R3_ .*K$HH V_\ A-_$7_0?U3_P,D_^*H_X3?Q%_P!!
M_5/_  ,D_P#BJQ** -O_ (3?Q%_T']4_\#)/_BJ/^$W\1?\ 0?U3_P #)/\
MXJL2B@#WSX5?%D:R(])UB7%\!B*X<\2^Q_VOYUZO7Q<CM&X96*LIR"#@@U],
M?"+7=7UWPRLFJPMB,[(;ENLR^I'MZ]Z .YHHHH *DG_UI_#^51U)/_K3^'\J
M (Z*** "BBB@ HHHH **** "BBB@ HHHH DG_P!:U1U)/_K6J.@ HHHH ***
M* "BBB@ HHHH **** "I)_\ 7-]:CJ2?_7-]: (Z*** "BBB@ HHHH ****
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M#&+TB6$G5X9(XW;?_K%M@V3DG (S7V'Y+>J_]]"CR6]5_P"^A0\TFVGR*_\
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M(4U!W3&44_R6]5_[Z%'DMZK_ -]"N$V"7JO^Z*94TL3';ROW1_$*9Y+>J_\
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MCE?^^A0!!13_ "6]5_[Z%'DMZK_WT* &44_R6]5_[Z%'DMZK_P!]"@!E%/\
M);U7_OH4>2WJO_?0H 913_);U7_OH4>2WJO_ 'T* &44_P EO5?^^A1Y+>J_
M]]"@!E%/\EO5?^^A1Y+>J_\ ?0H )_\ 6O\ 6F5--$QE;E>O]X4SR6]5_P"^
MA0 RBG^2WJO_ 'T*/);U7_OH4 ,HI_DMZK_WT*/);U7_ +Z% #**?Y+>J_\
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M_(^HKZ7^'GQ#M?&^G@$K#J,2CSH,]?\ :7VH ["BBB@ HHHH **** "I)_\
M6G\/Y5'4D_\ K3^'\J (Z*** "BBB@ HHHH **** "BBB@ HHHH DG_UK5'4
MD_\ K6J.@ HHHH **** "BBB@ HHHH **** "I)_]<WUJ.I)_P#7-]: (Z**
M* "BBB@ HHHH **** "BBB@ HHHH ?/_ *U_K3*?/_K7^M,H **** "BBB@
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MZWOMI>VJ1YW-7U_X'F=AXJ_:!\0V.M:EI/A;X>7/BZ\T&WCFU]H=32"*SD=
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M <\U[G7DXR-*-6U&UK+:]KVUWU.FDY./O[A1117$;#Y>J_[HIE/EZK_NBF4
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M)N6]5LAQT4=RWM4.B^$M5U[4H;*VLY1)(<;G0JJCN23VKZ5\"^!K+P1I@@@
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MHVI_>/Y4RB@!^U/[Q_*C:G]X_E3** '[4_O'\J?.$\ULL>OI4-23_P"N;ZT
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M444 %23_ .M/X?RJ.I)_]:?P_E0!'1110 4444 %%%% !1110 4444 %%%%
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M16G]AB]#^='V&+T/YT 9E%:?V&+T/YT?88O0_G0!F45I_88O0_G1]AB]#^=
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MF4J7EVE+C]TWR'S0>, #=UOXE>,M+\=:E91:%)=Z!:W%OB>#1+UW$!>(3,)
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M57CL .@KG]/^#'@BPTJ?3W\,:3?P7$YN;@WUC%,T\NYF#R%E^8KO(4GD#@4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[+L;:D)4,GE%EQ)$S;A(0=V=@.<[>E?!S7O[:MI=0O[=--BN%DN(8+VXD:_
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M?RHCL&"9X16Y.!]VNTU'P#KVI_#W1+%YH+K58G^U7]M=W<L,-Q(ZL64R1AG
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>btai-20250331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20250331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '4 \,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT/MI_P" ES_\;K\=**T_U7PG\\OP_P B?[1J]D?L7_PVU\$O^A]M/_ 2Y_\
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M_P" ES_\;H_X;:^"7_0^VG_@)<__ !NOQTHH_P!5\)_/+\/\@_M&KV1^Q?\
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MA/YY?A_D']HU>R/V+_X;:^"7_0^VG_@)<_\ QNC_ (;:^"7_ $/MI_X"7/\
M\;K\=**/]5\)_/+\/\@_M&KV1^Q?_#;7P2_Z'VT_\!+G_P"-T?\ #;7P2_Z'
MVT_\!+G_ .-U^.E%'^J^$_GE^'^0?VC5[(_8L?ML_!(G'_">VG_@)<__ !NM
M#Q#^UU\(O"NN7^CZKXTMK/4K&9K>YMVMK@F.13AE)$9!P?0U^,J??7ZUZ1^T
MG_R<!\0_^PY=_P#HUJQ?#6%510YY:IOITMY>9?\ :%3E;LC]0O\ AMKX)?\
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MA/YY?A_D']HU>R/V+_X;:^"7_0^VG_@)<_\ QNC_ (;:^"7_ $/MI_X"7/\
M\;K\=**/]5\)_/+\/\@_M&KV1^Q?_#;7P2_Z'VT_\!+G_P"-U>UG]K_X/^'[
MP6FH>-K6VN#%',$:VN#\CH'0\1GJK _C7XS5WWQN_P"1WA_[!.F_^D<-9/AK
M"J:CSRU3[=+>7F5_:%2S=D?J;_PVU\$O^A]M/_ 2Y_\ C='_  VU\$O^A]M/
M_ 2Y_P#C=?CI16O^J^$_GE^'^1/]HU>R/V+_ .&VO@E_T/MI_P" ES_\;H_X
M;:^"7_0^VG_@)<__ !NOQTHH_P!5\)_/+\/\@_M&KV1^Q?\ PVU\$O\ H?;3
M_P !+G_XW1_PVU\$O^A]M/\ P$N?_C=?CI11_JOA/YY?A_D']HU>R/V+_P"&
MVO@E_P!#[:?^ ES_ /&Z/^&VO@E_T/MI_P" ES_\;K\=**/]5\)_/+\/\@_M
M&KV1^Q?_  VU\$O^A]M/_ 2Y_P#C='_#;7P2_P"A]M/_  $N?_C=?CI11_JO
MA/YY?A_D']HU>R/V;L/VNOA%J>EZGJ5KXTMI;+3$C>[F%M< 1*[A$)!CR<L0
M.,]:S_\ AMKX)?\ 0^VG_@)<_P#QNOR^^'G_ "2/XK_]>FG?^ET=>:UC#AK"
MRE-.<M';IV3[>9;S"HDG9:G[%_\ #;7P2_Z'VT_\!+G_ .-T?\-M?!+_ *'V
MT_\  2Y_^-U^.R1/)G8C-CKM&:5XGC WHRY_O#%:_P"K&$_GE^'^1/\ :-7L
MC]B/^&VO@E_T/MI_X"7/_P ;H_X;:^"7_0^VG_@)<_\ QNOQTHI_ZKX3^>7X
M?Y"_M&KV1^Q?_#;7P2_Z'VT_\!+G_P"-T?\ #;7P2_Z'VT_\!+G_ .-U^.E%
M'^J^$_GE^'^0?VC5[(_8O_AMKX)?]#[:?^ ES_\ &Z/^&VO@E_T/MI_X"7/_
M ,;K\="".M%+_5?"?SR_#_(/[1J]D?L7_P -M?!+_H?;3_P$N?\ XW1_PVU\
M$O\ H?;3_P !+G_XW7XZE&"ABI"GH<<&DH_U7PG\\OP_R'_:-7LC]F[S]KKX
M1:?I&G:I<>-+:*PU$RBUF-M<$2^6P5\#R\C!('-9_P#PVU\$O^A]M/\ P$N?
M_C=?E[XX_P"2+_#'_?U7_P!'QUYM65+AK"SBVYRW:Z=&UV*EF%2+M9=#]B_^
M&VO@E_T/MI_X"7/_ ,;H_P"&VO@E_P!#[:?^ ES_ /&Z_'2BMO\ 5?"?SR_#
M_(C^T:O9'[%_\-M?!+_H?;3_ ,!+G_XW1_PVU\$O^A]M/_ 2Y_\ C=?CI11_
MJOA/YY?A_D']HU>R/V+_ .&VO@E_T/MI_P" ES_\;H_X;:^"7_0^VG_@)<__
M !NOQTHH_P!5\)_/+\/\@_M&KV1^Q?\ PVU\$O\ H?;3_P !+G_XW1_PVU\$
MO^A]M/\ P$N?_C=?CI11_JOA/YY?A_D']HU>R/V+_P"&VO@E_P!#[:?^ ES_
M /&Z/^&VO@E_T/MI_P" ES_\;K\=**/]5\)_/+\/\@_M&KV1^Q?_  VU\$O^
MA]M/_ 2Y_P#C='_#;7P2_P"A]M/_  $N?_C=?CI11_JOA/YY?A_D']HU>R/V
M+_X;:^"7_0^VG_@)<_\ QNC_ (;:^"7_ $/MI_X"7/\ \;K\=**/]5\)_/+\
M/\@_M&KV1^[?@7Q[H'Q+\-V^O^&M135=(N&=(KJ-&0,58JPPP!X((Z5T%?./
M_!/K_DUSPW_U\WO_ *4R5]'5^>XNC'#XBI2CM%M?<SW*4G.$9/J@HHHKD-0H
MHHH _#7XS?\ )8/'/_8=OO\ TH>N.KL?C-_R6#QS_P!AV^_]*'KCJ_=Z'\*/
MHOR/C)?$PHHHK8D**** "BBB@ HHHH **** "BBB@#O_ ('?\C\/^P;J'_I'
M-7 5W_P._P"1^'_8-U#_ -(YJX"L(_QI>B_4M_"OG^@4445N0%%%% !1110
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M5P%=_P# [_D?A_V#=0_](YJX"M(_QI>B_4E_"OG^@4445N0%%%% 'W9^S/\
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M%0>,CG.,UC>-?CYX$G^"?B'X?>#_  OK.F)JVK1ZLUWJ=['.0P8$IA57Y0
MO4^I-9_PU_:)T[P+\)++PA/I%U=7-OXHMM?-S'(H0QQ;<QX/.XXZ]*I4L7[%
MVOS<Z:O:]K+MI\A<U+FZ6M^)U7CG]D'0M"TSXD1Z!XXN-<\0>!A#)?V$FE&*
M.1).5"2"1LL!D$8ZC&>]=]\'?V6?!7@SXI+X;\5ZW;^(_%D?AZ?4;OP_/IN;
M2+='E-DQ;YI%RK8VCC<<\5YA??M4:=<:M\;KV'1KV%O'\4*6>)ES9-'NY<]_
MO#IZ5U^D_MG>#/\ A-8_'NJ^"-3D\<3Z*VC7DMM?I]CQMV^='&5W!SA0<M@
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M^VE[;VJ6T6F[C^%^H1=&UI6_'^[_ ,$O^'OV8=#:#PSXH\.>*8?%.GQ>*8M
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M_ [_ )'X?]@W4/\ TCFK@*PC_&EZ+]2W\*^?Z!1116Y 4444 %%%% !1110
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M^F_PH_L>_P#^?*Y_[]-_A7[;?98?^>,?_? H^RP_\\8_^^!1_K _^?7X_P#
M#V<>Y^)/]CW_ /SY7/\ WZ;_  H_L>__ .?*Y_[]-_A7[;?98?\ GC'_ -\"
MC[+#_P \8_\ O@4?ZP/_ )]?C_P ]G'N?B3_ &/?_P#/E<_]^F_PH_L>_P#^
M?*Y_[]-_A7[;?98?^>,?_? H^RP_\\8_^^!1_K _^?7X_P# #V<>Y^)/]CW_
M /SY7/\ WZ;_  H_L>__ .?*Y_[]-_A7[;?98?\ GC'_ -\"C[+#_P \8_\
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M^F_PH_L>_P#^?*Y_[]-_A7[;?98?^>,?_? H^RP_\\8_^^!1_K _^?7X_P#
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M^?7X_P# #V<>Y^)/]CW_ /SY7/\ WZ;_  H_L>__ .?*Y_[]-_A7[;?98?\
MGC'_ -\"C[+#_P \8_\ O@4?ZP/_ )]?C_P ]G'N?B3_ &/?_P#/E<_]^F_P
MH_L>_P#^?*Y_[]-_A7[;?98?^>,?_? H^RP_\\8_^^!1_K _^?7X_P# #V<>
MY^)::/?[U_T*XZ_\\F_PKT7]I#2[V7X^_$%TM)W1M;NR&6)B"/-;VK];_LL/
M_/&/_O@58U&VA:_N"8D)+G)*BL7GS=12]GLGU[V\O(T5./*]>WZGX@_V/?\
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M , /9Q[GXD_V/?\ _/E<_P#?IO\ "C^Q[_\ Y\KG_OTW^%?MM]EA_P">,?\
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MC_[X%'V6'_GC'_WP*/\ 6!_\^OQ_X >SCW/Q)_L>_P#^?*Y_[]-_A1_8]_\
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M>E_VLF4\5'Q)YOD'D&[-QY.-W7G;N_'':D\/_!B71-(\*V1U9)CHFMW&KEQ
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M /*?:_\ QJO*:*/J.%_Y]1_\!7^0?VIC_P#H(G_X%+_,]6_X:E^)_P#T,_\
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ME,2L% (89Z':<=*YO3O OC+X>77B6V\'C1+_ $G6KZ;4X6U:[FMY=.N)L>8
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MAWQ?#]NM;/7;K7)];T/4(BS?99&1542?*#A@&5P,@JQZTTJ=VI6\OZ_I@/\
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M]W_!'_JAF5KWC]__  #X1HK[I_X8\^'O_//4_P#P+_\ L:/^&//A[_SSU/\
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MZG_X%_\ V-/^W\'Y_=_P1?ZHYCWC]_\ P#X6HK[I_P"&//A[_P \]3_\"_\
M[&C_ (8\^'O_ #SU/_P+_P#L:/[?P?G]W_!#_5',>\?O_P" ?"U%?=/_  QY
M\/?^>>I_^!?_ -C1_P ,>?#W_GGJ?_@7_P#8T?V_@_/[O^"'^J.8]X_?_P
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MYQ&H^4?>.2=Y^SY7R_U_7W?,9U>G>(9=1\7ZQI:1Q_8].A@W2C.XS2;F*^F
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MW@#]D >!-5\.W<?B>*>+1_$-UKRV\6E+ K^? L1A4+)M0+MR"!C'&!C-<?\
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M ,]XOS/^%'V9?^>\7YG_  K+UG7-.\.Z?)?ZMJ%KIEC&0'NKR988DR0!EF(
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M]:JWWP]\*ZG8Z;97GAK1[NSTW_CQMY[")X[7I_JE*X3H/NXZ"K=:#O[MONT
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M7Y\S<?*F6VHJA45<G"H 23DE.:<6KW]?Z_JXCI****YP"BBB@ HHHH ****
M"BBB@ KXK_X*/?\ '_\ #S_KUO?_ $9'7VI7.^/?A9X3^(T>E2>)=#M=8>TC
MD6!K@']V&;YL8(ZX'Y5U86LL/7C4DM%?\F<6.PTL7A9T8.S=M_5,_(&BOU0_
MX9A^%G_0E:;^3_\ Q5'_  S#\+/^A*TW\G_^*KZ/^V*/\K_ ^-_U=Q'\\?Q_
MR/ROHK]4/^&8?A9_T)6F_D__ ,51_P ,P_"S_H2M-_)__BJ/[8H_RO\  /\
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MPW^_\BO1115$!1110 4444 %%%% !1110 5/>_Z__@*_R%05/>_Z_P#X"O\
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M//UJO]O3_GVB_-O\:;;_ /'G=_1?_0JK4DM6-PAV1;^WI_S[1?FW^-'V]/\
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MR2>22?2O"]8^&.HZEHFB0Z7X-O?#$%G/;G5+>Q;37FO]D$B;E2;S(7",P.9
M&;.>"HK=^%OPGN/#GQ!BU6\TRZ:RMM BM+.YU:2VEN(9OM=S(Z 0@(F$D3&Q
M0H!V@G!K.45R:SVZ?TRD]=CZ9\/?\@J/ZM_.M*LWP]_R"H_JW\ZTJ^>G\3.Y
M;(****@84444 <+>_P#'Y/\ ]=&_G4-37O\ Q^3_ /71OYU#7KK9'*,F<QQ.
MPZJI(S7PU'^V;\3YO#6H^(5O?A3#:V<LX_L:ZOIHM5E6-RNU8#.268#Y>.<C
MBON2=2\,B@9)4@?E7Y_Z9\!/B)IG@G5_#EQ^SYH6M:C=-=B+Q-=:Q9+<QF5G
M,<G$F[Y-PQA@?E[5Z>#5)J7M+=-[>=]VCGJ\VG*>_>/_ -I36?A;+X0\2^)-
M%BM_A_KVG;IFB@D:^T^^,9=8W.[:R-P!\@(.<]*IW7[1?CCP]\)/#NN:MX:T
M^Y\9>,=06U\/:!:AXEC23_5&X=G;+;<,<;1\P'')&%XJ_9]\=?%2U\%_#SQ/
M+-:>"/#VDHU_K<-U&[ZGJ BVH$7<7"H3U=1G#>QIEU\)OBUXB^%WA6&\L[:W
M\=_#W6%N-)N;NZC>VUJW0X4G8Q,;% %(?&<=1DD:J-"T;VO?77IK;_@_\.3>
M=V=]X*\?_&73M?OM,^('A#1!:_V9-?V^M^'7E-I"\8/[F82.26)QC:1P>X!(
MZ[]GWXBZI\6?@SX<\6:K#:6VJ:E%*\D5FC+"I69T&T,S-C"CJQ[UQOA#5/CA
MXWUS4'\5^%]*\%^&TTN>W_LM;V*]N+VY=3L=9$8B,+P,-ZG@Y!7@_@1=_'CX
M5>"/#/@N?X/VT^G:>QBEU)O$5H&"/,SL_EAST#G@'G%93IJ47;E4M-FO/S]-
MBE)IK>QTOB/XG_&/PY\6?"G@I&\$ZQ=:T[W$T=I87:/:62'YYG9K@@<9 XY;
MCVK)M/VJ?%=Q<6GBHZ1HP^'%WXH/AF-!YO\ :0/(%R7W>65++]P+GGKWKT/X
M>^ _$$/Q_P#B1XSU[3_L]I=Q6FG:),9T?=:QH"^%5B4!DRQ# ')Z5XW8_L]_
M$"&RT_X</HEN/"EGXQ_X2,>*/MT15[4%F$(ASYGF9;&2NW@\]ZTC[%Z2MLOQ
MW^:T1+YUL>@7'[2^MWG[1?ASP'I_AIK/PW>7E]8SZMJ<3+)=2VT;ES;8<#8'
M3!8AL\XP17T-7BWQ+^'GB#Q!^T1\*O$]AI_VC0]$6^&H77G1KY/F0LJ?*6#-
MDD#Y0<=Z]IKBK<EH."MIKZW9M&^MPHHHKF++%A_Q\?\  6_D:KU8L/\ CX_X
M"W\C5>EU'T"L#QWX,LOB%X4OO#^HRW$-G>;!(]JRK(-KJXP6!'51VZ5OT52;
MB[H6YYSK/P(\.:TOC 2RW\+>*)+:2\:*5,Q>2X=1%E"%!8$MG.2QZ<8FU'X,
MZ=?:W?W<6M:UI^FZC<)=ZAHEG<1I:7DRX^=B8S*I;"!A'(@;8,@\Y] HK3VL
M^_\ 7](GE1YMJOP-T[4M1O[V+7M:TZ:XU5-:A^RM;$6=X$$;21;X6SN0 %9-
MZ^@%&C_!*+P]!JITWQAXFL]1U/4!J=SJ*S6SRO-Y2Q-E&@,15@JG:4(!'R[>
ME>DT4>UG:UPY4><6GP*T.QLM%M[>_P!2B.G&[\R4/$6OENFW7*S9CP [<_NA
M&1_"5'%5_#WP$T[0=4T6]D\1Z_JPT:TEL=/MKZ6W\J"WD38T>(X4+<!<,Q+?
M*/F(R#R_QT^+VM>$_$Z6_AW48(H/#=DFN:]:,L;/=6S3!?LZE@2K>6L\GRX;
MY$[-SUWBCXK3&2^T_P +:8^N7L&BC6))HIT18HI _DA0P(>1O+8A#@8 R1D5
MT6K63OO_ %^OXD>[?T*]K^SQX<338[&]OM4U:"+25T:/[5)$K) DWG1$&.-,
M/&P7:W7Y%)R<D]7X0\$GPK->W-SKNK>(]0N]B/>ZO)$76-!A8U2&..-0"6;(
M3<2QW$\8\WT+X_R1>&M.26S_ +<U6TT"UU?5YC<Q6NWS$+!8U( >1@K-M&T8
MQR,UI7O[041GU^32M GU32]$TVVU:ZO1<I%FWFC,F40C+,JJ3M)&<<'/%*4*
MSNF-.&Z.[\'^"+'P2-;%C+<2_P!K:I/JT_VAE;;++C<JX484;1@')]S7*>,/
M@/I?C&_\23/KVN:79^(XXTU;3]/F@6&Z:.,1HY9XFD0A50$(ZJVP!E(+!DU?
MXW0V<_B"73]&GU32O#D4,VKWB3)&T"O&LI$:'_6,D3!V&1Z#)XJPOQ?.HZCJ
M7]B>'[W7-'TN\AL;V_M#EUED5&/EPXW2*BRQESP1DX!P:A*JGS+^MO\ @#O%
MZ$][\&=%OK#Q7:27>H>7XDDM9;QEDC#(8(HHD\OY.,K"I.<\DXQP MS\']/E
MUZYOK?6=8TZQO+N.^OM'LYHTM+NX0+B1SY9E4G8A8)(JMM^8')SAK^T#8Q^*
M](TB\TQK%-6U)]+M5GNXUO=Z^8!)):GYTB9HF ;.<%3@;JBT7]H$ZYH>D:C!
MX:G5M=U*72]'MFNDWW4L33"9GXQ'&H@D;<<D@# Y%5RUE_7]=OP%>!M6_P #
M="L_ ^F>&K>\U* :7?S:GI^II+']KM;F2664NC;-A_UTBX9""IP0>M17OP.L
M;ZWTZ63Q'K_]OV.H/J47B S0-=^<R-&V4:$P!/+.S8L0  &!G).#XC^.DGAS
M4K=]3T;6=+GM[#5+F?2W\D0S?9?+.X.R;G5@X*.C*O)W D8&J_QU@TF*_DU_
M1+G2/(T9==A1)DG::W+A-A QMDW,@VY(RW#'%.U;?N%X#],^ .C:1]BEM]:U
MO[=:ZT^O+?2S0R2O</$8Y0VZ(J4D#,2,9!/RE0  RQ_9\TC1-,TZWT37]>T&
M\LX+BT_M*QF@-Q/!-,\S12"2%D(#N2K! Z]FY.8M>^.Y\(6NIQZ[X<N+36+6
MPBU.'3K>Y28W4#RK$=KX #H[J"I_O+@D9(9JGQQO]"F\0IJ'A*6)?#R07&I2
MQ7\;HD,OW&C^4%VP')4A<;1R<T6KO^E_747N'7^(_AKI7B+X=S>"S)=V.D26
MR6JR6\V^>-$(*D/*'W-\HY<-GOFJ>D_"Z.W\0VFMZUXBUGQ9?V(86)U;[,D=
MHS AW2.WAB4LP.-SAB!P,9.</QY\>++P!J-Y'?Z>L5C:310/-<WD<$TY?:2;
M>%N9E4.,D$=P,XKU.LFZD(Z[/^F7[K9YCI?P!T72]2TJ;^V-9N].TF>>?3]'
MN)83:6PF5UDC $0=U(<X\QV*XP" 6#,_X9]T6;0[K0[O6]>O]";3I]*L],GN
MHQ%86\J[66(I&K.0H 4S-(5 P.^?4:*7MJG<.5'DNK?LZ:;K,.L0S>*O$D<&
MMZ=#INL1PRVJ#4$B1T1W(M\HP5]I\HHK!1N4\YZWP7\-=-\"ZEJM]8W-Y<3Z
ME#9PS?:G0@"V@$*%0JK@E1EO?I@<5UM%)U9R5F_Z_I HI:A1116105\[_M@_
MZWP=_P!<+G_T8M?1%?._[8/^M\'?]<+G_P!&+7MY+_O]/Y_^DLY,7_!E\OS/
MG2BBBOU(^="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ Z5])?L]?&)KWR/"VLS,\X^6RN'Y+#_GFQ]1V/X5\WQ1/-(L<:EW<A551
MDD^E?6GP+^#R>";!=7U2)7UNY0;5;G[.A_A'^T>_Y5\_G<\.L*XUMW\/>_\
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MACN?_ 9?_BJ]^HH_MC'?\_/P7^0?5:/\IX#_ ,,DV'_0QW/_ (#+_P#%4?\
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MJO?J*/[8QW_/S\%_D'U6C_*> _\ #)-A_P!#'<_^ R__ !52Q?LAZ?)%,_\
MPDER/+4-C[*O/('][WKWFK-M_P >UY_N+_Z&M)YSC_\ GY^"_P @^JT?Y3Q[
MP!^SQH_@C7%U26\DU:>(?N5FB"K&W][&3DUZQ117!7Q-7%2YZTKLWA3C35HJ
MP4445S%A1110 4444 %%%% !5B^_UX_W%_D*KU8OO]>/]Q?Y"EU'T*]%%%,0
M4444 %%%% !1110 4444 6;?_CSN_HO_ *%5:K-O_P >=W]%_P#0JK5*W8PK
MFO'/@J/QO::5!+=-:"PU*WU(,B!MYB;<$// /K72T5:;B[H35SRWQ+\"[?6]
M=UV]M=333[;77BDOT-BDMPKHH1FMYR08BZ*@.0V-N5VDG.9XJ_9V_P"$A;Q#
M#;^(!I]EK5Y%?39T]9;I&01@1+,7_P!43$I*[<\G#"O9:*V5:HMF3R)GEVI_
M!6>ZNI(++Q')8:%+KL/B"73_ +(LDAG25)6C64MQ&[IN(VE@6.&QQ4DGP5$E
MW):_VT__  C$FM#7FTDVP+_: XEV>=N_U1E7S"NW.21NQQ7IM%+VT^X<J/+/
M^%)7"ZG8[/$;IHMEK[>(8K 6:^89F9G:-I=W*;G8C"AAD<D#%=;X#\'OX(TV
M\L/MPO;:6]N+R',.QXQ+(TC*QW$-AF." O&..]=-14RJ2DK-C44M@HHHK,99
MG_X\K7ZO_,56JS/_ ,>5K]7_ )BJU3'8;"N ^)W@R]\4W.G3VFG6MZUK'*(Y
MAJ-QIUW;R, H:.>'G81N#(1@\>F*[^BM(R<'=$M7T/G76_@KXP01L9-/U*,-
M8WUW<K(R2O+;V,ENZ)$L>#N9E8<CN,5R8^$7B>.?X97Q\(V$B(UK#<:02_D#
MR].NE::Z/E?NR6D5>5/(4$DD5=\$^.KWP5XJ^)<<M[-)_;6LZC%I<4LI8"\2
M[6!40'H3]HBX'9,XXJ3X5?$G6?#G@KPQX:MKJ9[J1M;NY]0DTB\U>1Q%JD\2
M)Y<&6&202[' "@ $GCUOWL4[6?\ PS_(Y_=9HR?!;7?#MQH-DMQ)>W][-;:=
M-=V\,CQ_8%L$BNQ,^W;&-T2%-QRQ10,DG'9_'/X8>)/B ]E!H4EA;6D5G+ S
M2B)91(SQE1ND@E(3"'B,QMG!W<<8MG\<O$U_8ZEK#V-KIUCI/AR'6+G3KFUD
M%Q+.S3(T88L/+3,.02A.#TJ/XT>(/%GA#PEX:UK5I(M?6/7=-GCL]!LY(;B5
MOG+Q!3(^\'C'3W!K']XYQO:Y7NV9QFH_";7/&'CS5-,MM+5D@;5);C6[^TN;
M=;G[1>VTL<!>6%1*$2.1%,;2+M0'*A@*ZGQ/^SIK^L>*]?NK35A:6=TMR;.2
M*6&/RA);+"L#(+8R&,$=#,4 53LR*]4\'^-7N/AJOBW6]2T^YM)+9]1:;3(G
M$,4&"VP;B6=E P20I)!^5>E>*_L]>(9]%\?/9>*);S2]8UBV+:;:7$;R2ZS%
M)+-<+>RE&=%=(_D89^3@$C<BTU4J-2:^S_3"T=/,DUC]FGQ#K%LS22VDTSVF
MK(%OIXF$<UQ!;QPLHAMHD7!A8DA 1P>2:N^,?V<-=U:5AIMU;6>G>;<@:=;2
M11HRS6MO%YG[VWF565H7^Z@;$A(93G/>^+(5\4_&K1O#.K,\F@)H=QJ8L"Q$
M-Y<">*/]X/XQ&K9"GC,@)&0,4IM8_P"$-\3Z5X(\(ZG;M-JVH74C?;,W,6D)
M'"DKP)&K*PW;U*H6 4,<<!14JK4=K/I?;2P<L3C/$/[-.L:EH^I00OILM[=2
M:GF[N9&,DJ36R1PB1]F2=Z GTZC)KZ"T:*2&S"RV%OIS\?N;9]Z_='?:OTZ=
M /I6%\-?%-[XJT*Z?44@&H6%_<Z;<26H(BE>&0H9%!)*AL9VDG'(R<9KK*YJ
MM2<O=ET-(I+5!1117.6==X>_Y!4?U;^=:59OA[_D%1_5OYUI5Y4_B9U+9!11
M14#"BBB@#A;W_C\G_P"NC?SJ&IKW_C\G_P"NC?SJ&O76R.41F"*68@*!DD]J
M\TT3]I'X<^(XM;ET_P 2+/'H]E-J-VQL[A +:+/F2Q[HQYJC:>8]WMU%>D7$
M;2V\J(55F4J"R[@#CN._TKX\?]F_QA\._#'Q&U#[1I=AH<GA/5K8:)H%W>3Q
M7UQ) ^V403 B!L8&V-F'  QWZZ,*<T^=V?0RFY+8^@/"O[1/P[\:2WR:5XEA
MD-E9G4)VN;>:V46XZRJTJ*'0=RI(%0Z7^TI\-]9T?6=3M?$@-GH]L+R\,ME<
M1.D!.!*L;QAI$SQN0,/>O&-!_9U\7?%3PII4OBJ^TG1[2'P@=%TT:8)3.QE\
MMQ)<HZJ%V[%!12>K<UJ^(/V=/'_CW2]8D\07OAFSU1?"Q\,Z9%I<DY@D#2*[
M33LT8*_<4!%5@,GGFNAT<.G9R_'_ (&OZ$<T[;'JFC?M(_#C7[36KFS\31F#
M1[87MZ\]K/#L@)P)%WHOF*3P"F[)P.XJ&'XY_"[Q+X6U#Q1)K%E-I>D2K#<3
M7]E+'-#(P#(HBEC$A+9&T*IW=LFN2\6?L^ZUKWB"^NXI-"DL;CP5!X;^RWZR
MR1O.DQ<ED0*?+*G 96#*>0.!7$:/^R;XWA\+WUO/KNF6=Q::S9:SH>C"]NK^
MPMWMU;]V\DRB0(Y<\ -MP#\W2DJ>':OS-;?UL-RGV/9G_:7^&L/A7_A(G\2K
M'I0OETUG:RN!+'<,&*QO#Y?F(2%8@LH!'?D4]OVD?ATFHZ=8R>(6@NKY(I(E
MFL+F,1B0XC\YFC A+<8$A4G(]17ENL?LU>,_%VI3^(M9OO#\.OZAXGTW5[NR
MLGF^QQ6UI&\85':/=)(P(/S*HSGFH?B-^R+>^,/C!K7B5(=#U/2]:N;2XFDU
M6]OX[BR\I45UCB@=8Y0=@(WL-I/?'(J6&O9R?X>7EZ_<)RJ=$=G\5_VJO#/@
M6\.CZ/=P:SXDAU.UT^YLF298H_,D57'G!/+,BAL^6&W<'(X./<:^5=?_ &8_
M'>-;T'1K_P -OX5U#Q7'XH6XOGG%\K>:KO#@1LH P</N).,$#<2/JJL*T:48
MQ]F[_P!(N+DV^8****Y30L6'_'Q_P%OY&J]6=.8K= C&0K=1GL:7^TIO2+_O
MRG^%3K?0?0JT5:_M*;TB_P"_*?X4?VE-Z1?]^4_PHU#0JT5:_M*;TB_[\I_A
M1_:4WI%_WY3_  HU#0JT5:_M*;TB_P"_*?X4?VE-Z1?]^4_PHU#0JT5:_M*;
MTB_[\I_A1_:4WI%_WY3_  HU#0JT5:_M*;TB_P"_*?X4?VE-Z1?]^4_PHU#0
MJT5:_M*;TB_[\I_A1_:4WI%_WY3_  HU#0JT5:_M*;TB_P"_*?X4?VE-Z1?]
M^4_PHU#0JT5:_M*;TB_[\I_A1_:4WI%_WY3_  HU#0JT5:_M*;TB_P"_*?X4
M?VE-Z1?]^4_PHU#0JT5:_M*;TB_[\I_A1_:4WI%_WY3_  HU#0JT5:_M*;TB
M_P"_*?X4?VE-Z1?]^4_PHU#0JT5:_M*;TB_[\I_A1_:4WI%_WY3_  HU#0JT
M5:_M*;TB_P"_*?X4?VE-Z1?]^4_PHU#0JU9N?^/6S_W&_P#0C2_VE-Z1?]^4
M_P *L7%_*MM:D"/+*2?W2_WC[4G>Z&K&;15K^TIO2+_ORG^%']I3>D7_ 'Y3
M_"GJ+0JT5:_M*;TB_P"_*?X4?VE-Z1?]^4_PHU#0JT5:_M*;TB_[\I_A1_:4
MWI%_WY3_  HU#0JT5:_M*;TB_P"_*?X4?VE-Z1?]^4_PHU#0JT5:_M*;TB_[
M\I_A1_:4WI%_WY3_  HU#0JU9U3_ )"-S_OFE_M*;TB_[\I_A5C4+^6.^G4"
M/ <@9B4G^5+6X]#-HJU_:4WI%_WY3_"C^TIO2+_ORG^%/46A5HJU_:4WI%_W
MY3_"C^TIO2+_ +\I_A1J&A5HJU_:4WI%_P!^4_PH_M*;TB_[\I_A1J&A5HJU
M_:4WI%_WY3_"C^TIO2+_ +\I_A1J&A5JS;?\>UY_N+_Z&M+_ &E-Z1?]^4_P
MJ>WOY6M[HD1Y5 1B)?[P]J3O8:L9U%6O[2F](O\ ORG^%']I3>D7_?E/\*>H
MM"K15K^TIO2+_ORG^%']I3>D7_?E/\*-0T*M%6O[2F](O^_*?X4?VE-Z1?\
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M@Z'24:S-UY\<AR)-FW#_ $/K50IRJS4(*[_X .2BFV=!17F/_"[8_P#H$/\
M^! _^)H_X7;'_P! A_\ P('_ ,37;]0Q/\OXK_,Q]M3[GIU%>8_\+MC_ .@0
M_P#X$#_XFC_A=L?_ $"'_P# @?\ Q-'U#$_R_BO\P]M3[GIU%>8_\+MC_P"@
M0_\ X$#_ .)H_P"%VQ_] A__  ('_P 31]0Q/\OXK_,/;4^YZ=17F/\ PNV/
M_H$/_P"! _\ B:/^%VQ_] A__ @?_$T?4,3_ "_BO\P]M3[GIU%>8_\ "[8_
M^@0__@0/_B:/^%VQ_P#0(?\ \"!_\31]0Q/\OXK_ ##VU/N>G59U3_D(W/\
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M%"$B0,AW$%?O;#\HUOAC\9XOB#XBU31);6Q@O;*UBN]^F:B;Z!D=F0J9/+C
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M[59KHES-;7B7T81AY;NID7:S H3&^#G/RG(!K/\ "?Q\\/>,G\,+8VFIQ_\
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MMI]L"%,UU*L2 ^FYB!6T9RBG&/4EI-W9X[#\,M?CT5(/L*"?_A/9]=($R?\
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MBC_A3.M_\_5A_P!_'_\ B*]FHKT/[2Q'=?<8>P@>,_\ "F=;_P"?JP_[^/\
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M#FNK\)^*[+QKX:TW7M+EDET[48%N+=Y%*,R,,@D'D4GA9K=_@'U^WV/Q_P"
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M_P#?!H^P7/\ S[R_]\&L?>W]X_G1O;^\?SH^KR[_ (!_:"_D_'_@&Q]@N?\
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MC[!<_P#/O+_WP:/L%S_S[R_]\&L?>W]X_G1O;^\?SJ_J\N_X$_V@OY/Q_P"
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M\]M7_P# '_[*C_AN_P"%O_/;5_\ P!_^RK\WZ*/[(P_G]X<J/T@_X;O^%O\
MSVU?_P  ?_LJ5?V[OA:6 \_5AGN;$\?^/5^;U%']D8?S^\.5'[+^'O$&G^*M
M%L]6TJZCO-/NXQ+#/&<AE-:-?G#^R=^TI+\*-97P_KLY?PI>R?><D_8Y"?OC
M_9/<?C7Z-03Q74$<T,B30R*'22-@RL#R"".HKYK%X66%J<KVZ,AJQ)5S6/\
MD*W?_75OYU3JYK'_ "%;O_KJW\Z\U_&O1_H6O@?JOU*=%%%:&84444 %%%%
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M]I6@B4:9IEGIPEP9/LD"1;\=,[0,XR?SJ95$[Z"<DS0HHHK$@**** "BBB@
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M^/D?]<T_]!%5:M:E_P ?(_ZYI_Z"*A_$OZ[&B^!_+]2K1115F84444 %%%%
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M33);PR2R';&BEF.,X &361X;\8Z1XO\ "UKXCTB[-YHUS$9X;D1.F] 2"=K
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MVY\/^*O%'@[4M,\2P:I=WTGPO,GDRM(':=+EW@W[3S)M6+<#R>0P()%?>_\
MPBFI?\\5_P"^Q1_PBFI?\\5_[[%-X^EW7WC]E6_D9^?4A\/1:'H,>J_\)0G@
MY/"NWPXNF_V@,:QYK_: V/G\SS,;?,_=[>G&VO1OAUX$U/QS\6M'_P"%APW]
MU>:?X*TRYEMWN9HH3>^;(&:548*[@<,IRN6/'2OK_P#X134O^>*_]]BC_A%-
M2_YXK_WV*EXZFUI)??\ U\Q.C6?V&<OHGAS2_#<#P:5IUMIL+D,T=K$(U)
M!P/8 ?A6C6O_ ,(IJ7_/%?\ OL4?\(IJ7_/%?^^Q7-[>D_M+[S/ZO6_D?W&1
M16O_ ,(IJ7_/%?\ OL4?\(IJ7_/%?^^Q2]O2_F7WA]6K?R/[BEIW_'U_P!__
M $$U5K>LO#.H0S[GB4#:P^^.X(J#_A%-2_YXK_WV*E5Z7,_>7WEO#UN1+D?7
MIZ&116O_ ,(IJ7_/%?\ OL4?\(IJ7_/%?^^Q5>WI?S+[R/JU;^1_<9%%:_\
MPBFI?\\5_P"^Q1_PBFI?\\5_[[%'MZ7\R^\/JU;^1_<9%%:__"*:E_SQ7_OL
M4?\ "*:E_P \5_[[%'MZ7\R^\/JU;^1_<9%%:_\ PBFI?\\5_P"^Q1_PBFI?
M\\5_[[%'MZ7\R^\/JU;^1_<9%%:__"*:E_SQ7_OL4?\ "*:E_P \5_[[%'MZ
M7\R^\/JU;^1_<9%%:_\ PBFI?\\5_P"^Q1_PBFI?\\5_[[%'MZ7\R^\/JU;^
M1_<9%%:__"*:E_SQ7_OL4?\ "*:E_P \5_[[%'MZ7\R^\/JU;^1_<9%%:_\
MPBFI?\\5_P"^Q1_PBFI?\\5_[[%'MZ7\R^\/JU;^1_<9%%:__"*:E_SQ7_OL
M4?\ "*:E_P \5_[[%'MZ7\R^\/JU;^1_<9%%:_\ PBFI?\\5_P"^Q1_PBFI?
M\\5_[[%'MZ7\R^\/JU;^1_<9%%:__"*:E_SQ7_OL4?\ "*:E_P \5_[[%'MZ
M7\R^\/JU;^1_<9%%:_\ PBFI?\\5_P"^Q1_PBFI?\\5_[[%'MZ7\R^\/JU;^
M1_<9%%:__"*:E_SQ7_OL4?\ "*:E_P \5_[[%'MZ7\R^\/JU;^1_<9%7;S_C
MQT__ *YM_P"AM5K_ (134O\ GBO_ 'V*LW/AN_DM;1%B4M&C!AO'&6)_K42K
M4KKWE_29I'#UDI>X]NWFCGZ*U_\ A%-2_P">*_\ ?8H_X134O^>*_P#?8J_;
MTOYE]YG]6K?R/[C(HK7_ .$4U+_GBO\ WV*/^$4U+_GBO_?8H]O2_F7WA]6K
M?R/[C(HK7_X134O^>*_]]BC_ (134O\ GBO_ 'V*/;TOYE]X?5JW\C^XR**U
M_P#A%-2_YXK_ -]BC_A%-2_YXK_WV*/;TOYE]X?5JW\C^XR**U_^$4U+_GBO
M_?8H_P"$4U+_ )XK_P!]BCV]+^9?>'U:M_(_N,BKFL?\A6[_ .NK?SJW_P (
MIJ7_ #Q7_OL59U'PU?W%_<2I$I1W+ [QTS4.M2YD^9=?T+6'K<C7(]UT]3GZ
M*U_^$4U+_GBO_?8H_P"$4U+_ )XK_P!]BK]O2_F7WD?5JW\C^XR**U_^$4U+
M_GBO_?8H_P"$4U+_ )XK_P!]BCV]+^9?>'U:M_(_N,BBM?\ X134O^>*_P#?
M8H_X134O^>*_]]BCV]+^9?>'U:M_(_N,BBM?_A%-2_YXK_WV*/\ A%-2_P">
M*_\ ?8H]O2_F7WA]6K?R/[C(JW9_\>E]_P!<E_\ 0UJY_P (IJ7_ #Q7_OL5
M8MO#5_';W2M$H:1 J_..3N4_R%1.O2:^)=/S+AAZR>L'L^GD8%%:_P#PBFI?
M\\5_[[%'_"*:E_SQ7_OL5?MZ7\R^\CZM6_D?W&116O\ \(IJ7_/%?^^Q1_PB
MFI?\\5_[[%'MZ7\R^\/JU;^1_<9%%:__  BFI?\ /%?^^Q1_PBFI?\\5_P"^
MQ1[>E_,OO#ZM6_D?W&116O\ \(IJ7_/%?^^Q1_PBFI?\\5_[[%'MZ7\R^\/J
MU;^1_<9%%:__  BFI?\ /%?^^Q1_PBFI?\\5_P"^Q1[>E_,OO#ZM6_D?W&15
MK4O^/D?]<T_]!%7?^$4U+_GBO_?8JQ>^&;^:8,D2D;%'WQV %2Z]+F7O+[RU
MAZW*UR/IT,"BM?\ X134O^>*_P#?8H_X134O^>*_]]BJ]O2_F7WD?5JW\C^X
MR**U_P#A%-2_YXK_ -]BC_A%-2_YXK_WV*/;TOYE]X?5JW\C^XR**U_^$4U+
M_GBO_?8H_P"$4U+_ )XK_P!]BCV]+^9?>'U:M_(_N,BBM?\ X134O^>*_P#?
M8H_X134O^>*_]]BCV]+^9?>'U:M_(_N,BBM?_A%-2_YXK_WV*/\ A%-2_P">
M*_\ ?8H]O2_F7WA]6K?R/[BI:?\ 'A??[J?^A"J==!;^&K^.TND:)0T@4*-X
M[,#5;_A%-2_YXK_WV*B-:E=^\OO\D:2P]9J/N/;MYLR**U_^$4U+_GBO_?8H
M_P"$4U+_ )XK_P!]BK]O2_F7WF?U:M_(_N,BBM?_ (134O\ GBO_ 'V*/^$4
MU+_GBO\ WV*/;TOYE]X?5JW\C^XR**U_^$4U+_GBO_?8H_X134O^>*_]]BCV
M]+^9?>'U:M_(_N,BBM?_ (134O\ GBO_ 'V*/^$4U+_GBO\ WV*/;TOYE]X?
M5JW\C^XR**U_^$4U+_GBO_?8H_X134O^>*_]]BCV]+^9?>'U:M_(_N*ES_R#
MK/ZO_,53KH)O#5^]G;1B)=R;MPWCN>*K?\(IJ7_/%?\ OL5$*])+XEU_,N>'
MK-Z0>RZ>1D45K_\ "*:E_P \5_[[%'_"*:E_SQ7_ +[%7[>E_,OO(^K5OY']
MQD45K_\ "*:E_P \5_[[%'_"*:E_SQ7_ +[%'MZ7\R^\/JU;^1_<9%%:_P#P
MBFI?\\5_[[%'_"*:E_SQ7_OL4>WI?S+[P^K5OY']QD45K_\ "*:E_P \5_[[
M%'_"*:E_SQ7_ +[%'MZ7\R^\/JU;^1_<9%%:_P#PBFI?\\5_[[%'_"*:E_SQ
M7_OL4>WI?S+[P^K5OY']QD45K_\ "*:E_P \5_[[%'_"*:E_SQ7_ +[%'MZ7
M\R^\/JU;^1_<9%%:_P#PBFI?\\5_[[%'_"*:E_SQ7_OL4>WI?S+[P^K5OY']
MQTOA3_D"0_5OYFM>L[0+.6PTR.&90LBEL@'/>M&OG*S3J2:[GU=!.-**?9!1
M116)N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSNQCIU_D/2@#YQO_ (G:FEIJ%Y8?$ 7/AQI3'%J3-:M<12):SN20J;5CED5
MBL-Q\M\<,*W[/X@7&JZC,/\ A/%T]H-.\W5X9VMD6QG818CB4H7!3+!G8,J[
MAG)&*]V\I "-BX/M2^6F2=JY/7B@#C?@]X@O/$W@"PO=0N?MEYYD\,ERI5DE
MV2N@9'4*'4A1APJ[A@[5S@=I2 !1@# ]!2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?-\7[+>MZCK8N=7B\-O9279N;NU@#&.Y<6]W&)"GD*NXM<1G#;B AR[&NH\
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M9# 'T=17S7_PS/KPDM&\[2F:/3#9Q2&[FSIPV3J;>']UEHCYJ<[D  ;]V1M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>btai-20250331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 12:17:33 PM-->
<!--Modified on: 5/12/2025 12:17:33 PM-->
<xsd:schema targetNamespace="http://www.bioxceltherapeutics.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:btai="http://www.bioxceltherapeutics.com/20250331" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>99940501 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>99940601 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940701 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" id="DisclosureDebtAndCreditFacilitiesDebtSummaryDetails">
        <link:definition>99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" id="DisclosureDebtAndCreditFacilitiesInterestDetails">
        <link:definition>99940905 - Disclosure - Debt and Credit Facilities - Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" id="DisclosureLeasesMaturitiesDetailsCalc2">
        <link:definition>41002 - Disclosure - Leases - Maturities (Details) - Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" id="DisclosureLeasesMaturitiesDetails">
        <link:definition>99941301 - Disclosure - Leases - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99931203 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>99940201 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" id="DisclosureRestructuringDetails">
        <link:definition>99940401 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" id="DisclosureTransactionsWithBioxcelLlcDetails">
        <link:definition>99940801 - Disclosure - Transactions with BioXcel LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" id="DisclosureDebtAndCreditFacilitiesCreditAgreementDetails">
        <link:definition>99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" id="DisclosureDebtAndCreditFacilitiesWarrantsDetails">
        <link:definition>99940903 - Disclosure - Debt and Credit Facilities - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" id="DisclosureDerivativeFinancialInstrumentsDetails">
        <link:definition>99941001 - Disclosure - Derivative Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" id="DisclosureCommonStockFinancingActivitiesDetails">
        <link:definition>99941101 - Disclosure - Common Stock Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" id="DisclosureStockBasedCompensationDescriptionDetails">
        <link:definition>99941201 - Disclosure - Stock-Based Compensation - Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" id="DisclosureStockBasedCompensationNonOptionsDetails">
        <link:definition>99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" id="DisclosureStockBasedCompensationOptionsDetails">
        <link:definition>99941203 - Disclosure - Stock-Based Compensation - Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>99941205 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" id="DisclosureStockBasedCompensationEsppDetails">
        <link:definition>99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" id="DisclosureFairValueMeasurementsHierarchyDetails">
        <link:definition>99941401 - Disclosure - Fair Value Measurements - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" id="DisclosureFairValueMeasurementsLevel3Details">
        <link:definition>99941402 - Disclosure - Fair Value Measurements - Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" id="DisclosureFairValueMeasurementsInputsDetails">
        <link:definition>99941403 - Disclosure - Fair Value Measurements - Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" id="DisclosureFairValueMeasurementsWarrantsOutstandingDetails">
        <link:definition>99941404 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>99941501 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" id="DisclosureNetLossPerShareAntidilutiveDetails">
        <link:definition>99941502 - Disclosure - Net Loss Per Share - Antidilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99941601 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" id="DisclosureSegmentInformationDetails">
        <link:definition>99941701 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941801 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>995210101 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>995210201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>995210401 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>995210501 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>995210601 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210701 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" id="DisclosureTransactionsWithBioxcelLlc">
        <link:definition>995210801 - Disclosure - Transactions with BioXcel LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" id="DisclosureDebtAndCreditFacilities">
        <link:definition>995210901 - Disclosure - Debt and Credit Facilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" id="DisclosureDerivativeFinancialInstruments">
        <link:definition>995211001 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" id="DisclosureCommonStockFinancingActivities">
        <link:definition>995211101 - Disclosure - Common Stock Financing Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995211201 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995211301 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995211401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995211501 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211601 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995211701 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211801 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>99930503 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>99930603 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930703 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" id="DisclosureTransactionsWithBioxcelLlcTables">
        <link:definition>99930803 - Disclosure - Transactions with BioXcel LLC (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" id="DisclosureDebtAndCreditFacilitiesTables">
        <link:definition>99930903 - Disclosure - Debt and Credit Facilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99931303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99931403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99931503 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99931703 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" id="DisclosureDebtAndCreditFacilitiesMaturitiesDetails">
        <link:definition>99940904 - Disclosure - Debt and Credit Facilities - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>99941302 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20250331_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element name="OrganizationAndPrincipalActivitiesAbstract" id="btai_OrganizationAndPrincipalActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentMilestonesMember" id="btai_DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SalesMilestonesMember" id="btai_SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentsPotential" id="btai_CollaborativeArrangementMilestonePaymentsPotential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BioxcelCorporationMember" id="btai_BioxcelCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMilestonePotentialPercent" id="btai_CollaborativeArrangementMilestonePotentialPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="JefferiesMember" id="btai_JefferiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncentiveAwardPlan2020Member" id="btai_IncentiveAwardPlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlan2020Member" id="btai_EmployeeStockPurchasePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" id="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPlan2017Member" id="btai_StockPlan2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="btai_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FinancingActivitiesAbstract" id="btai_FinancingActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancingActivitiesDisclosureTextBlock" id="btai_FinancingActivitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" id="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RegisteredOfferingMember" id="btai_RegisteredOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CreditFacilityMember" id="btai_CreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaidInKindInterestPercentage" id="btai_PaidInKindInterestPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TickingFeesPercentage" id="btai_TickingFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" id="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityInvestmentMember" id="btai_EquityInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantOaktreeAndQiaMember" id="btai_WarrantOaktreeAndQiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PremiumSharePricePercent" id="btai_PremiumSharePricePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RightToPurchaseStockLenders" id="btai_RightToPurchaseStockLenders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" id="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheMember" id="btai_TrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheBMember" id="btai_TrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheCMember" id="btai_TrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnkosxcelWarrantMember" id="btai_OnkosxcelWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdLiquidityEventAmountForExerciseOfWarrants" id="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfFairValueConsiderationToBePaid" id="btai_PercentageOfFairValueConsiderationToBePaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfValuationApplicableToInitialProfits" id="btai_PercentageOfValuationApplicableToInitialProfits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentInterestRateDiscountRatePercentage" id="btai_DebtInstrumentInterestRateDiscountRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfOutstandingLoan" id="btai_PercentageOfOutstandingLoan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfaAdministrativeAgentMember" id="btai_OfaAdministrativeAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetCashRequiredMinimum" id="btai_NetCashRequiredMinimum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SubsidiaryOwnershipPercentage" id="btai_SubsidiaryOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TimeBasedProfitSharingUnitsMember" id="btai_TimeBasedProfitSharingUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsOnkosxcelMember" id="btai_RestrictedStockUnitsOnkosxcelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheDMember" id="btai_TrancheDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditFacilityExitFeePercentage" id="btai_LineOfCreditFacilityExitFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityAmendmentFeePercentage" id="btai_LineOfCreditFacilityAmendmentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityInvestmentAllowed" id="btai_LineOfCreditFacilityInvestmentAllowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" id="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NewWarrantsMember" id="btai_NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheTwoMember" id="btai_TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockMaximumValueSharesToBeIssued" id="btai_SaleOfStockMaximumValueSharesToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VimalMehtaMember" id="btai_VimalMehtaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RichardSteinhartMember" id="btai_RichardSteinhartMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="JavierRodriguezMember" id="btai_JavierRodriguezMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MatthewWileyMember" id="btai_MatthewWileyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FrankYoccaMember" id="btai_FrankYoccaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" id="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FromAndAfterFundingOfTrancheBLoansMember" id="btai_FromAndAfterFundingOfTrancheBLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" id="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Warrants2024Member" id="btai_Warrants2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentIncrementalOnVariableRatePercent" id="btai_DebtInstrumentIncrementalOnVariableRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodOneMember" id="btai_PeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodTwoMember" id="btai_PeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodThreeMember" id="btai_PeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Warrants2024AccompanyingWarrantsMember" id="btai_Warrants2024AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RegisteredDirectOfferingMember" id="btai_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" id="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" id="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SingleReportableSegmentMember" id="btai_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentExpenseLaborAndRelatedExpense" id="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" id="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseProfessionalFees" id="btai_ResearchAndDevelopmentExpenseProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseClinicalTrialsExpense" id="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" id="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" id="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" id="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseProfessionalFees" id="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" id="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="November2024AccompanyingWarrantsMember" id="btai_November2024AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="btai_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="November2024PrefundedAccompanyingWarrantsMember" id="btai_November2024PrefundedAccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" id="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" id="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" id="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccompanyingWarrants2024StrikePriceNotAmendedMember" id="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccompanyingWarrantsMarch2025Member" id="btai_AccompanyingWarrantsMarch2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrefundedWarrantsMarch2025Member" id="btai_PrefundedWarrantsMarch2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OptionWarrantsMarch2025Member" id="btai_OptionWarrantsMarch2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BioxcelWarrantsAggregateMember" id="btai_BioxcelWarrantsAggregateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Warrants2023Member" id="btai_Warrants2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantShares2024Member" id="btai_WarrantShares2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" id="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ArmisticeCapitalMasterFundMember" id="btai_ArmisticeCapitalMasterFundMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HeightsCapitalManagementMember" id="btai_HeightsCapitalManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HudsonBayCapitalManagementMember" id="btai_HudsonBayCapitalManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IntraCoastalCapitalMember" id="btai_IntraCoastalCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OriginalWarrantsMember" id="btai_OriginalWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercialCostsLaborAndRelatedExpense" id="btai_CommercialCostsLaborAndRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsShareBasedPaymentArrangementExpense" id="btai_CommercialCostsShareBasedPaymentArrangementExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsProfessionalFees" id="btai_CommercialCostsProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsCommercialAndMarketing" id="btai_CommercialCostsCommercialAndMarketing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsTravelAndOtherExpenses" id="btai_CommercialCostsTravelAndOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentCostsOtherExpenses" id="btai_ResearchAndDevelopmentCostsOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CommercialCostsOtherExpenses" id="btai_CommercialCostsOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SellingGeneralAndAdministrativeCostsOtherExpenses" id="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="btai_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercise" id="btai_StockIssuedDuringPeriodSharesWarrantsExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RetentionBonusExpense" id="btai_RetentionBonusExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="March2024AccompanyingWarrantsMember" id="btai_March2024AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2024PreFundedWarrantsMember" id="btai_March2024PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2025AccompanyingWarrantsMember" id="btai_March2025AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2025PrefundedWarrantsMember" id="btai_March2025PrefundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="March2025OfferingMember" id="btai_March2025OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Warrants2025AccompanyingWarrantsMember" id="btai_Warrants2025AccompanyingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseObligationPriorYear" id="btai_PurchaseObligationPriorYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" id="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>btai-20250331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 12:17:33 PM-->
<!--Modified on: 5/12/2025 12:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureInventoryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesInterestDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureLeasesMaturitiesDetailsCalc2" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638826490494949577" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638826490494949577" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638826490494959593" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638826490494949577" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638826490494959593" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638826490494959593" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638826490494949577" xlink:to="us-gaap_ReceivablesNetCurrent_638826490494959593" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638826490494959593" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638826490494949577" xlink:to="us-gaap_InventoryNet_638826490494959593" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638826490494959593" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638826490494949577" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638826490494959593" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638826490494959593" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638826490494949577" xlink:to="us-gaap_OtherAssetsCurrent_638826490494959593" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638826490494959593" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638826490494959593" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638826490494969565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638826490494969565" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638826490494969565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638826490494969565" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638826490494969565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638826490494969565" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638826490494969565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638826490494969565" xlink:to="us-gaap_LiabilitiesCurrent_638826490494969565" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638826490494969565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638826490494969565" xlink:to="us-gaap_AccountsPayableCurrent_638826490494969565" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638826490494979562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638826490494969565" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638826490494979562" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638826490494979562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638826490494969565" xlink:to="us-gaap_LongTermDebtCurrent_638826490494979562" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638826490494979562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638826490494969565" xlink:to="us-gaap_OtherLiabilitiesCurrent_638826490494979562" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490494979562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638826490494969565" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490494979562" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638826490494979562" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638826490494969565" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638826490494979562" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638826490494989565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638826490494969565" xlink:to="us-gaap_LongTermDebtNoncurrent_638826490494989565" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638826490494989565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638826490494989565" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638826490494989565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638826490494989565" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638826490494989565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638826490494989565" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638826490494989565" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638826490494989565" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638826490494989565" xlink:to="us-gaap_PreferredStockValue_638826490494989565" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638826490494999576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638826490494989565" xlink:to="us-gaap_CommonStockValue_638826490494999576" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638826490494999576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638826490494989565" xlink:to="us-gaap_AdditionalPaidInCapital_638826490494999576" order="4" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638826490494999576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638826490494999576" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638826490494999576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_638826490494999576" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638826490495009575" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpenseNonoperating_638826490495009575" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638826490495009575" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638826490495009575" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638826490495009575" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638826490495009575" xlink:to="us-gaap_CostsAndExpenses_638826490495009575" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638826490495009575" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638826490495009575" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638826490495009575" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638826490495009575" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638826490495009575" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638826490495009575" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638826490495009575" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638826490495009575" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638826490495009575" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638826490495019563" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638826490495009575" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638826490495019563" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638826490495033075" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_ProfitLoss_638826490495033075" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638826490495033075" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638826490495033075" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638826490495043829" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_Depreciation_638826490495043829" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490495043829" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490495043829" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638826490495043829" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_PaidInKindInterest_638826490495043829" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638826490495049576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_ShareBasedCompensation_638826490495049576" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638826490495049576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638826490495049576" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638826490495049576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_IncreaseDecreaseInInventories_638826490495049576" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638826490495049576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638826490495049576" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638826490495049576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638826490495049576" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638826490495049576" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638826490495049576" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638826490495059573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638826490495059573" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_638826490495059573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490495033075" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_638826490495059573" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490495059573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490495059573" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638826490495059573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490495059573" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638826490495059573" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638826490495059573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490495059573" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638826490495059573" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638826490495069567" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490495059573" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638826490495069567" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638826490495069567" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490495059573" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638826490495069567" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638826490495069567" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryRawMaterials_638826490495069567" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638826490495069567" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryFinishedGoods_638826490495069567" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638826490495079572" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638826490495079572" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638826490495079572" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638826490495079572" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638826490495079572" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638826490495079572" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_638826490495079572" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_638826490495079572" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638826490495089573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638826490495089573" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638826490495089573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638826490495089573" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638826490495089573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_638826490495089573" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638826490495089573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638826490495089573" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638826490495089573" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtCurrent_638826490495089573" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638826490495099571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtNoncurrent_638826490495099571" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Debt and Credit Facilities - Interest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638826490495099571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseDebt_638826490495099571" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490495099571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490495099571" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Maturities (Details) - Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638826490495099571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638826490495099571" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490495109571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638826490495099571" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490495109571" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638826490495109571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638826490495099571" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638826490495109571" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638826490495109571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638826490495109571" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638826490495109571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638826490495109571" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638826490495109571" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638826490495109571" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>btai-20250331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 12:17:33 PM-->
<!--Modified on: 5/12/2025 12:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureTransactionsWithBioxcelLlcDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesWarrantsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDerivativeFinancialInstrumentsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureCommonStockFinancingActivitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationDescriptionDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsLevel3Details" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsInputsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsWarrantsOutstandingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureNetLossPerShareAntidilutiveDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:title="us-gaap_OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OtherLiabilitiesCurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To us-gaap_DerivativeLiabilitiesNoncurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_1" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_DerivativeLiabilitiesNoncurrent_1" order="3" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:label="AcceleratedShareRepurchasesDateAxis" xlink:title="AcceleratedShareRepurchasesDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:label="AcceleratedShareRepurchasesDateDomain" xlink:title="AcceleratedShareRepurchasesDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AcceleratedShareRepurchasesDateAxis" xlink:to="AcceleratedShareRepurchasesDateDomain" xlink:title="definition: AcceleratedShareRepurchasesDateAxis to AcceleratedShareRepurchasesDateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember" xlink:title="btai_VimalMehtaMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_VimalMehtaMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_VimalMehtaMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember" xlink:title="btai_RichardSteinhartMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_RichardSteinhartMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_RichardSteinhartMember" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember" xlink:title="btai_JavierRodriguezMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_JavierRodriguezMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_JavierRodriguezMember" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MatthewWileyMember" xlink:label="btai_MatthewWileyMember" xlink:title="btai_MatthewWileyMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_MatthewWileyMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_MatthewWileyMember" order="4" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember" xlink:title="btai_FrankYoccaMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_FrankYoccaMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_FrankYoccaMember" order="5" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="btai_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Transactions with BioXcel LLC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_BioxcelCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="btai_DevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="btai_SalesMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_OfaAdministrativeAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_OfaAdministrativeAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityExitFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PaidInKindInterestPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_TickingFeesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_NetCashRequiredMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_SubsidiaryOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfOutstandingLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Debt and Credit Facilities - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OriginalWarrantsMember" xlink:label="btai_OriginalWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OriginalWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantShares2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_RightToPurchaseStockLenders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PremiumSharePricePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Derivative Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_EquityInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2025AccompanyingWarrantsMember" xlink:label="btai_Warrants2025AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2025AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OptionWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Common Stock Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_JefferiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RegisteredDirectOfferingMember" xlink:label="btai_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_RegisteredOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025OfferingMember" xlink:label="btai_March2025OfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_March2025OfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2024AccompanyingWarrantsMember" xlink:label="btai_March2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_March2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2024PreFundedWarrantsMember" xlink:label="btai_March2024PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_March2024PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025AccompanyingWarrantsMember" xlink:label="btai_March2025AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_March2025AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025PrefundedWarrantsMember" xlink:label="btai_March2025PrefundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_March2025PrefundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OptionWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Stock-Based Compensation - Description (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_IncentiveAwardPlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_StockPlan2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Stock-Based Compensation - Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941205 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_EmployeeStockPurchasePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_BioxcelWarrantsAggregateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xlink:type="extended" xlink:title="99941402 - Disclosure - Fair Value Measurements - Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_AccompanyingWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OptionWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Fair Value Measurements - Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OptionWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_AccompanyingWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99941404 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantShares2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_AccompanyingWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ArmisticeCapitalMasterFundMember" xlink:label="btai_ArmisticeCapitalMasterFundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_ArmisticeCapitalMasterFundMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_HeightsCapitalManagementMember" xlink:label="btai_HeightsCapitalManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_HeightsCapitalManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_HudsonBayCapitalManagementMember" xlink:label="btai_HudsonBayCapitalManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_HudsonBayCapitalManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_IntraCoastalCapitalMember" xlink:label="btai_IntraCoastalCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_IntraCoastalCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Net Loss Per Share - Antidilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="btai_BioxcelWarrantsAggregateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PurchaseObligationPriorYear" xlink:label="btai_PurchaseObligationPriorYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="btai_PurchaseObligationPriorYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SingleReportableSegmentMember" xlink:label="btai_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="btai_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentCostsOtherExpenses" xlink:label="btai_ResearchAndDevelopmentCostsOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="btai_ResearchAndDevelopmentCostsOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCostsAbstract" xlink:label="us-gaap_DirectOperatingCostsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_DirectOperatingCostsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsLaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsCommercialAndMarketing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsTravelAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="btai_CommercialCostsOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="us-gaap_OtherCostAndExpenseOperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024AccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PrefundedWarrantsMarch2025Member" xlink:label="btai_PrefundedWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_PrefundedWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OptionWarrantsMarch2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RetentionBonusExpense" xlink:label="btai_RetentionBonusExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_RetentionBonusExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>btai-20250331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 12:17:33 PM-->
<!--Modified on: 5/12/2025 12:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrelated Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrelated Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current portion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 16)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 200,000 shares authorized as of March 31, 2025 and December 31, 2024; 5,468 and 3,102 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total selling, general and administrative costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (income) expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (income) expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss (numerator)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share attributable to common stockholders (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share attributable to common stockholders (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares (denominator) - basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares (denominator) - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repricing of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:to="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital, Pre Funded Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of pre-funded stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="btai_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of pre-funded stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of pre-funded stock purchase warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, net of employee tax obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, net of employee tax obligations (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of debt discount and amortization of financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payable-in-kind interest on Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses, other current assets and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable, accrued expenses, due to related parties, and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Interest Payable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of principal of Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of principal of Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs for common stock and warrants issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of employee tax obligations related to vesting restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow information:</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OrganizationAndPrincipalActivitiesAbstract" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OrganizationAndPrincipalActivitiesAbstract" xlink:to="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Credit Facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Credit Facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FinancingActivitiesAbstract" xlink:label="btai_FinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FinancingActivitiesAbstract" xlink:to="btai_FinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Financing Activities</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FinancingActivitiesDisclosureTextBlock" xlink:label="btai_FinancingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FinancingActivitiesDisclosureTextBlock" xlink:to="btai_FinancingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for Financing Activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of service charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities on debt</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:to="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of interest expense associated with long-term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI RSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI PSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance stock units</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TimeBasedProfitSharingUnitsMember" xlink:to="btai_TimeBasedProfitSharingUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to OnkosXcel time based profit-sharing units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time Based Profit Sharing Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel PSU</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RestrictedStockUnitsOnkosxcelMember" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Onkosxcel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to PSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees eliminated (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued restructuring costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computers and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccruedResearchAndDevelopmentExpenses" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BioxcelCorporationMember" xlink:to="btai_BioxcelCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents BioXcel LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement [Member]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DevelopmentMilestonesMember" xlink:to="btai_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones defined by the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SalesMilestonesMember" xlink:to="btai_SalesMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones are payable when annual sales reach certain levels.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fees per month to be paid to enter into collaborative service agreement option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Fees Per Month to Enter into Collaborative Service Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly agreement option fees</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential maximum payments that could be paid under the collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Milestone Payments Potential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CollaborativeArrangementMilestonePotentialPercent" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum percentage of net sales payable under a collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Milestone Potential Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone (as as percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_OfaAdministrativeAgentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents OFA as debt administrative agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OFA Administrative Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OFA</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CreditFacilityMember" xlink:to="btai_CreditFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to a Credit Agreement and Guaranty (the "Credit Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Increase, Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total long-term debt liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt premiums, discounts and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheMember" xlink:to="btai_TrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheTwoMember" xlink:to="btai_TrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A-2</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheBMember" xlink:to="btai_TrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheCMember" xlink:to="btai_TrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche C</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheDMember" xlink:to="btai_TrancheDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the statement scenario, from and after the funding of Tranche B loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and After Funding of Tranche B Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and after the funding of Tranche B loans</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the statement scenario, from and after satisfaction of the funding conditions for the Tranche C loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and After Satisfaction of Funding Conditions for Tranche C Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and after satisfaction of funding conditions for tranche C loans</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodOneMember" xlink:to="btai_PeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the first period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period one</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodTwoMember" xlink:to="btai_PeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the second period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period two</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodThreeMember" xlink:to="btai_PeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the third period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period three</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityInvestmentAllowed" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount the Lenders agree to permit the entity to invest in subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Investment Allowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum investment allowed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument fee</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Amendment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityExitFeePercentage" xlink:to="btai_LineOfCreditFacilityExitFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The line of credit facility exit fee, expressed as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Exit Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exit fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount borrowed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate, Discount Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental percentage points added to the reference rate and variable rate on the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Incremental on Variable Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PaidInKindInterestPercentage" xlink:to="btai_PaidInKindInterestPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-kind interest rate for funds borrowed, under the debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt paid-in-kind interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TickingFeesPercentage" xlink:to="btai_TickingFeesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents ticking fees percentage relating to debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ticking Fees Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ticking fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_NetCashRequiredMinimum" xlink:to="btai_NetCashRequiredMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Required, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash maintenance in controlled accounts</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum liquidity required per the financial covenant of debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Financial Covenant, Minimum Liquidity Requirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Liquidity Amount</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SubsidiaryOwnershipPercentage" xlink:to="btai_SubsidiaryOwnershipPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of ownership of common stock of subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Ownership, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary ownership (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfOutstandingLoan" xlink:to="btai_PercentageOfOutstandingLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Outstanding Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding loan (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Gross Proceeds From The Issuance of Common Stock, Warrants And (Or) Pre-funded Warrants For Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum revenue required from equity sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed rate</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:to="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the quarterly amortization payments as percentage of principal amount of funded loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Quarterly Amortization Payments as Percentage of Principal Amount Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payment of loans (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:to="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of budgeted amount allowed for disbursement in applicable period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Percentage Of Budgeted Amount For Disbursements in Applicable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of budgeted amount allowed for disbursement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_WarrantOaktreeAndQiaMember" xlink:to="btai_WarrantOaktreeAndQiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Oaktree (OFA) issued April 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Oaktree and Qia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Date Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_NewWarrantsMember" xlink:to="btai_NewWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OriginalWarrantsMember" xlink:label="btai_OriginalWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OriginalWarrantsMember" xlink:to="btai_OriginalWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OriginalWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the Original Warrants issued per the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OriginalWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OriginalWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2023Member" xlink:to="btai_Warrants2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued in 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_WarrantShares2024Member" xlink:to="btai_WarrantShares2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_WarrantShares2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrant shares issued in 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_WarrantShares2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Shares 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_WarrantShares2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Warrant Shares</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OnkosxcelWarrantMember" xlink:to="btai_OnkosxcelWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to OnkosXcel warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RightToPurchaseStockLenders" xlink:to="btai_RightToPurchaseStockLenders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity investment allowed for lenders in entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to Purchase Stock, Lenders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity investment allowed for lenders</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PremiumSharePricePercent" xlink:to="btai_PremiumSharePricePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents premium percentage for share price determined over a specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium Share Price, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium share price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of  liquidity event for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Liquidity Event Amount for Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of liquidity event for exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfFairValueConsiderationToBePaid" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fair value of consideration to be paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Fair Value Consideration to Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fair value of consideration to be paid</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfValuationApplicableToInitialProfits" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of valuation applicable to initial profits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Valuation Applicable to Initial Profits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of valuation applicable to initial profits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EquityInvestmentMember" xlink:to="btai_EquityInvestmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Equity Investment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Rights</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024AccompanyingWarrantsMember" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2024 Accompanying Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024, Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to 2024 accompanying warrants Strike price amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024 Accompanying Warrants Strike Price Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants, Strike Price Amended</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_November2024AccompanyingWarrantsMember" xlink:to="btai_November2024AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_November2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to November 2024 Accompanying warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_November2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_November2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2025AccompanyingWarrantsMember" xlink:label="btai_Warrants2025AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2025AccompanyingWarrantsMember" xlink:to="btai_Warrants2025AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2025AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2025 Accompanying Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2025AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2025, Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2025AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OptionWarrantsMarch2025Member" xlink:to="btai_OptionWarrantsMarch2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OptionWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to March 2025 Option Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OptionWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Warrants, March 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OptionWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Option Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) carrying value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on derivatives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_JefferiesMember" xlink:to="btai_JefferiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Jefferies LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RegisteredDirectOfferingMember" xlink:label="btai_RegisteredDirectOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RegisteredDirectOfferingMember" xlink:to="btai_RegisteredDirectOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to registered direct offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Direct Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered direct offering</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RegisteredOfferingMember" xlink:to="btai_RegisteredOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RegisteredOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the registered offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RegisteredOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RegisteredOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Agreement</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025OfferingMember" xlink:label="btai_March2025OfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_March2025OfferingMember" xlink:to="btai_March2025OfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_March2025OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the march 2025 offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_March2025OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_March2025OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Offering</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2024AccompanyingWarrantsMember" xlink:label="btai_March2024AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_March2024AccompanyingWarrantsMember" xlink:to="btai_March2024AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_March2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to march 2024 accompanying warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_March2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024, Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_March2024AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2024PreFundedWarrantsMember" xlink:label="btai_March2024PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_March2024PreFundedWarrantsMember" xlink:to="btai_March2024PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_March2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to march 2024 pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_March2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024, Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_March2024PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_November2024PrefundedAccompanyingWarrantsMember" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to November 2024 Pre-Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Prefunded Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024 Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025AccompanyingWarrantsMember" xlink:label="btai_March2025AccompanyingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_March2025AccompanyingWarrantsMember" xlink:to="btai_March2025AccompanyingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_March2025AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to march 2025 accompanying warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_March2025AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Accompanying Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_March2025AccompanyingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025PrefundedWarrantsMember" xlink:label="btai_March2025PrefundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_March2025PrefundedWarrantsMember" xlink:to="btai_March2025PrefundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_March2025PrefundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to march 2025 pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_March2025PrefundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Prefunded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_March2025PrefundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Prefunded Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate net offering price of shares permitted to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Maximum Value Shares to be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value shares to be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants, stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:to="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Offering Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_IncentiveAwardPlan2020Member" xlink:to="btai_IncentiveAwardPlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2020 Incentive Award Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Incentive Award Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Incentive Award Plan</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockPlan2017Member" xlink:to="btai_StockPlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the 2017 Stock Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Equity Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xlink:to="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to RSU vesting 100% at one year anniversary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Vesting 100 Percent at One Year Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU vesting 100% at one year anniversary</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xlink:to="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to RSU vesting 25% at one year and remaining in 12 quarters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units Vesting 25 Percent at One Year and Remaining in 12 Quarters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU vesting 25% at one year and remaining in 12 quarters</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in shares available for grant (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in shares available for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-options outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-options granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested aggregate (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted average price ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted average price beginning balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares under options that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end balance (in dollars per shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of options vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining unamortized expense period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EmployeeStockPurchasePlan2020Member" xlink:to="btai_EmployeeStockPurchasePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2020 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of shares issued or transferred under ESPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares issued or transferred under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price as a percent of fair market value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current portion of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to renew the lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of Fair Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BioxcelWarrantsAggregateMember" xlink:to="btai_BioxcelWarrantsAggregateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BioxcelWarrantsAggregateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to the aggregate of BioXcel equity Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BioxcelWarrantsAggregateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel Warrants, Aggregate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_BioxcelWarrantsAggregateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value money market accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccompanyingWarrantsMarch2025Member" xlink:to="btai_AccompanyingWarrantsMarch2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccompanyingWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to March 2025 Accompanying Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccompanyingWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accompanying Warrants, March 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccompanyingWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Accompanying Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 liabilities reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination of Derivative liabilities - Equity Investment Right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions of derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024Member" xlink:to="btai_Warrants2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued in 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to 2024 accompanying warrants strike price not amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accompanying Warrants 2024 Strike Price Not Amended [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Accompanying Warrants, Strike Price Not Amended</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (annual)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value warrant classified as equity</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ArmisticeCapitalMasterFundMember" xlink:label="btai_ArmisticeCapitalMasterFundMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ArmisticeCapitalMasterFundMember" xlink:to="btai_ArmisticeCapitalMasterFundMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ArmisticeCapitalMasterFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Armistice Capital Master Fund Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ArmisticeCapitalMasterFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armistice Capital Master Fund [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ArmisticeCapitalMasterFundMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armistice Capital Master Fund</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_HeightsCapitalManagementMember" xlink:label="btai_HeightsCapitalManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_HeightsCapitalManagementMember" xlink:to="btai_HeightsCapitalManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_HeightsCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Heights Capital Management.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_HeightsCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Capital Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_HeightsCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heights Capital Management</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_HudsonBayCapitalManagementMember" xlink:label="btai_HudsonBayCapitalManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_HudsonBayCapitalManagementMember" xlink:to="btai_HudsonBayCapitalManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_HudsonBayCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Hudson Bay Capital Management.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_HudsonBayCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hudson Bay Capital Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_HudsonBayCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hudson Bay Capital Management</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_IntraCoastalCapitalMember" xlink:label="btai_IntraCoastalCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_IntraCoastalCapitalMember" xlink:to="btai_IntraCoastalCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_IntraCoastalCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to IntraCoastal Capital, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_IntraCoastalCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intra Coastal Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_IntraCoastalCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IntraCoastal Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement expected cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase agreement expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase obligation originally due in 2024</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PurchaseObligationPriorYear" xlink:label="btai_PurchaseObligationPriorYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PurchaseObligationPriorYear" xlink:to="btai_PurchaseObligationPriorYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PurchaseObligationPriorYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of purchase arrangement pertaining to prior year but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PurchaseObligationPriorYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation, Prior Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PurchaseObligationPriorYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase obligation, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 Purchase obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 purchase obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SingleReportableSegmentMember" xlink:label="btai_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SingleReportableSegmentMember" xlink:to="btai_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to single reportable segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Items [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Items [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Segments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs:</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to salary, wage, profit sharing incentive and other employee benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Labor And Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel and related costs</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to expense for award under share-based payment arrangement. Excludes amount capitalized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to a fee charged for services from professionals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to clinical trial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Clinical Trials Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trials expense</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense during the period related to chemical, manufacturing and control costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Chemical, manufacturing and controls Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chemical, manufacturing and controls cost</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentCostsOtherExpenses" xlink:label="btai_ResearchAndDevelopmentCostsOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ResearchAndDevelopmentCostsOtherExpenses" xlink:to="btai_ResearchAndDevelopmentCostsOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ResearchAndDevelopmentCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expenses related to research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ResearchAndDevelopmentCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs, Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ResearchAndDevelopmentCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCostsAbstract" xlink:label="us-gaap_DirectOperatingCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCostsAbstract" xlink:to="us-gaap_DirectOperatingCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectOperatingCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct Operating Costs [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectOperatingCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial costs:</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsLaborAndRelatedExpense" xlink:to="btai_CommercialCostsLaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs for salary, wage, profit sharing; incentive and other employee benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel and related costs</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs for award under share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsProfessionalFees" xlink:to="btai_CommercialCostsProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs related to a fee charged for services from professionals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsCommercialAndMarketing" xlink:to="btai_CommercialCostsCommercialAndMarketing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsCommercialAndMarketing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The commercial costs recognized in the period for promotion, public relations, and brand or product advertising.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsCommercialAndMarketing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Commercial and Marketing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsCommercialAndMarketing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial and marketing</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsTravelAndOtherExpenses" xlink:to="btai_CommercialCostsTravelAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commercial costs related to travel expenses during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Travel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel related expenses</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CommercialCostsOtherExpenses" xlink:to="btai_CommercialCostsOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CommercialCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expenses related to commercial costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CommercialCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Costs, Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CommercialCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Cost and Expense, Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total commercial costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative costs:</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense for salary, wage, profit sharing; incentive and other employee benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel and related costs</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense for award under share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense related to a fee charged for services from professionals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of selling, general and administrative expense related to travel expenses during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense, Travel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel related expenses</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expenses related to selling, general and administrative costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Costs, Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PrefundedWarrantsMarch2025Member" xlink:label="btai_PrefundedWarrantsMarch2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PrefundedWarrantsMarch2025Member" xlink:to="btai_PrefundedWarrantsMarch2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PrefundedWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertains to March 2025 Pre-Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PrefundedWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prefunded Warrants, March 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PrefundedWarrantsMarch2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2025 Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RetentionBonusExpense" xlink:label="btai_RetentionBonusExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RetentionBonusExpense" xlink:to="btai_RetentionBonusExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RetentionBonusExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of retention bonus during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RetentionBonusExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retention Bonus Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RetentionBonusExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retention bonus</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>btai-20250331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 12:17:33 PM-->
<!--Modified on: 5/12/2025 12:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureNatureOfBusiness" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureBasisOfPresentation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureRestructuring" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureInventory" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureAccruedExpenses" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureTransactionsWithBioxcelLlc" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilities" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDerivativeFinancialInstruments" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureCommonStockFinancingActivities" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureLeases" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureNetLossPerShare" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSegmentInformation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSubsequentEvents" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureInventoryTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureTransactionsWithBioxcelLlcTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureLeasesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSegmentInformationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureRestructuringDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureInventoryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureTransactionsWithBioxcelLlcDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesWarrantsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDebtAndCreditFacilitiesInterestDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureDerivativeFinancialInstrumentsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureCommonStockFinancingActivitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationDescriptionDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsLevel3Details" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsInputsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureFairValueMeasurementsWarrantsOutstandingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureNetLossPerShareAntidilutiveDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20250331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638826490496439653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638826490496439653" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638826490496449741" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638826490496449741" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638826490496449741" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638826490496449741" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638826490496449741" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638826490496449741" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638826490496449741" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638826490496449741" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638826490496449741" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638826490496449741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638826490496449741" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638826490496459643" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638826490496459643" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638826490496459643" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638826490496459643" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638826490496459643" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638826490496459643" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638826490496459643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638826490496459643" order="18" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638826490496469641" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638826490496469641" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638826490496469641" order="21" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638826490496469641" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638826490496469641" order="23" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638826490496469641" order="24" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638826490496469641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638826490496469641" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638826490496479641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638826490496479641" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638826490496479641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638826490496479641" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638826490496479641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638826490496479641" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638826490496479641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638826490496479641" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638826490496489646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638826490496489646" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638826490496489646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638826490496489646" xlink:to="us-gaap_RelatedPartyDomain_638826490496489646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638826490496489646" xlink:to="us-gaap_RelatedPartyMember_638826490496489646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638826490496489646" xlink:to="us-gaap_NonrelatedPartyMember_638826490496489646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638826490496489646" xlink:to="us-gaap_StatementLineItems_638826490496489646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496489646" xlink:to="us-gaap_AssetsAbstract_638826490496489646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638826490496489646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638826490496489646" xlink:to="us-gaap_AssetsCurrentAbstract_638826490496489646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638826490496489646" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638826490496499653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638826490496489646" xlink:to="us-gaap_ReceivablesNetCurrent_638826490496499653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638826490496489646" xlink:to="us-gaap_InventoryNet_638826490496499653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638826490496489646" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638826490496499653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638826490496489646" xlink:to="us-gaap_OtherAssetsCurrent_638826490496499653" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638826490496489646" xlink:to="us-gaap_AssetsCurrent_638826490496499653" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638826490496489646" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638826490496499653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638826490496499653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638826490496489646" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638826490496499653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638826490496489646" xlink:to="us-gaap_OtherAssetsNoncurrent_638826490496509644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638826490496489646" xlink:to="us-gaap_Assets_638826490496509644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496489646" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" xlink:to="us-gaap_AccountsPayableCurrent_638826490496509644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638826490496509644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638826490496509644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" xlink:to="us-gaap_LongTermDebtCurrent_638826490496509644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638826490496519645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" xlink:to="us-gaap_OtherLiabilitiesCurrent_638826490496519645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638826490496519645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638826490496509644" xlink:to="us-gaap_LiabilitiesCurrent_638826490496519645" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490496519645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490496519645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638826490496519645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638826490496519645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638826490496519645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_LongTermDebtNoncurrent_638826490496519645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638826490496519645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_Liabilities_638826490496519645" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638826490496529644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_CommitmentsAndContingencies_638826490496529644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638826490496529644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638826490496509644" xlink:to="us-gaap_StockholdersEquityAbstract_638826490496529644" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638826490496529644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638826490496529644" xlink:to="us-gaap_PreferredStockValue_638826490496529644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638826490496529644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638826490496529644" xlink:to="us-gaap_CommonStockValue_638826490496529644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638826490496529644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638826490496529644" xlink:to="us-gaap_AdditionalPaidInCapital_638826490496529644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638826490496529644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638826490496529644" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638826490496529644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638826490496539646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638826490496529644" xlink:to="us-gaap_StockholdersEquity_638826490496539646" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638826490496539646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638826490496529644" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638826490496539646" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638826490496539646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638826490496539646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638826490496549654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638826490496549654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638826490496549654" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638826490496549654" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638826490496549654" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638826490496549654" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638826490496549654" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638826490496549654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_638826490496549654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638826490496559651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_CostsAndExpensesAbstract_638826490496559651" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638826490496559651" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638826490496559651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638826490496559651" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638826490496559651" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638826490496559651" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638826490496559651" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638826490496559651" xlink:to="us-gaap_CostsAndExpenses_638826490496559651" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_OperatingIncomeLoss_638826490496559651" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638826490496559651" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638826490496559651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638826490496559651" xlink:to="us-gaap_InterestExpenseNonoperating_638826490496559651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638826490496559651" xlink:to="us-gaap_InvestmentIncomeInterest_638826490496569647" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638826490496559651" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638826490496569647" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_NetIncomeLoss_638826490496569647" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_EarningsPerShareBasic_638826490496569647" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_EarningsPerShareDiluted_638826490496569647" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638826490496569647" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638826490496569647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638826490496549654" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638826490496569647" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638826490496579648" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638826490496579648" xlink:to="us-gaap_StatementEquityComponentsAxis_638826490496579648" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638826490496579648" xlink:to="us-gaap_CommonStockMember_638826490496579648" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638826490496579648" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638826490496579648" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638826490496579648" xlink:to="us-gaap_RetainedEarningsMember_638826490496579648" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638826490496579648" xlink:to="us-gaap_EquityComponentDomain_638826490496579648" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638826490496579648" xlink:to="us-gaap_StatementLineItems_638826490496579648" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638826490496579648" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_StockholdersEquity_638826490496579648" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_CommonStockSharesOutstanding_638826490496589653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638826490496589653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638826490496589653" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638826490496589653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638826490496589653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638826490496589653" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638826490496589653" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638826490496589653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638826490496589653" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638826490496589653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638826490496589653" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued" xlink:label="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued_638826490496599650" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodValueWarrantsExercised_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="btai_StockIssuedDuringPeriodValueWarrantsExercised_638826490496599650" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_StockIssuedDuringPeriodValueWarrantsExercised_638826490496599650" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercise_638826490496599650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638826490496599650" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638826490496599650" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638826490496599650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_NetIncomeLoss_638826490496599650" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638826490496599650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_StockholdersEquity_638826490496599650" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638826490496579648" xlink:to="us-gaap_CommonStockSharesOutstanding_638826490496609650" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_ProfitLoss_638826490496609650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_Depreciation_638826490496609650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490496609650" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638826490496609650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638826490496609650" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_ShareBasedCompensation_638826490496619657" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_PaidInKindInterest_638826490496619657" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638826490496619657" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638826490496619657" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" xlink:to="us-gaap_IncreaseDecreaseInInventories_638826490496619657" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638826490496619657" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638826490496619657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638826490496619657" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_638826490496629649" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638826490496619657" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638826490496629649" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638826490496609650" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490496629649" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638826490496629649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638826490496629649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638826490496629649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638826490496629649" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638826490496639650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638826490496639650" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490496639650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638826490496629649" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638826490496639650" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638826490496639650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638826490496639650" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638826490496639650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638826490496639650" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388264904966396501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388264904966396501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638826490496639650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638826490496639650" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638826490496639650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638826490496639650" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638826490496639650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OrganizationAndPrincipalActivitiesAbstract" xlink:label="OrganizationAndPrincipalActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638826490496649651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationAndPrincipalActivitiesAbstract" xlink:to="us-gaap_NatureOfOperations_638826490496649651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="995210201 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638826490496649651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638826490496649651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638826490496659659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638826490496659659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" xlink:type="extended" xlink:title="995210401 - Disclosure - Restructuring" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638826490496659659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638826490496659659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventory" xlink:type="extended" xlink:title="995210501 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638826490496659659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638826490496659659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="995210601 - Disclosure - Property and Equipment, Net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638826490496669658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638826490496669658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210701 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638826490496669658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638826490496669658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" xlink:type="extended" xlink:title="995210801 - Disclosure - Transactions with BioXcel LLC" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638826490496669658" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638826490496669658" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" xlink:type="extended" xlink:title="995210901 - Disclosure - Debt and Credit Facilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638826490496679657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638826490496679657" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" xlink:type="extended" xlink:title="995211001 - Disclosure - Derivative Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638826490496679657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638826490496679657" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" xlink:type="extended" xlink:title="995211101 - Disclosure - Common Stock Financing Activities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FinancingActivitiesAbstract" xlink:label="FinancingActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FinancingActivitiesDisclosureTextBlock" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_638826490496679657" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="btai_FinancingActivitiesDisclosureTextBlock_638826490496679657" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995211201 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638826490496689656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638826490496689656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995211301 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638826490496689656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638826490496689656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995211401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638826490496689656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638826490496689656" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995211501 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638826490496699659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638826490496699659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211601 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638826490496699659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638826490496699659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995211701 - Disclosure - Segment Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638826490496709659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638826490496709659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211801 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638826490496709659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638826490496709659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638826490496709659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638826490496709659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638826490496709659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638826490496709659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638826490496719662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638826490496719662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Property and Equipment, Net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638826490496719662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638826490496719662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638826490496729664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638826490496729664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Transactions with BioXcel LLC (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638826490496729664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638826490496729664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Debt and Credit Facilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638826490496729664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638826490496729664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638826490496729664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638826490496729664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_638826490496739660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490496739660" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490496739660" xlink:to="us-gaap_AwardTypeAxis_638826490496739660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638826490496739660" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638826490496739660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" xlink:to="us-gaap_PerformanceSharesMember_638826490496739660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638826490496739660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_638826490496739660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_638826490496739660" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490496739660" xlink:to="us-gaap_EmployeeStockOptionMember_638826490496749661" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490496739660" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638826490496749661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_638826490496749661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638826490496749661" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638826490496749661" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638826490496749661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490496749661" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638826490496749661" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99931303 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638826490496759659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638826490496759659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99931403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638826490496759659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638826490496759659" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_638826490496759659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_638826490496759659" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638826490496759659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638826490496759659" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99931503 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638826490496769664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638826490496769664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638826490496769664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638826490496769664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99931703 - Disclosure - Segment Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638826490496769664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638826490496769664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638826490496779663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638826490496779663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss_638826490496779663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638826490496779663" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Restructuring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638826490496779663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_PaymentsForRestructuring_638826490496779663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638826490496779663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_RestructuringReserveCurrent_638826490496779663" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638826490496789664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryRawMaterials_638826490496789664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638826490496789664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryFinishedGoods_638826490496789664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638826490496789664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryNet_638826490496789664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638826490496789664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryWriteDown_638826490496789664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638826490496789664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638826490496789664" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638826490496789664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638826490496789664" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638826490496789664" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638826490496789664" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638826490496799664" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638826490496799664" xlink:to="us-gaap_ComputerEquipmentMember_638826490496799664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638826490496799664" xlink:to="us-gaap_FurnitureAndFixturesMember_638826490496799664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638826490496799664" xlink:to="us-gaap_LeaseholdImprovementsMember_638826490496799664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638826490496789664" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638826490496799664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638826490496799664" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638826490496799664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638826490496799664" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638826490496799664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638826490496799664" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638826490496799664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638826490496799664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638826490496799664" xlink:to="us-gaap_Depreciation_638826490496799664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_638826490496809662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638826490496809662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638826490496809662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_TaxesPayableCurrent_638826490496809662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638826490496809662" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_RestructuringReserveCurrent_638826490496809662" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638826490496809662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638826490496809662" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Transactions with BioXcel LLC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638826490496819666" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638826490496819666" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638826490496819666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638826490496819666" xlink:to="us-gaap_RelatedPartyDomain_638826490496819666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638826490496819666" xlink:to="us-gaap_RelatedPartyMember_638826490496819666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638826490496819666" xlink:to="srt_CounterpartyNameAxis_638826490496819666" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638826490496819666" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638826490496819666" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638826490496819666" xlink:to="btai_BioxcelCorporationMember_638826490496819666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638826490496819666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638826490496819666" xlink:to="us-gaap_TypeOfArrangementAxis_638826490496819666" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638826490496819666" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638826490496829665" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638826490496829665" xlink:to="us-gaap_CollaborativeArrangementMember_638826490496829665" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638826490496829665" xlink:to="btai_DevelopmentMilestonesMember_638826490496829665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638826490496829665" xlink:to="btai_SalesMilestonesMember_638826490496829665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638826490496819666" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_638826490496829665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential_638826490496829665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent_638826490496829665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638826490496829665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638826490496829665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638826490496839664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638826490496839664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638826490496839664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="us-gaap_CostsAndExpenses_638826490496839664" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638826490496839664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638826490496829665" xlink:to="us-gaap_OtherLiabilitiesCurrent_638826490496839664" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638826490496839664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_DebtInstrumentTable_638826490496839664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638826490496839664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638826490496839664" xlink:to="us-gaap_DebtInstrumentAxis_638826490496839664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638826490496839664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638826490496839664" xlink:to="us-gaap_DebtInstrumentNameDomain_638826490496839664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638826490496839664" xlink:to="btai_OfaAdministrativeAgentMember_638826490496849668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638826490496849668" xlink:to="btai_CreditFacilityMember_638826490496849668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638826490496839664" xlink:to="us-gaap_DebtInstrumentLineItems_638826490496849668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638826490496849668" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_638826490496849668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638826490496849668" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638826490496849668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638826490496849668" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638826490496849668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638826490496849668" xlink:to="us-gaap_LongTermDebt_638826490496849668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638826490496849668" xlink:to="us-gaap_LongTermDebtCurrent_638826490496849668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638826490496849668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638826490496849668" xlink:to="us-gaap_LongTermDebtNoncurrent_638826490496849668" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_7" xlink:to="us-gaap_LineOfCreditFacilityTable_638826490496859663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496859663" xlink:to="us-gaap_DebtInstrumentAxis_638826490496859663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638826490496859663" xlink:to="us-gaap_DebtInstrumentNameDomain_638826490496859663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638826490496859663" xlink:to="btai_OfaAdministrativeAgentMember_638826490496859663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638826490496859663" xlink:to="btai_CreditFacilityMember_638826490496859663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496859663" xlink:to="srt_StatementScenarioAxis_638826490496859663" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638826490496859663" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638826490496859663" xlink:to="srt_ScenarioUnspecifiedDomain_638826490496859663" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember_638826490496869672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_TrancheMember_638826490496869672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember_638826490496869672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_TrancheTwoMember_638826490496869672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember_638826490496929677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_TrancheBMember_638826490496929677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember_638826490496929677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_TrancheCMember_638826490496929677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember_638826490496929677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_TrancheDMember_638826490496929677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_638826490496929677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember_638826490496929677" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_638826490496929677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_638826490496929677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_PeriodOneMember_638826490496939687" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_PeriodTwoMember_638826490496939687" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638826490496859663" xlink:to="btai_PeriodThreeMember_638826490496939687" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496859663" xlink:to="srt_RangeAxis_638826490496939687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638826490496939687" xlink:to="srt_RangeMember_638826490496939687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490496939687" xlink:to="srt_MinimumMember_638826490496939687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638826490496939687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490496939687" xlink:to="srt_MaximumMember_638826490496939687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496859663" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638826490496949673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638826490496949673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_638826490496949673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed_638826490496949673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638826490496949673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_DebtInstrumentFeeAmount_638826490496949673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_638826490496949673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage_638826490496949673" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_638826490496949673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_LineOfCreditFacilityExitFeePercentage_638826490496949673" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638826490496959671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_DebtInstrumentFaceAmount_638826490496959671" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638826490496959671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638826490496959671" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638826490496959671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638826490496959671" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638826490496959671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638826490496959671" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_638826490496959671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage_638826490496959671" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638826490496959671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638826490496959671" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638826490496969673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638826490496959671" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_638826490496969673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_638826490496969673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent_638826490496969673" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage_638826490496969673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_PaidInKindInterestPercentage_638826490496969673" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage_638826490496969673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_TickingFeesPercentage_638826490496969673" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum_638826490496969673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_NetCashRequiredMinimum_638826490496969673" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638826490496979671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638826490496979671" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage_638826490496979671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_SubsidiaryOwnershipPercentage_638826490496979671" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan_638826490496979671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_PercentageOfOutstandingLoan_638826490496979671" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638826490496979671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_LongTermDebtCurrent_638826490496979671" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_638826490496979671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_638826490496979671" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638826490496989671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638826490496989671" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638826490496989671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638826490496989671" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638826490496989671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638826490496989671" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded" xlink:label="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_638826490496989671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded_638826490496989671" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod" xlink:label="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_638826490496989671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490496949673" xlink:to="btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod_638826490496989671" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Debt and Credit Facilities - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638826490496999672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_6" xlink:to="us-gaap_LineOfCreditFacilityTable_638826490496999672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490496999672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496999672" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490496999672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490496999672" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638826490496999672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" xlink:to="btai_WarrantOaktreeAndQiaMember_638826490496999672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" xlink:to="btai_NewWarrantsMember_638826490497009683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OriginalWarrantsMember" xlink:label="btai_OriginalWarrantsMember_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" xlink:to="btai_OriginalWarrantsMember_638826490497009683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" xlink:to="btai_Warrants2023Member_638826490497009683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" xlink:to="btai_WarrantShares2024Member_638826490497009683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490496999672" xlink:to="btai_OnkosxcelWarrantMember_638826490497009683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496999672" xlink:to="srt_RangeAxis_638826490497009683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638826490497009683" xlink:to="srt_RangeMember_638826490497009683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490497009683" xlink:to="srt_MaximumMember_638826490497009683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638826490496999672" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497019676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497019676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="btai_RightToPurchaseStockLenders_638826490497019676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="btai_PremiumSharePricePercent_638826490497019676" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_638826490497019676" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid_638826490497019676" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits_638826490497019676" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638826490497019676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638826490497009683" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638826490497019676" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Debt and Credit Facilities - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638826490497029674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638826490497029674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638826490497029674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638826490497029674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Debt and Credit Facilities - Interest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpenseDebt_638826490497039685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638826490497039685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpenseNonoperating_638826490497039685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Derivative Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638826490497039685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638826490497039685" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497039685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497039685" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" xlink:to="btai_EquityInvestmentMember_638826490497039685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_638826490497039685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_638826490497039685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_Warrants2024AccompanyingWarrantsMember_638826490497039685" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638826490497049681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" xlink:to="btai_November2024AccompanyingWarrantsMember_638826490497049681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2025AccompanyingWarrantsMember" xlink:label="btai_Warrants2025AccompanyingWarrantsMember_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" xlink:to="btai_Warrants2025AccompanyingWarrantsMember_638826490497049681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497039685" xlink:to="btai_OptionWarrantsMarch2025Member_638826490497049681" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638826490497039685" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638826490497049681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638826490497049681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497049681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497049681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497049681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638826490497059679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638826490497059679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638826490497059679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497049681" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638826490497059679" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Common Stock Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_FinancingActivitiesAbstract" xlink:label="FinancingActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638826490497059679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638826490497059679" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638826490497059679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638826490497059679" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638826490497059679" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638826490497059679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638826490497059679" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638826490497059679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember_638826490497059679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638826490497059679" xlink:to="btai_JefferiesMember_638826490497059679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RegisteredDirectOfferingMember" xlink:label="btai_RegisteredDirectOfferingMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638826490497059679" xlink:to="btai_RegisteredDirectOfferingMember_638826490497069683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RegisteredOfferingMember" xlink:label="btai_RegisteredOfferingMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638826490497059679" xlink:to="btai_RegisteredOfferingMember_638826490497069683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025OfferingMember" xlink:label="btai_March2025OfferingMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638826490497059679" xlink:to="btai_March2025OfferingMember_638826490497069683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638826490497059679" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497069683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497069683" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2024AccompanyingWarrantsMember" xlink:label="btai_March2024AccompanyingWarrantsMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_March2024AccompanyingWarrantsMember_638826490497069683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2024PreFundedWarrantsMember" xlink:label="btai_March2024PreFundedWarrantsMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_March2024PreFundedWarrantsMember_638826490497069683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_November2024AccompanyingWarrantsMember_638826490497069683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_638826490497069683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember_638826490497069683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025AccompanyingWarrantsMember" xlink:label="btai_March2025AccompanyingWarrantsMember_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_March2025AccompanyingWarrantsMember_638826490497079679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_March2025PrefundedWarrantsMember" xlink:label="btai_March2025PrefundedWarrantsMember_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_March2025PrefundedWarrantsMember_638826490497079679" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497069683" xlink:to="btai_OptionWarrantsMarch2025Member_638826490497079679" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638826490497059679" xlink:to="srt_RangeAxis_638826490497079679" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638826490497079679" xlink:to="srt_RangeMember_638826490497079679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490497079679" xlink:to="srt_MaximumMember_638826490497079679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638826490497059679" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_638826490497089684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638826490497089684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638826490497089684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638826490497089684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638826490497089684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497089684" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638826490497089684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_SharesIssuedPricePerShare_638826490497089684" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497099679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497099679" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638826490497099679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638826490497099679" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638826490497099679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638826490497099679" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638826490497099679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638826490497099679" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_638826490497099679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_638826490497099679" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497109680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497109680" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638826490497109680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638826490497079679" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638826490497109680" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Stock-Based Compensation - Description (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497109680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497109680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638826490497109680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497109680" xlink:to="us-gaap_PlanNameAxis_638826490497109680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638826490497109680" xlink:to="us-gaap_PlanNameDomain_638826490497119687" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638826490497119687" xlink:to="btai_IncentiveAwardPlan2020Member_638826490497119687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638826490497119687" xlink:to="btai_StockPlan2017Member_638826490497119687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497109680" xlink:to="us-gaap_VestingAxis_638826490497119687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638826490497119687" xlink:to="us-gaap_VestingDomain_638826490497119687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638826490497119687" xlink:to="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_638826490497119687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638826490497119687" xlink:to="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_638826490497119687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497109680" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638826490497119687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638826490497119687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638826490497129683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638826490497129683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638826490497129683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638826490497129683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638826490497129683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638826490497129683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638826490497129683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638826490497129683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638826490497129683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638826490497129683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638826490497129683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497119687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638826490497129683" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497139686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497139686" xlink:to="us-gaap_AwardTypeAxis_638826490497139686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638826490497139686" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497139686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497139686" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638826490497139686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497139686" xlink:to="us-gaap_PerformanceSharesMember_638826490497139686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497139686" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638826490497139686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497139686" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_638826490497139686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638826490497139686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497139686" xlink:to="us-gaap_VestingAxis_638826490497139686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638826490497139686" xlink:to="us-gaap_VestingDomain_638826490497149685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember" xlink:label="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638826490497149685" xlink:to="btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_638826490497149685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember" xlink:label="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638826490497149685" xlink:to="btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_638826490497149685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497139686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638826490497149685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638826490497149685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638826490497149685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638826490497149685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638826490497159682" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638826490497159682" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638826490497159682" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638826490497159682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638826490497159682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_638826490497159682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_638826490497159682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638826490497169686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638826490497169686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638826490497169686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638826490497159682" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638826490497169686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638826490497169686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638826490497169686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638826490497169686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638826490497169686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638826490497169686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497149685" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638826490497169686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Stock-Based Compensation - Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497179684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497179684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638826490497179684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497179684" xlink:to="us-gaap_AwardTypeAxis_638826490497179684" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497179684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497179684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638826490497179684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497179684" xlink:to="us-gaap_EmployeeStockOptionMember_638826490497179684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497179684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497179684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638826490497189690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638826490497189690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638826490497189690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_638826490497189690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638826490497189690" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388264904971896901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6388264904971896901" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638826490497189690" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638826490497199685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638826490497199685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638826490497199685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638826490497199685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638826490497199685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638826490497199685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_638826490497199685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_638826490497199685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6388264904971996851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6388264904971996851" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638826490497199685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638826490497189690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638826490497199685" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497179684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638826490497209684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638826490497209684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638826490497209684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638826490497209684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638826490497209684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638826490497209684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638826490497209684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638826490497209684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638826490497209684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638826490497209684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638826490497209684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638826490497209684" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638826490497219685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638826490497219685" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638826490497219685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638826490497199685" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638826490497219685" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497219685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497219685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638826490497219685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497219685" xlink:to="us-gaap_AwardTypeAxis_638826490497219685" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638826490497219685" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497229691" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497229691" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638826490497229691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497229691" xlink:to="us-gaap_EmployeeStockOptionMember_638826490497229691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497219685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497229691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497229691" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638826490497229691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497229691" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638826490497229691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497229691" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638826490497229691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638826490497229691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497229691" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638826490497229691" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941205 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497239690" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497239690" xlink:to="us-gaap_IncomeStatementLocationAxis_638826490497239690" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638826490497239690" xlink:to="us-gaap_IncomeStatementLocationDomain_638826490497239690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638826490497239690" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638826490497239690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638826490497239690" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638826490497239690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638826490497239690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497239690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638826490497239690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638826490497239690" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638826490497239690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638826490497249691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638826490497249691" xlink:to="us-gaap_PlanNameAxis_638826490497249691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638826490497249691" xlink:to="us-gaap_PlanNameDomain_638826490497249691" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638826490497249691" xlink:to="btai_EmployeeStockPurchasePlan2020Member_638826490497249691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638826490497249691" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638826490497249691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638826490497249691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638826490497249691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_638826490497259692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_638826490497259692" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638826490497259692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638826490497259692" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638826490497259692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638826490497259692" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638826490497259692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638826490497259692" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638826490497259692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638826490497249691" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638826490497259692" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638826490497269694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638826490497269694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638826490497269694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638826490497269694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_OperatingLeaseLiability_638826490497269694" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638826490497269694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638826490497269694" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638826490497269694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490497269694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638826490497259692" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638826490497269694" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - Leases - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638826490497279690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense_638826490497279690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638826490497279690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638826490497279690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638826490497279690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638826490497279690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638826490497289698" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638826490497289698" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638826490497289698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638826490497289698" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638826490497289698" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638826490497289698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638826490497289698" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638826490497289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638826490497289698" xlink:to="us-gaap_FairValueInputsLevel1Member_638826490497289698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638826490497289698" xlink:to="us-gaap_FairValueInputsLevel2Member_638826490497299691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638826490497289698" xlink:to="us-gaap_FairValueInputsLevel3Member_638826490497299691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497299691" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497299691" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497299691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497299691" xlink:to="btai_BioxcelWarrantsAggregateMember_638826490497299691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497299691" xlink:to="btai_OnkosxcelWarrantMember_638826490497299691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638826490497279690" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638826490497299691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638826490497299691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638826490497299691" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638826490497299691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638826490497309693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638826490497299691" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638826490497309693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xlink:type="extended" xlink:title="99941402 - Disclosure - Fair Value Measurements - Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638826490497309693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638826490497309693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497309693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638826490497309693" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497309693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497309693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497309693" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497309693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member_638826490497309693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497309693" xlink:to="btai_AccompanyingWarrantsMarch2025Member_638826490497309693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497309693" xlink:to="btai_OptionWarrantsMarch2025Member_638826490497319698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638826490497309693" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638826490497319698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638826490497319698" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638826490497319698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638826490497319698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638826490497319698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638826490497319698" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638826490497319698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_638826490497319698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_638826490497319698" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638826490497329695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638826490497319698" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638826490497329695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Fair Value Measurements - Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497329695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497329695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497329695" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638826490497329695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_OnkosxcelWarrantMember_638826490497329695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member_638826490497329695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_OptionWarrantsMarch2025Member_638826490497329695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_AccompanyingWarrantsMarch2025Member_638826490497339699" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_WarrantOaktreeAndQiaMember_638826490497339699" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_Warrants2023Member_638826490497339699" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_Warrants2024Member_638826490497339699" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsMember" xlink:label="btai_Warrants2024AccompanyingWarrantsMember_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_Warrants2024AccompanyingWarrantsMember_638826490497339699" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_Warrants2024AccompanyingWarrantsMember_638826490497339699" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638826490497339699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_Warrants2024AccompanyingWarrantsMember_638826490497339699" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638826490497339699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497329695" xlink:to="btai_November2024AccompanyingWarrantsMember_638826490497339699" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638826490497339699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" xlink:to="us-gaap_MeasurementInputTypeAxis_638826490497339699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638826490497339699" xlink:to="us-gaap_MeasurementInputTypeDomain_638826490497349695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638826490497349695" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638826490497349695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638826490497349695" xlink:to="us-gaap_MeasurementInputSharePriceMember_638826490497349695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638826490497349695" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638826490497349695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638826490497349695" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638826490497349695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638826490497349695" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638826490497349695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638826490497349695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" xlink:to="srt_RangeAxis_638826490497349695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638826490497349695" xlink:to="srt_RangeMember_638826490497359694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490497359694" xlink:to="srt_MaximumMember_638826490497359694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" xlink:to="us-gaap_DebtInstrumentAxis_638826490497359694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638826490497359694" xlink:to="us-gaap_DebtInstrumentNameDomain_638826490497359694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638826490497359694" xlink:to="btai_CreditFacilityMember_638826490497359694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638826490497329695" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638826490497359694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638826490497359694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638826490497369698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_638826490497369698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_638826490497369698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_DebtInstrumentFairValue_638826490497369698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638826490497369698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638826490497369698" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497369698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497369698" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638826490497369698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638826490497369698" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638826490497379695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_638826490497379695" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497379695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497379695" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638826490497379695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638826490497379695" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638826490497379695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638826490497379695" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497379695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638826490497359694" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497379695" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99941404 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638826490497389698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638826490497389698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497389698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638826490497389698" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497389698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497389698" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638826490497389698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_WarrantOaktreeAndQiaMember_638826490497389698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2023Member" xlink:label="btai_Warrants2023Member_638826490497389698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_Warrants2023Member_638826490497389698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_WarrantShares2024Member" xlink:label="btai_WarrantShares2024Member_638826490497389698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_WarrantShares2024Member_638826490497389698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_NewWarrantsMember_638826490497399703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember" xlink:label="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_638826490497399703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrants2024StrikePriceNotAmendedMember" xlink:label="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_638826490497399703" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_November2024AccompanyingWarrantsMember_638826490497399703" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_AccompanyingWarrantsMarch2025Member" xlink:label="btai_AccompanyingWarrantsMarch2025Member_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497389698" xlink:to="btai_AccompanyingWarrantsMarch2025Member_638826490497399703" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638826490497389698" xlink:to="srt_CounterpartyNameAxis_638826490497399703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638826490497399703" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638826490497399703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ArmisticeCapitalMasterFundMember" xlink:label="btai_ArmisticeCapitalMasterFundMember_638826490497399703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638826490497399703" xlink:to="btai_ArmisticeCapitalMasterFundMember_638826490497399703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_HeightsCapitalManagementMember" xlink:label="btai_HeightsCapitalManagementMember_638826490497409698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638826490497399703" xlink:to="btai_HeightsCapitalManagementMember_638826490497409698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_HudsonBayCapitalManagementMember" xlink:label="btai_HudsonBayCapitalManagementMember_638826490497409698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638826490497399703" xlink:to="btai_HudsonBayCapitalManagementMember_638826490497409698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_IntraCoastalCapitalMember" xlink:label="btai_IntraCoastalCapitalMember_638826490497409698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638826490497399703" xlink:to="btai_IntraCoastalCapitalMember_638826490497409698" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638826490497409698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638826490497389698" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638826490497409698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497409698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497409698" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638826490497409698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497409698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638826490497409698" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638826490497409698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638826490497419699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss_638826490497419699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638826490497419699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638826490497419699" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638826490497419699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638826490497419699" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638826490497419699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638826490497419699" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638826490497419699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638826490497419699" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Net Loss Per Share - Antidilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638826490497419699" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638826490497419699" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638826490497419699" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638826490497429702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638826490497429702" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638826490497429702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638826490497429702" xlink:to="us-gaap_EmployeeStockOptionMember_638826490497429702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638826490497429702" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638826490497429702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638826490497429702" xlink:to="us-gaap_PerformanceSharesMember_638826490497429702" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_BioxcelWarrantsAggregateMember" xlink:label="btai_BioxcelWarrantsAggregateMember_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638826490497429702" xlink:to="btai_BioxcelWarrantsAggregateMember_638826490497429702" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638826490497419699" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638826490497429702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638826490497429702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638826490497429702" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638826490497429702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_638826490497439706" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638826490497439706" xlink:to="srt_RangeAxis_638826490497439706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638826490497439706" xlink:to="srt_RangeMember_638826490497439706" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490497439706" xlink:to="srt_MinimumMember_638826490497439706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638826490497439706" xlink:to="srt_MaximumMember_638826490497439706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638826490497439706" xlink:to="us-gaap_OtherCommitmentsLineItems_638826490497439706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638826490497439706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638826490497439706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_638826490497449704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_638826490497449704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_638826490497449704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_638826490497449704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PurchaseObligationPriorYear" xlink:label="btai_PurchaseObligationPriorYear_638826490497449704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="btai_PurchaseObligationPriorYear_638826490497449704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638826490497449704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_638826490497449704" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_638826490497449704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_638826490497449704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_638826490497449704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638826490497439706" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_638826490497449704" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941701 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638826490497459707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638826490497459707" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638826490497459707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638826490497459707" xlink:to="us-gaap_SegmentDomain_638826490497459707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SingleReportableSegmentMember" xlink:label="btai_SingleReportableSegmentMember_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638826490497459707" xlink:to="btai_SingleReportableSegmentMember_638826490497459707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638826490497459707" xlink:to="srt_ConsolidationItemsAxis_638826490497459707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis_638826490497459707" xlink:to="srt_ConsolidationItemsDomain_638826490497459707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain_638826490497459707" xlink:to="us-gaap_OperatingSegmentsMember_638826490497459707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_638826490497459707" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638826490497469706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638826490497469706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense" xlink:label="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense_638826490497469706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense_638826490497469706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseProfessionalFees" xlink:label="btai_ResearchAndDevelopmentExpenseProfessionalFees_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="btai_ResearchAndDevelopmentExpenseProfessionalFees_638826490497469706" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense_638826490497469706" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense" xlink:label="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_638826490497469706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense_638826490497469706" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_ResearchAndDevelopmentCostsOtherExpenses" xlink:label="btai_ResearchAndDevelopmentCostsOtherExpenses_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="btai_ResearchAndDevelopmentCostsOtherExpenses_638826490497479705" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_638826490497469706" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638826490497479705" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCostsAbstract" xlink:label="us-gaap_DirectOperatingCostsAbstract_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_DirectOperatingCostsAbstract_638826490497479705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsLaborAndRelatedExpense" xlink:label="btai_CommercialCostsLaborAndRelatedExpense_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="btai_CommercialCostsLaborAndRelatedExpense_638826490497479705" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsShareBasedPaymentArrangementExpense" xlink:label="btai_CommercialCostsShareBasedPaymentArrangementExpense_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="btai_CommercialCostsShareBasedPaymentArrangementExpense_638826490497479705" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsProfessionalFees" xlink:label="btai_CommercialCostsProfessionalFees_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="btai_CommercialCostsProfessionalFees_638826490497479705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsCommercialAndMarketing" xlink:label="btai_CommercialCostsCommercialAndMarketing_638826490497479705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="btai_CommercialCostsCommercialAndMarketing_638826490497479705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsTravelAndOtherExpenses" xlink:label="btai_CommercialCostsTravelAndOtherExpenses_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="btai_CommercialCostsTravelAndOtherExpenses_638826490497489703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_CommercialCostsOtherExpenses" xlink:label="btai_CommercialCostsOtherExpenses_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="btai_CommercialCostsOtherExpenses_638826490497489703" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DirectOperatingCostsAbstract_638826490497479705" xlink:to="us-gaap_OtherCostAndExpenseOperating_638826490497489703" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" xlink:to="btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense_638826490497489703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense" xlink:label="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" xlink:to="btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense_638826490497489703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseProfessionalFees" xlink:label="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_638826490497489703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" xlink:to="btai_SellingGeneralAndAdministrativeExpenseProfessionalFees_638826490497489703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_638826490497499703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" xlink:to="btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses_638826490497499703" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SellingGeneralAndAdministrativeCostsOtherExpenses" xlink:label="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_638826490497499703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" xlink:to="btai_SellingGeneralAndAdministrativeCostsOtherExpenses_638826490497499703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638826490497499703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638826490497489703" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638826490497499703" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638826490497499703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_CostsAndExpenses_638826490497499703" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638826490497499703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638826490497499703" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638826490497509703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638826490497499703" xlink:to="us-gaap_InterestExpenseNonoperating_638826490497509703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638826490497509703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638826490497499703" xlink:to="us-gaap_InvestmentIncomeInterest_638826490497509703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638826490497509703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638826490497499703" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638826490497509703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638826490497509703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_NetIncomeLoss_638826490497509703" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638826490497509703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_NumberOfOperatingSegments_638826490497509703" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638826490497519701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_638826490497459707" xlink:to="us-gaap_NumberOfReportableSegments_638826490497519701" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941801 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638826490497519701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638826490497519701" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638826490497519701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638826490497519701" xlink:to="us-gaap_SubsequentEventTypeAxis_638826490497519701" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638826490497519701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638826490497519701" xlink:to="us-gaap_SubsequentEventTypeDomain_638826490497519701" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638826490497519701" xlink:to="us-gaap_SubsequentEventMember_638826490497529712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638826490497519701" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638826490497529712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638826490497529712" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024AccompanyingWarrantsMember" xlink:label="btai_November2024AccompanyingWarrantsMember_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" xlink:to="btai_November2024AccompanyingWarrantsMember_638826490497529712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_November2024PrefundedAccompanyingWarrantsMember" xlink:label="btai_November2024PrefundedAccompanyingWarrantsMember_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" xlink:to="btai_November2024PrefundedAccompanyingWarrantsMember_638826490497529712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_PrefundedWarrantsMarch2025Member" xlink:label="btai_PrefundedWarrantsMarch2025Member_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" xlink:to="btai_PrefundedWarrantsMarch2025Member_638826490497529712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_OptionWarrantsMarch2025Member" xlink:label="btai_OptionWarrantsMarch2025Member_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" xlink:to="btai_OptionWarrantsMarch2025Member_638826490497529712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638826490497529712" xlink:to="btai_NewWarrantsMember_638826490497529712" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638826490497529712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638826490497519701" xlink:to="us-gaap_AwardTypeAxis_638826490497529712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638826490497529712" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497539709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638826490497539709" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638826490497539709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638826490497519701" xlink:to="us-gaap_SubsequentEventLineItems_638826490497539709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638826490497539709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638826490497539709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercised_638826490497539709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_StockIssuedDuringPeriodSharesWarrantsExercise" xlink:label="btai_StockIssuedDuringPeriodSharesWarrantsExercise_638826490497539709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="btai_StockIssuedDuringPeriodSharesWarrantsExercise_638826490497539709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638826490497549706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638826490497549706" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_638826490497549706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_638826490497549706" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20250331.xsd#btai_RetentionBonusExpense" xlink:label="btai_RetentionBonusExpense_638826490497549706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="btai_RetentionBonusExpense_638826490497549706" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638826490497549706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638826490497549706" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638826490497549706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638826490497539709" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638826490497549706" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-38410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioXcel Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1386754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Long Wharf Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-6837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,056,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,013<span></span>
</td>
<td class="nump">$ 29,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,737<span></span>
</td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,777<span></span>
</td>
<td class="nump">37,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">38,566<span></span>
</td>
<td class="nump">38,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,450<span></span>
</td>
<td class="nump">15,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,986<span></span>
</td>
<td class="nump">5,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">5,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,546<span></span>
</td>
<td class="nump">22,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">3,274<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">99,918<span></span>
</td>
<td class="nump">102,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">128,738<span></span>
</td>
<td class="nump">131,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000 shares authorized as of March 31, 2025 and December 31, 2024; 5,468 and 3,102 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">567,220<span></span>
</td>
<td class="nump">557,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(657,451)<span></span>
</td>
<td class="num">(650,197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(90,172)<span></span>
</td>
<td class="num">(93,101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">38,566<span></span>
</td>
<td class="nump">38,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">5,468<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">5,468<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">5,699<span></span>
</td>
<td class="nump">13,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,267<span></span>
</td>
<td class="nump">24,745<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,099)<span></span>
</td>
<td class="num">(24,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">3,993<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(6,559)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,254)<span></span>
</td>
<td class="num">$ (26,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (13.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (13.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">4,834<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">4,834<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in-capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 534,060<span></span>
</td>
<td class="num">$ (590,598)<span></span>
</td>
<td class="num">$ (56,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued', window );">Issuance of pre-funded stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,791)<span></span>
</td>
<td class="num">(26,791)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">544,992<span></span>
</td>
<td class="num">(617,389)<span></span>
</td>
<td class="num">(72,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">2,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">557,047<span></span>
</td>
<td class="num">(650,197)<span></span>
</td>
<td class="num">$ (93,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="nump">2,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued', window );">Issuance of pre-funded stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations (in shares)</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,254)<span></span>
</td>
<td class="num">(7,254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 567,220<span></span>
</td>
<td class="num">$ (657,451)<span></span>
</td>
<td class="num">$ (90,172)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">5,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,254)<span></span>
</td>
<td class="num">$ (26,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of financing costs</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(6,559)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payable-in-kind interest on Credit Agreement</a></td>
<td class="nump">2,668<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use assets</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivable</a></td>
<td class="nump">131<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, due to related parties, and other current liabilities</a></td>
<td class="num">(2,269)<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,043)<span></span>
</td>
<td class="num">(17,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">14,006<span></span>
</td>
<td class="nump">26,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs for common stock and warrants issuance</a></td>
<td class="num">(803)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee tax obligations related to vesting restricted stock units</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">13,202<span></span>
</td>
<td class="nump">26,626<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">8,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">29,854<span></span>
</td>
<td class="nump">65,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 31,013<span></span>
</td>
<td class="nump">74,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_OrganizationAndPrincipalActivitiesAbstract', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#8217;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has proven its potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these condensed consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#8220;OnkosXcel&#8221; refers to BTI&#8217;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#160;(dexmedetomidine or &#8220;Dex&#8221;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>&#160;is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s most advanced neuroscience clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#239;ve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#8217;s principal office is in New Haven, Connecticut. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_OrganizationAndPrincipalActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_OrganizationAndPrincipalActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2. Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying unaudited interim condensed consolidated financial statements do not include all the information and notes required by Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) in the U.S. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March 31, 2025, the results of its operations for the three ended March 31, 2025 and 2024 and its cash flows for the three months ended March 31, 2025 and 2024. The results for the three months ended March 31, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025, any other interim periods or any future year or period. The accompanying unaudited interim condensed consolidated financial statements of the Company should be read in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March&#160;28, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying condensed consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, the Company had cash and cash equivalents of $31,013 and an accumulated deficit of $657,451. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $7,254 and $26,791 for the three months ended March 31, 2025 and 2024, respectively, and had net cash used in operating activities of $12,043 and $17,706 for the three months ended March, 2025 and 2024, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement (as defined in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>), its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report on Form 10-Q. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">This going concern evaluation takes into consideration the potential mitigating effect of management&#8217;s Reprioritization (as defined in Note 4, <i style="font-style:italic;">Restructuring</i>). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#8217;s Board of Directors.&#160; The Company&#8217;s Reprioritization was approved by the&#160;Board of Directors on August 8, 2023; however, such plans, including the additional restructuring actions taken in the second and third quarters of 2024, will not mitigate the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>) or other potential sources of debt or equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other actions, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise funding through the sale of the Company&#8217;s equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise funding through third-party investments in or other strategic options for OnkosXcel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raise funding through debt financing and/or restructuring of its existing Credit Agreement; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish collaborations with potential marketing partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce overhead and headcount to focus on core priorities; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any combination of the foregoing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt;">If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3. Summary of Significant Accounting Policies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been no material changes to the significant accounting policies previously disclosed in Note&#160;3 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures beginning in the first quarter of fiscal year 2025. For additional information, see Note 17,&#160;<i style="font-style:italic;">Segment Information</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2024, the FASB issued ASU 2024-01, Compensation &#8211; Stock Compensation (Topic 718) &#8211; Scope application of profit interest and similar awards, which clarifies how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or if it is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. The adoption of this guidance did not have a significant impact on our financial statements, and the Company does not expect this guidance to have a material impact prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, Income statement-reporting comprehensive income-expense disaggregation disclosures, which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the effect of adopting this guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 4. Restructuring </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On May 8, 2024, the Company took actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. The Company reduced its workforce by approximately </span><span style="background:#ffffff;">15%</span><span style="background:#ffffff;"> and notified impacted employees on May 8, 2024. All related restructuring costs were paid in the second quarter of 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On September 17, 2024, the Company reduced its workforce by an additional </span><span style="background:#ffffff;">28%</span><span style="background:#ffffff;"> to extend its cash runway and prioritize clinical development of BXCL501. </span>The Company completed the Clinical Prioritization in October 2024, paid $475 of the related costs during the first quarter of 2025, and expects to pay approximately $128, the remaining costs, in the second quarter of 2025, which are included in Accrued Expenses on the Condensed Consolidated Balance at March 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Inventory consists of the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 506</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 173</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 679</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">The Company recorded inventory write-downs of </span><span style="font-weight:normal;background:#ffffff;">$0</span><span style="font-weight:normal;background:#ffffff;"> and </span><span style="font-weight:normal;background:#ffffff;">$45</span><span style="font-weight:normal;background:#ffffff;"> for the three months ended March 31, 2025 and 2024, respectively. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment, net consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,502)</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 475</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Depreciation expense was $76 and $78<span style="white-space:pre-wrap;"> for the three months ended March 31, 2025 and 2024, respectively.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,107</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,604</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 322</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 603</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,762</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with BioXcel LLC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Transactions with BioXcel LLC</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8. Transactions with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which BioXcel LLC has agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Services Agreement, the Company had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. The Company agreed to pay BioXcel LLC $18 per month from March 13, 2023 to December 31, 2024 in exchange for this option. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the original contract. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10,000 in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30,000 in the aggregate. The Company did not exercise its option to renew the agreement for product identification and related services utilizing BioXcel LLC&#8217;s EvolverAI. Subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement for the three months ended March 31, 2025 and 2024, respectively were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 186</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 234</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, there were no outstanding service charges related to the Services Agreement included in Due to related parties in the Company&#8217;s Condensed Consolidated Balance Sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Credit Facilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 9. Debt and Credit Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Debt, net of unamortized discounts and financing costs, consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,319</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,403</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,722</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,865)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,214)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,508</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,608)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,508</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#8220;RIFA&#8221;; and together with the Credit Agreement, the &#8220;OFA Facilities&#8221;) by and among the Company, the purchasers party thereto (the &#8220;Purchasers&#8221;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $260,000 in gross funding to support the Company&#8217;s commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#8217;s disease, and for general corporate purposes. The Lenders and Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and First Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from $25,000 at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#8217;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.26;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On December 5, 2023, (the &#8220;Second Amendment Effective Date&#8221;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $202,319 in senior secured term loans, including the initial Tranche A of $70,000, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $72,319. In addition, the $30,000 in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865 at any time outstanding in OnkosXcel, increased from $30,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First Amendment). As of March 31, 2025, $80,000 in commitments under the Credit Agreement remains unfunded. The blended effective interest rate on the Tranches A-1 and A-2 as of March 31, 2025 was approximately 15.3%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The remaining tranches may be borrowed at the Company&#8217;s option subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $20,000 and is available upon satisfaction of certain conditions and financial milestones. Tranche B expired on December 31, 2024. Tranche C of the Credit Agreement is $30,000 and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $50,000 and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025. As of March 31, 2025, Tranches C and D, totaling $80,000, remain available for borrowing if the milestones above are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a </span><span style="font-size:10pt;">200</span><span style="font-size:10pt;">-basis point original issue discount and bear interest at a variable annual rate of TERM </span><span style="-sec-ix-hidden:Hidden_buvaqAws5kSR-ouHGNXICQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> (but not less than </span><span style="font-size:10pt;">2.5%</span><span style="font-size:10pt;"> or more than </span><span style="font-size:10pt;">5.5%</span><span style="font-size:10pt;">) plus </span><span style="font-size:10pt;">7.5%</span><span style="font-size:10pt;">, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above </span><span style="font-size:10pt;">8%</span><span style="font-size:10pt;"> per annum is, at the Company&#8217;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through</span> <span style="font-size:10pt;">March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to </span><span style="font-size:10pt;">0.75%</span><span style="font-size:10pt;"> per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s obligations under the Credit Agreement are guaranteed by BTI&#8217;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#8217;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) a pledge of all of the equity interests of all of the Company&#8217;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#8217; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $15,000, (b) from and after the funding of the Tranche B loans, $20,000, and (c) from and after the Company&#8217;s satisfaction of the funding conditions for the Tranche C loans, $15,000, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $37,500), provided that the minimum liquidity amount will in no event exceed 50% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#8217;s fiscal quarter ending on December 31, 2024 (such six-month period the &#8220;Revenue Covenant Measurement Period&#8221;), that requires it and its subsidiaries&#8217; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#8220;Revenue Covenant Measurement Testing Date&#8221; and the covenant described in this clause (ii) the &#8220;Revenue Covenant&#8221;). The Company&#8217;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#8217;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">minimum required revenue amount and the Company&#8217;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#8220;Employee Holdings&#8221;), a subsidiary of BTI, and their respective subsidiaries, the &#8220;BXCL701 Subsidiaries&#8221;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#8217;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#8217;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events, including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least 20% of the equity interests in the BXCL701 Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#8217;s secured creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and Third and Fourth Amendments to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#8217;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least </span><span style="background:#ffffff;">$40,000</span><span style="background:#ffffff;"> in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants</span> on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 20, 2024 (the &#8220;Effective Date&#8221;), the Company entered into the Fourth Amendment to the Credit Agreement and Guaranty (the &#8220;Fourth Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Fourth Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to the Company&#8217;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#8217;s independent registered public accounting firm&#8217;s report contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $25,000 from $15,000, unless and until the Company has received, after the Effective Date and on or before November 30, 2024, at least $50,000<span style="white-space:pre-wrap;"> in gross proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.  On March 27, 2024, the Company received </span>$25,000 in gross proceeds from the issuance of its common stock, warrants, and pre-funded warrants discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, satisfying the April 15, 2024 covenant requirement of the Fourth Amendment. During the third quarter of 2024, the Company received $467<span style="white-space:pre-wrap;"> of gross proceeds from the issuance of the Company&#8217;s common stock.  As of September 30, 2024, the Company had satisfied </span>$30,943 of the $40,000 required to maintain the Minimum Liquidity Amount and the $50,000<span style="white-space:pre-wrap;"> gross proceeds requirement.  As a result, at September 30, 2024, the Minimum Liquidity Amount increased to </span>$25,000. As of March 31, 2025, we were in compliance with all restrictive and financial covenants under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Waiver and Fifth Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#8220;Fifth Amendment&#8221;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2024, and the Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024 (the &#8220;Fourth Amendment&#8221;), the &#8220;Existing Credit Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#8217;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#8220;going concern&#8221; or similar qualification, (ii) permanently waive the Credit Agreement&#8217;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#8217;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fifth Amendment includes a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants(&#8220;Raise 1&#8221;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#8217;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#8220;Raise 2&#8221;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#8217;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1until March 30, 2025. On March 31, 2025, the minimum liquidity amount increased to $10,000 and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">The Fifth Amendment also modifies the interest rate of the loans provided under the Credit Agreement from a floating rate of Term </span><span style="-sec-ix-hidden:Hidden_OkIKnOdDH0OalG3pChCxZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SOFR</span></span><span style="font-size:10pt;"> plus </span><span style="font-size:10pt;">7.50%</span><span style="font-size:10pt;"> per annum, to a fixed rate of </span><span style="font-size:10pt;">13%</span><span style="font-size:10pt;"> per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates ending December 31, 2024, March 31, 2025, and June 30, 2025, the Company will have the ability to make interest payments of up to </span><span style="font-size:10pt;">10%</span><span style="font-size:10pt;"> per annum &#8220;in-kind&#8221; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement. In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to </span><span style="font-size:10pt;">5.0%</span><span style="font-size:10pt;"> of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#8217;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#8220;OnkosXcel&#8221;), which previously provided unsecured guarantees of the Company&#8217;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fifth Amendment amends the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company (including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also agreed to covenants requiring that the Company&#8217;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses for its employees or executives during the fiscal years 2024 and 2025 without OFA&#8217;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Sixth Amendment to Credit Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On March 4, 2025, the Company entered into the Sixth Amendment to our Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which the Lenders agreed to, among other things, delay the date on which the Company is required to engage an investment banker (which date has been subsequently extended to July 31, 2025).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants and Equity Investment Right</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to 17 shares of the Company&#8217;s common stock at an exercise price of $320.64 per share (the &#8220;Closing Date Warrants&#8221;). Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Closing Date Warrants&#8221;), the exercise price of the Closing Date Warrants has been reduced to $58.3232 per share. In addition, the Company granted new warrants to the Lenders to purchase up to 4 shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $58.3232 per share (the &#8220;2023 Warrants&#8221;<span style="font-size:12pt;"> </span>and together with the Amended and Restated Closing Date Warrants, the &#8220;Warrants&#8221;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holders election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#8217;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). BTI entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of the Company&#8217;s common stock issuable under the Warrants (including the Closing Date Warrants and the 2023 Warrants) and Lenders&#8217; Equity Investment Right was 366 as of March 31, 2024.<span style="font-size:12pt;"> </span>On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase 175 individual limited liability company units (which number of units is not in thousands; referred to herein as the &#8220;OnkosXcel Warrants&#8221;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the closing of the Fourth Amendment discussed below, the Company granted new warrants to the Lenders to purchase up to 6 shares of its common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $49.1568 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Fifth Amendment Warrants, Registration Rights Agreement and Equity Investment Right Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). The Equity investment Right was terminated as part of the Fifth Amendment. We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#8220;Amended and Restated Registration Rights Agreement&#8221;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Closing Date Warrants, 2023 Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Closing Date Warrants, the 2023 Warrants and the Lenders&#8217; Equity Investment Right was 366. On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of 313 shares of common stock on the closing date of the Fifth Amendment, at an exercise price of $0.16 per share (the &#8220;New Warrants&#8221;). The New Warrants will expire on the seventh anniversary of their issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#8220;Original Warrants&#8221;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company, and the exercise prices of $58.3232 per share and $49.1568 per share were reduced to $7.68 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the date of issuance of the New Warrants, the Company agreed to amend and restate its Second Amended and Restated Registration Rights Agreement with the Lenders, dated March 20, 2024. Pursuant to such amendment and restatement (the &#8220;Third Amended and Restated Registration Rights Agreement&#8221;), the Company will agree to register the shares of common stock issuable under the New Warrants, in addition to all Original Warrants, for resale. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Maturities of debt are expected to be as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,431</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,960</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,564</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,607</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 10. Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options. The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#8217;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheets. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement, and the Company recorded a termination gain, reducing the carrying value of the Equity Investment Right to $0. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">With respect to the Purchase Agreement discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, BTI determined that the Accompanying Warrants fail the equity classification criteria and are therefore classified as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. We value the Accompanying Warrants using the Black-Scholes option pricing model as discussed in Note 14, <i style="font-style:italic;">Fair value measurements</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 21, 2024, the exercise price of&#160;534&#160;of the Accompanying Warrants was reduced from $51.20&#160;to $9.136&#160;per share. For the three months ended March 31, 2025, the Company recorded total net gains of $1,679 in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the Accompanying Warrants was $641. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On November 25, 2024, with respect to the Underwriter Agreement discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, the Company issued additional warrants (the &#8220;November 2024 Accompanying Warrants&#8221;). The November 2024 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. For the three months ended March 31, 2025, the Company recorded total net gains of $3,080&#160;in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the November 2024 Accompanying Warrants was $1,193.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">On March 3, 2025, with respect to the March 2025 Offering discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, the Company issued additional warrants (the &#8220;March 2025 Accompanying Warrants&#8221;). The March 2025 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $2,831&#160;and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations. For the three months ended March 31, 2025, the Company recorded total net gains of $1,429&#160;in Other (income) expense, net, in the Company&#8217;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the March 2025 Accompanying Warrants was $1,402.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;">In connection with the March 2025 Offering discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, the Company also issued option warrants (the &#8220;Option Warrants&#8221;). The Option Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are initially recorded as Derivative liabilities. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $369. The Option Warrants expired on March 18, 2025 without being exercised, and the Company recorded a termination gain of $369 in Other (income) expense, net, in the Company&#8217;s Condensed Consolidated Statements of Operations. As of March 31, 2025, the fair value of the Option Warrants was $0.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Financing Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_FinancingActivitiesAbstract', window );"><strong>Common Stock Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_FinancingActivitiesDisclosureTextBlock', window );">Common Stock Financing Activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;11. Common Stock Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;">Jeffries At-the-Market Program </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">In May 2021, the Company entered into</span><span style="font-weight:normal;"> an </span><span style="font-weight:normal;">Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to </span><span style="font-weight:normal;">$100,000</span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#8220;at the market offering" program to </span><span style="font-weight:normal;">$150,000</span><span style="font-weight:normal;">. On March 26, 2025, the Company and Jefferies terminated that certain Open Market Sales Agreement. There have been </span><span style="font-weight:normal;">no</span><span style="font-weight:normal;"> sales of the Company&#8217;s common stock under the Sale Agreement for the three months ended March 31, 2025. </span><span style="font-weight:normal;">For the three months ended March 31, 2024, the Company sold </span><span style="font-weight:normal;">40</span><span style="font-weight:normal;"> shares under the Sale Agreement for gross proceeds of </span><span style="font-weight:normal;">$1,743</span><span style="font-weight:normal;"> and received proceeds of </span><span style="font-weight:normal;">$1,691</span><span style="font-weight:normal;">, net of issuance costs of </span><span style="font-weight:normal;">$52</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">March 2024 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers in a registered direct offering (the &#8220;Offering&#8221;) under an effective shelf registration statement on Form S-3 (File No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission on March 25, 2024 (the &#8220;Prospectus Supplement&#8221;) an aggregate of 191 shares (the &#8220;Shares&#8221;) of Common Stock, and accompanying warrants (the &#8220;Accompanying Warrants&#8221;) to purchase up to 191 shares of common stock at a combined offering price of $46.416 per Share and Accompanying Warrant and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 348 shares of common stock and Accompanying Warrants to purchase up to 348 shares of common stock, at a combined offering price of $46.40 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">less the $0.016 exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants and Accompanying Warrants are not listed on the Nasdaq Capital Market or any other securities exchange or trading system and the Company does not intend to list them. On March 27, 2024, the Company received $25,000 of gross proceeds from the Offering, incurred costs of $248, and received net proceeds of $24,752. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.016 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. For the year ended December 31, 2024, all 348 Pre-Funded Warrants were exercised and the same number of shares of common stock were issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Accompanying Warrants have an exercise price per share of common stock equal to $51.20 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">November 2024 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On November 22, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Canaccord Genuity LLC, as underwriter (the &#8220;Underwriter&#8221;), in connection with the issuance and sale by the Company in a public offering of (i)&#160;</span>350<span style="background:#ffffff;">&#160;shares of the Company&#8217;s common stock, and accompanying warrants (the &#8220;November 2024 Accompanying Warrants&#8221;) to purchase&#160;</span>350<span style="background:#ffffff;">&#160;shares of Common Stock, at a combined public offering price of </span><span style="background:#ffffff;">$</span>7.68<span style="background:#ffffff;">&#160;per share, and, in lieu thereof to certain investors, (ii) Pre-Funded Warrants to purchase&#160;</span>563<span style="background:#ffffff;">&#160;shares of Common Stock, and accompanying warrants to purchase&#160;</span>563<span style="background:#ffffff;">&#160;shares of Common Stock, at a combined public offering price of </span><span style="background:#ffffff;">$</span>7.664<span style="background:#ffffff;">&#160;per pre-funded warrant, which equals the public offering price per share of Common Stock and accompanying warrant less the </span><span style="background:#ffffff;">$</span>0.016<span style="background:#ffffff;">&#160;exercise price per share of the pre-funded warrants, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission. </span>The Company received net proceeds from the offering of approximately $6,128, after deducting underwriting discounts and commissions and offering expenses of $871. The Company intends to use the net proceeds of the offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.016 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. <span style="background:#ffffff;">For the year ended December 31, 2024,&#160;</span>80<span style="background:#ffffff;">&#160;Pre-Funded Warrants were exercised and the same number of shares of common stock were issued. For the three months ended March 31, 2025, the remaining </span><span style="background:#ffffff;">483</span><span style="background:#ffffff;"> Pre-Funded Warrants were exercised and the same number of common stock were issued in exchange for </span><span style="background:#ffffff;">$8</span><span style="background:#ffffff;"> of proceeds received. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The November 2024 Accompanying Warrants have an exercise price per share of common stock equal to $7.68 per share. The exercise price and the number of shares of common stock issuable upon exercise of the November 2024 Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The November 2024 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accompanying Warrants are exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The November 2024 Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">March 2025 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 3, 2025, the Company entered into a purchase agreement (the &#8220;March 2025 Offering&#8221;) with a purchaser. Pursuant to the March 2025 Offering, the Company agreed to issue and sell to the purchaser and the purchaser agreed to buy in a registered direct offering (i) an aggregate of 188 shares (the &#8220;Shares&#8221;) of Common Stock at an offering price of $3.50 per Share, (ii) Pre-Funded Warrants to purchase up<span style="font-size:11pt;"> </span>to 3,812 shares of Common Stock, at an offering price of $3.499 per share underlying the Pre-Funded Warrants, which equals the offering price per share less the $0.001 exercise price per share of the Pre-Funded Warrants, and (iii) an aggregate of 4,000 accompanying warrants (the &#8220;March 2025 Accompanying Warrants&#8221;) to purchase up to 4,000 shares of Common Stock at an offering price of $4.20 per accompanying warrant, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the SEC on March 4, 2025. The Company received net proceeds from the offering of approximately $12,957, after deducting underwriting discounts and commissions and offering expenses of $1,039.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.001 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. For the three months ended March 31, 2025, 1,688 Pre-Funded Warrants were exercised and the same number of common stock were issued in exchange for $2 of proceeds received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The March 2025 Accompanying Warrants have an exercise price per share of common stock equal to $4.20 per share. The exercise price and the number of shares of common stock issuable upon exercise of the March 2025 Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The March 2025 Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The March 2025 Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the March 2025 Offering, the Company also issued to the purchaser option warrants, to purchase up to 4,000 shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000 shares of Common Stock. The exercise price of the Option Warrant is $3.50 per underlying share of Common Stock or $3.499 per underlying pre-funded warrant to purchase one share of Common Stock and accompanying warrant. The option accompanying warrants have an exercise price per share of common stock equal to $4.20 per share. The Option Warrants expired on March 18, 2025 without being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FinancingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Financing Activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FinancingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;12. Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">2017 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">2020 Incentive Award Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2020 Plan was approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) 57 shares of the Company&#8217;s common stock and (ii) 15 shares of the Company&#8217;s common stock, which represents the number of shares that remained available for issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) 4% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by 124 shares and 75 shares on January 1, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock options granted under the 2020 Plan have a term of ten years. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, there were 118 shares available to be granted under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BTI Restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to BTI RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the three months ended March 31, 2025, the Company granted 3 time-based BTI RSUs which fully vest on the <span style="-sec-ix-hidden:Hidden_pBakmeRXJUyagPAg9k_X7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-year anniversary of the grant date. The weighted average grant date fair value per share for the BTI RSUs for the three months ended March 31, 2025 was $6.14. The remaining outstanding RSUs generally vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. Unrecognized stock-based compensation expense related to the BTI RSUs was approximately $537 and $1,308 as of March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Performance stock units </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes activity relating to Performance Units related to BTI common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In July 2024, the Company granted 87 Performance Units to employees. The Performance Units vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value per share of Performance Units granted in 2024 was $19.20. None of the Performance Units had vested as of March 31, 2025. Unrecognized stock-based compensation expense related to these Performance Units expected to vest was zero as of March 31, 2025 since it is uncertain whether any performance criteria will be met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel profit sharing units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,686</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,006</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,533</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2024, OnkosXcel Employee Holdings, LLC, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted 15 individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. These PSUs vest ratably over 48 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair values of PSUs granted in 2024 were estimated at the date of grant using a Black-Scholes option pricing model and assumptions below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized stock-based compensation expense related to these awards was $319 and $782 as of March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the OnkosXcel RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 176</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Cancelled</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, the Company had 140 OnkosXcel Restricted Stock Units outstanding. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $50 and $420 as of March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BTI Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A summary of the Company&#8217;s stock option activity for the three months ended March 31, 2025 is presented below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 265.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 384.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 268.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2025, the intrinsic value of options outstanding was $0. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#8217;s common stock as of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No stock options were exercised for the three months ended March 31, 2025. As of March 31, 2025, the total intrinsic value of stock options exercisable was $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value per share of options granted as of March 31, 2025 was $6.21.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value per share of options vested as of March 31, 2025 was $196.53.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average remaining contractual life is 5.0 years for options exercisable as of March 31, 2025. The weighted average remaining contractual life was 6.2 years for options outstanding as of March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized compensation expense related to unvested stock option awards as of March 31, 2025 was $1,675 and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 1.1 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of stock options granted during the three months ended March 31, 2025 and 2024 was estimated using the Black-Scholes pricing model with the following assumptions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">112.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">108.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2025, the Company continued using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#8217;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the life of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is zero percent as the Company has no history of paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel RSUs and PSUs, of $180 and $3,433 for the three months ended March 31, 2025 and 2024, respectively, which were comprised as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (514)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,281</p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,152</p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,433</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">2020 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was also approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#8217;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that were initially available to be issued pursuant to rights granted under the ESPP was 6 shares of common stock. In addition, the number of shares available for issuance under the ESPP increases on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#8220;Section 423 Component&#8221;) shall not exceed 31 shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by 31 shares and 19 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">shares on January 1, 2025 and 2024, respectively. To date, no shares have been sold under the ESPP. There were 106 shares available for issuance as of March 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 13. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;) under an operating lease that expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also leases equipment such as copiers and information technology equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The future minimum annual lease payments under operating leases, as of March 31, 2025, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 294</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (350)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current portion of the Company&#8217;s operating lease liability of $350 as of March 31, 2025, is included in <span style="-sec-ix-hidden:Hidden_-dJ9RC_4H0GYGleZlqoJAg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span> on the Condensed Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lease expense was $101 and $99 for the three months ended March 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lease renewal options are not included in the ROU asset or lease liability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 14. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, <i style="font-style:italic;">Summary of Significant Accounting Policies</i>, for additional information on the accounting policies related to fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts of cash and cash equivalents, accounts receivable, net, and accounts payable approximate fair value due to the short-term nature of these instruments. As of March 31, 2025 and December 31, 2024, the Company had $30,310 and $29,036, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the three months ended March 31, 2025 and the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities measured at fair value on a recurring basis are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,236</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,274</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities are comprised of the OnkosXcel Warrants, BTI Warrants, and Option Warrants. The fair value of the derivative liabilities was determined using Binomial Option Pricing and Distribution models for the OnkosXcel Warrants and Option Warrants, and using a Black Scholes model for the BTI Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2025. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Addition of derivative liabilities - BTI Warrant (March 2025 Accompanying Warrants)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Addition of derivative liabilities - Option Warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Termination of derivative liabilities - Option Warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_PWqzCLVmi0aOXGZBWK1euA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - March 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,817</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The change in fair value of the derivative liabilities was reported in the Condensed Consolidated Statements of Operations as Other (income) expense, net, for the three months ended March 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at 115% based on the historical volatility of the Company&#8217;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the Option Warrants, the valuation inputs used were a strike price of $3.50, the Company&#8217;s stock price of $2.70, volatility of 39.2% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), a term of 0.04 years and a risk-free rate of 4.39%. The Option Warrants expired on March 18, 2025 without being exercised, and the Company recorded a termination gain of $369 in Other (income) expense, net, in the Company&#8217;s Condensed Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In estimating the fair value of the derivative liability related to the BTI Warrants &#8211; March 2025 Accompanying Warrants, the valuation inputs used were a strike price of $4.20, the Company&#8217;s stock price of $2.70, volatility of 39.2% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), a term of 5 years and a risk-free rate of 4.01%. The Company remeasured the fair value at March 31, 2025 of $1,402 and recorded an unrealized gain of $1,429 for the three months ended March 31, 2025 within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were a strike price of $4.20, the Company&#8217;s stock price of $2.03, volatility of 38.5% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), term of 4.9 years and risk-free rate of 3.96%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated fair value of the Credit Agreement as of March 31, 2025 and December 31, 2024 was $96,403 and $94,204, respectively. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table presents the BTI warrants issued by the Company and the corresponding balance sheet classification:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Warrant Recipient</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Closing Date Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">4/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2023 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">12/5/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2024 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/20/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">New Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 0.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 9.136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 51.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heights Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hudson Bay Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IntraCoastal Capital, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Murchison Capital Partners, LP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">March 2025 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/4/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 4.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total warrants issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 5,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of the Closing Date Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $3,245 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $320.64, the Company&#8217;s stock price of $238.88, volatility of 95%, term of 7 years and risk-free rate of 2.95%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment<span style="font-size:12pt;"> </span>of the<span style="font-size:12pt;"> </span>Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Closing Date Warrants granted to the Lenders to have an exercise price of $58.3232 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants&#8217; fair values at the original strike price of $320.64 and the amended strike price of $58.3232 were $548 and $802, respectively, as of the Second Amendment Effective Date. The Closing Date Warrants&#8217; incremental increase in fair value for the repricing of $254, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Second Amendment, the Company issued 4 &#8220;2023 Warrants&#8221; at a strike price of $58.3232 per share. The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $200 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $58.3232, the Company&#8217;s stock price of $59.36, volatility of 99%, term of 5.4 years and risk-free rate of 4.14%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, the Company issued 6 &#8220;2024 Warrants&#8221; at a strike price of $49.1568<span style="white-space:pre-wrap;"> per share.  The fair value of the &#8220;2024 Warrants&#8221;, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of </span>$224 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $49.1568, the Company&#8217;s stock price of $44.48, volatility of 112.2%, term of 5 years and risk-free rate of 4.25%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in connection with the Fifth Amendment of the Credit Agreement, on the Fifth Amendment Effective Date of November 25, 2024, the Company amended and restated the Closing Date Warrants, 2023 Warrants, and 2024 Warrants granted to the Lenders to have an exercise price of $7.68 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; fair values at the previously amended strike price of $58.3232 and original strike price of $49.1568 the amended strike price of $7.68 were $105 and $164, respectively, as of the Fifth Amendment Effective Date. The Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#8217; incremental increase in fair value for the repricing of $59, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The fair value of the Accompanying Warrants at issuance on March 25, 2024 was determined using a Black-Scholes pricing model and was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2.  On November 25, 2024, </span>534 of the 539 Accompanying Warrants&#8217; strike price were amended to $9.136. The Company remeasured the Accompanying Warrants&#8217; fair value at March 31, 2025 of $641 and recorded a net gain of $1,679, within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were strike prices of $9.136 and $51.20 for 534 and 5 Accompanying Warrants, respectively, the Company&#8217;s stock price of $2.03, volatility of 120.2%, term of 4.0 years and risk-free rate of 3.93%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the November 2024 Accompanying Warrants at issuance on November 25, 2024 was determined using a Black-Scholes pricing model and was recorded as a derivative liability with the offset recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The Company remeasured the November 2024 Accompanying Warrants&#8217; fair value at March 31, 2025 of $1,193 and recorded a net gain of $3,080, within Other (income) expense, net in the Company&#8217;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were a strike price of $7.68, the Company&#8217;s stock price of $2.03, volatility of 115.3%, term of 4.7 years and risk-free rate of 3.94%. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 15. Net Loss Per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Basic and diluted net loss per share are as follows</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,791)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,929</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13.89)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding are as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 303</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567</p></td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total common stock equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Note&#160;16. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the items below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned </span><i style="font-style:italic;background:#ffffff;">Martin v. BioXcel Therapeutics, et al.</i><span style="white-space:pre-wrap;background:#ffffff;">, 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. On February 24, 2025, while the Company&#8217;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint. The Company filed an opposition to the motion on March 17, 2025 and Plaintiffs filed a reply in support of the motion on April 7, 2025. On April 9, 2025, the parties filed a joint motion requesting that the Court stay the action pending the outcome of a private mediation session scheduled for May 12, 2025. The Court granted the motion, staying the action until May 23, 2025, by which date the parties are required to file either a motion to continue the stay or a motion to lift the stay.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Panancherry et al v. Mehta et al</i><span style="background:#ffffff;">, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation</i><span style="background:#ffffff;">, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption </span><i style="font-style:italic;background:#ffffff;">Smith v. Mehta et al,</i><span style="background:#ffffff;"> 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption </span><i style="font-style:italic;background:#ffffff;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i><span style="background:#ffffff;">, 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On May 7, 2025, Plaintiff Yaakov Portnoy filed a stockholder derivative complaint in the Court of Chancery of the State of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep &#8220;Steve&#8221; Laumas, Michael P. Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan, and the Company as Nominal Defendant under the caption <i style="font-style:italic;">Yaakov Portnoy, derivatively on behalf of BioXcel Therapeutics, Inc. v. Vimal Mehta, et al</i>, 2025-0508-BWD (Del. Ch.).&#160; The complaint alleges similar claims to those raised in <i style="font-style:italic;">In re BioXcel Therapeutics, Inc. Derivative Litigation</i>, 1:24-cv-00041 (D. Del.), including business torts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total </span><span style="background:#ffffff;">$10,000</span><span style="background:#ffffff;"> for the </span><span style="background:#ffffff;">three-year</span><span style="background:#ffffff;"> period, of which </span><span style="background:#ffffff;">$5,000</span><span style="background:#ffffff;"> was originally due in year ended 2024. On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the &#8220;Product Supply Agreement Amendment&#8221;) that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications. The Company&#8217;s renegotiated agreement reduced the minimum commitment for 2024 to </span><span style="background:#ffffff;">$1,000</span><span style="background:#ffffff;"> and thereafter for the term of the agreement in annual amounts ranging from </span><span style="background:#ffffff;">$2,000</span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;">$5,000</span><span style="background:#ffffff;"> subject, in certain instances, to the extent that the Company receives approval of an sNDA or NDA from the FDA for enumerated indications. In accordance with the Product Supply Agreement Amendment, the minimum commitments were reduced to </span><span style="background:#ffffff;">$1,000</span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$2,000</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$2,000</span><span style="background:#ffffff;"> in the years 2024, 2025, and 2026.</span> <span style="background:#ffffff;">In addition, the Company agreed to make a reconciliation payment of </span><span style="background:#ffffff;">$1,200</span><span style="background:#ffffff;"> in the third quarter of 2024 for full settlement for amounts due prior to the July 11, 2024 amendment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Note&#160;17. Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company views its operations and manages its business as&#160;one&#160;operating and reportable segment, utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. The Company employs various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (&#8220;CODM&#8221;), reviews weekly cash usage and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company&#8217;s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 582</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,630</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (514)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,281</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,307</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,068</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 549</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 566</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">     Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,401</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,149</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 268</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 71</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 196</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">    Total commercial costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,148</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,037</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,884</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,240</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 708</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">    Total selling, general and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,116</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"> Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 24,745</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,607</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (947)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,791)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consolidated Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,791)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 18. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 11, <i style="font-style:italic;">Common Stock Financing Activities</i>, in connection with the March 2025 issuance and sale in a public offering of (i) 188 shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase 3,812 shares of Common Stock, and (iii) accompanying warrants to purchase 4,000 shares of Common Stock, after March 31, 2025 but before financial statement issuance, certain investors exercised 300 pre-funded warrants to purchase 300 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As discussed in Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i>,<span style="font-size:12pt;"> </span>in connection with the Fifth Amendment of the Credit Agreement and issuance of new warrants to the Lenders to purchase an aggregate of 313 shares of common stock, after March 31, 2025 but before financial statement issuance, the Company issued 284 shares of Common Stock in connection with the cashless exercises of 313 warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">On April 3, 2025, the Company entered into</span><span style="font-weight:normal;"> an Equity Distribution Agreement (the &#8220;Equity Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) to sell shares of the Company&#8217;s common stock, par value </span><span style="font-weight:normal;">$0.001</span><span style="font-weight:normal;"> per share, with aggregate gross sales proceeds of up to </span><span style="font-weight:normal;">$8,135</span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market&#8221; equity offering program under which Canaccord will act as sales agent. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On April 8, 2025, the Board unanimously approved (i) the payment of a retention bonus to all non-executive employees in the total aggregate amount of $1,545, to be paid in two equal installments and (ii) the issuance of 66 RSUs which fully vest on the one-year anniversary of the grant date. The first installment of the retention bonus was paid on April 30, 2025 and the second installment shall be paid upon successful completion of the Serenity Trial data readout and securing additional financing. Each such installment payment is subject to the applicable employee&#8217;s continued employment through December 31, 2025. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,254)<span></span>
</td>
<td class="num">$ (26,791)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures beginning in the first quarter of fiscal year 2025. For additional information, see Note 17,&#160;<i style="font-style:italic;">Segment Information</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2024, the FASB issued ASU 2024-01, Compensation &#8211; Stock Compensation (Topic 718) &#8211; Scope application of profit interest and similar awards, which clarifies how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or if it is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. The adoption of this guidance did not have a significant impact on our financial statements, and the Company does not expect this guidance to have a material impact prospectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, Income statement-reporting comprehensive income-expense disaggregation disclosures, which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the effect of adopting this guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 506</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 173</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 679</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,977</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,502)</p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 475</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,107</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,604</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 322</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 603</p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,762</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with BioXcel LLC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of service charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 186</p></td></tr><tr><td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 234</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,319</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,403</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,722</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,865)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,214)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,508</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of long-term debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,608)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,508</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities on debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,431</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,960</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,564</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,607</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense associated with long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 265.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 384.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 210.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 268.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (514)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,281</p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,152</p></td></tr><tr><td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,433</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of activity relating to RSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of activity relating to PSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of activity relating to PSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,686</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (84)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,006</p></td></tr><tr><td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,533</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of activity relating to RSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 176</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Cancelled</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of March&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">112.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">108.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remainder of 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 294</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (350)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,236</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,274</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total derivative liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,633</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of changes in Level 3 liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Addition of derivative liabilities - BTI Warrant (March 2025 Accompanying Warrants)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Addition of derivative liabilities - Option Warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Termination of derivative liabilities - Option Warrant</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_PWqzCLVmi0aOXGZBWK1euA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   Change in fair value</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - March 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,817</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Warrant Recipient</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Closing Date Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">4/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2023 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">12/5/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2024 Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/20/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Lenders and RIFA Purchasers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">New Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 0.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 9.136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 51.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Armistice Capital Master Fund Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heights Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hudson Bay Capital Management</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IntraCoastal Capital, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">November 2024 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">11/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 7.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Murchison Capital Partners, LP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">March 2025 Accompanying Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">3/4/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 4.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Derivative Liability</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total warrants issued</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 5,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,791)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,929</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13.89)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 303</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">BTI Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567</p></td></tr><tr><td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total common stock equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of reportable segment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 582</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Less:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,630</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (514)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,281</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,307</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,068</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 549</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 566</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">     Total research and development costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,401</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,149</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 268</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 71</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,347</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 196</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">    Total commercial costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,148</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,037</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,884</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,240</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Travel related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 708</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="white-space:pre-wrap;">    Total selling, general and administrative costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,116</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"> Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 24,745</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other (income) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,607</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (947)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,559)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,791)</p></td></tr><tr><td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments and reconciling items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consolidated Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (26,791)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">657,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="nump">7,254<span></span>
</td>
<td class="nump">$ 26,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 12,043<span></span>
</td>
<td class="nump">$ 17,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>May 08, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employees eliminated (as a percent)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,502)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 2,011<span></span>
</td>
<td class="nump">$ 3,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring costs</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,986<span></span>
</td>
<td class="nump">$ 5,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="nump">$ 11,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,699<span></span>
</td>
<td class="nump">13,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,267<span></span>
</td>
<td class="nump">24,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement', window );">Monthly agreement option fees</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC | Development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC | Sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePotentialPercent', window );">Maximum milestone (as as percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fees per month to be paid to enter into collaborative service agreement option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CollaborativeArrangementMilestonePaymentsPotential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential maximum payments that could be paid under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CollaborativeArrangementMilestonePaymentsPotential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CollaborativeArrangementMilestonePotentialPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of net sales payable under a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CollaborativeArrangementMilestonePotentialPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_BioxcelCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_BioxcelCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btai_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btai_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btai_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btai_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Debt summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="nump">$ 109,391<span></span>
</td>
<td class="nump">$ 106,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt premiums, discounts and issuance costs</a></td>
<td class="num">(3,865)<span></span>
</td>
<td class="num">(4,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">105,526<span></span>
</td>
<td class="nump">102,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion of long-term debt</a></td>
<td class="num">(5,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">99,918<span></span>
</td>
<td class="nump">102,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">7,072<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="nump">$ 102,319<span></span>
</td>
<td class="nump">$ 102,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 12, 2023</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,391<span></span>
</td>
<td class="nump">$ 106,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SubsidiaryOwnershipPercentage', window );">Subsidiary ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PercentageOfOutstandingLoan', window );">Outstanding loan (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA | From and after the funding of Tranche B loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA | From and after satisfaction of funding conditions for tranche C loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_LineOfCreditFacilityInvestmentAllowed', window );">Maximum investment allowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,865<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_LineOfCreditFacilityAmendmentFeePercentage', window );">Amendment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_LineOfCreditFacilityExitFeePercentage', window );">Exit fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,319<span></span>
</td>
<td class="nump">$ 102,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentInterestRateDiscountRatePercentage', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentIncrementalOnVariableRatePercent', window );">Incremental interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PaidInKindInterestPercentage', window );">Debt paid-in-kind interest (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_TickingFeesPercentage', window );">Ticking fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of principal of Long-term debt</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded', window );">Principal payment of loans (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod', window );">Maximum percentage of budgeted amount allowed for disbursement</a></td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Tranche D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Period one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Period two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement | Period three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required from equity sale</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity required per the financial covenant of debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentIncrementalOnVariableRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage points added to the reference rate and variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentIncrementalOnVariableRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentInterestRateDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentInterestRateDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the quarterly amortization payments as percentage of principal amount of funded loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityAmendmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityAmendmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line of credit facility exit fee, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityInvestmentAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the Lenders agree to permit the entity to invest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityInvestmentAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of budgeted amount allowed for disbursement in applicable period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_NetCashRequiredMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_NetCashRequiredMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PaidInKindInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paid-in-kind interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PaidInKindInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfOutstandingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding Loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfOutstandingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SubsidiaryOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SubsidiaryOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_TickingFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents ticking fees percentage relating to debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_TickingFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_FromAndAfterFundingOfTrancheBLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_FromAndAfterFundingOfTrancheBLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Warrants (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="nump">$ 320.64<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_RightToPurchaseStockLenders', window );">Maximum equity investment allowed for lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OriginalWarrantsMember', window );">Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member', window );">2024 Warrant Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ThresholdLiquidityEventAmountForExerciseOfWarrants', window );">Threshold amount of liquidity event for exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PercentageOfFairValueConsiderationToBePaid', window );">Percentage of fair value of consideration to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PercentageOfValuationApplicableToInitialProfits', window );">Percentage of valuation applicable to initial profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfFairValueConsiderationToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of consideration to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfFairValueConsiderationToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfValuationApplicableToInitialProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation applicable to initial profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfValuationApplicableToInitialProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PremiumSharePricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents premium percentage for share price determined over a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PremiumSharePricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_RightToPurchaseStockLenders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum equity investment allowed for lenders in entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_RightToPurchaseStockLenders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ThresholdLiquidityEventAmountForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of  liquidity event for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ThresholdLiquidityEventAmountForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OriginalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OriginalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 22,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">$ 86,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 3,643<span></span>
</td>
<td class="nump">$ 3,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of financing costs</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Total interest expense</a></td>
<td class="nump">$ 3,993<span></span>
</td>
<td class="nump">$ 3,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember', window );">Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2025AccompanyingWarrantsMember', window );">March 2025 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">$ 2,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (decrease) carrying value</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2025AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2025AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Financing Activities (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Nov. 22, 2024</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,006<span></span>
</td>
<td class="nump">$ 26,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember', window );">Jefferies Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SaleOfStockMaximumValueSharesToBeIssued', window );">Maximum value shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember', window );">Registered direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember', window );">Registered direct offering | March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember', window );">Registered direct offering | March 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember', window );">Underwriting Agreement | November 2024 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember', window );">March 2025 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="nump">$ 12,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="nump">$ 1,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember', window );">March 2025 Offering | March 2025 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember', window );">March 2025 Offering | March 2025 Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights', window );">Offering price of warrants</a></td>
<td class="nump">3.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember', window );">March 2025 Offering | March 2025 Prefunded Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember', window );">March 2025 Offering | March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SaleOfStockMaximumValueSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate net offering price of shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SaleOfStockMaximumValueSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_March2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_March2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_March2024PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_March2024PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024PrefundedAccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024PrefundedAccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_March2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_March2025AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_March2025AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_March2025PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_March2025PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Description (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member', window );">2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant', window );">Annual increase in shares available for grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance (in shares)</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btai_StockPlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_StockPlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_StockPlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Non-options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | RSU vesting 100% at one year anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | RSU vesting 25% at one year and remaining in 12 quarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested aggregate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average price beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average price ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options (Details) - Employee Stock Option<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares) | shares</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Options cancelled (in shares) | shares</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable (in shares) | shares</a></td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per shares)</a></td>
<td class="nump">$ 265.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">7.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per shares)</a></td>
<td class="nump">124.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in dollars per shares)</a></td>
<td class="nump">384.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end balance (in dollars per shares)</a></td>
<td class="nump">210.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per shares)</a></td>
<td class="nump">$ 268.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, outstanding | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options vested (in dollars per share)</a></td>
<td class="nump">$ 196.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 1,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining unamortized expense period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility (as a percent)</a></td>
<td class="nump">112.00%<span></span>
</td>
<td class="nump">108.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 3,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs</a></td>
<td class="num">(514)<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs</a></td>
<td class="nump">$ 694<span></span>
</td>
<td class="nump">$ 2,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - ESPP (Details) - 2020 Employee Stock Purchase Plan - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant', window );">Annual increase in shares available for grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred', window );">Maximum number of shares issued or transferred under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percent of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance (in shares)</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of shares issued or transferred under ESPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of the operating lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">$ (350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to renew the lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 3,274<span></span>
</td>
<td class="nump">$ 6,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value money market accounts</a></td>
<td class="nump">30,310<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,274<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">1,834<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">1,834<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,274<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">6,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_BioxcelWarrantsAggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_BioxcelWarrantsAggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Level 3 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Level 3 liabilities reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">$ (1,431)<span></span>
</td>
<td class="num">$ (88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,440<span></span>
</td>
<td class="nump">$ 1,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Level 3 liabilities reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions of derivative liabilities</a></td>
<td class="nump">2,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Level 3 liabilities reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Termination of Derivative liabilities - Equity Investment Right</a></td>
<td class="num">(369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions of derivative liabilities</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Inputs (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 18, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 05, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 03, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 19, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Increase (decrease) carrying value | $</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.385<span></span>
</td>
<td class="nump">0.392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0396<span></span>
</td>
<td class="nump">0.0401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="nump">$ 320.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.3232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member', window );">2024 Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember', window );">March 2024 Accompanying Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Not Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Not Amended | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Share price input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Warrants outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">5,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Closing Date Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="nump">$ 320.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.3232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member', window );">2024 Warrant Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember', window );">March 2024 Accompanying Warrants, Strike Price Not Amended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 51.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Armistice Capital Master Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Heights Capital Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | Hudson Bay Capital Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember', window );">November 2024 Accompanying Warrants | IntraCoastal Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member', window );">March 2025 Accompanying Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantShares2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrants2024StrikePriceNotAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_November2024AccompanyingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_ArmisticeCapitalMasterFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_ArmisticeCapitalMasterFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_HeightsCapitalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_HeightsCapitalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_HudsonBayCapitalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_HudsonBayCapitalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_IntraCoastalCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_IntraCoastalCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_AccompanyingWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (numerator)</a></td>
<td class="num">$ (7,254)<span></span>
</td>
<td class="num">$ (26,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares (denominator) - basic (in shares)</a></td>
<td class="nump">4,834<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares (denominator) - diluted (in shares)</a></td>
<td class="nump">4,834<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (13.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (13.89)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=btai_BioxcelWarrantsAggregateMember', window );">BTI Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Common stock equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">5,792<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=btai_BioxcelWarrantsAggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=btai_BioxcelWarrantsAggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase agreement expected cost</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase agreement expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase obligation originally due in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_PurchaseObligationPriorYear', window );">Purchase obligation, 2024</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">2025 Purchase obligation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2026 purchase obligation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Reconciliation payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase agreement expected cost</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase agreement expected cost</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PurchaseObligationPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement pertaining to prior year but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PurchaseObligationPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total selling, general and administrative costs</a></td>
<td class="nump">5,699<span></span>
</td>
<td class="nump">13,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,267<span></span>
</td>
<td class="nump">24,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">3,993<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(6,559)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,254)<span></span>
</td>
<td class="num">(26,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=btai_SingleReportableSegmentMember', window );">Single reportable segment | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense', window );">Personnel and related costs</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">3,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense', window );">Non-cash stock-based compensation</a></td>
<td class="num">(514)<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseProfessionalFees', window );">Professional fees</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense', window );">Clinical trials expense</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense', window );">Chemical, manufacturing and controls cost</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_ResearchAndDevelopmentCostsOtherExpenses', window );">Other expenses</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCostsAbstract', window );"><strong>Commercial costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CommercialCostsLaborAndRelatedExpense', window );">Personnel and related costs</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CommercialCostsShareBasedPaymentArrangementExpense', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CommercialCostsProfessionalFees', window );">Professional fees</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CommercialCostsCommercialAndMarketing', window );">Commercial and marketing</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CommercialCostsTravelAndOtherExpenses', window );">Travel related expenses</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_CommercialCostsOtherExpenses', window );">Other expenses</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Total commercial costs</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense', window );">Personnel and related costs</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense', window );">Non-cash stock-based compensation</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseProfessionalFees', window );">Professional fees</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses', window );">Travel related expenses</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SellingGeneralAndAdministrativeCostsOtherExpenses', window );">Other expenses</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total selling, general and administrative costs</a></td>
<td class="nump">5,492<span></span>
</td>
<td class="nump">10,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,267<span></span>
</td>
<td class="nump">24,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">3,993<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(6,559)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,254)<span></span>
</td>
<td class="num">$ (26,791)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsCommercialAndMarketing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commercial costs recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsCommercialAndMarketing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsLaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs for salary, wage, profit sharing; incentive and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsLaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expenses related to commercial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs related to a fee charged for services from professionals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs for award under share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CommercialCostsTravelAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial costs related to travel expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CommercialCostsTravelAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentCostsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expenses related to research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentCostsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to chemical, manufacturing and control costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to salary, wage, profit sharing incentive and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to a fee charged for services from professionals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense during the period related to expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeCostsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expenses related to selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeCostsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense for salary, wage, profit sharing; incentive and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense related to a fee charged for services from professionals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense for award under share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense related to travel expenses during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=btai_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=btai_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Apr. 03, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>May 09, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 13, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_PrefundedWarrantsMarch2025Member', window );">March 2025 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member', window );">March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_SaleOfStockMaximumValueSharesToBeIssued', window );">Maximum value shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_RetentionBonusExpense', window );">Retention bonus</a></td>
<td class="nump">$ 1,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-options granted (in shares)</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | March 2025 Option Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants, stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btai_StockIssuedDuringPeriodSharesWarrantsExercise', window );">Exercise of pre-funded stock purchase warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_RetentionBonusExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of retention bonus during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_RetentionBonusExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SaleOfStockMaximumValueSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate net offering price of shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SaleOfStockMaximumValueSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_StockIssuedDuringPeriodSharesWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_StockIssuedDuringPeriodSharesWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_PrefundedWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_PrefundedWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OptionWarrantsMarch2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  Y(K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  Y(K%K# 89$\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    (  Y(K%J9]?'3R 4  . >   8
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M+;@OE'D OE]*J0\7Y@>*0^WQOU!+ P04    "  .2*Q:<@R-QCT&   )'@
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MCR8X81:VG;P$K^.=I"OD=3(I&W#+QU0  $=)OX.Z5XB>;<@P(3B>X-8@!Y"
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M@UDCL3>RQP)E19&U9/6L+GIM@RY2[?&+'=R5DLPMP<1EBN(&75X^6^39K3F
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M]VK8M1HZ4.P-<:_IXR]]<5U@]?O:+R"V>W&W9U\13=S)]=K26L832[N=HXS
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M"&S3ZYH)F2KTE[DA[E9A6/#O :T/X/V%X2.YF_@$[0]G\AM02P,$%     @
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MP&,>#D=83=I7E<TT !%E7P'75QI5X0O >;@B:.&0,#GX-L]?VF37(PP;G5*
M7OMY8+"4"VG+IEF?UB/GK.RTK^;EO$(6:R8-X;!"UZ@][ =$ES.@%*S*?=]=
M*HM=W&\S')N@G0'J5PH?8"6X /4@GOT&4$L#!!0    (  Y(K%K/G;<6LP(
M ! '   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*55VW*;,!#]%0WI
MY,EC0.!+')N9.$FG?4CK27IYEF$Q3$"BDHC=O^]*7$+CQ).9O"#M:O?HK!8=
M+?="/JH,0)-#67"U<C*MJX7KJCB#DJFQJ(#C2BIDR32:<N>J2@)+;%)9N-3S
MIF[)<NY$2^O;R&@I:EWD'#:2J+HLF?R[AD+L5X[O=([[?)=IXW"C9<5V\ #Z
M9[61:+D]2I*7P%4N.)&0KIPK?[$.3;P-^)7#7@WFQ%2R%>+1&%^3E>,90E!
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MP/%.T\F1Z\(GW[$Y$A7K1?=>1H8T..9)Z?#HM*QC74ML,9:O7BG5I_-C4EY
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M;X^(_[CDO-*TV8IQI ]F;UEO1@#T*#B9116(T;I(T6:5Z0+&S_@ID_>EB6>
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MZN)P+-L*<]H;;A%-3%N""H)L%Q&0A R9Q(A9!Q9F^X?A=#G_-+C&S) +L0:
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MHG\N502\B _ ?3QS4?_ "39%>4/@O?P?4$L#!!0    (  Y(K%K^S*9_( 4
M +@/   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;.U7;6_;-A#^*P<U
M*#; L"S;29,V,>"D31=@78*F7?:5EDX6$8I422I._OWN*%E66L?MN@[;AWVQ
M1>KNN>=>*1ZOC+UU!:*'^U)I=Q(5WE<OX]BE!9;"#4V%FM[DQI;"T](N8U=9
M%%E0*E4\'HT.XE)('<V.P]Z5G1V;VBNI\<J"J\M2V(=35&9U$B71>N.]7!:>
M-^+9<266>(W^8W5E:15W*)DL43MI-%C,3Z)Y\O)TRO)!X'>)*]=[!O9D8<PM
M+RZRDVC$A%!AZAE!T-\=GJ%2#$0T/K6846>2%?O/:_3SX#OYLA .SXRZD9DO
M3J+#"#+,1:W\>[/Z!5M_]ADO-<J%7U@ULI-)!&GMO"E;96)02MW\B_LV#CV%
MP]$3"N-681QX-X8"R]?"B]FQ-2NP+$UH_!!<#=I$3FI.RK6W]%:2GI^]1BOO
M!$<&SJ46.I5"P85VWM84>N^.8T]66#9.6\33!G'\!.($WAGM"P=O=(;98_V8
MV'44QVN*I^.=@.^$'<(D&<!X--[?@3?I7)X$O,D/=+E!G&Y'Y,9YZ2J1XDE$
MG>'0WF$T>_XL.1B]VL%WVO&=[D+_+KZ[$7\S'B$9#>%KT'#ZX0)D1H\REYA!
MBM93HT-N$9T7.I-Z"7FG*7N:]#(V%K!<8$9U #D*7U-PP!?"4SM_JJ5%<%@)
M*XB-2%-3DQG&LZ8D*82%L10JVG)04RW9L'EY/H=SD4HEO40WA ^%=&0X5746
MP$E"WQKW1XH*;H2UHB4#;\BB?R#O[H@Z<X0P@:! E<'B(:C^BFS'#4 H0TQ6
MTA>=SU7MXU0H!:;B>1),_V5CF0%M/)0\;M? +J41"WB?8@/<.OMQ>#V$M_/Y
MU0 J*VEB2O4 "TQ%[3"0Q7NTJ:0%O4ZQL:MKBK<%DX,K!$>;GECVS)25T _/
MGQV.DQ>O'*2F+&DFTGA);T$Z5XN%PEZ4'V62\G1'YEED$*Q\+A'<X4T:AU++
M,&[)L*!U5U\;^1 XFKW&$AQIN2_-64R-Y:H1KE^CBCBTB2>5UC'BK!V)TI,S
M2F9431F<"D4UB7#-@[%-%86CPG (]'GU,5?XR+:'7$A+OJL:P33V&)Y]"S%C
M"QR/AG*0RU@015K06=%0:,[6H,<%KNC\H[>?>^S0>\7:U#+WE>30--57"+W<
MN-LCM$"_0N23L3(V-$Y%7IG,;3Q@!%*\)$T+/U&3F!)_9GR.V  T\>K"^+@^
MG@CKM:>_AC3%X)(,BK87Y@XRZ>C 8AT"#2/F:$#96_@0HS.+F?2]U@4V-IJ\
M@AOVLTT.>!/X7-66/*?*F"]IU(0&^A(^H3/AK"GDZU#([0RC4,PYSXV9\TW(
M2A2.9E#CP-K\):/=8>B;<7/*3 =;&HP]WI],UQTUIX$58L;FNMY?"0Y_5J<\
M\7B.[>TGP_&(W=H[&B:3 TY2TYM#H,^* .4+\A'*YM3D"90!G7E4).M#;]#/
MT2:]WG@:NIS%)<V1D)*]9'#PX@AV)WVP(^O?F&O:V4:QWR]?"]/>P309;L_"
M_CH+JRVE\9&'U,I*3Y)_OSJX-/_=\?7$T&+=+Z+\_R#[CD'V+27]3[3B9# Z
M'/V'6G'37]1;NQHS&21'DT>MV1I8XV]KRT:$W\-EGE,""?9[FW)M^4+3AXK6
M[04N6/W!IK9]GL>]VU2)=AGNC/S)1%7?7*RZW>Y:.F]N8QOQYDY+3)=<#@IS
M4AT-7^Q'8)M[8K/PI@IWLX7Q=-,+CP5=K=&R +W/#;G2+MA =UF?_0E02P,$
M%     @ #DBL6E@^K;N\"0  "2T  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL[5IK;]NX$OTKA#=8)(!CRX\D;O, DG2SMXNV"9KMW<^T1-O<2J1*
M4G%\?_W.#/5TY,1]; KT]DMB2>3PS.O,D-+)4IN/=B&$8_=)K.QI9^%<^K+?
MM^%")-SV="H4/)EIDW 'EV;>MZD1/*))2=P?!L%A/^%2=<Y.Z-Z-.3O1F8NE
M$C>&V2Q)N%E=B%@O3SN#3G'CO9PO'-[HGYVD?"YNA?N0WABXZI=2(ID(9:56
MS(C9:>=\\/)BC.-IP'^E6-K:;X::3+7^B!>OH]-.@(!$+$*'$CC\NQ.7(HY1
M$,#XE,OLE$OBQ/KO0OH5Z0ZZ3+D5ESK^2T9N<=J9=%@D9CR+W7N]_(_(]3E
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MIQ/ZN1 <?(4#X/E,:U=<X +EU\]G_P!02P,$%     @ #DBL6M.,DLSN#@
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M=OG^#7L'\FF9X!AKZ*J0 -<H>DETEMA,N$8"DHNQQ3T6,5IDG'0#2Q&IZP_
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M"]JJ_<:+R3#H)OM[T\,BL%_VGE >S^:A"J+1,)Y_L<;KU9WC^XX.]U:M$(3
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MJ^T7PWEX*)^/A\\-<FC!29O @J!)]],P AV>\#"QJO;/YEQ9>H3]T/52U.X
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M>+;@!F0+SB2J;0UJEWC2.&@PN31NBJ&;ZM,MSEPS*HL9'57;,"1!#-3B/L:
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MPG ?AX9MLQ,E%S$-[\EM"*D2I@%(<$.O+FPAEX@AV.N<1*>+.CG'?<(%3>9
M@"<;N]LCO2@W>C2YL<F%R!9$3+$4,(DJRI#4!HID7"=:W0P\ZQQ**A0W^;I.
M%9LI* @40TH/N3@0JJ5FI6PAY,=S(=??/^VYZZJB/:523?M.(Y?Y)C_>;R>
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MA  CE^E10-RZHF'15<,DCZN6FI?5VS&@Q7JZ"%L5S\M,=KA71\-S[%&P9_D
MM<)XW"X@)L.C*K,_V9G7>S9,UF^1H$)RI4RO4+\T,[' X*:97EDD])4B= ,
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M<$+3NFE I C\GP98->8@:%:JFF^^"KKKW@^*N^^.M%W\NRVP[\+T@/,@4'?
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M@LWXWZ62J,FT >MSB_I3/1"#YA/HZ7\ 4$L#!!0    (  Y(K%K)M-;^IP8
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MA':LTBVKM^F+@.^D.1>C)!)IG(Y?P!OMK!QYO-%?LS* 9/T@G!YO[$;F=#6
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MVVS+Q<<VU]:%H&T0=N7@ZPJ&Y#E*'N)$SR8[D&2U@,("L2XMKT"M<6O&WZL
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MG'OMG*[]XYID088G8'RI\1+8-GB#W6>]Z_\"4$L#!!0    (  Y(K%K\=E*
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M6J+ =8"ZWS(F#X9.T*_E]#=02P,$%     @ #DBL6A.MA^M$ @  B@8  !D
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M\'V=%E Q?2IK$+B22U4Q@Z;:^+I6P+(65'&?!L',KU@IO&31^NY5LI"-X:6
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M31.?/!7XN-D<XWT(U!/8I ML\M.![0H)7G JT' LK/UH;]V-G@KL%J1J_V[
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M=#I6@ :00'Z4(80RU+4RS2S#K3!HV0%4I@#@#WH)6;09J#4<(#?6JX[AH1<
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MHITWLKD7'ZI'HS@N75(65N,J1YR=W6#>ORICR"UHLLB9!G)^SY8"3&<26MS
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MSP1I!N#_M1#ZT# 3=#?7Y;]02P,$%     @ #DBL6D:-0[KQ @  A D  !D
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M>H/ZOF1,;B<Z0/?P2OX 4$L#!!0    (  Y(K%I!X_GPW (  $ *   9
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M+E6B>=VOU!/)2E.0GYA4Y=T,,]7B =<&ZON",;F=: =MTQC] U!+ P04
M"  .2*Q:4F/(XL0"   \"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6RM5FUOFS 0_BL6JZ966LL[Z;($J0FKU@^5JKYLGUVX!*M@9[83VG\_VQ":
M%\(:J5_ -O<\=\\9WWE4,?XB<@")7LN"BK&52[D8VK9(<RBQN& +H.K+C/$2
M2S7E<ULL..#,@,K"]APGLDM,J!6/S-H=CT=L*0M"X8XCL2Q+S-\F4+!J;+G6
M>N&>S'.I%^QXM,!S> #YM+CC:F:W+!DI@0K"*.(P&UM7[C 9:'MC\)M )3;&
M2"MY9NQ%3VZRL>7H@*" 5&H&K%XKF$)1:"(5QM^&TVI=:N#F>,U^;;0K+<]8
MP)05?T@F\[%U::$,9GA9R'M6_8)&3ZCY4E8(\T15;1N$%DJ70K*R :L(2D+K
M-WYM\K !< \!O ;@[0*" P"_ ?@?!00-(#"9J:68/"18XGC$686XME9L>F"2
M:=!*/J%ZVQ\D5U^)PLGXAJZ 2L;?T&D"$I-"G*%S]/20H-.3,W2""$6/.5L*
M3#,QLJ7RJ'%VVK!/:G;O +N/;AF5N4 _:0;9-MY6D;;A>NMP)UXOX2WF%\AW
MOR'/\<*.>*8?AP<=\*0?GD!Z"+ZEQF^3[QL^_W_)[\IL#0VZH;H:#,4"IS"V
MU'$7P%=@Q5^_N)'SHRLMGTF6?!+95LJ"-F5!'WM\CROU^TO@!!>=/V0-CPQ<
MU[Q5'$1JKU:;V>AU<6PV]AV&3M0ZW!(9MB+#7I'7A!)UI#,T9ZS[V-7X<,.I
M.[C<4=GKXUB570[];I51JS+J5?G()"Y4@>DY ]&>URCP=F3V.CE69K2WF='@
M>[?,02MST"OSO<)6G$@XSUA%._=TL.?;V9&Z;Q&$VR9);RS'GDU[HZ^4P.>F
M/PN4LB65=<UN5^LKP,0=3DVKW%E75X,KTQ'M=YKZ7J$J\IQ0@0J8*4KG8J V
MF]>]NIY(MC#=ZYE)U0O-,%?7&^#:0'V?,2;7$^V@O3#%_P!02P,$%     @
M#DBL6K;F7 :T P  #A0  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
MK5AKCYLX%/TK%ENM6JD=7@$FV01I)K3:E7:J4:?M?O; 3; *F-HF:?_]VL 0
M2!@R&?E+@@WG7)_C!Y>[W%/V@Z<  OW*LX*OC%2(<F&:/$XAQ_R*EE#(.QO*
M<BQDDVU-7C+ 20W*,].Q+-_,,2F,<%GWW;-P22N1D0+N&>)5GF/V^Q8RNE\9
MMO'4\85L4Z$ZS'!9XBT\@/A6WC/9,CN6A.10<$(+Q&"S,F[L163["E _\9W
MGO>ND9+R2.D/U?@G61F6&A%D$ M%@>7?#M:098I)CN-G2VIT,16P?_W$_JD6
M+\4\8@YKFOU'$I&NC&L#);#!52:^T/W?T KR%%],,U[_HGWSK.\:**ZXH'D+
MEB/(2='\XU^M$3V Y!D'."W .0;,G@&X+<!]*6#6 F:U,XV4VH<("QPN&=TC
MIIZ6;.JB-K-&2_FD4//^()B\2R1.A/=,+B$F?B-<).CCSXJ4<E+%>_19+KFW
M$0A,,OX.?4#?'B+T]LT[] :1 GU-:<4E@"]-(<>@F,RXC7?;Q'.>B>>B.UJ(
ME*./10+)$&_*L7<"G"<!M\XDX1UF5\BUWR/'<KR1\:Q?#I^-P*-I> 3Q<_"!
M&K>;#K?F<U\R'7"8C@+$F-<-V6R<3!T9"U[B&%:&/!,XL!T8X9]_V+[UUYA1
M.LDB360#$V>=B;,I]O K%3A#Y:B58RXV;'[-IL[)76C/@V!I[OKN3(:\U)TS
M$0>JO4ZU-ZGZ)HZKO,JP@$0>?'(4,<'J:!U3W#!YO?@?;"^X/I(\&>]2R:,A
M+6=<L]]I]E\]T\]N&O]D).Y\?B1],NRETD\#S@)O7'C0"0\FA4=G)C@X"1GX
M1Q*#DS5XO "BR3&\<A-?=PJO)Q6N:5Y6 A@_OW\GB2X]!76219K(!@;..P/G
M.E\E<YTFZB2+-)$-3+2M0WYD:7V9M'3]K>?TCKG&G^F8EQIT)N10>"\QM">%
M?ZI8043%8%3E)/;2Y:*5+=+%-O3-.?CFZ-QW+9LN)W6R1;K8ADX><F%[,DN\
M?.NY)_O Z[UH6X>TIKEG0@Z%'_)7>SJ!_1?DEVQ*LP217,K?@5(\_K&E,RU=
M:V6+=+$-33RDP[:G=1_JS';76MDB76Q#)P])MOWZ+'O42O_T\\:QK..-J#7'
M/A>SD6[V"B4YL&U=<.(HIE4AFI)#U]L4M6[MQ;JN_1SUW]B+F[K$8QYHFDK9
M'69;4G"4P4926E>!G#O6%)^:AJ!E78YYI$+0O+Y, 2? U /R_H92\=10 ;H2
M8/@_4$L#!!0    (  Y(K%K3CT3\T0(  -,(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;*V676^;,!2&_XK%JJF3MO)-DHX@M<FF[6):U8_MVH%#
ML J8V2;)_OV.(;720*-<[":QX;SG/*\_B;=</,L"0)%=5=9R;A5*-=>V+=,"
M*BJO> ,UOLFYJ*C"KEC;LA% LTY4E;;G.)%=459;2=P]NQ-)S%M5LAKN!)%M
M55'Q]Q9*OIU;KO7RX)ZM"Z4?V$G<T#4\@'IJ[@3V;),E8Q74DO&:",CGUHU[
MO9CI^"[@%X.M/&@3[63%^;/N?,_FEJ.!H(14Z0P4_S:P@++4B1#CSSZG94IJ
MX6'[)?O7SCMZ65$)"U[^9IDJYM;4(AGDM"W5/=]^@[V?4.=+>2F[7[+M8T//
M(FDK%:_V8B2H6-W_T]U^' X$;O"&P-L+O',%_E[@=T9[LL[6DBJ:Q()OB=#1
MF$TWNK'IU.B&U7H6'Y3 MPQU*KE)4]%"1K[L<%U(D.1R"8JR4GX@G\C3PY)<
M7GP@%X35Y+'@K:1U)F-;86$MM]-]D=N^B/=&D1]47!'?_4@\QPM'Y(O3\B6D
M1AZ\EMMHUWCVC&>OR^>?Z7G,4)\A&,^@M]:U;&@*<POWC@2Q 2MY_\Z-G,]C
M]OY3LE=F?6/6/Y7=F-69J4@+@E.(ZWR#^[?!W:@(G!B%/G74I=;GP2;Q'->-
M[<VANV&0[SH3$_2*.C#4P5G4*:\T'>VW/)*OH(:<J5':/F5X2'O,.@SQPW'2
MT)"&9Y$V@N<@]>%&2Y+#^'B&@_*N[T^/&$>"(B<8IXP,9706I:*[<;)H4#0*
MC[B&(3-WG&IBJ"8GJ7ZJ @2>Y#W;J84X&=0.//^(;QCC>]XXX-0 3L_=/$JT
MJ6H%J]>X*.7X IP.9\X[GMUA3.3XXY0S0SD[2?G(%:ZY<X9Q-MRJLVET1#@,
M"B?1\4#:!U>.ON[QB%^S6I(2<I0Y5Q-T*/HKM.\HWG2WT(HKO-.Z9H%?'2!T
M +[/.5<O'7VQF>^8Y!]02P,$%     @ #DBL6K<HIHTK!0  7B,  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&ULM9I_;Z,V&,??BL5.4RO="@9"DBZ)
MU :F[735JK:W[5\W<1)T@#/;:5II+_[,CT(,U%=.SZJJ >+G8_-]X@=_&\^.
MC'\5.THE>DZ33,RMG93[2]L6JQU-B;A@>YJI=S:,IT2J4[ZUQ9Y3LBZ"TL1V
M'2>P4Q)GUF)67+OEBQD[R"3.Z"U'XI"FA+]<TX0=YQ:V7B_<Q=N=S"_8B]F>
M;.D]E5_VMUR=V35E':<T$S'+$*>;N76%+R/7RP.*%G_%]"A.CE%^*X^,?<U/
M_EC/+2<?$4WH2N8(HEZ>Z)(F24Y2X_BW@EIUGWG@Z?$K_;?BYM7-/!)!ERSY
M.U[+W=R:6&A--^20R#MV_)U6-S3*>2N6B.(O.I9M@Y&%5@<A65H%JQ&D<5:^
MDN=*B), [+\1X%8!;CO@K1Z\*L![;P]^%>"_-V!4!12W;I?W7@@7$DD6,\Z.
MB.>M%2T_*-0OHI5><99_4.XE5^_&*DXN'CC)!"F2)E37<H>N8_;/BB;H\^<E
M.@NI)'$BSM$OZ,M]B,X^G*,/*,[0PXX=!,G68F9+-8J<9:^J'I=EC^X;/7KH
MAF5R)U"4K>E:C[?5Z.M;<%]OX=HU C\=L@OD.1^1Z^!QWWC,X3>$JW"<A[NC
MGO#P_>%^3WAD#@_IZJUP30ROSJ=7\+RA^>P9VG6)\OM1>8FZ%'NRHG-+U2!!
M^1.U%C__A /GUSZ5(6$A)"P"@FGY\.M\^";ZXDX1"5_MD)HLJH ]J<J\5W56
M]J7#2!J:CA(6%+#\:?&T\$<C]0E[.I6YVPACW\%ZJPAH7)I^HUJ_D5&_>_4(
MB;/M1[2E&>4D*70D:U4)8R$YR9\R?5(:H4.E+&&C$Y5&P73:DK+;"'MNT!(\
M AJ7)F502QD8I7Q@4NFGEABY;-D6T6>UVA"TKX1?&TE#]0NZTCAN,&X)V&WE
M^F-_U!(0:&":@.-:P/%WYG)")%VC6\+E2Y]JQO"AJD'"0DA8! 33<C"I<S"!
M>[Y-(/,!"0LA81$03,O'M,['U#@G_I0[RM5"E7/U4$-)3![C))9Q?U4QHH;F
M8]JM*KA=E"$[C*;=AZ73%#%-/>PTRV_G_34%_7>Z^NY3T$P;*B$H+02E15 T
M/2\GM@C#U9F*!9452%H(2HN@:'I6W"8KKG&V%,XQ>4%DRRG-E]%J.5/\OV%#
M^RM.Q=,F[40O$DMSGX/UAJ1%4#1=[\9,8J,W&N1>S*C!D\#KEG>_7=[[&DV"
MUHH1:ERZA(W_PV8#^(,&QDP=K*;?$2J8M,7LMO$G;2W_#RN(&R^(S69PB(,Q
MHP8+V+5W+FX[F*K1:;%QO;8#A!J7+F'C ;'9! Y:KYE9@S4,.O(X;04A.XR@
M:+K4C5O$ ^RBOK139V%335$:)U1(EKV1!5!;"4H+06D1%$U/6&,M,:"WQ*#F
M$I06@M(B*)J>E<9@8K/#O&52S9%8%?YZFJ ]><DG3O]TZ3&&COIIK_H@O6$(
M2HN@:/K7*8TG=7_8DZJS>Z*R\)V29>Y@Z.0 I86@M B*IJ>JL:DNH$UU06TJ
M*"T$I450-#TKC4UUS39U:,ERNR[5ZRE9YEX'*PYJ5*%HNN*-477-1O6&/,?I
M(3W1^XP(I'Z55U@IV<][92^9^7^:FA7IA>.U90?]9A.4%D'12MGMDWT$*>7;
M8@.'0"MVR&3Y?7Q]M=PDLL278;&7HG7]"E]>%5LF[ 93[CRY(7P;JUJ5T(U"
M.A=C]9SFY6:.\D2R?;%;X9%)R=+B<$?)FO*\@7I_P]3DJD[R#NHM-8MO4$L#
M!!0    (  Y(K%J%WG(76P,  .(+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;*U6:V_3,!3]*U9 :$C;DCA-THXVTM:"0&+2Q!A\=I/;UEIB%]M9
M@5^/[619'UX&J%_:V+[G^)SKUQUON+B7*P"%?E8EDQ-OI=3ZPO=EOH**R'.^
M!J9'%EQ41.FF6/IR+8 4%E25/@Z"Q*\(95XVMGTW(AOS6I64P8U LJXJ(GY=
M0<DW$R_T'CN^T.5*F0X_&Z_)$FY!W:UOA&[Y'4M!*V"2<H8$+";>97@Q#;$!
MV(AO%#9RZQL9*W/.[TWC4S'Q J,(2LB5H2#Z[P&F4):&2>OXT9)ZW9P&N/W]
MR/[!FM=FYD3"E)??::%6$V_HH0(6I"[5%[[Y"*VAV/#EO)3V%VV:V#3U4%Y+
MQ:L6K!54E#7_Y&>;B"V YG$#< O ^X#D&4#4 B)KM%%F;<V((ME8\ T2)EJS
MF0^;&XO6;B@SRWBKA!ZE&J>R&<P5(JQ 4P$%5>@#R6E)%06)SI =;!<8G<Q
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MN'E"VPV<9ZMB^U_KOGGLX,2:;XHR6S>#JRU8)^G#O]&/Y@?Q9,#X[)D!PV;
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MZJ&:CVH!JH6HIBA-3V5;,YKTKAGM5KT?.S.)%HU0S4$U@6H2U5Q4\U#-1[4
MU4)44Y2F1[<M&DU>5S2:H$4C5'-03:":1#47U3Q4\U$M0+40U12EZ1%MBT:3
M%ZY2U.O&[V:L=W#1FA&J"523J.:BFC<YO #3\' M[J.3!J@6HIJB-#V1;<MH
M\NJ6T55G)M&6$:HYJ"903:*:BVH>JOFH%J!:B&J*TO3HMBVCR>M:1A.T981J
M#JH)5).HYJ*:AVH^J@6H%J*:HC0MHM.V930UMXSZK7?-6-_@HIJ#:@+5)*JY
MJ.8UFGY]S</U+CII@&HAJBE*TQ/9=HVFYJZ18;WK=&82;1JAFH-J M4DJKFH
MYJ&:CVH!JH6HIBA-CVY;2)H.7[7>G:*U(U1S4$V@FD0U%]4\5/-1+4"U$-44
MI>D1;6M'4_/-R7JN=]$R$JHYJ"903:*:BVI>HST]OSOI6N^B+2-4"U%-49J>
MR+9E-#6WC#K6NY_C/,D65I9V7A/;[/4.)5HR0C6!:A+57%3S4,U'M0#50E13
ME*9GM^TB32>O6_"BG2-4<U!-H)I$-1?5/%3S42U M1#5%*7I$6T[1U/N_F;3
MPYM<S0YO]V*>L'<<T7X1JDE4<U'-0S4?U0)4"U%-49H>Q[9?-/TOW@5M>G@K
MK-G!D<N5>0MZY_-PSJ[["J*32E1S4<U#-1_5 E0+44U1FAZ\MD8T[5TC:@XS
MR_NL,VQHCPC5'%03J"91S44U#]5\5 M0+40U16EZ=ML>T?1U/:(IVB-"-0?5
M!*I)5'-1S4,U']4"5 M135&:%M%9VR.:O= CZG&8.3MLG-B'9^"OS#/VS6/7
MI'M7CA3HC!+57%3S4,U'M0#50E13E*:GK.T&S5ZX$]J?.7IL;"T!9QVQ0QM
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MGY3974U:UUE99NOMA[=QM(CS^@'5]Y=95NX^J2>XS_)OV\V[_ ]02P,$%
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M5E#LK$?LM$?LO$?LQ$?LS,=?88G2QA*E9DOTQ65%S6\/: <>\LS<A).E ?5
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MORF*U?,7ZPD>B_+/S8]S^7]02P,$%     @ #DBL6F.T\G6L P  JA0  !D
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M>U-FFWK;Q,>L++-U_7(IXKG(JP/D]T]95KZ^J0+L]_:\^1]02P,$%     @
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MM4BSRQ70&*1]P?R^$$+O;VP'Y8G5[!]02P,$%     @ #DBL6NTVCC[? P
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M540/E56T;K#$RSEG>\#+:(56?JAZ4V4K-K0HA_%!<O4M57ER^1%3#K[A;$O
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M\NKCFF!5=AF@OG]B3+X=E&_)-&]%+?\'4$L#!!0    (  Y(K%J"JF]>^P,
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M96BG1Q\ID^0K37,@-T!5+@'W2"MR0JYA"2D)R=$E:,I2=8QC#_>7Y.C#,?E
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MJ*903:.:036+:H[2_(0U_8LR/E@C<0>(%C%0K4(UL=>\+Y;D_4$1;@''QUO
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MISW$ R&+]EE,M%C;#O0D-/8S.TSPCP.D<<#UI1!Z-S$;5/\PX1]02P,$%
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M5__Q"$1AK:3>R:E:3]YLO34GDI7U9M0=DY+E]6$&. 6N!ZC[:\;D\XD.T&V
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MC'M=DO;EK=T5!K$XC-A32[?-3'O;SV&$(NP9^,1PE837DM]5NXF]9DPFW9F
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M+L+Q5<"&- SLWORN-Y0\L)([5(P8(EGWTQJZ5V^!Z3C-1;L30M<$M#[)J/-
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M]\ZM_SA^?):=;?JW?#;^(V[Q E!+ 0(4 Q0    (  Y(K%I&QTU(E0   ,T
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ #DBL6L,!AD3R    *P(  !$              ( !PP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ #DBL6IE<G",0!@  G"<  !,
M     ( !Y $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  .2*Q:
MF?7QT\@%  #@'@  &               @($E"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ #DBL6G(,C<8]!@  "1X  !@
M     ("!(PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M  Y(K%K^3B/A[ (  %0*   8              " @984  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  .2*Q:2\#EWX $  #$$   &
M            @(&X%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ #DBL6DUC^!J,!0  O1\  !@              ("!;AP  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  Y(K%JRL%]O; 8  (T9
M   8              " @3 B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  .2*Q:8'DVYMP%   $#0  &               @('2*
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ #DBL6D^TXZET
M"0  PQ@  !@              ("!Y"X  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    (  Y(K%KGO(=UD 8  -01   8              "
M@8XX  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  .2*Q:
M6!9/I=T"  !\!@  &0              @(%4/P  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    (  Y(K%H#?3.*J0(  *X&   9
M      " @6A"  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ #DBL6JUL)1O8 @  E <  !D              ("!2$4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  .2*Q:SYVW%K,"   0!P
M&0              @(%72   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    (  Y(K%K$1A4AN04  )8.   9              " @4%+  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ #DBL6CY%]SL
M(@  $(H  !D              ("!,5$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  .2*Q:_LRF?R %  "X#P  &0
M@(%H<P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  Y(
MK%I8/JV[O D   DM   9              " @;]X  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ #DBL6M.,DLSN#@  ?#<  !D
M         ("!LH(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  .2*Q:B6(8?_$#  !3"0  &0              @('7D0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  Y(K%JPNUUS7@P  %PX
M   9              " @?^5  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ #DBL6E_WH[]% P  0PD  !D              ("!E*(
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  .2*Q:87DO
MG7H*   .'0  &0              @($0I@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    (  Y(K%K)M-;^IP8  .(3   9
M  " @<&P  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M#DBL6OQV4H!%!   6PD  !D              ("!G[<  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  .2*Q:E:1QP4L"  "B!0  &0
M            @($;O   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    (  Y(K%H3K8?K1 (  (H&   9              " @9V^  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ #DBL6HWN-TY-!@
M&Q$  !D              ("!&,$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  .2*Q:=#<_Z%P"  #S!0  &0              @(&<
MQP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  Y(K%IV
M<);REP(  ,D&   9              " @2_*  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ #DBL6OAKW(BK @  X08  !D
M     ("!_<P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Y(K%J4N3JF$P4  #T7   9              "
M@1G?  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ #DBL
M6M!N%.@2 P  W0@  !D              ("!8^0  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  .2*Q:%^P?5FX$  #%#@  &0
M        @(&LYP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   (  Y(K%I&C4.Z\0(  (0)   9              " @5'L  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ #DBL6D'C^?#< @  0 H
M !D              ("!>>\  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  .2*Q:4F/(XL0"   \"0  &0              @(&,\@
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  Y(K%JVYEP&
MM ,   X4   9              " @8?U  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ #DBL6M./1/S1 @  TP@  !D
M ("!<OD  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  .
M2*Q:MRBFC2L%  !>(P  &0              @(%Z_   >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  Y(K%J%WG(76P,  .(+   9
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M970T."YX;6Q02P$"% ,4    "  .2*Q:='V[MOH&  #F2P  &0
M    @(%R(P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M  Y(K%H.T27+@P\  ''M   9              " @:,J 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ #DBL6F.T\G6L P  JA0  !D
M             ("!73H! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  .2*Q:EC^<^: (  #G4P  &0              @(% /@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  Y(K%KS#M,]J00
M +T2   9              " @1=' 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ #DBL6NTVCC[? P  +14  !D              ("!
M]TL! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  .2*Q:
M\5"[K?$"  #N"@  &0              @($-4 $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    (  Y(K%K/.9$ZMP,  +00   9
M      " @353 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ #DBL6@NR/%HK P  -@L  !D              ("!(U<! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  .2*Q:GGLG%(H"  !!!P
M&0              @(&%6@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    (  Y(K%HO+_XH^P0  "$E   9              " @49= 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ #DBL6H*J;U[[
M P  'P\  !D              ("!>&(! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  .2*Q:8T8@WI,>  #82P( &0
M@(&J9@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (  Y(
MK%KY\;@N30@  -UF   9              " @72% 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ #DBL6I$J/N[L @  SP@  !D
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M=#8W+GAM;%!+ 0(4 Q0    (  Y(K%K9DY7Q9P,  )47   -
M  "  0"H 0!X;"]S='EL97,N>&UL4$L! A0#%     @ #DBL6I>*NQS
M$P(   L              ( !DJL! %]R96QS+RYR96QS4$L! A0#%     @
M#DBL6MB#*(M7!0  02P   \              ( !>ZP! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  Y(K%K(7,%2( (  - G   :              "
M ?^Q 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  Y(
MK%KB(3)"\0$  !DG   3              "  5>T 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !+ $L A!0  'FV 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>284</ContextCount>
  <ElementCount>306</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Transactions with BioXcel LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc</Role>
      <ShortName>Transactions with BioXcel LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Debt and Credit Facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities</Role>
      <ShortName>Debt and Credit Facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Common Stock Financing Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities</Role>
      <ShortName>Common Stock Financing Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995211701 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995211801 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureInventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Transactions with BioXcel LLC (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables</Role>
      <ShortName>Transactions with BioXcel LLC (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Debt and Credit Facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables</Role>
      <ShortName>Debt and Credit Facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99931403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99931503 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99931703 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureRestructuring</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Transactions with BioXcel LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails</Role>
      <ShortName>Transactions with BioXcel LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails</Role>
      <ShortName>Debt and Credit Facilities - Debt summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails</Role>
      <ShortName>Debt and Credit Facilities - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Debt and Credit Facilities - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails</Role>
      <ShortName>Debt and Credit Facilities - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Debt and Credit Facilities - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails</Role>
      <ShortName>Debt and Credit Facilities - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940905 - Disclosure - Debt and Credit Facilities - Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails</Role>
      <ShortName>Debt and Credit Facilities - Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Derivative Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Common Stock Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails</Role>
      <ShortName>Common Stock Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Stock-Based Compensation - Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails</Role>
      <ShortName>Stock-Based Compensation - Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Non-options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941203 - Disclosure - Stock-Based Compensation - Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941205 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails</Role>
      <ShortName>Stock-Based Compensation - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Leases - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails</Role>
      <ShortName>Leases - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941302 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Fair Value Measurements - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941402 - Disclosure - Fair Value Measurements - Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details</Role>
      <ShortName>Fair Value Measurements - Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941403 - Disclosure - Fair Value Measurements - Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails</Role>
      <ShortName>Fair Value Measurements - Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941404 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails</Role>
      <ShortName>Fair Value Measurements - Warrants outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941502 - Disclosure - Net Loss Per Share - Antidilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99941701 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="btai-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99941801 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>btai-20250331.xsd</File>
    <File>btai-20250331_cal.xml</File>
    <File>btai-20250331_def.xml</File>
    <File>btai-20250331_lab.xml</File>
    <File>btai-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="btai-20250331x10q.htm">btai-20250331x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>btai-20250331x10q006.jpg</File>
    <File>btai-20250331x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="675">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "btai-20250331x10q.htm": {
   "nsprefix": "btai",
   "nsuri": "http://www.bioxceltherapeutics.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "btai-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "btai-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "btai-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "btai-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btai-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "btai-20250331x10q.htm"
     ]
    }
   },
   "keyStandard": 251,
   "keyCustom": 55,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 53,
   "hidden": {
    "total": 19,
    "http://fasb.org/us-gaap/2024": 14,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 284,
   "entityCount": 1,
   "segmentCount": 84,
   "elementCount": 612,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 675,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness",
     "longName": "995210101 - Disclosure - Nature of the Business",
     "shortName": "Nature of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation",
     "longName": "995210201 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210301 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring",
     "longName": "995210401 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventory",
     "longName": "995210501 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet",
     "longName": "995210601 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses",
     "longName": "995210701 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc",
     "longName": "995210801 - Disclosure - Transactions with BioXcel LLC",
     "shortName": "Transactions with BioXcel LLC",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities",
     "longName": "995210901 - Disclosure - Debt and Credit Facilities",
     "shortName": "Debt and Credit Facilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments",
     "longName": "995211001 - Disclosure - Derivative Financial Instruments",
     "shortName": "Derivative Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities",
     "longName": "995211101 - Disclosure - Common Stock Financing Activities",
     "shortName": "Common Stock Financing Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "btai:FinancingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "btai:FinancingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation",
     "longName": "995211201 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeases",
     "longName": "995211301 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements",
     "longName": "995211401 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare",
     "longName": "995211501 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211601 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation",
     "longName": "995211701 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents",
     "longName": "995211801 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables",
     "longName": "99930503 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "99930603 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930703 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables",
     "longName": "99930803 - Disclosure - Transactions with BioXcel LLC (Tables)",
     "shortName": "Transactions with BioXcel LLC (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables",
     "longName": "99930903 - Disclosure - Debt and Credit Facilities (Tables)",
     "shortName": "Debt and Credit Facilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99931203 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables",
     "longName": "99931303 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99931403 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables",
     "longName": "99931503 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables",
     "longName": "99931703 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
     "longName": "99940201 - Disclosure - Basis of Presentation (Details)",
     "shortName": "Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails",
     "longName": "99940401 - Disclosure - Restructuring (Details)",
     "shortName": "Restructuring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_9_17_2024_To_9_17_2024_c8nGfcMfH0inkxdc7P07ZA",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_17_2024_To_9_17_2024_c8nGfcMfH0inkxdc7P07ZA",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails",
     "longName": "99940501 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "longName": "99940601 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940701 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "btai:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "btai:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
     "longName": "99940801 - Disclosure - Transactions with BioXcel LLC (Details)",
     "shortName": "Transactions with BioXcel LLC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TM9ElQRCBUSIjpJ3xXkJVA",
      "name": "btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
     "longName": "99940901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)",
     "shortName": "Debt and Credit Facilities - Debt summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
     "longName": "99940902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)",
     "shortName": "Debt and Credit Facilities - Credit Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
     "longName": "99940903 - Disclosure - Debt and Credit Facilities - Warrants (Details)",
     "shortName": "Debt and Credit Facilities - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q",
      "name": "btai:RightToPurchaseStockLenders",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails",
     "longName": "99940904 - Disclosure - Debt and Credit Facilities - Maturities (Details)",
     "shortName": "Debt and Credit Facilities - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
     "longName": "99940905 - Disclosure - Debt and Credit Facilities - Interest (Details)",
     "shortName": "Debt and Credit Facilities - Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
     "longName": "99941001 - Disclosure - Derivative Financial Instruments (Details)",
     "shortName": "Derivative Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_G6llnlti5k20g5RAYF9w8w",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
     "longName": "99941101 - Disclosure - Common Stock Financing Activities (Details)",
     "shortName": "Common Stock Financing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_3_3_2025_To_3_3_2025_Oqo3T2TPe0OI8F2BWWq60A",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_sIswvAbnK0SSZ3U84h3-cQ",
      "name": "btai:SaleOfStockMaximumValueSharesToBeIssued",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "btai:FinancingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
     "longName": "99941201 - Disclosure - Stock-Based Compensation - Description (Details)",
     "shortName": "Stock-Based Compensation - Description (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ntB7xLQOW0eFtXjIxuvYzw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ntB7xLQOW0eFtXjIxuvYzw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
     "longName": "99941202 - Disclosure - Stock-Based Compensation - Non-options (Details)",
     "shortName": "Stock-Based Compensation - Non-options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FrgKxTMEe0mg8BmgwnLOgQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
     "longName": "99941203 - Disclosure - Stock-Based Compensation - Options (Details)",
     "shortName": "Stock-Based Compensation - Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "longName": "99941204 - Disclosure - Stock-Based Compensation - Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "longName": "99941205 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails",
     "longName": "99941206 - Disclosure - Stock-Based Compensation - ESPP (Details)",
     "shortName": "Stock-Based Compensation - ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_RtIxFX89CUiClmbyPTCq5Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_RtIxFX89CUiClmbyPTCq5Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails",
     "longName": "99941301 - Disclosure - Leases - Maturities (Details)",
     "shortName": "Leases - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "99941302 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
     "longName": "99941401 - Disclosure - Fair Value Measurements - Hierarchy (Details)",
     "shortName": "Fair Value Measurements - Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_PJWCjTtyrkmhOnNFeBDLAg",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
     "longName": "99941402 - Disclosure - Fair Value Measurements - Level 3 (Details)",
     "shortName": "Fair Value Measurements - Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
     "longName": "99941403 - Disclosure - Fair Value Measurements - Inputs (Details)",
     "shortName": "Fair Value Measurements - Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
     "longName": "99941404 - Disclosure - Fair Value Measurements - Warrants outstanding (Details)",
     "shortName": "Fair Value Measurements - Warrants outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
     "longName": "99941501 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
     "longName": "99941502 - Disclosure - Net Loss Per Share - Antidilutive (Details)",
     "shortName": "Net Loss Per Share - Antidilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99941601 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_7_11_2024_To_7_11_2024_v4ITxGp84kCgCzwKJY2GDw",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_11_2024_To_7_11_2024_v4ITxGp84kCgCzwKJY2GDw",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
     "longName": "99941701 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941801 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_3_3_2025_To_3_3_2025_Oqo3T2TPe0OI8F2BWWq60A",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_YlCT5Ht1C0ySlRxPWi7pMA",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20250331x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "btai_AccompanyingWarrants2024StrikePriceNotAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "AccompanyingWarrants2024StrikePriceNotAmendedMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to 2024 accompanying warrants strike price not amended.",
        "label": "Accompanying Warrants 2024 Strike Price Not Amended [Member]",
        "terseLabel": "March 2024 Accompanying Warrants, Strike Price Not Amended"
       }
      }
     },
     "auth_ref": []
    },
    "btai_AccompanyingWarrantsMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "AccompanyingWarrantsMarch2025Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to March 2025 Accompanying Warrants.",
        "label": "Accompanying Warrants, March 2025 [Member]",
        "terseLabel": "March 2025 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r596"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "btai_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r108",
      "r445"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees per month to be paid to enter into collaborative service agreement option.",
        "label": "Additional Fees Per Month to Enter into Collaborative Service Agreement",
        "terseLabel": "Monthly agreement option fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r596",
      "r824"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in-capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r714",
      "r715",
      "r716",
      "r718",
      "r767",
      "r825"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "btai_AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments To Additional Paid In Capital, Pre Funded Warrant Issued",
        "terseLabel": "Issuance of pre-funded stock purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r301"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of stock purchase warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r21",
      "r76"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Reconciliation of net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r628",
      "r638",
      "r670"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r631",
      "r641",
      "r673"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r666",
      "r674",
      "r678",
      "r686"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation costs",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r335"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseNonoperating",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of debt discount and amortization of financing costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r575",
      "r576",
      "r708",
      "r777"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Common stock equivalents",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "btai_ArmisticeCapitalMasterFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ArmisticeCapitalMasterFundMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armistice Capital Master Fund Ltd.",
        "label": "Armistice Capital Master Fund [Member]",
        "terseLabel": "Armistice Capital Master Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r91",
      "r110",
      "r129",
      "r162",
      "r168",
      "r186",
      "r190",
      "r198",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r350",
      "r354",
      "r391",
      "r437",
      "r507",
      "r565",
      "r566",
      "r596",
      "r609",
      "r736",
      "r737",
      "r783"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r115",
      "r129",
      "r198",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r350",
      "r354",
      "r391",
      "r596",
      "r736",
      "r737",
      "r783"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "btai_BioxcelCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "BioxcelCorporationMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BioXcel LLC.",
        "label": "BioXcel Corporation [Member]",
        "terseLabel": "BioXcel LLC"
       }
      }
     },
     "auth_ref": []
    },
    "btai_BioxcelWarrantsAggregateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "BioxcelWarrantsAggregateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to the aggregate of BioXcel equity Warrants.",
        "label": "BioXcel Warrants, Aggregate [Member]",
        "terseLabel": "BTI Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r106",
      "r553"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value money market accounts",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65",
      "r126"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Common stock issuable (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "btai_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Offering Price Of Warrants Or Rights",
        "terseLabel": "Offering price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)",
        "verboseLabel": "Number of Warrants (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "btai_CollaborativeArrangementMilestonePaymentsPotential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CollaborativeArrangementMilestonePaymentsPotential",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential maximum payments that could be paid under the collaborative agreement.",
        "label": "Collaborative Arrangement, Milestone Payments Potential",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CollaborativeArrangementMilestonePotentialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CollaborativeArrangementMilestonePotentialPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum percentage of net sales payable under a collaborative agreement.",
        "label": "Collaborative Arrangement Milestone Potential Percent",
        "terseLabel": "Maximum milestone (as as percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsCommercialAndMarketing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CommercialCostsCommercialAndMarketing",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commercial costs recognized in the period for promotion, public relations, and brand or product advertising.",
        "label": "Commercial Costs, Commercial and Marketing",
        "terseLabel": "Commercial and marketing"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsLaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CommercialCostsLaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs for salary, wage, profit sharing; incentive and other employee benefit.",
        "label": "Commercial Costs, Labor and Related Expense",
        "terseLabel": "Personnel and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CommercialCostsOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expenses related to commercial costs.",
        "label": "Commercial Costs, Other Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CommercialCostsProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs related to a fee charged for services from professionals.",
        "label": "Commercial Costs, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CommercialCostsShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs for award under share-based payment arrangement",
        "label": "Commercial Costs, Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CommercialCostsTravelAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CommercialCostsTravelAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial costs related to travel expenses during the period.",
        "label": "Commercial Costs, Travel Expenses",
        "terseLabel": "Travel related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 16)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r85",
      "r439",
      "r494"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r230",
      "r231",
      "r549",
      "r727",
      "r734"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r714",
      "r715",
      "r718",
      "r767",
      "r823",
      "r825"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r495"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r495",
      "r513",
      "r825",
      "r826"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 200,000 shares authorized as of March 31, 2025 and December 31, 2024; 5,468 and 3,102 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r441",
      "r596"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r134",
      "r162",
      "r170",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r565",
      "r566",
      "r736",
      "r737"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r134",
      "r162",
      "r170",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r565",
      "r566",
      "r736",
      "r737"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Reconciliation payment",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r430"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r253",
      "r282",
      "r418",
      "r428",
      "r436",
      "r555",
      "r557"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "btai_CreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "CreditFacilityMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to a Credit Agreement and Guaranty (the \"Credit Agreement\").",
        "label": "Credit Facility [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt and Credit Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and Credit Facilities",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r128",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r236",
      "r237",
      "r249",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r272",
      "r273",
      "r275",
      "r400"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r83",
      "r84",
      "r134",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r709",
      "r728",
      "r729",
      "r730",
      "r776",
      "r778"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total long-term debt liability",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r84",
      "r276"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount borrowed",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r400",
      "r401",
      "r573",
      "r574",
      "r595"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value debt",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r390",
      "r573",
      "r574",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt instrument fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "DebtInstrumentFinancialCovenantMinimumLiquidityRequirement",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum liquidity required per the financial covenant of debt agreement.",
        "label": "Debt Instrument, Financial Covenant, Minimum Liquidity Requirement",
        "terseLabel": "Minimum Liquidity Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "btai_DebtInstrumentIncrementalOnVariableRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "DebtInstrumentIncrementalOnVariableRatePercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage points added to the reference rate and variable rate on the debt instrument.",
        "label": "Debt Instrument, Incremental on Variable Rate, Percent",
        "terseLabel": "Incremental interest rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_DebtInstrumentInterestRateDiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "DebtInstrumentInterestRateDiscountRatePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.",
        "label": "Debt Instrument Interest Rate, Discount Rate Percentage",
        "terseLabel": "Discount rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r279",
      "r400",
      "r401",
      "r595"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Fixed rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r251"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r709",
      "r776",
      "r778"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r134",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r709",
      "r728",
      "r729",
      "r730",
      "r776",
      "r778"
     ]
    },
    "btai_DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the quarterly amortization payments as percentage of principal amount of funded loans.",
        "label": "Debt Instrument, Quarterly Amortization Payments as Percentage of Principal Amount Funded",
        "terseLabel": "Principal payment of loans (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r22",
      "r23",
      "r33",
      "r74",
      "r75",
      "r134",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r595",
      "r709",
      "r776",
      "r778"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt premiums, discounts and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r277",
      "r399",
      "r400",
      "r401",
      "r573",
      "r574",
      "r595"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r19"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r356",
      "r363"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities",
        "verboseLabel": "Warrant derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ]
    },
    "btai_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones defined by the collaboration agreement.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DirectOperatingCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectOperatingCostsAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Operating Costs [Abstract]",
        "terseLabel": "Commercial costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r303",
      "r331",
      "r332",
      "r334",
      "r583"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r151",
      "r153",
      "r155",
      "r156",
      "r157",
      "r161",
      "r344",
      "r347",
      "r365",
      "r366",
      "r432",
      "r450",
      "r558"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r153",
      "r155",
      "r156",
      "r157",
      "r161",
      "r344",
      "r347",
      "r365",
      "r366",
      "r432",
      "r450",
      "r558"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r158",
      "r159",
      "r160"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining unamortized expense period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "btai_EmployeeStockPurchasePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "EmployeeStockPurchasePlan2020Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2020 Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan 2020 [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of shares issued or transferred under ESPP.",
        "label": "Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred",
        "terseLabel": "Maximum number of shares issued or transferred under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r101",
      "r119",
      "r120",
      "r121",
      "r135",
      "r136",
      "r137",
      "r139",
      "r144",
      "r146",
      "r148",
      "r163",
      "r199",
      "r200",
      "r213",
      "r286",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r402",
      "r404",
      "r411",
      "r449",
      "r467",
      "r468",
      "r469",
      "r483",
      "r537"
     ]
    },
    "btai_EquityInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "EquityInvestmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Equity Investment agreement.",
        "label": "Equity Investment [Member]",
        "terseLabel": "Equity Investment Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r628",
      "r638",
      "r670"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r625",
      "r635",
      "r667"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r390",
      "r573",
      "r574"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value assets and liabilities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r382",
      "r588"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r382",
      "r588"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair value inputs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r591"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r591"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Level 3 reconciliation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r589"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r589"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r381",
      "r382",
      "r384",
      "r423",
      "r424",
      "r425",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581",
      "r588",
      "r591"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r573",
      "r574"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r588",
      "r771",
      "r774"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r431",
      "r588",
      "r592"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r290",
      "r295",
      "r369",
      "r382",
      "r423",
      "r579",
      "r580",
      "r581",
      "r588"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r290",
      "r295",
      "r369",
      "r370",
      "r382",
      "r424",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581",
      "r588"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r369",
      "r370",
      "r371",
      "r372",
      "r382",
      "r425",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581",
      "r588",
      "r591"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Level 3 liabilities reconciliation",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r588",
      "r771",
      "r774"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r383"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions of derivative liabilities",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r383"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Termination of Derivative liabilities - Equity Investment Right",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r383"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r383"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r381",
      "r382",
      "r384",
      "r423",
      "r424",
      "r425",
      "r573",
      "r574",
      "r579",
      "r580",
      "r581",
      "r588",
      "r591"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r774"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in Level 3 liabilities",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r378",
      "r383"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r383"
     ]
    },
    "btai_FinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "FinancingActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Common Stock Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FinancingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "FinancingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Financing Activities.",
        "label": "Financing Activities Disclosure [Text Block]",
        "terseLabel": "Common Stock Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r674"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r674"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r674"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r674"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r674"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "btai_FromAndAfterFundingOfTrancheBLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "FromAndAfterFundingOfTrancheBLoansMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the statement scenario, from and after the funding of Tranche B loans.",
        "label": "From and After Funding of Tranche B Loans [Member]",
        "terseLabel": "From and after the funding of Tranche B loans"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the statement scenario, from and after satisfaction of the funding conditions for the Tranche C loans.",
        "label": "From and After Satisfaction of Funding Conditions for Tranche C Loans [Member]",
        "terseLabel": "From and after satisfaction of funding conditions for tranche C loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (loss) on derivatives",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "btai_HeightsCapitalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "HeightsCapitalManagementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Heights Capital Management.",
        "label": "Heights Capital Management [Member]",
        "terseLabel": "Heights Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "btai_HudsonBayCapitalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "HudsonBayCapitalManagementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Hudson Bay Capital Management.",
        "label": "Hudson Bay Capital Management [Member]",
        "terseLabel": "Hudson Bay Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "btai_IncentiveAwardPlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "IncentiveAwardPlan2020Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Incentive Award Plan.",
        "label": "2020 Incentive Award Plan",
        "terseLabel": "2020 Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r221",
      "r225",
      "r374",
      "r378",
      "r383",
      "r464",
      "r466",
      "r522",
      "r552",
      "r590",
      "r794"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r225",
      "r374",
      "r378",
      "r383",
      "r464",
      "r466",
      "r522",
      "r552",
      "r590",
      "r794"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Increase (decrease) carrying value",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r707"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, due to related parties, and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r666",
      "r674",
      "r678",
      "r686"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r690"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r690"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r690"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseNonoperating",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r269",
      "r280",
      "r575",
      "r576"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "terseLabel": "Interest expense",
        "totalLabel": "Total interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r705"
     ]
    },
    "btai_IntraCoastalCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "IntraCoastalCapitalMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to IntraCoastal Capital, LLC.",
        "label": "Intra Coastal Capital [Member]",
        "terseLabel": "IntraCoastal Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r554",
      "r596"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r171",
      "r190",
      "r565",
      "r704"
     ]
    },
    "btai_JefferiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "JefferiesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Jefferies LLC.",
        "label": "Jefferies [Member]",
        "terseLabel": "Jefferies Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r410"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to renew the lease",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of the operating lease liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "verboseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r39",
      "r42",
      "r43",
      "r44",
      "r45",
      "r129",
      "r198",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r351",
      "r354",
      "r355",
      "r391",
      "r493",
      "r559",
      "r609",
      "r736",
      "r783",
      "r784"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r86",
      "r443",
      "r596",
      "r710",
      "r726",
      "r775"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r105",
      "r129",
      "r198",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r351",
      "r354",
      "r355",
      "r391",
      "r596",
      "r736",
      "r783",
      "r784"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityAmendmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "LineOfCreditFacilityAmendmentFeePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.",
        "label": "Line of Credit Facility, Amendment Fee Percentage",
        "terseLabel": "Amendment fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityExitFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "LineOfCreditFacilityExitFeePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The line of credit facility exit fee, expressed as a percentage.",
        "label": "Line of Credit Facility, Exit Fee Percentage",
        "terseLabel": "Exit fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityInvestmentAllowed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "LineOfCreditFacilityInvestmentAllowed",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the Lenders agree to permit the entity to invest in subsidiary.",
        "label": "Line of Credit Facility, Investment Allowed",
        "terseLabel": "Maximum investment allowed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r709",
      "r735"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r41"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r41",
      "r237"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r41",
      "r237",
      "r709",
      "r735"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r84",
      "r262",
      "r278",
      "r573",
      "r574",
      "r595",
      "r792"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Less current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r134",
      "r267"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r134",
      "r267"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Purchase agreement expected cost",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Period",
        "terseLabel": "Purchase agreement expected term",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "btai_March2024AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "March2024AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to march 2024 accompanying warrants.",
        "label": "March 2024, Accompanying Warrants [Member]",
        "terseLabel": "March 2024 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_March2024PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "March2024PreFundedWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to march 2024 pre-funded warrants.",
        "label": "March 2024, Pre Funded Warrants [Member]",
        "terseLabel": "March 2024 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_March2025AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "March2025AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to march 2025 accompanying warrants.",
        "label": "March 2025 Accompanying Warrants [Member]",
        "terseLabel": "March 2025 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_March2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "March2025OfferingMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the march 2025 offering.",
        "label": "March 2025 Offering [Member]",
        "terseLabel": "March 2025 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "btai_March2025PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "March2025PrefundedWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to march 2025 pre-funded warrants.",
        "label": "March 2025 Prefunded Warrants [Member]",
        "terseLabel": "March 2025 Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r297",
      "r336",
      "r372",
      "r429",
      "r463",
      "r465",
      "r472",
      "r485",
      "r486",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r570",
      "r577",
      "r582",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r738",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "btai_MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of budgeted amount allowed for disbursement in applicable period.",
        "label": "Maximum Percentage Of Budgeted Amount For Disbursements in Applicable Period",
        "terseLabel": "Maximum percentage of budgeted amount allowed for disbursement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Strike price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility (annual)",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Share price input",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r591"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r591"
     ]
    },
    "btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.",
        "label": "Minimum Gross Proceeds From The Issuance of Common Stock, Warrants And (Or) Pre-funded Warrants For Debt",
        "terseLabel": "Minimum revenue required from equity sale"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r297",
      "r336",
      "r372",
      "r429",
      "r463",
      "r465",
      "r472",
      "r485",
      "r486",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r570",
      "r577",
      "r582",
      "r591",
      "r592",
      "r593",
      "r597",
      "r738",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_NetCashRequiredMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "NetCashRequiredMinimum",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.",
        "label": "Net Cash Required, Minimum",
        "terseLabel": "Cash maintenance in controlled accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net losses",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss (numerator)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r67",
      "r87",
      "r103",
      "r117",
      "r118",
      "r121",
      "r129",
      "r138",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r154",
      "r198",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r344",
      "r347",
      "r366",
      "r391",
      "r448",
      "r515",
      "r535",
      "r536",
      "r607",
      "r736"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "btai_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued per the credit agreement.",
        "label": "New Warrants [Member]",
        "terseLabel": "New Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r632",
      "r642",
      "r666",
      "r674"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "terseLabel": "Nonrelated Party",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r712"
     ]
    },
    "btai_November2024AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "November2024AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to November 2024 Accompanying warrants.",
        "label": "November 2024 Accompanying Warrants [Member]",
        "terseLabel": "November 2024 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_November2024PrefundedAccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "November2024PrefundedAccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to November 2024 Pre-Funded Warrants.",
        "label": "November 2024 Prefunded Accompanying Warrants [Member]",
        "terseLabel": "November 2024 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r721"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r569",
      "r721"
     ]
    },
    "btai_OfaAdministrativeAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "OfaAdministrativeAgentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents OFA as debt administrative agent.",
        "label": "OFA Administrative Agent [Member]",
        "terseLabel": "OFA"
       }
      }
     },
     "auth_ref": []
    },
    "btai_OnkosxcelWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "OnkosxcelWarrantMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to OnkosXcel warrants.",
        "label": "OnkosXcel Warrant [Member]",
        "terseLabel": "OnkosXcel Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r560",
      "r720",
      "r722",
      "r723",
      "r724",
      "r725"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities of the operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less current portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities",
        "verboseLabel": "Long-term portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r565",
      "r566"
     ]
    },
    "btai_OptionWarrantsMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "OptionWarrantsMarch2025Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to March 2025 Option Warrants.",
        "label": "Option Warrants, March 2025 [Member]",
        "terseLabel": "March 2025 Option Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_OrganizationAndPrincipalActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "OrganizationAndPrincipalActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r80",
      "r473",
      "r474"
     ]
    },
    "btai_OriginalWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "OriginalWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the Original Warrants issued per the credit agreement.",
        "label": "Original Warrants [Member]",
        "terseLabel": "Original Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r596"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Total commercial costs",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r451",
      "r565"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r596"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r630",
      "r640",
      "r672"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r633",
      "r643",
      "r675"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r633",
      "r643",
      "r675"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Payable-in-kind interest on Credit Agreement",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "btai_PaidInKindInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PaidInKindInterestPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid-in-kind interest rate for funds borrowed, under the debt agreement.",
        "label": "Paid-in-Kind Interest, Percentage",
        "terseLabel": "Debt paid-in-kind interest (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r706"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Offering costs for common stock and warrants issuance",
        "verboseLabel": "Stock offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of employee tax obligations related to vesting restricted stock units",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "btai_PercentageOfFairValueConsiderationToBePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PercentageOfFairValueConsiderationToBePaid",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of consideration to be paid.",
        "label": "Percentage of Fair Value Consideration to Be Paid",
        "terseLabel": "Percentage of fair value of consideration to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PercentageOfOutstandingLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PercentageOfOutstandingLoan",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding Loan.",
        "label": "Percentage of Outstanding Loan",
        "terseLabel": "Outstanding loan (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PercentageOfValuationApplicableToInitialProfits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PercentageOfValuationApplicableToInitialProfits",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation applicable to initial profits.",
        "label": "Percentage of Valuation Applicable to Initial Profits",
        "terseLabel": "Percentage of valuation applicable to initial profits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "BTI PSU",
        "verboseLabel": "Performance stock units",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PeriodOneMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the first period.",
        "label": "Period One [Member]",
        "terseLabel": "Period one"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PeriodThreeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the third period.",
        "label": "Period Three [Member]",
        "terseLabel": "Period three"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PeriodTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the second period.",
        "label": "Period Two [Member]",
        "terseLabel": "Period two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r281"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r495"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r281"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r495",
      "r513",
      "r825",
      "r826"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r440",
      "r596"
     ]
    },
    "btai_PrefundedWarrantsMarch2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PrefundedWarrantsMarch2025Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to March 2025 Pre-Funded Warrants.",
        "label": "Prefunded Warrants, March 2025 [Member]",
        "terseLabel": "March 2025 Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PremiumSharePricePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PremiumSharePricePercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents premium percentage for share price determined over a specified period of time.",
        "label": "Premium Share Price, Percent",
        "terseLabel": "Premium share price (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance of common stock and warrant",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r476"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r117",
      "r118",
      "r124",
      "r129",
      "r138",
      "r144",
      "r147",
      "r148",
      "r198",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r344",
      "r347",
      "r349",
      "r352",
      "r353",
      "r366",
      "r391",
      "r433",
      "r447",
      "r482",
      "r515",
      "r535",
      "r536",
      "r586",
      "r587",
      "r608",
      "r703",
      "r736"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r410"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r95",
      "r98",
      "r99"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r107",
      "r446"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property and equipment, net",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r410",
      "r434",
      "r446",
      "r596"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r410"
     ]
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "2026 purchase obligation",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase obligation originally due in 2024",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2025 Purchase obligation",
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "btai_PurchaseObligationPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "PurchaseObligationPriorYear",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement pertaining to prior year but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, Prior Year",
        "terseLabel": "Purchase obligation, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r289",
      "r297",
      "r326",
      "r327",
      "r328",
      "r336",
      "r372",
      "r426",
      "r427",
      "r429",
      "r463",
      "r465",
      "r472",
      "r485",
      "r486",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r570",
      "r577",
      "r582",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r601",
      "r731",
      "r738",
      "r771",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r289",
      "r297",
      "r326",
      "r327",
      "r328",
      "r336",
      "r372",
      "r426",
      "r427",
      "r429",
      "r463",
      "r465",
      "r472",
      "r485",
      "r486",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r550",
      "r551",
      "r570",
      "r577",
      "r582",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597",
      "r601",
      "r731",
      "r738",
      "r771",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of reportable segment",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r625",
      "r635",
      "r667"
     ]
    },
    "btai_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to registered direct offering.",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered direct offering"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RegisteredOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RegisteredOfferingMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the registered offering.",
        "label": "Registered Offering [Member]",
        "terseLabel": "Underwriting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r296",
      "r415",
      "r416",
      "r438",
      "r444",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r512",
      "r514",
      "r542"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r415",
      "r416",
      "r417",
      "r418",
      "r438",
      "r444",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r512",
      "r514",
      "r542"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Transactions with BioXcel",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r518",
      "r519",
      "r522"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions with BioXcel LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r296",
      "r415",
      "r416",
      "r438",
      "r444",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r512",
      "r514",
      "r542",
      "r782"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Transactions with BioXcel LLC",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r479",
      "r480",
      "r481",
      "r520",
      "r521",
      "r522",
      "r540",
      "r541"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Payment of principal of Long-term debt",
        "terseLabel": "Payment of principal of Long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r477"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r253",
      "r282",
      "r418",
      "r428",
      "r436",
      "r556",
      "r557"
     ]
    },
    "btai_ResearchAndDevelopmentCostsOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ResearchAndDevelopmentCostsOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expenses related to research and development costs.",
        "label": "Research and Development Costs, Other Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Total research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r552",
      "r565",
      "r791"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development costs:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to chemical, manufacturing and control costs.",
        "label": "Research and Development Expense, Chemical, manufacturing and controls Expense",
        "terseLabel": "Chemical, manufacturing and controls cost"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseClinicalTrialsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseClinicalTrialsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to clinical trial expenses.",
        "label": "Research and Development Expense, Clinical Trials Expense",
        "terseLabel": "Clinical trials expense"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseLaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseLaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to salary, wage, profit sharing incentive and other employee benefit.",
        "label": "Research and Development Expense, Labor And Related Expense",
        "terseLabel": "Personnel and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to a fee charged for services from professionals.",
        "label": "Research and Development Expense, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense during the period related to expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Research and Development Expense, Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r626",
      "r636",
      "r668"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r627",
      "r637",
      "r669"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r634",
      "r644",
      "r676"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "btai_RestrictedStockUnitsOnkosxcelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RestrictedStockUnitsOnkosxcelMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units Onkosxcel [Member]",
        "terseLabel": "OnkosXcel RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "BTI RSU",
        "verboseLabel": "Restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to RSU vesting 100% at one year anniversary.",
        "label": "Restricted Stock Units Vesting 100 Percent at One Year Anniversary [Member]",
        "terseLabel": "RSU vesting 100% at one year anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to RSU vesting 25% at one year and remaining in 12 quarters.",
        "label": "Restricted Stock Units Vesting 25 Percent at One Year and Remaining in 12 Quarters [Member]",
        "terseLabel": "RSU vesting 25% at one year and remaining in 12 quarters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r227",
      "r229"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Employees eliminated (as a percent)",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Accrued restructuring costs",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r732",
      "r733"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r76",
      "r442",
      "r470",
      "r471",
      "r478",
      "r496",
      "r596"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r135",
      "r136",
      "r137",
      "r139",
      "r144",
      "r146",
      "r148",
      "r199",
      "r200",
      "r213",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r357",
      "r359",
      "r360",
      "r362",
      "r364",
      "r402",
      "r404",
      "r467",
      "r469",
      "r483",
      "r825"
     ]
    },
    "btai_RetentionBonusExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RetentionBonusExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of retention bonus during the period.",
        "label": "Retention Bonus Expense",
        "terseLabel": "Retention bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Product revenue, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r162",
      "r169",
      "r170",
      "r184",
      "r190",
      "r193",
      "r195",
      "r196",
      "r287",
      "r288",
      "r430"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RightToPurchaseStockLenders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "RightToPurchaseStockLenders",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity investment allowed for lenders in entity's common stock.",
        "label": "Right to Purchase Stock, Lenders",
        "terseLabel": "Maximum equity investment allowed for lenders"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock and warrants",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SaleOfStockMaximumValueSharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SaleOfStockMaximumValueSharesToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate net offering price of shares permitted to be issued.",
        "label": "Sale of Stock, Maximum Value Shares to be Issued",
        "terseLabel": "Maximum value shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SalesMilestonesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones are payable when annual sales reach certain levels.",
        "label": "Sales Milestones [Member]",
        "terseLabel": "Sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r298",
      "r696",
      "r717"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r22",
      "r23",
      "r33",
      "r74",
      "r75",
      "r573",
      "r575",
      "r713",
      "r776"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation charges",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) [Table]",
        "documentation": "Disclosure of information about employee stock ownership plan (ESOP) by plan."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769"
     ]
    },
    "btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest expense associated with long-term debt.",
        "label": "Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]",
        "terseLabel": "Schedule of interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities on debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r410"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r518",
      "r519",
      "r522"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of service charges",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of activity relating to PSUs",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity relating to RSUs",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r162",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r196",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r226",
      "r228",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r562",
      "r565",
      "r566",
      "r571",
      "r598",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r180",
      "r182",
      "r183",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r561",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeCostsOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SellingGeneralAndAdministrativeCostsOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expenses related to selling, general and administrative costs.",
        "label": "Selling, General and Administrative Costs, Other Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Total selling, general and administrative costs",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense [Abstract]",
        "terseLabel": "Selling, general and administrative costs:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense for salary, wage, profit sharing; incentive and other employee benefit.",
        "label": "Selling, General and Administrative Expense, Labor and Related Expense",
        "terseLabel": "Personnel and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SellingGeneralAndAdministrativeExpenseProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense related to a fee charged for services from professionals.",
        "label": "Selling, General and Administrative Expense, Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense for award under share-based payment arrangement",
        "label": "Selling, General and Administrative Expense, Share-Based Payment Arrangement, Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "btai_SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense related to travel expenses during the period.",
        "label": "Selling, General and Administrative Expense, Travel Expenses",
        "terseLabel": "Travel related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled, Weighted average price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Non-options granted (in shares)",
        "verboseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted average price (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "terseLabel": "Non-options outstanding (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted average price ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, Weighted average price beginning balance (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility (as a percent)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate of interest (as a percent)",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in shares available for issuance (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Options"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period",
        "negatedLabel": "Options cancelled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable (in dollars per shares)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value, outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end balance (in dollars per shares)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per shares)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested aggregate (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested, Weighted average price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant",
        "terseLabel": "Annual increase in shares available for grant (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ]
    },
    "btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in dollars per shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per shares)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting (as a percent)",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Terms of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual life, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options vested (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percent of fair market value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r127"
     ]
    },
    "btai_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r102",
      "r162",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r196",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r226",
      "r228",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r562",
      "r565",
      "r566",
      "r571",
      "r598",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r50",
      "r51",
      "r101",
      "r119",
      "r120",
      "r121",
      "r135",
      "r136",
      "r137",
      "r139",
      "r144",
      "r146",
      "r148",
      "r163",
      "r199",
      "r200",
      "r213",
      "r286",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r402",
      "r404",
      "r411",
      "r449",
      "r467",
      "r468",
      "r469",
      "r483",
      "r537"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Disclosure",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r163",
      "r404",
      "r430",
      "r475",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r516",
      "r517",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r602"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r298",
      "r696",
      "r697",
      "r717"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r163",
      "r197",
      "r404",
      "r430",
      "r475",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r516",
      "r517",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r602"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r629",
      "r639",
      "r671"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under ESPP",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r46",
      "r47",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r46",
      "r47",
      "r76",
      "r476",
      "r537",
      "r548"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r46",
      "r47",
      "r76",
      "r312"
     ]
    },
    "btai_StockIssuedDuringPeriodSharesWarrantsExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercise",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercise",
        "terseLabel": "Exercise of pre-funded stock purchase warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Exercise of warrants, stock issued (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r46",
      "r47",
      "r76",
      "r483",
      "r537",
      "r548",
      "r608"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r50",
      "r51",
      "r76"
     ]
    },
    "btai_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of pre-funded stock purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_StockPlan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "StockPlan2017Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2017 Stock Plan.",
        "label": "2017 Equity Incentive Plan",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r69",
      "r497",
      "r513",
      "r538",
      "r539",
      "r596",
      "r609",
      "r710",
      "r726",
      "r775",
      "r825"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r422"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SubsidiaryOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "SubsidiaryOwnershipPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock of subsidiary.",
        "label": "Subsidiary Ownership, Percentage",
        "terseLabel": "Subsidiary ownership (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Shares issued",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "btai_ThresholdLiquidityEventAmountForExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "ThresholdLiquidityEventAmountForExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of  liquidity event for exercise of warrants.",
        "label": "Threshold Liquidity Event Amount for Exercise of Warrants",
        "terseLabel": "Threshold amount of liquidity event for exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TickingFeesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TickingFeesPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ticking fees percentage relating to debt instrument.",
        "label": "Ticking Fees Percentage",
        "terseLabel": "Ticking fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TimeBasedProfitSharingUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TimeBasedProfitSharingUnitsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to OnkosXcel time based profit-sharing units",
        "label": "Time Based Profit Sharing Units [Member]",
        "terseLabel": "OnkosXcel PSU"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche B.",
        "label": "Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche C.",
        "label": "Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TrancheDMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche D.",
        "label": "Tranche D [Member]",
        "terseLabel": "Tranche D"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TrancheMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A.",
        "label": "Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A2.",
        "label": "Tranche A Two [Member]",
        "terseLabel": "Tranche A-2"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r93",
      "r94",
      "r96",
      "r97"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Repricing of stock purchase warrants",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285"
     ]
    },
    "btai_WarrantOaktreeAndQiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "WarrantOaktreeAndQiaMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Oaktree (OFA) issued April 2022.",
        "label": "Warrant Oaktree and Qia [Member]",
        "terseLabel": "Closing Date Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_WarrantShares2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "WarrantShares2024Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrant shares issued in 2024.",
        "label": "Warrant Shares 2024 [Member]",
        "terseLabel": "2024 Warrant Shares"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "Warrants2023Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued in 2023.",
        "label": "Warrants 2023 [Member]",
        "terseLabel": "2023 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "Warrants2024AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 Accompanying Warrants.",
        "label": "Warrants 2024, Accompanying Warrants [Member]",
        "verboseLabel": "March 2024 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "Warrants2024AccompanyingWarrantsStrikePriceAmendedMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertains to 2024 accompanying warrants Strike price amended.",
        "label": "Warrants 2024 Accompanying Warrants Strike Price Amended [Member]",
        "terseLabel": "March 2024 Accompanying Warrants, Strike Price Amended"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "Warrants2024Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued in 2024.",
        "label": "Warrants 2024 [Member]",
        "terseLabel": "2024 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2025AccompanyingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20250331",
     "localname": "Warrants2025AccompanyingWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2025 Accompanying Warrants.",
        "label": "Warrants 2025, Accompanying Warrants [Member]",
        "terseLabel": "March 2025 Accompanying Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstrumentsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding value",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value warrant classified as equity",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769",
      "r773"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "verboseLabel": "Weighted average shares (denominator) - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r157"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares (denominator) - basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r157"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001558370-25-007269-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-007269-xbrl.zip
M4$L#!!0    (  Y(K%I/P:\@%Q4  .[U   1    8G1A:2TR,#(U,#,S,2YX
M<V3M7>USXCC2_WY5]S_XR9?;JSH2")/936IGK@A)=K@C@0WLSNZG*V$+T(V1
M65G.R_WU3TNVP<:6)4,FI\RY:BH#J+NE[I]>6E)+^O'O3RO?>< L) ']<-0Y
M;A\YF+J!1^CBPU'$YZT?CO[^\<]_^O'_6JW?+N^'CA>XT0I3[K@,(XX]YY'P
MI3,-UFM$G5O,&/%]YY(1;X$=I],^AG_PQVFU/DH9ER@$GH Z4MCI<2=-Z"?B
M GKAG)UT3D].VZ=G3N?THO/]1;?KC&]3PELHVYQH*9]"[R)TEWB%'([8 O,[
MM,+A&KGXP]&2\_7%R<GCX^/QC 1/+O;Y$C.TQA$G;GCL!BLIL]WM=HX<Q#DC
MLXCCFX"MKO <13X'R] _(N3+@H#!?"Q,DB/()(.%:7@!!<KE_-@]#M@",FIW
M3GZ['4YD65/B&4>D9CEC1@^O&7:%)7/L3S/FI]F=G[# QR=;RI37C1@#[)\W
MG)(KQ.[Q(G@X25-%EN]2EBAL"6'AAF6.PIG,*$W)D3,\5Q;K_0FD;HP%"1[/
M%R2A.SN)$S>DOE)D]^2W(:%?,H7ESVM%865*KK AXRKE-DEY8W!6871(S11D
M@="ZM!PB(2?5!PTJ-!3),VA4FU+S-2L'4*3D%22N@I*X!4LH++=)RC%@&JU.
MR] [;9_@)XYI2&8^;@DRJ,\<NIZP=2JZGJ0B!A'E3%4/X\1<?A1S774'DFT;
M(>6B(2$O%D$S*R>523GBIP)020OOG)^?G\C430$XV[%GKM"0?"*2A?C35KO;
MVC9OBA<F;3LAV\#QY"[+U1 I.2T,>KM-G2BM#7F;0%ZDHO(2&G)$7;SM(XF^
MCVSM<GF5[<[;MCO9<9#27N5]W*N0G2;:PC-U,Q6).77=9Z^%YJTPFBFJ[B8]
MWUI<3X&.Z^T2JH4GB3'#QS\YCAP"$:4!ERU,_)3^N%X3.@_B7^ W43<O1,69
M0JUSQ(=?[@=&PX^L;1/(0 Z _8!ZT+:Q!Q_"P">>J(27R!=@3988\_#((:!K
M'8:TD&DQ/3PGE$B%SL_/1,UHMYV6LQ$)G_NCNZOKN\GUE?@T&0T'5[TI?+GL
M#7MW_6MG\NGZ>CKY\617W$Y&$11K1#_*SS!2AB!;VE&,* ES0E+!Z"+?C?SZ
M?-MB*=F2'U/87@?,36HXFH_6:=]M@JJ"4POOJ2F\DRG\=WM]-YTXHQMG-+Z^
M[TT'0-  ?2C0?10N;_S@L3;.6T8MS._V@[G?FWQR;H:CSPW,"IBO2.CZ01@Q
M/* /H'/ GJ\PS"[\!,V*]$K0SM^US]HPKW.V N#+1H;S72+EKPTP.F#&+( .
MD3_WJ'?]1T36H@'<8:Z 24.M ^U]$;14HH.HYVQD_LT!J0V,YC#V7)=%V+M^
M6HM.,53 IZ#2P?9]$;9$DI.*:K RQ^H*SS@TH#[#'N$WR"4^%$B@,>.3:+5"
MRD[2G%&'Z'D142%%-L)8O+.5GR:&<1X-U =#/: <@SE4O:PAEQ[DLUH@I_(;
M@,T!'F($O=\MXA%+VJ*T7!]4.MV%M9*V LQW,,L\W44R%@8?MO*VN D/%J0Z
MIPV >P)HB)VN#7:ZQ8ZV$KD&L(,GC$M$%Z*SG/# _;(,? \S@&M.7,*%?\F?
M:\\D]1*U4\SNGE/,3[V[GZXGSN .$D;]?WX:#:^N[R=_@0IS?3/H#Z9_=:Y_
M_F4P_;VI-[J&+L&3.X#]8"6<5JG&%,U\7&CME;353;[;.6UW=YN\E)=L/V8E
M.M_%,IMFKX4/C$>@+8XSNBNZZ@I*G<=T6NRMI30GF#M9>4U_;0[</7B4+'+%
M4$<7"LA*:71@O2N"E9/3@&0.TI0AZ))<N2S^F?#E9<PV]%T%8GH&'7P_%.'+
M"HU#.T#L;R#6&0[[#9P'3SOC[[T%P]()J3?[5##K)Z&%J4OE)#3Y;9-/ _O!
ML']&#!H65TUM#+GT0!?<GDJ@4_D-P'4 9N0!BOZ ;PA%U"7('U QY,F9BA)?
M$R;=1+9=MF*8"G8VDIV,Z 99<V1A5K *X@EF8DNZZ,%(^%"U*&'&I$.V4T0V
M%AQ/6YR-:&<KNX'VT(GG%0Y=1M85\QAC/AW );,:Y814M.I-!@W*AZ)\%]"1
M-*6J"9NRZ3$NN%D5&(/\5A!GT&!\*,;[ %P;7?,EI98S:I!]&61[81BM]D"W
MA$^/\+L:"&<R:% ^%.4DA*$6PCL\>G0+.[$5Z";"&V0/1C9<K^O!FF'08_J^
M#J:3\;@!U!S0&T38K\B/\"U&XKN<4'XBP,3<I2H^QHQ)!VS)NK(0[$C)3E8T
MI&RD-^ >".X0/V"_6P?9/(<>UH*'K(95BG:Z#:@'@CJ@ZTBY,&7 H0>UX!BK
M08U%-Y@>B&FZ<#L"8W)$/?6V7EUV/=H%)UF-]F9].=AFU&!OCOT=YL,@#,>8
M39:(J=QC!94.R9+H?1'P+40Y(,N1PAJT]D:K1SGQB!^)Q7DSY,HX]"@6AM02
M%&&ZFI'=@%IO4X!PV:&)#;H S$@7F+K5.P(:#AVH)6<T,E+C[;RLW ;0&M-4
MO!!6'-!YP%95,4QJ0AU\)6<U$F%.1EH#6@W0HEF(_XA [^N'BFU6%9D.L)(X
MF*TH)Y;5P*6%*[D9)OU?'%"#3HH_9RI]@I@)925H(IZW?2[B>5,9V8_R')L4
MF&UP#6X'']\?@S-!00H(0'[ML_QY;BV^';EB6_M@O_-=+I^FN>H=5W$( H_F
MEU%(* Z+;NINN@:Z3KLDGB$6(J)XH3A.*JH!9X^@:X-H:SU$IG'6#4)ZYT2>
MR1S-)V1!R1PZ'1C17'E-$7CH8^@*A8]>]%6,N+0XEIQN2D0+)#/"G:UT)Q7?
M@%LK=+XR9EX/E2Y:OD'#^ H+Y=T5>A2J;JUH$-CSK@K#2RKTZ-2[GJ+!J^:E
M%)K;*/3X&-Q#T8"R_U$?\S,^>JCJGNYI<-OS<(?A:0X]8K6N!&G@.NRH1KTS
M&EKP]CF=T4!XV)F,>H<Q]!#N<PRCP7"_P$"S:$ ]9C5.5C10F=W$4G[QBAX*
MY44KC>'WBO(QBN71PV(>3-G@5#/&0Q/0H<?&* BG@>6 *(T:X1EZN.H&9C3(
MU0_'T,=AZ'$RB\!HT*D;=Z$+N- C8Q)JT>#R,EM.AVT]F6U!G9^VNR7G7HUW
MH)SOTD_-1KWY]D?YE6F[R=7 ==MGQ<C]S/W=S;5HAVV)E&-43:Q#['T1L<K+
MNQL,]]LF*<>NG$B'V?=%S(HW=S= ';QU4HZ9EEX'WP]%^#1WI#58'K:=4@YD
M-;$.Q7HW8S40UELP+$<LEZ8!J-,M I1<TMR <= B8CDV5:0ZJ&H<^&RPVW-A
ML1RU<B(=7B5N?ME!OP:JO9>L%#=8J^AT@)5XC*7GAQK$#G,TM"\.&/-5(RHN
MYBR<FJZ\F+-YEF!_9Z3G>;(<(GQ#=\;/@$,#;:=D]6OSNL16\/_BP3_Q1[Q,
M?(_GCGS^]H(#S8>CD*S6OGB\5?ZVE&]"B_>N6^E;UO\"58^?5GY*(L17/"(K
M:\&N=9*,4Q&(N04IA>=Y08A<2X%F=Y(6_L@Y>2FM (>L5IQP4:#^%AU'%#S\
MFX/\6JKOX&NAYE"3ZN*9KWP6ZN2C65V=@ 7[7U6=EPG7@5$),4\,?%'(@U7O
MB817P0H1Z!/E>] E-WGI6:K[4?DTRTX03RS3Z8DQ4DIUA%@GENND@K_-/O3'
MDYUWFI,?<J\YR[><H:(&C#L4K7"X1FY2B\*=9]>[V5ZBU3GN'#FA?$Q[&+CR
MMRW;3N4MLAY#MDG-JRB!^BUK5<:EY/)9:_%AOURW+[H;Y9J2BP_U<M4]Q%Z6
M_2Z;SUB.JR7DM#JGK<[[_<I1^I"\$>XEG/)[N+=!LH^]FQA#LHAOF^?>A3FZ
MPAS=FE4P$7<6/_'.C?-/&43&9\999E^)%VB&)A5P]VGYI.Y#_[814Z\^E@H\
MJ!#RQ?O]RA R7BO_E#[.&[X=T .(_B.,9GOW/<!;FCOVXU/I(OL/1R.V0)3\
M1TJ% 6O,"'7)&OG;..'>+.0,N<E)*>%+_*L.4^R6B&*2"_B-T,6 XY48,$"I
M",@(CX2<GU@0K5-" B1'#DJ$?#CB+ )R2GQ?K!RDWV-:\"U(X$UE-E[$DE <
ME;Y7XG*^0&XUWA*HG#R@,"_&JQEF&04KJ6*-H*-IR8[EPI/C^G]5JPF"0E;H
MHTBW4)-^(&0$3!X^Z(E;V!8X!\,8/<LEVG' X3^2WN8@U=R'.5L_5T#"$7LV
MMD"YQK/X[H@/1ZY<(2DS1#PT<+4=DNV^?L#606RS JAJDC>):PK)&#,74UX+
MU@+OK@76<<*!P)8BN+76'/F;J4V)"?Z!YW,04-(\"RD6 CB@PH "@$>8W(RA
MAL/@TBZH4DUFH5YR$Z%X"_NVEET^;TF2_B/6+:Y2:(%'<]":B;6S <V<Y.D]
M("*+=Q.PGQC*5>E7S?7K-P:]F:]7:S]XQO%IF7'$W"447%F+C*@MK$S*<M^B
M)[**5G>1*/IH+K$-!V$8P82:R; ,Z "8F&_I;6 N*^=[Q62OB7E<<HE:Y_NB
M3U*6:B&F2<S3/0ZQN*P;_-V,=Y@_GB[U,J2WU.\H.7Y8,@&HI++,XR\I:R;*
M"C_Q2Q\J8K5RI0R[=96G2:_;R/8=29*77OJBRO@^]@9T+#-^B5%*+?N_W27I
M- KKJO09D\628Z_W@!F,RM=/,+@2Z*@9<7$=4[YPQB5COA3_JM:^QPL2<@R]
MT4@ZN'11& 74)!8.!;G]].>"+N7)!^I1I]R[.JOT&","U>B?A,)?8?N0;]W*
MC#[59#9.L:;$_0)5Z ;CL%0C1?IK.LC&NFSWX)/BW@:4+Z?!M< "  ERT^()
M9@_0\#=/WV8=D@,%?05/Q= T.VZ-AV>DPG419PC$3:P/4%'E\D!A5J$@L+"%
M)@\0C- 7#CB #_DS005]JH@LU&G,\(I$*SD,R5&JN-*C)K&RB=Z+$7@:I),S
M.:,98NIAEIT05%)]Y<:E[D(54P:EX^0NL1?Y<M4A'@N2J4PO# .7B%T_<4IA
M&-#%%+.5"!*347YE#O8+R'I=W]M\_('V",H56NK.[Q8VSJ2$EZJB7]I?]KZJ
M['V+RSZB7X)0+.,GG7E!!Q6!A;I,E]"6EX'O#0F,M-"=/,MCT;V5.#M[$[!T
MBC*:I^_K9+':@_FM=)[91=O- 09QVSB!02 .L XNL7"WLV-A#28K1\>L J+P
M\8QWO?:)*WOS8" "C) _9L&<Y.I";4XK]1?CUO;.M'2HNX?A32PGB6HM/I?.
M4^JS6FF!+(Z9)[N& :(*M M45NHUFJ.>MR*4"'JYV;4HFV]4DUG8@=]AWD?A
M\AY##PQ=VBT4?16M,AJI"&SIB#4S1'%A!PPMX@J)1PKN]Y*L2YN?AL[.E8]5
MLG0H^T0Q@X(V] OTD\7M9@-:"RNGO'&<N# YD#,H6=R-<U2RKFA ;:&6>R^Y
MIXL;FSLZ1R)>>KI$]&LN].^3ZRMM 1@WG5=0?F>M7N[+7\$(OO'K7A<+@^*\
MZOY!W?GUE6JF=V5QRQX2"@Y.?H_@^@D^XW(?T)#>2@>IK.P]2/<$31V%54QO
M1NOM:G//]X/'7(2'(;TMSI5NEIN?M&SNC>X',(\7"Q>QL[B9WB=.Y,YFQ2%"
M;#&4Q@N]PX_I$D:A'RM)L[ K2WK;Z6.@ZH@S21:67X1#C^;2,4R"J>2H%T=2
MB565.)IJ)X#:B,.:S3)=:_V5K! XPDM>W%<J)EF(X3UQP?C@W6-"X4-Q]JTB
ML%"7?Z '@ME]X#&RB/!_BO'!Y>D6:G*+.#B=CY^)CXOQ$66)%NIP UW8E]\#
MURVVC&*2E>4/5CWJ]>8<?';@#>?QE5^C^4TD5];$@Y<R(B"\"5BZ1R*6VXKC
MT0O(LMQ"B1ZC>;K1I3=$-8N%^B9>$^06AF,6N!A[H5!(#%IBM  G=!M GOH?
MH.V(C1D6VL*4,?D54!8N6K95?P7AUHRB&E<N+;@X9Z<*S\@E6E@Y=O<:W-B=
M1OZ(_HH8$=EE-ALJ-BETC%;.V>)%J1$M[MD74BS$+BYCF1]>2+&W]$N&5=;/
MI5FH0;:)BSNB5VM$GV%H4,[O3!DLU'4;J7L%,VZ7&X3TEA-:J5MQM^!7^ U*
MW6FWDQZLQZ$S^!TCUJ.4/& 6PJ!DM.]02]+;LL[I65$E[QZ+(HMS'[1S^G,$
M<R]0L8ZEZDNUT&H3*"J,@%B<]1>RDYOPBN>@JNDLU*SR:--01!)+N'P1R)?\
MFL>]/O=;<0@KE2MNVVPW=6K:R4C4-V$TL4>-PW 3OVYJH2+?-V&.O@]]H(O\
M*3C8?EBSUBB8OPW#+/%*Z':+:"06*>3#Y,E#22RH;RI3<6_%>!/L _J+GS#%
M#/EB*2,7FF3:>Q\FYMLR5KW^_ 5E?EMFK.CA]Q7P;1EHRA!T3V+)3 1TE!PY
M/TS,6S'67? @?6+CR;8I@X4NMIP2Q7N*5W+HB==#XOW&M/QI2'QNH[(F8Q9\
M&X*QLIB-&9[+]>'::!MQ6@A[?DDUF>3ZS[T5S V3^];2*ZQZF1.LH_GV"K;X
MO(147KE6>[A@*]=RDYWY;/$O(V^!1:1;>HSDBH2SB(7QD?M!YE!!(2;R1:19
M:2?=(N2$,_(E/G\IXZ^P5WL=4RW"PE97IH!0+*/$7<!5IMB+^XU8X5;,C\3-
MT49:%Z@MU'(S,NA5U)-:J%\<ZJM73D-GH6;)=8>;'>3%@LG;AE7W(BH)+=0M
MTV]TJ_K:KOTZQ)YFU89XD<)";7K>OZ,X#C><!ML;-.(K4?IH3;@X?IB/7RA$
M#1XBQ)I9F2Z0L,=6,-.$42Y1Z!:%28Q,<=#0DEI8$S[)PQ+AIL@4);>/[FJG
M([11M\@+ WJ)G@VTTY):J-^  ED_@&J&_+3<Q1M+E306:C1B9$&@#U%.@U4$
M%NHBXL+$0H0([P]YJ%U[-J2WIN?4K&?MJ%-O-7D?YC=JF(KU82WE&U5Y^Q7J
M-SCG7[ (BU KKJ)_H^IK%[P-Z=^*^N4[D5(UE07,6=Z*$78P-83^C2JKV;&I
MM, >O&_&+.6[%_*LU1Z['BH^:\RAO76MSF[.OKM ]FT"W6/YG@-,-P(:E49N
ME*9; ZNFEJ>K;6:[F$;4%GKWFW(7CGFH55226JS?62T4*ZEMUK*X&JY444EJ
MLW[*<'8EA87:9):*S:JE*8.%NJ;WJ8YF/EG$.]@@CHEH\>PF3A755QXP7NQF
MA;Z/PG!S\>&(R1MET^HH=QBWMR(FJ3F7>2_VDJWKE[X!IO*:J_CAT/C=NX__
M#U!+ P04    "  .2*Q:?W#,L7,,   YIP  %0   &)T86DM,C R-3 S,S%?
M8V%L+GAM;.5=6W/J.!)^GZK]#U[V9;=J"+>0A%1RI@B0,ZDE@0+.SNS3E&*+
MH!ICL9))R/[Z:1D;#%BV[! L2)W4"3&MMK[^6FVI=?'-+XNI;;QBQ@EU;@N5
MLW+!P(Y)+>*\W!;F[KAX5?CEV]]^NOE[L?C[W:!K6-2<3['C&B;#R,66\4;<
MB3&BLQERC$?,&+%MXXX1ZP4;1J5\!C_PGU$L?O-TW"$.9:AC>,JJ9Y7@BY:O
MCCK71KU4J9:JY6K=J%2O*Y?7M9K1?PP$'Z%N8Y(H:1/GSVOQWS/<T0"0#K]>
M<');F+CN[+I4>GM[.WNKG5'V N7+E=+OC]VA.<%35"0.=Y%CXH(!\M?<N]BE
M)G(]"X6*+YZ9'2BHE5;WDDJ(OXJ!6%%<*E:JQ5KE;,&M@E]%\;7"30)Q\2V)
MD0]A6<KOZ/=M4&DT&B7OV\*WGPSCAE$;#_#8\"Y=N^\S?%O@9#JSA2KOVH3A
M\6WAV46D* @HUY9 _C%T@4?A(2WJ6-@!NN$#IS:Q!+]WR!;U&4XP=GG!$+?Y
M,7C8J-$SH0L3V^X$,S3#<Y>8_,RDTY*0+:72[F%6LF;I4T&OON6]<6\&L(0K
M[1^][#8ZFJ&%^.3>IF^?:X7070YGA#;AIDWYG.$'YQ7J0=E[&X.4G05KG+(\
M(/49!<]RWYN.U?G?G,R$H9^PNP^ 2:KS@-LT33;'5F<Q$W[&]P%3IC(/>&W\
M[(*YX=EK$?<>F<0F+A%U>G:'\^D4[<=S4]Q%(R,\."YFF._%M55OD0?\+@:%
M_!&Y<^;3XE6FA6RS^B'0\8HU@OH9*-,#]# @9@9 _8^K:G'0$M)0K95\B1(7
MC4@\ZXL$GGR%1!,%VK;J!!I-X&9N+W55SI;FV]:^K&U(L@N:??VB.I_5EPN!
MP@L70PEK=96XXKZ-1EUTY<MEHVBL=,/G5N^IW7D:=MKBT[#7?6@W1_#'7;/;
M?&IUC.&OG<YHF((P80!!&#4W:F6+,0)ET;;V5(T1?_;TS7GQ!:&9,/IY"<S#
M@RO"<\\]L_L7_FAR'L)OHV=LWQ:"BZ4<JM*:,P9VW:I1I,P?%[6KJ^K%>:-\
MWA#_ZI>7ZSJ'/*C)-JL/CAVH]WT\6Q,8,SI=&\N_ TU36<HLS&!87##F'"I!
M9^(>R"X8;YB\3%SOFQDC%-K^^VVA>FA&1/]6/%?@E^@RO2);]'N;;@LQ]@XC
M^/\@>XXE3"F5W31*'?[5<F!0G:]=CK/#5.'^L'0/L(D!P;.-.72,XQMBI.SQ
MTZD.RZ>OJ@]]JQ$<U%S"6ECD^,E*1.-S5-.'HS[#,T2"T1D$CI[HNZ@\^11*
M'C^C64'Z1)]K^AQ5)OD4.4U'85VGMKI,&/5AH.!N98VDC51>1 \FY;W5U'57
M>0+FV>B6*6KGQ1M"#T25>N,?$%6$!63M+Z[,IA$N&O6+NE8$IJ^\RO-1C[#Y
M1!U3-7*N9;5G3+G2FC_@N@0]^TE'B!Q#EYI_3J@-5>8BBKCO6Z0EB^=6?8E[
MA23T<"I5BX?=+0F$YMF(4/7C>U&[@GIPILI#+'-QB-(16#MX@L\TZ=QQ>1^]
MBQ%V0J8O4EA;(N/J%Y$95 >G>:/TIQN5VZ94?A/\)8"O'BFS*?!IWH7N4N=E
MA-E4S"\FA-Q=R1,A5!69?KDFKW>IW# ETB?"8AIT*GWM/(>R 8SWY$%14CEM
MV56E-1- _5+W;<S(*P!YQ2$;)-*;4.K8R<T"3[\H''Y^)#(:+;R)]$J?3F^&
M1V@"*OUB;XM.I\3U%GR*>5[JB'"#'5.>*X@IH0>367(':4'I%V,3LU)RP>.E
M31&+YHG@@5CTYF"K@Y@#;L=AD#6?"IMCJXW'Q"3R50I)!?6@-B5=NSQG!*IY
M<J$/:C \+);.'K?:*$+R1)A5198NE7">QV.4.HD\;HMM0FTTZI<7QTBB$JQT
M0?C@##8MBRQKU$?$>G!::$9<4;WH/%^T](GPF09=NJF[@-:;TM82Z ,MBY9N
M\@J1$;L^NJJZ/GHX@E^/G:?1T.C=&[U^9] </8" KBNEG[#[X( 5<9=R6==_
M2R:'?!^,KVB0%%E6Q5],%9?VDQ;2J[E&,K"3Y4L'1K]5N&)5(_=&6LO:![MX
M8I9T1HD?&76I8.@WN RJZ[M:V >EO$E+A#'7RV7 G&?/58&Z=$@2^SG%_!+L
MB1$^0O+(Z%)%H&,JCGO9IV!OJW0,L2FF%S^JYH\:1"C@2GR>';YQ#;$-ZEZ^
M8P>0VP"@:4V)0[C+O.1^?/]$K;!>%"L1%9&KRPY5OU[, ',,-A-[H]KX%=O4
M6TH<SW5LF9.@.#U"_;HZ GIO_)U2RTM#8_9*3,R',(J.B<?1!4Z"TY3P])NA
M'( G.G-\#\80\SH,F>YOQ)VTYMR%!Q3K+$Q[+LYK$@N5X<<:H86T :?6M&FC
M2J-^D>?^ENP/YWU!5V[O.B2(PN??J.:'SK/EAUK-X:_&?;?WF[;Y(6&,K6W
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MHO+A<\,S*I&N.2!55P)@S#74U>J9J1IE#ZO5.7I&$<X/:,,()2F.)2>B^N(
MA&"F7)O%2@FGCRQ6'NW$A,^2@@".3RPY+ $"9MM8&IBZ\TM]-6>GEZ:(Q&>7
M5E;$X >9TA2,ZRR"EP@EMXA\IB3,'_ %,U*OXA17%+6(YMP8LZ(QU[9% (/3
M1@\ZP=QWVC_I;+.>48H(W^06I_2?L/9N;.-6 )Q.6DNS"4[W$ES30K7/EPS-
M!HT .'_L07XUF'#.(^]0@BB;YM3V+9E5[$)97,O(:5@'P(EEDY55@PJ.R.Y1
M1)M[^A7%B'@1"UL(%I31[/E6IH%JV9E6!G!GI)%Y9 @/CC3YQ9/B#B<E36;&
MUHL!R/?>1$)U('!D,64A!*7'CB<9(?*8*FEI #G:FTA&B@= [,8Y>F21)Q."
MJ.5[Z?D%B>SK^VRQ\,C*.H;CQWH,!VN.7XG*^QEM.UK_F.2=P8_G8-1>Q73>
MRW3WH80EAPZ**I.@\/&+"H*)K5"PO!H75<?@."2M3) V?Z2\. P'O%R9Y%+H
M^7!Q.O.J=LCX2>8Z-R@/P&&K4YG-WDB-I(^-:WF%$(>7*,JY?C_ 1%&V^TXA
M!$!3B<XU*RWMS".KH5\^@>SM?9$JC/4;3&/?I[0$5\R?B!*9 6Q8%X"'M;%<
MI:#@;%JJ!$\\0E9T!YR_FF4DN-TJ 'RHC>6UBP6JF+[$7G[7! 5L!\*(O25H
M$68+[GYZY.\HL6Q/?+LLO\W1NE4 #M?&PFX %XX^7./XZ0&1!:-3(MQJ$0!N
M50M)56F'R7:U>T=8$H!;M*$0S+TY3F1Q@V/?6!SEP@#<H TE4D8!U\66_[TY
M/&[@9OM@Y68KOMMT"-_5Q@0^G55W8RJ'FZ+\P>UF[W;3LO_@?#LXWP[.MX/S
M;2^=;YH;1)OWZ^Y]%'O4B)#<\)*4 W/%RV@25P 9GO%%]U_B9(G\<!;2/:CL
MJI:BK/NK64H-VG!=CJ"/UUD(W;3/D>(EEFH!Q[>NM*JP?3:E2G=_K'MXP5KN
ME<HX]- V8F")]/YX>*;EX)D+_IUVP+^S_KDWT7)OXH)['SO@WJ1_[IUKN7?N
M@GN?.N#>>8_<NZ1DL9B_68K(91:S1Y*GL[7.7V-/<N/0LJY#'Z =Q\TA]2R+
M>VI.)[,\!&TZ*TB9X#B_Q<!?MBZ&EH60&C;JT%_87'H-L?8@UCQ;^C166&>U
M(@[C(>U87J.\-P8J#;1:D2$9^&-[!O9KGA5]T#):':P4&G27<-P!%\O$#Y^:
MA-UBD3@32K^!R:Y@[$ H$>^&J4*EK?WJWC%0TX *!YTIYF?*CD6VD')QYW?7
M&5GJ$E^S<8?0X1GIO:H96?W=L8] Q<@JH6Z/M 73T+4F#%)3QUDPI!&6RN&V
M? [>O\!($9A"T\XP(?B%6>#>DOZ2KBP$*V\"0)AD)Q*7(^S[TK*(FJOX&24I
M/XR,(ORRC5$H6XN&%0$$1AI+R 87G(B@ZM'F)4(68:RET@""&JV'DA2,BU$S
MIC0$!1W%I77O:3>>Q;HV@ C&]N-'!LZ%F"Y>PV82$E0$$-G87C@"7& G-\^W
MFMU*Q0&$/+:=WDIHH IHSVY22"Z"MQ04W/L4(F!WB'&&DMO&0E<UXM 1VZF-
MKL((1\2[5['RNU=W7HHN9C/$7JJ6+WT-VW#I).YHR&HQ]FVIR,E9W])AG]5&
MBWT;@TJNK<>D(4:H0_/,2\+D?DF0%TSCKQX)F=.'$7]B-"I5U0<5:U=N$7-X
M4"6Z)K.LE2RS\06[Z9&$])>+F!8DZG>,6K0(+LY:K^-R#;#$/O0$[1/N?_6B
M*C!%9C_;%@:59B>N,UN$?<OLU@N#J_B_PWAS!UV]@*K+#RJ/MAXR SQ]<_\A
M]+]1([G(MJI@NZ3@H/SNQ/4E =(WHV\0W7(F\SOT1Q922HLS4A&G924'974G
MCBP9DF&7@<LP]F(_]*()?D;T8UK0<1U2L@*^9^3TR?(PMVEM4)FU]6BU1MNW
M7.^SQX3VZI'5]"5&))F'2_6DI:DPJ'3:NK%, /6^5F_ZFLZF69JD'H_79*&9
MDE@U>?%!F=_6Y:2' V>_LT>)(#YTY2CJ-Q^$9#04<R%_<?N68!^A(&&QS>OD
M+!0!7BQP?)]B_]MO_/45GB!V2FX)8J'.*%A_>XF)(%U*;[T,*N-.7$I]< '.
MD!4B(NRMDNF,O4DL=?.;5!Q4V%TYFDR P9'?'5H6+QE,9P;IC^3%!Y556W>"
M'@X<"<E=TOR:<-#BN*7>P*!2["=,1PUPV W<WS./4&JBU3A/BL:=B>NG0\9)
MV2R[)2'=KBR]*#_6S2=^_::N?0^#BKP3/TC7'.C=VLJC+\N4G&7!$Z*J61!"
MU_4P><Q(DC]Z=Q6/E\LH])E',[]X(C2ONFAV4.EWXIKI!#;<W%YK6Z]!4J]3
MJZ1>ZXX.R;QZ(WP2>0FU+ I.3\E=^#17Y?12E-_/U%X*0&X?>!'1I4SRI:P!
M(\^75MNTDNDQ?\RZ(^];2A"B\][?0T]^5515&L IM('Z;)8K%91>#FM>UA.[
MG+V"0@!NNMAP58"@CS1U)'P*:6MZCLI* KB>8L-6&8S^)H2$_G*JG0@JI0#<
M)&DP 50@],?/^[E'-[]LP=,RM5X4P&60!IRMX^AC*HB_X829]46GBJE 4A+
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MMMP_?:IZEUQ_0^HN\$.XT'EK,O;90H&E^-:L=^ZETB&J.4$L--H)!6_+O]5
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M?C\Q?3;<>Z-J>A<FWRX)8N$WB* D'4I)Q?WN\^'\<"HJYMT;5=#U>#P/G\,
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MG><_R?/WFU4&L&FRDJTA+#A'?$+C;7UVM7W;>4(' 0K.5FOCK2AHY<&S:17
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M,H.LJMW,$>J(VRGSA:QJ?) Y9%OIX0!MP:_1[H!<QGZRH7P%N.E_M4C=&C=
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MH-G?#S=":&O>')][.N'%!'W1QX]]);4% 1[E))XYN_P38^7HTKM]$YP^04D
MF$&OO3 ESV4:<%!Q(6P*_L#FX:YFU.7CS\T21JKS&E5CW*'=K6/C&*VU)=X@
M[I'71(V+UG)=L*$(Z\/S5V!J)<M0IUJ#)>T5A;4(;=5VFOU\?D'G/\(X*#=O
M5=NK;0UQAZ=:M\8^_T$KO&'9(>M8IRQ>.C@!HHXW\&TH]P9'%:#?;Z!?6!"&
MJ<)I2H.0P<]C2CGXN(B^:B?N"FYGWL(#BJOU3QE=9AG-Y=5$@8<*RXT@@SMR
MQ]I%CNNA-/!&_6A-QE=0*G=E.<<%X3Q/DO4)XTHXVT5Q12#TR2T-=KZS736'
MQHGXE>JTM,V._8<'7)W,MP]+NE2"%M=O>TX#!Q' #1_#;2$#AWYOO) Q0H?1
MUZ_;BQ_585*]H>0V?V="DXC5>;9WP,6A@>_/.5Z:'UIBZ8N-R64<K/(GFMY2
MGX;/,'52;> /I3$WP-"P2#=F=!"8$VSHJ&$8.4J6/%0X4R)Q=;2E-ZUE*A.D
M%5$<0'$9/[.E4I*& X"AV6=N0-"B<7?@2QWF%.AM8AL.;(D%FB@VJ[:@]88C
M5F]2"@6>SNB:IBD-BO5/"5=\?:0?Q)K$YA;=0VS4'?8ZE.:$!X/T,0P4!>_R
M%$":""S;UM?NT&,2(Y76*$X)L@5)N"W\'>,))_[UPD+\@&H3@ANBF,X4V[',
M/I# L&/6KA="^JNV 13G!D>#K=6S;Z%+;D[ -%PITSL; HG**7HA H^_0@AR
MI5S@.]OKF,QJE6&V@LN">(55:@ +=OSZ2$K%:[=;+P76"PG#2G!#MU52GDT5
M-E1G+FEVG1M$J?7O6Q;M]YL3Z'1(;WR15!Q1WI3A8SJ/:3R(6+!"B9AA^\FS
MZZ,3?JA4HN/;\)WE@_YS"_<>2VB>FS0[SRGP^U2P=FK"^543B?TM!>=')H;-
ML7^HZGC8U[_KK;#<( *X,6&X+<;52<"+"B-TF+ N@J/-D(F-,O36H!F 3'(O
MFK$17&)E=?OEV%HSW81FB9T:MM' T XJL\-2'5TL86K%&G^M&9M6NKB\7EZ?
MHJHU<^=%=+7F6?.G29PQ2Z3%.]AP*$Z#57R?>G'F^5TW2P;2P(TGHRS2N(<R
MA !>%!FGQNA[&XP;+_LH2D(V.)*2):242TS=//$\J5D 5ZOW?>0'@OQDLV'6
MX&4@7=W@F=02-Z45^'M)*E/PW6V7KQ_>TJVX<Y6MUE=)_'A/TPU<I%;8L*,Y
M;I3LT[-9/+>]+5[LZY5X?.F6DC!X+I ^ =K\KKVC1:8U7<O+A[RZ?\CF5%LO
MJK3.0>O M-;ZQ7PQZ3S1)<12X>J1!P!07C=!8:6>+K@!2D??YA5%=7N\0*4E
M]9'.G%7SLKUJ(!8!Z[[_(J-%Q5?K-4VK4AZ\!KERDE%-11S-PJP:0GSUI&$.
ME^!U*Y(9[I-FD?6+)!U4"N$(<O, O;%V:@/$H;3P@^5HC8X$TL7^2P;%TP?J
M8@V.IH2N#=7YF$&9T)0GY+EX&J']703<&_5'[TJB!Z/AMABW(8\7<$;H,.$&
M/*;3/%LFX:=Y6\DD=9DVMR=Z8 3X_^?_V(7/7B30MD0Q^&$9!\T_2"U%68##
MS)&BE/CYJ\\OQ]XRG#QG<S?E:>#D0N &+#??1 :]:27 "YR.[##Z+CH38"'@
M5Y)C0:2GKD036#CN_;'90\A.6C+7Y*<"2A4(Z$"$$D[0?&;?"4:$L#1M&(O1
M ;X)_P>M19O=B&#C^[QOO#8.O^\43=& HPV VW((.H\[5\/NS=>*40M"X2:/
M>$];*&+/1'>YE^:S--(#?0SCN'A 46FJ:7)M=MMMQ/=UO*A\,N\R7B?IAF]M
M]#V)J-T;-VH/M$(CLT:O*UXD'JK Z'U[B8\ 4N!$)%:NL^^<6(*CPQHL$=:L
MQJ3=/>1>"/']P[???_^)QSC\Y>^K]-&+BU)X#.]NRA/@WO3<X;UQQOA(*T",
M#^SJ-L:#Q-]QGVHY9!JKR.A%34("N@[CD(>U]^R%$5P<_-I&6+=AV^3Z>ODN
MI>5H_GF7A3%U\XR<D&2U+JXB)+%R4[^M(<X([M>ML4E_T KOV-LAZ_&N6!,E
MO][3UYQ\9B[WFZ/$=IN*NHXY&6@@ZS2)PJ!&'9J5H%P]#>-%U4/5?9=C3-'&
M'=E&+=@H!FV",%[\,*O>V$C\[&4A3\B26<XN$.&5IBC)&*8 6'*LM&'U=C;O
M.#P[[&HL4EMXO-.@[=)T=&JA))"XYE*)Q#>P9*$@S"NQ2"T7J05S/]M 9V$T
M"%D4:0KCQQMF%%_CK>BN#KA1JU_7QJ.,RM9XD41#YO%[5)N-E[[Q-.OP,0[7
MH>]!'F#%D90LG>Q:UR(=VJ!O^-;NC-N]A]F@L66MU1.OVP^4?W0(=/N]^V%N
M*CN@A@)^@+?S\QW<!N '>CP55[OZQ)#^N %AL"6:]R$U.^.%A>$JC+\Q*7%"
MZ?3ZB]F1I&8>"IJ+TC%T9AP@-I8^#:9%/HVX+"&57<&T>'1O)3>U,(LW#&KM
M>M\-Z^J!&Q\TM&U6N%0VQQOM.D+/],6+ \7Z!KF>+K-SULY!JZO]K-S5'+Q6
MQ%&---.H[.1N= I5"O.WFPC6IG$ >95;V%WM&5-T^N$.5FW-&]>:^SKA#5M]
MT8\HLL0Y\+EC1;ZM/+I;U]8?C0:2F*G#:XY60_K/, QL0'O);$$XNV9@H!KA
MG)@%"U"(QQ*R\K45+^K;BNSN@1P&^K7=*^2A:HXXR#6$/O8]C.(I,2=;Z?O/
M!!V\$50^<";]J0[D4_%R3]_@9YP)[KBP8].6@VM#'/!&GR4]CW[NJGJOI^41
ML(7TA*'T9VF,7I!",O>#-3X#.T?$8N_WQF/3"JEP;/^98F\WW*BEJW?SK*2[
M#UYDT99\K"O+1,E+F#^1SV'R5Y^I=75UBLFOAQP;#J$P3V_7/B34[CZ_&+!S
MV"4. #DST@@.3(O7*4V"#B&@\K#V4:"R,>ZX[]91#O'VEGBCN4?>L5X*9/F,
M]C2E09B3"\]W^%A;4\F^ 4O=>DY.VCD0*9K.Q4W-H2GW4TQ#B55%$05D&CY[
M>?A,+V-(9Q&WS.+@SS1X;)11'#"P'$,1>V ?;:UF\(\FAQD@CE=J?&R5O*4+
M3Y(8,XFP_G'Q*)+O+L9Z1MCQ]-Y5E)D<PJHPD[CS0:W@CS51%(O93*&3HH"0
M_H.>&LUQPH6NGE5-(+1/</86 ;+YE&3\C3=I@1^;NIR*MU7$8R,:E<K-!EC_
M\#VLY[S"KF<P'M!M?L%H97/QB1(F1L@&S: >/^$%H3;'GK9(UT0F:'WL%\-D
M8DHCV,"TXY<TE:*KM?QN2['[SM^,XB^[@ Y!^0I,W[[!L41Q J99FS46-D=1
M1+RT,:/746^5%4\IR>Q1!]IGV12]VP='4WTGH=9MM5&QUD[R'01;CV*CHZW[
MX3($.P:N#80(CJ[@P8N^<?R@$6ZP:-=)COUF"[RAK)!SK.,)<F[<+,LH+<J.
MQH]"D+Y!K;<3=C?4T;GIEET],+NIEMSCW1;(+TC%@ @.[D<2ZXJ[BM<++TQ_
M]J(=K<?*OD&BIPON6-715X[4KO9XXU1+ZM%[.XPXX=3)%^:WC+:S\]DV/?L&
MF[X^\_/?SJ&FL\.\/-C@]F3MPA)]]\/,9%J[#MQS+X7WF.#]/[X ZQER.IKC
M#M<^/>5(5;7%&Z2]$H]^:X#FY"K),G@+4[R/CL%)^T:6KO;S<M/.$479>#Z.
M:@Y32\JUIUH?19YI^I!TCR/V],41F7"R%N9E M!IPLNBTM@?DNLZE ;N"!YE
MD<:[IT,(X(WT<6H<<\);<!-IX3*__8-]/)'1-Y -)O(.8J-SR!M&8>;1838!
M0AD>*-)!,!K&28%_^@C2W-)MDH(D?>_0JIOCAH(^/1ME^Q5M\89WK\2C#S(%
M8?GQ6 Q>JC^BZ?6<E^]JCET:W>;CT3; N'3NB@FJD6E*"[@.[]U#1O^Q8Y*<
M/VLD'78T1Q[(/7HVGSMO;XLX9/LD'O\N2DF8",H8?+1WX.EH/R\O[1YD5(WG
MXZ<F'_#9<U0$H\ATRKJ(RI\RNEJ?9WG(!B^J>H'[H!'N^&O720ZZ9@N\D::0
M<ZS',7+P-E9%<"'>PWHCOQ;_ZSK8+.OKY)E[^B(]>98F,?NG+XZ/A='%_^T;
M#4>0P1VD8^TBA_%0&G@#?;0FXT^C7AKOXC58HL.%R<US2WVZ]W)@@ZN3";3_
M1(-=Q!"R>C&C+&4*55![Y]/ZW7$CQU [-&;;FGWQ(L5@#49/3PM&,()6K.0B
MP,#..3(X,4>(\L6:T8]YS"?T]777>KAC!N$^0'8[CW0@B?,)["!'>..%#EJ_
MT!&[>:&C1KG#6N<#!W\- K@Q8+@MVB< ?;WQ8L(('4S$1,NK 5C0P9%%O,(B
MU&'A_UIU517H@0"A368N,#',+NU@H4=C#I Q4!,38=)111T=?C@P3T;3Y]"G
MQ'_RTD?7( )U>J7B?/JPT=%Q+D#1IWL[-*AZS0$,>F4WX=]72?QX<D_3#>%%
MH.7:F>C"?Q*#!(R)VRC_XL'[[3 [6JWA\\#7 =4'3A6TR<P% 8;9I1T/]&C,
M 1T&:F(B-&J6+<B!#BT<&&@C&2@>BR2*\I[R7BJS LWRXD6S998E?@CSHE_"
M_$D;,(P1Q0D?9FU6U0L]FB+R4J+F]!M=9=1[V$5>*I<8Y9OZ0IIR-4^\2A[Q
MSE$$:)0#&D'835M\U+W1FL=!A:D*(<ARSU0@!T$#W @MN.]L;J>#=24WN=::
M5) N^_QV4.UM^>*E 3=1[SAY/'V<(X U2[;/+(\D/H<IIRD53<2H7*11ED:N
MU)B1AS?26LT19"J ;Q_M)GHXDZUB0Y_!&J^E^%,<YMGMW4]?Z.:!IHKOT-<'
M=Q1J:=Q\#K.C ]YHT1-[?.932;THO\WIDP^,0_:1_"JXN'KFTJ;BG^\O":/F
MJ.[$9!\UXQ]U!_2=9*_0E-^48M',83/K!"1U:]Q0U*-E(SFEO2E>^.D3>'0:
M2DU7C*B96[2QI2?@S(TSG)GBZQT',8K-J?MP4TSZTF0=YB!\&#]RG&R%$.U.
M.)%DF,[5YE%O#^2;0_KRCQ\*MTQR/G7/GRA;B%<7=PED?'DAE'\B>4)6\6])
MQA^VSIE0A#^[0+9<K)-,R-7JXW8W@NP;"#B08C'#>9""23$3= +*$^E>?_-#
MA#X"N]HF=YS5*V.E1B^];HCQ:X#>%8)I]$&.84,T..H!"09>Y4GUP69UY<D+
M\O(4^D\DS C[7&R&D(>P%\L 3@S324J\F*>X/GL1I[2!*R^P >)[V=.">&L6
ME<0CV9;ZX3H$$*1IF 30@B,CH_#R1.-F@VHRP)@&H4CV 9$W=.*=\RF^AF+-
M7+%QB)E3J%^C)FP2.*DWNME&R1NE7,?5%MRM<UW9U1XGGFIKVJ@WJFKL%D%U
MRG#V2CX:.07J<9)N<NWZMKA5.]Q784PO<[I1W=(W0ABW]YNS7>.$Y6BJ>'=K
M#.IVU%REYQREYQ@%A"%<&E=U@3'8$=&;6'TG=FW3#FZ.X@G/MX&9AJ:X((<W
M.U8=<IH\D 5BX+.DJ D4;'GR;T%:%Q&+\LW;-]=)-&CMVKB/5=@JA5L<Q3Z>
MJS7)@*0&U=@A;:KSW[@Q?V8&I@%<@7UE"V[VS_L$_F0$4&W+-&_XG>2+C4S]
M,2_0?*%]&K/8G YWIQ4MB"1^T8 KL"!"!7&%OU ",!#^/)<!!/G7ZQMN;I .
M-]).2F9T$JY%>-[ KV^[(>C=3W6^$#Q -VL3:L%^?C/H*6PG7S^6-D0K2,."
M8#+JRW:!M_C$:)%EN\UV3)T#0TSFAVS'V[0/Y<9SF!?B&=#3=*+ZWD11["04
M8BU()1B1),.,BT@LW&HWMQA9G9")ZA&*N73$Q6#_@LH6?O(8A_])8?H<)JQ=
M-J2^@WE^<T%.2Y9N!U'#S.: I[94MC:Q+"X.BF7VJ;<-<R\":=A44^3.H -4
M=";>GW^>B/1*7]X/<5@/YXIF&:6K+4WYNOZ*,NG*DF)OQ:U_O=7S.$JXH?$(
MZ\B@-X(,7C@[1IFQ421XPD*WX$HXVT55H>]M 3M2#Y3!6,C0J10#"SZYL-G=
M;K/QTK?]4AIKG@R>5(:,0!82E<*XG>I5;]NSR2?ESRQ*Y0V+]^B#5<PP>Y="
M1C1#]G#H:M@,#]RX9<6B[=,X PSP8IT=-4W,)4 >OEAC("A$XG,TN6)I*164
MSZGD(EPP++B(U[YKL.\S" 3F\TA:&? !.+N R<I$US0_8W/59P;@S\)>]5BB
ML-1/<?( U1?!8)?Q=I?#M#?V61\^ ]6"T"GYXX;7R;^$#+V3,<<+R].;8"RD
MR##-A"6UM *UR8=*X(]=@+T@LMR$"TZ:DF/!]/E\'!GOV1(\9DMP$L9L:?',
M[/1]-2=V]=QVO4D,^P9/210PT\-K /G;=9+37SS8J<FS57H;/CX-V> <3@\W
M'!]M*<4ISS!B>.'R>)6,G-U(O/^)".X$V"](*0!<L!,B8 $S'*9[J>RSR[.<
MS?,97CH^D_%2N#V>W="TW&(-?39I/PNC'20D#5N2#Z4V%S@:927%:<D04G.
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M0^20U"NV@?VBK> AI_V#-_*QLAA' YI#?>V8.6KRS,91CV1;ZH?K4!R;ATD
M,X\\W-"):YC9,D]!6.S;BKF5PR>.K*LI?VMK3X2P7[.G) JJ\K#GSXQ#=;NE
MG+K5T\(V4XRB@AC QENE?GED, GDH'>$0N/+@Q4LI=O54IEL**>4<U2DY0*#
M-7"S@>[4.G5I9\ZTO%4'ECF7+*/8H)X *I'XCJ[KV"E">^&%Z<]>M*.G29R%
M0?'&YWWRF<*[4ZTCS)#>B.%TN!5:*]9V=T4.GR,4,5/G=<V8D6?@)FI021QA
MI?= ^:-D[JK<3FH,8$8X-W*Z;XG/;$K).+JM@XO0->R@(2C).=47IN^3RSC,
M0R^Z29-UV#[3'$YB)K@XP!ZMX*C1?T8(.40;,['P7'*4JS:P( @%4RA'"US=
MX>3T)JDXRJ48F$D*IJ3@ZA8PT7H*FB-4]1GSN><_-=N:.;MNI8L3AXU;[HAD
MD$.B,SMR':7:] DA(,Q!+SS'L=-:44X X<5J <T<9X)<)?'C/4TW4'7MBY<7
M5KBE91T^J:S:97Q-7_/[%QH]TR])G#^I<MF.I8D;OHQ83(:NHPCBA2TS:HT-
M-N!^ NQY;?P%*21X6Y"_42\EJ]A-L5NW1F'1_\_H00:^S_U+8L* -:EW!"E[
M]AF-) 6==P(@^]I8P@W& C]NF+(%B^-_<0$790WP\]<MC3/:\E!3=TO<P=ZA
MG1S++<WPAFJ7L.-K+!7%Z@NBB^E?N9E$/2J(HMG#N(=ER9!%5-D!=]CUZ]J[
MG<!;XPU"#9DM%.#C# S6WQ-/PUQ6"8+JBYW*EC@=44.[ZK2AO1GR0X4>H2W4
MVA,<R:643>JF9HTEU0_U<W>G<S(56Z]LF"E=\X>E[R>;K1>_A?%C?]DL[9Z(
M 6>8]FUE;SJZ(0>D@4I8OWG."R+(@E1I8LYJY-BTBUPWYP^+=L6M MHS31\2
MO8(Z-NWPA<7J4\?'GP[J[O(T_$TD4"\W<-<B& ]^';1F#(=]%M(&2!6AF4-F
MKUJ&BP,5 )I5\.G)$515'!-B%?G[GA ,%Z9:,UP#914@6YA'W) MV+LO.#2]
MK?J0>-%J*8-UGI-GKLCPJ:AV3\38.TS[NDRT5C?DN#I0"8LH6DK2$@9NKG-,
M9)H.O2>9C/;4G$9C!"NST1]&+[R[>R)&NV':M\TK.[HA1[N!2DRQ\/X!V<+;
MIEWD*>$/+A;>VM,_FU:H)GN*3V^P%N46?*X2'_A"HXZ2E#T=$,.:EJYU@<JN
MULA!3$]VBS,UR8&%+(Y0RZXA]E1;R&H[K&!I56?UET63!7 5QO0RIYM!]2KE
M3C@Q;)C.O1D!58^9904<RFTA,P"8$,YEV@">2/,SFH;/#+6?*;D(8R_VX4)2
M_7"YDU"^C/V4>I"A)/[W,JZEO J]AS#B>8,*@^GWQAW< ZW0S+K3ZHHWW(<J
M,#XK0] G'TI.'Z%HFQ04$C='27M36R*H+.$SS.&+#7[C&\V@OMKE6>[% 9-L
M"&8VN^&.?5V]>X=VJ0_>:->6W,+-/XD-GN'=I.YU'=F::,=U/=LI"Y/I75_I
MK"S@^)+BCVQ)?)4PK24(EV9:US2_26GNO2HL-J [;G ;:@<9Y'3[X@6[P1J,
M#0!@1#X JX\D:<QI)'8+PA@NB&#I!  GMD=4VB.HN#E9XY2@M(P#D2K:/ZOI
MZ8([Z'7TE0.]JSW>X-:2^NB1'!XI%^2=3U^F45B>NCA;B]SM'K(P"+WT;96*
M?.\O-']* I'T3>F=%]'5FM>;_OQVV+ALUG4QR3 +W(A@PYXR@IBDCQ=QK&@Y
M-F!K^K#"*BY%"'E(R6E!0"1>:D54BK]G=CGB I;!N)9LM7P-5?N+7>WG$G$*
M3=O#9Z_Q'&)!)?)HQY9=EOP*--WX:JW7M;=A_[QG V3F^7#Z=I9LV Q791J=
MCLB]5UOWAAOW]D+LS_JR&W)L0=7@/=C_AZ[7;*%%.]+D#IO@],,N?:I4D;W?
MD2>'J*2UDPY2I+%53,G5U>FT.2"F]:U5<9?C84\GC@W+\BJRP=>VZ&.80=F(
MX"Q,J9^O.,/X40T1O3T0(X:>MO6S6YW-D>.)IO!6X26M9" !%X(-;T**B5_=
MLFV+2DU!GY0,'&+1=#KO?5H;X#0$EN8)2-I0-%,0,NQ^'24\)-!QC3;V8@X5
MP!A6\R=XLN\%ZM$Q_2S,>:K<VWY443=%#"H]^E68HFB''%+ZI+: *)LZN=H-
MHMC26<X:=P\H$VII'DP&WK[6ZS8#D!ER[UJCSTS !T7QGPJ6%#4LW&#4-'5O
M\-U!G%9_VQ<0*VUN4GJQ@YH5 S!-W6<.@-:C\2&:*3K,!<KZQ)\2QUB/DS47
MQC6*V;**#&&,!Q%,4 &8?=5!\Y,]S>W4Q&&,A#^-+XZC1P(QLHVT1VNY'(W^
MR'%OK#:3%=!IB0UWY7.FL-"!^L4(@&V&Y]PN]B"S6GJ/6\7.MJ3. +T/M\UF
M"X%#-+ (>]*V&J+UJ\L",@AF?^^C?DZE3873 \!,W6<.2-:C\2&,*3K,!</Z
MQ)\&P- L7*W90PK>>HJ&";B<*(XF2?ZJI[I.;R><V#9,Y]Z<^2O\U74TY3[^
M6LC>Y0_WU75L:\YOF_-G<DU68)9D_>*]AIO=!AXUIX+;??*97G*&;="EWQ5G
M<([1OYI_:/9#/@T9JL7X08@3)][C8TH?O9R2F-8I=T69>A;*HJ0"S%(V85ZD
M,#S0PNFGG9%,99J]*VREI3@S4@2]L,)E6^A/,$69VDGXM=S2%60'<#%;N4D3
MG](@NV"0 7IZ#$Y6:_%R.3>)8C30Z8<3%@=K+D];>COAG;GHBS[6P4L.! Q-
M2AX0_(*+P  GDQ?[RO^8)AE#]H8)0LD$OC!!UF*":98E'&\$E/'7+FYHRO^F
MFNYUM,<=V+V:-M8AJL9X [E?Y"/GX(+THG@4A5$7X[2;58<U95?-V1E4O J2
M*/)2/C\3X_.8XE>JA0@$OM#C; =\F2)A$@C]ROV*\U>:^F&F6(\,I8 S3(^P
M1KTZ&=0=^R)EG#)'!CFL1OC&@IA[$B\C'F$_[")8N/"<(%KPA/]VLVTZM6FX
M000_(A@2P;%<J50[JA53!^N5:8URWN(%BZ;O.*X6V#ZY*RTQ:$8H=<*)GL-T
M[E^ZE#WP3G<TY3:_:%$<(KA<L%C2^L7X"6][S=)BQL7G<;4RQ:_[@7H,'9RQ
M>[1EJOG/&"+(9T%'J61H#5#-^Z$F%_S'+@YS>=R#OZ>BG*!4:&_:.9$30XFR
MT*NZ+/2J?/6A,J%8+:ZD(L)EFVD1%(TW27[C9%;$M(!:2!WUV?::X$3-+GT:
M\QOI=\2SF38I1X_BK!\!:@[KK)4*==94.V@T#U=3UTIKML#O;H9JH$D.9[S^
MV27[+#$4F5XRU R $VOSK3HAL*<]3@_3UK2:ZG4U1CZETQ+=:H4CX$<J,0B7
M@X @TT[9K!I"J>/TLRX4>AZ[1R_$_O0O:N1I;X88<#KT:FZI-]L@AY<NB2V4
M&0$N12[>] AB0U>N4%%YNHXK-\CA5+])YLD_TPPJ)G6LQIHM<,))AS;R]%CZ
M&>_<N$W(L;Y6T'*X#BLDZ%R&[;>9A8^I%V&-!NC]S- 2K/(TXPNP6T8Y#7TV
MY'$T_BD.\ZS@]NG;;V]H"A"ZS%<Q_1OUTF4<,SA-,R]]ZRK[>"Q)G"YJTEY2
M$<FCZ"&?K9G2SNIZ\?;N)_)<!!B3ZK\3+R=)3,D;$XEXM4Q35ZQT;;J2?S'_
MY1*0GVM#D4((L!<3@X <1!+$:1U,Q\;3=*E)</R['PX5#F[I1D3 9?SIN[_L
MO!0,.@K31Y"?)[Z/M:,.U@^E/5_<'ZWI9&/ =S_LQVM TE) >/[ZTW?D'X6,
M:,8$!V;M'!_@9F[+\,"?YMNS92D8SO%B>L..=$5G]PL^,[&#TV2SI7'&8VL)
MY]^/O$+TY[>ZR8WW!G_B>[CB]>'56N0O+G?Y4Y*&_WF0 FV3#\Y!R+IE#^Y!
MF&2"=SUN3]6C4K)/.#\BRT0DH<C#&Y';%8*)<Y %J=_P+C*5:_'<W=M 9>2:
M5)&K/&>4?/;"")Z!O$C2'R'#R/)7:&'W^\!,E9UM0.<^K_>/H$J-40%I*25A
M*P;"Y9PUHAHW>M- CSP]]+@;(:KC^;$6**;MWB-=K2]C/Z6LP64LW?[MPU,'
M[''BJZOO4*<I3,<;^<:*"TL8*C:^K20 G)6*IE38FU67%.5[\XW7[8M+BN%F
M0X.0]8[>H,R;3_F/OA?1.&#+9+%6AKN-8:$J[/$TB'HM^ 5EQ%(AZ_2Y'C/Z
ML&(@?= <<!_:!MQ::K@\4,K-_M&H&B$-PQ=.AN'9?9IE'.^\J';[:D1N=?@/
M/$:*P'1RB_/H^<TR"$+HXD53;25U<L0Y@$]H;:-K)#6[=[Q,TE :Q4JIEO.]
M[#Y9M/QE'R!758,<7ZOGFC_T&_%AWXCGK]LPY8U%98*NCV2(_@S UJ0E#Z#5
M!''D0&I418>P6<M4U!9QAY H3'I/TPU?Z7E ?E8S3_Y_BL-A88U/I@>D=A8S
M@#O#]C0RF6RACQST3&OI$/?$A:TR*<0U]&$Q;&F/;9L]<*.?N%IS&6=YRG<J
MLU7^1-/[)R]>;8%$=IW$D+U"BUFUZ<\Q@O\[Q<VQ7\((J YE_@X1=[0)7$Y#
MRXMQE="$2TUR)C8IY&:+_%+R<KUO [(%^)W'@178GOSKK.I3B@6AXK3BP8MZ
MUO0&+7F7>VG^#FWY0!_#.)[0G/;F$I,;DM$[203IQC$:ADTFNP:\3:+H(DFA
MD[NOV!3B=S\/:?DF$T]&) E^US.2-CO,<%HB)6S]"BJ10B=';R7-Z[M=[^5=
MO*^!@!^G9Y<:AQ'3L/^]@G_[=Y@&]IN\?X^ K[  ?J@7@L-IZ1SW#*?^+O(T
MGV?V=)9G-V*\9YH^)._$?#_VFFSF@^'/?/+@;# \8/]['0S;O\,T@V&3]^]Q
M,%18 /]@* 2W-!C^47R2F"=C.]J+-?QE"GOANH[2:X13V-N,(B5..V"/$Z==
M?8?CKZ,,Y_U>KZ,<88G1*4=/\ET3R@4H+B=L"U@.:WD6A+[ZT8[OEHL;(Q\2
M\33$1Y*4P,Q@.B<O-*7$+\4E@7A!"FZ1I'2;I-)!_TQNE#CX-M.-I97LSH;3
MV7V<VF1S72 UIAG+&-(9*11[N4_@3])IHYV<E>'L<0Z\KKZ#D0720-[O<($T
MU@(.07U_"03UCTJQX4HG_)FUDM,%["6LV-LOG/K+E-:L[N#.%=CU3\Y^H?#<
M$[/N,TV]1\JW_,Z8ZA=>F/[L13N*(F%@H)3O=)BP^U4G3CD8(N([''0L&PK_
M@D-*6B@U)(6*XI2+@)($M"1<3?+K\H&1]/S\W:8Q3/JI*ZM[A=7Y0WV_UV$.
M\4?_KP%MP/?#-HK]U]"E99UW.%Z]Y[L!]C]L8^W:/E2UW28(V #II5G]>/$[
MOUB XT.T7T7H_18SGUPTLVWPS3"&R_=[G6:,_)(NLC7_:\)AT$3X9QW[^9XN
M)Q]H\D+M?^ B\U$YX!D;WMQETPP=KS#)A7.<PF2AR1-SD(]+&#)V[,/6 5JM
M84!XYKNG7E86B14U+@,8,/83?GC5(5[EE;6NAZ,BT4?.\BD:U9D^<9(3^DI3
M/P1"24JV.T@<RA-"UVOJYZ+N+/MVNR@O)4E\?Y>F%!8,4/)(RA:BS\R4[RXO
MZ#W-3"JE4$Y)WL\7;;.SI<G(#!*1]NQ]7@#.#1C"6?9!CU X9RMHS.,@E:E+
MHG>X?C9KEWFE/1V,3:52Y*;EN!/Y.AG'A_QY_Q@$]7#TT&_GAWT[R[7M;D')
MK"Y9W_5-+?":P>!AR\)&ZOIV,4(.]=;415/W4D@HOWHQK_*_5JU=&LG]8Q3G
MFVV4O%%Z1]-GAO#MPU=U),F-DMTGN1?)OY\F67Z=Y'^C^2WUD\<8RL?7E$2G
M_666XGNYE <W'CO_4C)F.Q,&+ZZ[-XD)[*\PO49(*3^F+NU>WA,4,BP(",[:
MY>2-YJ26G8T*FV3GZ"'!^7Z1G^*T8B9V:(M-7%\>FNDK_'M>:9V%A:3UC,5+
M"'W,< .^71N;W)5IYX07JBWKBV$711)Q@CJ!-BLCV;7Y?E'%F8.IU<N\O[];
MNY-<S_T=W</%?>%VHCNU=A.]K5GZ'1=[G\9F0XJZSV+<:6;N_9@FF6I7QPZG
M]SWV=%C7Y.C3PN;]CC]=RF(8@0Y3@KF,LSS)M&'KE7;!UUD *%O$K&F8[YC\
MM@J5=G)ZWP#:85V3 -K"YOT":)>R& !4DF^^M4,MVKH$T+6@C:YBZ"1U07]G
MU3_MU_C\O57RG*A>IPA+LHL#^.\B<M]G_4W+538?- >7A\[!9>YU-*T9N1Q5
M_/=2-;-(JO0>(FIU1[V-#\XAR+IE34[)#YB\WPFY6E4,TW%)NEE7J31OY1(R
MG^ML=UHSF3M^:J:KPT'N>JK4#WU!WC<"C_\VE@X]-:5XOQA^A"TP@/R0.SFS
M+?3H[E/U613NX7"9W_% X?9K_M>08.]"Y^_^YN8<KVBZOH4Y=0:-U0^SGU?3
M76?OO2383&=2S0*&2!=:V:!3=AMCJ%$)9CZ.FO\:@\92<^QG/)Y:,(+-,34;
MG_LSR_H&B#Y/6[80HNH%QUBQ)3? !?8/%^.=#P COXO146"@#.]X*!AK"13C
M06LJTSL=%*;^4.UI4&;6!&-3HOIL='!L/P#PW4B $^L=?@W]3"NC[.>>AF7'
M&&;?5B*0E?44^D_%;).!MI_LHH \L6;$\_^Q"U,H9/9$13Y7],9?61897B]A
M_@3E4Z'B%]0Z$S59.S*^D&5UX?I .BE?V1$Y7[C&X#E^H?9\L;ELR>GGBC@X
MTM+GCG-T=O05+&6?X1V5)\I)<[[<&I6IA@G?Y_91-!+;W@G0+X,@A']XT5F8
M^5&2P?*U3&^Q]!7[>+YO4->RN$DH[V3X?@%<3VT,L%U+2B11YYYE9M?^!9,Y
M0JYTL'\9YVD89Z%OY0$^#7[O&VI[+6TI":S)[/U";+_*&."UD4A3R3G'9^BL
MF[VV#G^3:4&2FM6L"N0?KA>:EOK4]6EL,9P!V%JUM9%Z^;W<D,.M79TQX&UC
M%P(-WN*T^P'@2ML,<YS;.GYR>K04,X#FZ;^*O0IMR!_CM#EGGN%3T$.R.R=[
M67&":LU3?ZJ2PTEY*,]/X4_X0ZC20ZG)NCI51YH4>L18*][N.FK@F(3[# :,
MZ;Z"R8F])FOD \2$!L P,!R\N(?GH=VY?9;A@T!Q2/E^Q@#U*>\MW7@A7(,[
M36)^CK#SHGN:;B;8SAD@R?L>&X[X.I8V@'3%>+]CQC'&P#!^=">N5#H020D"
M6LQR)''QL0[R?=/*IKYDTRA<(]F#.L*^Z@O:*OM^9^E+CY/D?0\?1WP=D\/'
M"#'>[_!QC#$P#!_=I3RF'3YT]Z5F]KD&#2".3XWM/9D)5UJ*CZ#XME/QQCU(
M3/H%IGG25V*,=R"85OWIGNH5G']O#_2:M'GC,5Y?'F\=/L!KS73BQ.8B28L_
M03O5'M'D0OQ.H;OSFTR"X:T2_ [!O-L.TZ&Z$LV%@%#8@$@BOB]TM_,1ZK7.
M+O8V\(@&X'T!\<5K&K/:TZD.5I99MMN4&VAPQYP&5G;^=1CB1G#[MC:R$=/+
M#2\R3Z"SPVV5^J"62&+")KT0=(8[[_;M7ADG/S0.[LS-+MO\G$2,3!3F;[=>
M;CQ;<Q#G&6#N--8WDI6ISQ8Y"D^D/&8XKD4F(/.\KC1-^"TJ@XG*1*+BT7-M
MO ]>1CR8(_M,N'E=YF^SXFV8_7:14KBR0-DWSZ="< 7?WQ%^=UG>&GJW,?V=
M8'>GZ@B1&^0E(# I)7XGP&WE0P#1DS58*X4<R&1-PM)J[PRQRP'J+'P. QH'
M4\^Y]_C^CA"[R_+6Y]LRT]\)8G>JCA"QJZEC*? [ 6PKWZ$R5E :ZRVD48
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MS5:$>R,=BRI#ITM?O-=PL]M<[P G5VN^.LHNLVQ'@U5ZSY:&V9JF*0T&(>\
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M(E**1'ZMA2+G\6[#229NBBHU+=M=*$'5=DZ1UU$&H;7A7&+"U 7_ P=W6=3
MCHJ<F,L'[MH6ZN>O#)YH# F=XG&_^X2CQ/[5H;$T<,?H*(OT[7HI">"-Z7%J
M&-_EJEC" ":8PI:Y8$M^S=,=)6LOR@Y*$K@[0;-GI5I_-KK3%YY"Q"?F6*#C
M%L02+SH/,%BSU_S@H47K/D"0NLP+ MH$-Q[T!1.73Z#;UKU4T=5K7'*Q;9IG
MRSB0DA^_,&UW*0U6\2V%O0!F -;@.H$G>L5_?O:RL+-XD4GZN!'!N"5E[#!&
M'"_*F%=Q;$S6Q?4!@@KZO*R@S/"($DCFHO;S6V$96-M?I/0?.S;A>.NH$Z_7
M<R:1UJ]]:PRIN\T@.C2$'YV77A,F%66'=>,KG=LT[JP>K]=S)E[>KWVKEZN[
MS<#+-80W[.4.J\BW:9U5 T]G86G-KO/S=)7^?:Z^WV]>OJZ4WNQ4QFEUZ$GT
MKNCAF9WQ">K@F9G<:R91W*UU_XRLZC*#V.T1W,08Q:DZG(7=B,/_95XI7?VC
MKI_6.4@-HX#;RT=80_;X =WQ>O\8)4;7_2A23[Q<?O-.C@_%8#9-Q<XL#S=>
M3E?KT<$QD 3NZ!ACCT9]S@']\<;'*"U&%WHKF/'$CD$1,LUT;U)CU 9P/.^K
M_OGGD*;PDM';%;QBI#?]Z^Z,&P&&V4 Q&>SHB3?J!\I_O(N3BKK8FU[^C&RO
M+CNTP^!=NRX:,XF$(1;IW=Y0$9A!7 Q2PTYX8-CDNXRWNSSC@/!);V^OM<=,
MG%^M;:NK'S:?@6-W"&UBWTZ07Q#.@'Q"LGMG0>E"02S1^=W@Z/QNQM'YW;#H
M_&Z.T;DOM/GH_ Y?=)I2NE 02W1^/S@ZOY]Q='X_+#J_GV-T[@MM/CJ_QQ>=
MII0N%#3WP,CG,'GU:?2+!]6?\VSY^)CR2XGJI]AZ>^ ,NP':5N]^=#='_JB'
MIO!VGEW+RD?7O)(M;%PRD?[*1"+T'SLH!EJ*-NVC'9;M4NI8TE^0BH/#Q]9L
M*WU_62D\U_3FJY[7UDSSP F35BUJ.M7Y"O_S;7;4-#%G$@+Q33-)I/)$*2 ,
MS#NRHHMTA2O'#[\A-"]_EX)XM76C6B(7V'CJ94],;?B?<S;N,O$:.[/UX9S"
MQ$/ZX\:TP9:0\4J[,UXL&J["V$  %MSW^3\D9@OY\+IFZ 0[IC.'A N;)*9O
MY1,VGL_KHF&8,K5@)0?'G^+D(:/I,]R!X>M9]C.+-(9G?+X_X$[8D1QP0XL%
M:W9,EHXACQ>>;"AI<*+4/C'B(D%)QEHHL1M%FF(=<8U,L7.S9."QV7KQ&Q.C
M7'M]@8-0:*K>OM'KAC/:ANI=;>1H]$&^FS-$ XM;.IPE?RR R!(YVLJ9PBBM
M:BYD0[C;U9E"_[XO/M^YR\ -'P-<<**J9:N:G\?,;]O'F**(YC/(MGZ<F[@\
M>TP;])W"8_=>F(YY3KW(WT7\G[=)%%TD*;P#V_=%+/*="83:MGPKJ-IB.@.8
MM:ZZ">#MWV;71=\%D<0EOX+ I)#8,1BC_1 E/$N[\9B@6LJ:_B7,GPYLE#6-
ME-WN'6$4M6 YK;YO9)C73"#9AH7[\OB/9C0#Z+6BK@FXE>_&O3#)6F U.\#5
M RRN!&R]<&;$S%O^GO5YW%D('J>]F=!@JP>/]?<M&N<N]])\?N;Y3!_#.%9;
M"/48H[#,'<WS2%SO,?PMM!B^S]%&W]8FAIQ^;N]OW!F@,\+!9T$D0='4\T%B
M=ZC0&L9>^7;)&1LQGME_/=/&9/^$YR&P<?PR?J99SK_,;?CXY.3=,,/6_-$+
MXZLDRRYC/]H%-+B,S[T4QIV)(+J3_^\*L?N_A$4 5S/_W>"YA@E0PCO(33Z
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M8HCV\]<M]7,:0$+^P.EX2\=YQ;E:]^[)^'ZO^41XA^Q&I^*""P$VN&+;@@&
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MPA._80_6[^]N(7"B^O'AM_9?FLX??@%02P,$%     @ #DBL6LBY DZY5@
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M?00@';V^T(=1E"QDPZ_[B#XBR(\G\N!O?D CZ-%R*1%WN75UIERQFSMLF^H
M#AVXS8+R1ON,E3E/'%9R\]K8M7]U(9C0G@LYTC)^01OP=^ 5>,?2D&\TKPWL
MD;],Q&S:69K7!G9QE![#WL66[PBR)G-_2X.K'A&X<4UJ &_HQZ[C>@DZ34J
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M;'?(Y_(19>P:3Z%$T>M8<7E70$FLR]G,GG9B16>6(^RV*_!*2+DS'L6^P=[
MGHBBA";5:[;S)75;&$,[.P+!XU":4!LJ!\ -ZXN'#?KD:D,W(K9D PN]>*71
MULBAV_Y_6R(HH[\//^1R<*I49P<Y1$-OVK,'VQ*8A& )=Z[7.9SBB8!\3*6[
M"'8RL32V@RQK+!;))@L-EL5, OE,/K$^T/2-'KNS[3"!/7:M%]=+=R/L6S76
M%G>0B.UD8U:,>=UBD)W;<\'@;;4L5:L2/+J ?S*=78Q",,L"0I!K>B(O!A7.
MHY.Y_@X2BD<29IDPV+T/6GN#Z<8K:8X7+44B]8G-SC-38X2QNKIMZW9(:$@7
MP@ER.^1%:MC#WI8'\D3]R$L9"B;,4QDA8PQPQOYS:/D1% ;A;I*G#5W8(Y@5
M-1>2K:4B.8N*@NB\I?61N[[?!?[L&82+:_""FYEPQ7>&05P",,W2-5E!7P51
M0W&"U"4)>[V-K[(SI.$6@E@;U;,>^^]""H_ 2WL55,-/;X.0R_NF:7-5@1\K
M]_F2SCHA FIKI])M*F.7>NL]^LX0KJ5(I#Y[V[EG/9($^@>%W;[";6<Z$(NX
M?/2+H>]4?U JF:4DV3;>V%Z"AN[-NYV^3/<(Q]+-= JP!\EN.Z$+T7D/H1I(
M2:HAI/,#;"N!RJ#R3C)3RCK.\'# GFXUDC_<2;X="EO5\>D#NC?/)<NEETK5
M\@JICOQI$"XRE9)MNXRU^SICM8$G];KIHFN:Z)$Z5H/S1AM*;!-,C#@Z"<Z4
MF= $A?]Y092$X"%-U3R>7B:1ZX.(/6_)X0'\W^#S8-T4_$O6VB"8#N!W!Z4V
M9>0GP62['(<SR\\][.&",PE=>'Q<6A[U_HRG8L?FAEQ)^<5HX&/-"EL%J_Q%
MR7W4["7XM5*Q#;#AZB1_2#?C\M**W&@\G91:Y1B:1]M#,VT0C<R-)K7,'%1F
MRSK54D&==?]7D<V6M\["Q#"\6[39<317FTZO]?\,V7()>_@#%^TE^#,ZSCJM
M>52)\>I"8 9-9T_)8F&%'^/IDSOSW:EKPPU6[O6*<BA#\=DE8SG##'>\/</E
MWT!S7.DK@_5G!J7O:#GM;4L$,Y>1"G9\G"7IDS;ML%6NCHU3E'A2R61"UT[E
M*-L<F]1QWT6^Q/6P3,T]B1VGJ=(YAO?)]O#>;$K+$5SI9&KN2F]/F7WW..HK
MR,--ZAC[9J-)4[K, 8WUO)5A6X0 #+)#%&%_'QR3Q.GV)%%N1LL)8M7!=;>I
MH>^$&EU'5FQUA3;8255T&]0,NJE&1W!",VBX3L)@"<+X \Y>Z YGB<XUI>@L
MAL%[MCUXBT8'EN\,5LW^GT'6L);#N>CRQ$/[O)(P,(.:H7SG26KK.\0^Q'F:
MJ(Z+,_1$FY(ASZRWC>2U[8 :M+'/ U3SP&F>D_OY]L#/&QN46M-SM&=AE%$1
MH&MYN/T\L63'-XD;P<5;D<5%U'OI1VOM7"4A&D.T.4#L1[29)>CZKEPNRA>"
M02;!4JQ,A!R++[-J=Y[-,9E\W9Y,RNT.WF## ]CR/V'+@[N[*UUGEOP(.+'@
M\E(&@)E>Z,6[M@[4]X?'*,#<@BZS ZO.JD?_=C -&O\H[@E.B%>PSVY\:]D;
M6448!O_%]N!'C:;'AZS90:5=+4<^ZC&S+0!7N.N$RB\<QP-,Z2J]SY7G>B'K
MH9KKF!V004?^=3KGU97FR$>&S$79$98^; \/ZH9MT?9@U?B@VKJF@[?H=ZFS
M<%+[%3BS2L@*QPAOT:*JO.K,7:7/%<V;U&]":<V-^@SK@D1CT-14>I:.$(+'
M,#75N#1F;0_2Q@>KU@>5YCOT;F1/!T(L*>)9\9H/T$<Z1TU=!C2#R%?/@[=
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MEDW<6$5\9$]H>6*48-=8D_M4';E71W,0OKJY[7A;95[:#?@GY(-L!S/?_3=
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MLQ5-/,M'8>>$Z.ER$5U4WXW":DY<-%GHK&-BK'.U4!7;(<1VKE3/5+GC544
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M=!O];8)>_LE/31/K(Y7H(T"7> X*I[AU(]ORN*8,]B9-898T69CUKB=FLGT
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M3TA[Y5E1-)[^;B%/J7@</KJS>4R8F;'E=>< Q]S,AU&[A.-MM4^<QPDU=&,
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M2<-0=2WN5A*SIME-3)ZP.!L6% JVX<%S8+'7] JP@$O"MF6T>%T>F52=K%<
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M:#5;OG5X;Z,[?,5>9.V2'[)VSRS+N;V&*)(B6#-6T$"YYX5Z-KW5@*S8#K"
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MV&.R- <XG4DG^^%&*B17LNKOB<_OM#_]@- C'E+6$$T=K.]P+)BB]ZO=VV&
MID%"IX$!+$&+&5),TA5#@3:2@"C-3(>0D^OUNM^>B$RNW,PQHV:V66A',\%N
MQ;?K]8GY;UW=\A$"/+07<P&*H%$-T#X#)%\2[2.80]1T2;LE=D9AOC72ICV;
M VJ7L?I:KQZT[QL[9TS[H1%S9&6\OMX1JC$CZ\042P45+H-/0$&)1WR[UMV1
MWO'#ZG4!BL[1.R \"4MM-V2J0K6(M:A, >?KOHV!^%[O? =B]J_/"\6ZMM L
MS3A=*LXCW7*238*;KR0?3G2XYBUM-$]XDR?//N9HJ*:]90\OA6$\F;2;&J_4
M&=W @<BK<G)6]*TB??>8X\%)WBA[@41W51-7X.A:_]%;=I>?[H8<,#DLU @V
M#$8!@P1+SYN=_N1^0?+H=T/NFX7T^6;AMHJZN2/ALRHA\C3;LB)U1F-&19Y.
MIW*]N5KW;>[#LTK(/3A$GT/^K:M'#NKUC%H?X%DN[2B-J*:!?!#WK07\K/'H
M1V1[3MJ!=%N?*?6FI$=(MXXK3'HJ\]-1F;19\FY-EZ=2_Y"WN9-=_.W0_Z)J
M%M6P)<>F#;+**:E)NJKJDWK)ORD>SVH6?@3Z)8[HV^([ESF?=*R4P6NS(<9@
MU4A&'$5FHANZ7[/\[-(]3X?S$\ -+@]=XPODKMZLTXXTP=B_M%5$,QN#V$2P
M)/0]^L$2>M-H<2K&<IV^.NL+Y5&6:]=S$]_N4&U/;GW+ZO'9W0P ..+JYK3U
M*0#L-;U]BC BPQN]<SSEQQC%S;J1KD34D!5-*XUN'M=:OK4>=V;W3!+_  ).
M)\T64\Z$EK+U*)ZH%PDQDZ$J3/C>4/ \9G46$HXEI@ZRC6&ZH\JNFA],N6IQ
MH!L\Z]NEX @&GD>9CG#?,P7JD(YQP092Q3)[BE<_")KYGJ L01 <UN2*SCIM
M%="A4%#CPRZ1]:UKM0<"SR!X=XY/+"Q][+?:<KVYN#KO$RG$BJ[>M=1RK2MI
ME4$O;>3O95E8NK;OSO(Q\4"O+A"!>*#W+Q/YG)L:#SN):B=+V3@FD;-!'4L
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M]2.M(E^.Y-A,N]XZ),KSYQ_HWR)4'<5 =3SK=']B+G7 ?T/ C29B/ ?J/--
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MC12?(OO!1HY&>U3<&.(_N2]#?S@LQ%0RR9#QRT[H[>'[QQ(8_MY:=QC:&<^
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MHF2V>X)4J?2RD\Q(R_7'D$$9Q*#I+Y#8$"R6[:D72(Y\,Q/%@OS7T5$?1+Z
M'%DYV(W>1C"K[R3R7:<PT;5:1HJGV-1S?L:*%,I-2$?3J0LZ/=T896,&_P*:
M^J/()Q]F\)I.#E8ST<X(=8/M%9DZL72T)F1PE'HYR9P_I.VJXLC.:CZW;+29
MUBAB6.8XYJKV#*SX$!=<O%<%"8?5WZD\4@'\UP;LEP7<]S90-9=4=YM7B2S'
M3PK-[%B=JHZX$BF4=3 198CW?#4Q*V-6OD/+2*ATZF.8!+*>&G&MB*T:DJLJ
MD;EDX\MKK#=@P\!/'L3!^2FV?#YJ #;:M&W)=/S7.<^;XU_8M>:<?*2JSH:J
M+6[R9:TT6X^V'%-85X93KS\=;'\[9OQ#.D@J)_3<^<2F.6DJ]NI#@I-B3:"#
MH-Q])(ES]V&HP":&WS(QG!<JYI-1C*GRF9C.,T,V69?(;JS].5#A%OLT]TRT
M!8[?,ELG7UMKPR8+H0+>J! /$QY^JBC4)1S]OB3:X8P8/PHL_Z+Y+\XB6]4L
MTPYCYJQ85)Z'S4R&DQ9F<U/N6;7DYK?S:7P(,S>-YXRYSE4;>FQ$9)_7U0F?
M[ #QRD]#F,)I"#&Z7#HL#8/+N<2QT^A"6+)J:!LS*4B37'8C+.SG47+\*>BR
M'3;'P_8\'N-B2JF?[,0'@TR#A>B"ZD@\<!&)DT6K<#3&5]%2<2C\ UU!?03I
MID1UVN,+S%!0$X*972X<K2P".0HE-Z02T40<.\-@#/B*<?X/X37S(0R@IN6%
MP"XJ%4ZMKLF.WJQ*Y3$+,0!(.Q05I>CWU*E[,D'YKZCL?6..'&:L5\4IL&$*
M7[D_C/=,Z,X=$_)=$?(#93-XB&/U986%W2&[>3<'L.%5&_I@6Q"Y6&'=3.2H
MYB!% DD;)>9CSE_IZ<:DRBQX8@G6;'F9H_7&9HM5"6Q.>#!SPH&!CY2*=Q&O
MDK5CF5)VNR1XLE)-SBQS0.> 7I'RXVRH=^VH& \P'F#3P@W+0#^/!YE*>Q-S
M>FN"X)_UQF@XC!4\M0GQ $I 4>9AS0PX! ??/V/OEGL3>(Y#>-[%-3'5KVN)
MAKP58F8NR2I:51S.5B*5AG)..AU-DSB,!\,!=D>Y;WGGPW P6!<5<YW*##DU
MOJB)FT*E4^@U(1P@=UXJFG@WK._.K3VG2C <D^[<5F.(> $-P/_S/4U>F(3.
MQ1A8$\15]' ASCL0M [,?ZK\ILL_9P8<9PE,@RB7Q_Q@Y*[&(DV@0"HJ%4V^
M6]$&HP=&#UR#\Y'ELG?1HQBGA<68R35T3:OD\ES+&7/-)D0/*(S19#1.OQ>*
M^7%A["W"N %#U+7*^'RM.5_?2^!+NKO<P"I@:O\:<[Z^\\SY%N'.K0S^*S+6
M;*:Y,Q7F:@=R"1(\P !44P;"0.2/FN6J$9+Y$RL#^%+Y"SB9O+\PJ*/C@FVX
MGN,5U^7V&>DZZW*3[AH77*C[\VK@74O6)V">JNW\O\@?BCK29,W],Z(N/#!C
M+$W?J32-*SIB"OTB%'J#:MQ#5G0,;H(;MCI2;5N%<P!'1S3RW^^;F+/:4E-4
M9&!V)I*M.J(L%O/C5C]IZCPQ7<_K\VK)'OWV)56QEOLI._-^'N@$;$AVW>9=
MF+.B(QF>VE!M'HYV;X(F?!-T3;)MT4P9=;+0:\0(E<H8S)#J/*?S8[#\%UN(
MGS*X?^)*E*N%?*Z5[)&")Z77A..5)*?8_/8/(!F"/&&'?_4%3*L:6<*W1#]Z
M41$L74S;-L2^)E9U:?N\+E'YY[Y9^NR+SI<+AU;)83UW8MF E937MQ=HP6:-
M=&G0TNNBD!^(DBH7K&G18G]$.K\^^TO>U/S"]'EYU!FWAFN5J*?-S<1DJ:W!
M-Z$;390@3M49>DTP_@)$I/UK_KI%PHDYJ@Q7;V79BJ.:'UFXHN-X;RQ:3'66
ME9S;F J+:FG+;CAU2)/-VZ29\\Z\.Y_79UQEF./J^5Z:I]92LV8!H#6MCY.*
MAKI']D3+<QVX*C J7')@E'A5LN6)?T[39-3_ +<<-<^J,LI<%/X]_B5,*=AR
M\M5-D"<<"EXL#>3VF+:.^>ORO8#^(PX3):LY86I)CAG:WGB]M8LTUSQI9_G5
M0?M_PH[ ,@+P,?XZ-ML$7QT'R@?[]'7LH)AY;\!9Z/YX=R:7,HMQ9EOG-D4N
MU=]L>DS%7=TB[]Z3J757U\F:S2SSSO5F?Q(_KRJV5_-LJ=9.5+G9("-T!*&J
ME.3[59I_=1F&0X9HY9[[&[W.#EKCS&RKS/KL5]&8CU;M0_IB/>'FK5I5'>HQ
MIU@@&UUZ4/)N5/4Y]]R7&S8;DPMC1: VFOR\'G<VVRU@&(KX967Y-[6>F]2U
M?WK9W]$WO<8PUU#4GLHMUDZFM*3KW45O#$MWQ9FP4SI:KH>@Q/I!,3ZY+N.6
MW:D,!9L0F'FNP=3[CJ)![*:C)!&NO;BCNP^(&X/XH%VI)941E]&28Z$WK_;G
MW:NH"KZ9X*6PX6_PCV=1[("=K++Q(A":*C5]8F7GG25[C5D<63A>3^6W.#\:
M 1LZ5V68'L# M\+W>N?V)3V*'R&DZ@BQD8AY(C(B3Y:9>-7@#2)3<)U&KQ*C
MK-Y*I%$%A<0%ZU-],8+^@DQ\_1OVAXAL^@ 3+V)4ONG&VS-NH?.\[:G/Y4T6
M,3'S[9_X>2*;;MFY@ 4OA!.3#*#H:DI,,V.R--=<R<!&VX<VVN+*FS<O@QQX
MLP%8LVAF?,8\A6*R.NXG!_DU(?77+DVK.:K89T4:%2%(,,DH19TR7V &QPS^
M.)<M]R>??)S!F\Z2I3DG/^$V_75.)3)I:;ML0@8'8DHBD8P2\0>K<LG*LC?S
M_%K@@8\\5J!^!YUN.-O$V661&TX9$9I\Y(][DTM:JBMIIJIPDFV"M7..6#7K
M<RI ,#!YT/$)*&N;]B+?2LT:A-1KI)5<+IF<=\8BG82R"@.@+)X(7\N=+P05
M\_Z#\O[M9_'[+-:_I,CR>[S?B4OM 47G6YR4BID"6V*7(XJ%O(]*.!!1,AT6
M8_Y\')O+<6U(YW/B &]F\C>GG%T;*FYLF>XR>]\#2%/'\< <XOWW$%1NQ!Q^
MO'87G)3CY566<$6ZM1)I5!(B#0 T&78/P/D[,)C<B'_NM9?I%K#DDN+9SX&)
M%D_3=J<YL;B,54WV!E[92S81F !Q+ U]C=[5Q.[)JD3%CT2OHV3)R _GDT2Q
MKX4!IU1/&C"\8GE#0[T)8/SO2YF<KC#/FS"6?TZ.8]943N+<:WBC1WPAF28[
M!<';3MU85E\9\613I%%9"3H533 7+,V-F?T!F?V4C>FK\OHGI23^*+-+J5:1
M2W.)C.Y5Q4VQZI0SO,Q"9F<0L]/O)CE'HLQ_7 GLXKDV*936ZFC79!6LIOV:
M7.'-UX\29 6.QQ]DZCN8"9#))FI$DF5K!AIN8*2X:;E0,+/!UV9$ _V/;>2>
M9+O0H]J=J(X*Z1',VE%1SDJD0Z";PI%F2J:L(?,:^ )EMGQZ 7.*MMS]"_[9
M#4PV5,F&[#\)IK+G;CB+ .,(XM\7X>&7:P@EU0AQ^'_PRN3KH?_7\=@/:E9,
MM@S+_KZ#H:-)3?PUIQ BC=78T%8E/2:-P'N_2\9*VC@[(3WUQ.R1_/L>RFBT
MJ^030?\[XG\FGN@$6H[06LZD=>QHQ0($C!GJR/T>/+;[#J'7=[_?O^:6@V[#
MO]NJ@<KBP=Y?](LVQK7FWRGRB8%P#_X,9A8GGY*)"VW5*^*F#QOSMQ29V! 2
M_]6N9T[1^H\#"-H0<R!=9R#" G+=4ZMT3+'OTBI:VAA8V\-H@Z4]?/ER3T)+
M[?\(0%7^ [:(_&^$0D_^^6H37NWFX83;[27ZZHWNS[LMMP"P$CI^1)*4J1%)
MC\11/$Z(<3F=$J7XB!'5%*VHJ00C)4>C;_Z6WL#<GXOU7H:K1-H%KL4V.*%=
MS/!!Z$FQEGDZFAC?9MM<E:NU^7JNW@"MV\5ZC1=3<8I.T+<SH4R]EN5J/)>-
M@$]\O5+,@F%G(X?11^JYR&'\9SP:PZ-$WVCP<'*_OP0/2'7#4R2'YOOMGS^D
M&0!QUP%''CCD+,\!8ID3C:AK604SG:NV'^85"9K]^?=_AN<\Y7]F*B%N>G=>
MGBEY"I"HE<.0 [ZA*(6(,\.T*!'24(PK4E*4DK0D2D,Y#GB-HF5""L@L>()(
M)H9*6E7$!"$EQ'@\28E#68Z+(UD:QB6:("DY_N()*!K2*9V=LVV3Z/:?IQ.I
MN5QMNV,1"*^O6RI-V4T(E.9P:G64ZR9XH9\>LR(5;CF9YIQ>4YZF==52"6^V
MS+I6:P5:)EZW]#(5>CZ@O!I7WG+>5DYP$Z??%.,B\;KE<[\A.G6]G>6T_#"=
MW^:Y!LN.Q42X93%!;VH\NTIS>7U27U9'8Y'W8,O0..EJ/)VQE_26H+36PJ72
M);(Y:(*6H7'*8#ZY^C#3TS,,Q<UIO93*=,9B,OQVKD@Z&596*MQ"<..=<2'7
M;[6;8BK<4BG)SU3/FGE$MRBD/8M7I>%L+*;#+2>VZ*[*,]+0I<RJM20*9F_=
M WM$A)O2UM)Q+%=OZ(S8JF7FL46M6F@"# XWS:8<O5\C"[+@K?AB)I:(S=)Q
M%JHNH:8V[0VSAKWF]4V)3R<[V]2BSX->Z7!3I_[<HM9=5R-4I33JFRT[5G16
M(GEB2QU'R':, IWD\K03XW/DB.+78  G]C1767>4"K7<<-IR9K-UIY2WMV
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M2,DH=2)'"K898:3XM-"5+X\4EQ:7/HP46RG#"%N7ZPNQE=18]Z14O;)80:2
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M@=Y[:62_A)]Q6(9/F??&]H<T SCK.N"8! >CY3E WG'^O.* ?VH[__!,R5.
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M<^8&%N&34RB>U8CW1B+5Y^[<&? =:D1L:MYH6!)&([G^.PF9@'Q>-&5KIE:
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MK?EWBGQB(.Z"/X.9Q<FG9.)"6W6D7R$=Z[ Q?TN1B0UQZE_M>N84LZ'/  T
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M,X9#4I4U?K)@HX<:'FJ<P6#R,..Z<97W8X;9'R!!C26%S&Q5Y&:K<7'2:C0
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MJ53.N0>&CM\R=IBDJ4L*TO5S<_L4;W<#2TIJ7T R@ZTT[,0@$_LZ6& +BO#
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M;6[LX>TSK%L3_?13*,/M ;WC?HT$@[?TPMJ^M<J69*6PGTE-<HA(D/8[]BM
MT.'1P($T?LALB)>='9D@_$4M.UL$Z=EB'197^'%DDC@E>0S^BO[JHE ?D^5]
M;F-E5$U9A/G@Y9U$(5P7K*^YD\IY.ZG>3NH=[:1BI;0L+;J6G[3*;&OK';99
MX%*L=QA?^#W/ID(3HXB+YUPT7ULM+8L%T!-!*)JN?G;0]&CI2M"UMXFP"V#
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MWF&0ADE3A,C9?W+M=F^?@?_3)*OZ$10XW&9Z.$?[< CUSJ/UGY2<\YOU9=^
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M+Z^W&',Y#]D?1=$FJ34+K/FTB/>>5]$*6TC03CY<*'Z)H]"W#U<>X'B <P;
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MCFKV]AZ-OC_7?5+8R$!3ZJ-P24L'5_C*H[>WR[-\29P6A<ZF'R@WEW'UL5J
M9QZ]/<%'IY7!3*UD%I5L<E1L]#F_V'"K;&P.42LMY/@LFTKF_'-U/GS6:V.W
M*L2H5 ^@?FZ09#=AQ'8+1NIYO8(KC\:YF$<CM?;4R$YSC;K!ZK':1'B$;O%'
MXU2RB\>F_#28LHO00!GF\_)X;33<*AMSPVC6/Q)7J4PM9[YTQ\N:9,['@^CQ
ME:5$29ZE'D/=:6I26S468Z[PR$,_MV-ZUB>;5(]5\M-9K*HTFZ$&5\[#,X_&
M.1/E0;HL^&>=5D$:9K6G%1]:0:>5H[>/FO)4TY:C%S;0[ZY6PW973SPE:$^6
M UD*5+2ZE(J4.[E6*9LKC3<SJ;@:Q(^?F5Z(C>"X9#8ZD=;0+,Q:BB@F$_C*
MHQE-C!):+A>Q0(:/U&(%HY)!:P1%T3^IJG,:#8U3%9R+C\HHK_&QY733FT4Y
M-:L@*3$^KN#L?MU%*SB_;E6>/)D"U9R9^ ,#,R=9 2D-B9+!9'G!LI>VYU8^
MW1R&,?E(/3B\0)B84RHVC%ZPK2-B%H&92HL1CB0%6S[;)H ^6JM3-[:516GI
M*/!;/[=X%(R_H$!')%(C[5B<,LVD+%5CR_G4/PI$!V(AON V#:]<U">5BWJ]
MJ^7W+%9P8V4C @_AJ,>(&V $]Q#[I@75;HT1M*F7QXFK<\+#IAMAA(=-M\((
MVG3,X\0-577ZU-.J5]K0/8W#-S;)LY3&"%TW6_.MTAAO11S<:AV=L=C*%22"
MSN'XWPNP_DMSWBZ/?LS\/RZ.XD'??4_R+?/N/B;YEEMW%[/TY/5N)OF6J7]+
MLSS/6G+M?MG6KLPN?P0V/G(FK_&*L3F;<EY[EM?2UVO/^UQ-OV.W=]A]+Y7G
MTOEK=E;9_L;;+H.-:I&UM6GGFZ53[<*8WVRB;*FLMU_41DSU%_^D8Y)S$WGW
M]A2O:1M,\\0,=BQ=\BP33\LT^RA+N4ZJH Q&D\=JN[89PZR@EUO %^0N4OS"
MT_A[T/CK+$W7UG@NL$W/_B.5?\E64N%V-#7J^-/AU.,FF)YGPY^H\NMZ/*1,
M0C.!;9F17*@>17DU"2E3D=]1^2_H'==I?TF_I/BG$O2/_%$OE'[\17I30Z-L
MS[UX%WC=S%'M:[K+UZ;"]4#PC32E/X)$,6VF>_-U;9RI+;B<*LN"7);/!XD%
M18!>QR@A")J)Q(*E]R[86-.*_#H1R4Y9:9E?9[KCA%#GK3I@41\;#5S.&+IW
MO?' 8V<T>>#A/.[V48.J$'G&#Q 33],:WRKEV6#1+_965T"/0.8Y/YJ^5%H=
MLZ!-FN*"\X?F*UK4*^0+L<<MB.\M4O2^*@J,K"IC/W2[Q[P:&HQLG9/:G#ON
M>U-D\1Q-+[3TSM"2N"AJ4EG6V4PNW2D6&SVE9:"/G,!]I\NHJ5Q$$2M^E$FU
M!L-U/>5_; Y7M!06Q\9]P3CG18D\Y?6B1*Y1(DG)C(2G>K+7216D:F#!QD;=
MUOGLDS>U=_DDC.1<WURQL\TT\]*I(SV/&K36$\=&?-' *;?F"P9\.L[3.F!8
M8.MC)IDSW7=P>$?2=9.<6R9G=SQ7SG/E[B@.!-#V\VL;)@Y%3EN*6Z>J3.HL
MXTLM!2851:K(#?UZF0JJ\YLGO1,16X88>UFM"K4$K7<4],4BX2/L^\L# @\(
M[BBF<SD@^#PCYQQ(\%(;F\K$3 N=U@8%(HEQ*U]H6#6%0KX =UQ5Z"\O/N.(
MSWA1&<^Q\Z(R%S1^REC=VEC; ,]<\.NQU<VPJT6PF.'SE8G>V#RKU6>HN$&B
M,&%?.'"J;X2GK-]:6;THS+D-E#>T=3V=3,SP6D].:WT^Q$8B\YK>;6!MM=)L
MPNR%RVQ_=M2EC'2=$6A].V8.QAKFHCHZW.3QG"O/N?*B++=C:+Q2D1+JBV7&
M9BB9$4OL;)TT.MUR:"X-5H,8V!MA7\0%O[S(B:?<]Q0Y.;112!G4P-_?-BI0
M]N(!G^-B7+TL^B<&#*X^UVL[*9^TT%=517AUK6_5HLJJMZJ+[**P'#T]/0[]
M\PW4T\1K?3SNBW,7:7CFZ?VMZ<(GQAZN/M=KZ_UG!2=.*KZH<8G2X[K*=7+S
M)WTV,CDA3@KI_GZ8XK+-%CZLJI]>.;:F,(FY)LD,%R==% (^9RE]AA0N(;7W
MH4#_2F5(MS8TE@1',5G>/FNM_V)^2G\Q/'/R$#;S$]X DP^P?Q]>2;[F_OZ+
M&6YHZ]T9%@[GD'P,KY._L4IJZ@II/D; 6LY+F-3F4)=$B=>@)X!5T=:>R$A3
M9XR!J48Z#<#_D[X-M&4$_@H_='O[AAG3H:J:3LDA(TQ,33^XQSF/,KW"'KZ/
M#+[&3PT\+R:+H81Q=KO#6EDNIYB?ULVU;&([;SR0_7;#F+R8+O2!/R5"WB9:
M(L5$C)W>S62WO-B1W#FZ9F'[AK_)@PQUC& :S$HR)I10!XR@$]\-T%'G^#=X
M!'_,34V8\/IINM6W%^TH )3#+WR%$@],!TA-7K$_+OI:BQ-TFOCOW1NHH,+D
M?7;+"'Z,OQICB6:&R%@A1+\%03]\]%Q3EY*(&',.$O2_%P'9T("+ \8&WCQ;
M4!OQ^]T3$T :ZXS!I&_THH\#,\N6HJ-D<3H+Y\MRXR, +2FH-CHXS\"OI9DY
M2Q(MQ)*7XO%ZBK]W[1;2#?#=M5CO<AESK'7RXSPGH4[CQS^!".O#J^=QRQ#,
M'KP"ZSHS,FG?$$QSW9Q#I-:UU8>@SC"0"Q(T[,:/6!*F 084<HERI?!??.\>
MLA*LC$++I+]E/#F[W#.I>P>-(P <#XP'_#7!;"X: L@VY_\ 8D!'2Q._=23)
MLP>LD PL_C 'GXN ,KR&R$E.1:0M3YQ30FL\(]V*0POXN?!NS+-M@W8&&R+X
M8C*M9#]5#K.<C\&VC#"Q>Z3@%S!UD'4F"/(ZUO@9L)E*NF!B*<=PQ!OD8?@A
M_%@RK,8*"E91/$+(-22(D)!?,$EF4('*HK HZ7"PA.(0/-1ND"Y876Z(PL]5
M'>D/3/M #YTZJ$$&XPRO.="8!48QPK23\/UD8C9D8G&28%>_PBM8ZRD@E1_J
M#^1Q#=[@-4SL)<8^,IF$:4Q4#4O?PQE7T3W!> B$G3;8LZD;TFASL-+BBXX7
M6_:!P__Z6?KC&X6_>CS698U,,BMI&-D3>'XBF2,6ES=JFPP_R8:X5=N&FC-5
M=4E@D.&"Q*()^HZ7IH/U7'5= ;<+T9X1Q#,?X-'>TG=P\W;],R:\82\W5-6H
M4;7:O9=G9JHHC3!"$/6U)B#@F6,[P-CV0SH<"BQU&H%3::L[I'M239FJ>E]
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MAA6HJS"4:3P.;:, VQ "2=*R=G,LIT/'7@='%B+P/G@75M,@WQPO1=B,QP_
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MR($#B]EDW7Y9; J96FXZ3+4#G+PB:=@N(/!;C/ />1TO:G-5@G"Q)F'-Q%)
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M5;:WJ6OS:*F^ZWS7N>Z$64>M1O<)XB 4AXM#IA5K;,"Y)CY\KK]#:\G0'O-
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M^3-Z0;O"SEW,\U-K[%+/&KMGC=U?76-'7E5C%_N"&CM'I)NB^42V6]KX5+4
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MCNLH-" -W#-$K9B/!"^":4Z&@Z4KYE)Z5)=J5OJC4%:/E&$GF/8"0K5C@ "
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MSP+['K28;'I:5C)#8E@2>I/#C)@,F!WPUI,O\:B_\0'$Q8;0W7 SJ0"61%_
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MO3EHF+QTYZ&?1_!)Z69REUA7H]V10$>VRT*'GZ3C,0&=23@5D*^\6S.^'YV
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M'CBV!]V"D67H;\.\CPF[16[X FP&KVK83SN 2Y&71N"DD2&C\B(@K24!VD/
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M"(S0+;IA_NV;T8=1+&^MV0_(O\F:_4/5QUKTQ6RXQY $;@&JY\F%7]PY]A;
MD(=0]3Z9%QK.EI=BF*DL99O)ZRFYV+ 9]B /.U_)>*3\XBT(!&('@4"W\^(B
MTU^%Y>QLV@7EWCPGY1D76NB%C$;?04%X+D6[U][J,3+\YW(;Z(.;FC\K^+JU
ML2&\9FI^N\@+U1)+F;B>RJ5YSDY,:UJ-,$=D'UDA^L<O^B4:?\\*_294U%U#
MU(O#?'['D.1&L><7$<Q\ECY4E'G!;<_C@OEG]M(S7LH5 &@]ML([VU6/>6TG
MA/$, NT7ZPA_/UZ\&Q+MJZ.6:I2B98:9%3EJ00[6268>&Q3K#F)>_+1U^-^^
M=OK!HA\L?HP.<A>[\[G0\596YT_BQE(CGHD 4!?9ZK1-;"9*7$A,D#F"<6/T
MA2">+&[,Z(8()#]R?-S\$#^R]"-+/[)\^+O'\O5PW#U) 2\%HSZ0^Z?@I#[I
M)2X2([:;L[@-$>U7K)[1!K7(L/ZHMYEF4BW4K$+0(+++7'16:G+A; R#S.+K
M3").^=>9WRM"O5OVT+/0P4\*]7UM;UW,>6O1WY'1]P^J_*10/RGTQR\')-%!
MPO0C,S\R\R.SZT1F!SC0)YBD>\<C;P9FI4R&FS>'8H6--HHT*"7,:IVMHS0Y
M&)@E8GZ6Z3<+R_R+PTMDF=[,TMPHR?33=N;HKG#;,K:&:L3/6!^Y-XC1U4II
M*:^)M&03AEQ>+G"7()Q?2H?#WNGU=Z@YQQ;#^>9/6OW='" \;6.8<J=1SBO(
M]Q9V/I#3%<1*\R50*J5> GP OI]WY",P<;[#J/X(N-TV'81^D1?02GD+[+4.
M@5X?P$>' 0G5QT))P1U=3 ?7?MM3Q,#NX>L\;M"NQ]/)1'=KV[/?VH/1^(&B
MJ%.=E;H=H;WL)BEFS/SX1=*GF/]0ZI"IM'DE\)>F6ZAUBS71;1,RR/P[8$'2
MN:T@,,K\7NN'5Y[#?VS; NSZ_6R;46S;.,'O(#--)#%.,PE(RZTLF:\-:O:?
MZ[8,<EX[@V*"1!A-UX#6ZU0VX1L.?VJZ/\;])^!;H:E9!Q#TYZ<:#=U0RN[>
M;RB6*EGT.!'199L<31DV(@$M/_[Q*Q(/J) V$_/80%^KH\,GFB.(O&0XS8BP
MC&$.G[0=@B(10(M5L;#R%A9%U L)_<0Q;[:)[QT#204Z.L&F@ KXX1.QC@40
M*@KZ6M5'J(&"AOJFF+;J**#;0R'PD$T4]H6BB1J];)T#2%%'F%X7^D97!+(E
MVNEJ2B18JIBL-*)<.RXP8[\KPIV[(L0('QOY?#RX][O/"\8E0=YIGR\>Y L9
M"<4HGS'>8TPL%(OZ?/$>7Z A\_ER/;Y\_3KI0Q?@&0]B/]I>GW'-'VY=S[CH
MC[:%9USS1R;7PVOVS=DW-&>?AX=T+M&H4"3N.?3,]\ >\?F2<X*TUS@4X/-M
M?"SEG&Y*VLR^(,2H;P0><O7?U CX/HWOT_CF[%USYK&\D6U&0&"AH] ;$>-B
M5LQC2[V;87OPA)K=E?W,-L  I-7NJC%?KHGF)-_:6%I8:HKC]R_L(^@"[%((
M;L(PT3>2W6F7LTFSH!1&V:JLCO=O[,.WN:_?U='O79QMU:F]TZ8&;[UFT 2I
M70K-'-(OS4?8(DO98:N5[Y4:&ZD^B#CY>Z%3Z(^+[3D>4\O_7FQC\=C"[K_7
MW'/U#<F4@Z(! $K P+?OVX0-WTOVLI?L[QSWV3F0OF2@NN1=+7EKWY"-"!WK
M*9 <J>6JIW%&HIGN,0,:[1OAT%7RON\?JEQNCWA(F_'TP0=.1 3:*+"6@'(9
M,!X_ /$#$(]L(Z*T J/@!ACZ36*/M*M,;^T@PT9_(>3KN8),T80PH9<TRZ7'
M#D+]#H+&#S[\X.-Q@X_=Q@)]*=6/-YXFWOB-I.N;F/PS^?MKP!MGS?SP8S,_
M_!TSWX*B3>Z,^FBC:K;>JD2(Z+34[=.+ZK(>7 YBR*@'Z%#\I-#J&<("1&O3
M#PW\8KK?+RCA- ,(^EB#OT52HPNR6^PD[&EH *S0WV"_^,G"Y44\TDXSL.3-
MP'\^Z;RB@M1@NA!7YNI*(:(EN=ULM K->/B^E:C!WSOSV%8;-IT"KO,.[ Y7
M#,_9;.D6K^Q_G])-JZ);/0!7O&7"ZY.<'QT7O^T\V?!>^=*TG@*J; ^K;'!1
MSJW)RF+5Z(]__ J3B=-Z-U3,<UUF?7&7T3*QDJCWM1H!NF- ;::I4@$LGX99
MF_QT$>GEQS%VK65CE>9BE6+R]1^_8F= Y/;!1P)AMR,=YJ!3_FH $^V"T@(H
M:Z<D#3T!<4;2G$2<PS3;O61B08&[!MH2)O\<VJLPL@S7R"9^,PF)BFSW@IU=
MHN+'*<+_.LB$WD49J%9)-WYND4#V5N5F8%-X'QN#H)-HS8OPQ3]Y9<FOS>T&
M'@]%J2UZ[\\=FD@8FTHR1(3_&W#^A@X]C>EQ0DQ4"+5'LH-:*/=GA^50SG,_
MS/AV.6/ILY\4&4*55WOE8!$R%*.OQ*NC'2/\RIG_XP,3 ^G\OUO5U-DT</0W
ME&*HGLI!MV7WHQ^_<%D=DNN44SMF[K9 ?C\S_%UAQ:0-DOLE<2YI7S\\Y,D)
MJ9TOH8(*?Z$1@?^!2H5^^?<1$XZX^>H7;7F)/WKC\5NV\%L/=1!G!2;:+1;9
M9E( [4U,+FE2?8 !2S !=B-'XB2OKE+]$;NNF0MJ:>7#W6D=6MF3D8-@GK*L
M5<^6UZ ?3)3Z1:74'0_H 7$\,C<70;G,]AI<-J[DYLNUG5#FZ-#C9&3,*&5&
MZAQ49&I5R5:J0%39]=(Y'CD<R:RBLTQ2C4MRL]+E9*/4LQB>@3[WR3/UU7C)
MSS.+FMPQC5&AD1\EB^1R$#\=V9S+I8F\670)>T&M-;Z^7&]JS"!Q9D7KLLPN
M1ZL-RU>C*V+2S*0$9GF.GE;*F,[ZJ=:2ZU07T1BS5BJ1(J)\Y'AD%]IU365C
M2:(YK\<*"3JGYZSQ.<KWFP5BU;6MBAQ-%(<ZI5A!NKZ$(T^>*>5J:RI12)@$
MM1'68V)143>1Y3D>D0H81CIBL,6"SFIL+;.S[,BLPY$GSXSQR5Z?(H4Q084S
MM<DFNYQ*]%ENVM9*UMKJ1&4[B7PPV6N.<HJ,1IX\L\K$QX5Y3>VR\U2O4^K2
M?,F(UL]QDVBGR4QPUM)DL"K)=KDSL,8YQ/>39_*C8KB256J&'%S4AM6JE#;J
MYEF^KW-:G)X5R!F1"@[,'C'O2JS$P)$GSTS1=K@0,=IS6>TG!M4N4Z:8;/V<
MA#0RG35G-LVL7-1;DU%*XB260B-/N#D'3$,>JK9(I A-Z]2-5JUHH9$G;T^O
M1:#/-F!)9#,D:<57>ID>HI'TB1;S=:,0BPPB7--(IIL=;D/G*PR"CCV9Z*J6
M[/1BB5Z6K29SA=*B+A6J03STY/W6>F9EUN5$FVL"DQI&Q*Z2ZV'<HY.GCIOJ
M/#I9]\)LME:HS1;)JD9D,$C)]JE'+L.VS+DPZK& 7D%)L$$P3VK1H4TMZ@,T
M-.RX?_ 7T/6Q/AH=N:P+<38&>PUL<,3S01+S*W0#NF.$0:*U#7\<T+==WO)=
M*OR=DFQ<9!\P;14.AD\R \@G7"#(!V>+T<9N'+8'1-%H<F;H:F7YC1VM<.$\
M]MGQNU?PW:[SWH^7F+*M#@VYVAB.E-I4S&K%^F<*\_>=[7-O<F <7!J\49E?
MS%HF*9+ZAK,Y,\FF)MULM,GXE?GWKLQ/A/P"<$_6LR;>+3[Q^7*GPOQH*$SZ
MC+D:8RYPN?>!1;L?67Z'+E<U'M^ !!_JZ>/0P%<)7R4>2"4N6-#J8 L'=/&P
M6-57B*=7"+1@A./N_/?B.N"A=H!?U9'#0Y'GU(_OJ!#/M"5X-0T02[G'TB)/
M.P\6>,WFC77 O6.^F*A[;.%;4W\Q&_\D*>6_W8SB<RF%GSDQ7J=&A:ZX2/)L
M<QJ,F4Q'*G'CA^T46,QT"X.16J#8XB*VB*S(N9).NW5)Y+O]*)YN0]V?Y\P
M^!0*B23Z7]8!+/8WU@?86._>O=>36^BG1=WI.G%I2?<R-6XI_![;@$\($_C+
M2XT@OG*#Z\7]V-&MMUI!P.V8LN:V/)J) ZXSY?7X4"7FTJ;NU .<IEO^_4UW
MXQ2O0?XK_G[\;.<^OGUZSSZA5U[1..VTZAW[)!2[>FT]:.;D;'76CDGB@+<'
MXT$<PQB<@M]<P4!YS)$X/9DH7[/SIN]*O>M*^9TW/U^%]!G;-;)FL72J!7B6
M'P[*XT)>J;?4I3=]JX_/.OB"T>H%QPF2Z B%5+-+<GU!9)S$6C)"?*>S#O_R
MX+'/.)ZA*/4HL_B!JU*9,U5O+P?=]";\+3HL_D;Q_&>LOZT'S4*98RQ.#7;3
M+<%LC-?ZV)O6_Q--%M?D,J;WB_R$3?4J@TYF4Y3&I?%YT[^?H_Z:<8])%<"T
M"NBOCE\H\)6RY&U1,MB!7^A.!T14I<S/9H:^PFWQE/4]:Y8OXRT\="%LM#,=
MT+J1ZLK1CEHHDD6ZW)XL?_RBSXC/G8N6/\.MS%#N<12I++EFC+7J*6,08>KC
MI^%6F6T;M24AA]EU>VW65F.VWFQ";D6H<^SZW;)E;Y4')5MYUS8Y[3#O6 _$
MN!5 ZZ-^LOB:)?:/Z58MN6T[=R5"J+DL&FU-$/2HT\,T #348?:(*Q)J/HM;
MR\+OG,:>7RL@JH^IS<!J4RDN6*0S()S6XIWI^'<K@/9;<WY0]"/VS:IN$ZD"
MT>DS/%E?$ZF:N/2+?FY4](.?0B="1.)[5BQXK':$"B4B/B,\P B2"I'?M(C'
M8YSP5<(SC/ UPA.,(&.AN*\27N"$;YLNRXC/WRQ\SF^]W:I1''@2B][DC/TC
M&?P.-/C06[M^38X7R?)<HO'YYIQOBDDBE+@!1JHO)G<3$W\#^=;L]_ &$O^$
M8?B#0F>?ZP^S-WQ5 CKX7V 4X.'2^#'P!<&W_@_ _M.\EO>$_+"F_R("[MKV
M.R9V?U7SG228P*,H_ 4Y?C&[_L#<GQF2  (SN/EC.?AN4N ;=0\R]P%HX)\)
M^:+QAS=9WU,R/KQ6^IYD>2*%^;.M]*X55O_<!N[&8?*]5WHY?!LWY/%6>7WX
MH$G,_<!MMI_N4G1?LQ7=;.!&*\PU)IU"BE#Y1;U<22]U<?&5CE-_G.KO)E'N
MZ<!105=X5] %M-2J44RU6UQ1BB?H<9NP)O;2;:I-DM=HA^H-M;E]7=/=U.M@
MW?^YW*;_R);":16,"P=<6R$,\MEQHQ?3Y"8Q7<VJLW+!$.]G*ZA[F8KMB3'C
M'!BS*V (D@EJZ$#A3$6H.4DD4[$D2;/5DK@9QS?23!TB T+_^$5%Z5#X/0"L
M[VI#O'X\L6O-AFL&?_S:87<]O&/\I*<(MW>;_@CQXV/#J,V3>DO+UN)RU$AD
MI?:P2"C=>SI1AU6164,W3XJEH!6<-G-\-3Y*Z)P=%_,ZL,-3>>)VEH_1U[.
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M=3,K2^A*-?SC%_4N8LM3>%GH\N;Y?*,G<GX\MN:;^S+?U7ZE;5"!,VHM@;(
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MX#'- Z1KU@]P5C5]URX$[@C 6B)P5G>#0!VGW)!JLN7OMA_4Y^-&-'+MXC*
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MEXHK[PI$_,_9*MQU(!A(MO*!#F\8/$;=N%!X>>^UWBGBO/>R+X'PZ:BFUUK
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M^(6'(3)*FLT[XRXH")(&==WZ25&A\"7LP^5G1L8/YH7%DWR5T3-IO9 S =X
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MCMZ(X'GA7SC>X-&W4%HMY\X /;,Z XZO;@;@(ZKP=T;@+TD3=!7\'0"K&7K
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MMPBE7MX8D.&(^V,L=Y_X'/\"NA2,'=AIKHWL)6C]-4U(+]F[1 %,G8"4\A:
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M013@V,6NEYM$<),BL6L-^'78)+B]\7_^@]/8OR1^%_[PK?@D9HNWLP7Q7K;
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M8LB;>[0$Y9@B0!CI:V@7J-!\_@L^*(4>1(:ZNP;0&+ZBZ4&8/GX(7=^_$T"
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M'"$7J5!P^EF++*FTZ]5\HS=H"Y4.6GHH?F2]YQG4O,^6R'R3S+3:<FX=+#U
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M:7M(A*&FC*G7\EU?,(+<<N; VL6-3W?;XK9DSBT&42.+^7)3@:X0)COS^<)
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M/JGG/57 /6PFB+K=V012)QB 0[\Z<NLK!7>>VZ]A?"<.ZWS1$$=\YALI2#^
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MPPP=/Q+<SS$[.BWG$^P/_!3<G[[)L3N%56 <"/Z)5^6BS\*1I5&<*JOLHZ^
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M)H-VB3LW=[VHPUX.=&4-Z[V,$$>S'"OGF?0*%,\JG54ZV^GJ^:$LITP PE?
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M^3M&Q^@9B:;)SJ  79BY<H0M1R'IO>+1UI,]"C^ENFX7D7S%1[!-_:*YY[C
M)2)#<D\_T\&_?7_0V@-5!#H(M9"%#5;". P9;P,X?<_Z%BBB"[(V[+M*-07Z
M<_NI&S;\5G. @XC2/+G&J<H- A1!-+3B-UXQ>\/>*;8T48L'^SQZC(F@U33-
M,?>#F%"*DW0[>K9U1[:Q(TKJ'@B;"=DN+?)I/ A<C0SFJ;IB$PSO@Q?X=SYV
M^SH>;XHB+*?@44^@:Y\ E\\9@-UP2NF2'/$339)JT<D\T!AN.;].".ZZ.%K]
M!HW$1%^0Q^L"OY00L1W!MMMIKPY-,1L)DF(OB@2>ED6"=-V^0V.&K_6"@!6)
M?L\5N],OSH[?(7C#SLO64J2\,C',02Y\D2)N$")(XSEV#R71)M.3Z#A?+H,W
MO/WD-9 3NZPTC1@1]1")$.2$SP ,"6,)$!@K[!J$6I[%@P'^XD)-,M@%',D^
M01#N-'A&*JN 5*\)!ZWQM<W(;_K3BP&#;$>#(!F7#'9*)T8X^6WVKR]Y1[[B
M8$MJ8@4.7CPE\I $28XV=^$\038V]P^^$]^+P)VB^3@2\.^#UKZ,QP,+OB+J
MG!>?+EX6-*H]_N7^):R.#]]HSP<3AU6-);OX=$&[ZG2;M.9BI?B5QQ F^S->
MP25AEB$R/.*#<P#*"(S+M[VWK/<.VWNO.WO?V4@B@LE'D_@200I)"O3HS W=
M/C%DH;W>P5>'.=#S3U,*B/$LU9/@[[]1\8#F^8C1"9E,?Y;D29#E8K\0-I>
MJQ0P)11UA0,!L4<,Q_$9TN7P(R)7*'UK&N_-@FB8"X%9NM*&8+J5SR=1NG;5
M[+&I=W[+D15CW.:?A=[TG%.AS9T$;I*,8N6VG$?!T=Z6F>%5(^!R5L-C#EQ&
M"_*E3T(:KF%@ LL6.:LIP6P^/R=+MW/8ZH) CYQ_.OLO"26D>U21S&(/64)>
M)N2**<8*5@O!3_#@"<A=2Z!."&.PJ)IUJ,(AI1@CK6&G=2AKV'V)L\(7RTT]
MD)[$)8K-H_9WL*&;N%@S9BG<J"28YQCG#;!!RU]QP'H&3=U?I*DK"AD^"9>R
MUT:%W/_!>B[2;+?Z;#!W'[L46DLZ(X<1<'E&3_,%=.%D9.3JBR-@X.-39P]L
M<XJ.=EX[G?W6[DN##C!?EM.#]G9:NW ?'_B=R=F["WY^ZT@_7C]D7YY!GS'?
MAQ<=?K>J\WE.Q6C+[WG1QKKT5T>6<P>]][_#K"K OT#E:=56%O?X71!3/,#0
M&$E^P_DM'@<\E,-2!+]C=A4;[&-!OJU\3=+<YJ<)#1-13TN#XM'/49/Z_(J#
MN>-)SE6IMYUDH]"TK'=G#W4S!+TMC+;Z!/(%H;8?XV6\S\%F/BXCJU\<OS?
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M'N3%VW#UGJ?48+!1Q_[,S.CCR7W6S(Q5>>E;MN/''R_.ELJ6'<,JYHNS -S
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MN9'#J]R?:%,5:;@>A,&"JVIP='!9.JXN1XB5.#9A_Y3 6!Y[%&<I<D+="+-
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MUHT);^1L(V<D9RPFSB]EENW8IE\P%(*7,\(G&$HWJQ/X&9,9-8?CFFE"_>W
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M*%V.MWG1];?H-I*6R$-)/-GM'6+T-:AV@ O]2WCUTCYI1LY&$-9 I4)E'E)
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MFNQ?+:FS6*TJ5L-DV1H1=C)?>VGFFB/F;4@X]ZRD&[#+*U]/RQ6-:.K#^:W
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MY<TZ0@\,W 6$N[0Y$+X$/,6T '@I9"BEXM)QH)>L3:*:BKZ0/_\2-$567H0
MB1!60I9D "L1!WP-+$4F*P\(P!I]9 =1&R"D?0TBI ,(Z5DH#?A<^/G/F@#2
M&_MV5OGMKV^9 IR)9K;B<X,>8[/<\9^UM* NM<_Y.MI=1BN1/5$CF8#O/6"
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MSGQ@6 C9*^?"\/259=664^*?G=15DNXPK>*:#;"(A*ZQX1$&I<1KV3#Q^G[
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M<D2A0YHQ6OYB!S@I3F!M5DW6&),I1@"P[A_HKP09)%AM6::L[EH3OJ*SRG:
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M$AE:UC=F2XJ$<H6_M_D?Z<!3'P#,U4WK?*&P<!34,J"X7U\@Z9RE!6&^70L
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MPAD_=BB_G6P,Q5=6^,ID'Q_=>I>7S-I_+60"1)Y'DS[5O]0U.7/($S4#B
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ME.%"_&6,]PE7I^9X>C<R?&B(0PO='29I7=#;C.Q9=L?7\)1>%#F'' QXAN)
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M4_=N9F=GD5:&GC5R!4H+*TD[(Y>XYF)(X<;+.)@FZ"0I%=36W-Q*] XR!E@
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M&9CE\*O@7S,X:?>+G87<0B^K_F+UM_J6&AXS?SKJ=]UC?\)PE-\O<)0%CK+
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MS;:'X/)F@L/R?5G\*-H+VN)_11X%*Y1_T$V?.24R&UU;+^OB!+I13(_KS?W
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ME;R**E*W=8[\V=;%>.V%@:-+@[:95/&VTYR)K)BG[Q3'0:$,8> S H5>&]+
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MJ3_HBHE3P9WY,3-4_J;PKQJ3()U^/]3D[P4+\+O+WQGCL\+J(ZD&S</KEK,
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MB3-!OUYK[S< \@LC2=.N;L:2-2?,"&8X%R7?U=*'6.R"[7@G]'S280Z6<+^
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M'^(H(&NN_@@IC0E!HPMP-LJ&R=VO!:_V7FU(WQYNP6EMOAR!C?><2G6OT;U
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MR[TPFXG/8*)XQ#BY':V)7B^Z7$UC.?4JUK5J<_PCM#'6J6UUI[.CNQPY8EC
M:*(D :!]53$#R,AG]&&)[\Z.+<V<X&3]]]6<I?(G].6;JD7#"#+7VHK& />;
MKKI)^ABHB/::[+@'V>7%C >%$E&>YA%KV\6JIV[PU?^4X0 +;_<);.63PI$]
MX70@I=J9< H6"R^-4D38H/\'?Y3CC6K_TL\1:>LECQ&^F<<PE+F@>$35._MX
MD_ FPP_,,(2(C?&2<K]P+%-3)/^ 3_-H%?&%]^K+ZE*+O'RHX]V+N&IXO?_]
MGT]^^_%G3SZ]_,WTD)>3G6BC*%'R/HZ7K]9#2Y(A3S[R)TP8T3-F&H@'!AG
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M!>[/1XQG+#6H'GU,A(%UHW5($ P<J+=6NL##4R/]<>T$&3('>'; ^#G'-SR
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M9I@).-T4%WGO:'3:*?GBKD;?2SIAEV6VWN5ZU2?G>M6Y7G6N5_V$R)\S&O!
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M4P1VI"!/F1EP+ TK)(]W=EKQ8<FIXX9-8.&X!::Y[J3K6ALQA5N0-9P$E49
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MP.BXF3:$Y)X0&#%/DJU5%D!VK&%29YD&:,5"&!6LIW[9)]DY$BW9E73/4 B
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M^]%%H0V.H_;E$(X"(<Y*:3(<O;0LHJ:B%82FLU:4 !SQ?R5$\,)M/(T$)E$
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M8@$MTD?(]$?FD^B*<B+A5N=ECOV89+Y?C@<R-JNGF!LJC%#)#YH4^W;#S&.
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M:USB4.+&$YO[DC*<,9]*MP!F!SG5/X.#8^E]ER* ";$5MRG>U<1Y6I@^*.^
M>5TAL7HBPP'0=*8XI1/(!AL+ZLZJ:8O6DG(2G6V$Z?T"7P#(MN%L6B:E4:I(
M4&TW)\4HK<NI=/,GZJQJ DY OWN6(N/L&*BKY206/ PB$]5Y9\H\3Z5,S51
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MZPYIT,]:[#720<:M:1-Q1@RNIGO6M1H/D./P58"C@49$%$\FT%2&/#9R),@
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M %F8#?8[5XV%Z4Q6]HP\FPFH8;:+95X)*1DIP9!$(>8+BNN:X!L;6-*R%Q!
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M &>@EX%L@G2\9*)EG%I2T82.R;?!FBMK>B%W*EV)RA/H2 *$G=(<1I1LS0M
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M- L2N3<N- 6)?,Q$^^T2BT@\(+*=SIX'1!Z)5^8!D4?C6F$>Q%;[0[OB\'A
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MD)43S)R=%3?U(EEU$54&;%\C?A,B"'.MN9<HDR*36SP<))I#U)KN(K7I\(W
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MJ#TP/L)G6+Y[=C/9ST;PU\Q.LCZA=?P[=MUZ?PZ!<E%*'?8$,D]/WK4*!S0
MXVAK:\-UY-K)I7O? 21^;'S;4""=G%:?2,F*O3_;KMF+&/JYHU&@7J=U?\3
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MGILY2*ZCB,U5?]D5,T3A:%VL;0;_OE'66(_J'5]Z08J/[OAKZV[R9J_;KY6
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M_$[%]^7$FW9*3QL;W<0YUTW/TH9/GPD.2G\4Y=**4'L[U]X.WU6TO+W(*C3
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MEM=5K&3<P!;1SV=/\F%;[2#J3%5&69.J\>>!ON$WT05+^DNUSEG@4,^%2UN
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MW@1G#?R7Y-7_GQWCO'\U=$'I1_<+ZR+B-F3.C=IFIKZQ#5_GJOD6/%)_5_"
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MB.BUEP:M:70^FJ@4X=G";%2BFZRC GWF2M*#"%QL-B84:JW.HKMQI&!M>?Q
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M9I9WUDZ?140A-_KUUA:4W#V%PWPH4:2#6'JA%$LZ7$]"ENG2OM3"S#WDH(F
M11/K:7US[^G-I)G'P*=^EP>F^RP^5F@*ZP3=J"BI&<JL#$31\F?[IH1?9TN5
M/DM_S+3MR2TQ^Z4;?'JV7/>YI*+8,9?0O3KHJQ#)50-WG2Y+)QN?\3#]B'?A
M4HMJ:]/A;B#?#O=9-LO4D_4G,/&:L 97U71#X_H0CS/+C&^_9.%4'79H&())
MG.797;==X]NJ#AU#[4IC7=:9U_>5'G_$"*,TKH]8E U:^-^,U[!]]Z&F\IFM
M,*-\11S**/I<Z<WPIOWI^AOA3RN9D/2?UBR/;FTMH$9Z-9^9L.@]_NHO !_3
MT7H4!;@B<U+/<%Y&IYDD=!_)NS=PUMVG*<?G]"9WI@?=<):_P\R*FN#.:*&
M@*/@1!&2C$M,BH617>M5N$(+$:L\\G*?HE Z9XZQ;MV3JT]_P#@R#K8WU%QK
M-J!1EC?K$")-8+:I5 4\O'WJQC-5'B1O^LC+N*?==>1R9T.L9PHNM*D/SHJ,
MCETM5F:XUZ*M NB80\L/+_/F2__TA/M@HV5J2\)N:G>7!__<GKNLUHP X% A
M%B 0'=A7E1+[749@8]1;;%2C**0M=YD ($8=?M=7OWI&_J\T?H,F.3U\05X3
M:TH5SU6F'N;3;;F2K/YO)J"!.$&'.P*>UB WTMPB5_14X)J"^%W!M00!SY@[
M^Z\/T]!%3")M;6?.@O/3M+:5HG@Z[2R7O=5M3R+@,<1$$1A7K<Y,G5^TT/Z>
M1$FT<E\FE_=M_;&:9;_*N+AOW\M8Z.]J'9S6PN_JYGEE8Y_S$ !>Z5B-Q4-&
MX:>'14.Y/^'@']J%,M#W7GIYQFF_]7H_=&U&)4Y)UBO@5^&>#S>SF\<8A85I
MX0_>K_P0Q].Q:OT^5,-^F7:\;_,__\HR.\G_B-=O$7A%"R+<)\+_>?/5HZ]8
MW@4%:P( *#6U#EPT77ML+DX 1"4[[5-M%[K7^U-B+Z8!(PD :-INGSJG873*
M*#LO5V(D@#4KYK(.=$0MY7Y$H%[?'/4RI4L:/7PN%HK ?TJ 'UY:F3,[@P(U
M^X(:/"Y,,F[>EV--F(&=LJUN1'9D77.Q=K_*J/A9[/V$^EQ$QL5%I0@YH7>.
MB5T77?G3P*;XCC1R)\F5E'LP\@/$OK2#K[AZCMFKN<0T;W'5A56V#ST3E7LM
MC^F!QQ7(/-Y!PVZF-6WVVJ*8 JJ'GG_L[%4(B\AGKI\;?UIZZ7;=DR+&6DSO
M+&*S/'&ZRSL#EXO*W<%IW:C54&LO&4RB$42%Y^KS6=X_N>7,N\C!$8GQ/KKI
MH[HIW*QY2SY""QS8TOHN;<SX]9Y4_U+@Z7E1-=770D8>*O46;I_T'S #[&'6
M1GE5#HLXF%J]49EW&ACZ<<\9XSH;<;7UR!3]67H_/EKU^$T$#?^-D"?/[OUY
MR(-NK?:1A(_@YB1<*O,]U%-(DBM4WN-(*,/5D9KZ4=A\"]_[)W(4Y ?V)IBQ
M64W8C'343LU&"!#)N!905S>NE64\)G&<A#<2'+DP<E6DI>TLR8SR-(V9YD9+
MU#DH"$]#.JA@]NY+EV?A5^3]26E-I2$PLQCRH^+L"29FJ^,1S3E3;79P*ST'
M4&\7MJU#<NA0T^\8YIB/618F#4^=]P A\?5MX.327'0QAV;TQTO_..3AH@*%
M$1K>H'4"*MZ"# K9@5"-C]I['&%77GI8;$LMC(:W<'3,K9)(;E/"UVA0&MWR
MS<:F! #=SI'\J!NB9* ,4UJC;.]&<=L1I)#/#G;==N3:4CO]2,5E!QZ.EQW:
M)0  F/?;K62<)5!K[5I-%@=4I. -%*G;UJ?VKJXRK4XQD:N1=KX1^F4)"\PQ
MR[T?L8K3:QR-%7)UK0G6>T9E]A]]O28MX<FBMS/Q]]S1;^[>=1XHMT>=@2 -
MVO23*(=&4N4&:JV<<Z'ZBV8)1R"M $B3:UMIOF;%I9>)QZEY!5_4PZ7[X%18
MY=D"1LKC;>:E0PJ.;O<UJK#7G"@S4\I32WB5M(-%W,_T=C^[9<_0_](MEOVV
MO7ZO,3%4O6KOKT[B-'FTMW)IRV!!0'4K1VF0%'O(@]N;F@43 ":P0U29?DFX
M7L2B5"8!<.Q"_1]W59%$U)IVG0"H'\?:%8BAH&MW8VQ?J]+:F4U4\SV-T33@
MPR=SI!SXMM?LO0(M]H,VRK]5^G]TAP@@\?W2A]G/?:S<K%"^0MMW1++R,EON
MHF_M7>AV83_7F9?V^E)$Y.:+^Q98#M9<U\U4>3.^(P.YD]M?^V_NQ5?8<GI6
M5]*<OB#R?-UL@/DX=):'KJ:I$X2>K^#J]VW?%2XEUG)*(02 ;P6F_P<!T!!J
MK-.(H(]9NLF8+3T?&V.^5WFD.<OG$703NU@G]),1&9-:SRK0X:!>T;:$R=.A
M=*5#(E?SI9@=A-?$TW'6H$+_YCK;1OAY.7K6G;KG\"S^KI*CZ!68K3_>EP9_
MY+29L28"ZWT+FW+ 2\XK46$2%$!G:AD*[,T?I/OF?S$QK(WFX]G@3KCK @ <
M:WW$E[FQ1IEI9(=T\U_::D14>%QP[O)PI:MUW#05X.*PO2@0<W[\^=WU-DN-
MT9HQ/PM/=XB+8M ? TCX9E$=[&@=K<%;:Q.:"(!28" 6O,FN=6J\@V'HY/!$
MZ,GJD/GM@H\+0<^E,(AYW_PFRN+#\'F?JYB6').5^&KWITX*^O&I'*7]NRQW
MJ$OHH<TQ5W/&0&Z# J+^K3:Z7-Y^Z9X.5OL<X_A?^MR^$4MS=&UIWUI]H$S%
MU0MI*CTX:=YULG0PXXJ5N*I3C5 :_W'+=HK3;71OX*4L%7N/[ZC/K& <"^-;
MO?G5.<,EF^E=: ,UQQJWSLXK1'DY/H\M@Y^K/1*N8NWXY7PQ/U/HXYVBH)G>
M>S)_SYS^V9%N^5!A2$1+DQ'RYM;;J-KC&M3' J4?*D9)^8".;GV=Y(_G5V3]
M9)>47R%BDED6AZ51/1I-!0ORB>JQ@=FL%)[)N? >UA9X^W%\'W/VUV,ZS\+"
M#F%/RAA6=\_P!\8)OJF)ZN3S&?(,U[%,.[#>^N@M4DC: F/=U=#4P<\JEWOG
M03DKRC1,*ONN3"_?Z]$(>-30XV>E/9CA(D8>0:;A]%F]8P?BHA1P=!.X_35M
M?QP6 ?QCXA0Q850W(3J;9(,[W>Z=EIZ^0EDCR$!+,CZ3B5IO=R&I-9VP&%FD
M5A5RV$]8^5W4.7/UC(F.=!LM >GJEP_3!*);69Z$IS2[T%)C50>36"ZDP&\O
MQ*T1O3?PZQ5KWUY&%:F9J>60/8&YMR?HY:O"HF +MPF>[G*0^(I_X+[6?#:[
M4O)J[U[LH/5@@6-V7]&:B7;Y,P>QXYL?)Q4&"VJ=PYDOB8F%IXJXKJD6)S@U
M"RMUK:N6_SDEHWY8@(B(Y2FFN?A.#7X6QN4I$Y%E#;X.3FA)3/\=3\XY&=RR
M2*NK(:-6FP8"/>6/&FF9#,OO98WS<+L<R@!>JUV>F2();K 99P-T13_ME@R*
M)0""6.;'?-L/J7ZY%((:(#1N3@P^UP9GI&B6C$]N!!$ 98+IKUO7I)9T.9\7
M&MUJVE??6#'/->I,X_^([7"-6=MG1_Q@&IL_W:/W-CL.=M-THVO]ZK+<67_.
MZ"[NI]D=G!^"/&R4!=1E.?>5%M[#&D$S&X?TCS>.MOC;%.Z@)NR U'8B;>_-
M.+5O?0WFDM&C>$1:9@5KM"R$]>EOX/%)AW9&2EP-D@8P*1]%/XX&E?RW7Q^N
ME6I!"8#GL*:I':&EJ?TY;0+@-%%/^%>S0?A&>Q$I\5X;,2&]*9C"X21^X(4X
M8J(A $ PAHL$0/XKX4-2++MW&Y8#STH I'O<(@#@[%$85:PB 7!U/84 \ -#
M05ANN47<24=BM;R4@:=A<<4_JX#M[_3C(HBN2H.'^^/N-\#Z0#,TDZ 9('H?
M=Z;: W= ^Z..1+?.B") 7_D]" "8)A#]:B5MAZZ&.%16U.I#+2P.>Q^XPGT&
M_Y2H0>KF3VIDX*D) "I87TTV;"K:G(H ((NL(@"43>!'AS8_*VAY#[:X,<M&
M !B)0':H,-?W?]8"B([">.,#)N3QV% T#'/3K?>0?(( F!I4_5&[?YB&]+#C
M&9$SK)&G]@<]^(A5<I""(MUX#GH]^6GD"]Y5Q9,^!,"/0MGVSFIZJ0@@Z\9%
MUZTD0:.5R5-(O!@_SNK35MDND5W-#^QX?_2>@3\!\*>/0#^8RV!/B@?OAQ?C
M^9]BYG_1+L#1T;2#(TP[:.0F/8X$3ZTX^Z,2JC_-Z%K@#_/V)^WPK<T$0.]4
MJS*^Y"[\*Q =LG,J?::7"NS)3G5VJ9*TE%S>F[SHYY5%!F-<&9"U'EX?B]*Q
MDICZ04F=$M,;ZG+P\-"$\].FR8;_/KW^=7]'HDFC6HMSLY?/7L!0J%Z>[28
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MNODS%+I:OUBY9+]^<=I!9QWT>/D=IFFF$OS&8^@$@OVJ( 'PT5%A=$3VA.,
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MVPH/N830+,1N]-T$K\#G\=2+*I5?9@J:FL/\6_MI,S,/I!T;<G(#XF2JS D
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M("5>:%&3%&+D$!+"\7$P:V@W[$A1?XDMP*W&W^=1IC&I\$N^2;U*52=IOD<
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MS_??4\^-2P^_7=_)# G/=ZF#U?(>9[R,_\T-OXE(S$UI/\4Z6D#G_WN*8P7
M+Y W;Y\?A>V\??+S#L(3\HQ">W=6QOX--[-;\P([*S))GNN<1SFA8EK,>)*D
M.E-0Z\;Q">P-S!T4A-+P5CD"&9"A>B+&=V+Z&8GW>5',2&D&@V[X@]5D [_K
M':7))J]8C^'>8<5G"0 :8QMMVWJVOO7=,^XU@_<1$FUE8=H!*K.<%.I?I&:J
MVDA7S%\EE85'UQ2LU;"?8WC^_@I/UBW[%D&LT:9X<[_O"RQ?Z4!+89@S77-U
MW9>''\TN?E(KP);S=%J;2JV]R[W38 I,62< K.',=L;6(2.]GSR,!0L_VF=?
M&.3P5LLPFJV9D!H.>:)'KJ[SN;<BC\9\Z)$$7Y=1CL/>R^K#PJ37D:6H<GA'
MQH;>4 $K:8ICND@Z<H#LU+#2\X5*>:I(8^X\U.52;Q9Y@[HD%LNC"_9A]MJ<
MU!KS9 JM=[^ GYV:G2KS.4!%C1TU,ZH4S'HK4C5JN4[[%]G*A9L#*U(XHK2?
M<KPT?<LO)5[9JO:0I%1/^ R6:C/<&)_@83&]A.7/CF*4RCV9H47C^ZQO[+F*
MO"ENY!.RJE5$#" Q\[1QJTHN=RFKZZW7BO<.SHML)/?Q2ZWW95$A7D)AL\)G
MH0^,.)-U$/<K0T<;RF*D B_$89MJ^+?2VTC3;M2A@,P86&/UJ?2"Y>JZS*R$
M[&:KJDI;DM-#WA0Q6E?>G-<"G'>&L/DH8(1GJ<YBX W2ZN@AI#TC^PH(63T_
M/*=YMD"A',%/(FHPJ9?8[W*%PUV. B&9Z]?C)[EY-G&6X2X&BJ0>]I%GY$X*
M')%1R6 9J!(5<&A<%2QN[\&Y8)](X'L:MW.J.Y%F$_8;DE.: L1:Q]LKWBEA
M>VWIRQ&2TKQS[HIE30!VE^K<6;%EKW-R2160TQ-^O>;R0WZ7;9$160$P8HJ=
M;-4 ?C0:NX4T=7Y:S7$YQ9SMHBB[8(._QQ+$/>?2%1[.LUH%GM!:2060\,><
M3-BGKYDZ=^ 2#A8V;T.WN]M^VS/X;0/A+ZASP8=ADP:\N7HX9'Q]X,8A>-;(
ME(SC<CRP.?&H_=85BP:^R;A!O1M"0@-7-15O:YMF?=B4;T(*53EE]+KWYG3#
M3J7,@1FX9;-4H?NL3^@B(E7L\]);6A%7DKQ/TKU.0JJC&':B2B;)V,LB5R<D
M:\X\.+N>?@%2;?J0L^@V@]8F>?^[X8J+VD:,6J$/W0KL30<*DJYY9&C2TBO'
MDC.JZ>@AO;&%\ C[OD&3P!DPG8;QR,-:^7?F=DGAJ)'&'NY4SU?GJ6GOOZ9(
M)<TD@UP_B>075]X\H70I<EU-<'TZ<G*F8-]LO/3J0[XT,<4IW],6@<S,P!OS
M9?"(>CHT;J'.P=,9&F-CRS09]R$Q1F3QS/9)I/AHS+$&#C9FXVQ9>:Z<9 U]
MCY<&PF^P:OT*ZBC^E+,=1;!2P;79ZGCY,+*9TY%B-6%OD%K[)J2!GPY,6, W
MWZ+6.,FRB[7!=!S_0-EG\H+?BN9U!KN3!-[E Y83:XY>*'SC@SG97Q-[Z;$]
MIW$' F"Q%K(_FK%63@!L3PH?K1JTZMXF'5MRI2@HXU)U M_55(<PV\K530;!
MZ.9?=I]L5N7KPD;E%&7B67VNE6W6IQ[C/YMQ/DJ.8I< L/7-(2G^:^U@#*.:
MUQXBYIH"4-#6F]-?_^:3)6+!4O ;F5WD+ZN';R5-]V[.,K%"1$B//.'XF^+A
MV.\52-KW>N37[[JPV&[#B#0B;MG=^#)\*:#S;VH:*4MBI*;5_AZT_RE>$^\K
M66VJKH7D8KR;607+PSZ-T'M!@B3)! J%(,UH93?>:\\VD:4F7Z+[=5^GBIM1
M1<'MU/V F,#9:[5HM^'6;%_*TGK&0*:WL'**?-IT)<BZ$=E!4.^G7N=4JA9(
MR7Y8F0,$=3&J"48EJ0&C6::7ED+V%"V49U@RUQY_?L6]!#=-LKMAHB2&2ZIU
M1:WIC!LXT8X;VZ72EI>%-9Z-:6^W"CNE7KB5<I^_-.#+\6G7'K^,L7E$Q&I<
MV?"!2=Z*]UKFVGO5E&X(!,-J;8$J0I(V2\F-9+[#F,S,]X8523!!%Q!(%DVV
MT![5*ZB+ANG29T]AG^3U>ZW++/G0;4;[V,X>8*626$:2/GR-1[;''Y3?4EC@
MZ(2Z8_,KY]9!(Y6)]8Q8/71%L ^X *JTW\0^VR)Z32CS5+; T4/A\R*!)NZ&
MO4G9G&MNI@XL+H_&E)BP!FA$<X>"T=LO&)-F:6ECNL($;ZD/$GL1G/TQO>SO
MM&4 L8.2K4L65F<-M[(=6"8V,C<&Z^!FW;KO>3Q\C\YCE7$YO?YX21,?A6(T
M+C+ST<K#!S5U",L/O(/ ZNA:A]H Y.@7\4KRM"NX[/LCM1:4L1BY/6'*97KZ
M<N-;971(#:[=EAPG,5%'P.682-IX6?[Q"M#LQA,_14Q(_A<N7%N 0ZFOHX/8
MOE[J&1?A_/ER73%5)[:0F^V?7^G'^?.]MF36?N/74R\Q6#8AU%*6PMW5)'=R
M+SO7EG[DZ1R<9H),*I'C\18!X/[ 15;V4WL!+I5DC'\\";F\7XZO&!A!;IB=
M7BCHGH<)KUC68$";\-N8:)0OK.FPUW]=X?)[6V>PRSWOH>I3E\G(.?E(XX09
M1%]O3M;=JQ6?AC<0 (Q0"$HE%[5!#[&!V54/(#03)2XB17,[2TCI*_BT:35+
MZ3Z1'NN57'>;F^6X(>F@,E*"W*LKF[J3%1L;!:\D1H[FATK?RZ8[\\OP]5"K
M/SZWHXM%(89FT:TYC^UA9793#YSMJ1\]S>0X$\\).+:(+K"[G&W]2$D=,XA.
M@V!<T3UX>[,;9AZWDE7+!X4'8-Q37=#U6>C%B_U&)0,WS_A\EEX<*:U516LT
M>Z4%"#T>ISIM/&:3@"SK_JS$RMW=\SKBP0<5]RH;NIL-$Z%.;I/DQ\?SEJ7
M;GR?Q%*;[^L@O%J[.?.+7('W"WW2,_UZDN8G,V82)>$42',:[J=2'Q6[3#H6
M<$F=AHXZ6J\2_5R"TBFH?!@_9/D(#I=.F,PL/E^O[SUOYIE7,";0J!JE];$N
M9KG["BFK$;?,A]<G7>3OU6=GK9H=[46,MJZZAFHQ:6_@;+-WYU@[>=%.H00
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MO:-TUE? <\KZ/O2)3;TT0T7#,M+:@.!NTWL,OV8K#O702><P26=YJ%"">=I
MK]8^=LOX#0SY/,Q-\>80&=.P^\2BXI9F-(%VRP+8'T/?)@-4%%/?NZX_&K"\
MZE7A2F,9II==AJ>6!0^;4;1=M0S;1TX$M8RU4]6Y6,V?=!< ,?_,!.'?R%5N
M2V_SO7U1,_LY8H1>$GGV0N_K"ST/]+4N GKT?)CF(?(UQ(,\47O2Y+*N:3#2
MZR;M^1[E0YA85^)T'L)5^Z<2G90_Z8!8P+G'GNUK&L+[C%R?3EO\>Q"C_2W6
M<6W\>*&&$6X^J]@,9SS93%K3]H[$AK09\P+*TT[?+_='X7!79\ 6UNMU%#%5
M3Q+VY<>0%XI(KU:-%\HV!4[MP H57:^/"6=1J6BY;=&Q<G!;S:?R6Q2]Y_C
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M&XAYXJBX2^;>++@KN^H^M>=(T:B'A#K6HQI1(^-NP$Z0^=QT(J*!? EG>>1
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MEV4,%OSJ<%EFB0"RXV2H8>AUT_4B#PN^"./)JO6^8@:+>K8&56NU^Q*HU7?
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M#5*W >F^7V#T"B;,VR>I1**Q0BN'EQ1+Y9QS>=>VN.&#L>+++OL]:I)@^!T
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MN0&M\85B[S%9R9*[D%4(N#[A'G-=KUG>>:>,I8<#$&H)/WP%J;$9G/X%L)S
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M#WX&P[?6RO$T&O.E[PKWO6OW$C76*\>4C \@S@CKR<6W>;BN+!>93[71\><
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M'<1TM9IV%0A=R(# RA50!9+XCJ$5?,1J0P&6AXL@+ _OZ;#ZN*2O]$_9.E
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M5."8K>R@ K[(QDF$M[JF9L#:<"C!Z"2S[S<Z4[WQD9Z#R/6N-V,Q/:-SI4_
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M "=OM,O/FA ,-+'['.]');Z.+7K.;SGB\M4-CJSAS\SQR AUE9FC!MD.LMQ
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MG[6*/"$+4]?!E>L3P'/*>U&"TL*[D[J"81C+7/T%.KO3PGF6^QF!-W#R$.G
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M,>'BB\>Z=K$'V3<MD74]WJA?9FEN>UB;Y$:M<^'#T_G6<XCU.SXS,#I"EOG
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M,\N>+91F,QY6!WL5P;OV^1T2#7'XB"_ZWT5<=[X*7!#*H7$=>_I!CJ>5>)U
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M2L=8GXQ[3@SL#L/BE:Y+4WJ%N<2LEHJ@]Z=5,B5#^*9-6Z+@4'J-S)BO7R]
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M4$B5FYC$\D_(KK"HIKV73V<4)CYJ]T)@$^F<:, 7UW TP(<9#5BMA/P3NNN
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MVA.B,2S.,&U@O;LQBG*$R?/LSV\E6:Z_V%#24YG8"C1IL-K SD[T2GE)I?$
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M&UT3A$[CR(Z2:!XY%'>B(<[*V:Q](ARG#K,[N8N-:9)>2S/<6I%+4K 53R+
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MTZ^_%[G:LRT6D5^RK\]Z*R#):7A;4)*NVJONX:H/-.62:]W9PZ5>RR]>#R,
M:Q11AWY&ZX>><M41PLTJ7<KE?3-R]1.EK*;@1 <L[9_2'ZF(Q(R0XM2;5$\N
M'1] A=>5,X7UK"9ZR]I+O71^ICU*T;.U0E8-01-TQ>G2(J**16U)_E[)LN$2
MVDM#76)JGCMS'M(7FY$%55OGP)18M;=5#GO=T%!;V62@N:*0,BW<[NJQ+_*)
MJ9Y<#XL3UUA'&Q49I[K@A]$[0_H,B5BE)V39^EZNFC6>OA74G:ZNWG@=DET
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M:L>C&'(VV+3Y:ZW.,5364#Y99\V3>>PKU8&PP>$F=:KD:T[=J8. *+R?D,E
M]9(6G)V;M,U0L-DZL!J:X,#.D:05;?+Y515RC/1IRW%2>)9J3"C7L&LZYI5:
M(X0CT@\%HR=S_8GO$DWWH;6G;2%;62I.;09K8>[:TWCVY2A,IZ&XKV:!HTWF
MZYH3[ADD_/4>?-TGO%K4CNR4(2%W'98./XQ11F8$2\R4LXT(SN_37_TDLUT5
M+#_.JI.R#\4P:;$J7W]?U%3V9%KP^$,Z'GW6'PC  6R5.6M-G/)!6^EIBRNT
MIM0(FM0C1C6JII,B"E1J/6D:S<V,Y6R:4?N J9">26-'<133M;6< 6'H%C!D
M\/UJH_C0JZ!:[>FX-EW8QTIO7\EDL5%S9I$VC[/T5-M'JI]G>$#WZ6^!C;R5
M/]+]Q$24.>/UN[;97\J<>:M!DR=K[Z<B]:>_RK*L.8(V3D$W.RO#F05EOYME
M!G8QK_^O5<M_?L;AU_>7H[E3D5A0* +P#GS*9YBD^NO9LB__NIJ 10^1/MP.
M;6&WN?F,S[VR9."E7IJ$+(Z?[D4?ETXW J'@IXD55['9,(8*K#L"K +0(?@9
M_LXE^REX:_7-$V_0$TK?0!" B="3S*_!5!\=@*<_/+O]D;QSY_:>SP^Z6Z/\
MJ(V_GC[FM3E\FJIP+"D[L* 3*ON"UK-(8[SH14[\!2S\9_WI56  ,;1*ANL^
M6'IKH+?@%:DZ6<(G*ZQU<"^P>0YGTJ$1V9 \B1A/N<]> NT!5"?^QYV-MR-8
M>_0K"A"*\".'^'DDEFZ,]J_BMUKQ)#X;9-'^4M)Z7?W+^R HRP5!E=QI;*1/
M4P##27J@B:VU)VI!@>TEDSG*5'V$.>=PU2#]]*:&:82DW@K9_M1>E75M;'YO
MP'1YS;DS[R,W,W*;GFZ=C_S<N)_?R$JJ^SRNTC^-MY;&3P3_>@*.\%^B ( 6
M'42@76"9/5+&5]!^XYDTHZ/H%TN.'LZ\\8;YOQY/57 WE[%Q6@)]S,6CG1"1
M@N,.@Q$ H";%U;THH1' M5?[H+.+>S6"*!" \#*+K&:L0U99]RM"7W1R'@3@
ML:4> I!1A'5[KUJ8-,7)=_?6ZYMR!* U]CY>UZI2E;U,I&FX#9X5AV1 U816
M8'?:H)7[N'R=$0$(X2E! $:FPNY@(#AU<TH$L+J";&:1O ,M"@'H2+X7]_9>
M)QP.1 "P96%,:8[P@&+@\08" ,$[F%2]RPT_:EF]?"9B^5_2&_L'N6CE@1O
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M2G6"2$1PUH\Q; PIQ_W4S#RS=^MOS5=25.U/>)(P@E"%2%WG4SO4]> 2%PC
M40#P!$OI;Y73E"IU]ZV% IK4>=,"_NY5VW.L-/Y,]*!]X,N#VYPB@+<(IJ (
MIFW124;$09/M6HF X?AFO(&P:J #V[(TXX\H[D=H<?)K%F#0._^ %;/[2>B=
M^XIQ_?VDZ TZ#I;]!V/38K_,96=Y91F8IC*UN7)"<!D$5^F%/V@U-W>J^ME.
M2:(7'S8Z2?&[ISKOMF/UW<851>LM?9&CXS'%<-[>Z9;-IHC/IDK2+RQV?]KE
MG[VT;Q=N>\^R?4%><'<CK2106\8A"BPC%H9D]C<&T_L'-21_]-@[/8:B_1M)
M%?]0 N^?*,R.?Y$0?7BW<3UVX>T)0[J5 #'\QP9?<06^BMV6^8/GFZ9&^(.[
M;ZV?_N]0[>9O:' /%3YJ](>A\_\%9NQO8RSV_X..YM8FD)!8&?L]6) 5QR]#
M(J'XSR5/\4LDP&J"TWMKP(C]&^.F^(.&/\0=6S38NDHQ_^0:2 %%[?WW!AK[
M!WJ!7WS*_E(HUK])FD<!ZEM\GZ\^XP-A*Y;L)7D(U.XBZ[(6!HS8=1*Y;Q?T
M&@M]W8YR!_VMSIYUN-!GP> (0/*8WHMTJ@+UF *Z,:N$Q'ZW_<:]_U+CH%_L
M;?_/RJZ( %\+=7X2G9:6YBVRB%]/_=TO^%.#O8[ELWZ]=WJ>"(!]H7F8=8E"
MC"CO"OMR0$#(R'\N^*)?MHCS_Q6#F4J3&5@[/B(RCOM<3_E>9$9T2^#>8C0O
M/$T*#6"]=[:>5P5>GC\2$("2QS<WFXY_#&V#_VI,[;7\8B(0^/_<.O\G_$"%
MH[D3VU%@D+@"X('4R ^6C#_@ZU5YW-)=_0!-<8 NI[]K>R1NRI*G@O^8-!O_
M<T13?ZCX(>C_[+C]GY!,^NG VG=D"2H2K2P*">T_X!;I1H+G9>_%D@>ZE%:9
M^E_M?7=4E,N6;R-(1A2)D@4!)2>1C!);! 0D1R5G 4D2&E% 8A,$%"1(D-@@
M.6?)27).W>38-- TT#2O.6_6O>?<,V=FUEOWO9DW:_ZH/WIUU=[[JV^'W]Y5
M]=6BD-Y]BTENOV8P^MK)ORF\SA43HO^R>O_O3WA&4.^2H0DN7F!,#3VYU#CH
M;UP*/*,7S9M.P?/JEX!=XMS?AG]<GG712I-F3^?#@/Y=B4K^&W@0@L>B":WE
MU=>(B*Z7/602+[@$_!T:%)LTE^]@+,;/S\/S?Y/H\_*L40+/6_6YQKK_T!.4
M7#'2^)]P_U=SG[&AV6#H:+^E^4Y*H'7;D"IV64L]@D@*L=@_T>BMH\>STC#D
M]JEVF<X+F\?K*GV[2AJ2[641-['2%$/0 WJ%=\#H#WR@[4*0L,[V=A8\:WG]
M0'B=?W9 %4U1KA-'J+]=)0=TPPGS<3:3<F(\G!6%F9%?0]D@0U"N[H4.3;@'
MQO%]'@[V4GB\4 <@$T63Y3:E0^-K?=(T(0U'YDH_FR4G BA3U$4\5)J/S$SM
MD-JLW/B:WMMU@O>S'+7-I'XX*(^EE%/^"@VBS1FKE5@I?"@5:YM .P#8W0UC
MPZ__9BB8VXV^!%!\BHL"1Q57DA.!9SQ=;HD&;Z*>IK&I<-0<XHQ> JH^^#W3
MHYVB#5)NTF#F?1N2X+JD(FO/'!YU\%2-CH])4CY;]F/_$UR[5=)3);-X\2YU
M]_J%IG!F0C2UU$T_%BG)EY< PA[_=?7I\\;9D[WCP3WWKV,!W"CA)1"CX29R
MYNI+U*+Z.VRWC/QS2*14\*^%#.[XWE:;C-BO;"X9<[9+YT(KCV'NS'BS+7=,
MMI^RE<,;F\%:JOFK_ RJ7.:6_B.N/_A&"!^1A)^5@2(#R&O@F-I\VP6.X4I8
M]C305TK"":U'^C%<79^-@H!V0%(?);KD<A-EI@''ZF)(Q7D4B;H3LHK)=.J;
MLYN<EK@X>]I*_ LT-D587@]V\M 7 1-/Z3\N,!)-W5*@)5IVSIL[$L_[M,Q>
MXH^WDBQC<B ;S ^1M>Q;I+<O&MTV%9K@\8BR7SZ=M3XA6?FI@3[4$72=]90@
MWO.@AF?Z.:&JQ<*RJM);!;PMGJ;H1%T"QBO"Y=L(">Y5?6AA#-"<TQMQ6O:_
M8T9&3BZ3[L+QD3<X=XH15W'E704'N3F JG\:38P"62QS[Y/.>NMIA#YN2K"N
M*XLB!*:J/-!?Y[S^&) FJ#'+>?7QIP#=&QYC"+.@A3OC33RHK [9VZ)J%-*X
M\A,5GX_\"9[6@==]7Y@?S/4*SA64';1(60(TJOP>P!.& C$,WE[MU?&*KA[?
MIY6=>'[86 A%4M0"8%L/DMXU$7O3+U?E/LQ9!I$9V$Z6/W%:29NZ.4!G]:HA
MOE-'8]FDT4K+;T@M[%/)#TU%JK#K$$F,3/,2^24@([E0MV(?=88U5UE,D#WD
M"2K]>&X833*.>:=(J?,E^!_O#_SWFDG#)0#,*(NIK<:$C#\M7@!U1:=? HQG
M+P'R]H-&79-'UC]05IMGF0F4FH9T?QIM/"&[PHW%HB9&I^,2M46@;MU]3%WU
M8=%B9R/SAFT3P5:S5NK5P#^(951^=1GM_ME*\]F=\:?5-I< IJ3%XQ[0D6A>
MVJ+H:;+VXLHEX&X.I::N]3\N)%,Y:&''QF(%Q)K28RI=B+W9 4)V.QFT<?<;
M6O5L!\L2<?&T0E/1X/,_UO?<1C%2_,WS&A>$.A*UV$2"B69Q+Q?SX4&J#>/J
M]AF;P2ZSQM7-QG]^2!H^T JCS565*M48ZXEB/-)_.UKL<7-V[1(@;)B"3EH)
M"N<J%/K3]9W_TB2'B$'=%,Q8IV5X'+NL<7I-_MAES<&TR;#YP&IKJ+S]$H#/
M=%7E;]FXZBTUJHGE$3QTX>&R9M^H/P9:877_;7Z32\Q,F(.9R67#@OW6STTV
MV8S'FZCU&6^,_@SR]]3!]#;5G$N),6\,>E:D&-G"Q%LWS93TR&"[],O[T<<F
M8FT+?'<X\@L8Y@UL3PYS9VA?OHN]RUL3R>U& $]_NO"UULI5<7KNU*M]@0F^
M!G8XZ&MO$A[=1=-GR]O9Y"MF;7J!["M_N'#?&B#]&G"1/8W8-8XC8)E0#FI0
M+FJ'BT&'PH[IYQ4Q/ I5B4F[;FDF'6E?.V]&T3($(PR!)#?0R)ZS[["ED[:A
MZZA7FWQ^TAD;=<1#C//M<Q]"<.[&L-E8L[Q6Z507\M\.Z%*'.S=#4[4P/6]2
MY4W#QWE$":ICV1-87S;>_?+X$1Y#8'OL:/@FLL_7$\U[>GQZQSVK$[1LZL<-
ME_Y2!Y_?,73Y*,I,:BKUT+/Z9W$N37QBLF+/H;YE#'"OBX".\:1EFTS2Y.(K
M^G;.EF"[AY7'<I\^'^^J+$]L!3&=RA&;:/WR4% :'CQR<M1V@7+D:-HETY:/
MB?!:16SU@I8O[AQQSO+^],ERUX?C"'\]9;AG4N[6P_.&PL^L[=]7'TR)[Q4I
MP_1[[9].6M9R@!.7X"'QW]$LJ-H#[K:9-P$,E6.<)K>?A6IP"#*E,LX]'V(5
M']P49.6LDN:N@=N\#UI$F\!!'T3KP63>KP8<^2CMLH&KB>7D4IK"EDK&,';+
MR#3N337)UF3J^.7WR[-J#R88";-C4Z642.]9\@P2I_4;A)TEOV]K)O<37?*G
M=F*3&W8\2GWX:H"WLNBE3A\IA;\W%#)9!YIT0:"5UEZGE^G/GDMZ<UE^->SI
M$9?=SBXQ+E*[.RD'UZE*6AZ0W3%\IE[&&Y)<]H"&Y+ FBJC/@OVK#1VD;CUE
M+3[)C;Z^!NN1\!)_[X0,1YMAVQC )>",J*"2! J:=%>&\^N=7?^C">M4\JH/
M*?U(.W]>']39BR>DZN[.$OUHS,/:F@4@K08PR"QKD(8VWNZ8*#.Q->Q,AQ@I
M<GXZM)L$2K M,69_8V$0>'3$-@&Q?]L8'>: 3%5"+K3-OE5<-WE:^OW$/*_V
M%;[!1X 7.X[ZT,O$C8*).SEIA91QTR:M/@QN(GQ(!'>PQR,K=B9:)L(M,GGF
MCR*U%5[C66-%BT\5O1Q64TF)"U1>F4G*X=U4]V[-["<YTKN7ZV<"YRL!D46%
M1OE)^OH*?X1658^;QRF[#^O(QP%WKGM4B$PL7UV"_>%?V_%"U>9G@X5>RQI!
M/U">S!324)EOI$,$T^:'WD"!Z16+?>*];6@SZKXLVM_OX26@1'7_@I[1XR57
MUZV/P>([^Z?"]F_SWP;D'0VAG"\!P<V'LWI8&,>,Z07_P^]FL8V2?$QW^^G%
M"B+KZ#V&OGG9!8W$^B<XP26@+.L??I<,G'']UGFY%SQ"_N^3SCIG(U\_"7T@
MJR*[7(^AQN(\)S,LK 2=/]"YJ&^B3L0=&@_Q3;G=A9$V2QG3O(@-/3QO3V N
MPS =X*=#(=1#NB/%60VC>S"*=BD;UD\340&O,3V+%=G-Q*()<$R].(C8M.?D
M:SQ2G.@<=A$_%R!Z)HIW8/*8X5=WO/S=4"";>6\+@I MKR2Y8]DJ.+\7N=%M
M_S/!71_K'B&+6/>X_F)KK?02P&K4?+:U.-@P>5"B?$;]_UW(^73L_ZI+;I3/
M@_'I'CT)B:60FOOK90I11B!GC@7*'<KW#IKZ5$VB<\]R3.N6.Y)[&UBT;@OL
M2B[M_]C_I64N(U"%;JVV&:PKEB1S<W1O%[)67STJZBO]!#E#V ^^5Z&%[\?2
MX]0@ V#?@9:A@0>J[0$L=;7Q[=1EWM6:I<,E?.HE&92?-[>>.WU4"]'DB<2?
M@FMT XV)-Y_7U=XW8:I5]--J$FJZ;0JR<(A1S5U ,6LFQ*LVUM3==V5X7D97
MS!#L$-L8@:? W1SC)CBS300EOU'AV423KIM\^!Q./KL>?C\[S:Y8=VV.[KD@
MYP!B-87>ASWZQG7;#:-\X]!?)QC!D3>[IOX/#%;]G](K-ONJ^MI9QW<+T;8'
M*]YK,E?"UZ#K%"^4V/\H<G4=R[V%7#=>IP5;R'AO8G_<(P53G*U^ I@9!PJF
M#8>/23GX+S$:^M:_@'MD1M0;U5H3<<Z^:^L&LB)C:W!C-%@8)O;!)4>S8?R[
ME>>S'PX*4)U#.U7\DB$.LI7RJR*NN._)$X6,:.?K.44NPG^)D^<71,=#IK9+
MYX OW9(T9P>1(R+^U"\>>:#)J0[QZV'BDU#\%.FJ?*HHA'<GO62]9'UM[M@,
M?JU*C^U8MB=RP> 13S&M$'JV[!F1A+<;KAUIXD2=(:KI$G#NP7=\W\DB&.CN
M@ Q]/D#IJ/Z8!9_5S55U:K.FEAS"52*!HG+W]5J:S7?F4YR/MQ=CGA[A 3_P
M3WH]0Z&L8W?S(;Q8KA=&1\LY[$#$I_?J3CD?-OOJEACZ;6>01"T6*;!LRUXM
MKKW8YG(Z!'W)4<.H(AY? <._ H",Z\&R*T3DX\U?(&^[X;GH=ZQGU8>B)6:\
M9JBR8YOIY4O >W(%K!V8O[GJS627A^7W9/T*Y(F:%OT^.2LI!K>!0]-_MC5Q
MHQ*<"E'RL.9.?NH-O:239&34\K9#O4BLEM4'U0^Q03N#4[&I8S:H *?VNTUC
M!3W?#;I\1&=FY*K=N8 VM]ZQY6W0E<81?(-LCB&=ZHW9^+27TYE0O5NPEC2I
M7V^:F4S]E.!S:8RE8\XN^^S @81MDY^D3UX\!W /)?J8HM>*[64$)QJH\OR,
M:X=+5H;C]HWAQU&84LJ7BQH5<9..Y:1!.+BX7DYSYDN3TW!O/<7*TK1>1J8V
M;LD0,M$ZH[M=K+#$YP(:N"4YZG5,7X-V^-+M,P^>S+TC!DOA5!# UFAA:7.Z
MF 5)MTN (2C6;[OT8&"R@YD29=W7(?$]&"8MW]E$"M>MSQVZ*.$IY#8S?)IA
MW#+2>:W_UE?S=YW2]Q<) MC0ZI-27KDHEQ?U8QY$.XEFU&H,[G@.?>(0"P=?
M@?XG@??\:SCIR*;T)@QGO-U;,3?&UIHKRDOA\U$-U6*NO'D"14])ZFG'U?=P
M'@'B#6;V(]',2^F$LM$>1$Y'%[><,@:S$YV'5NH+?M9KDL#>A%^#11XQ#.]J
MZSZ?$R_Y!1\*:Z;P&+#H-.1(@$)L=%#WOP&_FYCR9"*FK6KKH@)5!MJ2(LFR
MJ_I72Z-KBHW:F?A1[PX,061&6S)\$U)"(]Y\Y[JU3@+L%"858J\>W6N_3VCB
M5\V.D\!.BE_B,]+TT(\']2W7WHDZUZ;(: -.O_V9_^A4!QJ)^T7WO@5I"VED
MGK3K0B%*#_D1I0:+<MDY4Z]UD,E%TIG(#.=J.".,,LCO*HW\K&_!]>Q@C\F&
M$:O8JW&[.:W0V#F^O@24EX2Y8!XX+-R>//[2-.^?A7K&7DW6ZAL1$933S> L
M..N.N00T^G.:RL,O <A@E")4S6U( =Y4;D=U<0GH<2'>C)\N6GW,JI/&KO5V
MR48F87L\V.C0ODBA>@J+OG\&3:1> IC-K@+E+S6=0D,OM#^HA1GK\D5UO_EI
MG.W98JYCK4PN,_Q!_]\.]C0,P5;3TO.\]9Y6-X^OP0\932=4U0S,H[UYG74B
M%$:S8KX+*8G#[OE0;290C1>)38S,SK4S=C04:*GD/._>>AM$CJ>CB*B/DI1,
M%T/5=S7=AX\W1R;:OJ&34B.K2K,YD UEL[IET.-YU^6A&)^N"LPFAN*G^3K@
MAJV?Z=B]BE#C7SRB$:E><D'K[=5!1H7QGA/50O9<$-K/*\NQ;/$6%$H[D=PX
M9JIV9S>^9!OTV%GD&AH8/E65HH;SV*X$$CT $+#@H%YX+MP9WME12VA*L+@>
M&_/,"5:M&%G#$C*#+T0<_18NS6VEPY<^$7S(MGX)P/6N?G&@$<8VXG$)H+"G
MO@-LGJ3C8ZM_N,L38_PAG%_L_8>H+T&X@W,Q3Y*/-*9S;=#W-6Z<>N'O2<WM
MUCSJS]H56JXYWC;9'0HYBNB3=W#-,=!PM!(^%9K-XOSLGC2C).;FL]U3Z)GH
MB:3>='' \_S%X=E!?%VGIZ>%X8;:L[7LHIB4VC4F_(4 7K^7B#+VPXK=FNWT
M'\7<@V_2P^H:AT("**YVII.6;7E-)-?;<W'B&QC2BW<?$AAG?Y0XLD*6Y+PJ
M#R):3WO$%FW7+=2=AZLBUS+GN^0ZH!G1-L,C%F?2E:VO[,$MW+#M^&[^\\V?
M54) TL?2"'];'1J="\/6?O!U.*2X/'\1]7!DNV.!)8Y7NU7+P6O%K.Q+\:?9
M8"NVSRWG\HQY<I)ZGGON-!^D7/.]9[H4F#@.I"="">&6$MG:L\;^G^:-XQ2J
M2=OI^U]JKYRG-[*7//.G8OIB0Z+08W=-1-/G5D+DM=@#Q(U'9I]<1]]MZA3[
M"6<MS!H9&=L]%)Z=N03DA1A96D9<M"C1P N0^4?,@DMFY%)J4##CHO1:?8GQ
MAIXGAKQL+(A.K;%(3XLN=.:>.H[QW5+=T]<:#*0>9@0>YS52.I< 0@S$(\_8
M/FZC![3&5UR7&MQ65$_:O4(0->N6VL"*M\M\7W0;VCOOS%YS4X$S%L^%ZW'M
M)QMB#2U\#:9C/2 <F9 1IO3EN\%FFS&=3,\UQ69&X0I2&.=A?H+"?L;7>)$K
M8_K#9>TEX9> I>Q+P,$Q?!;3R-]\Y.B!S/'K.G?UHSI([_@B1<0?+*)=T&7A
MY%F-9]Q^HVTDW^PXNG9P=%2:NQ[G43N5NI:G(>;93-K(T87FZ;JBKS):L+J3
M^>SV$(:TZ!* .F:&=R[2@C8T9%%"6)@'&T<N&GZ[!,C2+ 2[=VR47%W.]A"%
MS;*?^%P"6A/2L3 L"T,["R._(,+J-+XN"/T6#'E^"4B/V'_\3^J?8S8U"2,R
M)_] 2% [!GF$C9@5_O:A:+396Y(TIR597/O%6PW:%AFV56O0LTTD>"_SQ%,Z
MD''[V&%9-E"YG1E@QT1_[C<3;Z!86<S)OF?10RS)M2-)#)6U;I[>ZUL"![<;
M%WG)<#0^GZPVM[')5@'5R6JC],HF>ZT?+1;UQ3$3HU6<E_5$P:?$\Y> 25V,
MAWJQ S."JOZW0+W=!KIS!/JFNA10>'Q_6)'JVQ]0JTZ]+.H(BU.*5:_.*KXH
M] 0=;/ICH6_2)4#>,&SWT.Q+CC1& _$ FP%:O_S39JM*?M0I\_& [-$M'?N)
M'*PW9</4YF*"'C#_;"[NC%@"\8\5_FLU*AI>65C;^<48UO$&:Q<FIA\L^V.V
M0!M/\B=<%TR;,T73AH\N]#5-V6";'M)ZT-"PBN/)2A-9C5'T_8NLZU7IGK^X
M:A>Y#("FZH#S[%TI9P)<AH[T:%%^RHWJF>A&:$HC,:*O=<:S))=$-=8^WE@5
M%RBRBH\W%:OY4,"*OK2:CSM?R\ET!9'^=-QW5VE4M?IPW_EEQ7NWW!2I=S3L
MRTH:=.R!T@-^/1!44D=R28B? Y1[P$'GUS&$^_%PB?F/BB^9(8-[^EY#G\'D
MAZYE<LH$D?%&3**3'B7XIMXPE1^3'N*\.T;MAZV\XZ.J0J(=/TN'0J6"72G0
M6<1"4[B/<G?20=L:A\RL1R94AQ/I!=L"'5@GANMPEEUMT^62_9&]SL*9EZPG
MH@?1M EPHZ=_U_6(ML@;P^H@[%W?7O?A#M8 K,8:-#D^7P)LQVF!(J:6I9^#
M8WJ5\JA>G]Y0P4/8(M6.;VAOH(YWA0S,PT3IE>.\XKAB;;0LWYQO94DE=+&\
MV=<K7*4GO^D@@PMO^MQ$6U-?UW#N%<YQ3EHMI($,^T91P=7Z.?[PP5<O]K0B
MX,1X@U&>;0"-411!1_59_PPX2)11XWF<4?MKI[V[U>1D;3<"!I^![^Z:%'@"
M:.ZK#4\J,82.4NI%^DDTC%64,*)>=:K9:(WM'H.)HY[LBI(D?J5/\+X$>*<T
MK2E$$A?3O.M4<IC>IE-.B!F/2))%W"B_.GZI7OQ[C-M+[[>X9J<-BD/'7"GA
MGW;\_4LC\/E[I:U,ZCX6%ZL$8%&JPV2?'H:GT0#I#5IJ'\8JGSXCSG]HF4&@
M)%14FDVGK'2BP8H*4W]1:W,@ZNBDX\)Y,^>;;41>A.33*G4@02 !P_J>1.\8
M6O/[QME@?(Y)_\&B?0F[9VP1Q2-/!;YI*ZW\8+S5CT./XSO>:*>$]"[36, D
MSR\\&KS<KPU!XP\^H!IX=&&[S"\QW7-9&4S*L:LK<0'.#="Z(2*[)FP6% PI
M0/&('E7)X,=KCA=Q)BI/^R+SWAMT]FL,E>;$1\80Y^V:&:@)&;6SES&69B9:
M1"[AQ!LPT1]$QT(O 22&*+!*O5BR:+^2M[.">LHO"J*9%C&+5CJ(B?5DFYYL
M+!P<N'+ E[7,S%A4%W4\WH5FG?D\R9,\B&:NI)WB^K+';HM>FOW!\CR;&C:Z
MV"31=3>@LX!42[C+)DOX+JLUCC,$>"HW!&#N;01AO2%E@S T555]]&A><:UQ
M3.2P8/8)LEQAR)'9^K 1?S$E"A*"+'Q;#:Y@)-!J+!WC[_B*-/2U3R+C4;\;
M/@W$E^>8_WK3>] 7&J;C#$3LYHD_1,J8H8*A$$F8<OBW"2DZQM6]] QOHQ=@
MG3&F-@<K"]YZ=EW8@"+?+,81H-R7/ _7:$DUTH;3?&C0AJ;3+:""I&G:(0_C
M,R\!-JWVB>![:;^*-L1Z*M7Q]X" ^#'F[V\:U6<-1YT\2,3]ME7S$FTM9_3<
M!'J_WB3L9H.H>GB01554TU!DWU3(64E4(B[(RF<_HN(K5TU\T+:^ 4Z2M=E_
M9]@<UG ;WFYZ(!99XE(1=>NVYFB#Y$4J6=WL,QSB.SKT<Z1I]!!_3?VFVP??
MPV 0X7/YQV/?QHI.RNCN=K>2OEBY2;C"8.DFH/08OZI0(O[3ZOYMCMFKVSN[
MX_X/<.E_M/VQW)^CYR(+Z]+ 6H$3UOM7VO#"ML^$]?V$L&'W:3@7A/1/I]1_
M%U:V4G^W%##A C,%'XF8X1Z;Y:M?C?R#8)#I2T!7SLF%F]D%F7W.[RLS8QHN
MR>B!^_L(4*Q6.%>A\)^JZ97YH*YN+#^[2T!&>.'OXLUSS+T+3RS#TX <0Z[,
MHOY_W##_A^J+<066)<G^B38V9E.IET<CCB]N%2'!N5O=3&TSP.PO$*B=);C7
MA_A:?_H\9\W*@4ZQE'2.R05X:)1G[9SVVFQ_M1)",-*Q^_3MC;2@"BZ(L[5N
MDEIY#0V34Q&%?\;U%#_ST\ W9%V/3K)35,MJ?4P=5.[9>?I$'MSGKXC[TKV.
M%R<MK)N7N:1[Q^JS6M (69I+>G4?[:%PZH4,TF?(L*CIS@C%\3[-TS*C:O/]
MU[RC_=8$+(F=P&X"F?$<11ISK5"%44BN</M+!\I.I4_=,7FO=@0&8H3C '@G
MWXV\?;'#*JM'>9:,6B-BJ>JXTDL66TZ;#K:W_!V>A/.UO.-QRDH4UUJX%R>"
MB&T#Z#PZ?;SSB,'WQ9&FBF)?^BF!P=6YHER]OZ]X*#P\;>Z?^'X)N'?*<J5B
M?]*!?VDW#MO2$7BA6U=+N9;>VABYF NCT^3)DL02M,';\AUL1M8:FHE]AS\D
M?CN1(/+[=0VCZC3:,8[Z-,6PI^7EN UO.+#H[8.VUB4@C?L2X!]^YCV9T]NX
M>I+.+"5MP[DG6]-=PH!J<PGM&/IP"; 68[8^5\]!@KD]^_V#3.H/NA8ZA1<:
MMS&WU%0QWB472*X_T)IXE*SIM6;FG<A4=DZ^)W,#]7(YY1) 6MTZ[\8YD3-V
MW#$.J7SOX2'U\8#0&A&;]4KG6LP'<](8X609"F_U_=8#/]JF,LQD^+;!R+&W
MZ$O>G[MT"M6IR_*W)-F(>^L]@P=QQ*4F%V3AX?9FAQV@_5)E]-WD)/2!V?F.
MGGS7J->X/Z9Y'46S4PABDY6 5H](I8?JR4A%_.14QPIY"^93I+OO77<N3_OS
M.W-ZB=R<C;,W9#:='%78P71CK&*(HK7 9!$(;^A9Z1TAL!M972 [UQ!RTJ_&
M[5D18(DU\[T$M-W/!PU170*:.IC_)H(:;-/+S/LBP67%9GTLM'W8]BWIVQ+T
M/:*E%7CQX@V^E(L,P2*?$F3@U"EZ2)C>;VA^=[-SYL@EU!1O#.U^X*",#3JA
M9!?C:^E+$*$U(Z_:9"ZU_106ZP3-H/IW[?=[5\&,W-M8$*XHRG\*;3Z9ROK;
MQ#\PE4@Q!&+!XV2_>I0-DJYO(XUA!"V&VYIC-S'CR"<OXEE*.!8#(,"=PD'I
M1CG\Z](;+RS$GZON"Y\UNJR 7&,5_Z*;ZNP(QNHD=!P[L>?AO_>0U44-PGGR
M,NMA<C/M^]%+X>__+I[.6^.A!3,?%W*C6#[ER=QO?TE<9W<3)'3>?5;Y;XJ@
M7)V#[MLG+]3%*)_04>HV_^W-:V(3KN]8,"REASFG]'UKUM\$_Q]2_YFD_ACE
M#/_@'\K=E^M/>9UNO=(:SL*G[Z)[!8(H%&K5G20=?<E^?1R75(/<78L.")_\
MPR#99<JQYG5LDKOXJN0W1?QR85B-P/JIS,I+P-__ __=2'ZGKI'AW&9_X:RD
M&_FQKLK_GT^K,+D+'>Q\"< B7(GJW\T3E8TF?/RBX^)G/L4G+YX;!Z.B-RKY
M+$^3S'Y5AD*Z)]GFWQR+G_TEBV87U=.D!>7_O*?Z0[):^_OG>C7;KG<P.\^M
M\"U;KO P6GU5MON%>B-'T[W10S[:MSW;!.6;*^::5P?Y_^RY=<ZOE <A S$Z
M99ZS_(M.FK_YB/:M\>;8BTY%JI+?*Q_H[WK+M)!TR-_PSR>E U'%R"A?N&M<
MX.DL_FT2"VF:Z)J3S7LH8DN5%QD#J?@:^:SV^1NP[[)WDFWS5\M?37X!\JCY
MB__*_X57]$^DE?][1/>&&G.G.7ID\\X],I;G6=X[+>,N?Z.=%V6O%X X1\=F
M_SA.!E\9</]?<_C?.FQS;+_8C8'=_6L[!__6CUD7@@;O"7%!0/]*_./Z;1:7
M_]FDH#E#Z/=%F!)TAW9QD N966-JQ:M[<RG59+!::.'O]$.!>T05:@(26@\M
M6HCQY4M3^FM5,OO-A[+]9RGO_UM27:I_+PR45Y"(.XIT+W]YTIU3AC/T=KCD
M:]%H/D=]NM[C1R/A_E<%AK":?SP ^C_MOW7#B;$8RSH@&X,(.G'-\"<QT:Q\
M%K:96[$HH3H\8KY3F4[NK:<VR7.<=) PE^Q7;O_6Q]>3FG^M,X+;D:A4SY=:
M[V6"]B$?$?,S;05;X6!<:>]M.28:\JYT"M'@#^^?5-2E(2=\NZ_7AU&_J++#
M_,*)!M+PE+;=)I6S^Z&*$S\@?Z[B'0=5X3><Z.1^C7?]9VQEP6G<=.X,!V(U
M)K.-CYT'[VLPWDX/R=&OYX*!^!*NP-4\VAG!S7# Z8+9C)YAB,-KGHJPJ2Z:
M,P87SO0WC'O/YYX(8_(52.YWR[(QO;T3<H($'YB&VS@T,C]KT@DST.I6*2:9
MZGI#-(>:29EZJ-)-UWM4DL'RZ\VYTZMMG?!IO>=UX8^L4SAYPNK-.U\+-M:]
M'=^-N!@^?4XP-+%801#.[VA9!U8?T:77)DRH]OF^HAK JY,E^&SC,X$K??:J
MRI X=3Q,O3(3S8/R*3#>NB-R%EV_UN&5M_B>@;#'1:2F3>"T6N%F9#1P<Z1Q
M[NZ[P SR')LM)L;12J,+/N3>N'7MR)K/SER<5*[M H<Y3FNO"NSK\7$&.?&X
MK-WV+*,KK[9&)6(P+4FX74+$S:!OU:AW:Z5)'^_+T%FE,9=D-"UAB:S=A1:O
MYD!3:JZI72<".3.YLS<"]"Y5%6)5*])WUO\5,M7MYM;3&1 NF,^^2R=](!>%
M+Z/9I<Z%NZ9F@8P]N+<>LH?'!AS^[J :!AUG3Q0#IE)?^Z' EOSB=L!I-%U8
MFXVY.&X]ZMN!K-XO/U6KS*GYJ<W 5!FU2:DYT[!B!3=V +I&D<Z9Z+1K?MNT
M>95#L-1U,UPK_"=%1NSHW4 91S R?]RY@=<*A/\E-^7+J_)SA33[C[SW$DG"
MV*/EV8>#63-> &K87+?DM$?1&JA**#GA%A-)<[6JKZ2)JG)]?>TH7PB\G*MJ
MMDE.N8_YZXYG]!/!HZXJ'[N@AWSDCEH)9&.XV-GB&I/R+7 P(^7SD/2W (XX
MP\:BDK="+*ZG]ML]G-]D8\\4V!*@#06<3>+DH.T/9-'L=:(YW[,HD2<3^=?:
M"SLHBVP<EDFZR^1ZRQ_@(A)F:'%BB&";)A'5SL/5HPR:JWE=O8\VNYX"3LNU
M+K(\^DIH>G*FZ(&\//N[)ZIDI<JU&@^]5ZJ)1P1O&#YJ86?M\Q\ACGN/_#9I
MU!:W%6=W)AVFZK.7"-WS$*A7=BPG,584WOT47^%L_EIX]3T"G"-5.>@9>;RI
MWW0?;AH+4\6Q*&P5[8B=8YJ1S'\9;:Y$W%U:%D893=RD;,J%VX-A1+\>;]"$
M^CH]V-CTU*S?F_9G*SIYMUZC5C6K1)[(JN5&OKA2C"/B(?MQX=ZHE$U^[^2=
M$J1525AP: KG-/[7*NB"F #SJ=-:Z:N;,93E&?-C>LW*>*\S'RCEY3W,TP%P
M'5$B,I!,C5CMV":?<3!I^C6!<# A5^6SM*II3#5DT1T;6J&*MOGY!2? 6OOP
M_8];%4,>YX]1B8Q)B$VD;B)B3LTZYAG#O0RC0F]#W^^#GAE?O@3MMLC'#^HM
M\AUQDYR?T_?L)JJF4'M5NZD@^O@F'C$P1(L7YE!BXQXZ#W>=S :V&%Z2\5&_
M*W<&!^EQNYV^^2NBQS/B[@JL5]9:#S?_AHSS"LKG8%M_?'<7LN?W.(-^HE%E
M[0ZXIPG'R8FM.[*,C\B.]L%U-_UC (4,>*IYGCF!\U/ZG%EOH(SQ.,A.&J0]
M9K1#,T$]XU^:.F$5R-H@;^7*;H[+G< *I1V<&"*-",K]5G7QS4_>7[H1 DF+
MXRO>'VE]F=1OQT/4:&3N+,=V;[QA'->%J=%A@_^^;$US E\']NU=<.%V2<D?
M#&XKH^0SO'.R*JK&11_:)L[#[.[&*0 -$H#>;>N]["ZN[V+$'N*Z:P4,8^[:
MIFWQ\JN>BW9](<L4C'^K4FH(K%,B(,TVN16(<_IXR/Z,)3,V* /\3+,45"?[
M  !GO\@X7JFO+T_N>TJ3[+\SH49XB+OEF#3D&-!?'Z95\&V*\4)NR:\M"2W2
M5%[X.)L/[)35X^J1J^CA-D+'KL)!?7M>C8BX)43WO351]Y T]P8D(L8S$FR/
M9R_!Q1P,\";;WZ4OZ+#Q\:+Z'E=C"U,3S^'8FQ)ND3KU:G#]K)+P\1YLXVM,
MOXZ(1C06?(17+A(;U=O5"=2-\;Y*:V4W<.:#QA$9#]#C6R& +SKG$ &7 %H7
M$&(R_9/[9/A#OL<S0A(,SPE"O2=A$^7+B[?MSSQ2$U-DIZWB%B0-5"\R>0N)
MC,($7%=*/^6U,.RN( CD?0YH7B0MK^5(?GIO<J=HAEUH$[G+L4GMSIS"H%#*
MSF(SG;CJ&WY,%@Z45-+PT]IE>C\1*$7<A?S0/.HL$G7GC-9Z+-)S8I0^V]:F
MIN;<MNI3D0TMAU#9;DOG01IW%HKW('$=JKB6=2-SY@4954Y4O^9TO4LT$(V8
M0#A;?&&[&>@:[=Y28L"5O9+'.4D5M3R$;R=#%8<PD2$*&/;N/:$1T].:&^ ;
M#L8'&J38![VN;>EIH1,'+#=HPI@I4%Y0CDH7>PAD5GEYHJET>'<7KM:55EJ\
M1O=*R(<M<YU895UU:2ABST]U*2=%;XRLLY#A1)5;@[#*+4PRPX4+47 -!F]E
M?V_Z_MU76+IAD<CLR[R+^EYF>T0#6)CSP^".1:[9BC07[CK])2!L)MG0GB:1
M^>;UH= [V@R&\:*%QHIW#0=78O(K+1(5Y<+;71&+# *0<]F/-'>*LP2PV/S@
M#?*]^J&'MXV#I1'=E.)'J%9PZ[,?-N:]]2%N2MSS#=F J(CWNZJKWX$SM=+>
M&3?$EDX^\DNI+9&0S#]9WTU*LX3WN.48W)OFSK#T(&94T0PEK@^Y,3Y(8*<"
MT P4D+[.^Z<MHO_5FOO,T$_F&QLT7@^3ZHH$YV>5.))GI/IX;$%AL3CF@H.N
MHVF?+@'DWNOR!\:9TGPHXVYSHXP0SJC(9RIZ.(&]<;D$30^D0:V)AOGC_"_?
MT1C4CZ[\,,IG_''KT[)*#XZ;>\N>QMM#1H<ECIR";5/*L428AFHC19=*A5'<
MT)K2Q"3I";YP=>!!J6;WH,HC_$#IMIB8C+C7!%H.'4WT?C?'KO8XT6Y4.^6>
MU@T4&MVOKDF(@\K?SC)6^Z 6O1JRF_&#I*^V\]%V\W3ZSQ-#FQ">4#1;[./L
M!9(\Z(V?,USU%!6:-=7T[SL)7Q7>[!'79?A%\*L.%%X!T7X2;U#5H#<R;#*S
MF9#PL&3A98Q0@P<#TWB.BROC?(-V&U0EY_D&+.L^'7Z372CRQ5B&@S?N1HE]
MG4I9CXVF\Z)-HCAKM"#3G?OL\0.O],GZ?W8.A#"NMUX"0B9-;QYP0'@2@2]?
M.A'+V^!9G*B*A-&;T-;@=5I&"K#SJ8KA4N)LCS_=-B@K&W-TY*Q1*>&OODBF
M/A_9H4]G?CS@MTBS4PW9DIBJ'8?"9Z>!GL[.N^:D%K6N+EZT,;DQA365/VW(
M:@)#^3KKP  TR:0?[\%MX&0ET9OZ_;*L+\>R$KJ-*1[9KS^JW'_/X$1/=:],
M_F)<O)N@W"%Y%QQR-"U*]G3)<$:I&\**A^YOI03@L">: Q@'=.&3$6]*: U$
MU\!O7'AUJD[;.!4L,#WF8N2NL:9WFLOO[<XO?FRN5(HJZ +EY4#G%J@357/.
MO6OZNRUFBF+V@WWB63]>ITPHD&&X^.P!)GN<DSGK[: 5--XJX=_7QUBG8D&"
MS)EF\AMCK;J8"Z-?UY9C?J9I]I!Y>K2#PK[NXGC.E&Z,;<SY54VZN@][^*PV
M8O4SN"(X,.9I;Q'P4!T5VN^>L-]TQT^B!GX)B#HV4=J[Q=A8668T78!_BRA'
M?^8 NF!05=Y!P^/>VB-MBSOLD1K0WCYLU)-G3.)1D\K[[525)K:\4@X0ITZ^
M8E_G7:\<;VS"Z$%HI,U[-\)<?2<SZQ&:6D$6SFK*OPR:[KP$/)O@<1%ES9QO
M3,QW\9QD$1[PLW!(]*WUXNQSY4RG9:&0]3@9 CR&[4\7G'0T<4U6TGN_>631
MX- 7X6,Y=X^&HM4YMGM)N54Y^+, >U1+M"WNQEON=1,+I,N$**]%QXD6V0.,
MM*E-PK,3-[;YO1J*SG(P:ZS"@X=\J^EL94$OMM /4;>+O>4[9SS+\^;LJIWP
M",&^>&5$"8IU7<@73[[^+"*Y-G)K],3>!\"TZ.3!."/\4[^@GG4NV(> (._"
MWOX4(3M=C(!UW0FIS6/DV!+?6XZCZ.C/)Y_9RTD5+H\Z,'YPDUQ60,HC'X+I
M/UO[EFVGR:C4AL',;#D=FJBR/V8CH=2-YWY +=3.( 707DM\PFZ,P#G"SX=,
M;;215QGS<'@)_JRYEVU>M,(%B/,L9"!_6DU9* *\:^,0V,[R_OW.6[T!B>J=
MYJ)%!XGQ.0%O'XNZVCCO#R/=",D&+RYK:X1;T7=+\UR?WO0%+F)\ZQ2X:@>O
MKT_.XV^;3(Z>Y1VND,4LI['V 5S"[_.WNE\ ;]%3!-[P+)EG859K_O@&=5R:
M31_CP48Q@/30,M","+9X%T@4UL)9!ZUP6'.ZC329K&@T4Z\+V58>6> 5,KK/
MSV. 1AE#SMB4/R:]UJD+M.$&<P+,>:4P?3.0B22A'IK0'>MK=HZ.3H9*5:,V
MW+8%\-+(F\"J."7S OEG<@2)+,P*6X8#B3$3#CZO$]<0RT[FY)< WGOF*H_W
MGJ3W%D\.U6FT\-^:]5-Y_]/]8:@3X1BLH>:<OJRQ6_ES460F%7UO;X&\,,,W
MR<$=8A!%$X%WNL&!5Q@:>&LD>6&+X)W6N-FNV ]FE@B?\5=]]P6E'%6;]Q:#
MZ3UCR+,*4M=*K'(7I@R-C=G%Q! BNL.":WHO[&C),[.8VYILX4,[)U!IK46E
ML;4?HV^>)(D)*^<V(%A'$DIROOK@6/0LTC^X52<#(*6U>@##]$XFGKQ52)QH
M8K*%0+*BH31"2NQ?IX?P1J^5KI3ZL/G/"3OVL+R38U:TKQM(#'5A.#DA<J",
M5W:.OB"-$U PRW]% --S^'D$>E?W 43(*\48D*RB<ISGDMS+85.I:E4'-&3Q
MRR95T>6\E9GHWJ4KU8[IG]G[YK^L4DE4 12Y8+KE.-IIMGN75#WJVFUJ3\<$
M ;%@)M/Y&LE @I$W>H,(S. "6^/8D;215O.HJ).IN*'1]$JB2G!#D#ZZ-N.G
M8W\;;9R0,/.#&U BJG'ODZ6<Q8@&%\Z/3LX\.R4Z.QU5WT+.=<J4RHFJ;C90
M']X.;'FXX/I.CBG'H\C P)Y:5W@NVRNI'C-$PIQL\MX=MB&>:W>66EQ(66:H
M7IZM#73>:6Z_*ZAGEF>NO&Q*M\0\?:();X[P$RS6R$5YSI[S9@.='.EZ(V?9
ME=Y8?[S-5I=D[CJY+]@CCLTGYTNVZB;#^& IRA5!&.B>=31=-EE!]F2I>LQ\
M_"WBO-BZ:WCIVRF1E@($PV-Z R!X_QD\;KAA]WZRM,!T!VM]BL3K:8D4;Y!'
MXL?3_,$5 /[%-+W<]A'XW>0,?]L^%4JW%]JEX:_#AI#IJWTUQPL%XJ*SKBE'
MG=PD8NUAB5,$^)(>=CG@Q3^%/LK2VMMY38D3I_8<1+'IB@J0=BVQ,.%0T5IV
M'O2DG;L&.6(!#S8%I"!?C>VIQY&EO<-[K<C#2U<;]Z8B;$%K6"D*H$?*_OSI
M1]?W":^?1$*4D<8'3IAT!U*U98@$=!%H(NCL9!EK,+FS34>J.Z__[FY2C[,7
MZ77N1,"9H0N%7=79REOA.?"N^-W;D+)"81_+!-+7 O@O(I-3SJW[SFW..7>)
M+K*0H$K_=%0#9-;K0LS53$)VIPM*=*Q;!WS#RS>PN\>J)C1H@(X0O-N?^2@\
MD_%]/ZG*E)L1[=(7$?!TA%Y%BEH-:,<(*+(>O/.J.F%QQ\@ESI,02HGW.6'R
MM4*/&V$KCYQ,3)IE50@PQSRV,V<:+ ?H$:5.R9MUN.-?>?RUS]7._4X?:?[P
M<,ACYN<.Z]SDT^FFI=4U%,7!!?=33555^[XTI"HBU9OM4VZ]Y,#7>1GLV0N"
M+#\]3V^?I[X$M)O>&'GCK^C4L"LS0:]YKPARMYM"]'J3I4FS@+/X$F[::X"$
MQ%\<_ON?]I_39"^G_Q=02P,$%     @ #DBL6ABY/!TL"0   4,  !@   !B
M=&%I+3(P,C4P,S,Q>&5X,S%D,2YH=&WMG'M3VT@2P+_*'*G;0)7E!P1(9$)5
M0D@M5<MN-LM>W;]CJ86F&&FT,R,;WZ>_[AG)EFT(A@VVR3H5#)IGSZ-_T]V2
M?/*O(#C/4YY'$+.?KRY_8;&*R@QRRR(-W&+J2-B47:FBX#F[!*V%E.RC%O$U
M,-;KMO$_?AR\"8+3$VSLK*JE\I ==GK[G?WN_B'K[8>]X[#795\NV>Z?5V=[
M5#JUF<1/X/'I20:6LRCEVH!]O_/GU>?@[<[IB156PNE)I_[MRPY4/#X]B<60
M&3N6\'XGX_I:Y(%517C0+6P?:W8P>Z[,;3 2L4U1BNZ_^P6/8Y%?!Q(2&_9Z
M[>.C:9H6U^DT41EA!8Y&@^16#(%:;[0;2> Z'"B;]N>[N*MF4==+5&Z#A&="
MCL/75R(#PWZ%$?NJ,IZ_;OD4_&U B^1UWY4VXG^ 3>, I<@A2,'+V>Z]ZUNX
MM0&7XAI[H]2^GY*PFHW!3*\C7W&@9(R9Y[>I& C[TZO>4;=_@*V== 8X?\6S
MR3HK&I6>Z<?5?(N90V%0,"GL.$Q%'$..Q7]Z]7:_>] _Z5#19Y6R,:,1:@/H
M1TSIV?G7JXO/%V<?KBY^^_6/39C/=VN?SQDI+UKL/R+C$GF26MYB7]+VIW:+
M1:"M2,;,IMR&ZYZRE6_!#!%6"XE,+>:5^'XQ%\:WI-R6#R2P@=(QZ/<[W1U<
M "DK"DZN3<&C^KKJW=<((B4E+PR$]1_]OS=^3W%$J559V$@AKM\]06X @>1C
M5=HP$;<0]QL ]F+6TV<U_L3?9:6&M$\C+BL^.%2@D/U1*BP$-&$0YFJD>5&+
M0ZM436PE3Z^-QUK<%&DV?W&YGRJMOZ2&4"B-6M=O(JM*0IUD*1\"TS 4,,(#
MW*;"L'JWK%J8WTNND;ERS+Y"H;1%<X)]QDPT.(+?6:(TB@?LKTFI CM3,8,\
M1LDON8Y2=M!K,6=[J&1MP_@HU']1A]A5"K@9H,1=8UK^I+W(H_:ZQ)I"@'9@
MAS2CXU3I^5 V:V^1.CBM$;A@N0T#E[+L0;;%W<O#W?ZFX>XC-\Y+8=F8W:#T
M$M"A:7GJ:<^<6&''N4)/"!O@(F<\'[,RM[H$E!2]'.<F(5XXR_!*"S1H$AYA
MDF8J$Y99Y<LM%,@A F.X'E.1C-^ P]FD38-I,0J#74J2FOJ@ I'0Z)MA,?36
M#$J"R\UP$1!VIJ2/:?T1:*@:H0%DPJ";0M/MO3D-IH#("4CM5O2,%*XT3LI@
MW)R&+2RVL%@Q+ Y>#"R )2)'=23-GJI?"TF!Q3%;-_)%GE![%!+ OR-9DJV"
M*M[0M1;B03A[!C64X$+0D7)*CTIQS5S7"*C8Q1I:5**46 "1H5"O77?&R1-Q
MD[)$JI&I>:+A6ABK.7;$*='+C5*V&E@PM3 +TF[)L"7#BLGP9M/(<#6C1K1;
M>L=]4^E^%<^@8U<EB<!+IV 7C&MPJHRJ*6@SD4,#AM9%F)2*4[$,30XR.^@Z
M%B:2RI18CXP1K:37Z4*K"&),-FP753@&9(+7T_/;*.7Y-; />,Y_+266Z!WP
MH'>X"WNN:N\P]E?^4E",*_<LH?89&0,-Q'B5)UF6[BB9Z2C!CFK'K0D>+$&.
MY[I\H?"Y(?:-X!.K?PZ.'H)5I=2.>]WE(U/_8%;Y8O7,SE%C[2#CFP:R3V!P
M,*C2SI5XF#<M\G(B7IKEJY"[,0!D1]63=V!4J;$!M#5H2Y,%@Z4@=^U0''AJ
M^S3M)W]+!6%4>3!3H+0JVXHR!=I!*(M14L3NII0I!T;$@FM! Q#>SW(674XM
ME89\'\=NXQPE9^\H RB01?N**A6<%K^4G,PT')838NI#80WOD34=2?QK %00
M+2FLCWMXTRVG1Y#I'KYM4?6CH&JPV:A:VG!9(-;R)L_2X$+8#45,/.)&Y6Y'
M<X,LHX@-08KKN 8&(DQPKQ?DC]W5+>'3L<5APY-OIF@CXN-,R-MJ0$6I"\26
M<?YC%.'6<P*XV,\UY.@62J07YD!!6*0B96X]H1"?HD K[MD9M0".9T/4ED@_
M%I&B32/2^9#+TED8I*Z0)!#1 Q\YF#MB+1,G<0F+R5_>'7YQ ,**:.T8'^09
MX#K?+\$R-AV?E :*8"4/AX?9H(Z-.::"GPF4IT^-;QFR9<AF,B3>-(9\\NJY
MJ.9TUZD*L;B<.UGR"%N&G"H51:4F96YX,'>TFBEC,9T>@,*V#$YY?<^=[=Y3
M)4$JH94Q5[H2/$)6N!MF="\M+R=R[7FI4FXF[A[9)XYB$#O#S<U'952-F10W
M(*N[9W/E6W][BEX4N?:/M^3ZX<+<AYL&IZ>%N=T#17'-M=;45"#+I<F6J=5
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M)^[48G*FF:WQK^M02<._G%/5H]:+43G;S'"7W4'59G^,+GSZ??.>^Y*--UX
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M,2YX<V102P$"% ,4    "  .2*Q:?W#,L7,,   YIP  %0
M@ %&%0  8G1A:2TR,#(U,#,S,5]C86PN>&UL4$L! A0#%     @ #DBL6JE.
M65V[00  2UX$ !4              ( !["$  &)T86DM,C R-3 S,S%?9&5F
M+GAM;%!+ 0(4 Q0    (  Y(K%H4O/35*7P  )54"  5              "
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M-BYJ<&=02P$"% ,4    "  .2*Q:G W31_KW  "S/ $ &
M@ &+@ 8 8G1A:2TR,#(U,#,S,7@Q,'$P,#<N:G!G4$L! A0#%     @ #DBL
M6ABY/!TL"0   4,  !@              ( !NW@' &)T86DM,C R-3 S,S%X
M97@S,60Q+FAT;5!+ 0(4 Q0    (  Y(K%K7T:\@!PD  $!"   8
M      "  1V"!P!B=&%I+3(P,C4P,S,Q>&5X,S%D,BYH=&U02P$"% ,4
M"  .2*Q:5[P0+A8&  "5)P  &               @ %:BP< 8G1A:2TR,#(U
M,#,S,7AE>#,R9#$N:'1M4$L! A0#%     @ #DBL6I'P^KKA!0  =B$  !@
M             ( !II$' &)T86DM,C R-3 S,S%X97@S,F0R+FAT;5!+!08
1    #  , #(#  "]EP<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>btai-20250331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:btai="http://www.bioxceltherapeutics.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="btai-20250331.xsd" xlink:type="simple"/>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_vRuLpGrNJEaqdiLygHHIHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_NP8nyepU-UeJtuBMku2PLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QmfvUlDnnkmlBuPCyWobCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2025_To_3_3_2025_Oqo3T2TPe0OI8F2BWWq60A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_IqGrgtq8dk2Nmswn-jlaBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_1rBX_Jky_0K75YP6H-89Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JAHXTaO7WkO65OTNPeHiow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_FqusdZHmpEqdtLr0_l7HNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v4f9SlUsOUa4HdcmJWR1dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ev2K8DxaV0a9uKxJ00_XoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_10N7rnTIFU-ky4gxaDiVmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHjW0xYSkU2ePhegrPo-8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kELM8qU0EkWCrI-UkaL8Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JZy4BCURekiYxiqHcge_Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_x1Uqp2p3T0mT8txSjrqjPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zYjQFfZEOk2XX8euLUmtMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_QwlhBl02BUqKZ_B8CPqQ3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EqWnEmSp7UWllrfrANJBsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Pg-jCHaINE-WLGJKl1HB8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_6FxRGu28wE6I304fkcl32w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_afsb0jOiYk26yty0TiCjbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_jAh-mRl7UkGV1NOK3PBR4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:StockPlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ntB7xLQOW0eFtXjIxuvYzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_RtIxFX89CUiClmbyPTCq5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_2u5ZZheCfUSWL-ojEEShPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_9F-wNPBED0-yN2cUEWfCsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_lfzf6M4c4ESx9byf41wzhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_4V56383kUUSE1c7Tg5oaUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FrgKxTMEe0mg8BmgwnLOgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_QM1oFtti-EyHphWNZ9znYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3GMwf3ANwkuAIoCkKRuAEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_yCdJXfvBaESj-7sAWiLUgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uo-sJMUAtUm-XDTcsRgyog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_8_2025_To_4_8_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_P9AZ6PXW1kOHAK6MhEcNgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-08</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_G-3oLaoblUKb9ZcelJ9fng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btai:RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btai:RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_9_17_2024_To_9_17_2024_c8nGfcMfH0inkxdc7P07ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2024_To_5_8_2024_FZp7GPdyrUG_vHhSf2SCHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2022_kf6oTMRck0makoAqk28SXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ExIBEjJWbUexxXRMxChHSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_YzddE2_98UmIfS9DblB46w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_P-yi1ob4hUyuvFlo5q8PKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2PQahnIyZk-fOICX6AbWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_i3zFP68HVkiSR0fcAIqY9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lMS_6iH8DUiU4QxSYfIVZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_27_2024_To_3_27_2024_jrj6VftXi0yzxC3W-d_BuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iLcqzUZ0Ck-Z78lS626m2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_yGKiJmxfzE6HxLbjuYjZzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_mIIdBbQCCEaqnQyKXoN7yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_phf-6MSC-kS6bA7Oa1W-TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0oceliyn7UahFDyUqrBf7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pvRGjtD70kW6s3ZG9tjiZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BWpsZSV2f0yNufbJUffcOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_McmLj4N3TUGjlqTWqM7wYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_4mTezm6jGU2Tt0387MyZ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="Duration_7_11_2024_To_7_11_2024_v4ITxGp84kCgCzwKJY2GDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-07-11</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_Vj8qPsXKFkSdJSawI_izbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kHi1rm9DF0qHlbl4VlnXNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cVbjkTPdU0mE_eF3eSJOLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__iSlOGcFMUmoZ6cGWFMGPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_3_18_2025_To_3_18_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_zFe6GfQFg0-WdZKVa-mIuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-18</startDate>
            <endDate>2025-03-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_9wVA-iTdq0y5EEN-cGB0Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2025AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_RvkyKbPjBEK4lRpESDkZxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_Cn5-JcfDR0qcNSKrdqLIBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_nOFA42sxOU-Rl_psGJmlJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_10sTlzzOBUiJqkaSyPhFIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_XbHYq2dE_UGUYLas9E-Hnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_dtp7DCTeaEab_MgJIlQTmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t0gcHwftwUuD02CHseIM2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_nF7LfoZnP0eXge2zjCLJew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_FbkYU21lwUS7EtQCr_4AQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_SVurPgE3cUqj3MtsSbmcYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_PLtorYr2Ck-Sp5y9dKuZjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_rp6M6rMw0kqyDbuEBr22PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eQXdiGPGikaZ3eg2SLqU6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wMIMNY2AHE6iuFOidhFOtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__892NuyTDUO55WW4yX_gTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_dmsZTMfbJUO8_pb6kAYEhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_QjBKLYfu3UOftjkz3HF_ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZQ9kR5BADEqDL0CF2MD1zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_DFyNXKIPgEKmArMsW0gQGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xATPzL0AD0u1BGyIwTMdLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_ZVXHoCZAKU-UscfH64BvJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfJEoyAEkke0QHoyrB3b0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_TcgKfaj7gUmuOyYcYRMQNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_BggKgNfY0USZzws7g5S5Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_vZatyzeFWUKoVmXlyUbWJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pLWARFxxtEigtbUjIwm1fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_3xEadpqpTkSF6M_S7kMmYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_y8iIi7tP7ku5odeEUQmnRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wV5E2FZOwUyvzrEwdAj5sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_6Gs70ljVX0-T7tm9G61m5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_q2bl4kv7E02ZqMbp6lNHdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_c8VoZNoCiEe75FKiODf1LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CWILIty2pkCdQ4BijefAOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eZWNvJQCgEqQKzXrXgAoJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_gukmUIFIc0iqBD5w9_5uHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_mzVT50GU30m-ov3gJU8nPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ub31Uz9ocEKq02canhoV-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__xc5-0WLKUuKskXTA4r91g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2M20XZ8qKEKKmuDwGSOUAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_5SJ7xQVeDkK5uvXlaHFGNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_jchly8ehyE2tL32MrOzqYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_zeDW5gQHa0eSgEOzkDCljA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_9KILTf0tCkqIWN0JAKeHVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jJnh5eroP0GCxqLxuMWfvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_um20DfDizEmScCi5XDUA2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5nb_8Nk5UEyJL1GzeHRhRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_raXKhs6OsEWwo5Ew1U2bVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Otlhw_JHk0O7aWKiFegSPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MucGrtBbn0W75wiVlwPE0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_uNtDcCko1UyxQn5jeaw1_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EPMTFamnQUKwjPkhv202_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rqZf9XPGIECruOB5VZyF7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bQalOe5mP0y-IbH-aKaF9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Gzu0uopwJUi4ddhDOAgn4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P_Qm7GZ7c02Je803Yy_hCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RUa6fxCGUUmCyEdDsmfEsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2zTp8JJdwEuWNCrhPNXy7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_prSUZ2Vk1keXeIwPcPdHBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NU_bnWHgP0u3mu2YN8K9VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SMshi1uQUeFzJdBkvobzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qG6PA1YTT0mFdtjqdPZt5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_PbHyP1wRzkWN4ZQmOt6QaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2025AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_QLIVwjVCD0quI55_NwdJQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_k-Kye-ecsEGNgr32jEq1GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_dwaRvaALY0OiHiyuF7H6Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2025AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__NmDuNpoV06Ia2-1ixub5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tlr0bx5Lk0umFnmNNGd4sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vgkPllpRpE6UxSwit2t12w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_a7UuWWdWIEerkqNo73GtgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wRxXXGVLeEmgQL5oobXHSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AYpdz6Od1kSaVgoALMsuJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_c2LU5Sjq3USpPWVHuKrnqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RSoI2qJZEEOhEloDLwu0WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_znla2RdJtUGZPRsAxS6c6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VPNR0fGdgUKLLXoJnK_u5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_G6llnlti5k20g5RAYF9w8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_I6j_31dAZkOaSKH03J-dWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7HNwLTU3EyiG-P0bxBDiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zFMC5T7CfU-D5CYy3DpF5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qVwLBWQhP0C7ghgBC6SW2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zeDII7Hjq0G2YU6LERXHGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_S352yBVXFEqz_Y-5P-1a6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_yclrnHVBYEmASqLsg1GLwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_fdyMamGLJEanvbZYQzjwvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7jkhG9xOeECCQCuuL2gEdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nwCEzZi7MUOLNYUtq0AhqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fGM3WlQIOkCMWEoncwc2Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mWRWF3v2JEGzrKxCrcvnRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-03</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_hFX2ulHzj0Wonqj3FtS7mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_9zAfUgBtvEi6ov_a7qysFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_eSxn4MEvbkq34vrvkL54Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-0WZ3XTjU0qB5FR91C9j6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="As_Of_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wQc4SgRdUEicS5pdoMt99A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_YlCT5Ht1C0ySlRxPWi7pMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:PrefundedWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_H1m79MxGEESZ-YgtaaXWXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_sOc9QAFpIkiocfp6gFyENg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_g5MICnEV20aws4tbDts1AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_ZjpISjnlM0KcHdFRUWnJgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_wQUERamXr06SR40KJckzOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:IntraCoastalCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_PVo46D0n4k6-QNq-niA4gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HudsonBayCapitalManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_m8B2gPtU0ESdDuqJrEcuow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:HeightsCapitalManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_piXKgE8oLECIyWjuYpp4BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:ArmisticeCapitalMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_3dKYWVuao0m_9mO0sa3-sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_MIO3Q71fCk-LePjJ87vN6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_UjYm4-P8Z0eyskPAdnjmLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrantsMarch2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:AccompanyingWarrants2024StrikePriceNotAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_4DLfIusP5UOtgAlpPFhBiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_zb2gHq4d8UOFHYORuG5uDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_QFx83QhiX0OZiI-xchFZ7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsStrikePriceAmendedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_W4qAVPHELES2fLUz4KcqKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_Wz5TY_agyEaaN18D5dyCEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OriginalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2024PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2024AccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JbvOkxvjdkmJ6LmN2Rd0Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024AccompanyingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_mCSz1-9t-k2mWS0W2FTi7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_PJWCjTtyrkmhOnNFeBDLAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_J7mlkOfyo0Wnq0ZjtLDsPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_85gLhLsX40qMOQrtKaj64g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_tqFj1TLzLE-k4JolNuUzZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wE7ROgr2I0i_O7Oti3HboA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_ZTqvtqbD3U6ROpLx6ZSAKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cwe90g33bUq1Ikc8GOiESA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_uh20TIQks06ogYnvmFGT-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbpFUXyy0EK9y5v8zoZeAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_pfEI4UeUmEGDh7VF6gPIkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">btai:BioxcelWarrantsAggregateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hYwcEJOWJEqWIWLY9H5bPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q7_XqlxfsUekbErhlfT5sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_aQAnItAirkePUH0weLiB8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e7w7dYu6okaQM-X3HL0_TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_9_2025_u6AbsaWNyUmdMz8bODSDew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jEJ-6V5VnEiejCS4zWZhwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OptionWarrantsMarch2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_gxIXr8TElEqM_4GFJfzkTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_jTTHkTj0IUGtiV9lleK50A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Wdm82uT0iEGxg_xqO2sS2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:November2024PrefundedAccompanyingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Q7rgAxV2QUiFwGQkmwTNSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2024PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4ANH0Ryp-E-Q8Hcq8ycu6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_3_2025_To_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_B7tCQZI3s0-d2yjT-Ceoug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-03</startDate>
            <endDate>2025-04-03</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_sIswvAbnK0SSZ3U84h3-cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_4HyrlxwEJEq43QPtl9kACg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_4_8_2025_To_4_8_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKVZkA0td0assUa8qAOlvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-08</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <context id="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-07-11</instant>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_PoDngmaLSkWSK6VPUhLyWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantShares2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_5K0sWmEJwUa7Vv6SUtp_GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_52So6KoOMEungxS0l0MsEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_bbbkIzsXpkmOj02U5piNIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_SSD-lVaNm0i_gSF3npZAOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_5oKzEf9LG0ObCnvYEfaywQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_CsZ-KkxpOUakCJAE_KixSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterFundingOfTrancheBLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T63fAxu4W0KEPABUzNyrnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3m8_BPw0G0OPp__QShJQ-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hgzEHqmylEubMQ6IsaLqbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_TgEuBFjXIkKWUIDM6bWI0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eKfoQwlPkUyNgcgidh5-dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kzDv9FgG30O_Q6Inae8txA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fJEBahyH2E68UBP6QHFHZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7PXdMmavEKzCaO6o0HcTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qwP76czkUUiKqJXva8OQCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3EM8qIytm0Ke9WUqaxD5ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-12</instant>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tKgYE7x10U2ucISeOhEC6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jAx_EojGEketsDRJCeRRzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_gtTfRBkLIUCQ1ZyESr-Bhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eeKV4-Us0k-PErQbocl43A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_j4lmqYFO50Sd2zbIjyRJlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_OFejCh9UM0ObmQn7f9J2Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_J81r1ZkU4U-0Pa_Y2zZH7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_VHV8Q0yfikOv6dYy4wL6Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">btai:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_hZBCN15vmkq8K-1LPWLUKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_Fkdg6L1osUqn8ergQvAGeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:March2025PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:March2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TM9ElQRCBUSIjpJ3xXkJVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">
        <measure>btai:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g">
        <measure>btai:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      id="Hidden_YLTqldmlUUS3H6k8IvPT2A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      id="Hidden_RFjC0V2uSE6algVQh2dd3Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      id="Hidden_b5JoQh6N7E6brugxzrI3EQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      id="Hidden_mcJCqgCzOEyIE8YyyX6Ltw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_K88lX1VtPkCOy5lnJyRi1A_2_1">0001720893</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_JI-v0c6v4kCvhPCE4AMFxQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_qlDoZb0Cu0qgSie7sM3ryQ_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_HfkoLrwnbE6q_5EdtgzXlg_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_YhLsiArug0SzwB_47HFSvg_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Hidden_9ME-9m_E10Sp7UrzgYpmtg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Hidden_iisnM82KOEe0mVroHBrApg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Hidden_Z4ZTLN7dfECi7gUXpMYpWQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3102000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Hidden_IVJ2GMA4IEyILNkhoDpVvA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      id="Hidden_-dJ9RC_4H0GYGleZlqoJAg">http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      id="Hidden_PWqzCLVmi0aOXGZBWK1euA">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Hidden_J06tcXhzNUq7mLhmMVU1aQ">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q"
      id="Hidden_pBakmeRXJUyagPAg9k_X7w">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg"
      id="Hidden_buvaqAws5kSR-ouHGNXICQ">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw"
      id="Hidden_OkIKnOdDH0OalG3pChCxZg">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_uqronKZxlE6CTNeKnI00aQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_OQ_1pw4nsUmLpKo7YX3G5A_3_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_QW3FQQb4-UyN5e2UnatbXw">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_mJ4AYh3lUkW0vEKxt01n0g_9_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_UJbkk3dTfkyHgXKYYxCsgA">001-38410</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_3Toet0QqHEKSs2X7gO_OGw">BioXcel Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_m3DyQSbeoUydtOnKW85r-Q_2_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc__S31qwkfK0iVhCFzXwwGWQ_2_1">82-1386754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_Gtv4HyyH6UKaaKKDgj_G2g_5_0">555 Long Wharf Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_HpabPqN1aUOJdsgmc-KHrg">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_h_448Cu7wkyqFK6zE6s--Q">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_bozhomSi_USQQEMlY0p1vQ_6_1">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_tAJyAMaMkE6edIvG6nP0Ag">475</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_-kzWJPc_FkirW1Av73Ybgw">238-6837</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_0H7R66owuUWzLGWqUz2Ghw">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_KTA_1gPbJEi8VnMac-larg_5_2">BTAI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_oit348FIzE2XW1Y_TulnJA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_CtbZI3DsDEutbeWLCAJ8rQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_7chLKACUXk-nDLBOMsaB6w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_UOrFs0JcWEeXJnXxAsJPFQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_b6R5GcfDJ0OUvKcocnvPNA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_T3bhdZJjU0WYenyR2R75Pg">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_S6HrDQZYEEaytcIU592gdw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_9_2025_u6AbsaWNyUmdMz8bODSDew"
      decimals="INF"
      id="Narr_oFfN2MDzNEKWCJvzAviJeQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">6056046</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_BGYhB6mlpkOKaN_Ka6p8tg_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">31013000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_2bFgcVrY-kmKrzoV_7s_mw_8_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">29854000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_tsURDEG6G0CfedYN7SZmIA_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">131000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_5x7HHi2eG02KO7EPQWD5_A_10_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">642000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_SDiYJ0n9p0Oad_4uRRSPJA_10_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">679000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_bTIXueNq_UK2IHnnQ0HF-w_11_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4737000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_6h1PfaHjGEiufke9EM_7Ow_11_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_H4a1dbF29UCswaBzgnC5IA_12_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1385000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_ND2rJV_Pw0GlVVF_DZiw-Q_12_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1440000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_wy3Ks9IwQ0aRJ9sq3Vzxxg_13_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">37777000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_y1E_T5bgg0efLv9ckXdIWQ_13_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">37394000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_lcTPOg9yo0GUudXGCrSJUg_14_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">399000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_bNnrhzB73k-bUQ5x-nrpAQ_14_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">475000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_ZL0TQKWZ6U2Kj1-2XzS-nA_15_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc__5uSUnOORUuTcz7Qjk8McQ_15_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">382000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_69aeuP56zk674ylP_VcrZQ_16_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">87000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_j-_u60Qhg0-_KsrfjPJVnw_16_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">87000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_C7qBDBvLSUOFnPGtTSjOYw_17_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38566000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_ONfqky5f0ECjcdtz-N2tuw_17_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38338000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_rwQZ5-cwTEir8Zkr4BypUQ_21_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">15450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_nLQw5JnTXUaLLXDhCfiFYg_21_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">15990000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_oYs5GWsHhkiNCa48A8BGmA_22_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_Nk1Zwm_rCUOlAXI6O0vsiQ_22_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5762000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_Qv2WzGe0DEShHQDgejes_w_23_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5608000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_yGKiJmxfzE6HxLbjuYjZzA"
      decimals="-3"
      id="Tc_8FUXtphr3Eaj_XOb0Ea-QQ_24_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">119000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_phf-6MSC-kS6bA7Oa1W-TA"
      decimals="-3"
      id="Tc_tIY3EB0TUESz6zsGNxibQA_24_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">107000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_mIIdBbQCCEaqnQyKXoN7yw"
      decimals="-3"
      id="Tc_yPBCnxFMPk-f0DBxMhS7VQ_25_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">383000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_0oceliyn7UahFDyUqrBf7g"
      decimals="-3"
      id="Tc_zbQgbTp4-E-dJY7V4ZZCPA_25_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">374000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_j0MjXSH6bUe5UnDvqsiK_Q_26_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25546000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_2jKqUAqLLEeMx1VkQMaKgA_26_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">22233000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_luMPkZzH_E-HxQ5F2QZ81Q_27_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">65000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_LDr-CJDzv0S1LM7monZ3FA_28_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3274000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_CLTy-sXx00SBkPfbb-HueQ_28_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc__8YOi5PczU-nF7AdiM_bmw_29_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">99918000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_ZxIdnx8CbEe4qN_yHLVHXQ_29_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">102508000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_6tSBCZEEoU6P0KKgSZftwg_30_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">128738000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_I43Uqg6FPkiiLFGERsgEQQ_30_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">131439000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="INF"
      id="Narr_n8lO1HXP-0e2Cl6b2VB9Gg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="INF"
      id="Narr_KMHGFR7X1Uua9x0suJasIQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_mP9JZRkO_UGZ_aecHojIoA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Narr_ScfVgRbxe0O9nyhnA2zlSQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_-esvLFtPjUqMJzAyEeb31Q"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Narr_WppOmELbFEOGX9S2xaQNog"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="INF"
      id="Narr_TwpDJNT5MEmZCUVUUMdJcg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="INF"
      id="Narr_bb60RFBYykOAZRgCmzdmYA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_O5tGoNMebk-sIH1PW3ZJuQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Narr_vyAD-cHgdU2yicBxgVyzzg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_uPbFPdeXeEqxsCJv3OWqXg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5468000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Narr_gRrVLbUr0U6pFP6OYsdicg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3102000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_G1K64MlSl0CHtsPXL-2oXw_35_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">59000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_q-2GQt4TmEqkSSrueBKyDw_35_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">49000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_qcegY7ZGx0aYxt33eF2IYA_36_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">567220000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_QsvA3EsGhEyYxFe0C9azvQ_36_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">557047000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_TnrqGR8mP0aXP9dFF77pVg_37_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-657451000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_V4aTZ23GREa8-nUAJAvf2A_37_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-650197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_cP-sSgxtqEaFScwD0t_3Rw_38_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-90172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_i493rVQhoECoM7XZuKu7Qw_38_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-93101000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_3fSH791VHUuzjt-Dkwl47Q_39_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38566000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_a8RIE9E5CkuM_yIMsKCScA_39_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38338000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_20FgNCTGDEqOvbq5YnLvXQ_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_NcSVyU0_EkavnkzwsIRYOA_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_Fu6OLYc2G0WE2UdsjYFdLw_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">14000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_FKg-57WjykGKUksGQKO6Qg_8_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">80000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_NHBu7OCZB02a5bGvXTIDUA_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4554000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_xOdN4DI2hEqGCQWTWLakTQ_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">11401000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_Ur41bK3Qx0OzQgsuMLnAyw_10_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5699000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_qgToWbWB6kWwVWPwXtloAg_10_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">13264000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_ja7yb9mb-0env_3baEk6gQ_11_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10267000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_e3BPtX1pgEi2S-tVedcvFA_11_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">24745000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_9o3q5H7X0E-63S4Z-TV8ig_12_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-10099000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_IUW7U6QHqkuL5u4MELpGbQ_12_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-24163000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_3wGexc4p1U-QrVmjEsSvsg_14_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3993000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_-JvVuM2zmEuLnpONyOSBPg_14_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3607000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_KSqPBe-tY02XPSmmkhkADw_15_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">279000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_eQBG_Kai70ODDPlQbu2VVw_15_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">947000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_8HNPbgLYW0u9JDABI8ZsLQ_16_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6559000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_a9PHp0HVoU-uQjGBU0amcQ_16_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_6EtiTmfH-E6wd__XmOAyEA_17_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_zaC6UztEYU-waPxXa8OLqw_17_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="2"
      id="Tc_4cDgM4P3tkazxtBTiea7VQ_18_3"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">-1.5</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="2"
      id="Tc_4cDgM4P3tkazxtBTiea7VQ_18_3_2"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">-1.5</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="2"
      id="Tc_-yhV02bAw02P5w40SvQVKg_18_6"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">-13.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="2"
      id="Tc_-yhV02bAw02P5w40SvQVKg_18_6_2"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">-13.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_ukyjyq9cZ0KQdSatgsuSTg_19_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4834000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_ukyjyq9cZ0KQdSatgsuSTg_19_3_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_aSOir70HNUitltrSq1esVA_19_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1929000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_aSOir70HNUitltrSq1esVA_19_6_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1929000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g"
      decimals="-3"
      id="Tc_TVku3ywrDUqG03p9usSRkw_4_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1871000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_um2RaYtPHEidvDY1PNmY6g"
      decimals="-3"
      id="Tc_HaTAU02hM0O6ZWsOSf5CnA_4_5"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zYjQFfZEOk2XX8euLUmtMw"
      decimals="-3"
      id="Tc_s6jjjVsxvk64Whx48MCIbg_4_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">534060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_x1Uqp2p3T0mT8txSjrqjPg"
      decimals="-3"
      id="Tc_4e3Xb6ufCkOhbytn0ZOjhQ_4_11"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-590598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA"
      decimals="-3"
      id="Tc_rssXW_pXPEKUfxPONp-OxA_4_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-56508000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JAHXTaO7WkO65OTNPeHiow"
      decimals="-3"
      id="Tc_Q0skpKvPkU2uKA0DIouRvw_5_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">231000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JAHXTaO7WkO65OTNPeHiow"
      decimals="-3"
      id="Tc_XY3eT6xxbEC8_jiQjz_YeA_5_5"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg"
      decimals="-3"
      id="Tc_gYKSOkCk606zg8uNrZnSdg_5_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_6F1loFMOYEGUa7_CZh5XCQ_5_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg"
      decimals="-3"
      id="Tc_dwqspjrGYka-gGbaEmykEw_6_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_1c0NOqO4FEyEIAL_xJotEw_6_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3433000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg"
      decimals="-3"
      id="Tc_p4-EVVrinEO7OGZwEA1dYw_7_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_O5wp-YkNpkqT-IGQ7yOPeA_7_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xNLdZVlL-kOXTqtCSf2QUg"
      decimals="-3"
      id="Tc_rubojnGGi0mB7QUgXRAEIQ_8_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3570000</btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_v-U7yb_p80amio2xP9snVw_8_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3570000</btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BWpsZSV2f0yNufbJUffcOw"
      decimals="-3"
      id="Tc_htRKlPn9OUO2pkhd6bGYZQ_9_11"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_hp2qvvFVh0q8z2A-QOoKKw_9_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fGM3WlQIOkCMWEoncwc2Vw"
      decimals="-3"
      id="Tc_d9_tKbdD9kSXhLE_CsdCUQ_10_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">2102000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fGM3WlQIOkCMWEoncwc2Vw"
      decimals="-3"
      id="Tc_EpMvTVG6kkKpGO57H7Qj0g_10_5"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JZy4BCURekiYxiqHcge_Zw"
      decimals="-3"
      id="Tc_2iSD650MUU-isRXi7tYuYQ_10_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">544992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kELM8qU0EkWCrI-UkaL8Ng"
      decimals="-3"
      id="Tc_7rkL1AJs1kOZt06uCNOmqA_10_11"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-617389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ"
      decimals="-3"
      id="Tc_imMOsm49pk25SJuovjqVOw_10_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-72363000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nwCEzZi7MUOLNYUtq0AhqQ"
      decimals="-3"
      id="Tc_5kqnn53Pb0qK-Q587rn1GA_15_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3102000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nwCEzZi7MUOLNYUtq0AhqQ"
      decimals="-3"
      id="Tc__3-PPNOaeE6LXvIV80S_gg_15_5"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHjW0xYSkU2ePhegrPo-8A"
      decimals="-3"
      id="Tc_YA0tEoWVtEiqmbAljxFfDw_15_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">557047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_10N7rnTIFU-ky4gxaDiVmg"
      decimals="-3"
      id="Tc_esPPD851_EaJnN9zbrbaRA_15_11"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-650197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_HHnb6Y4S10GnuAq_EmcELg_15_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-93101000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w"
      decimals="-3"
      id="Tc_k-xb6n3GlEuzEYkvZF4K9A_16_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">2358000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w"
      decimals="-3"
      id="Tc_cUZGFe7aRE6V8X6KrgGh5Q_16_5"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ"
      decimals="-3"
      id="Tc_Qr8xZhy8D0y5HEMU7sH-hA_16_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">471000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_o068Q1lUzkqrcC13yEIP3w_16_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">481000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ"
      decimals="-3"
      id="Tc_FStI0W4O7EKWJpFSUiqJqg_17_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_d4slw6FoJUiXdAF-g7xRgw_17_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ"
      decimals="-3"
      id="Tc_2x30uDGRzEqeJPZKnr3Tlg_18_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">9523000</btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_jQZm5f_nm0e6I0pkyZKfnQ_18_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">9523000</btai:AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C46H2V3Da0m1tIIiDBcj5w"
      decimals="-3"
      id="Tc_ZXfhlb9XnkSllCRoMzkTMg_19_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">8000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_i3Ys_7Mmd0qp8_KOjERJgQ"
      decimals="-3"
      id="Tc_HDQYc2VU90GEjKOxFbAAuQ_19_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-1000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_3pv0qyYnXEGinIxrVhNXjA_19_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-1000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pvRGjtD70kW6s3ZG9tjiZQ"
      decimals="-3"
      id="Tc_8-434SxgzkekhlgMoASdCw_20_11"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_bHZSbHjFwESV0tG2U_4n-g_20_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7jkhG9xOeECCQCuuL2gEdA"
      decimals="-3"
      id="Tc_qpaNYeAee0CyOEluIbyC7w_21_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5468000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7jkhG9xOeECCQCuuL2gEdA"
      decimals="-3"
      id="Tc_yTaFV6-ueESed8fQtx0Z8Q_21_5"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ev2K8DxaV0a9uKxJ00_XoQ"
      decimals="-3"
      id="Tc_6KmkgtYbsEmodcgEZ97Ljw_21_8"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">567220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v4f9SlUsOUa4HdcmJWR1dQ"
      decimals="-3"
      id="Tc_xjMldEq5tEKw_UDctJgQEw_21_11"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-657451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_Q-Q1P2l6Pk-fCd9TaG7oLg_21_14"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-90172000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc__hsh5T_8MEuEAC7jd5rfcw_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_28zsInTZbUm56TedMJk4ag_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_9PxNyn2bu0aLHMRTR_LkzQ_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">76000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_GqerzlI8G0aCFFH0t5gLcw_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">78000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_Pn_24HVvgkO5cMLUuoT-Eg_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">350000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_Eq3tVeOuC0ap40Szj-QjWw_7_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">43000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_z5uVzBvPy0WekLhsNlYkKA_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6559000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_TR67a-ZU3kikNR-ppjsnWQ_8_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_gqvkWElcKk6iYPPDdIk94A_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">180000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_Hazdtor4ZkWJ54peQZSQbw_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3433000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_wChajgkgK06l4ZycssWV8A_10_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2668000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_9_FYEB55HEOcGddgMSkW9w_10_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1216000</us-gaap:PaidInKindInterest>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_0ofR3vVHdU-OwJjl7VsVZw_11_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">79000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_m5NYo-ly3kSvCYIuAF0vOQ_11_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">75000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_RJD9o-BIyUmLZrIBsr6vuA_13_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-131000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_ARj6vv2CnUusdYsUqAKpJg_13_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">307000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_gpkcJsQXdUqLWfytQtBjGg_14_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-37000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_65Sy3DBmu0KUzxYMHfMnJw_14_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">448000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_OXt_CFlMEE2VLgzxNvWSZw_15_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-608000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_N06ZirE7tUWLNa7bK9OPHQ_15_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-901000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_m_WxvdYfIEidXKnA2CTYRA_16_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-2269000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_MYLHrlH87EioC5qkbvVGCQ_16_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4826000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_e9RWj5SQGU-M-IlqvgbMMA_17_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-619000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_QZ3i24hHxU-SX6yK7MVBjA_18_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-90000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_uX_eco8BcEmwJ1mwgJhSQQ_18_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-83000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_87gn77u-sUWoT9YHPRgtJQ_19_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-12043000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_VIKbdc6RUkeOWNpupiBmSA_19_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-17706000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_UlCYuE0jnEeorzpK1dTccw_26_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">14006000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_ob87L1D97kq5XErwuR61ig_26_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">26743000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_jSlyNVEyckiOoKugRsBNbg_27_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">803000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_NKqqnxg8xEyWX1zQvNMl5A_27_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">117000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_VLdiwQx7GkCHJfqaF5OCGQ_28_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_TdwsSd3qu0atgjgo52Izfg_29_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">13202000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_UBnYETnO4k6V8KTHUilaBQ_29_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">26626000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_zoEdxoPaNkWfQTNj80J1KQ_31_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_ryFTv1NTu0azNgTzGkFWXw_31_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">8920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_UNt8P3memkS5tjWGx0Rnxw_32_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">29854000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA"
      decimals="-3"
      id="Tc_Np3MJU2XOUyeyAyB75Ii6w_32_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">65221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_tsQaEGSb6E2o-lucvY179w_33_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">31013000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ"
      decimals="-3"
      id="Tc_2cRrhxBqdkS33_IVLSKu-w_33_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">74141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_FQOmFq6-kk6afqUPSHMVOA_36_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">224000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_QKpiBihNwUWEomU_cTelLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;1. Nature of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BioXcel Therapeutics, Inc. (&#x201c;BTI&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company utilizing artificial intelligence (&#x201c;AI&#x201d;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#x2019; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#x2019;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has proven its potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As used in these condensed consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#x201c;BioXcel LLC&#x201d; refers to the Company&#x2019;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#x201c;OnkosXcel&#x201d; refers to BTI&#x2019;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On April 6, 2022, BTI announced that the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration (&#x201c;FDA&#x201d;) approved IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&#160;(dexmedetomidine or &#x201c;Dex&#x201d;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&#160;is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, was commercially available in doses of 120 and 180 micrograms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s most advanced neuroscience clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#xef;ve to checkpoint inhibitors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#x2019;s principal office is in New Haven, Connecticut. &lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_XvkIWEFRIECovXReHQztDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2. Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The accompanying unaudited interim condensed consolidated financial statements do not include all the information and notes required by Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) in the U.S. The accompanying year-end balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of March 31, 2025, the results of its operations for the three ended March 31, 2025 and 2024 and its cash flows for the three months ended March 31, 2025 and 2024. The results for the three months ended March 31, 2025 are not necessarily indicative of results to be expected for the year ending December 31, 2025, any other interim periods or any future year or period. The accompanying unaudited interim condensed consolidated financial statements of the Company should be read in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March&#160;28, 2025. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying condensed consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of March 31, 2025, the Company had cash and cash equivalents of $31,013 and an accumulated deficit of $657,451. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $7,254 and $26,791 for the three months ended March 31, 2025 and 2024, respectively, and had net cash used in operating activities of $12,043 and $17,706 for the three months ended March, 2025 and 2024, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;The Company&#x2019;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement (as defined in Note 9, &lt;i style="font-style:italic;"&gt;Debt and Credit Facilities&lt;/i&gt;), its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#x2019;s assessment that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report on Form 10-Q. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;This going concern evaluation takes into consideration the potential mitigating effect of management&#x2019;s Reprioritization (as defined in Note 4, &lt;i style="font-style:italic;"&gt;Restructuring&lt;/i&gt;). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#x2019;s Board of Directors.&#160; The Company&#x2019;s Reprioritization was approved by the&#160;Board of Directors on August 8, 2023; however, such plans, including the additional restructuring actions taken in the second and third quarters of 2024, will not mitigate the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, &lt;i style="font-style:italic;"&gt;Debt and Credit Facilities&lt;/i&gt;) or other potential sources of debt or equity capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#x2019;s cost structure and operating plan. Management&#x2019;s plans to improve the Company&#x2019;s liquidity and reduce its operating expenses and capital requirements include, among other actions, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#x2019;s control:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;raise funding through the sale of the Company&#x2019;s equity securities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;raise funding through third-party investments in or other strategic options for OnkosXcel;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;raise funding through debt financing and/or restructuring of its existing Credit Agreement; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;establish collaborations with potential partners to advance the Company&#x2019;s product pipeline;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;establish collaborations with potential marketing partners;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;reduce overhead and headcount to focus on core priorities; and/or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;any combination of the foregoing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt;"&gt;If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_k2sFvzopJ0StYyicaMInsw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">31013000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_fpZrSxJqPE6itvqjTw5T5A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-657451000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_IR4YQXSQoUSiJjuX2uxF6w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Narr_j7HweqjjmEy-1PK4rCu_cA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_SZ4pSdvk10OOVBxrnApwBw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-12043000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Narr_CxJMzn0QQk6wHnrkbn9ACQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-17706000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_V88yNeFo3UKe0zTDkjYXww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;3. Summary of Significant Accounting Policies &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;There have been no material changes to the significant accounting policies previously disclosed in Note&#160;3 to the Consolidated Financial Statements in the Company&#x2019;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures beginning in the first quarter of fiscal year 2025. For additional information, see Note 17,&#160;&lt;i style="font-style:italic;"&gt;Segment Information&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In March 2024, the FASB issued ASU 2024-01, Compensation &#x2013; Stock Compensation (Topic 718) &#x2013; Scope application of profit interest and similar awards, which clarifies how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or if it is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. The adoption of this guidance did not have a significant impact on our financial statements, and the Company does not expect this guidance to have a material impact prospectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements effective in future periods&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Income statement-reporting comprehensive income-expense disaggregation disclosures, which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the effect of adopting this guidance on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_EbWPiUw9i0yR8pZMzlMHUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_qc7rmp_GAUuykOWzcItPKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted the new standard in fiscal year 2024 for annual and retrospective reporting periods with all interim disclosures beginning in the first quarter of fiscal year 2025. For additional information, see Note 17,&#160;&lt;i style="font-style:italic;"&gt;Segment Information&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In March 2024, the FASB issued ASU 2024-01, Compensation &#x2013; Stock Compensation (Topic 718) &#x2013; Scope application of profit interest and similar awards, which clarifies how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or if it is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. The adoption of this guidance did not have a significant impact on our financial statements, and the Company does not expect this guidance to have a material impact prospectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements effective in future periods&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Income statement-reporting comprehensive income-expense disaggregation disclosures, which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is evaluating the effect of adopting this guidance on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_fIyalb_42ky0c2Fl5nDYQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note 4. Restructuring &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On May 8, 2024, the Company took actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. The Company reduced its workforce by approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;15%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and notified impacted employees on May 8, 2024. All related restructuring costs were paid in the second quarter of 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On September 17, 2024, the Company reduced its workforce by an additional &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;28%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; to extend its cash runway and prioritize clinical development of BXCL501. &lt;/span&gt;The Company completed the Clinical Prioritization in October 2024, paid $475 of the related costs during the first quarter of 2025, and expects to pay approximately $128, the remaining costs, in the second quarter of 2025, which are included in Accrued Expenses on the Condensed Consolidated Balance at March 31, 2025.&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_5_8_2024_To_5_8_2024_FZp7GPdyrUG_vHhSf2SCHQ"
      decimals="2"
      id="Narr_xCA0EtwwhUWFXk6Ug091ZQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.15</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_9_17_2024_To_9_17_2024_c8nGfcMfH0inkxdc7P07ZA"
      decimals="2"
      id="Narr_G0ygoEtRS0SlG-DvPXAoIA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.28</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_zxSHi03phUyvr5v2MlI9cg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">475000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_OpupRuwi7EKxoz5TEKruSA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">128000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_1VNM2pQxQ0-vpqRGB8ylGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;5. Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 642&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;The Company recorded inventory write-downs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$0&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$45&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; for the three months ended March 31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_fNrUpF509EmLhtlgDFcfQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 464&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 642&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_Jax1uo4Ja0i-KA5eD9eaCA_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">464000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_TVE56Lnb806QK9SBfsbsXA_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">506000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_reVjJ22oAUu2GfHn07XaNg_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">178000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_0ORLjJA100uUVCSSgwMmBg_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">173000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_nA-YEIIbr0OqnaGJoZUuCg_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">642000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_Ec7WggKvVEm1XshUQh5i5g_7_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">679000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_x_X-fbJCq02apQz6JEugHw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Narr_s9A_0jYASkWsyva0Qd5VKg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">45000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_fHSWQ9KOsEuBixUxoSENRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;6. Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment, net consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,578)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,502)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Depreciation expense was $76 and $78&lt;span style="white-space:pre-wrap;"&gt; for the three months ended March 31, 2025 and 2024, respectively.  &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_G3Jon0HWSEiRwxHnxstD8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,578)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,502)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_P-yi1ob4hUyuvFlo5q8PKA"
      decimals="-3"
      id="Tc_Vl0sNv-nZEyv-E1abjO6gA_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lMS_6iH8DUiU4QxSYfIVZA"
      decimals="-3"
      id="Tc_V67unltS7EeTJ4ROhAogBw_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_YzddE2_98UmIfS9DblB46w"
      decimals="-3"
      id="Tc_Dtqaytnjhku4khxFDdcIJA_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_i3zFP68HVkiSR0fcAIqY9g"
      decimals="-3"
      id="Tc_zgSPRF-F0EK6ELXIwmxvwQ_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ExIBEjJWbUexxXRMxChHSQ"
      decimals="-3"
      id="Tc_06JQ8hAsX0eSghWdqFA_Ng_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2PQahnIyZk-fOICX6AbWrQ"
      decimals="-3"
      id="Tc_6mbVL-l6UUWFIS4JpZJVEw_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_m1j2m1BFtky3EWz5VfXFYA_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_1HpcbyJ-yE2QmmigIZl5eg_7_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_59A1ZxHpfEuscbe77tUsJA_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1578000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_U_Xdq9p2dEW9bV_x8DCGQg_8_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1502000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_10lvV1EszkWDRNXYjFkT7Q_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">399000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_EDbD5zEsa0qsdtI8vw2sWA_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">475000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_YE9vVST5z06q0AZadlJL2A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">76000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Narr_JJ18TKyzAUGFqEgGUaWLdg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">78000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_m5yR8PzQ9k6e4j9RPxF5Sw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;7. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,604&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 423&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued restructuring costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,762&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_gctuQFYE80G-sbMARVNKmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,604&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 423&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued restructuring costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,762&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <btai:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_Z5ESN5GuJEycXAN6noBRRQ_3_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2011000</btai:AccruedResearchAndDevelopmentExpenses>
    <btai:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_lk3_VuR-1Uu-v1QcMZsdzw_3_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3107000</btai:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_m5M_sFXLh0KifYMCUGcQgQ_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">21000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_gMPJeEI_H0aaLT2FM7C1CQ_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">35000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_Rfcnz5MiRECwLXdU-wuQRw_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1338000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_M6mh63iSvUerFETtAbilCA_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1604000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_LLvKu83rdEu8VWdYlkZYgQ_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">65000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_S9VfD9-H60SAw4Kak49QBw_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">91000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc__J7IAcaogUCVgzWft3InKQ_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">423000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_6Ftd1Z78zUGQQdI-xERHDw_7_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">322000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_oGxJfPhMxkqh2XdZGKoYow_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">128000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_FEhyLbHm8EWZFdf76-9q0Q_8_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">603000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_bQOjifLnEU2DIhHk-4h-Sg_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_dKjnAwleYkuMwCNedF8LCg_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5762000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_2Z25b_qQsEGkR9cB5av9Hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;8. Transactions with BioXcel LLC&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#x201c;Services Agreement&#x201d;), pursuant to which BioXcel LLC has agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Under the Services Agreement, the Company had an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. The Company agreed to pay BioXcel LLC $18 per month from March 13, 2023 to December 31, 2024 in exchange for this option. This option was not exercised. However, BioXcel LLC continues to perform certain administrative services under the terms of the original contract. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10,000 in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30,000 in the aggregate. The Company did not exercise its option to renew the agreement for product identification and related services utilizing BioXcel LLC&#x2019;s EvolverAI. Subsequent to December 31, 2024 no development activity has been carried out by BioXcel LLC and none is contemplated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Service charges recorded under the Services Agreement for the three months ended March 31, 2025 and 2024, respectively were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of March 31, 2025, there were no outstanding service charges related to the Services Agreement included in Due to related parties in the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement
      contextRef="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_TM9ElQRCBUSIjpJ3xXkJVA"
      decimals="-3"
      id="Narr_b8PaEwpQZkezcHfO80YscA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">18000</btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement>
    <btai:CollaborativeArrangementMilestonePaymentsPotential
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_Fkdg6L1osUqn8ergQvAGeA"
      decimals="-3"
      id="Narr_kLmhGMbgtUyd0_8e6pBwxQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10000000</btai:CollaborativeArrangementMilestonePaymentsPotential>
    <btai:CollaborativeArrangementMilestonePotentialPercent
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_hZBCN15vmkq8K-1LPWLUKg"
      decimals="2"
      id="Narr_w3uXHUhZaEqA-pYX9paT3A"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.03</btai:CollaborativeArrangementMilestonePotentialPercent>
    <btai:CollaborativeArrangementMilestonePaymentsPotential
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember_hZBCN15vmkq8K-1LPWLUKg"
      decimals="-3"
      id="Narr_-BqdsHKOakmkBw4M4ESfNA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000000</btai:CollaborativeArrangementMilestonePaymentsPotential>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_cAIYV4gsg0q9TD5XNV16Fg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA"
      decimals="-3"
      id="Tc_Xf7eyBrRI0uZq9Wjw7M0IA_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">149000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA"
      decimals="-3"
      id="Tc_v4artByUh0eHg3w2HNCZMg_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">186000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA"
      decimals="-3"
      id="Tc_aZm7WAyr4EGT2PVUe0gaPg_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">68000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA"
      decimals="-3"
      id="Tc_nG6Y-Qdya0OGeVCUjHtRUw_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">48000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_KPLyl7bgDEWnHNGg82vipA"
      decimals="-3"
      id="Tc_WXbfoIsVqUqq_RCRt6eg-Q_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">217000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_e1Ma8xDqRkK9p5shgGpfrA"
      decimals="-3"
      id="Tc_yIoL3gyKbE-xipN1ifobdg_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">234000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_iLcqzUZ0Ck-Z78lS626m2g"
      decimals="-3"
      id="Narr_PVbJO_fkVku13w4GvjM9Ng"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_JYnfHra8vkyWm71oFneiAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 9. Debt and Credit Facilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Debt, net of unamortized discounts and financing costs, consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit Agreement and Guaranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payable-in-kind ("PIK") interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,722&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt premiums, discounts and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,865)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,214)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less current portion of long-term debt &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,608)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#x201c;Credit Agreement&#x201d;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Oaktree Fund Administration LLC (&#x201c;OFA&#x201d;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#x201c;RIFA&#x201d;; and together with the Credit Agreement, the &#x201c;OFA Facilities&#x201d;) by and among the Company, the purchasers party thereto (the &#x201c;Purchasers&#x201d;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $260,000 in gross funding to support the Company&#x2019;s commercial activities of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#x2019;s disease, and for general corporate purposes. The Lenders and Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and First Amendment to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#x201c;First Amendment&#x201d;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from $25,000 at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#x2019;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.26;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On December 5, 2023, (the &#x201c;Second Amendment Effective Date&#x201d;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#x201c;Second Amendment&#x201d;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $202,319 in senior secured term loans, including the initial Tranche A of $70,000, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $72,319. In addition, the $30,000 in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#x201c;Tranche A-2 Term Loan&#x201d;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865 at any time outstanding in OnkosXcel, increased from $30,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;First Amendment). As of March 31, 2025, $80,000 in commitments under the Credit Agreement remains unfunded. The blended effective interest rate on the Tranches A-1 and A-2 as of March 31, 2025 was approximately 15.3%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The remaining tranches may be borrowed at the Company&#x2019;s option subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $20,000 and is available upon satisfaction of certain conditions and financial milestones. Tranche B expired on December 31, 2024. Tranche C of the Credit Agreement is $30,000 and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $50,000 and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025. As of March 31, 2025, Tranches C and D, totaling $80,000, remain available for borrowing if the milestones above are met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;200&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-basis point original issue discount and bear interest at a variable annual rate of TERM &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_buvaqAws5kSR-ouHGNXICQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; (but not less than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;2.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; or more than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;) plus &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;7.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;8%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum is, at the Company&#x2019;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;0.75%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s obligations under the Credit Agreement are guaranteed by BTI&#x2019;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#x2019;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) a pledge of all of the equity interests of all of the Company&#x2019;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#x2019; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $15,000, (b) from and after the funding of the Tranche B loans, $20,000, and (c) from and after the Company&#x2019;s satisfaction of the funding conditions for the Tranche C loans, $15,000, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $37,500), provided that the minimum liquidity amount will in no event exceed 50% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#x2019;s fiscal quarter ending on December 31, 2024 (such six-month period the &#x201c;Revenue Covenant Measurement Period&#x201d;), that requires it and its subsidiaries&#x2019; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#x201c;Revenue Covenant Measurement Testing Date&#x201d; and the covenant described in this clause (ii) the &#x201c;Revenue Covenant&#x201d;). The Company&#x2019;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#x2019;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;minimum required revenue amount and the Company&#x2019;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#x201c;Employee Holdings&#x201d;), a subsidiary of BTI, and their respective subsidiaries, the &#x201c;BXCL701 Subsidiaries&#x201d;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#x2019;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#x2019;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events, including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least 20% of the equity interests in the BXCL701 Subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#x2019;s secured creditors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and Third and Fourth Amendments to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#x201c;Third Amendment&#x201d;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#x2019;s independent auditors that contains a &#x201c;going concern&#x201d; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#x2019;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$40,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in gross proceeds from a registered public sale of the Company&#x2019;s common stock, warrants and/or pre-funded warrants&lt;/span&gt; on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 20, 2024 (the &#x201c;Effective Date&#x201d;), the Company entered into the Fourth Amendment to the Credit Agreement and Guaranty (the &#x201c;Fourth Amendment&#x201d;), which amended the Credit Agreement. Pursuant to the Fourth Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#x2019;s independent registered public accounting firm that contains a &#x201c;going concern&#x201d; or similar qualification with respect to the Company&#x2019;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#x2019;s independent registered public accounting firm&#x2019;s report contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 contains a &#x201c;going concern&#x201d; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#x201c;Minimum Liquidity Amount&#x201d; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $25,000 from $15,000, unless and until the Company has received, after the Effective Date and on or before November 30, 2024, at least $50,000&lt;span style="white-space:pre-wrap;"&gt; in gross proceeds from the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.  On March 27, 2024, the Company received &lt;/span&gt;$25,000 in gross proceeds from the issuance of its common stock, warrants, and pre-funded warrants discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, satisfying the April 15, 2024 covenant requirement of the Fourth Amendment. During the third quarter of 2024, the Company received $467&lt;span style="white-space:pre-wrap;"&gt; of gross proceeds from the issuance of the Company&#x2019;s common stock.  As of September 30, 2024, the Company had satisfied &lt;/span&gt;$30,943 of the $40,000 required to maintain the Minimum Liquidity Amount and the $50,000&lt;span style="white-space:pre-wrap;"&gt; gross proceeds requirement.  As a result, at September 30, 2024, the Minimum Liquidity Amount increased to &lt;/span&gt;$25,000. As of March 31, 2025, we were in compliance with all restrictive and financial covenants under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and Fifth Amendment to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 21, 2024, the Company entered into the Fifth Amendment to Credit Agreement and Guaranty and First Amendment to Fourth Amendment to Credit Agreement and Guaranty (the &#x201c;Fifth Amendment&#x201d;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Oaktree Fund Administration LLC (&#x201c;OFA&#x201d;) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the Third Amendment to Credit Agreement, dated as of February 12, 2024, and the Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024 (the &#x201c;Fourth Amendment&#x201d;), the &#x201c;Existing Credit Agreement&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Fifth Amendment, the Lenders agreed to, among other things, (i) waive the Credit Agreement&#x2019;s covenant that the report and opinion the Company will receive from its independent registered public accounting firm with respect to the financial statements for the year ending December 31, 2024 will not contain a &#x201c;going concern&#x201d; or similar qualification, (ii) permanently waive the Credit Agreement&#x2019;s minimum revenue covenant, and (iii) waive the Fourth Amendment&#x2019;s requirement that the Company raise, after the effective date of the Fourth Amendment and on or before November 30, 2024, at least $50,000 in gross cash proceeds from the issuance of its common stock, warrants, and/or pre-funded warrants, and/or in cash and/or non-cash consideration from newly entered-into partnering transactions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Fifth Amendment includes a new capital raising covenant requiring that the Company receive (A) after the effective date of the Fifth Amendment and on or prior to November 27, 2024, at least $7,000 in gross cash proceeds from the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants(&#x201c;Raise 1&#x201d;), (B) after the effective date of the Fifth Amendment and on or before March 15, 2025 (provided that the Company was required to use its commercially reasonable efforts to satisfy the requirement by February 15, 2025), at least $18,000 in net cash proceeds (including the proceeds of Raise 1) from (i) the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants, (ii) non-refundable cash consideration from partnering transactions entered into after the effective date of the Fifth Amendment (so long as such partnering transactions would not require the Company or any of its &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), (iii) the issuance of the Company&#x2019;s subordinated debt (subject to terms set forth in the Fifth Amendment), and/or (iv) asset sales permitted pursuant to the Credit Agreement or consented to by the Lenders (such capital raise, &#x201c;Raise 2&#x201d;), and (C) after the effective date of the Fifth Amendment and on or prior to the earlier of (x) August 15, 2025 and (y) the date that is 30 days after the final data readout of the SERENITY At-Home Phase 3 trial, at least $29,000 in net cash proceeds (including the proceeds from Raise 1 and Raise 2) from the same permitted capital raising activities listed in the preceding clause (B). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Fifth Amendment and the required capital raises described in the preceding paragraph, the Lenders agreed to modify the Credit Agreement&#x2019;s minimum liquidity covenant to require minimum cash liquidity of $7,500 (instead of $25,000) from and after the closing of Raise 1until March 30, 2025. On March 31, 2025, the minimum liquidity amount increased to $10,000 and on September 30, 2025, the minimum liquidity amount will further increase to $15,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Fifth Amendment, the Company paid a one-time amortization payment of $2,500 principal amount, together with accrued and unpaid interest and a portion of the prepayment fee and other fees payable in December 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Fifth Amendment also modifies the interest rate of the loans provided under the Credit Agreement from a floating rate of Term &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_OkIKnOdDH0OalG3pChCxZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; plus &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;7.50%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum, to a fixed rate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;13%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum, retroactive to and effective as of September 30, 2024. For the quarterly payment dates ending December 31, 2024, March 31, 2025, and June 30, 2025, the Company will have the ability to make interest payments of up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per annum &#x201c;in-kind&#x201d; by capitalizing and adding such interest to the outstanding principal amount of the loans under the Credit Agreement. In addition, pursuant to the Fifth Amendment, the Company will be required to make quarterly amortization payments equal to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5.0%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the principal amount of funded loans, together with applicable prepayment fees, beginning on March 31, 2026. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On the effective date of the Fifth Amendment and as a condition to effectiveness thereof, the Company&#x2019;s wholly owned subsidiaries OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (collectively, &#x201c;OnkosXcel&#x201d;), which previously provided unsecured guarantees of the Company&#x2019;s obligations under the Credit Agreement, granted security interests in substantially all of their assets to support such obligations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Fifth Amendment amends the negative covenants under the Credit Agreement to remove flexibility the Company and its subsidiaries previously had thereunder to undertake various transactions, including, without limitation, with respect to potential dispositions of OnkosXcel or out-licenses by OnkosXcel of its intellectual property. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Fifth Amendment, the Company committed to appoint a new independent board director (subject to customary background checks, applicable law, confirmation of independence and Nasdaq rules), and to provide the independent director with various privileges and committee memberships on the board of directors of the Company (including the appointment of such director on committee to be formed to focus on capital raising and evaluate strategic options). The Company also agreed to engage an investment banker reasonably acceptable to OFA and the Lenders to assist the Company and its board of directors with evaluating and exploring strategic options. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company also agreed to covenants requiring that the Company&#x2019;s cash expenditures be monitored by the Lenders according to a board-approved budget provided to the Lenders prior to the signing of the Fifth Amendment, which cash budget will be updated on a bi-weekly basis going forward. The Company will not be permitted to make disbursements for any two-week period in excess of 115% of the aggregate budgeted amount of disbursements for the applicable period. Finally, pursuant to the Fifth Amendment, the Company is restricted from paying cash bonuses for its employees or executives during the fiscal years 2024 and 2025 without OFA&#x2019;s consent or increasing the cash compensation for fiscal year 2025 for certain senior officers of the Company from their compensation for fiscal year 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Sixth Amendment to Credit Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On March 4, 2025, the Company entered into the Sixth Amendment to our Credit Agreement (the &#x201c;Sixth Amendment&#x201d;), pursuant to which the Lenders agreed to, among other things, delay the date on which the Company is required to engage an investment banker (which date has been subsequently extended to July 31, 2025).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants and Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to 17 shares of the Company&#x2019;s common stock at an exercise price of $320.64 per share (the &#x201c;Closing Date Warrants&#x201d;). Pursuant to the amendment and restatement of the Closing Date Warrants, dated December 5, 2023 (the &#x201c;Amended and Restated Closing Date Warrants&#x201d;), the exercise price of the Closing Date Warrants has been reduced to $58.3232 per share. In addition, the Company granted new warrants to the Lenders to purchase up to 4 shares of the Company&#x2019;s common stock (the &#x201c;2023 Warrant Shares&#x201d;) at an exercise price of $58.3232 per share (the &#x201c;2023 Warrants&#x201d;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;and together with the Amended and Restated Closing Date Warrants, the &#x201c;Warrants&#x201d;). The Amended and Restated Closing Date Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holders election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#x2019;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#x2019; election to proceed with such equity investment (the &#x201c;Equity Investment Right&#x201d;). BTI entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of the Company&#x2019;s common stock issuable under the Warrants (including the Closing Date Warrants and the 2023 Warrants) and Lenders&#x2019; Equity Investment Right was 366 as of March 31, 2024.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#x201c;Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase 175 individual limited liability company units (which number of units is not in thousands; referred to herein as the &#x201c;OnkosXcel Warrants&#x201d;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#x201c;Next Equity Financing&#x201d;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the closing of the Fourth Amendment discussed below, the Company granted new warrants to the Lenders to purchase up to 6 shares of its common stock (the &#x201c;2024 Warrant Shares&#x201d;) at an exercise price of $49.1568 per share (the &#x201c;2024 Warrants&#x201d;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of the Company&#x2019;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#x2019;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#x201c;Second Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fifth Amendment Warrants, Registration Rights Agreement and Equity Investment Right Termination&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Prior to the Fifth Amendment, pursuant to the Credit Agreement, the Lenders had the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#x2019; election to proceed with such equity investment (the &#x201c;Equity Investment Right&#x201d;). The Equity investment Right was terminated as part of the Fifth Amendment. We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#x201c;Amended and Restated Registration Rights Agreement&#x201d;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Closing Date Warrants, 2023 Warrants and the New Warrants for resale. The maximum shares of our common stock issuable under the Closing Date Warrants, the 2023 Warrants and the Lenders&#x2019; Equity Investment Right was 366. On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#x201c;Second Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the closing of the Fifth Amendment, the Company agreed to, substantially concurrently with the closing of Raise 1, grant new warrants to the Lenders to purchase an aggregate of 313 shares of common stock on the closing date of the Fifth Amendment, at an exercise price of $0.16 per share (the &#x201c;New Warrants&#x201d;). The New Warrants will expire on the seventh anniversary of their issuance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In addition, the Company agreed to, substantially concurrently with the closing of Raise 1, amend and restate all warrants to purchase stock of the Company issued to the Lenders prior to the effective date of the Fifth Amendment, to revise the exercise price thereunder to an exercise price equal to the lower of (i) the price per share of the common stock of the Company issued in Raise 1 and (ii) arithmetic average of the volume-weighted average price of the Company&#x2019;s common stock on the Nasdaq Capital Market during the 30 trading days preceding Raise 1 (such existing warrants, as amended and restated, the &#x201c;Original Warrants&#x201d;). The Original Warrants provide the Lenders with the right to purchase a total of 28 shares of common stock of the Company, and the exercise prices of $58.3232 per share and $49.1568 per share were reduced to $7.68 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On the date of issuance of the New Warrants, the Company agreed to amend and restate its Second Amended and Restated Registration Rights Agreement with the Lenders, dated March 20, 2024. Pursuant to such amendment and restatement (the &#x201c;Third Amended and Restated Registration Rights Agreement&#x201d;), the Company will agree to register the shares of common stock issuable under the New Warrants, in addition to all Original Warrants, for resale. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#x201c;Next Equity Financing&#x201d;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Maturities of debt are expected to be as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,431&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Interest expense was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,643&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of debt discount and amortization of financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_ERBliN8vpk-f27_dI9q1yQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit Agreement and Guaranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payable-in-kind ("PIK") interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,722&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt premiums, discounts and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,865)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,214)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less current portion of long-term debt &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,608)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,508&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"
      decimals="-3"
      id="Tc_AZvD0YliGUCIn_fhYNTOyg_3_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">102319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zFMC5T7CfU-D5CYy3DpF5g"
      decimals="-3"
      id="Tc_xP94nh4mc0Su6G4P7eHoBw_3_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">102319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg"
      decimals="-3"
      id="Tc_OrJaxA6Fk0ivHxEVgAcPaA_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">7072000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_I6j_31dAZkOaSKH03J-dWw"
      decimals="-3"
      id="Tc_2EjHfkzMSUuIrhRdq1-4pw_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4403000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_ro16ndM-eECS_bxPC-YRbw_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">109391000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_vZcflGXuw0mykEzUPesHeQ_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">106722000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_WEMePayZsU6dStd8zwwIOA_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3865000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_zOgunhuDcUSye26AgSHIQg_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4214000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_YSVE0wq3JEaHMhsQyjoNjg_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">105526000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_xkhhu5xsBkOXa4066pOsVQ_7_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">102508000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_nEgu4BEdK0mxBtUVL4pi_w_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5608000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_SO7nwWwPd0qIvfZZYb-pyw_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">99918000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_dr1AKYxN1UGpZsmfu1c9Jw_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">102508000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ"
      decimals="-3"
      id="Narr_V2aVxdPV1EugrUHgH1ieUQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">260000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA"
      decimals="-3"
      id="Narr_ET_JSuZ2nUizs3bQGwP0Mw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3EM8qIytm0Ke9WUqaxD5ng"
      decimals="-3"
      id="Narr_bDp4fo_XlEientrmNrO6eA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA"
      decimals="-3"
      id="Narr_m4X6QITRAE6X8iC3QSqpfQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">180000</us-gaap:DebtInstrumentFeeAmount>
    <btai:LineOfCreditFacilityAmendmentFeePercentage
      contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jAx_EojGEketsDRJCeRRzw"
      decimals="4"
      id="Narr_CIufEuGEtkKJWKLXvT6BFA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0025</btai:LineOfCreditFacilityAmendmentFeePercentage>
    <btai:LineOfCreditFacilityExitFeePercentage
      contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jAx_EojGEketsDRJCeRRzw"
      decimals="4"
      id="Narr_p2OsbnxaXk292yJAtIxLkQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0025</btai:LineOfCreditFacilityExitFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qwP76czkUUiKqJXva8OQCg"
      decimals="-3"
      id="Narr_jW01q8c3hEyis4xvIJxB_A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">202319000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7HNwLTU3EyiG-P0bxBDiA"
      decimals="-3"
      id="Narr_73XUK6M3hkmVy6tNk7SgGw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">70000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zeDII7Hjq0G2YU6LERXHGQ"
      decimals="-3"
      id="Narr_hQByeHFNcUW7_p8qTUxo7Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">72319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qVwLBWQhP0C7ghgBC6SW2w"
      decimals="-3"
      id="Narr_IyWbm0-zGESKBrI2vSo1uA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qwP76czkUUiKqJXva8OQCg"
      decimals="-3"
      id="Narr_hX6qKVqeK0e-AY3wjBFVrg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30865000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_jvQLeDynH0G_9e-4g-cghA"
      decimals="-3"
      id="Narr_TbIbM7g0PEKbSe3Hy-Qirw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityExitFeePercentage
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_tKgYE7x10U2ucISeOhEC6w"
      decimals="4"
      id="Narr_wPjvOYiLeEyBbYZZagRUFw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0025</btai:LineOfCreditFacilityExitFeePercentage>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"
      decimals="-3"
      id="Narr_-IXiJ2AID0a5M81rdGMG8w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">80000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"
      decimals="3"
      id="Narr_bBxEvuxxsEWgFITA28122A"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.153</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember__iSlOGcFMUmoZ6cGWFMGPA"
      decimals="-3"
      id="Narr_y8HwnHvl80GxoDP0pP_V4Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cVbjkTPdU0mE_eF3eSJOLQ"
      decimals="-3"
      id="Narr_gb1QCMBKYkOq8WWX3IHdpg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kHi1rm9DF0qHlbl4VlnXNQ"
      decimals="-3"
      id="Narr_4BaRUrMM1EWxezUYTuWq1Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"
      decimals="-3"
      id="Narr_4LC0LAVYF0-O3ckB-KrX4Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">80000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <btai:DebtInstrumentInterestRateDiscountRatePercentage
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw"
      decimals="4"
      id="Narr_qmhxTzqyIEOGkbCT21lweA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0200</btai:DebtInstrumentInterestRateDiscountRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_S352yBVXFEqz_Y-5P-1a6A"
      decimals="3"
      id="Narr_6F9KP-sYZUqTYrUXhnK2zg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_yclrnHVBYEmASqLsg1GLwQ"
      decimals="3"
      id="Narr_wifQrJ1x50yiFWhy9O3Mqg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.055</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <btai:DebtInstrumentIncrementalOnVariableRatePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw"
      decimals="3"
      id="Narr_w1CE-yFx6UqRFtZ7tqiLVA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.075</btai:DebtInstrumentIncrementalOnVariableRatePercent>
    <btai:PaidInKindInterestPercentage
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_SSD-lVaNm0i_gSF3npZAOQ"
      decimals="2"
      id="Narr_pnSgZqb4WEu8OUdPcPvX2w"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.08</btai:PaidInKindInterestPercentage>
    <btai:TickingFeesPercentage
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_AbzJnAfwIU2OXPk_sywKqw"
      decimals="4"
      id="Narr_kMFRxwfmqUeHlvAvvstGVQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0075</btai:TickingFeesPercentage>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ"
      decimals="-3"
      id="Narr_SF0bSfVFl0CNeni6znFtWA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">15000000</btai:NetCashRequiredMinimum>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_CsZ-KkxpOUakCJAE_KixSw"
      decimals="-3"
      id="Narr_DAVXDX_iKkyEkhspJkDgrA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">20000000</btai:NetCashRequiredMinimum>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_5oKzEf9LG0ObCnvYEfaywQ"
      decimals="-3"
      id="Narr_bpyB-7FBKkeKRTaXfuRrvA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">15000000</btai:NetCashRequiredMinimum>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ"
      decimals="-3"
      id="Narr_jPbckXWC80KwAJknjNhaoA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">37500000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:PercentageOfOutstandingLoan
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_52So6KoOMEungxS0l0MsEA"
      decimals="2"
      id="Narr_J4YK9eBxBUWSRKOOFHq8pg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.50</btai:PercentageOfOutstandingLoan>
    <btai:SubsidiaryOwnershipPercentage
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_hXtW7Y_uF0K7fBJkm5HLlQ"
      decimals="2"
      id="Narr_SSyREBTQF0m1Zj1Z2EZ6gw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.20</btai:SubsidiaryOwnershipPercentage>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_k7PXdMmavEKzCaO6o0HcTg"
      decimals="-3"
      id="Narr_o65q4EVkHUWEMoiTSnFWag"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fJEBahyH2E68UBP6QHFHZA"
      decimals="-3"
      id="Narr_xQq-4k3TQUGHQPYO0un8dg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ"
      decimals="-3"
      id="Narr_z_B4NyRt4UaSWstx_7Z1Cw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_kzDv9FgG30O_Q6Inae8txA"
      decimals="-3"
      id="Narr_B-jLIeVb-Ei4utDPb3Mttw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_J81r1ZkU4U-0Pa_Y2zZH7g"
      decimals="-3"
      id="Narr_FSCwh_6mukWRp_mmDiEVSg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_OFejCh9UM0ObmQn7f9J2Fw"
      decimals="-3"
      id="Narr_MC0dnrCUSUqMAkCpfsUXuQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">15000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ"
      decimals="-3"
      id="Narr_9Ej2eOK9TESD_olNitC7Ug"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_27_2024_To_3_27_2024_jrj6VftXi0yzxC3W-d_BuA"
      decimals="-3"
      id="Narr_2QBSF2C8O0SB704xhD0YnA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_v_YbOHNsdUCs5oWI64z4MQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">467000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_dDuDWpxOgEOq1GollclLlg"
      decimals="-3"
      id="Narr_n63wG0rDMESvLjt0bxfqkg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30943000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_T63fAxu4W0KEPABUzNyrnA"
      decimals="-3"
      id="Narr_5v5IVqqinEuzPg7cp02K4A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_3m8_BPw0G0OPp__QShJQ-g"
      decimals="-3"
      id="Narr_WTg5Pj--cEOOBS30qKr5ZQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"
      decimals="-3"
      id="Narr_JLDCcgEkekCF-MtISKefUg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_CEOlqQAwW0mFwSgtmbsQPQ"
      decimals="-3"
      id="Narr_E6Gd8VExjUqWXAtvs3bd6g"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eKfoQwlPkUyNgcgidh5-dA"
      decimals="-3"
      id="Narr_-1ZZiGFMbkaRH9F35F1X5Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">7000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_hgzEHqmylEubMQ6IsaLqbg"
      decimals="-3"
      id="Narr_kXhnf__9UkO5n3cAaidwpQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">18000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_TgEuBFjXIkKWUIDM6bWI0w"
      decimals="-3"
      id="Narr_TDjncDpiwkmKbN-mD0tTgw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">29000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_j4lmqYFO50Sd2zbIjyRJlg"
      decimals="-3"
      id="Narr_eBFj_rBtX0OWD-TXiZ3r_Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">7500000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_VHV8Q0yfikOv6dYy4wL6Cg"
      decimals="-3"
      id="Narr_sxd7HZpfzUCcG9kZ4KrJug"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_gtTfRBkLIUCQ1ZyESr-Bhw"
      decimals="-3"
      id="Narr_Nolqq53EaEe8E09GSis57w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_11_21_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_eeKV4-Us0k-PErQbocl43A"
      decimals="-3"
      id="Narr_-htMwCZ7q0WC_ASww4BObg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">15000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw"
      decimals="-3"
      id="Narr_gQJcacuNkEmJOiNwGJKsmQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw"
      decimals="INF"
      id="Narr_c6HixluuLkGvNf2UfVTc_Q"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_bbbkIzsXpkmOj02U5piNIA"
      decimals="INF"
      id="Narr_Lh_AyaxMiEeBrKxQffT1eg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <btai:PaidInKindInterestPercentage
      contextRef="As_Of_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_bbbkIzsXpkmOj02U5piNIA"
      decimals="INF"
      id="Narr_vSyh34LLbEWYfui8aS-8Ng"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.10</btai:PaidInKindInterestPercentage>
    <btai:DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw"
      decimals="INF"
      id="Narr_koO1iwrsLEOuwkC_29BAhw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.05</btai:DebtInstrumentQuarterlyAmortizationPaymentsAsPercentageOfPrincipalAmountFunded>
    <btai:MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_0Zle6nNsLE2WhHdmU9bDKw"
      decimals="INF"
      id="Narr_EnJWHrZps0Sk--_NRmLoyg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.15</btai:MaximumPercentageOfBudgetedAmountForDisbursementsInApplicablePeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="-3"
      id="Narr_Nusdrt7Ky0-Jp1IGc0j19w"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">17000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="2"
      id="Narr_AOKQtlv1Xk-o_rO30uAP-A"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">320.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"
      decimals="INF"
      id="Narr_Akd-DquezkiuvIusVVXpnQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q"
      decimals="-3"
      id="Narr_QquPmgzRZ0WYBnul_osNTA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q"
      decimals="INF"
      id="Narr_oJYH5zuHH0-3Pa_HIIGXtg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:RightToPurchaseStockLenders
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="-3"
      id="Narr_OprJj3f0sUCdvt5hHOfKdQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5000000</btai:RightToPurchaseStockLenders>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_5K0sWmEJwUa7Vv6SUtp_GQ"
      decimals="2"
      id="Narr_2_MAwfm9JUq2H7s3kaURGg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.10</btai:PremiumSharePricePercent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_g5MICnEV20aws4tbDts1AA"
      decimals="-3"
      id="Narr_JZ9Q_7Ro8EyUGthnFBllrQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">366000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"
      decimals="-3"
      id="Narr_-MNoZx_CEkKH3_W0xnLgvA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">175000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"
      decimals="-3"
      id="Narr_dKzcGfRdiUy_hEPb2RjynQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"
      decimals="-3"
      id="Narr_3sv8vxzenUW6PdJZUvcUlA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"
      decimals="2"
      id="Narr_Avv9JhWcE0GV7KpzysOfNg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.10</btai:PremiumSharePricePercent>
    <btai:PercentageOfFairValueConsiderationToBePaid
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"
      decimals="2"
      id="Narr_CvoxaBiyVEqXIbeW6BnQHA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.75</btai:PercentageOfFairValueConsiderationToBePaid>
    <btai:PercentageOfValuationApplicableToInitialProfits
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"
      decimals="2"
      id="Narr_gnlivZrOeEeKhf6qXZEHFQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.50</btai:PercentageOfValuationApplicableToInitialProfits>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A"
      decimals="-3"
      id="Narr_Ugub2pdp5Ee8MPrlzMC2lA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A"
      decimals="INF"
      id="Narr_hD1vILFM802rzqkBjHPU9g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:PremiumSharePricePercent
      contextRef="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_PoDngmaLSkWSK6VPUhLyWQ"
      decimals="2"
      id="Narr_KxRdtqfqmke7jupw6zAbAA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.10</btai:PremiumSharePricePercent>
    <btai:RightToPurchaseStockLenders
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="-3"
      id="Narr_sCLIQ9CdckCNwS0KkeZwcQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5000000</btai:RightToPurchaseStockLenders>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_5K0sWmEJwUa7Vv6SUtp_GQ"
      decimals="2"
      id="Narr_eE_PrTU1eUS5efOi6QktMg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.10</btai:PremiumSharePricePercent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="-3"
      id="Narr_CpRuAXCYekKVbzwA6x8LAA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">366000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q"
      decimals="-3"
      id="Narr_Yf24vsh8ZkS80_4LySKjIg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">313000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q"
      decimals="INF"
      id="Narr_yKrzdEKZgUatg-09xo3Z3g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_Wz5TY_agyEaaN18D5dyCEg"
      decimals="-3"
      id="Narr_ZO0kQzz9ok6uuapq4qeHcw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">28000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"
      decimals="INF"
      id="Narr_PQoFYQ0to0Scq1RsRvTCaA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_i22GzKPjdk-2mejYvTMc7A"
      decimals="INF"
      id="Narr_rB45BgqP4kWt0-Sf4Gcb4g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OriginalWarrantsMember_Wz5TY_agyEaaN18D5dyCEg"
      decimals="INF"
      id="Narr_oyAeXy_HekuIpN92EgRlWw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"
      decimals="-3"
      id="Narr_1-OnY9QwIU-2I3qgq5l0Bw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">175000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"
      decimals="-3"
      id="Narr_k_fjrhKA1UaomHWjHiHy1w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_vwwYWl_iTEmn0ec_kgDyMQ"
      decimals="-3"
      id="Narr_j553MuLZOUmRRl-dZTxihA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"
      decimals="2"
      id="Narr_ETLqvgzK3Umj_LTiOJ2Etg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.10</btai:PremiumSharePricePercent>
    <btai:PercentageOfFairValueConsiderationToBePaid
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"
      decimals="2"
      id="Narr_FdieiwjGxU-uKrt2x7GSfA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.75</btai:PercentageOfFairValueConsiderationToBePaid>
    <btai:PercentageOfValuationApplicableToInitialProfits
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_KCrKtpePkkuzTFEt8BXmTg"
      decimals="2"
      id="Narr_bDadVCSPA0aM3mKgCk1Tgw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.50</btai:PercentageOfValuationApplicableToInitialProfits>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_VYXA8rwQ-USsiGrhCGQlsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,431&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_p4FaSRK9e0Wt7iI3diAyUQ_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">22431000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_92GG_V2XEE2SkCplrImyww_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">86960000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_h3S_A-f9c0SdGHhFphqidA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,643&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of debt discount and amortization of financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_k39CFQXGu06A3g6A-Zi7qQ_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3643000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_ERNFZlsspk2FJlmcZxp_2Q_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3564000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_-UqVi4ZVdEK114UbWmabkA_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">350000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_7iWeBUQ4ekyIJpdwiU5yHQ_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">43000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_3SbvQfPwokafItwjzQFKWg_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3993000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_SuYnewcyBUOGdYIfCcLgsg_7_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3607000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_0xsm2UKLIkmdDealGReivQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 10. Derivative Financial Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"&gt;BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options. The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#x2019;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheets. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Condensed Consolidated Statements of Operations. As discussed in Note 9, &lt;i style="font-style:italic;"&gt;Debt and Credit Facilities&lt;/i&gt;, the Equity Investment Right was terminated on November 25, 2024 in connection with the Fifth Amendment to the Credit Agreement, and the Company recorded a termination gain, reducing the carrying value of the Equity Investment Right to $0. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;With respect to the Purchase Agreement discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, BTI determined that the Accompanying Warrants fail the equity classification criteria and are therefore classified as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Condensed Consolidated Statements of Operations. We value the Accompanying Warrants using the Black-Scholes option pricing model as discussed in Note 14, &lt;i style="font-style:italic;"&gt;Fair value measurements&lt;/i&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;On November 21, 2024, the exercise price of&#160;534&#160;of the Accompanying Warrants was reduced from $51.20&#160;to $9.136&#160;per share. For the three months ended March 31, 2025, the Company recorded total net gains of $1,679 in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the Accompanying Warrants was $641. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;On November 25, 2024, with respect to the Underwriter Agreement discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, the Company issued additional warrants (the &#x201c;November 2024 Accompanying Warrants&#x201d;). The November 2024 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations. For the three months ended March 31, 2025, the Company recorded total net gains of $3,080&#160;in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the November 2024 Accompanying Warrants was $1,193.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;On March 3, 2025, with respect to the March 2025 Offering discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, the Company issued additional warrants (the &#x201c;March 2025 Accompanying Warrants&#x201d;). The March 2025 Accompanying Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheet as of March 31, 2025. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $2,831&#160;and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations. For the three months ended March 31, 2025, the Company recorded total net gains of $1,429&#160;in Other (income) expense, net, in the Company&#x2019;s Consolidated Statements of Operations. As of March 31, 2025, the fair value of the March 2025 Accompanying Warrants was $1,402.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;In connection with the March 2025 Offering discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, the Company also issued option warrants (the &#x201c;Option Warrants&#x201d;). The Option Warrants failed to meet the requirements to be indexed to equity and equity classified, and meet the definition of a derivative instrument. Therefore, these instruments are initially recorded as Derivative liabilities. The respective derivative liabilities were recorded at fair value on the date of issuance in the amount of $369. The Option Warrants expired on March 18, 2025 without being exercised, and the Company recorded a termination gain of $369 in Other (income) expense, net, in the Company&#x2019;s Condensed Consolidated Statements of Operations. As of March 31, 2025, the fair value of the Option Warrants was $0.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_G6llnlti5k20g5RAYF9w8w"
      decimals="-3"
      id="Narr_7oR53ca7d0SBfcMF6jJ9fA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_eSxn4MEvbkq34vrvkL54Cw"
      decimals="-3"
      id="Narr_7wRr52jYpkuQs2or4qT5aA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_JbvOkxvjdkmJ6LmN2Rd0Jw"
      decimals="INF"
      id="Narr_0OHkElaKcUermWCCfB8xbA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">51.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_W4qAVPHELES2fLUz4KcqKg"
      decimals="INF"
      id="Narr_jZ1UbKdZJEml7DLgaSdrHw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">9.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_RvkyKbPjBEK4lRpESDkZxg"
      decimals="-3"
      id="Narr_AFBIEoo0SkCe4YGqvraByA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1679000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_QLIVwjVCD0quI55_NwdJQw"
      decimals="-3"
      id="Narr_2GaAJ78U002gCMntORvf9g"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">641000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_Cn5-JcfDR0qcNSKrdqLIBA"
      decimals="-3"
      id="Narr_tfPdn6qzLE6BJNNpZtYCNQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3080000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_k-Kye-ecsEGNgr32jEq1GA"
      decimals="-3"
      id="Narr_aTPZrSF9vUmwJtX-vVhQog"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1193000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_dwaRvaALY0OiHiyuF7H6Aw"
      decimals="-3"
      id="Narr_oXx_FqVL_0WbvQSri4KITA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2831000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_9wVA-iTdq0y5EEN-cGB0Ng"
      decimals="-3"
      id="Narr_XuOa1xMYLEi25DzL0OIdgg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1429000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2025AccompanyingWarrantsMember_PbHyP1wRzkWN4ZQmOt6QaA"
      decimals="-3"
      id="Narr_kLHN-vq0t0-Ut38jiQ9S0g"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1402000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_H1m79MxGEESZ-YgtaaXWXQ"
      decimals="-3"
      id="Narr_U05FxyORNECXPzDCuaW4ig"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">369000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q"
      decimals="-3"
      id="Narr_dt7xq0HK9EGets_uJI0vEg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">369000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_vRuLpGrNJEaqdiLygHHIHA"
      decimals="-3"
      id="Narr_5aY7tjK8kU2PUavzGgCH_A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:WarrantsAndRightsOutstanding>
    <btai:FinancingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_OUpZAMjxNEqewdQQXOsf5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;11. Common Stock Financing Activities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;Jeffries At-the-Market Program &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In May 2021, the Company entered into&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; an &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$100,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, from time to time, through an &#x201c;at the market offering&#x201d; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#x201c;at the market offering" program to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$150,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. On March 26, 2025, the Company and Jefferies terminated that certain Open Market Sales Agreement. There have been &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; sales of the Company&#x2019;s common stock under the Sale Agreement for the three months ended March 31, 2025. &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;For the three months ended March 31, 2024, the Company sold &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;40&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares under the Sale Agreement for gross proceeds of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1,743&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and received proceeds of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1,691&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, net of issuance costs of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$52&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 2024 Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 25, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with the purchasers named therein (collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchasers in a registered direct offering (the &#x201c;Offering&#x201d;) under an effective shelf registration statement on Form S-3 (File No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission on March 25, 2024 (the &#x201c;Prospectus Supplement&#x201d;) an aggregate of 191 shares (the &#x201c;Shares&#x201d;) of Common Stock, and accompanying warrants (the &#x201c;Accompanying Warrants&#x201d;) to purchase up to 191 shares of common stock at a combined offering price of $46.416 per Share and Accompanying Warrant and pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 348 shares of common stock and Accompanying Warrants to purchase up to 348 shares of common stock, at a combined offering price of $46.40 per share underlying each Pre-Funded Warrant and Accompanying Warrant, which equals the offering price per Share and Accompanying Warrant &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;less the $0.016 exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants and Accompanying Warrants are not listed on the Nasdaq Capital Market or any other securities exchange or trading system and the Company does not intend to list them. On March 27, 2024, the Company received $25,000 of gross proceeds from the Offering, incurred costs of $248, and received net proceeds of $24,752. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.016 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. For the year ended December 31, 2024, all 348 Pre-Funded Warrants were exercised and the same number of shares of common stock were issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Accompanying Warrants have an exercise price per share of common stock equal to $51.20 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;November 2024 Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On November 22, 2024, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Canaccord Genuity LLC, as underwriter (the &#x201c;Underwriter&#x201d;), in connection with the issuance and sale by the Company in a public offering of (i)&#160;&lt;/span&gt;350&lt;span style="background:#ffffff;"&gt;&#160;shares of the Company&#x2019;s common stock, and accompanying warrants (the &#x201c;November 2024 Accompanying Warrants&#x201d;) to purchase&#160;&lt;/span&gt;350&lt;span style="background:#ffffff;"&gt;&#160;shares of Common Stock, at a combined public offering price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$&lt;/span&gt;7.68&lt;span style="background:#ffffff;"&gt;&#160;per share, and, in lieu thereof to certain investors, (ii) Pre-Funded Warrants to purchase&#160;&lt;/span&gt;563&lt;span style="background:#ffffff;"&gt;&#160;shares of Common Stock, and accompanying warrants to purchase&#160;&lt;/span&gt;563&lt;span style="background:#ffffff;"&gt;&#160;shares of Common Stock, at a combined public offering price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$&lt;/span&gt;7.664&lt;span style="background:#ffffff;"&gt;&#160;per pre-funded warrant, which equals the public offering price per share of Common Stock and accompanying warrant less the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$&lt;/span&gt;0.016&lt;span style="background:#ffffff;"&gt;&#160;exercise price per share of the pre-funded warrants, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-275261) and a related prospectus supplement filed with the Securities and Exchange Commission. &lt;/span&gt;The Company received net proceeds from the offering of approximately $6,128, after deducting underwriting discounts and commissions and offering expenses of $871. The Company intends to use the net proceeds of the offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.016 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. &lt;span style="background:#ffffff;"&gt;For the year ended December 31, 2024,&#160;&lt;/span&gt;80&lt;span style="background:#ffffff;"&gt;&#160;Pre-Funded Warrants were exercised and the same number of shares of common stock were issued. For the three months ended March 31, 2025, the remaining &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;483&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; Pre-Funded Warrants were exercised and the same number of common stock were issued in exchange for &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of proceeds received. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The November 2024 Accompanying Warrants have an exercise price per share of common stock equal to $7.68 per share. The exercise price and the number of shares of common stock issuable upon exercise of the November 2024 Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The November 2024 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accompanying Warrants are exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The November 2024 Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 2025 Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 3, 2025, the Company entered into a purchase agreement (the &#x201c;March 2025 Offering&#x201d;) with a purchaser. Pursuant to the March 2025 Offering, the Company agreed to issue and sell to the purchaser and the purchaser agreed to buy in a registered direct offering (i) an aggregate of 188 shares (the &#x201c;Shares&#x201d;) of Common Stock at an offering price of $3.50 per Share, (ii) Pre-Funded Warrants to purchase up&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;to 3,812 shares of Common Stock, at an offering price of $3.499 per share underlying the Pre-Funded Warrants, which equals the offering price per share less the $0.001 exercise price per share of the Pre-Funded Warrants, and (iii) an aggregate of 4,000 accompanying warrants (the &#x201c;March 2025 Accompanying Warrants&#x201d;) to purchase up to 4,000 shares of Common Stock at an offering price of $4.20 per accompanying warrant, pursuant to an effective registration statement on Form S-3 (File No. 333-275261), including the base prospectus included therein, and prospectus supplement filed with the SEC on March 4, 2025. The Company received net proceeds from the offering of approximately $12,957, after deducting underwriting discounts and commissions and offering expenses of $1,039.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Pre-Funded Warrants have an exercise price per share of common stock equal to $0.001 per share. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The Pre-Funded Warrants are exercisable at any time after the date of issuance. The Pre-Funded Warrants meet the equity classification criteria and are therefore classified as equity. For the three months ended March 31, 2025, 1,688 Pre-Funded Warrants were exercised and the same number of common stock were issued in exchange for $2 of proceeds received. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The March 2025 Accompanying Warrants have an exercise price per share of common stock equal to $4.20 per share. The exercise price and the number of shares of common stock issuable upon exercise of the March 2025 Accompanying Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The March 2025 Accompanying Warrants will be exercisable at any time after the date of issuance and will expire on the fifth anniversary of the date of issuance. The March 2025 Accompanying Warrants do not meet certain scope exceptions under U.S. GAAP, primarily because they did not meet the requirements to be indexed to equity and equity classified, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Condensed Consolidated Balance Sheet as of March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In the March 2025 Offering, the Company also issued to the purchaser option warrants, to purchase up to 4,000 shares of Common Stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000 shares of Common Stock. The exercise price of the Option Warrant is $3.50 per underlying share of Common Stock or $3.499 per underlying pre-funded warrant to purchase one share of Common Stock and accompanying warrant. The option accompanying warrants have an exercise price per share of common stock equal to $4.20 per share. The Option Warrants expired on March 18, 2025 without being exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</btai:FinancingActivitiesDisclosureTextBlock>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_4HyrlxwEJEq43QPtl9kACg"
      decimals="-3"
      id="Narr_54oatrIlnEC8PFoKJwaC3w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">100000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_sIswvAbnK0SSZ3U84h3-cQ"
      decimals="-3"
      id="Narr_9RD4ePdPEUWUS-5iQWm9XQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">150000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_IqGrgtq8dk2Nmswn-jlaBg"
      decimals="-3"
      id="Narr_ePsiydr92kuHApMDXv3CAg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q"
      decimals="-3"
      id="Narr_-ZabsaVCkkKinWn-C7EWeA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">40000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q"
      decimals="-3"
      id="Narr_8PSFjxMgpEmO4oI7HA--cA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1743000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q"
      decimals="-3"
      id="Narr_keY8EBe2j0qEYy7z0wjx-Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1691000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_pxLt_GsQZ0G7LP2ZMc183Q"
      decimals="-3"
      id="Narr__hD-luAkSUOeKWLN09u_UQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">52000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_25_2024_To_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_1rBX_Jky_0K75YP6H-89Qg"
      decimals="-3"
      id="Narr_cfpljdxjU0SxjOhOTV9RAA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">191000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g"
      decimals="-3"
      id="Narr_m7xbJumbEUWcpgV0WvmWLA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">191000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_25_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Pg-jCHaINE-WLGJKl1HB8Q"
      decimals="3"
      id="Narr_OaA8bHo9W0WGiS_yf0_Vaw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">46.416</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw"
      decimals="-3"
      id="Narr_E2N9f66_n0Womqu3AFWETw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">348000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw"
      decimals="-3"
      id="Narr_ZK4WSaPeCEKtX4Hua4x6vg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">348000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g"
      decimals="2"
      id="Narr_8LFsZpvbW0GGl6QO_xIKVg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">46.4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw"
      decimals="3"
      id="Narr_88sfhZ6fsU2kp3yWy33fjg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ"
      decimals="-3"
      id="Narr__vAMzMOz0UGZkCfKIunpEw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">25000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ"
      decimals="-3"
      id="Narr_mEeo4iaQ3k2OWEA383PYJg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">248000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_27_2024_To_3_27_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Z8kbjQU7ckS7noF_N9ibrQ"
      decimals="-3"
      id="Narr_2w5pJ1RYiU-vjDQe_843ig"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">24752000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_dz3tZ7OyGU-GfLQBHnvUbw"
      decimals="3"
      id="Narr_OqDOhESpX0KG-H3-WzA96g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_Q7rgAxV2QUiFwGQkmwTNSA"
      decimals="-3"
      id="Narr_GOpUKy28rkCmht_P9yinhw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">348000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_March2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredDirectOfferingMember_B1pVuPZ7ZEiX7IMHEnj85g"
      decimals="2"
      id="Narr_FEF5uC8sO0avIWV7EbOZ8w"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">51.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA"
      decimals="-3"
      id="Narr_kaFbGhRea0uEzHbo0OEBTg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_sOc9QAFpIkiocfp6gFyENg"
      decimals="-3"
      id="Narr_NTZxVpUI-0a5xKFdwdXpzg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">350000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EqWnEmSp7UWllrfrANJBsA"
      decimals="2"
      id="Narr_Ejc77HM2X0e9RXZT7PZ_jA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg"
      decimals="-3"
      id="Narr_IO25txozL0WZYXIKN936sQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">563000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg"
      decimals="-3"
      id="Narr_ag7KHAJoqEqCXY70D5FRRg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">563000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_sOc9QAFpIkiocfp6gFyENg"
      decimals="3"
      id="Narr_gaTbbJitKkO4JdfRmpk3Sw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.664</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg"
      decimals="3"
      id="Narr_MEpEniBljUSe9bgq1NJy9g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA"
      decimals="-3"
      id="Narr_iTc_x8NGYEi-r2L5hH1PIg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6128000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_11_22_2024_To_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EKUumdOhdUetY_eYtx9TBA"
      decimals="-3"
      id="Narr_PUYFwUaDUEa9dxGKRGYxmA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">871000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_22_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_nBDIUhSGuUqZ7muP8prkPg"
      decimals="3"
      id="Narr_Q25F8g0LPEStGgwJpWlBuw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.016</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_Wdm82uT0iEGxg_xqO2sS2Q"
      decimals="-3"
      id="Narr_LoOmVuOAnEiPmOVDqkP9EA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">80000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_gxIXr8TElEqM_4GFJfzkTg"
      decimals="-3"
      id="Narr__179mpJ7rEaxVQoRCOLNBw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">483000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024PrefundedAccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_gxIXr8TElEqM_4GFJfzkTg"
      decimals="-3"
      id="Narr_hN1y9MZFvk2k1ngpOPaPnw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">8000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_22_2024_us-gaap_SubsidiarySaleOfStockAxis_btai_RegisteredOfferingMember_EqWnEmSp7UWllrfrANJBsA"
      decimals="2"
      id="Narr_-lCIQhZ2602e25x6Mg-VQg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w"
      decimals="-3"
      id="Narr_LLXyYLIB5kSdZw0B9rsgZQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">188000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_QwlhBl02BUqKZ_B8CPqQ3A"
      decimals="2"
      id="Narr_LI1GXYykG06y1O-2TWhp_g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">3.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ"
      decimals="-3"
      id="Narr_sx_AlcnVcEyoZ34-lalxJA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3812000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ"
      decimals="3"
      id="Narr_ts4SPO3LFUGLwnp7VOm7Og"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">3.499</btai:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_4DLfIusP5UOtgAlpPFhBiQ"
      decimals="3"
      id="Narr_nRmIYxdyKE6TvGG9_jNgRw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"
      decimals="-3"
      id="Narr_GsNMnu4G7UuiwrbhiKaaNA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"
      decimals="-3"
      id="Narr_6UK25BcJhk2b_lbE62uNCA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"
      decimals="2"
      id="Narr_7AC2eHPXG0SikqDDFHFtdA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">4.2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w"
      decimals="-3"
      id="Narr_mMnnTd72s062joMimhI9FQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">12957000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_3_2025_To_3_3_2025_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_VKvx3ANEHUSEl3EaG2iR2w"
      decimals="-3"
      id="Narr_3DgU88YnhEukmK-HiIQZ0Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1039000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ"
      decimals="3"
      id="Narr_8P00Y3XytkKSAVqF_W21OA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_jTTHkTj0IUGtiV9lleK50A"
      decimals="-3"
      id="Narr_rbIqauXYXUiUseoEGdCu3w"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1688000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_jTTHkTj0IUGtiV9lleK50A"
      decimals="-3"
      id="Narr_sLmyBU5kiE-QZViCx_nSqA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"
      decimals="2"
      id="Narr_ExCiqPmE3EGzvzjVQ1bGGw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">4.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_zb2gHq4d8UOFHYORuG5uDg"
      decimals="-3"
      id="Narr_JcCAtgSlPkCyPvqGAkniQQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"
      decimals="-3"
      id="Narr_I9Pq4eoG40-r-VhvIEUPng"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_zb2gHq4d8UOFHYORuG5uDg"
      decimals="2"
      id="Narr_0_YEhVNg20O4Wbd2Tu0D5w"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember_5XfR7QB4xku5am67xoOWPQ"
      decimals="3"
      id="Narr_mcVwIDg2zUanqNMzOZjlIg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">3.499</btai:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_March2025AccompanyingWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_btai_March2025OfferingMember__htxA7FYs0-TwlX5Anh0yw"
      decimals="2"
      id="Narr_MWFeU0KZJUiRpjs9dWRtVQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">4.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_JdYEe5xmXEue-I1n6bu2vQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;12. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;2017 Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020 Incentive Award Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s 2020 Plan was approved and became effective at the Company&#x2019;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) 57 shares of the Company&#x2019;s common stock and (ii) 15 shares of the Company&#x2019;s common stock, which represents the number of shares that remained available for issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#x2019;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#x2019;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) 4% of the aggregate number of shares of the Company&#x2019;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by 124 shares and 75 shares on January 1, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock options granted under the 2020 Plan have a term of ten years. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally four years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of March 31, 2025, there were 118 shares available to be granted under the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Restricted stock units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to BTI RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;During the three months ended March 31, 2025, the Company granted 3 time-based BTI RSUs which fully vest on the &lt;span style="-sec-ix-hidden:Hidden_pBakmeRXJUyagPAg9k_X7w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-year anniversary of the grant date. The weighted average grant date fair value per share for the BTI RSUs for the three months ended March 31, 2025 was $6.14. The remaining outstanding RSUs generally vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. Unrecognized stock-based compensation expense related to the BTI RSUs was approximately $537 and $1,308 as of March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Performance stock units &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes activity relating to Performance Units related to BTI common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In July 2024, the Company granted 87 Performance Units to employees. The Performance Units vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value per share of Performance Units granted in 2024 was $19.20. None of the Performance Units had vested as of March 31, 2025. Unrecognized stock-based compensation expense related to these Performance Units expected to vest was zero as of March 31, 2025 since it is uncertain whether any performance criteria will be met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;OnkosXcel profit sharing units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in whole dollars)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested units as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;During 2024, OnkosXcel Employee Holdings, LLC, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted 15 individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. These PSUs vest ratably over 48 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair values of PSUs granted in 2024 were estimated at the date of grant using a Black-Scholes option pricing model and assumptions below. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024 grant profit share unit valuation inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Unrecognized stock-based compensation expense related to these awards was $319 and $782 as of March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;OnkosXcel restricted stock units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to the OnkosXcel RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of March 31, 2025, the Company had 140 OnkosXcel Restricted Stock Units outstanding. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $50 and $420 as of March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity for the three months ended March 31, 2025 is presented below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 265.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 384.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 210.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and exercisable as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 268.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of March 31, 2025, the intrinsic value of options outstanding was $0. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#x2019;s common stock as of the reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;No stock options were exercised for the three months ended March 31, 2025. As of March 31, 2025, the total intrinsic value of stock options exercisable was $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average grant date fair value per share of options granted as of March 31, 2025 was $6.21.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average grant date fair value per share of options vested as of March 31, 2025 was $196.53.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average remaining contractual life is 5.0 years for options exercisable as of March 31, 2025. The weighted average remaining contractual life was 6.2 years for options outstanding as of March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Unrecognized compensation expense related to unvested stock option awards as of March 31, 2025 was $1,675 and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 1.1 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair value of stock options granted during the three months ended March 31, 2025 and 2024 was estimated using the Black-Scholes pricing model with the following assumptions: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;112.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;108.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In 2025, the Company continued using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#x2019;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the life of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is zero percent as the Company has no history of paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#x2019;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel RSUs and PSUs, of $180 and $3,433 for the three months ended March 31, 2025 and 2024, respectively, which were comprised as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (514)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020 Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was also approved and became effective at the Company&#x2019;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#x2019;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that were initially available to be issued pursuant to rights granted under the ESPP was 6 shares of common stock. In addition, the number of shares available for issuance under the ESPP increases on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#x201c;Section 423 Component&#x201d;) shall not exceed 31 shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by 31 shares and 19 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;shares on January 1, 2025 and 2024, respectively. To date, no shares have been sold under the ESPP. There were 106 shares available for issuance as of March 31, 2025.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ntB7xLQOW0eFtXjIxuvYzw"
      decimals="-3"
      id="Narr_bLQrPhiNkkCLKyxrLDlUbQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_jAh-mRl7UkGV1NOK3PBR4g"
      decimals="-3"
      id="Narr_qBdTNn-6RUac-m8dmptzIw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww"
      decimals="2"
      id="Narr_VK-K27yRM0mcXLiD3-JCVQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.04</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_2u5ZZheCfUSWL-ojEEShPw"
      decimals="-3"
      id="Narr_IZW9rxmpQ0W6W7egWYhGgQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">124000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_lfzf6M4c4ESx9byf41wzhA"
      decimals="-3"
      id="Narr_uetiJ6kZIUyAuyDImacvkg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww"
      id="Narr_R1oZqgIGCECd97TQFKiFaA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_x9MxcAJZhkyhaOqIUYTJww"
      id="Narr_i_aiaRbPyE6dGun0ljsY7g">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_6FxRGu28wE6I304fkcl32w"
      decimals="-3"
      id="Narr_FENCp3v3W0ORa1iStMLqbQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">118000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q"
      id="Tb_-b2e5On20kGBBeTSxjkxtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FrgKxTMEe0mg8BmgwnLOgQ"
      decimals="-3"
      id="Tc_MZVb6IZP5UOBLYfJx5VLjw_5_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q"
      decimals="-3"
      id="Tc_SkU2K72AE0qwRvLnQR7IMg_6_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q"
      decimals="-3"
      id="Tc_NRVtg8GGnUmoaufc0WGfWQ_7_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MFtw4dIT90CTM1cHH3PE7Q"
      decimals="-3"
      id="Tc_wiOpRE-IWEG7dcjcFFhdww_8_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_10sTlzzOBUiJqkaSyPhFIw"
      decimals="-3"
      id="Tc_Vi2Vuuvtd06dHZxqytSRXw_9_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q"
      decimals="-3"
      id="Narr_RIGV_r2Ol0GbCafGGHSK7Q"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting100PercentAtOneYearAnniversaryMember_tLEMebkcH0mEOkjv9i348Q"
      decimals="2"
      id="Narr_PQRM_jweckGOGrTdl7pmPA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">6.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_G-3oLaoblUKb9ZcelJ9fng"
      id="Narr_8Rz0mBl3pkCTCRAkXRq5Hg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_btai_RestrictedStockUnitsVesting25PercentAtOneYearAndRemainingIn12QuartersMember_G-3oLaoblUKb9ZcelJ9fng"
      decimals="2"
      id="Narr_k0F9zJJKPk2dmmL1MfJNEA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_10sTlzzOBUiJqkaSyPhFIw"
      decimals="-3"
      id="Narr_dSUwBsdN80223TW-meIaxw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">537000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t0gcHwftwUuD02CHseIM2A"
      decimals="-3"
      id="Narr_n5GH0O2ISUesAM5aT_9Cvw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1308000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw"
      id="Tb_6_pWbf-aC06Ul0ox8AK4Gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_QM1oFtti-EyHphWNZ9znYg"
      decimals="-3"
      id="Tc_0bDf6E3JVESf4kSz7_5pfA_4_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw"
      decimals="-3"
      id="Tc_oSiQIfkCi06lBKiRLdKTaQ_6_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">10000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_XbHYq2dE_UGUYLas9E-Hnw"
      decimals="-3"
      id="Tc_Ov6U_-E5tEirgdaFkO4KDg_8_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg"
      decimals="-3"
      id="Narr_Hn9F2YpkGU-6gXC3Hhefjg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">87000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg"
      id="Narr_b0ywWvG7y0G_sEEJofVPfw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_5noczgth7ESj_eD56TtTTg"
      decimals="2"
      id="Narr_na_rGJBuqUOgKoBEMMh3yw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">19.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_jIVpGZkgukKjxUQMjmn_Sw"
      decimals="-3"
      id="Narr_eyYsffCdr0-6eMZ6evCSFA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_XbHYq2dE_UGUYLas9E-Hnw"
      decimals="-3"
      id="Narr_1KdjL1VOzkec-O-7AMn7dA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"
      id="Tb_TZArxxr86E-fSVYrSuiMkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in whole dollars)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (84)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested units as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3GMwf3ANwkuAIoCkKRuAEw"
      decimals="INF"
      id="Tc_5VIfvFZx3kGpjXeMYqHiIA_6_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_3GMwf3ANwkuAIoCkKRuAEw"
      decimals="0"
      id="Tc_NiF8oCHDaUu9jPnP0sd1ZA_6_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">5686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"
      decimals="INF"
      id="Tc_CRL6MAApKU2v1_yBAq7_KQ_8_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">84</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"
      decimals="0"
      id="Tc_LR8F4eeQfEOjV0zhl8c9hQ_8_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">6006</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ"
      decimals="INF"
      id="Tc_sBmJPtJ-r0GwH6pLSU3G7Q_10_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ"
      decimals="INF"
      id="Tc_LFFUqSbfNE6RK5eL9sOQEQ_12_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ"
      decimals="0"
      id="Tc_kY_75ONLwky0Diu0rkMwvw_12_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">5533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"
      decimals="INF"
      id="Narr_Ana_llmjoEiXWcVwXB2AgA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"
      id="Narr_7CLt5g94oku1djAE4ienIg">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_5pRgPmStYke4665l_7u1IA"
      id="Tb_1TfuDOCf0E2KBNR6UV8cAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024 grant profit share unit valuation inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg"
      decimals="3"
      id="Tc_q0ShDa4EKE2u3tTIYLRziQ_4_2"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg"
      decimals="3"
      id="Tc_kr457Yl_20CwxYnUr9SDYA_5_2"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg"
      decimals="3"
      id="Tc_bRZvcIQHJk250ch5w5EUDg_6_2"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_cb9ZrBXjXUu1sJlJdGOkmg"
      id="Tc_dzmnuoTN406jLXZ5vOwQ-w_7_2">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_v9dEXHtUz06ZNtYrVeP4bQ"
      decimals="-3"
      id="Narr_jQCemkubOE-vMHy1NvxRZg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">319000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_nF7LfoZnP0eXge2zjCLJew"
      decimals="-3"
      id="Narr_zIjv4YIg7EynG7NSvxCAIQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">782000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ"
      id="Tb_KGts1f1ozUuUsBEChXG6SA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 140&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_yCdJXfvBaESj-7sAWiLUgQ"
      decimals="INF"
      id="Tc_KFXJ_dmJ2EKv7v4x1qlDDA_5_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ"
      decimals="INF"
      id="Tc_2tqukdpf_UWjao8bm0qizQ_7_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_Z8LAMumbrkORbdlPjfGnKQ"
      decimals="INF"
      id="Tc_cKXoPy_SHkGOpV7if_au_g_8_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">34</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_dtp7DCTeaEab_MgJIlQTmw"
      decimals="INF"
      id="Tc_aJrTY-g910WcJCSX1UZcfA_9_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uo-sJMUAtUm-XDTcsRgyog"
      decimals="INF"
      id="Narr_y1w7oZKahECYN_WFzKigLg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_dtp7DCTeaEab_MgJIlQTmw"
      decimals="-3"
      id="Narr_6Wj_5orCXk6WmJK1K5MVhw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">50000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_3_31_2024_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_FbkYU21lwUS7EtQCr_4AQg"
      decimals="-3"
      id="Narr_MEVrPw0k3EyVysPxgEQSSw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">420000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_fZsOou0CJ0WZAa1Qy0CPfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 265.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 384.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 210.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and exercisable as of March&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 268.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ"
      decimals="-3"
      id="Tc_enCxRKCVTUKi895gV0thuw_5_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RT3URhWJC0mavQMNDwofvQ"
      decimals="2"
      id="Tc_sh9BC7B15EOLfzg8zipmbw_5_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">265.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="-3"
      id="Tc_jSHaO8d9oUu8fIoeu3jkhg_6_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="2"
      id="Tc_vVKeh-CcmUC0IV9IwH4M8w_6_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="-3"
      id="Tc_DmIczcCQx0i3DOv9FJs0AA_7_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="2"
      id="Tc_J_3wbxww2UuyrVCQO7NHxQ_7_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">124.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="-3"
      id="Tc_CZhnImx9Bk-qboGBcsVC2Q_8_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">14000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="2"
      id="Tc_ZZ26w920CUikloPG7yHS1A_8_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">384.6</btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="-3"
      id="Tc_DWry8VSt60eZxa5c2bAo7w_10_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="2"
      id="Tc_pHgsCnmRAUmLNxU16ChbtQ_10_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">210.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="-3"
      id="Tc_fdqtQl_nQE-fgbkx3Xmm5A_12_2"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">259000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="2"
      id="Tc_6eJEg11F60KjPcBmisiJ_w_12_5"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">268.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="-3"
      id="Narr_KeOl431OL0yVCcacpA5FFQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="-3"
      id="Narr_Ix-xLFLTkUOMWsmT7mg7zg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="-3"
      id="Narr_bCGA5qog-EKNOUxlXfuO1w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="2"
      id="Narr_lNApnHZju0a9gU-O79HPbA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="2"
      id="Narr_Ly6qcJNU_UOi7GoC2EivZg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">196.53</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      id="Narr_TZkyHfMXQUywyaosm9yywg">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      id="Narr_IUQnTKSacUGh5jKHNejRKQ">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_I6UROqJGNUudsrBRLW2gcA"
      decimals="-3"
      id="Narr_R5_EeX_OgkqoHbsA5KrHJQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1675000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      id="Narr_Se9Cjw5ua0aEkNJQXnJsFQ">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      id="Tb_owKX_IoMs02TK9ezNrmcZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;112.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;108.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tc_l9Fqr0MrUkqqugZrUPz9Ww_5_5">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      id="Tc_YctY4vxVNkuG2TosURY9-Q_5_11">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="3"
      id="Tc_qgKoGgrw_kORsWCsrus0_Q_6_5"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="3"
      id="Tc_D-1iGgZVk0uzKL22hEcMxA_6_11"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="3"
      id="Tc_8RDw5YPXRUOcqsyYTc-Txg_7_5"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="3"
      id="Tc_flx-3v-xKUaww0y6U84sjQ_7_11"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="3"
      id="Tc_lc0TQD92TUC47K0BhX7jLg_8_5"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="3"
      id="Tc_dnRauHOQ_kSHyoa3Q6WkXA_8_11"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nqBoTnGP8k6r9GiVbK0lXQ"
      decimals="2"
      id="Narr_SNLZwJWouESQqKnAUUkyIA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_mq7vwLe9A0e05YPDu8xOtA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Narr_4Iv-qd4p6kKuO6wsg3ZJlQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_JchkmFacGE2sNtjNAQVZNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (514)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_q7_XqlxfsUekbErhlfT5sw"
      decimals="-3"
      id="Tc_XrKpXd1e1EqU84hqAQHQ9g_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-514000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e7w7dYu6okaQM-X3HL0_TA"
      decimals="-3"
      id="Tc_NrQHtNUxp0u5BsXWgpgVKw_4_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hYwcEJOWJEqWIWLY9H5bPw"
      decimals="-3"
      id="Tc_uCMiw7n20UmcWW1AQrjREw_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">694000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_aQAnItAirkePUH0weLiB8Q"
      decimals="-3"
      id="Tc_MOO68BZrdU2YF9HdyxC9Qw_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_AaT3OhHaDkiJSJZsVcG5RA_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_7X9Muc6nH0GQxFjb0d0NSA_6_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_RtIxFX89CUiClmbyPTCq5Q"
      decimals="-3"
      id="Narr_sR0nbRZJrkGonjF_mmOkHQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg"
      decimals="2"
      id="Narr_p2orEVKFwkm3MVMwOR4pDQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.01</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant>
    <btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg"
      decimals="-3"
      id="Narr_QyRrZdaMnU6tlXt261lBhQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">31000</btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Zotx-InY40OTcSHffl_PVg"
      decimals="2"
      id="Narr_-XukXa541EKRC3qXkU48GQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2025_To_1_1_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_9F-wNPBED0-yN2cUEWfCsw"
      decimals="-3"
      id="Narr_JlOX2JfrL0i05drD9ZVrwA"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_4V56383kUUSE1c7Tg5oaUA"
      decimals="-3"
      id="Narr_pViPKXoEAEKaeg72QmYoWw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_FqusdZHmpEqdtLr0_l7HNA"
      decimals="-3"
      id="Narr_a8VqmBenYEKU1qOdhR-f2w"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2025_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_afsb0jOiYk26yty0TiCjbw"
      decimals="-3"
      id="Narr_Ioc7yfAbik-K4offgEuqQg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">106000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_eOWqTSOA8EGYBD6Jg_4viQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 13. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#x201c;HQ Lease&#x201d;) under an operating lease that expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company also leases equipment such as copiers and information technology equipment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The future minimum annual lease payments under operating leases, as of March 31, 2025, are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Remainder of 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 359&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (350)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The current portion of the Company&#x2019;s operating lease liability of $350 as of March 31, 2025, is included in &lt;span style="-sec-ix-hidden:Hidden_-dJ9RC_4H0GYGleZlqoJAg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt; on the Condensed Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Lease expense was $101 and $99 for the three months ended March 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Lease renewal options are not included in the ROU asset or lease liability.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_l7YhQdIfgEml264lHDZz9g">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      id="Narr_PRWk0Efxz0qahPUH1dPy2Q">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_D7XCjqsSykW5_rDW7i-r6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Remainder of 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 359&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (350)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_HdRzB3PwO0mT_YPHOzpMiw_3_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_F2nDra7u0E6dEvTegBJjWQ_4_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">65000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_McfNTSSfqkOjzIpWAFyRJQ_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">359000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_UcXQQprsB0SLGwlpar3mrw_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">9000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_nYTByHvq40WPxAWYRTsDXA_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">350000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_ov4EZzcjN0WN1htT51kzHw_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">350000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Narr_Azu-f5WkNkiKLPs8xArLdg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">350000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Narr_Yda7ShRuRE2bzKnCcd6j6w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">101000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Narr_0pDs88YjVEeozj0IOslTjA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">99000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_r6op1MIJ50mLD4eIhWZg2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 14. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, &lt;i style="font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/i&gt;, for additional information on the accounting policies related to fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The carrying amounts of cash and cash equivalents, accounts receivable, net, and accounts payable approximate fair value due to the short-term nature of these instruments. As of March 31, 2025 and December 31, 2024, the Company had $30,310 and $29,036, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the three months ended March 31, 2025 and the year ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative liabilities measured at fair value on a recurring basis are summarized below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,274&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative liabilities are comprised of the OnkosXcel Warrants, BTI Warrants, and Option Warrants. The fair value of the derivative liabilities was determined using Binomial Option Pricing and Distribution models for the OnkosXcel Warrants and Option Warrants, and using a Black Scholes model for the BTI Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2025. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Addition of derivative liabilities - BTI Warrant (March 2025 Accompanying Warrants)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Addition of derivative liabilities - Option Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Termination of derivative liabilities - Option Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_PWqzCLVmi0aOXGZBWK1euA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;   Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - March 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The change in fair value of the derivative liabilities was reported in the Condensed Consolidated Statements of Operations as Other (income) expense, net, for the three months ended March 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at 115% based on the historical volatility of the Company&#x2019;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In estimating the fair value of the derivative liability related to the Option Warrants, the valuation inputs used were a strike price of $3.50, the Company&#x2019;s stock price of $2.70, volatility of 39.2% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), a term of 0.04 years and a risk-free rate of 4.39%. The Option Warrants expired on March 18, 2025 without being exercised, and the Company recorded a termination gain of $369 in Other (income) expense, net, in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In estimating the fair value of the derivative liability related to the BTI Warrants &#x2013; March 2025 Accompanying Warrants, the valuation inputs used were a strike price of $4.20, the Company&#x2019;s stock price of $2.70, volatility of 39.2% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), a term of 5 years and a risk-free rate of 4.01%. The Company remeasured the fair value at March 31, 2025 of $1,402 and recorded an unrealized gain of $1,429 for the three months ended March 31, 2025 within Other (income) expense, net in the Company&#x2019;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were a strike price of $4.20, the Company&#x2019;s stock price of $2.03, volatility of 38.5% (adjusted to set the value of securities in the March 2025 Offering equal to the consideration paid), term of 4.9 years and risk-free rate of 3.96%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The estimated fair value of the Credit Agreement as of March 31, 2025 and December 31, 2024 was $96,403 and $94,204, respectively. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The following table presents the BTI warrants issued by the Company and the corresponding balance sheet classification:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Recipient&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Closing Date Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;4/19/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2023 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;12/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2024 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/20/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;New Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 9.136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 51.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Heights Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Hudson Bay Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;IntraCoastal Capital, LLC&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Murchison Capital Partners, LP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;March 2025 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/4/2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 4.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 4,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 5,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair value of the Closing Date Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $3,245 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $320.64, the Company&#x2019;s stock price of $238.88, volatility of 95%, term of 7 years and risk-free rate of 2.95%. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;of the&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Closing Date Warrants granted to the Lenders to have an exercise price of $58.3232 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants&#x2019; fair values at the original strike price of $320.64 and the amended strike price of $58.3232 were $548 and $802, respectively, as of the Second Amendment Effective Date. The Closing Date Warrants&#x2019; incremental increase in fair value for the repricing of $254, was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the Second Amendment, the Company issued 4 &#x201c;2023 Warrants&#x201d; at a strike price of $58.3232 per share. The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $200 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $58.3232, the Company&#x2019;s stock price of $59.36, volatility of 99%, term of 5.4 years and risk-free rate of 4.14%. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the Fourth Amendment, the Company issued 6 &#x201c;2024 Warrants&#x201d; at a strike price of $49.1568&lt;span style="white-space:pre-wrap;"&gt; per share.  The fair value of the &#x201c;2024 Warrants&#x201d;, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of &lt;/span&gt;$224 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 2. The inputs used were a strike price of $49.1568, the Company&#x2019;s stock price of $44.48, volatility of 112.2%, term of 5 years and risk-free rate of 4.25%. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In addition, in connection with the Fifth Amendment of the Credit Agreement, on the Fifth Amendment Effective Date of November 25, 2024, the Company amended and restated the Closing Date Warrants, 2023 Warrants, and 2024 Warrants granted to the Lenders to have an exercise price of $7.68 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Using a Black-Scholes pricing model, the Company determined that the Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#x2019; fair values at the previously amended strike price of $58.3232 and original strike price of $49.1568 the amended strike price of $7.68 were $105 and $164, respectively, as of the Fifth Amendment Effective Date. The Closing Date Warrants, 2023 Warrants, and 2024 Warrants&#x2019; incremental increase in fair value for the repricing of $59, was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The fair value of the Accompanying Warrants at issuance on March 25, 2024 was determined using a Black-Scholes pricing model and was recorded as a derivative liability with the offset recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2.  On November 25, 2024, &lt;/span&gt;534 of the 539 Accompanying Warrants&#x2019; strike price were amended to $9.136. The Company remeasured the Accompanying Warrants&#x2019; fair value at March 31, 2025 of $641 and recorded a net gain of $1,679, within Other (income) expense, net in the Company&#x2019;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were strike prices of $9.136 and $51.20 for 534 and 5 Accompanying Warrants, respectively, the Company&#x2019;s stock price of $2.03, volatility of 120.2%, term of 4.0 years and risk-free rate of 3.93%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The fair value of the November 2024 Accompanying Warrants at issuance on November 25, 2024 was determined using a Black-Scholes pricing model and was recorded as a derivative liability with the offset recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Condensed Consolidated Balance Sheets. This fair value measurement is classified as Level 2. The Company remeasured the November 2024 Accompanying Warrants&#x2019; fair value at March 31, 2025 of $1,193 and recorded a net gain of $3,080, within Other (income) expense, net in the Company&#x2019;s Condensed Consolidated Statements of Operations. The valuation inputs used as of March 31, 2025 were a strike price of $7.68, the Company&#x2019;s stock price of $2.03, volatility of 115.3%, term of 4.7 years and risk-free rate of 3.94%. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_PJWCjTtyrkmhOnNFeBDLAg"
      decimals="-3"
      id="Narr_-6KQ23sSxUebZ3b14SMcSw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">30310000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_J7mlkOfyo0Wnq0ZjtLDsPg"
      decimals="-3"
      id="Narr_iQpPW8CqxkGs5qk4RRdyug"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">29036000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_TZRlUyFAD0WIrNA_uTfAww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:51.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,274&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.3pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P_Qm7GZ7c02Je803Yy_hCQ"
      decimals="-3"
      id="Tc_nzFhLIRBl0uNxnwyzJ9nfw_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3236000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Gzu0uopwJUi4ddhDOAgn4g"
      decimals="-3"
      id="Tc_4q71JeqZokqvEet2zjei2Q_5_9"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1834000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bQalOe5mP0y-IbH-aKaF9w"
      decimals="-3"
      id="Tc_XXV8E5OLPkeIwgBaYiH4Vw_5_12"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1402000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9SMshi1uQUeFzJdBkvobzA"
      decimals="-3"
      id="Tc_HXrRCSNoSEKlQZpJLGenWA_5_15"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3236000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rqZf9XPGIECruOB5VZyF7w"
      decimals="-3"
      id="Tc_NHOpQk75hk6aRi2ADS9J_g_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EPMTFamnQUKwjPkhv202_A"
      decimals="-3"
      id="Tc_0QaXw5isnEy8pCmviWmQNA_6_12"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NU_bnWHgP0u3mu2YN8K9VA"
      decimals="-3"
      id="Tc_697O9lZCw0i9ULiBz2z7sQ_6_15"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_prSUZ2Vk1keXeIwPcPdHBA"
      decimals="-3"
      id="Tc_sd_hXqdUHkCIiIg5ahn3ng_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3274000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_2zTp8JJdwEuWNCrhPNXy7Q"
      decimals="-3"
      id="Tc_ofcc6-X17UGTYuY-mRgsFw_7_9"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1834000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RUa6fxCGUUmCyEdDsmfEsQ"
      decimals="-3"
      id="Tc_3RYkRmq6S0ObCDbgwJ0K0Q_7_12"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1440000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qG6PA1YTT0mFdtjqdPZt5A"
      decimals="-3"
      id="Tc_1cXBNe_fDU-85cBmYOaSjQ_7_15"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3274000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_a7UuWWdWIEerkqNo73GtgQ"
      decimals="-3"
      id="Tc_18ONUEB-oEucVXYESCuvcg_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vgkPllpRpE6UxSwit2t12w"
      decimals="-3"
      id="Tc_myMCkizllk6ta0D6B7vlcQ_6_9"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_BioxcelWarrantsAggregateMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_znla2RdJtUGZPRsAxS6c6w"
      decimals="-3"
      id="Tc_HzyRDfzDpEGuWLK482Bpgw_6_15"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Tlr0bx5Lk0umFnmNNGd4sg"
      decimals="-3"
      id="Tc_-aJcR4X7Dki3FH_T64OB0g_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__NmDuNpoV06Ia2-1ixub5g"
      decimals="-3"
      id="Tc_G-vGIW8DnECaSs-a0oYAyw_7_12"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_RSoI2qJZEEOhEloDLwu0WA"
      decimals="-3"
      id="Tc_T-BdzNrlyEaNWknHVg2W-A_7_15"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_c2LU5Sjq3USpPWVHuKrnqg"
      decimals="-3"
      id="Tc_H_jbH-jrb0-knveAwRKtNw_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AYpdz6Od1kSaVgoALMsuJg"
      decimals="-3"
      id="Tc_80jVbNGCokOxfs7oYLsLfw_8_9"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6593000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wRxXXGVLeEmgQL5oobXHSg"
      decimals="-3"
      id="Tc_cp0wPDv-C06fROiz4613BQ_8_12"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VPNR0fGdgUKLLXoJnK_u5A"
      decimals="-3"
      id="Tc_w3WkcpSgjk6BH8hs_3Cqdw_8_15"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6633000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_R_GKmYTK0Uy5k8jGsygpPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Addition of derivative liabilities - BTI Warrant (March 2025 Accompanying Warrants)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Addition of derivative liabilities - Option Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Termination of derivative liabilities - Option Warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_PWqzCLVmi0aOXGZBWK1euA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;   Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - March 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2024_inEfcZPBWUCIiN2q08fVSw"
      decimals="-3"
      id="Tc_G6wdALPfqU6cdIrkeCl3rQ_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">40000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_RXwRHlspG0CBhKKGGIsZiA"
      decimals="-3"
      id="Tc_C8HeOD2U4k63vC3r60EDOg_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1905000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_nOFA42sxOU-Rl_psGJmlJQ"
      decimals="-3"
      id="Tc_03He1_RdUE2r_Icr2xDJ7Q_6_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2831000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q"
      decimals="-3"
      id="Tc_AScHMFUMvUiHr1GsHtS5eg_7_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">369000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_hsmzO6OPm0OUreXt3TRN4Q"
      decimals="-3"
      id="Tc_-95-E9yHiUy_qvNGaFv2bA_8_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-369000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_6AOaBjx_mkGOdca86o8trQ_9_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-1431000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_NBQnhjJQkE6mhPBUBFmCng_9_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-88000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_KL1teDjPkUWDTqQUqMwHcA_10_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1440000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_3_31_2024_ZyPv9VyYzkatP9EyiR00mQ"
      decimals="-3"
      id="Tc_xNuwPeYHIkGt3IMlkCACng_10_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1817000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xATPzL0AD0u1BGyIwTMdLg"
      decimals="2"
      id="Narr_1uStjDcJ-E2HLwHBv3fBQg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.15</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_DFyNXKIPgEKmArMsW0gQGQ"
      decimals="2"
      id="Narr_9YTu3GHVok6IWBb3eDqFzQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">3.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember__892NuyTDUO55WW4yX_gTw"
      decimals="2"
      id="Narr_9I90XMlJeUyF2LmUrW35Ig"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">2.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_QjBKLYfu3UOftjkz3HF_ZA"
      decimals="3"
      id="Narr_uf3gflt7ME-_Tud6pIhKLg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.392</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZQ9kR5BADEqDL0CF2MD1zg"
      decimals="INF"
      id="Narr_HQfTkgX8A0OIT-5YrX6DHw"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">0.04</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_dmsZTMfbJUO8_pb6kAYEhQ"
      decimals="4"
      id="Narr_Zer7Lmtbd0WdOTU90B7J8w"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0439</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="Duration_3_18_2025_To_3_18_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_zFe6GfQFg0-WdZKVa-mIuA"
      decimals="-3"
      id="Narr_SUsfNz1VPkmGuocPwlGIEg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">369000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_gukmUIFIc0iqBD5w9_5uHA"
      decimals="2"
      id="Narr_qmv1yfXj1kKMvMMmfzZ2Dw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">4.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_q2bl4kv7E02ZqMbp6lNHdw"
      decimals="2"
      id="Narr_1hIPYihz4k24JyuviHcGtA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">2.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CWILIty2pkCdQ4BijefAOA"
      decimals="3"
      id="Narr_pF_XU4rNs0S_qskCCilz2Q"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.392</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eZWNvJQCgEqQKzXrXgAoJw"
      decimals="INF"
      id="Narr_7HlbxU7UgkaflM1_xn0w3w"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_c8VoZNoCiEe75FKiODf1LA"
      decimals="4"
      id="Narr_aBj_WvwHl0Od-KuIjk0oNw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0401</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg"
      decimals="-3"
      id="Narr_BUMU9WOhW0-krXWounRc7A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1402000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_nOFA42sxOU-Rl_psGJmlJQ"
      decimals="-3"
      id="Narr_Y7tEzu--jUyr0VLeW-RKzw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1429000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wV5E2FZOwUyvzrEwdAj5sA"
      decimals="2"
      id="Narr_g_9P8m7CO0eOzudw9mvlyw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">4.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_vZatyzeFWUKoVmXlyUbWJA"
      decimals="2"
      id="Narr__PGS33kbVEmmCGinE2hv5g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">2.03</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_3xEadpqpTkSF6M_S7kMmYA"
      decimals="3"
      id="Narr_j9rYBQbR6kKosNPIxPWAmA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.385</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_y8iIi7tP7ku5odeEUQmnRg"
      decimals="INF"
      id="Narr_W6nZLQvIvEurD0LE77B7yQ"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">4.9</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pLWARFxxtEigtbUjIwm1fA"
      decimals="4"
      id="Narr__QUMsqXf8kmqQl4o1rFP8Q"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0396</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_DCTIgayy70KLsTzoQ8o-Jg"
      decimals="-3"
      id="Narr_T2kyI0onDEuqXeHA1r6z3A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">96403000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_zFMC5T7CfU-D5CYy3DpF5g"
      decimals="-3"
      id="Narr_azl2hFTncEia9FxL0ipt2A"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">94204000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_20_ToI0qv0KIJDft6Wst1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Recipient&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Closing Date Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;4/19/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2023 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;12/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;2024 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/20/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Lenders and RIFA Purchasers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;New Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 9.136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 51.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Armistice Capital Master Fund Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Heights Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Hudson Bay Capital Management&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;IntraCoastal Capital, LLC&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;November 2024 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;11/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 7.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Murchison Capital Partners, LP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;March 2025 Accompanying Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;3/4/2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 4.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 4,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Derivative Liability&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total warrants issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 5,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_MIO3Q71fCk-LePjJ87vN6w"
      decimals="2"
      id="Tc_B-bxM99r_0KHQ1nYI6yjVw_3_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_MIO3Q71fCk-LePjJ87vN6w"
      decimals="-3"
      id="Tc_ZxKkTeHciUK7gEkSEbGz0g_3_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">17000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_3dKYWVuao0m_9mO0sa3-sA"
      decimals="2"
      id="Tc_G1j-iMxW40mhNOh-uf8a0Q_4_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_3dKYWVuao0m_9mO0sa3-sA"
      decimals="-3"
      id="Tc_A5uuKo5ilEmduTXH9KzkOA_4_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw"
      decimals="2"
      id="Tc_-EDvG0oEXEaZXId6fmwjgA_5_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantShares2024Member_wMIVEu8kMEuDr5SYa9cZjw"
      decimals="-3"
      id="Tc_5qGKxLKUy0K5lbwEeSk8EQ_5_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">6000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_UjYm4-P8Z0eyskPAdnjmLA"
      decimals="2"
      id="Tc_yLCYrB2mFkKN_kPQjxm6dg_6_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_UjYm4-P8Z0eyskPAdnjmLA"
      decimals="-3"
      id="Tc_34TN8-Y9t0yFQL45t95crQ_6_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">313000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw"
      decimals="3"
      id="Tc_VVfoAVPWgUGHEB-JtN1T5g_7_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">9.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw"
      decimals="-3"
      id="Tc_B2CiWezAak6UxoACc7AUiw_7_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A"
      decimals="2"
      id="Tc_uYAJHmVOoUmoITxX2Gk2sw_8_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">51.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A"
      decimals="-3"
      id="Tc_wPKJvTHPaEWLruwVNHReAQ_8_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_piXKgE8oLECIyWjuYpp4BA"
      decimals="2"
      id="Tc_xAwJ5qO5f0mjy8RIPRtTbw_9_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_ArmisticeCapitalMasterFundMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_piXKgE8oLECIyWjuYpp4BA"
      decimals="-3"
      id="Tc_WPNlWom2NEehMHwYMmuN6g_9_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">846000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_m8B2gPtU0ESdDuqJrEcuow"
      decimals="2"
      id="Tc_xR7E47HMQEG0A_FYsKS5Rw_10_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HeightsCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_m8B2gPtU0ESdDuqJrEcuow"
      decimals="-3"
      id="Tc_dFmgsjQ21kihkxoGAGrEKw_10_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_PVo46D0n4k6-QNq-niA4gg"
      decimals="2"
      id="Tc_SUr2arkIYEOuV_M9TPHfOA_11_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_HudsonBayCapitalManagementMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_PVo46D0n4k6-QNq-niA4gg"
      decimals="-3"
      id="Tc_pUUiBvKhhUa9xuXvzeObJg_11_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_wQUERamXr06SR40KJckzOg"
      decimals="2"
      id="Tc_ehaOxtVJzE-AKjGKAWE2ug_12_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_srt_CounterpartyNameAxis_btai_IntraCoastalCapitalMember_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_wQUERamXr06SR40KJckzOg"
      decimals="-3"
      id="Tc_sXAHSGybI0S5hnMoed8Inw_12_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">13000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg"
      decimals="2"
      id="Tc_5ILpzN_OikWPmR6b4RncOg_13_7"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">4.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrantsMarch2025Member_fpUADFPX4EuhslgM1cBgDg"
      decimals="-3"
      id="Tc_Dg3-tOaDLkOMpeRY4TjnzA_13_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_dqJriLls0EGDUJJQWnSteA"
      decimals="-3"
      id="Tc_f33ZDocrJk-G42npgqxwwA_14_9"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5792000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="-3"
      id="Narr_xQTnNgpLS0CtX1UcE0J4CA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3245000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_uNtDcCko1UyxQn5jeaw1_w"
      decimals="2"
      id="Narr_ckQpEzL55UuJNnLjmShrWQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">320.64</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_5nb_8Nk5UEyJL1GzeHRhRQ"
      decimals="2"
      id="Narr_F3a8JROprUiKP8yXg6ppZQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">238.88</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Otlhw_JHk0O7aWKiFegSPw"
      decimals="2"
      id="Narr_wCQsOH1h90u6_Mq2N-Rn3w"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.95</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MucGrtBbn0W75wiVlwPE0g"
      decimals="INF"
      id="Narr_6xmb4aUPJEancNtYlTn4WA"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_raXKhs6OsEWwo5Ew1U2bVw"
      decimals="4"
      id="Narr_BNdSk4Yxy0uQgHO2iLHxnw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0295</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"
      decimals="4"
      id="Narr_kCH7Ze6dpUK7GYvGld_V4w"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="2"
      id="Narr_ySdHL0JHf0uEgrJO8fShSA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">320.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"
      decimals="4"
      id="Narr_N2uQ46AbXE2hhzrNSfxOrg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_FD0jvZ3sOUSa1Epn2ap36Q"
      decimals="-3"
      id="Narr_4hdDEC87hkOpWib0KYhRwA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">548000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"
      decimals="-3"
      id="Narr_2a_-xDmW6EuSDJd_PB1Dig"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">802000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_QmfvUlDnnkmlBuPCyWobCw"
      decimals="-3"
      id="Narr_mxpnOWuAr0egIK3BinUZTg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q"
      decimals="-3"
      id="Narr_A_Kkk_C2rkyP3uwv9LaXDw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q"
      decimals="4"
      id="Narr_u2_oFZt5hESDCqGkOYwntw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_awstT3XqQEaqL87M8_HC_Q"
      decimals="-3"
      id="Narr_6kf3kz3250CWfrEdfA78IA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">200000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_um20DfDizEmScCi5XDUA2w"
      decimals="4"
      id="Narr_2QCxRZKzsES6OENhJzwQyA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_jchly8ehyE2tL32MrOzqYQ"
      decimals="2"
      id="Narr_xSZ2G26huUCEyhK9auGQzg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">59.36</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_9KILTf0tCkqIWN0JAKeHVQ"
      decimals="2"
      id="Narr_i7vStfEzP0WYLBVOKRrePg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.99</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_jJnh5eroP0GCxqLxuMWfvg"
      decimals="INF"
      id="Narr_x-Pjin08HkebLG4_z2zJ-w"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">5.4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2023Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_zeDW5gQHa0eSgEOzkDCljA"
      decimals="4"
      id="Narr_TxilxCZRgUe60gTXK_ygmA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0414</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA"
      decimals="-3"
      id="Narr_waD4qw5SUkmzjQM-jP6eNQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA"
      decimals="4"
      id="Narr_szGMNt2Rq0SPfNEjO4hHDQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_HJRkU0Cqkk-enw5eXVVbsA"
      decimals="-3"
      id="Narr_IkqBDGPfPkGClU5owR7Z6g"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">224000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_5SJ7xQVeDkK5uvXlaHFGNA"
      decimals="4"
      id="Narr_XBxG-O2TZEquVKEHSJFP7A"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">49.1568</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_mzVT50GU30m-ov3gJU8nPQ"
      decimals="2"
      id="Narr_NWdlJG9ce0e8RmK2G6oU3g"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">44.48</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember__xc5-0WLKUuKskXTA4r91g"
      decimals="3"
      id="Narr_MZy35e3jaU-0gm42lOvWwQ"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.122</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2M20XZ8qKEKKmuDwGSOUAw"
      decimals="INF"
      id="Narr_jRf4R_44RUaZIPNyPubjdw"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ub31Uz9ocEKq02canhoV-Q"
      decimals="4"
      id="Narr_UDA4UXCDf0apd21YOyRmXw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0425</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g"
      decimals="2"
      id="Narr_xZAXdb7OMUWxeAPVmb9bHw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_9T5GRsG_Pk6kv5hPDuARDQ"
      decimals="4"
      id="Narr_G0mw6mA3wkKxqBm9LkdKyA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">58.3232</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_mCSz1-9t-k2mWS0W2FTi7A"
      decimals="4"
      id="Narr_RyqT0n-DnkWT-T54VfQrrg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">49.1568</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g"
      decimals="2"
      id="Narr_ZFkch1B6zkyhuaQoLQJ-CQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_mCSz1-9t-k2mWS0W2FTi7A"
      decimals="-3"
      id="Narr_W6GZ5F4Ar02XyWA5_AwfJA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">105000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_JzZ_1wDYFEGoCBEGPjPq2g"
      decimals="-3"
      id="Narr_dSfacofYr06y6vhi0CgARg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">164000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_11_21_2024_To_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_NP8nyepU-UeJtuBMku2PLg"
      decimals="-3"
      id="Narr_0LGpv3GP_kSL-lP3J-foHA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">59000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_hFX2ulHzj0Wonqj3FtS7mw"
      decimals="-3"
      id="Narr_CwvEY4Ao6kq7T0Nq6nnfIw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_9zAfUgBtvEi6ov_a7qysFg"
      decimals="-3"
      id="Narr_sAOyH0tkHEihacvOmLUfQg"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">539000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_25_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_QFx83QhiX0OZiI-xchFZ7A"
      decimals="3"
      id="Narr_6T0NZfjJlkCza5sXk2Ot_w"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">9.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_QLIVwjVCD0quI55_NwdJQw"
      decimals="-3"
      id="Narr_Kzd1hu85aU-JJFLvo3U7OA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">641000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_RvkyKbPjBEK4lRpESDkZxg"
      decimals="-3"
      id="Narr__QBzybRFOUGspZegqGLajQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1679000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_SVurPgE3cUqj3MtsSbmcYA"
      decimals="3"
      id="Narr_z7EkTrFGUEe7bcLXFr5waA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">9.136</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_6Gs70ljVX0-T7tm9G61m5w"
      decimals="2"
      id="Narr_JGQKa89WKE6m01qRpMGYFw"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">51.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsStrikePriceAmendedMember_XoIJFxTODEWujqx3bTI-Gw"
      decimals="-3"
      id="Narr_KKrD_1ZJ30udHN2ZjhelHQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">534000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_AccompanyingWarrants2024StrikePriceNotAmendedMember_NKroYyzrt0aeVVmu1RZH1A"
      decimals="-3"
      id="Narr_3m4EuMqgaESIxCixSugt9A"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_wMIMNY2AHE6iuFOidhFOtA"
      decimals="2"
      id="Narr_Mw5WLZaS_UGiSalh70AyTA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">2.03</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_rp6M6rMw0kqyDbuEBr22PQ"
      decimals="3"
      id="Narr_HJ_TGVDPrkeaG7r0NCg_Ng"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.202</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eQXdiGPGikaZ3eg2SLqU6Q"
      decimals="INF"
      id="Narr_fkizeltnmka1DHCcrwn8fw"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_PLtorYr2Ck-Sp5y9dKuZjQ"
      decimals="4"
      id="Narr_uoq95ZPUWkKKdf9yqQYiCg"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0393</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_k-Kye-ecsEGNgr32jEq1GA"
      decimals="-3"
      id="Narr_Ro3XXqYyD0ySDo3zqzysSA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1193000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_Cn5-JcfDR0qcNSKrdqLIBA"
      decimals="-3"
      id="Narr_a4YkXqxyT0agdQNjYEDL1w"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3080000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_ZjpISjnlM0KcHdFRUWnJgw"
      decimals="2"
      id="Narr_tXwGBmqhOEO2LC2YtzSWgA"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">7.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_ZVXHoCZAKU-UscfH64BvJg"
      decimals="2"
      id="Narr_XyXZfJt59k6dn3QazJWGvQ"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">2.03</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_TcgKfaj7gUmuOyYcYRMQNA"
      decimals="3"
      id="Narr_ji5eZTJJJES3dUrLbQ4ckA"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">1.153</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_BggKgNfY0USZzws7g5S5Wg"
      decimals="INF"
      id="Narr_ovz-1cv7lkaoU7KFYskIRA"
      unitRef="Unit_Standard_Y_nNBDXde_EESbpXfN3HfnPg">4.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_November2024AccompanyingWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_QfJEoyAEkke0QHoyrB3b0w"
      decimals="4"
      id="Narr_1ivq3zuLlUO5JAWKGVg2yw"
      unitRef="Unit_Standard_pure_eDmXxRqwy0ShITztn3iSfg">0.0394</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_koLoXDJoTki476zjcnmQ1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 15. Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic and diluted net loss per share are as follows&lt;/span&gt;:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss (numerator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares (denominator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13.89)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_830fA63lNkaCaGqI6EFK3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss (numerator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares (denominator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13.89)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_-JoEmTXnikeeSDfYZ5iYTg_5_3"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_piwMUdXWdU6YpxyMNu5z4g_5_6"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_hQvPYHezlkKpEd4dBB7Qbg_6_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_53EvMiFp8USu0xrZ53gOYw_6_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">1929000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="2"
      id="Tc__v1Pk3ulKEeVWS3W54SIiA_7_3"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">-1.5</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="2"
      id="Tc_Zco8Yq3mUEa__-v1SufJ5A_7_6"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">-13.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_6IOUpy2-L0uuJk7s3-cXYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;BTI Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wE7ROgr2I0i_O7Oti3HboA"
      decimals="-3"
      id="Tc_ucRR1NbCPkWXwZi1BOCyBg_5_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">367000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_IbpFUXyy0EK9y5v8zoZeAQ"
      decimals="-3"
      id="Tc_poefJqW46ESTBFuHj4XdOw_5_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">303000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_85gLhLsX40qMOQrtKaj64g"
      decimals="-3"
      id="Tc_IO6KsfT9H0yKmxBWcaEEYA_6_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_cwe90g33bUq1Ikc8GOiESA"
      decimals="-3"
      id="Tc_umzcc8--WUKQruflBsyecQ_6_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">12000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_tqFj1TLzLE-k4JolNuUzZg"
      decimals="-3"
      id="Tc_1qnWIIt6ykiTAi0YWc-2Ew_7_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">60000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_uh20TIQks06ogYnvmFGT-w"
      decimals="-3"
      id="Tc_8eSZwdDFSE2z9oUtdP6YQA_7_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">32000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_ZTqvtqbD3U6ROpLx6ZSAKw"
      decimals="-3"
      id="Tc_M1sToJxRCUabo4zzqLU63A_8_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">5792000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_btai_BioxcelWarrantsAggregateMember_pfEI4UeUmEGDh7VF6gPIkQ"
      decimals="-3"
      id="Tc_ZKCeramuwU-LIFDOrA2mNA_8_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">567000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_iuDRoE0g-k2g4twL5sYMZQ_9_3"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">6239000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_p8AzEcrxvU6m6LBtJ2DWDg_9_6"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">914000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_ae42lUotqEqDwqNqJi8I0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Note&#160;16. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the items below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Martin v. BioXcel Therapeutics, et al.&lt;/i&gt;&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;, 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;) and SEC Rule 10b-5 promulgated thereunder. On July 11, 2024, the Court dismissed the amended complaint without prejudice and, on August 1, 2024, co-Lead Plaintiffs filed a second amended complaint. The second amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#x2019;s-related agitation. The Company moved to dismiss the second amended complaint on September 6, 2024. On February 24, 2025, while the Company&#x2019;s motion to dismiss remained pending, Plaintiffs moved for leave to further amend their complaint. The Company filed an opposition to the motion on March 17, 2025 and Plaintiffs filed a reply in support of the motion on April 7, 2025. On April 9, 2025, the parties filed a joint motion requesting that the Court stay the action pending the outcome of a private mediation session scheduled for May 12, 2025. The Court granted the motion, staying the action until May 23, 2025, by which date the parties are required to file either a motion to continue the stay or a motion to lift the stay.   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Panancherry et al v. Mehta et al&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 3:23-cv-1554 (D. Conn.). The consolidated action is currently stayed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Smith v. Mehta et al,&lt;/i&gt;&lt;span style="background:#ffffff;"&gt; 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption &lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;In re BioXcel Therapeutics, Inc. Derivative Litigation&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, 1:24-cv-00041 (D. Del.). The consolidated action is currently stayed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On May 7, 2025, Plaintiff Yaakov Portnoy filed a stockholder derivative complaint in the Court of Chancery of the State of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep &#x201c;Steve&#x201d; Laumas, Michael P. Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan, and the Company as Nominal Defendant under the caption &lt;i style="font-style:italic;"&gt;Yaakov Portnoy, derivatively on behalf of BioXcel Therapeutics, Inc. v. Vimal Mehta, et al&lt;/i&gt;, 2025-0508-BWD (Del. Ch.).&#160; The complaint alleges similar claims to those raised in &lt;i style="font-style:italic;"&gt;In re BioXcel Therapeutics, Inc. Derivative Litigation&lt;/i&gt;, 1:24-cv-00041 (D. Del.), including business torts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$10,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; for the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;three-year&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; period, of which &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; was originally due in year ended 2024. On July 11, 2024, the Company entered into an amendment to the commercial supply agreement (the &#x201c;Product Supply Agreement Amendment&#x201d;) that reduces the specified minimum annual payment over the next three years starting in the year ended 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the FDA for enumerated indications. The Company&#x2019;s renegotiated agreement reduced the minimum commitment for 2024 to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and thereafter for the term of the agreement in annual amounts ranging from &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; subject, in certain instances, to the extent that the Company receives approval of an sNDA or NDA from the FDA for enumerated indications. In accordance with the Product Supply Agreement Amendment, the minimum commitments were reduced to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the years 2024, 2025, and 2026.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;In addition, the Company agreed to make a reconciliation payment of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1,200&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the third quarter of 2024 for full settlement for amounts due prior to the July 11, 2024 amendment.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_4_1_2022_To_4_30_2022_Vj8qPsXKFkSdJSawI_izbQ"
      decimals="-3"
      id="Narr_GM8hVkWv_EuteYKeeewxxw"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="Duration_4_1_2022_To_4_30_2022_Vj8qPsXKFkSdJSawI_izbQ"
      id="Narr_GgSP9-qvN0GWyQduR6c8ZQ">P3Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="As_Of_4_30_2022_kf6oTMRck0makoAqk28SXg"
      decimals="-3"
      id="Narr_dTz_l-PpN0yXMz23JP3HHA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5000000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_7_11_2024_To_7_11_2024_v4ITxGp84kCgCzwKJY2GDw"
      decimals="-3"
      id="Narr_5DjV9ezR20GesLVl9MvVGg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MinimumMember_McmLj4N3TUGjlqTWqM7wYA"
      decimals="-3"
      id="Narr_cSNuTobhsEGDcJS49s9KDQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_7_11_2024_To_7_11_2024_srt_RangeAxis_srt_MaximumMember_4mTezm6jGU2Tt0387MyZ0A"
      decimals="-3"
      id="Narr_gn8HTo7aSUqAg3uZAxA0Ww"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <btai:PurchaseObligationPriorYear
      contextRef="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg"
      decimals="-3"
      id="Narr_N3so0tjay0uf6xrYin4c8Q"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1000000</btai:PurchaseObligationPriorYear>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg"
      decimals="-3"
      id="Narr_dvtXq46p0Ei4neWoxfuWbQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2000000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="As_Of_7_11_2024_X_BCsAXMCESifeWiDYoPAg"
      decimals="-3"
      id="Narr_sgb5G-_WH0-yuPtywv3aUg"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2000000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_7_1_2024_To_9_30_2024_fdyMamGLJEanvbZYQzjwvA"
      decimals="-3"
      id="Narr_9laxNxOGVESrjfpBCVownQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1200000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_5uaMargNHkmzTrKxMYny4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Note&#160;17. Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company views its operations and manages its business as&#160;one&#160;operating and reportable segment, utilizing artificial intelligence (&#x201c;AI&#x201d;) to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#x2019; lives. The Company employs various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Consistent with the operational structure, the Chief Executive Officer, as the chief operating decision maker (&#x201c;CODM&#x201d;), reviews weekly cash usage and allocates resources based on consolidated net loss that also is reported on the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company&#x2019;s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development and commercialization activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 582&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,630&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (514)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 779&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical trials expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Chemical, manufacturing and controls cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Commercial and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total commercial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,037&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total selling, general and administrative costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt; Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 24,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other (income) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (947)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other (income) expense, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments and reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consolidated Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="INF"
      id="Narr_ybBwAyVnqkOdYsTgTyOOwA"
      unitRef="Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="INF"
      id="Narr_NadIC7yMrkevWuYltwHkFw"
      unitRef="Unit_Standard_segment_q-5DU1c76kmfGEkKeL1M2g">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_QLd-LiIq1E-NwwX0U41dVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 582&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,682&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,630&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (514)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 779&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Clinical trials expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Chemical, manufacturing and controls cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Commercial and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total commercial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Personnel and related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,037&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Non-cash stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Travel related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total selling, general and administrative costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt; Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 24,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other (income) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (947)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other (income) expense, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments and reconciling items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consolidated Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (26,791)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_Zthmw9t2JUOgpKJmVXGL8A_4_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_VQhEfyEx4kudg_wlWWPRmA_4_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">582000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_Q3J9VgcxrEKbcT4AgxLkuA_6_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">14000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_-ZyObqJBSkuadU8yC9tpyQ_6_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">80000</us-gaap:CostOfGoodsAndServicesSold>
    <btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_fpo_9hAE40ei4B0BDxdCsA_8_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1682000</btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense>
    <btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_BwOh3NVu9U2PEQGF-T8KXA_8_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3630000</btai:ResearchAndDevelopmentExpenseLaborAndRelatedExpense>
    <btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_4tm8FqlUSESOo8QzZBJifA_9_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-514000</btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense>
    <btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_1wOhsm9KX0yBoItdB43s9g_9_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1281000</btai:ResearchAndDevelopmentExpenseShareBasedPaymentArrangementExpense>
    <btai:ResearchAndDevelopmentExpenseProfessionalFees
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_Rja9dFAP2EO2EDj6SYq2KA_10_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">779000</btai:ResearchAndDevelopmentExpenseProfessionalFees>
    <btai:ResearchAndDevelopmentExpenseProfessionalFees
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_7GF_NRNWFE6pVTAFaZJJNQ_10_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1307000</btai:ResearchAndDevelopmentExpenseProfessionalFees>
    <btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_kgnGdjwBvEmGoB8wBkNTYQ_11_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2018000</btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense>
    <btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_eKpPVg7zt0W7wThZs6SI_Q_11_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4068000</btai:ResearchAndDevelopmentExpenseClinicalTrialsExpense>
    <btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_-5AfrujwaEeGxM3_ObpFrQ_12_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">175000</btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense>
    <btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_8EK4migwwkyL_U4xXLd8Pw_12_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">549000</btai:ResearchAndDevelopmentExpenseChemicalManufacturingAndControlsExpense>
    <btai:ResearchAndDevelopmentCostsOtherExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_29J3gtP0JUueQ7iZq_ZRTw_13_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">414000</btai:ResearchAndDevelopmentCostsOtherExpenses>
    <btai:ResearchAndDevelopmentCostsOtherExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_5rrklZzqT0G8bKAHqxr0Bw_13_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">566000</btai:ResearchAndDevelopmentCostsOtherExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_Zhlta-pMNECoWEIhOdsLhA_14_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">4554000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_8CXvyO4L9kGaNhYqujEaXA_14_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">11401000</us-gaap:ResearchAndDevelopmentExpense>
    <btai:CommercialCostsLaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_dhN3AlarK0i0x_QbMSRIKg_16_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">79000</btai:CommercialCostsLaborAndRelatedExpense>
    <btai:CommercialCostsLaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_qc65ZCpKUUuzrdrL0AjFoQ_16_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1149000</btai:CommercialCostsLaborAndRelatedExpense>
    <btai:CommercialCostsShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_Rc6q3FQQsUit5KDEiVdIFw_17_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">268000</btai:CommercialCostsShareBasedPaymentArrangementExpense>
    <btai:CommercialCostsProfessionalFees
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_wyGfDXflakeKl2eyupw6fQ_18_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">38000</btai:CommercialCostsProfessionalFees>
    <btai:CommercialCostsProfessionalFees
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_NKaeDa0XkkypzPl6vNkigw_18_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">71000</btai:CommercialCostsProfessionalFees>
    <btai:CommercialCostsCommercialAndMarketing
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_fRyuWmSUCU6UQuooIq0BMw_19_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">169000</btai:CommercialCostsCommercialAndMarketing>
    <btai:CommercialCostsCommercialAndMarketing
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_ddMsFUq9YkmXWZa0VJz1PA_19_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1347000</btai:CommercialCostsCommercialAndMarketing>
    <btai:CommercialCostsTravelAndOtherExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_kU_933TM10SFwPv9beXXaQ_20_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">9000</btai:CommercialCostsTravelAndOtherExpenses>
    <btai:CommercialCostsTravelAndOtherExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_xjJmW9H4dUGgy_UUpE4gxA_20_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">117000</btai:CommercialCostsTravelAndOtherExpenses>
    <btai:CommercialCostsOtherExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_r_vQogRMVECRiCCBplXQBg_21_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-88000</btai:CommercialCostsOtherExpenses>
    <btai:CommercialCostsOtherExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_swEbzDSgmUuhOMUFeQoMNQ_21_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">196000</btai:CommercialCostsOtherExpenses>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_0ppNlpysL0i6PnN-BVU3iw_22_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">207000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_vwsOYmgprEmSVH_gbAID0Q_22_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3148000</us-gaap:OtherCostAndExpenseOperating>
    <btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_bR0j4b-g6EyhR-65Uul0Kw_24_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">993000</btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense>
    <btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_Tc5gj7PP7UiNEHEp-grE1g_24_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2037000</btai:SellingGeneralAndAdministrativeExpenseLaborAndRelatedExpense>
    <btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_CSydnsbdnEKpuvn3SsMdXg_25_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">694000</btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense>
    <btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_x0zq-z5i3EOjbrK8Vr7oJg_25_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1884000</btai:SellingGeneralAndAdministrativeExpenseShareBasedPaymentArrangementExpense>
    <btai:SellingGeneralAndAdministrativeExpenseProfessionalFees
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_6VDe9VTZJ0S1qDvoZKVl-A_26_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">2834000</btai:SellingGeneralAndAdministrativeExpenseProfessionalFees>
    <btai:SellingGeneralAndAdministrativeExpenseProfessionalFees
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_3mcmi9fEc0mwM7JUBzsizw_26_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5240000</btai:SellingGeneralAndAdministrativeExpenseProfessionalFees>
    <btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc__1HqQdz_NkWBEvOBMtGHvQ_27_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">116000</btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses>
    <btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_C6PYnaECn0andZO_I8uBuA_27_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">247000</btai:SellingGeneralAndAdministrativeExpenseTravelAndOtherExpenses>
    <btai:SellingGeneralAndAdministrativeCostsOtherExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_JoCE72KXmk6lOu7bPEU14A_28_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">855000</btai:SellingGeneralAndAdministrativeCostsOtherExpenses>
    <btai:SellingGeneralAndAdministrativeCostsOtherExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_iYzs1xSqbEWxmS8nujV7WQ_28_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">708000</btai:SellingGeneralAndAdministrativeCostsOtherExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_0s_4yvFqbUWZaIDlYafyCw_29_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">5492000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_lEywarm5yEe0so3GXsoMhQ_29_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10116000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_5YGrcb8ajkeIa9X8Fw52QQ_30_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">10267000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_5vVxYpsFv0u8ILluCRDE9g_30_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">24745000</us-gaap:CostsAndExpenses>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_yGVM21rziU-DnkN-OyM68w_32_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3993000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_0mkrLZLCwka1w0facmsQxw_32_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">3607000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_WOIAlmXbN0KhobS_4ICQxA_33_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">279000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_PCt-WH_eFUykHBfhD5juPQ_33_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">947000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_aLZA2sapQE2FF6QmGQgHGA_34_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">6559000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_wETPHZu7IkGt9Vp5MKZNTw_34_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_X0GWDHh4ekqsQk4eS3wGdg"
      decimals="-3"
      id="Tc_s7Lrsuy08UWY7JnhTk_izw_35_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_btai_SingleReportableSegmentMember_AH_HZu5j0EKXTGd5-AY7oQ"
      decimals="-3"
      id="Tc_NuwZiny8S0CdMdtBcTvKOg_35_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      decimals="-3"
      id="Tc_GtLnZobOKUSTOwsdf89xFQ_37_4"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-7254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_83wtf8KCrkisTDJcyJBxTQ"
      decimals="-3"
      id="Tc_ZwfEWnZtRUGgTKag7g9Oiw_37_7"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">-26791000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Tb_a2mkkn4MzkaH8vARVUpfTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 18. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As discussed in Note 11, &lt;i style="font-style:italic;"&gt;Common Stock Financing Activities&lt;/i&gt;, in connection with the March 2025 issuance and sale in a public offering of (i) 188 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants to purchase 3,812 shares of Common Stock, and (iii) accompanying warrants to purchase 4,000 shares of Common Stock, after March 31, 2025 but before financial statement issuance, certain investors exercised 300 pre-funded warrants to purchase 300 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As discussed in Note 9, &lt;i style="font-style:italic;"&gt;Debt and Credit Facilities&lt;/i&gt;,&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;in connection with the Fifth Amendment of the Credit Agreement and issuance of new warrants to the Lenders to purchase an aggregate of 313 shares of common stock, after March 31, 2025 but before financial statement issuance, the Company issued 284 shares of Common Stock in connection with the cashless exercises of 313 warrants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On April 3, 2025, the Company entered into&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; an Equity Distribution Agreement (the &#x201c;Equity Distribution Agreement&#x201d;) with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;) to sell shares of the Company&#x2019;s common stock, par value &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$0.001&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; per share, with aggregate gross sales proceeds of up to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$8,135&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, from time to time, through an &#x201c;at the market&#x201d; equity offering program under which Canaccord will act as sales agent. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On April 8, 2025, the Board unanimously approved (i) the payment of a retention bonus to all non-executive employees in the total aggregate amount of $1,545, to be paid in two equal installments and (ii) the issuance of 66 RSUs which fully vest on the one-year anniversary of the grant date. The first installment of the retention bonus was paid on April 30, 2025 and the second installment shall be paid upon successful completion of the Serenity Trial data readout and securing additional financing. Each such installment payment is subject to the applicable employee&#x2019;s continued employment through December 31, 2025. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_3_2025_To_3_3_2025_Oqo3T2TPe0OI8F2BWWq60A"
      decimals="-3"
      id="Narr_tIapP-u_AU2CnFgpzmpXlQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">188000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_PrefundedWarrantsMarch2025Member_YlCT5Ht1C0ySlRxPWi7pMA"
      decimals="-3"
      id="Narr_93dA_zupYUC7LV9mES8a4A"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">3812000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_3_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_H1m79MxGEESZ-YgtaaXWXQ"
      decimals="-3"
      id="Narr_lO1DQAq6ck-zn7N2gm8VsQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wQc4SgRdUEicS5pdoMt99A"
      decimals="-3"
      id="Narr_n01gDUnMSkCJnkIBAyB50Q"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_OptionWarrantsMarch2025Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jEJ-6V5VnEiejCS4zWZhwQ"
      decimals="-3"
      id="Narr__Fn1tZUcd0CBaAgNr2WNyw"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">300000</btai:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_21_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_nTAv5p8uZEOLDNDWrZLP6Q"
      decimals="-3"
      id="Narr_IXMUpkWok0ukKHQSRU950Q"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">313000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:StockIssuedDuringPeriodSharesWarrantsExercise
      contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4ANH0Ryp-E-Q8Hcq8ycu6g"
      decimals="-3"
      id="Narr_FHol3e52eEybHKKaG8P7jQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">284000</btai:StockIssuedDuringPeriodSharesWarrantsExercise>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_13_2025_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-0WZ3XTjU0qB5FR91C9j6g"
      decimals="-3"
      id="Narr_92uED-qTUEWGFqgT9tW2nQ"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">313000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_mWRWF3v2JEGzrKxCrcvnRQ"
      decimals="INF"
      id="Narr_DiT9sXRJFEuASzRYg3Ecrg"
      unitRef="Unit_Divide_USD_shares_c_IGgRY7nkS0jxpOpMJrfA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_4_3_2025_To_4_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_B7tCQZI3s0-d2yjT-Ceoug"
      decimals="-3"
      id="Narr_AZbSsxZNaEq7YAaspmRxKQ"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">8135000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <btai:RetentionBonusExpense
      contextRef="Duration_4_8_2025_To_4_8_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKVZkA0td0assUa8qAOlvw"
      decimals="-3"
      id="Narr_SGgEdTMQq06BuPXz0h5-eA"
      unitRef="Unit_Standard_USD_-DJ8lqmxl06LkVSRTJS83A">1545000</btai:RetentionBonusExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_4_8_2025_To_4_8_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_P9AZ6PXW1kOHAK6MhEcNgw"
      decimals="-3"
      id="Narr_TpVRgk4EVUSn24XK84a52g"
      unitRef="Unit_Standard_shares_-izP_Yi_MkazBxJ2GBYnJA">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_4_8_2025_To_4_8_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_P9AZ6PXW1kOHAK6MhEcNgw"
      id="Narr_1L9wtKzKmk2cktSQ77vrXQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_81HwXJ5FSUu8eIcgFf6ZHQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_9YG4M5oLsUaRF4IvQUdGFg">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_ZgILvsNOkUOL8JneR9YO3Q">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_Qg2z_tV2CU-K5Fe3Dn8Wjg"
      id="Narr_ymo9XH7pC0CaS3FiXM1nVA">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
